,ID,tags,text
0,NCT02564744,"34:68:cancer,72:104:cancer",Participants with a diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
1,NCT01754857,"26:60:cancer,61:93:cancer",Histologically confirmed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
2,NCT02498951,"7:16:chronic_disease,22:56:chronic_disease",Known infection with human immunodeficiency virus (HIV)
3,NCT02037048,"21:30:chronic_disease,36:70:chronic_disease",Patients with known infection with human immunodeficiency virus (HIV) will not be eligible
4,NCT02004275,"15:49:chronic_disease,50:59:chronic_disease",Patients with human immunodeficiency virus (HIV) infection are eligible
5,NCT03175978,21:30:chronic_disease,Active uncontrolled infection or severe systemic infection (enrollment is possible after control of infection)
6,NCT03016130,17:26:chronic_disease,Untreated major infection at presentation
7,NCT03009110,14:23:chronic_disease,Pre-existing infection around incision site
8,NCT02978638,18:27:chronic_disease,Active untreated infection
9,NCT02737202,9:18:chronic_disease,Current infection
10,NCT02641093,1:10:chronic_disease,infection
11,NCT02594111,1:10:chronic_disease,infection (major confounder with increased inflammatory markers)
12,NCT02579967,62:71:chronic_disease,"Life-threatening, organ-threatening, or severely disfiguring infection"
13,NCT02543866,",24:33:chronic_disease",A history at least one infection due to ESC-R Enterobacteriaceae
14,NCT02540330,21:30:chronic_disease,Presence of serious infection
15,NCT02532595,8:17:chronic_disease,Recent infection
16,NCT02520011,30:39:chronic_disease,"Have an active, uncontrolled infection"
17,NCT02518594,",112:121:chronic_disease",Rupture of membranes due to likelihood of pregnancy loss and preterm delivery as well as the risk of ascending infection which could be increased with pessary placement
18,NCT02515110,57:66:chronic_disease,"Unresolved post-surgical complications (eg, significant infection) with healing difficulties"
19,NCT02514083,",,89:98:chronic_disease",Fevers of greater than 100.5 F for greater than or equal to 2 weeks without evidence of infection
20,NCT02514083,",58:67:chronic_disease",Night sweats for more than one month without evidence of infection
21,NCT02490631,9:18:chronic_disease,Current infection
22,NCT02479698,89:98:chronic_disease,Persisting fever without other signs or symptoms will not be interpreted as progressing infection
23,NCT02477423,49:58:chronic_disease,Infant must be considered to have a low risk of infection
24,NCT02469662,61:70:chronic_disease,Patient has a currently active or history of repeated local infection at the surgical site
25,NCT02446236,49:58:chronic_disease,Patients may be eligible upon resolution of the infection
26,NCT02417701,84:93:chronic_disease,"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection"
27,NCT02370693,22:31:chronic_disease,No evidence of acute infection
28,NCT02346526,5:14:chronic_disease,Any infection ? National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 Grade 2
29,NCT02332863,9:18:chronic_disease,Current infection
30,NCT02323581,27:36:chronic_disease,Serious systemic or groin infection
31,NCT02307565,30:39:chronic_disease,Currently have an illness or infection
32,NCT02271711,23:32:chronic_disease,Evidence of untreated infection
33,NCT02135588,27:36:chronic_disease,Active clinically serious infection > CTCAE (version 4.03) Grade 2
34,NCT02108860,20:29:chronic_disease,Evidence of active infection (includes chronic infection)
35,NCT02101736,35:44:chronic_disease,Patients who have an uncontrolled infection
36,NCT02075671,13:22:chronic_disease,Scarring or infection in the area being treated
37,NCT02072148,44:53:chronic_disease,Active clinically significant uncontrolled infection
38,NCT02050347,21:30:chronic_disease,Severe intercurrent infection
39,NCT01940757,"21:30:chronic_disease,",History of previous infection with hookworm or residence for more than 6 months in a hookworm-endemic area
40,NCT01873131,13:22:chronic_disease,Scarring or infection of the area to be treated
41,NCT01614197,",,,77:86:chronic_disease",Fever above 38.2 within 48 hours of study enrollment with clinical signs of infection
42,NCT01554371,40:49:chronic_disease,Severe/uncontrolled concurrent illness/infection
43,NCT01505062,"25:34:chronic_disease,",Intercurrent illness or infection 28 days prior to SAR421869 administration
44,NCT01313533,34:43:chronic_disease,Subject has clinical evidence of infection that the Investigator deems significant to the completion of the procedure or that could compromise the subject's safety
45,NCT01189786,26:35:chronic_disease,"Severe life, threatening infection"
46,NCT01059786,30:39:chronic_disease,Presence of active untreated infection
47,NCT00967785,43:52:chronic_disease,Absence of a documented history of severe infection
48,NCT00906984,21:30:chronic_disease,Active uncontrolled infection
49,NCT00720785,19:28:chronic_disease,Ongoing or active infection
50,NCT00670358,19:28:chronic_disease,Ongoing or active infection
51,NCT02543866,"32:42:allergy_name,47:66:allergy_name",Allergy or hypersensitivity to omeprazole and polyethylene glycol
52,NCT02193191,"45:64:chronic_disease,111:135:treatment","Patients must have confirmed and measurable Sickle Cell Disease, defined by SS or S? thalassemia confirmed by hemoglobin fractionation"
53,NCT02675959,56:75:chronic_disease,Patients must demonstrate one or more of the following Sickle Cell Disease Complications (or patients in Cohort 2 can meet other high risk criteria instead)
54,NCT02562040,1:20:chronic_disease,Sickle Cell Disease
55,NCT01461837,",56:75:chronic_disease",Patients must demonstrate one or more of the following Sickle Cell Disease Complications
56,NCT02574728,"31:62:treatment,66:76:treatment",Currently receiving receiving potent CYP3A4 (enzyme) inducers or inhibitors
57,NCT02374333,"19:36:treatment,165:180:treatment","Concurrent use of systemic steroids at the time of cell infusion or cell collection, or a condition, in the treating physician's opinion, that is likely to require steroid therapy during collection or after infusion"
58,NCT02264236,27:44:treatment,Subjects who have been on systemic steroids will require a 6-week washout period
59,NCT01994382,"16:33:treatment,,",Current use of systemic steroids >20 mg QD prednisone (or equivalent)
60,NCT01474889,70:87:treatment,Receiving treatment for a medical condition requiring chronic use of systemic steroids
61,NCT02429830,"1:5:chronic_disease,30:41:treatment,","GERD symptoms, in absence of PPI therapy (minimum 7 days)"
62,NCT02561988,"14:21:chronic_disease,50:73:treatment",History of a seizure disorder or requirement for anti-seizure medication
63,NCT03176784,12:19:chronic_disease,history of seizure within the last year
64,NCT03093272,32:39:chronic_disease,Medications known to lower the seizure threshold must be discontinued
65,NCT02769000,12:19:chronic_disease,History of seizure activity
66,NCT02480114,12:19:chronic_disease,History of seizure disorder
67,NCT02452008,21:28:chronic_disease,Have a history of a seizure
68,NCT02366754,"23:30:chronic_disease,",Have had a documented seizure within 3 months of study screening
69,NCT02316574,44:51:chronic_disease,"History of severe alcohol withdrawal (e.g. seizure, delirium tremens, multiple detoxifications or ER visits for alcohol withdrawal)"
70,NCT02254863,",108:115:chronic_disease","Three or more of the early clinical markers: problems sleeping, increased activity, behavior difficulties, seizure-like activity, chewing behavior, inappropriate bladder training, inappropriate bowel training"
71,NCT01964261,12:19:chronic_disease,History of seizure
72,NCT01961557,16:23:chronic_disease,A history of a seizure in the past year
73,NCT01915095,81:88:chronic_disease,"Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold (see appendix 2)"
74,NCT01882153,",41:48:chronic_disease","medically unstable (e.g., more than one seizure a month)"
75,NCT01434316,"21:28:chronic_disease,",Patients with prior seizure history who have experienced a seizure within the three months prior to enrollment
76,NCT00739362,42:49:chronic_disease,Personal or first-degree relative with a seizure history
77,NCT02515110,"27:47:treatment,51:62:treatment",History of ipsilateral or contralateral breast or thoracic RT for any condition
78,NCT01953588,"30:50:cancer,",Mammogram for the unaffected contralateral breast is required within 12 months prior to registration
79,NCT02478255,"30:41:treatment,",Patient scheduled to undergo thoracic RT at Duke University to a dose of at least 20 Gy
80,NCT02323880,"1:33:treatment,,61:90:treatment",Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent
81,NCT01994538,"1:10:treatment,29:58:treatment","Treatment initiated with an empiric antimicrobial regimen that is underdosed, based on current guidelines and reviews"
82,NCT02574910,1:10:treatment,Treatment with growth hormone at enrollment or during the course of the study
83,NCT02477839,",105:114:treatment","device settings must be kept stable for >=2 weeks prior to Visit 1 and kept stable during the Baseline, Treatment, and Transition Periods"
84,NCT02453373,"1:10:treatment,",Treatment must be initiated within 8 hours from known time of symptom onset
85,NCT02414139,11:20:treatment,Cohort 5: Treatment-naïve patients with cMET dysregulation
86,NCT02346526,1:10:treatment,Treatment should be completed for spinal cord compression
87,NCT02336217,1:10:treatment,Treatment by Marshall Internal Medicine Department
88,NCT02130687,"1:10:treatment,",Treatment with any investigational drug in the 1 month preceding the study
89,NCT01584076,"1:10:treatment,",Treatment with topical atropine within the past 4 weeks
90,NCT00147056,",70:79:treatment,,",Size of the targeted portion of the tumor (i.e. prescribed Region Of Treatment) is less than 2.5 cm in diameter or 8 cm3 in volume
91,NCT03058146,"14:20:cancer,,53:77:cancer",treatment of cancer in the past 2 years (other than non-melanoma skin cancer)
92,NCT02945969,"12:18:cancer,30:54:cancer,",History of cancer other than non-melanoma skin cancer within two years prior to enrollment based on patient self-report
93,NCT02695433,"13:19:cancer,31:55:cancer,",Have or had cancer other than non-melanoma skin cancer in past 5 years
94,NCT02359864,"30:36:cancer,44:68:cancer",The patient has a history of cancer except non-melanoma skin cancer
95,NCT01365169,"16:22:cancer,35:59:cancer","History of any cancer, other than non-melanoma skin cancer (Arm 4)"
96,NCT03187951,11:17:cancer,Recurrent cancer following prior resection
97,NCT03181750,109:115:cancer,Meeting medium to high risk for death at 1 year using the CARING criteria (although excluding patients with cancer diagnosis)
98,NCT03174379,8:14:cancer,active cancer
99,NCT03146663,"48:54:cancer,",Patients who have a history of another type of cancer diagnosed within the past 5 years
100,NCT03135171,",,,89:95:cancer",Eastern Cooperative Oncology Group Performance Status of 0 or 1 (An attempt to quantify cancer patients' general well-being and activities of daily life
101,NCT03108820,35:41:cancer,have a self-reported diagnosis of cancer with short life expectancy
102,NCT03087903,"20:26:cancer,",History of another cancer is exclusionary unless it is believed to be likely cured or is unlikely to be fatal in the next 3 years
103,NCT03070535,27:33:cancer,"Remote history of treated cancer is ok, as long as current cognition and digestion are not affected"
104,NCT03059888,26:32:cancer,Subject has a history of cancer in the last 5 years
105,NCT03058029,"12:18:cancer,",History of cancer within the past five(5) years
106,NCT03043742,"13:19:cancer,","Untreatable cancer, current or within preceding 5 years"
107,NCT03042689,",,,,137:143:cancer",Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN (? 5 x ULN for subjects with liver involvement of their cancer)
108,NCT03042689,",,,104:110:cancer",Alkaline phosphatase limit ? 2.5 x ULN (? 5 x ULN for subjects with liver or bone involvement of their cancer)
109,NCT03042689,"22:28:cancer,",Subjects surviving a cancer that was curatively treated and without evidence of disease for more than 3 years before registration are allowed
110,NCT03040726,14:20:cancer,Diagnosis of cancer
111,NCT03037385,11:17:cancer,Patient's cancer has a known primary driver alteration other than RET
112,NCT03035773,11:17:cancer,"Had their cancer care primarily managed by either JHMI or PRMC, with JHMI or PRMC primarily responsible for the patients' survivorship care"
113,NCT03030859,16:22:cancer,No evidence of cancer (NED)
114,NCT03030859,18:24:cancer,any other active cancer
115,NCT03029442,22:28:cancer,Current diagnosis of cancer or history of cancer
116,NCT03006913,32:38:cancer,don't have a family history of cancer
117,NCT02986152,26:32:cancer,Have been diagnosed with cancer or are/were a caregiver to someone with cancer
118,NCT02963831,33:39:cancer,Previously treated for advanced cancer with no additional therapy options available known to prolong survival
119,NCT02939755,58:64:cancer,a spouse or cohabitating intimate partner of an advanced cancer patient being evaluated at the UPMC's LCC
120,NCT02937272,67:73:cancer,The participant must have histological or cytological evidence of cancer
121,NCT02932748,30:36:cancer,"Serious medical risk such as cancer, recent cardiac event"
122,NCT02916472,26:32:cancer,histologically confirmed cancer
123,NCT02914171,16:22:cancer,history of any cancer
124,NCT02911831,57:63:cancer,Patients currently undergoing treatment for any type of cancer
125,NCT02911792,12:18:cancer,History of cancer
126,NCT02881242,",50:56:cancer",Hospitalization within 30 days of enrollment for cancer related events
127,NCT02869789,110:116:cancer,Physically able to carry out light housework or office work through to being fully active as you were before cancer
128,NCT02865135,"7:13:cancer,",Other cancer in the past 5 years
129,NCT02836574,"12:18:cancer,",history of cancer within the past 3 years
130,NCT02826577,20:26:cancer,Medical history of cancer
131,NCT02802787,",22:28:cancer",Women diagnosed with cancer
132,NCT02793921,20:26:cancer,Prior diagnoses of cancer
133,NCT02791646,",52:58:cancer",current or past (<6 months) engagement in PCST for cancer
134,NCT02786251,"9:15:cancer,",Current cancer or cancer that has been in remission for < 5 years
135,NCT02753283,",106:112:cancer",We will suggest that participants stop long-term calcitonin as it has been discontinued in Europe due to cancer concerns
136,NCT02746458,22:28:cancer,Current diagnosis of cancer
137,NCT02724930,14:20:cancer,Diagnosis of cancer
138,NCT02663622,",,,40:46:cancer,",Karnofsky >70% (an attempt to quantify cancer patients' general well-being and activities of daily life. The score ranges from 0 to 100 where 100 is perfect health and 0 is death.)
139,NCT02657993,6:12:cancer,Past cancer
140,NCT02656550,"28:34:cancer,",Subject who has history of cancer in last five years
141,NCT02639065,"7:13:cancer,",other cancer for which the subject has been disease-free for at least 3 years
142,NCT02607033,8:14:cancer,Active cancer
143,NCT02584647,78:84:cancer,Disease site/type with pathologic confirmation of diagnosis at participating cancer site
144,NCT02584244,17:23:cancer,Subjects at any cancer stage will be enrolled
145,NCT02580981,23:29:cancer,Not willing to obtain cancer care at the University of New Mexico
146,NCT02578641,24:30:cancer,Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study
147,NCT02578641,"5:11:cancer,",any cancer curatively treated >3 years prior to study entry
148,NCT02576444,13:19:cancer,Progressive cancer at the time of study entry
149,NCT02568267,27:33:cancer,History of other previous cancer that would interfere with the determination of safety or efficacy
150,NCT02563574,30:36:cancer,Unstable medical conditions (cancer)
151,NCT02535832,8:14:cancer,Active cancer
152,NCT02505165,32:38:cancer,The child is being treated for cancer and returning to the medical center (CCHMC or OUHSC)
153,NCT02502006,"12:18:cancer,",History of cancer within the last 5 years
154,NCT02494869,64:70:cancer,Clinical breast exam interpreted as benign (not suspicious for cancer) at MSK
155,NCT02494869,10:16:cancer,Invasive cancer diagnosis
156,NCT02474368,37:43:cancer,Participants must have a pathologic cancer diagnosis
157,NCT02467478,"12:18:cancer,",History of cancer within the past 5 years
158,NCT02465541,26:32:cancer,Prior diagnosis of other cancer
159,NCT02460835,",,122:128:cancer,,",Zubrod performance status of less than or equal to 2 (Zubrod performance status is a measure that attempts to quantify a cancer patients' general well-being. Scores run from 0 to 5 where 0 denotes normal activity and 5 denotes death)
160,NCT02459769,62:68:cancer,"For caregivers, be currently undergoing active treatment for cancer"
161,NCT02459769,25:31:cancer,Have had a diagnosis of cancer
162,NCT02459769,1:7:cancer,cancer survivors
163,NCT02459119,"22:28:cancer,",Subjects surviving a cancer that was curatively treated and without evidence of disease for more than 3 years before randomization
164,NCT02436070,9:15:cancer,Current cancer diagnosis
165,NCT02413047,"5:11:cancer,",Any cancer within the past 5 years
166,NCT02408406,28:34:cancer,Malignant diagnosis in any cancer type at any stage
167,NCT02406885,"12:18:cancer,",History of cancer (within the last year)
168,NCT02406599,49:55:cancer,Multi-centric disease (histologically diagnosed cancer in two different quadrants of the breast)
169,NCT02389465,22:28:cancer,Current diagnosis of cancer
170,NCT02367196,"16:22:cancer,,","Prior systemic cancer-directed treatments or investigational modalities ? 5 half lives or 4 weeks prior to starting CC-90002, whichever is shorter"
171,NCT02366611,49:55:cancer,Patients are actively being treated for another cancer at the time of enrollment
172,NCT02360579,16:22:cancer,Patients whose cancer requires immediate attention or who would otherwise suffer a disadvantage by participating in this trial
173,NCT02356861,48:54:cancer,Presence of a life-threatening disease such as cancer
174,NCT02347995,8:14:cancer,active cancer
175,NCT02339948,"20:26:cancer,,","2002 AJCC clinical cancer stage as determined by either urologist or radiation oncologist must be T1c - T2b, N0, M0"
176,NCT02332928,45:51:cancer,Fatigue brought on by conditions other than cancer
177,NCT02312245,97:103:cancer,Willing to agree to periodic contact with a member of the study team during the period that the cancer has not recurred and/or has not become platinum resistant
178,NCT02258438,1:7:cancer,cancer
179,NCT02219711,14:20:cancer,Other active cancer
180,NCT02217345,12:18:cancer,History of cancer
181,NCT02178709,"5:11:cancer,",Any cancer curatively treated >3 years prior to entry with no clinical evidence of recurrence
182,NCT02169830,15:21:cancer,Patients with cancer
183,NCT02161380,"34:40:cancer,",Patients with a prior history of cancer will need documentation from their cancer specialist that the cancer was cured at least 5 years before study entry
184,NCT02139436,1:7:cancer,cancer
185,NCT02138214,33:39:cancer,Failure to confirm diagnosis of cancer in participant
186,NCT02129348,38:44:cancer,past history of successfully treated cancer
187,NCT02081404,13:19:cancer,Presence of cancer or mass lesion in the esophagus or stomach
188,NCT02081404,"21:27:cancer,,",recent diagnosis of cancer with a life-expectancy < 5 years
189,NCT02048722,",,,98:104:cancer",Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
190,NCT02013492,32:38:cancer,the first 10 patients may have cancer of any histology
191,NCT01983475,22:28:cancer,Current diagnosis of cancer
192,NCT01983475,12:18:cancer,history of cancer
193,NCT01918644,"14:20:cancer,",any invasive cancer in the last 5 years
194,NCT01851369,"11:17:cancer,",Any other cancer from which the patient has been disease-free for three years
195,NCT01836354,"25:31:cancer,","Patients with end stage cancer, or other medical conditions resulting in mortality less than 1 year"
196,NCT01804465,11:17:cancer,Any other cancer from which the patient has been disease-free for 5 years
197,NCT01684904,"4:10:cancer,",he cancer may involve the stomach up to 5 cm
198,NCT01684397,"33:39:cancer,",Subjects diagnosed with another cancer in the past 3 years
199,NCT01365169,110:116:cancer,"During clinician's pre-surgical evaluation, presents with high risk for non-therapeutic resection related to cancer diagnosis (PCS study)"
200,NCT01306019,83:89:cancer,previously diagnosed known genotype of the subject conferring a predisposition to cancer (no DNA or other testing for cancer predisposition genes will be performed as part of the screen for this protocol)
201,NCT01239095,15:21:cancer,Patients with cancer judged to be stage 4 are not eligible
202,NCT01238120,29:35:cancer,Have a primary diagnosis of cancer
203,NCT00906984,5:11:cancer,The cancer must be unresectable
204,NCT00819208,143:149:cancer,"Able (i.e., sufficiently fluent) and willing to effectively communicate with the physical activity consultant affiliated with the originating cancer center"
205,NCT00579514,70:76:cancer,Patients of Ashkenazi Jewish ancestry with a histologic diagnosis of cancer of any type
206,NCT02807272,1:25:cancer,non-melanoma skin cancer
207,NCT02579096,1:25:cancer,non-melanoma skin cancer
208,NCT02501954,1:25:cancer,non-melanoma skin cancer
209,NCT02493530,1:25:cancer,non-melanoma skin cancer
210,NCT02273375,20:44:cancer,adequately treated non-melanoma skin cancer
211,NCT02268253,1:25:cancer,non-melanoma skin cancer
212,NCT02257424,48:72:cancer,Subjects with a history of completely resected non-melanoma skin cancer
213,NCT02237183,1:25:cancer,non-melanoma skin cancer
214,NCT02176161,20:44:cancer,adequately treated non-melanoma skin cancer
215,NCT02152995,48:72:cancer,patients with a history of completely resected non-melanoma skin cancer
216,NCT01676259,20:44:cancer,adequately treated non-melanoma skin cancer
217,NCT02515110,"27:29:chronic_disease,33:43:chronic_disease",Clinical nodal staging of N2 or N3 disease
218,NCT02582957,"44:62:treatment,77:81:chronic_disease",Treating physicians being unwilling to use low VT ventilation strategy when ARDS is diagnosed as low VT ventilation is now considered standard of care for patients with ARDS
219,NCT02334865,"14:30:treatment,34:65:treatment",Patients had prior autologous or allogeneic stem cell transplant
220,NCT02939183,24:55:treatment,Previously received an allogeneic stem cell transplant
221,NCT02845596,7:38:treatment,Prior allogeneic stem cell transplant
222,NCT02670044,16:47:treatment,Ineligible for allogeneic stem cell transplant
223,NCT02576444,33:64:treatment,Patients must not have received allogeneic stem cell transplant
224,NCT02367196,"7:38:treatment,",Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ? 6 months prior to starting CC-90002
225,NCT02309580,"29:60:treatment,",Patients who have undergone allogeneic stem cell transplant > 12 months
226,NCT02035137,18:49:treatment,They have had an allogeneic stem cell transplant (received stem cell from someone else)
227,NCT01966367,92:123:treatment,Requirement for CD34+ stem cell selection for a second infusion of stem cells following an allogeneic stem cell transplant from a related or unrelated adult donor
228,NCT01877382,"8:29:treatment,,58:78:treatment",Had an autologous transplant within 3 months of starting study drug treatment
229,NCT01660607,15:36:treatment,Candidate for autologous transplant
230,NCT02923921,",80:110:chronic_disease,112:135:chronic_disease","Clinically significant bleeding within two weeks prior to randomization (e.g., gastrointestinal (GI) bleeding, intracranial hemorrhage)"
231,NCT03042767,9:39:chronic_disease,Current gastrointestinal (GI) bleeding
232,NCT03063892,12:35:chronic_disease,History of intracranial hemorrhage
233,NCT02342444,13:36:chronic_disease,Presence of intracranial hemorrhage
234,NCT02169739,10:33:chronic_disease,Previous intracranial hemorrhage
235,NCT02092324,1:24:chronic_disease,intracranial hemorrhage
236,NCT02053909,12:35:chronic_disease,History of intracranial hemorrhage
237,NCT01967823,15:38:chronic_disease,No history of intracranial hemorrhage
238,NCT02512926,"31:41:cancer,45:59:cancer",Patients may not have primary CNS tumors or CNS metastases
239,NCT02304458,"15:25:cancer,35:49:cancer",Patients with CNS tumors or known CNS metastases
240,NCT03178552,24:38:cancer,"Symptomatic, untreated CNS metastases"
241,NCT03069469,14:28:cancer,Known active CNS metastases
242,NCT02310464,57:71:cancer,"Subjects with known or clinically manifest, symptomatic CNS metastases in Dose Escalation Phase"
243,NCT02304458,28:42:cancer,patients with a history of CNS metastases that have been previously treated may enroll if sequential imaging shows not evidence for active disease
244,NCT02057133,11:25:cancer,Untreated CNS metastases
245,NCT01976585,7:21:cancer,Known CNS metastases
246,NCT01968109,14:28:cancer,Uncontrolled CNS metastases
247,NCT01697371,1:15:cancer,CNS metastases
248,NCT01453088,14:28:cancer,Uncontrolled CNS metastases
249,NCT01366612,14:28:cancer,Uncontrolled CNS metastases
250,NCT00412594,13:27:cancer,Presence of CNS metastases
251,NCT02013154,",23:29:cancer,115:127:cancer",Must have one or more tumors measurable on radiographic imaging as defined by the Response Evaluation Criteria in Solid Tumors (RECIST). Patients with evaluable but not measurable disease per RECIST criteria may be enrolled with the approval of the medical monitor
252,NCT03109041,34:40:cancer,Recurrent or previously resected tumors
253,NCT02519322,12:18:cancer,"resectable tumors are defined as having no significant vascular, neural or bony involvement"
254,NCT02490631,15:21:cancer,Patients with tumors
255,NCT02451423,30:36:cancer,Presence of PD-L1 antigen on tumors is NOT required for study entry
256,NCT02451215,",,59:65:cancer",Tumor volume less than 10 cm3 is mandatory for high grade tumors
257,NCT02442297,"20:26:cancer,,,,",HER2 expression in tumors on IHC should be greater than or equal to grade 1 and greater than or equal to 1+ intensity score
258,NCT02373644,1:7:cancer,tumors
259,NCT02324608,"131:137:cancer,","Patients must have untreated or relapsed SCCS that is considered to be aggressive and locally advanced by the following criteria: tumors 2 cm or more, tumors invading deep tissues such as muscle, cartilage or bone; tumors showing perineural invasion, and/or tumors metastatic to loco-regional lymph nodes; patients may have had prior surgical interventions or been treated with investigational agents with residual or recurrent disease"
260,NCT02312245,23:29:cancer,Prior consent to have tumors used for unspecified future research
261,NCT02271711,40:46:cancer,patient must have presented with these tumors in the posterior fossa (PF) or relapsed in the PF
262,NCT02213497,23:29:cancer,Patients with primary tumors located at or above the carina
263,NCT02176967,30:36:cancer,Patients with MYCN amplified tumors
264,NCT02124902,19:25:cancer,Patients with PR+ tumors are allowed
265,NCT02124772,25:31:cancer,Measurable or evaluable tumors
266,NCT02085941,19:25:cancer,"Participants with tumors involving the optic chiasm, brain, or spinal cord"
267,NCT02085941,1:7:cancer,"tumors that encase any major blood vessel (carotid, jugular, vertebral)"
268,NCT02079181,18:24:cancer,"Have one or more tumors visualized by conventional PET-CT, CT or magnetic resonance imaging (MRI) prior to the PET FMAU study"
269,NCT01734512,35:41:cancer,Patients with primary spinal cord tumors
270,NCT01591356,49:55:cancer,this may be one of the lesions mentioned above; tumors within a previously irradiated field will be designated as 'non-target' lesions
271,NCT01351103,15:21:cancer,patients with tumors of any histological origin with documented genetic alterations upstream in the Wnt signaling pathway (e.g. RNF43 or RSPO fusion) are eligible with prior agreement with Novartis
272,NCT01351103,1:7:cancer,tumors of any histological origin with documented genetic alterations upstream in the Wnt signaling pathway are eligible with prior agreement with Novartis
273,NCT01037790,5:11:cancer,All tumors must test positive for Rb expression
274,NCT03123783,"29:40:chronic_disease,55:70:treatment",History of (non-infectious) pneumonitis that required corticosteroids or current pneumonitis
275,NCT02530463,12:23:chronic_disease,History of pneumonitis
276,NCT02112565,42:53:chronic_disease,Patients with a history of noninfectious pneumonitis will be excluded during the dose-escalation phase of the trial
277,NCT02441140,"4:22:chronic_disease,36:64:cancer",No measurable disease or suspected Stage I or II ovarian cancer on preoperative imaging
278,NCT03153410,20:38:chronic_disease,Patients must have measurable disease
279,NCT02562716,20:38:chronic_disease,Patients must have measurable disease in the pancreas
280,NCT02542657,20:38:chronic_disease,Patients must have measurable disease according to International Myeloma Working Group (IMWG) criteria
281,NCT02487095,20:38:chronic_disease,"Patients must have measurable disease, per RECIST 1.1. Subjects with evaluable, but not measurable disease will be eligible for Phase 1"
282,NCT02452268,14:32:chronic_disease,"Evaluable or measurable disease, defined as by Response Evaluation Criteria in Solid Tumors (RECIST)"
283,NCT02452008,6:24:chronic_disease,Have measurable disease
284,NCT02437370,6:24:chronic_disease,Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
285,NCT02419495,11:29:chronic_disease,must have measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
286,NCT02401347,5:23:chronic_disease,Non-measurable disease only
287,NCT02383927,13:31:chronic_disease,Subject has measurable disease according to RECIST v1.1
288,NCT02343042,20:38:chronic_disease,Patients must have measurable disease
289,NCT02128906,20:38:chronic_disease,Patients must have measurable disease according to RECIST 1.1
290,NCT01876511,6:24:chronic_disease,Have measurable disease
291,NCT00914823,"18:29:treatment,34:61:treatment",seasonal allergy medications and hormone replacement therapy
292,NCT03179163,",42:69:treatment",Women are post-menopausal and not taking hormone replacement therapy
293,NCT02582905,",25:52:treatment",Oral contraceptives and hormone replacement therapy
294,NCT02467478,",34:61:treatment",post-menopausal women who are on hormone replacement therapy
295,NCT02322203,",,51:78:treatment,",Female subjects taking hormonal contraceptives or hormone replacement therapy may be included in this study only if they have been on a stable dose for at least 3 months
296,NCT02172651,",10:37:treatment,,",women on hormone replacement therapy with documented serum follicle stimulating hormone level >35 mIU/mL)
297,NCT01883258,",29:56:treatment",postmenopausal women taking hormone replacement therapy
298,NCT01591356,17:44:treatment,continuation of hormone replacement therapy is permitted
299,NCT01538966,116:143:treatment,"The patient has had appropriate dynamic testing of the pituitary axis and, if applicable, is receiving appropriate hormone replacement therapy"
300,NCT02982226,18:29:treatment,has receive such medications during the screening period
301,NCT02819440,"8:19:treatment,",Use of medications that strongly alter CYP3A4 activity
302,NCT02549937,15:26:treatment,Currently use medications known to cause QT prolongation or Torsades de Pointes
303,NCT02547818,18:29:treatment,Currently taking medications that could lead to difficulty complying with the protocol
304,NCT02547818,"24:35:treatment,",Stability of permitted medications for 4 weeks prior to study start
305,NCT02543944,54:65:allergy_name,report having had a severe adverse reaction to study medications
306,NCT02536794,"31:42:treatment,",patients must be off any such medications by the time of registration for at least 2 weeks
307,NCT02535169,"8:19:treatment,,,",use of medications that adversely affect glucose metabolism (such as glucocorticoid-containing medications or atypical antipsychotics)
308,NCT02519322,36:47:treatment,Any of the following procedures or medications
309,NCT02514070,25:36:treatment,Subjects initiating new medications or patients on multiple medications may also be excluded according to investigator discretion
310,NCT02508311,74:85:treatment,Use or are suspected of using over-the counter supplements or prescribed medications with anabolic characteristics (promotes improvements to muscle mass and strength)
311,NCT02498301,",94:105:treatment",Subject is currently taking or plans to take during deployment at least one of the following medications
312,NCT02495168,32:43:treatment,"Able to continue the following medications without a significant adjustment of dosage, formulation, dosing interval for the duration of the study"
313,NCT02487082,158:169:treatment,Drugs that induce or inhibit cytochrome P450 2D6 and cytochrome P450 3A4 (enzymes important for drug metabolism) will be allowed because any effects of such medications are likely to be lost in individual variability due to genetic polymorphisms
314,NCT02484300,12:23:treatment,Use of any medications that may affect sleep or breathing
315,NCT02481310,55:66:treatment,"Patients who have a known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent"
316,NCT02481245,22:33:treatment,Agrees not to change medications during the study
317,NCT02473250,51:62:treatment,History of clinical deterioration when any of the medications that the patient is taking at presentation have been discontinued in the past with the exception of any medications that will be continued during the research protocol
318,NCT02413047,28:39:treatment,Previous noncompliant with medications
319,NCT02411318,18:29:treatment,Currently taking medications that are not recommended to be taken in conjunction with alcohol
320,NCT02410954,"8:19:treatment,",Use of medications known to affect Central Nervous System (CNS) function within 5 half-lives screening
321,NCT02401347,19:30:treatment,Able to take oral medications
322,NCT02371720,"47:58:treatment,",Patients receiving automatic home delivery of medications since medication possession ratio is reflective of the patient initiation the refill when they have exhausted the home supply of HU
323,NCT02354703,"8:19:treatment,,","Taking medications (within the last 7 days prior to the Baseline Visit) that have the potential to prolong the QT interval, as judged by a study physician, or may require such medications during the course of the study"
324,NCT02265874,"16:27:treatment,",Doses of these medications must be stable for at least 1 month before study entry
325,NCT02252432,57:68:allergy_name,"Intolerance, allergy, or contraindication to use of any medications used in this study"
326,NCT02233868,18:29:treatment,chronically used medications are exclusionary from the study
327,NCT02213575,"135:146:treatment,","unwilling to discontinue vitamin or supplements, including probiotics, potentially affecting gut microbiota (vitamins/supplements and medications that possibly affect the gut microbiota should be discontinued for at least 2wks prior to stool collection)"
328,NCT02203513,",85:96:treatment",Patients must be at least 1 week from the last dose of complementary or alternative medications
329,NCT02201992,11:22:treatment,"No use of medications, herbals, or foods that are known potent cytochrome P450, subfamily 3A, polypeptide 4 (CYP3A4) inhibitors or inducers, included but not limited to those outlined"
330,NCT02192359,15:26:treatment,Use of herbal medications
331,NCT02165449,24:35:treatment,"Psychotic reactions to medications, alcohol or illicit substances in the past"
332,NCT02159027,44:55:treatment,Anticipated need for specific prescription medications
333,NCT02143726,13:24:treatment,Concomitant medications
334,NCT02059239,106:117:treatment,History of allergic reactions attributed to compounds of similar chemical or biologic composition to any medications listed in the protocol
335,NCT02056873,36:47:treatment,Must be willing to keep TS related medications stable and unchanged throughout the trial
336,NCT02047721,"1:12:treatment,,","medications affecting weight, Energy Intake (EI) or Energy Expenditure (EE) in the last 6 months"
337,NCT02001142,8:19:treatment,taking medications know to affect lipid and/or glucose metabolism
338,NCT01943851,",,,,127:138:treatment","In addition, male subjects whose partners are or become pregnant must continue to use condoms for 7 days after stopping study medications"
339,NCT01943851,"33:44:treatment,",This includes excluding current medications known or suspected to be associated QT prolongation
340,NCT01896921,69:80:treatment,Subject requires or is anticipated to require any of the prohibited medications noted in the protocol
341,NCT01684397,45:56:treatment,Unable to discontinue the use of prohibited medications
342,NCT01620216,"24:35:treatment,",Discontinuation of any medications known to contribute significantly to the risk of QT prolongation
343,NCT01532687,54:65:treatment,Unable or unwilling to discontinue use of prohibited medications
344,NCT01500551,53:64:treatment,The subject has discontinued disallowed concomitant medications for the required time prior to the first dose of study drug
345,NCT01438073,"4:15:treatment,",no medications known to affect reproductive endocrine function for at least 2 months except for medications used to treat the subject's reproductive condition
346,NCT01200940,7:18:treatment,Other medications may be permitted at the discretion of the investigators
347,NCT00914823,1:12:treatment,medications used to treat the subject's reproductive condition
348,NCT00914823,"17:28:treatment,",no prescription medications for at least 2 months
349,NCT00914823,"17:28:treatment,",no prescription medications known to affect reproductive endocrine function for at least 2 months
350,NCT02772562,"14:20:cancer,31:47:treatment,",Diagnosis of cancer requiring systemic therapy in the past 5 years
351,NCT03137771,",103:119:treatment",Patients must be registered within 35 days of administration of the last dose of first-line/induction systemic therapy
352,NCT02990481,72:88:treatment,"Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy"
353,NCT02807272,",32:48:treatment",At least 1 week since the last systemic therapy regimen prior to Cycle 1 Day 1
354,NCT02417701,",55:71:treatment",Patients must have completed at least 1 prior line of systemic therapy
355,NCT02309580,",41:57:treatment",Relapse or progression after at least 1 systemic therapy
356,NCT01670877,56:72:treatment,There is no limitation on the number of prior lines of systemic therapy
357,NCT02341287,",,,144:160:treatment,168:178:treatment","Have difficulty initiating sleep for at least two-weeks, including a sleep latency of at least 30-minutes, three days per week (as measured by wrist actigraphy and/or sleep logs)"
358,NCT02965638,"1:13:chronic_disease,17:31:chronic_disease",Fetal mitral or aortic atresia
359,NCT03157713,"1:7:chronic_disease,",stroke in the past 6 mo
360,NCT03152409,12:18:chronic_disease,History of stroke
361,NCT03123731,1:7:chronic_disease,stroke
362,NCT03120728,12:18:chronic_disease,history of stroke
363,NCT03113825,"7:13:chronic_disease,",Hx of stroke within 1 year
364,NCT03108950,16:22:chronic_disease,Diagnosed with stroke
365,NCT03105700,12:18:chronic_disease,History of stroke
366,NCT03096288,1:7:chronic_disease,stroke
367,NCT03056287,",47:53:chronic_disease",Unable to ambulate at least 150 feet prior to stroke
368,NCT03028012,1:7:chronic_disease,stroke
369,NCT03023449,",43:49:chronic_disease",Study can be initiated within 72 hours of stroke symptom onset
370,NCT02964039,17:23:chronic_disease,Experience of a stroke 6 months prior to participation
371,NCT02926378,",,,,165:171:chronic_disease",Participants must have experienced a left Cerebrovascular Accident (CVA) at least one year prior to study participation and the injury timeframe is 1-10 years post stroke
372,NCT02918175,17:23:chronic_disease,"Impairment from stroke, injury or other medical disorder that precludes participation in the intervention"
373,NCT02907983,1:7:chronic_disease,stroke
374,NCT02806570,"12:18:chronic_disease,",History of stroke within the prior 3 months
375,NCT02769000,56:62:chronic_disease,Clinically or radiographically significant evidence of stroke
376,NCT02737930,51:57:chronic_disease,Current use of a medication likely to impair post-stroke recovery
377,NCT02680574,"1:7:chronic_disease,",stroke within 12 weeks prior to or during Screening
378,NCT02667392,14:20:chronic_disease,Diagnosis of stroke
379,NCT02637947,"26:32:chronic_disease,",subject has a history of stroke within 1 month prior to enrollment
380,NCT02596776,10:16:chronic_disease,previous stroke
381,NCT02588664,",,54:60:chronic_disease",Must be 18 years of age and older at the time of the stroke
382,NCT02577406,1:7:chronic_disease,stroke
383,NCT02570256,"15:21:chronic_disease,",Chronic stage stroke recovery (8+ months post)
384,NCT02570256,40:46:chronic_disease,healthy individuals with no history of stroke or neural injury
385,NCT02565407,",25:31:chronic_disease",at least 3 months after stroke
386,NCT02551679,7:13:chronic_disease,Major stroke
387,NCT02533882,16:22:chronic_disease,Diagnosed with stroke
388,NCT02521818,12:18:chronic_disease,history of stroke
389,NCT02471833,12:18:chronic_disease,History of stroke
390,NCT02465034,31:37:chronic_disease,Individuals with a first time stroke that affects the corona radiata and/or internal capsule
391,NCT02457832,12:18:chronic_disease,History of stroke
392,NCT02453373,",,42:48:chronic_disease",Patients receiving IV tPA > 3 hours from stroke onset
393,NCT02451683,27:33:chronic_disease,History of head injury or stroke
394,NCT02445768,",24:30:chronic_disease",at least 6 months post-stroke
395,NCT02445768,27:33:chronic_disease,having ever experienced a stroke
396,NCT02366871,8:14:chronic_disease,recent stroke
397,NCT02359253,"7:13:chronic_disease,,",Had a stroke 1-12 months prior to enrollment
398,NCT02355912,1:7:chronic_disease,stroke
399,NCT02332291,1:7:chronic_disease,stroke
400,NCT02301546,18:24:chronic_disease,History of major stroke
401,NCT02299414,7:13:chronic_disease,Prior stroke
402,NCT02189889,"12:18:chronic_disease,",history of stroke within the last 6 months
403,NCT02186418,144:150:chronic_disease,"weaning transfusions is necessary, so that a selective pressure on gene-modified red blood cells is evident, and this will place subjects with stroke risk at risk for a recurrent stroke"
404,NCT02169739,"11:17:chronic_disease,,",Disabling stroke (Rankin Scale ?4)
405,NCT02165007,1:7:chronic_disease,stroke
406,NCT02033941,35:41:chronic_disease,History of clinically significant stroke
407,NCT02008136,8:14:chronic_disease,recent stroke
408,NCT01954966,12:18:chronic_disease,history of stroke or other medical conditions that the physician investigator deems as contraindicated for the patient to be in the study
409,NCT01948739,32:38:chronic_disease,No previous clinically defined stroke
410,NCT01807897,7:13:chronic_disease,"Prior stroke with functional impairment or other severe, uncontrolled medical problems that may impair ability to participate in the study exams, based on medical history and review of medical records"
411,NCT01801072,18:24:chronic_disease,History of prior stroke
412,NCT01686373,",45:51:chronic_disease",Patients must be greater than 6-months post-stroke
413,NCT01600131,56:62:chronic_disease,All caregivers of Veterans with a primary diagnosis of stroke
414,NCT01600131,"75:81:chronic_disease,,",provide the majority of care for a Veteran who has a primary diagnosis of stroke (ICD9 codes for stroke: 430-438)
415,NCT00903266,31:37:chronic_disease,active participation in other stroke recovery trials testing experimental interventions
416,NCT00903266,",13:19:chronic_disease",more than 1 stroke
417,NCT00903266,24:30:chronic_disease,right-handed (prior to stroke)
418,NCT00678145,1:7:chronic_disease,stroke
419,NCT00065676,1:7:chronic_disease,stroke
420,NCT03126110,21:39:cancer,Locally advanced or metastatic disease
421,NCT03096418,24:42:cancer,Patients must not have metastatic disease on staging work-up with CBC and liver function studies
422,NCT03085095,36:54:cancer,Newly diagnosed androgen-sensitive metastatic disease
423,NCT03042897,15:33:cancer,Patients with metastatic disease
424,NCT02997709,15:33:cancer,Patients with metastatic disease are encouraged to participate
425,NCT02977468,42:60:cancer,"Clinically node negative, no evidence of metastatic disease"
426,NCT02885649,16:34:cancer,"No evidence of metastatic disease on baseline imaging (chest x-ray [CXR] or chest CT, abdominal CT or MRI)"
427,NCT02876302,43:61:cancer,Extensive nodal involvement is defined as metastatic disease involving any nodal region outside of the involved breast
428,NCT02876302,23:41:cancer,Patients with minimal metastatic disease involvement in bone or viscera are allowed
429,NCT02843945,23:41:cancer,Patient does not have metastatic disease
430,NCT02680535,1:19:chronic_disease,metastatic disease
431,NCT02641093,11:29:cancer,Confirmed metastatic disease
432,NCT02578732,15:33:cancer,Patients with metastatic disease
433,NCT02562716,16:34:cancer,No evidence of metastatic disease
434,NCT02544880,9:27:chronic_disease,Distant metastatic disease
435,NCT02515110,53:71:chronic_disease,Known definitive clinical or radiologic evidence of metastatic disease
436,NCT02502708,15:33:cancer,Patients with metastatic disease are eligible for enrollment
437,NCT02488967,"47:65:cancer,",Definitive clinical or radiologic evidence of metastatic disease; required imaging studies must have been performed within 90 days prior to randomization
438,NCT02479230,32:50:cancer,Patients must have evidence of metastatic disease measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria or non-measurable lytic or mixed (lytic + blastic) bone lesions in the absence of measurable disease
439,NCT02474368,25:43:cancer,Cohort 2 (patients with metastatic disease with targetable lesions within the head and neck)
440,NCT02473536,15:33:cancer,Any number of metastatic disease is allowed in the Pilot phase of the trial
441,NCT02466009,12:30:chronic_disease,Measurable metastatic disease
442,NCT02456857,13:31:cancer,Presence of metastatic disease
443,NCT02427581,7:25:cancer,Known metastatic disease
444,NCT02423863,"52:70:cancer,",Radiologically or visually measurable recurrent or metastatic disease that is measurable and at least 10mm in longest dimension
445,NCT02353819,13:31:cancer,Evidence of metastatic disease by imaging study
446,NCT02349867,13:31:cancer,Evidence of metastatic disease
447,NCT02324582,37:55:cancer,Currently has active or progressive metastatic disease
448,NCT02315196,47:65:cancer,Definitive clinical or radiologic evidence of metastatic disease
449,NCT02286843,15:33:chronic_disease,biopsy proven metastatic disease
450,NCT02213289,12:30:cancer,Measurable metastatic disease
451,NCT02204098,7:25:chronic_disease,Known metastatic disease
452,NCT02201992,82:100:chronic_disease,if clinically indicated additional imaging studies must be performed to rule out metastatic disease
453,NCT02153229,23:41:cancer,Patients with distant metastatic disease or otherwise not confined to the ipsilateral hemithorax
454,NCT02141919,25:43:cancer,No clinical evidence of metastatic disease
455,NCT02101034,25:43:cancer,Incurable is defined as metastatic disease or a local or regional recurrence in a previously irradiated site that is unresectable (or patient declines resection)
456,NCT02072148,",160:178:cancer","Advanced Stage III,IV (N2C, N3) or surgically unresectable disease or disease that cannot be fully resected, obvious radiologic ECS, supraclavicular or matted metastatic disease, >3 cervical nodes. (These patients will be placed on the Quarterback trial due to advanced state of disease and poor prognostic features)"
457,NCT02035085,13:31:cancer,Evidence of metastatic disease
458,NCT02035085,16:34:cancer,No evidence of metastatic disease
459,NCT01903330,36:54:cancer,"History, presence, or suspicion of metastatic disease"
460,NCT01872975,47:65:cancer,Definitive clinical or radiologic evidence of metastatic disease
461,NCT01795313,34:52:cancer,"may have non-bulky, asymptomatic metastatic disease"
462,NCT01783535,13:31:cancer,Presence of metastatic disease or gross (residual) orbital involvement
463,NCT01730118,",,,,,,,,271:289:cancer","Chemistry parameters: Creatinine less than 1.5 mg/dL, SGOT and SGPT less than or equal to 3X the upper limits of normal and total bilirubin less than or equal to 1.5 mg/dl, Alk PO4 less than or equal to 3X the upper limits of normal (except for patients with documented metastatic disease to bone and/or liver)"
464,NCT01730118,",,,,,,,220:238:cancer","Chemistry parameters: Creatinine less than mg/dL, SGOT and SGPT less than or equal to 3X ULN, total bilirubin less than or equal to 1.5X ULN and Alk PO4 less than or equal to 3X ULN (except for patients with documented metastatic disease to bone and/or liver)"
465,NCT01676259,13:31:chronic_disease,Evidence of metastatic disease
466,NCT01562626,60:78:cancer,Patients must have measurable or evaluable advanced and/or metastatic disease by RECIST 1.1
467,NCT01238120,16:34:cancer,Have confirmed metastatic disease to the central nervous system
468,NCT01130077,13:31:cancer,"Presence of metastatic disease for patients in Stratum A, B, D and E"
469,NCT00715611,16:34:cancer,No evidence of metastatic disease
470,NCT02584647,38:60:treatment,Patients who are receiving any other investigational agents concurrently
471,NCT02584309,25:47:treatment,Currently receiving any investigational agents
472,NCT02573493,21:43:treatment,Receiving any other investigational agents
473,NCT02567422,38:60:treatment,Patients who are receiving any other investigational agents
474,NCT02536794,"42:64:treatment,",Patients may not have received any other investigational agents within 4 weeks prior to registration
475,NCT02535312,38:60:treatment,Patients who are receiving any other investigational agents
476,NCT02520791,38:60:treatment,Patients who are receiving any other investigational agents
477,NCT02503709,38:60:treatment,Patients who are receiving any other investigational agents
478,NCT02498613,"45:67:treatment,",Patients should not have received any other investigational agents within the past 4 weeks
479,NCT02496663,38:60:treatment,Patients who are receiving any other investigational agents
480,NCT02487095,38:60:treatment,Subjects who are receiving any other investigational agents
481,NCT02474173,"38:60:treatment,,",Patients who are receiving any other investigational agents within 4 weeks or 5 half-lives (whichever is shorter) prior to the first dose of the study regimen
482,NCT02464878,"12:34:treatment,",Use of any investigational agents within 4 weeks of enrollment
483,NCT02417701,38:60:treatment,Patients who are receiving any other investigational agents
484,NCT02369458,31:53:treatment,Currently receiving any other investigational agents
485,NCT02346253,23:45:treatment,Past history of other investigational agents
486,NCT02339922,"51:73:treatment,","Participation in other clinical trials with other investigational agents not included in this trial, within 21 days of the start of this trial and throughout the duration of this trial"
487,NCT02273362,"21:43:treatment,",Receiving any other investigational agents =< 6 months prior to registration
488,NCT02217709,41:63:treatment,Patients may not be receiving any other investigational agents
489,NCT02203513,38:60:treatment,Patients who are receiving any other investigational agents
490,NCT02201992,41:63:treatment,Patients may not be receiving any other investigational agents while on study
491,NCT02133196,38:60:treatment,Patients who are receiving any other investigational agents
492,NCT02128906,57:79:treatment,Patients may not be receiving any other anti-neoplastic investigational agents
493,NCT02124902,31:53:treatment,Currently receiving any other investigational agents
494,NCT02122185,38:60:treatment,Patients who are receiving any other investigational agents
495,NCT02122185,38:60:treatment,patients who are receiving any other investigational agents
496,NCT02122172,41:63:treatment,Patients may not be receiving any other investigational agents
497,NCT02111850,38:60:treatment,Patients who are receiving any other investigational agents
498,NCT02101034,31:53:treatment,Currently receiving any other investigational agents
499,NCT02076906,36:58:treatment,Patients currently receiving other investigational agents
500,NCT02073097,38:60:treatment,Patients who are receiving any other investigational agents
501,NCT01993719,34:56:treatment,Patients who are receiving other investigational agents
502,NCT01989546,38:60:treatment,Patients who are receiving any other investigational agents
503,NCT01967823,38:60:treatment,Patients who are receiving any other investigational agents
504,NCT01947140,10:32:treatment,No other investigational agents are allowed
505,NCT01869114,"37:59:treatment,",Patients must not have received any investigational agents within 21days of study entry
506,NCT01851369,47:69:treatment,Patients who are actively receiving any other investigational agents
507,NCT01849146,21:43:treatment,receiving any other investigational agents are ineligible
508,NCT01827384,38:60:treatment,Patients who are receiving any other investigational agents
509,NCT01720836,41:63:treatment,Subjects may not be receiving any other investigational agents
510,NCT01614990,7:29:treatment,other investigational agents (a wash-out period of five times the half life of drugs that prolong QT will be allowed with approval of prescriber)
511,NCT01572480,38:60:treatment,Patients who are receiving any other investigational agents
512,NCT01494662,52:74:treatment,Participants who are currently receiving any other investigational agents
513,NCT01174121,38:60:treatment,Patients who are receiving any other investigational agents
514,NCT01054196,41:63:treatment,Patients may not be receiving any other investigational agents
515,NCT00703105,41:63:treatment,Patients may not be receiving any other investigational agents
516,NCT03113825,"30:43:chronic_disease,",Hx of coronary events and/or heart failure within 1 year
517,NCT03112720,15:28:chronic_disease,Subjects with heart failure
518,NCT03089281,"20:33:chronic_disease,,,,,,,",Moderate to severe heart failure (NYHA Class III-IV) with EF ? 35% and QRS duration ? 120 ms
519,NCT03073343,"7:20:chronic_disease,,,","Known heart failure of New York Heart Association class 2, 3, or 4"
520,NCT03073070,1:14:chronic_disease,heart failure
521,NCT03060772,12:25:chronic_disease,History of heart failure
522,NCT03059355,1:14:chronic_disease,heart failure patients
523,NCT03058146,1:14:chronic_disease,heart failure
524,NCT03037931,"39:52:chronic_disease,,,",Either documented hospitalization for heart failure within 12 months of enrollment or elavated N-terminal-pro-brain natriuretic peptide (NT-proBNP) within 90 days of randomization
525,NCT02762825,"39:52:chronic_disease,",Any patient recently hospitalized for heart failure will have to wait at least 2 weeks before starting CR
526,NCT02582827,",,17:30:chronic_disease,",Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification
527,NCT02544880,"54:67:chronic_disease,",New York Heart Association (NYHA) Class 2 or greater heart failure in the last 3 months
528,NCT02538198,",,51:64:chronic_disease",New York Heart Association (NYHA) Class III or IV heart failure
529,NCT02513797,",56:69:chronic_disease",Currently exhibits New York Heart Association Class IV heart failure symptoms
530,NCT02513797,29:42:chronic_disease,Documented history of right heart failure specifically when right ventricle exceeds the left ventricular size
531,NCT02503722,",,,51:64:chronic_disease",New York Heart Association (NYHA) class III or IV heart failure
532,NCT02484404,",,26:39:chronic_disease",NYHA Class II or greater heart failure
533,NCT02476409,"18:31:chronic_disease,",Prior history of heart failure with this diagnosis for at least 1 month with preserved or reduced left ventricular ejection fraction
534,NCT02441101,"39:52:chronic_disease,,",Any other known conditions other than heart failure that could limit survival to < 6 months
535,NCT02441101,20:33:chronic_disease,Inotrope dependent heart failure condition
536,NCT02417701,",,17:30:chronic_disease",class III or IV heart failure
537,NCT02393885,",15:28:chronic_disease",NYHA Class IV heart failure
538,NCT02277548,",,,44:57:chronic_disease",New York Heart Association class III or IV heart failure
539,NCT02251431,",,,44:57:chronic_disease",New York Heart Association Class III or IV heart failure
540,NCT02178566,14:27:chronic_disease,uncontrolled heart failure
541,NCT02177695,",,14:27:chronic_disease,,",Class III/IV heart failure or known left ventricular ejection fraction (LVEF) < 50%
542,NCT02133885,28:41:chronic_disease,Current of past history of heart failure
543,NCT02121158,",,,23:36:chronic_disease",NYHA Class II and III heart failure
544,NCT02121158,23:36:chronic_disease,NYHA class II and III heart failure
545,NCT02025465,",55:68:chronic_disease",A low ejection fraction is not always associated with heart failure
546,NCT02025465,",,58:71:chronic_disease","Known ejection fraction <45%, regardless of a history of heart failure"
547,NCT02025465,"18:31:chronic_disease,,",Known history of heart failure with an ejection fraction <50%
548,NCT01990495,",,,140:153:chronic_disease","Subjects will be required to be in the peak VO2 range of 10 to 20 ml/kg/min, equivalent to moderate functional impairment in patients with heart failure"
549,NCT01990209,",,,51:64:chronic_disease",New York Heart Association (NYHA) Class III or IV heart failure
550,NCT01841333,",,,44:57:chronic_disease",New York Heart Association Class III or IV heart failure
551,NCT01754857,",,,38:51:chronic_disease",New York Heart Association class 3-4 heart failure
552,NCT01696734,12:25:chronic_disease,history of heart failure
553,NCT01627821,"33:46:chronic_disease,","Clinical conditions, other than heart failure, which could limit survival to less than three years"
554,NCT01626079,",54:67:chronic_disease,,,,,,,,,,",The subject has had at least one hospitalization for heart failure in the 12 months prior to subject registration and/or a corrected brain natriuretic peptide (BNP) ?300 pg/ml or corrected n-Terminal pro- brain natriuretic peptide NT-proBNP ?1500 pg/ml measured within 90 days prior to subject registration (corrected refers to a 4% reduction in the BNP or NT-proBNP cutoff for every increase of 1 kg/m2 in BMI above a reference BMI of 20 kg/m2)
555,NCT01505569,",,61:74:chronic_disease",Cardiac: ejection fraction ? 45% or no clinical evidence of heart failure
556,NCT01187368,"34:47:chronic_disease,",Presence of condition other than heart failure that would limit survival to less than 3 years
557,NCT00737893,1:14:chronic_disease,heart failure
558,NCT00065676,1:14:chronic_disease,heart failure
559,NCT03109431,13:26:chronic_disease,Established HIV infection (not acutely infected)
560,NCT03109431,33:46:chronic_disease,RNA test will determine whether HIV infection is acute or established
561,NCT03078907,1:14:chronic_disease,HIV infection
562,NCT03073343,7:20:chronic_disease,Known HIV infection
563,NCT03033888,1:14:chronic_disease,HIV infection
564,NCT03008408,32:45:chronic_disease,Patient has a known history of HIV infection (testing not mandatory)
565,NCT02898597,14:27:chronic_disease,Diagnosis of HIV infection
566,NCT02876510,1:14:chronic_disease,HIV infection
567,NCT02819440,7:20:chronic_disease,Known HIV infection
568,NCT02811679,21:34:chronic_disease,Subjects with known HIV infection
569,NCT02776059,7:20:chronic_disease,Known HIV infection
570,NCT02693145,"74:87:chronic_disease,",Residents within the health department jurisdiction with newly diagnosed HIV infection who have not linked to medical care within 90 days
571,NCT02663934,23:36:chronic_disease,documented history of HIV infection
572,NCT02582775,12:25:chronic_disease,History of HIV infection
573,NCT02570542,1:14:chronic_disease,HIV infection
574,NCT02555189,32:45:chronic_disease,Patient has a known history of HIV infection (testing not mandatory)
575,NCT02532621,66:79:chronic_disease,"Subject currently has a known or suspected bacterial, fungal, or HIV infection"
576,NCT02516696,19:32:chronic_disease,Subject has known HIV infection
577,NCT02514083,1:14:chronic_disease,HIV infection
578,NCT02512497,1:14:chronic_disease,HIV infection
579,NCT02469857,"7:20:chronic_disease,,,",Known HIV infection with CD4 count < 200 cells/mm3 or < 14% of all lymphocytes
580,NCT02466750,18:31:chronic_disease,Have a confirmed HIV infection (antibody positivity)
581,NCT02408861,47:60:chronic_disease,"the referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and/or current management of HIV infection"
582,NCT02367196,7:20:chronic_disease,Known HIV infection
583,NCT02291848,22:35:chronic_disease,Patients with active HIV infection at time of procurement (can be pending at the time of blood draw)
584,NCT02256631,18:31:chronic_disease,Documentation of HIV infection
585,NCT02256631,43:56:chronic_disease,"Mother with documented* 2-class resistant HIV infection, which may include historical documentation of lack of response"
586,NCT02140255,49:62:chronic_disease,"Any clinically significant diseases (other than HIV infection) or clinically significant findings during review of medical history or physical examination prior to entry that, in the investigator's opinion, would interfere with study participation or interpretation"
587,NCT02140255,20:33:chronic_disease,Confirmed in utero HIV infection
588,NCT01940757,32:45:chronic_disease,Positive confirmatory test for HIV infection
589,NCT01861106,1:14:chronic_disease,HIV infection
590,NCT01841333,7:20:chronic_disease,Known HIV infection
591,NCT01822522,19:32:chronic_disease,participants with HIV infection will be eligible provided they meet the criteria
592,NCT01333046,22:35:chronic_disease,Patients with active HIV infection at time of procurement (can be pending at the time of blood draw)
593,NCT00085982,7:20:chronic_disease,Known HIV infection
594,NCT00001651,12:25:chronic_disease,"Documented HIV infection (ELISA/Western blot positive or, for acute seroconverters, PCR positive)"
595,NCT00001651,70:83:chronic_disease,"Willingness to allow stored samples to be used for future studies of HIV infection and/or immunological function, and willingness to have HLA typing performed. (For previously enrolled patients, patients would be requested, but not required, to provide permission to use stored samples in the future, and to permit HLA testing"
596,NCT03066596,28:34:chronic_disease,Persistent or uncontrolled asthma as per clinic assessment
597,NCT03066596,",35:41:chronic_disease","in past month, > 2 days/week with asthma symptoms"
598,NCT03028350,32:38:chronic_disease,History of physician-diagnosed asthma
599,NCT03028350,8:14:chronic_disease,Stable asthma
600,NCT03028350,"50:56:chronic_disease,",no hospitalizations or emergency room visits for asthma at least three months prior to starting treatment
601,NCT03002389,23:29:chronic_disease,previous diagnosis of asthma
602,NCT02995733,"34:40:chronic_disease,",Clinical history consistent with asthma for > 1 year
603,NCT02953431,27:33:chronic_disease,No physician diagnosis of asthma
604,NCT02752165,26:32:chronic_disease,Participation in another asthma study at the time of enrollment
605,NCT02752165,31:37:chronic_disease,"Persistent or poor control of asthma, defined by NHLBI guidelines"
606,NCT02752165,30:36:chronic_disease,Prior physician diagnosis of asthma
607,NCT02752165,127:133:chronic_disease,a sibling participating in this or another study Other significant medical conditions that could interfere with assessment of asthma-related measures
608,NCT02740543,5:11:chronic_disease,Has asthma according to Phase I diagnostic criteria
609,NCT02740543,"86:92:chronic_disease,,","Patients will be recruited from the NYUBAR and will have no respiratory symptoms, no asthma diagnosis, no WTC dust exposure, no current tobacco use, ? 5 p-y history of tobacco use, and normal spirometry with no bronchodilator response and negative methacholine challenge in past 6 months"
610,NCT02740543,75:81:chronic_disease,"Patients will be recruited from the NYUBAR or advertisement and will have asthma as defined by NIH guidelines, persistent symptoms, absence of WTC dust exposure"
611,NCT02682147,14:20:chronic_disease,Diagnosis of asthma
612,NCT02624765,1:7:chronic_disease,asthma
613,NCT02580604,25:31:chronic_disease,Diagnosis or history of asthma
614,NCT02570984,60:66:chronic_disease,first degree relative with history or current diagnosis of asthma or allergy
615,NCT02554786,"14:20:chronic_disease,","diagnosis of asthma, for a period of at least 1 year prior to Visit 1 (Screening)"
616,NCT02547818,22:28:chronic_disease,Uncontrolled chronic asthma
617,NCT02508311,12:18:chronic_disease,History of asthma
618,NCT02495168,16:22:chronic_disease,Diagnosed with asthma as defined by the NAEPP 3
619,NCT02494869,14:20:chronic_disease,Uncontrolled asthma
620,NCT02472834,13:19:chronic_disease,Presence of asthma
621,NCT02458482,",215:221:chronic_disease",Patients will be evaluated using the Acute Asthma Intensity Research Score (AAIRS) which has been validated at Vanderbilt University Medical Center and is currently the standard of care when triaging patients with asthma
622,NCT02436070,21:27:chronic_disease,Previous history of asthma as represented in the medical record or by parental report
623,NCT02433977,44:50:chronic_disease,History of ICU admission/intubation due to asthma in the past year
624,NCT02401074,68:74:chronic_disease,Diagnosis of well-controlled airway allergy with mild-intermittent asthma (a stable clinical condition with good asthma control) and demonstrating an allergen-specific airway response to inhaled allergen provocation
625,NCT02291302,17:23:chronic_disease,grades K-8 with asthma attending sampling/intervention schools
626,NCT02148796,21:27:chronic_disease,Parental history of asthma
627,NCT02148796,54:60:chronic_disease,Participants may not have a physician's diagnosis of asthma
628,NCT02148796,"21:27:chronic_disease,,",Physician-diagnosed asthma in a blood sibling aged 4 years or more
629,NCT02025465,30:36:chronic_disease,history of being treated for asthma
630,NCT03112902,14:34:chronic_disease,diagnosis of cognitive impairment
631,NCT03105700,"13:33:chronic_disease,,",Significant cognitive impairment measured by the Montreal Cognitive Assessment (MOCA) <23
632,NCT03029884,"13:33:chronic_disease,,",Significant cognitive impairment or Dementia (MoCA < 25)
633,NCT02991534,15:35:chronic_disease,Patients with cognitive impairment precluding informed consent
634,NCT02951455,"7:27:chronic_disease,",Gross cognitive impairment as measured by the Mini Mental State Exam
635,NCT02926378,10:30:chronic_disease,Evidence cognitive impairment that would negatively impact capacity to understand and participate in this study
636,NCT02791646,1:21:chronic_disease,cognitive impairment
637,NCT02719327,6:26:chronic_disease,mild cognitive impairment on screening evaluation
638,NCT02712229,1:21:chronic_disease,"cognitive impairment or inability to consent to treatment, as determined by the patient's oncologist"
639,NCT02685358,7:27:chronic_disease,gross cognitive impairment
640,NCT02667119,13:33:chronic_disease,significant cognitive impairment
641,NCT02585232,21:41:chronic_disease,Experiencing severe cognitive impairment that would impair their ability to communicate during an interview
642,NCT02521818,52:72:chronic_disease,availability of cohabitating study partner without cognitive impairment
643,NCT02506192,52:72:chronic_disease,"other diagnosis that produces symptoms of fatigue, cognitive impairment, or pain will be excluded based on the Kansas GWI Case definition"
644,NCT02497300,1:21:chronic_disease,cognitive impairment prohibiting consent
645,NCT02466126,1:21:chronic_disease,cognitive impairment
646,NCT02454517,35:55:chronic_disease,Doctor of medicine (MD) confirmed cognitive impairment
647,NCT02442102,",48:68:chronic_disease",Unable to understand or speak English due to a cognitive impairment
648,NCT02435667,13:33:chronic_disease,Significant cognitive impairment
649,NCT02340650,37:57:chronic_disease,Patient with sufficient evidence of cognitive impairment that limits the subject's ability to understand the protocol
650,NCT02316574,13:33:chronic_disease,Significant cognitive impairment
651,NCT02269124,13:33:chronic_disease,Significant cognitive impairment
652,NCT02159027,78:98:chronic_disease,Ability and willingness to provide written informed consent Mild to moderate cognitive impairment with global neuropsychological (NP) test (NPZglobal)
653,NCT02157025,57:77:chronic_disease,Inability to understand study or communicate responses (cognitive impairment)
654,NCT02153229,37:57:chronic_disease,Patients unwilling or unable due to cognitive impairment to sign informed consent
655,NCT01974609,27:47:chronic_disease,those with a diagnosis of cognitive impairment
656,NCT01878617,"16:36:chronic_disease,,,",No significant cognitive impairment operationalized as either an IQ < 70 for children with St. Jude SJMB12 study baseline testing or based on clinician judgment baseline IQ missing
657,NCT01829958,",,45:65:chronic_disease","Patients scoring ? 11 on the BOMC (implying cognitive impairment) will be excluded since their ability to reliably complete the questionnaire will be in doubt Subjects meeting the following criteria will be excluded from enrollment in the pre-phase arm of the study, but may be included in the GA only arm"
658,NCT01175044,88:108:chronic_disease,Inability to provide informed consent or to comply with study assessments (e.g. due to cognitive impairment or geographic distance)
659,NCT03144245,24:39:chronic_disease,Clinically significant cardiac disease
660,NCT03140488,38:53:chronic_disease,Patients with history of significant cardiac disease
661,NCT03114319,24:39:chronic_disease,Clinically significant cardiac disease
662,NCT03042689,34:49:chronic_disease,Active or clinically significant cardiac disease
663,NCT02994940,",,,,259:274:chronic_disease","Patients who meet UCDCH criteria for PICU admission: on home oxygen pre-operatively, exhibit airway obstruction when awake (stertor above larynx, stridor at larynx), sleep study with apnea hypoxia index greater than 25 or sleep oxygen saturation nadir <80%, cardiac disease, difficult intubation"
664,NCT02990481,1:16:chronic_disease,cardiac disease
665,NCT02852239,33:48:chronic_disease,History or current diagnosis of cardiac disease indicating significant risk such as uncontrolled
666,NCT02774421,1:16:chronic_disease,cardiac disease risk factors
667,NCT02774421,13:28:chronic_disease,significant cardiac disease
668,NCT02665338,10:25:chronic_disease,Unstable cardiac disease
669,NCT02488967,8:23:chronic_disease,Active cardiac disease
670,NCT02488967,12:27:chronic_disease,History of cardiac disease
671,NCT02466009,34:49:chronic_disease,Active or clinically significant cardiac disease
672,NCT02464878,20:35:chronic_disease,Severe co-existing cardiac disease
673,NCT02435069,1:16:chronic_disease,cardiac disease
674,NCT02433626,51:66:chronic_disease,History of clinically significant or uncontrolled cardiac disease
675,NCT02387216,24:39:chronic_disease,Clinically significant cardiac disease
676,NCT02367196,53:68:chronic_disease,Impaired cardiac function or clinically significant cardiac disease
677,NCT02252588,10:25:chronic_disease,Unstable cardiac disease
678,NCT02048722,34:49:chronic_disease,Active or clinically significant cardiac disease
679,NCT01676259,1:16:chronic_disease,cardiac disease
680,NCT01474889,20:35:chronic_disease,Severe co-existing cardiac disease
681,NCT00788164,27:42:chronic_disease,No evidence or history of cardiac disease
682,NCT00467987,33:48:chronic_disease,"Any other life-threatening, non-cardiac disease"
683,NCT00432094,51:66:chronic_disease,Patients must be free of symptoms of uncontrolled cardiac disease
684,NCT03099070,97:113:chronic_disease,Any condition that would preclude the safe experience of a benign laboratory stressor including seizure disorder
685,NCT03017937,11:27:chronic_disease,Any known seizure disorder
686,NCT02924194,28:44:chronic_disease,Subjects with a history of seizure disorder
687,NCT02882802,35:51:chronic_disease,"Participants also must not have a seizure disorder and must not be taking any medications that would affect cognition or behavior on the aggression task, including pain medication"
688,NCT02864147,35:51:chronic_disease,Patients who have an uncontrolled seizure disorder
689,NCT02859142,1:17:chronic_disease,seizure disorder
690,NCT02833792,12:28:chronic_disease,History of seizure disorder
691,NCT02768727,12:28:chronic_disease,History of seizure disorder
692,NCT02737930,12:28:chronic_disease,History of seizure disorder
693,NCT02676193,67:83:chronic_disease,Marked organic impairment or unstable medical problems (such as a seizure disorder)
694,NCT02629120,14:30:chronic_disease,Uncontrolled seizure disorder
695,NCT02562430,16:32:chronic_disease,any history of seizure disorder
696,NCT02442102,8:24:chronic_disease,Active seizure disorder
697,NCT02414269,18:34:chronic_disease,Prior history of seizure disorder
698,NCT02404155,14:30:chronic_disease,Uncontrolled seizure disorder
699,NCT02234934,14:30:chronic_disease,Uncontrolled seizure disorder
700,NCT02202369,21:37:chronic_disease,Patients who have a seizure disorder
701,NCT02159027,14:30:chronic_disease,Uncontrolled seizure disorder
702,NCT02101853,28:44:chronic_disease,Patients with uncontrolled seizure disorder
703,NCT01967238,12:28:chronic_disease,History of seizure disorder for Flumist group participants only
704,NCT01964404,14:30:chronic_disease,History of a seizure disorder
705,NCT01912612,12:28:chronic_disease,History of seizure disorder
706,NCT01625923,12:28:chronic_disease,History of seizure disorder
707,NCT01618357,12:28:chronic_disease,History of seizure disorder
708,NCT03104699,1:16:chronic_disease,unstable angina
709,NCT03096288,11:26:chronic_disease,stable or unstable angina
710,NCT03078907,1:16:chronic_disease,unstable angina
711,NCT03072238,8:23:chronic_disease,severe unstable angina
712,NCT03043742,",,50:65:chronic_disease",Increased Troponin T (> 3X ULN) in patients with unstable angina at time of intervention
713,NCT03037983,1:16:chronic_disease,unstable angina
714,NCT02945293,1:16:chronic_disease,unstable angina
715,NCT02925923,15:30:chronic_disease,Patients with unstable angina
716,NCT02703220,9:24:chronic_disease,Current unstable angina
717,NCT02637947,13:28:chronic_disease,subject has unstable angina
718,NCT02583893,1:16:chronic_disease,unstable angina
719,NCT02513797,"23:38:chronic_disease,",Documented history of unstable angina within 3 months prior to the planned study intervention
720,NCT02497300,1:16:chronic_disease,unstable angina
721,NCT02353728,"12:27:chronic_disease,",History of unstable angina within 1 year of study entry
722,NCT02353728,1:16:chronic_disease,unstable angina
723,NCT02347995,1:16:chronic_disease,unstable angina
724,NCT02321501,"1:16:chronic_disease,",unstable angina within 6 months prior to screening
725,NCT02178566,1:16:chronic_disease,unstable angina
726,NCT02106598,1:16:chronic_disease,unstable angina
727,NCT02006069,"1:16:chronic_disease,",unstable angina within 40 days prior the enrollment
728,NCT01568177,1:16:chronic_disease,unstable angina
729,NCT01562626,1:16:chronic_disease,unstable angina (anginal symptoms at rest)
730,NCT00432094,1:16:chronic_disease,unstable angina
731,NCT03143894,1:9:chronic_disease,Dementia as assessed by a MMSE score on initial screening
732,NCT03136029,30:38:chronic_disease,These include a diagnosis of Dementia
733,NCT03104205,1:9:chronic_disease,Dementia
734,NCT02992275,"1:9:chronic_disease,,",Dementia (on medical record review or mini-mental status exam score <24)
735,NCT02924194,1:9:chronic_disease,Dementia per DSM-V criteria
736,NCT02875301,1:9:chronic_disease,Dementia
737,NCT02838797,"1:9:chronic_disease,,",Dementia (Mini Mental Status Exam < 25)
738,NCT02828618,1:9:chronic_disease,Dementia or significantly altered mental status that would prohibit the understanding and giving of informed consent
739,NCT02719327,1:9:chronic_disease,Dementia
740,NCT02665338,1:9:chronic_disease,Dementia
741,NCT02544503,1:9:chronic_disease,Dementia
742,NCT02522494,1:9:chronic_disease,Dementia
743,NCT02497300,1:9:chronic_disease,Dementia
744,NCT02471833,1:9:chronic_disease,Dementia
745,NCT02437110,1:9:chronic_disease,Dementia
746,NCT02436408,1:9:chronic_disease,Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol
747,NCT02415556,"1:9:chronic_disease,,",Dementia (Mini Mental State Examination [MMSE] scores ?20)
748,NCT02311361,1:9:chronic_disease,Dementia or significantly altered mental status that would prohibit the understanding or rendering of Information and Consent and compliance with the requirements of the protocol
749,NCT02159560,1:9:chronic_disease,Dementia
750,NCT02106052,"1:9:chronic_disease,,,,",Dementia based on a definition validated in people with MS using the MACFIMS (> 2 SD below the mean on at least one memory test and > 2 SD below the mean on at least one neuropsychological test in another domain)
751,NCT01581580,1:9:chronic_disease,Dementia as evidenced by formal neuropsychological evaluation
752,NCT01539109,1:9:chronic_disease,Dementia
753,NCT03145298,13:19:chronic_disease,Significant anemia or a falling Hb
754,NCT03130777,"1:7:chronic_disease,,",anemia (Hgb < 7 g/dL)
755,NCT03073070,1:7:chronic_disease,anemia
756,NCT02925923,"1:7:chronic_disease,,",anemia with HCT<30%
757,NCT02823665,"13:19:chronic_disease,,",significant anemia (hemoglobin <11g/dL)
758,NCT02690116,26:32:chronic_disease,Currently diagnosed with anemia (fatigue-related factor)
759,NCT02589977,1:7:chronic_disease,anemia
760,NCT02574910,"13:19:chronic_disease,,",Significant anemia (hemoglobin < 12 g/dl)
761,NCT02473354,5:11:chronic_disease,has anemia [measured by venous blood gas sample]
762,NCT02411773,"8:14:chronic_disease,,",Severe anemia with hemoglobin (Hbg) level < 10 g/dL
763,NCT02404012,"20:26:chronic_disease,,","Subject has severe anemia, with a hemoglobin > 7.0 g/dL"
764,NCT02341300,",,,,70:76:chronic_disease,,,,",Pregnant women of any age in their first trimester of pregnancy with anemia defined as a Hemoglobin less than 11 and/or a hematocrit less than 33
765,NCT02226341,"19:25:chronic_disease,,",Moderately severe anemia (Hgb < 8 mg/dL)
766,NCT02189889,29:35:chronic_disease,diagnosed with preoperative anemia
767,NCT02145351,"8:14:chronic_disease,,",Severe anemia (Hemoglobin <10 g/dL)
768,NCT01947673,"8:14:chronic_disease,,",severe anemia with hgb level <8 g/dL
769,NCT01803451,13:19:chronic_disease,significant anemia
770,NCT01573429,"21:27:chronic_disease,,,,,",Clinically relevant anemia as defined as hemoglobin concentration <13g/dL for males and hemoglobin concentration <11g/dL for females
771,NCT01572480,12:18:chronic_disease,Absence of anemia
772,NCT01326715,40:46:chronic_disease,Clinically significant iron-deficiency anemia
773,NCT00065676,1:7:chronic_disease,anemia
774,NCT03175159,21:38:chronic_disease,"Discovery of active suicidal ideation at the time of interview (participants will be referred immediately for treatment, but may join the study once resolved)"
775,NCT03060902,12:29:chronic_disease,mother has suicidal ideation + an active plan
776,NCT03034863,44:61:chronic_disease,evidence of current (within the past week) suicidal ideation
777,NCT03004170,8:25:chronic_disease,Active suicidal ideation as determined by the Patient Health Questionnaire 9-item Depression Module
778,NCT02927847,1:18:chronic_disease,suicidal ideation with plan or intent
779,NCT02914483,8:25:chronic_disease,Active suicidal ideation (PHQ-9 item #9 or otherwise reported during screening)
780,NCT02909387,"9:26:chronic_disease,",Reports suicidal ideation within the past month
781,NCT02859142,"9:26:chronic_disease,",Current suicidal ideation (past 6 months)
782,NCT02727972,21:38:chronic_disease,"active, significant suicidal ideation"
783,NCT02587312,33:50:chronic_disease,Participants who report current suicidal ideation on the MINI suicide subscale questions 4 & 5
784,NCT02582905,",,,,141:158:chronic_disease","High risk for suicide defined as > 1 attempt in past 12 months that required medical attention, any attempt in the past 3 months or current suicidal ideation with plan and intent such that outpatient care is precluded"
785,NCT02513225,",48:65:chronic_disease,",At least one episode of binge substance use or suicidal ideation recorded in the Apache community-based surveillance system in the past 90 days
786,NCT02452203,30:47:chronic_disease,Participant endorses current suicidal ideation with intent or plan
787,NCT02421315,8:25:chronic_disease,Active suicidal ideation
788,NCT02391402,20:37:chronic_disease,Clients who report suicidal ideation without imminent risk will be admitted into the study
789,NCT02283333,23:40:chronic_disease,Individuals with both suicidal ideation and clear intent
790,NCT02270619,18:35:chronic_disease,prior or current suicidal ideation assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)
791,NCT02101554,",53:70:chronic_disease",Columbia-Suicide Severity Rating Scale (C-SSRS) for suicidal ideation and behavior in past year
792,NCT02061553,",,,123:140:chronic_disease","At least mild depression and/ or anxiety as evidenced by a score of >5 on PHQ-9 and/ or GAD-7, but without endorsement of suicidal ideation"
793,NCT02061553,8:25:chronic_disease,active suicidal ideation
794,NCT02538198,",,,248:260:treatment","must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide"
795,NCT02538198,",,,,,159:171:treatment,",must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days and again within24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be filled within 7 days as required by Revlimid REMS®)
796,NCT02538198,71:83:treatment,no dosing or adverse event data are currently available on the use of lenalidomide in patients
797,NCT02538198,"107:119:treatment,","there is a potential risk for adverse events to nursing infants secondary to treatment of the mother with lenalidomide, lactating females must agree not to breast feed while taking lenalidomide"
798,NCT02446457,"17:29:treatment,",enrolled in the lenalidomide cohort must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategy (REMS) program
799,NCT02446457,17:29:treatment,enrolled in the lenalidomide containing cohort (cohort 2) must be registered into the mandatory Revlimid REMS program
800,NCT02389517,"28:40:treatment,,",Patients must be receiving lenalidomide 10 mg or 15 mg and be able to tolerate dose escalation to 25 mg daily
801,NCT02389517,"29:41:treatment,,",Patients must have received lenalidomide maintenance for 3 months (+1 month window for a maximum of 4 months lenalidomide prior to enrollment)
802,NCT02334865,",62:74:treatment",lactating females must agree not to breast feed while taking lenalidomide
803,NCT02253316,",,,267:279:treatment","This is defined as either committing to continued abstinence from heterosexual intercourse or beginning TWO acceptable methods of contraception (one highly effective method and one additional effective method AT THE SAME TIME) at least 28 days prior to the start of lenalidomide, for the duration of study participation, and for 28 days following the last dose of lenalidomide"
804,NCT01919619,",62:74:treatment",lactating females must agree not to breast-feed while taking lenalidomide
805,NCT01754857,",43:55:treatment",at least 28 days before she starts taking lenalidomide
806,NCT01754857,",62:74:treatment",lactating females must agree not to breast-feed while taking lenalidomide
807,NCT01619761,",,,,283:295:treatment","Woman with child bearing potential must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 4 weeks before she starts taking lenalidomide"
808,NCT01433965,",,,,,,201:213:treatment,",Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days and again within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be filled within 7 days as required by RevAssist)
809,NCT01433965,",62:74:treatment",Lactating females must agree not to breast feed while taking lenalidomide
810,NCT01433965,25:37:treatment,Not able to swallow the lenalidomide capsule as a whole
811,NCT01433965,",,,248:260:treatment","must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide"
812,NCT01054196,",,,,,,201:213:treatment,",Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days and again within 24 hours prior to prescribing lenalidomide (prescriptions must be filled within 7 days)
813,NCT01054196,",43:55:treatment",at least 28 days before she starts taking lenalidomide
814,NCT03158519,1:14:chronic_disease,schizophrenia
815,NCT03149783,1:14:chronic_disease,schizophrenia
816,NCT03105700,1:14:chronic_disease,schizophrenia
817,NCT03053908,1:14:chronic_disease,schizophrenia
818,NCT03018704,1:14:chronic_disease,schizophrenia
819,NCT02945293,14:27:chronic_disease,Diagnosis of schizophrenia
820,NCT02922569,1:14:chronic_disease,schizophrenia
821,NCT02901041,1:14:chronic_disease,schizophrenia
822,NCT02826577,1:14:chronic_disease,schizophrenia
823,NCT02724930,1:14:chronic_disease,schizophrenia
824,NCT02481245,1:14:chronic_disease,schizophrenia
825,NCT02473250,10:23:chronic_disease,lifetime schizophrenia
826,NCT02404155,63:76:chronic_disease,treatment would likely alter the presentation or treatment of schizophrenia or significantly increase the risks associated with the proposed protocol
827,NCT02361554,28:41:chronic_disease,"Subject has a diagnosis of schizophrenia as determined by a review of medical records, discussion with referring psychiatrist as well as the Structured Clinical Interview for DSM-IV (SCID-IV)"
828,NCT02261519,15:28:chronic_disease,The subject's schizophrenia condition is clinically stable with residual symptoms
829,NCT02118610,21:34:chronic_disease,DSM-IV diagnosis of schizophrenia
830,NCT01964404,14:27:chronic_disease,Diagnosis of schizophrenia
831,NCT01850355,22:35:chronic_disease,Current diagnosis of schizophrenia
832,NCT02882802,",43:47:chronic_disease",participants with sub-syndromal levels of PTSD will also be allowed to participate
833,NCT02856412,"19:23:chronic_disease,",Meet criteria for PTSD of at least 3 months duration
834,NCT02856412,"23:27:chronic_disease,,",have some symptoms of PTSD with a current CAPS score of 23 or higher
835,NCT02774642,47:51:chronic_disease,"Veterans who are engaged in treatment for non-PTSD symptoms (e.g., 12-step programs) will be eligible"
836,NCT02727972,31:35:chronic_disease,Clinical diagnosis of current PTSD as per DSM-IV
837,NCT02655692,14:18:chronic_disease,diagnosis of PTSD
838,NCT02553161,1:5:chronic_disease,PTSD
839,NCT02500602,52:56:chronic_disease,"Meet DSM-5 criteria for current (i.e., last month) PTSD"
840,NCT02479906,"33:37:chronic_disease,,",Subjects with at least moderate PTSD with a CAPS-5 score ? 25 at both Screening and Baseline visits
841,NCT02397889,",81:85:chronic_disease",Participants must fulfill DSM-5 criteria for current civilian or combat-related PTSD
842,NCT02391402,14:18:chronic_disease,Diagnosis of PTSD based on the Clinician Administered PTSD Scale
843,NCT02377089,"27:31:chronic_disease,,",with significant residual PTSD symptoms as evidenced by a CAPS score >50
844,NCT02356861,36:40:chronic_disease,Must meet screening criteria for a PTSD diagnosis
845,NCT02308202,29:33:chronic_disease,Meet DSM-IV TR criteria for PTSD
846,NCT02308202,87:91:chronic_disease,We anticipate that participants will be on a wide range of medications prescribed for PTSD
847,NCT01627301,63:67:chronic_disease,Prehypertensive and Normotensive OEF/OIF/OND veterans without PTSD (controls)
848,NCT01627301,138:142:chronic_disease,Prehypertensive and Normotensive Operation Enduring Freedom (OEF)/ Operation Iraqi Freedom (OIF)/ Operation New Dawn (OND) veterans with PTSD
849,NCT00875342,16:20:chronic_disease,Diagnosed with PTSD
850,NCT03145181,25:41:cancer,Documented diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria
851,NCT03145181,12:28:cancer,Measurable multiple myeloma that is relapsed or refractory to established therapies with known clinical benefit in relapsed/refractory multiple myeloma
852,NCT03145181,53:69:cancer,exhibits clinical signs of meningeal involvement of multiple myeloma
853,NCT03143985,44:60:cancer,Patient has been previously diagnosed with multiple myeloma based on standard criteria
854,NCT02519452,70:86:cancer,Participant is exhibiting clinical signs of meningeal involvement of multiple myeloma
855,NCT02516696,38:54:cancer,Subject has histologically confirmed multiple myeloma that has never before been treated
856,NCT02516696,41:57:cancer,Subject has previously been treated for multiple myeloma
857,NCT02278315,43:59:cancer,Histologically or cytologically confirmed multiple myeloma
858,NCT02253316,51:67:cancer,Histologically confirmed diagnosis of symptomatic multiple myeloma
859,NCT02253316,1:17:cancer,multiple myeloma
860,NCT02101944,",,,,,199:215:cancer",Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%) is required for eligibility; those patients with lower performance status based solely on bone pain secondary to multiple myeloma
861,NCT02046395,12:28:cancer,History of multiple myeloma
862,NCT02004275,20:36:cancer,"Primary refractory multiple myeloma, where primary refractory multiple myeloma is defined as disease that is nonresponsive"
863,NCT01464034,54:70:cancer,Cytopathologically or histologically confirmed dx of multiple myeloma
864,NCT01453088,22:38:cancer,Diagnosis other than multiple myeloma
865,NCT01415882,"23:39:cancer,",Measurable disease of multiple myeloma as defined by at least ONE of the following
866,NCT01241708,22:38:cancer,Diagnosis other than multiple myeloma
867,NCT02516969,13:31:cancer,Evidence of distant metastases on any staging or imaging modality
868,NCT02516969,16:34:cancer,No evidence of distant metastases
869,NCT02468024,16:34:cancer,No evidence of distant metastases
870,NCT02451982,4:22:cancer,No distant metastases
871,NCT02177292,38:56:cancer,Clinical or pathological evidence of distant metastases (M1)
872,NCT02163317,13:31:cancer,Evidence of distant metastases
873,NCT02158234,13:31:cancer,Evidence of distant metastases
874,NCT02138214,16:34:cancer,No evidence of distant metastases
875,NCT02041936,"13:31:cancer,",Evidence of distant metastases of stage IV
876,NCT02040610,13:31:cancer,Evidence of distant metastases
877,NCT02031250,24:42:cancer,Documented evidence of distant metastases
878,NCT01993810,52:70:cancer,"Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup"
879,NCT01950351,13:31:cancer,Evidence of distant metastases
880,NCT01436968,36:54:cancer,Regional lymph node involvement or distant metastases
881,NCT01220583,26:44:cancer,patients must be free of distant metastases based upon the following minimum diagnostic workup
882,NCT00924027,1:19:cancer,distant metastases
883,NCT00909909,4:22:cancer,No distant metastases
884,NCT03060473,"13:26:chronic_disease,,",Significant renal disease defined as serum creatinine known to be >2.0 mg/dl
885,NCT03043742,11:24:chronic_disease,End stage renal disease
886,NCT03016351,"13:26:chronic_disease,,",Presence of renal disease with a creatinine > 1.5mg/dL
887,NCT02966665,"13:26:chronic_disease,,",Significant renal disease (Glomerular Filtration Rate < 50 mL/min/1.73m2)
888,NCT02926248,15:28:chronic_disease,Patients with renal disease
889,NCT02852239,"8:21:chronic_disease,",Stable renal disease without evidence of renal progression in the past 28 days prior to dosing
890,NCT02833207,26:39:chronic_disease,Self-reported history of renal disease
891,NCT02819440,",,89:102:chronic_disease",Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2 by the modified diet in renal disease (MDRD) equation
892,NCT02366871,"13:26:chronic_disease,,",Significant renal disease as defined by creatinine clearance less than 30 mL/min
893,NCT02245841,1:14:chronic_disease,renal disease
894,NCT02207439,31:44:chronic_disease,Subjects with moderate-severe renal disease
895,NCT02202369,"15:28:chronic_disease,,",Patients with renal disease (documented glomerular filtration rate < 60mL/min/1.73m2)
896,NCT02139436,1:14:chronic_disease,renal disease
897,NCT01940757,"24:37:chronic_disease,,,","Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the upper reference limit, or more than trace protein or blood on urine dipstick testing)"
898,NCT01568177,5:18:chronic_disease,Any renal disease
899,NCT00875342,42:55:chronic_disease,"Significant health impairment, including renal disease"
900,NCT03137498,14:22:treatment,Currently on dialysis
901,NCT03089281,21:29:treatment,currently requiring dialysis
902,NCT03088033,"21:29:treatment,,",Currently requiring dialysis; or estimated-GFR <25ml/min/1.73 m2 by CKD-Epi equation
903,NCT03078491,4:12:treatment,on dialysis (since impact of fluid shift on sensor lag not clearly understood)
904,NCT03060473,4:12:treatment,on dialysis
905,NCT02764359,"13:21:treatment,,",Patients on dialysis or with unstable renal function (a change of >0.5 mg/dL in SCr concentration in patients with a SCr of <2 mg/dL or a 20% change in SCr in patients with a SCr of ?2 mg/dL)
906,NCT02593526,"21:29:treatment,",Has been undergoing dialysis for more than 12 weeks
907,NCT02578901,13:21:treatment,Subjects on dialysis
908,NCT02554903,12:20:treatment,undergoing dialysis
909,NCT02489539,20:28:treatment,patient undergoing dialysis
910,NCT02208362,31:39:treatment,Research participant requires dialysis
911,NCT02128802,21:29:treatment,Non-compliance with dialysis regimen
912,NCT02124902,4:12:treatment,On dialysis
913,NCT01895777,17:25:treatment,requirement for dialysis
914,NCT01758042,"27:35:treatment,,",Participants should be on dialysis or have an estimated or measured CrCl < 35 ml/min
915,NCT03028012,1:18:chronic_disease,Diabetes mellitus
916,NCT03006770,"1:18:chronic_disease,,",Diabetes mellitus with HbA1c >10%
917,NCT02957149,1:18:chronic_disease,Diabetes mellitus diagnosis
918,NCT02950337,1:18:chronic_disease,Diabetes mellitus with end organ damage
919,NCT02903511,1:18:chronic_disease,Diabetes mellitus
920,NCT02740595,1:18:chronic_disease,Diabetes mellitus
921,NCT02734888,1:18:chronic_disease,Diabetes mellitus
922,NCT02563678,1:18:chronic_disease,Diabetes mellitus
923,NCT02437110,1:18:chronic_disease,Diabetes mellitus
924,NCT02312596,"1:18:chronic_disease,,",Diabetes mellitus (type I or II) that is adequately controlled
925,NCT02217345,1:18:chronic_disease,Diabetes mellitus
926,NCT01996449,1:18:chronic_disease,Diabetes mellitus
927,NCT01950234,"1:18:chronic_disease,,,,","Diabetes mellitus, defined as pre-existing diagnosis, fasting blood glucose > 125 mg/dl, or glycosylated hemoglobin >/= 6.5%"
928,NCT01547429,1:18:chronic_disease,Diabetes mellitus
929,NCT00977977,1:18:chronic_disease,Diabetes mellitus
930,NCT02731326,77:80:treatment,"Ability to successfully use the AliveCor Heart Monitor, capture a baseline ECG, and transmit on the day of enrollment"
931,NCT02585973,27:30:treatment,"Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant"
932,NCT02585973,",,45:48:treatment",?470 msec for females required on screening ECG
933,NCT02555189,",,63:66:treatment,","On screening, inability to determine the QTcF interval on the ECG (i.e.: unreadable or not interpretable) or QTcF >450 msec (using Fridericia's correction). All as determined by screening ECG (mean of triplicate ECGs"
934,NCT02353728,41:44:treatment,Inability to monitor the QT interval on ECG
935,NCT02278367,"18:21:treatment,,,",Have a screening ECG with QTc > 450 msec if male
936,NCT02239913,35:38:treatment,"Abnormal screening outcome (e.g., ECG, blood chemistry result) that study physicians deem clinically significant"
937,NCT02129348,70:73:treatment,"unstable cardiac disease based on history, physical examination, and ECG"
938,NCT01943851,24:27:treatment,Clinically significant ECG assessments should be reviewed by the site cardiologist prior to study entry
939,NCT01943851,1:4:treatment,ECG findings or assessments
940,NCT01877382,",,42:45:treatment",> 470 ms for females based on triplicate ECG
941,NCT01817751,",27:30:treatment",baseline QTc on screening ECG meets exclusion criteria on screening assessment
942,NCT01366612,27:30:treatment,"Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant"
943,NCT00713492,22:25:treatment,"Abnormal findings on ECG, unless cleared for participation by cardiologist or Licensed Independent Practitioner (LIP)"
944,NCT03157713,"6:13:chronic_disease,,,,","With obesity, based on BMI of 30 to 40 kg/m2 during a prior visit in the past 6 months"
945,NCT03082157,"24:31:chronic_disease,","Participant in another obesity, eating or physical activity program or study -Psychiatric hospitalization in the past 12 months"
946,NCT03045341,",,,29:36:chronic_disease",BMI 27-30 with a controlled obesity-related co-morbidity
947,NCT03013543,226:233:chronic_disease,"Bi-allelic, homozygous or compound heterozygous (a different gene mutation on each allele) genetic status for either the POMC, PCSK1, or LEPR genes, with the loss-of-function (LOF) variant for each allele conferring a severe obesity phenotype"
948,NCT02881515,"1:8:chronic_disease,,",obesity (BMI > 30 kg/m2)
949,NCT02620449,"9:16:chronic_disease,,",extreme obesity (BMI ? 35 kg/m2)
950,NCT02527200,",,,,182:189:chronic_disease",BMI (body mass index) corresponding to equal or above 30 kg/m^2 for adults by international cut-off points1 and equal or above the 95th percentile for age and sex (for diagnosis of obesity)
951,NCT02429830,",43:50:chronic_disease,",Laparoscopic sleeve gastrectomy (LSG) for obesity >12 months prior to proposed device implantation date
952,NCT02270619,",,32:39:chronic_disease",BMI > 35 due to the effects of obesity on cytokine activity and risk for sleep disordered breathing
953,NCT02251431,8:15:chronic_disease,Morbid obesity or body girth that prohibits the ability to undergo echocardiography or MRI scanning with high-quality image results
954,NCT02148003,"8:15:chronic_disease,,",morbid obesity (BMI > 35kg/m2)
955,NCT02008136,11:18:chronic_disease,Excessive obesity
956,NCT01967849,",,,,,,,221:228:chronic_disease","Lean (not overweight or obese) will be defined as a body mass index (BMI) (kg/m2) less than the 85th percentile specific for age and gender, overweight will be defined as a BMI between the 85th and 95th percentiles, and obesity will be defined as a BMI greater than the 95th percentile"
957,NCT03088709,1:12:chronic_disease,Hepatitis C
958,NCT03061201,"12:23:chronic_disease,","History of Hepatitis C, unless viral assays in two samples, collected at least 6 months apart, are negative"
959,NCT03048448,1:12:chronic_disease,Hepatitis C test result
960,NCT02983240,1:12:chronic_disease,Hepatitis C
961,NCT02710396,"1:12:chronic_disease,","Hepatitis C (e.g., HCV RNA [qualitative] is detected)"
962,NCT02641093,1:12:chronic_disease,Hepatitis C
963,NCT02635360,1:12:chronic_disease,Hepatitis C
964,NCT02508038,1:12:chronic_disease,Hepatitis C antibody (Anti-HCV)
965,NCT02374021,1:12:chronic_disease,Hepatitis C Virus
966,NCT02324582,1:12:chronic_disease,"Hepatitis C (e.g., HCV RNA [qualitative] is detected)"
967,NCT02091999,"36:47:chronic_disease,,",Subjects who have been treated for Hepatitis C infection can be included if they have documented sustained virologic response of ? 12 weeks
968,NCT02072148,1:12:chronic_disease,Hepatitis C by history
969,NCT01481974,1:12:chronic_disease,Hepatitis C positive donor liver
970,NCT03035890,14:34:chronic_disease,Uncontrolled intercurrent illness
971,NCT03006302,1:21:chronic_disease,intercurrent illness
972,NCT02905578,15:35:chronic_disease,"Uncontrolled, intercurrent illness"
973,NCT02648282,54:74:chronic_disease,"Conditions, including alcohol or drug dependence, or intercurrent illness that would affect the patient's ability to comply with study visits and procedures"
974,NCT02552953,14:34:chronic_disease,Uncontrolled intercurrent illness
975,NCT02536794,35:55:chronic_disease,Patients who have an uncontrolled intercurrent illness
976,NCT02451982,54:74:chronic_disease,"Conditions, including alcohol or drug dependence, or intercurrent illness that would affect the patient's ability to comply with study visits and procedures"
977,NCT02213289,17:37:chronic_disease,No uncontrolled intercurrent illness or infection
978,NCT02159703,14:34:chronic_disease,Uncontrolled intercurrent illness
979,NCT01871727,9:29:chronic_disease,Serious intercurrent illness
980,NCT01515527,14:34:chronic_disease,Uncontrolled intercurrent illness
981,NCT01367444,"13:33:chronic_disease,",Significant intercurrent illness or infection during the 28 days prior to enrolment
982,NCT01228448,14:34:chronic_disease,"Uncontrolled intercurrent illness that, in the opinion of the investigator, would limit the participant's compliance with study requirements"
983,NCT03171168,"11:27:treatment,",No recent physical therapy (no more recent than 6 months) on the affected limb
984,NCT03135145,14:30:treatment,referred for physical therapy for mobility/gait training to regain functional walking and ambulation
985,NCT03072381,37:53:treatment,self-reported failure of supervised physical therapy
986,NCT02905370,23:39:treatment,Referred to home care physical therapy following acute medical deconditioning
987,NCT02890485,14:30:treatment,Referred for physical therapy
988,NCT02759211,26:42:treatment,Current participation in physical therapy
989,NCT02746458,84:100:treatment,Use of blood flow restriction (BFR) at any time between treatment and the start of physical therapy for the study
990,NCT02667392,11:27:treatment,Receiving physical therapy services for mobility and/or gait
991,NCT02383979,29:45:treatment,inability to cooperate with physical therapy
992,NCT02323945,23:39:treatment,Undergoing concurrent physical therapy
993,NCT02274116,12:28:treatment,concurrent physical therapy
994,NCT01420887,36:52:treatment,Not possible to have postoperative physical therapy appointment
995,NCT03092609,4:18:chronic_disease,No Claustrophobia
996,NCT02826343,1:15:chronic_disease,"Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning"
997,NCT02721303,1:15:chronic_disease,Claustrophobia
998,NCT02719327,"1:15:chronic_disease,",Claustrophobia requiring sedation for MRI
999,NCT02531880,1:15:chronic_disease,Claustrophobia to a degree that the subject would feel uncomfortable in the MRI machine
1000,NCT02489591,1:15:chronic_disease,Claustrophobia
1001,NCT02067975,1:15:chronic_disease,Claustrophobia
1002,NCT01986205,1:15:chronic_disease,Claustrophobia precluding chamber or hood tolerance
1003,NCT01738009,1:15:chronic_disease,Claustrophobia
1004,NCT01614990,1:15:chronic_disease,Claustrophobia (this would make lying in the scanner very uncomfortable)
1005,NCT01608438,1:15:chronic_disease,Claustrophobia precluding MRI
1006,NCT01604512,1:15:chronic_disease,Claustrophobia
1007,NCT02905578,19:34:treatment,Side effects from prior therapies that are still deemed moderate to severe by a physician
1008,NCT02594384,40:55:treatment,Not recovered from toxicity due to all prior therapies
1009,NCT02577406,80:95:treatment,"Subject has persistent, clinically significant non-hematologic toxicities from prior therapies"
1010,NCT02503722,15:30:treatment,Any number of prior therapies are allowed
1011,NCT02496663,15:30:treatment,Any number of prior therapies is allowed
1012,NCT02203513,36:51:treatment,There is no limit on the number of prior therapies
1013,NCT02132598,",,87:102:treatment",The subject has not recovered to baseline or CTCAE ? Grade 1 from toxicity due to all prior therapies
1014,NCT02048722,",9:24:treatment",up to 4 prior therapies are allowed
1015,NCT01947140,34:49:treatment,No upper limit for the number of prior therapies
1016,NCT01896999,30:45:treatment,no upper limit for number of prior therapies
1017,NCT01822522,",,141:156:treatment",The participant has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies
1018,NCT01241708,32:47:treatment,Recovery from complications of prior therapies
1019,NCT03181867,41:62:chronic_disease,Subjects with any coexisting medical or psychiatric condition that is likely to interfere with study procedures and/or results
1020,NCT03138512,52:73:chronic_disease,"Any severe or serious, acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation"
1021,NCT03104699,5:26:chronic_disease,Any psychiatric condition that would prohibit understanding or rendering of informed consent
1022,NCT02979860,1:22:chronic_disease,psychiatric condition that may impact sleep/weight status
1023,NCT02872935,23:44:chronic_disease,Any other physical or psychiatric condition that may impair their ability to cooperate with study data collection
1024,NCT02707692,14:35:chronic_disease,Uncontrolled psychiatric condition
1025,NCT02576444,46:67:chronic_disease,Any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results
1026,NCT02245997,41:62:chronic_disease,"Patients with any concurrent medical or psychiatric condition or disease which, in the investigator's judgment, would make them inappropriate candidates for entry into this study"
1027,NCT02243813,7:28:chronic_disease,Has a psychiatric condition judged to be incompatible with establishment of rapport or safe exposure to psilocybin
1028,NCT02025426,23:44:chronic_disease,Any other physical or psychiatric condition which may impair their ability to cooperate with study data collection
1029,NCT01886794,62:83:chronic_disease,History of prior noncompliance or the presence or history of psychiatric condition that would in the opinion of the investigator make it difficult for the subject to comply with study procedures or follow instructions
1030,NCT03108950,1:14:chronic_disease,Renal failure
1031,NCT03003390,1:14:chronic_disease,Renal failure
1032,NCT02981082,1:14:chronic_disease,Renal failure
1033,NCT02943590,1:14:chronic_disease,Renal failure
1034,NCT02919436,1:14:chronic_disease,Renal failure
1035,NCT02776059,1:14:chronic_disease,Renal failure
1036,NCT02679560,1:14:chronic_disease,Renal failure requiring dialysis
1037,NCT02564796,1:14:chronic_disease,Renal failure
1038,NCT02551679,1:14:chronic_disease,Renal failure
1039,NCT02533882,1:14:chronic_disease,Renal failure
1040,NCT00967785,"1:14:chronic_disease,,",Renal failure (calculated creatinine clearance [CrCl] <15 mL/min or requiring dialysis)
1041,NCT03016871,1:24:treatment,Prior radiation therapy is allowed
1042,NCT02504489,1:24:treatment,Prior radiation therapy is not exclusionary
1043,NCT02344355,1:24:treatment,Prior radiation therapy to the head or neck resulting in overlap of RT fields
1044,NCT02159703,1:24:treatment,Prior radiation therapy to the head and neck
1045,NCT02143726,"1:24:treatment,",Prior radiation therapy to the non-index lesions is allowed if ? 28 days prior to registration on this protocol
1046,NCT02094794,1:24:treatment,Prior radiation therapy that would exclude the use of TMLI
1047,NCT01804465,"1:24:treatment,",Prior radiation therapy must be completed ? 4 weeks prior to enrollment and the patient must have recovered from all toxicity
1048,NCT01766297,1:24:treatment,Prior radiation therapy to the ipsilateral breast or thorax
1049,NCT01737502,1:24:treatment,Prior radiation therapy
1050,NCT01434316,1:24:treatment,Prior radiation therapy
1051,NCT00967577,"1:24:treatment,",Prior radiation therapy encompassing >25% of skeleton
1052,NCT02852057,1:7:chronic_disease,Asthma
1053,NCT02696980,"1:7:chronic_disease,,",Asthma diagnosis when ? 18 years of age
1054,NCT02507011,1:7:chronic_disease,Asthma
1055,NCT02493257,1:7:chronic_disease,Asthma
1056,NCT02487082,1:7:chronic_disease,Asthma
1057,NCT02433977,"1:7:chronic_disease,,",Asthma diagnosed at age 9 or later
1058,NCT02433977,"1:7:chronic_disease,",Asthma-related ER visit within the previous 4 weeks
1059,NCT02433977,"1:7:chronic_disease,",Asthma-related hospitalization within the last 2 months
1060,NCT02193373,1:7:chronic_disease,Asthma
1061,NCT02025465,1:7:chronic_disease,Asthma
1062,NCT01536522,"1:7:chronic_disease,,,",Asthma diagnosed by a medical specialist and/or history of positive methacholine rest and/or reversibility of >10% of FEV1
1063,NCT02585973,20:36:treatment,Ability to swallow oral medications
1064,NCT02516696,36:52:treatment,Subject is unable to reliably take oral medications
1065,NCT02466009,36:52:treatment,Must be able to swallow and retain oral medications
1066,NCT02433626,23:39:treatment,Inability to tolerate oral medications
1067,NCT02417701,20:36:treatment,Ability to swallow oral medications
1068,NCT02321501,17:33:treatment,Able to swallow oral medications
1069,NCT02122172,19:35:treatment,Inability to take oral medications
1070,NCT01972919,20:36:treatment,Ability to swallow oral medications
1071,NCT01835626,78:94:treatment,Patients with any condition that may impair the ability to swallow or absorb oral medications/investigational product
1072,NCT01618357,30:46:treatment,Unable to swallow and retain oral medications
1073,NCT01595529,34:50:treatment,A child that is not able to take oral medications
1074,NCT03181126,19:41:chronic_disease,Participants with malabsorption syndrome or any other condition that precludes enteral administration
1075,NCT02876302,24:46:chronic_disease,Clinically significant malabsorption syndrome
1076,NCT02574910,16:38:chronic_disease,A history of a malabsorption syndrome
1077,NCT02419560,13:35:chronic_disease,Subject has malabsorption syndrome or other condition which may affect an enteral route of administration
1078,NCT02394535,1:23:chronic_disease,malabsorption syndrome
1079,NCT02187848,15:37:chronic_disease,Patients with malabsorption syndrome
1080,NCT02101736,1:23:chronic_disease,malabsorption syndrome
1081,NCT01972919,14:36:chronic_disease,Uncontrolled malabsorption syndrome significantly affecting gastrointestinal function
1082,NCT01835626,1:23:chronic_disease,malabsorption syndrome
1083,NCT01639508,1:23:chronic_disease,malabsorption syndrome
1084,NCT03158519,1:8:chronic_disease,dyspnea requiring oxygen
1085,NCT02833805,",92:99:chronic_disease,,",For patients < 8 years old or unable to undergo pulmonary function testing: no evidence of dyspnea at rest; no need for supplemental oxygen; oxygen saturation > 92% on room air
1086,NCT02688647,41:48:chronic_disease,"Acute or chronic impairment (other than dyspnea) limiting the ability to comply with study requirements (eg, pulmonary function tests)"
1087,NCT02508038,16:23:chronic_disease,No evidence of dyspnea at rest
1088,NCT02389309,"59:66:chronic_disease,,","Adequate pulmonary function as defined as: no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination"
1089,NCT02145351,38:45:chronic_disease,Other clinically important causes of dyspnea
1090,NCT02076906,15:22:chronic_disease,Defined as no dyspnea at rest
1091,NCT01966367,"108:115:chronic_disease,,","Adequate pulmonary function by pulmonary function test. For children who are uncooperative, no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry >94% on room air"
1092,NCT01896999,"35:42:chronic_disease,,",Patients must have no evidence of dyspnea at rest and a pulse oximetry > 92% while breathing room air
1093,NCT01614197,16:23:chronic_disease,No evidence of dyspnea at rest and no exercise intolerance
1094,NCT03112720,29:38:allergy_name,Subjects with an allergy to lidocaine
1095,NCT03051516,33:42:allergy_name,Known allergy or intolerance to lidocaine
1096,NCT02924441,44:53:allergy_name,Must not have a contraindication for using lidocaine: e.g no history of allergic reactions to lidocaine
1097,NCT02833207,16:25:treatment,Sensitivity to lidocaine
1098,NCT02832115,41:50:allergy_name,Hypersensitivity or contraindication to lidocaine
1099,NCT02638454,12:21:allergy_name,Allergy to lidocaine
1100,NCT02485639,18:27:allergy_name,known allergy to lidocaine
1101,NCT02233868,40:49:allergy_name,"Have a history of allergic reaction to lidocaine (self-report, medical history)"
1102,NCT01901562,25:34:allergy_name,Have a known allergy to lidocaine
1103,NCT01434316,34:43:allergy_name,Subjects with a known allergy to lidocaine
1104,NCT03057548,44:68:chronic_disease,Patients with any corrected or uncorrected congenital heart disease
1105,NCT02946892,6:30:chronic_disease,with congenital heart disease that has been palliated with a Fontan circulation
1106,NCT02816736,9:33:chronic_disease,Complex congenital heart disease
1107,NCT02589977,1:25:chronic_disease,congenital heart disease
1108,NCT02477839,43:67:chronic_disease,Subject has a hemodynamically significant congenital heart disease
1109,NCT02476409,9:33:chronic_disease,Complex congenital heart disease
1110,NCT02249039,28:52:chronic_disease,Postoperative from complex congenital heart disease
1111,NCT02145351,9:33:chronic_disease,Complex congenital heart disease
1112,NCT01883076,49:73:chronic_disease,Child with the following complications of their congenital heart disease
1113,NCT01878617,14:38:chronic_disease,Must have no congenital heart disease
1114,NCT03001830,"25:30:chronic_disease,,",Serological evidence of HIV-1 who have CD4 counts ? 200/mm3
1115,NCT02881320,"11:16:chronic_disease,,,,,,",Cohort 1: HIV-1 infected adolescents (12 to < 18 years of age and screening weight ? 35 kg) who are virologically suppressed for ? 6 months prior to screening
1116,NCT02881320,"11:16:chronic_disease,,,,,,",Cohort 2: HIV-1 infected children (6 to < 12 years of age and screening weight ? 25 kg) who are virologically suppressed for ? 6 months prior to screening
1117,NCT02881320,"11:16:chronic_disease,,,,,,,",Cohort 3: HIV-1 infected children (? 2 years of age and screening weight of ? 14 to < 25 kg) who are virologically suppressed for ? 6 months prior to screening
1118,NCT02610374,29:34:chronic_disease,Documentation of a negative HIV-1 antibody test
1119,NCT02471430,"23:28:chronic_disease,,,",Documented suppressed HIV-1 RNA (plasma HIV-1 RNA values <50 copies/ml)
1120,NCT02471430,1:6:chronic_disease,HIV-1 infection prior to entry
1121,NCT02285114,1:6:chronic_disease,HIV-1 infected
1122,NCT02256631,"12:17:chronic_disease,",Born to an HIV-1-infected woman who meets all maternal inclusion/exclusion criteria listed above
1123,NCT02191098,1:6:chronic_disease,HIV-1 infected adults
1124,NCT03182075,22:25:chronic_disease,primary diagnosis of OCD
1125,NCT03182075,24:27:chronic_disease,sufficient severity of OCD symptoms
1126,NCT02624596,22:25:chronic_disease,Primary diagnosis of OCD
1127,NCT02624596,24:27:chronic_disease,Sufficient severity of OCD symptoms
1128,NCT02437773,",8:11:chronic_disease,",Age of OCD onset after 15 years old
1129,NCT02437773,25:28:chronic_disease,subjects diagnosed with OCD
1130,NCT02421315,77:80:chronic_disease,Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Diagnosis of OCD as the principal problem
1131,NCT02206945,"30:33:chronic_disease,,","Primary Diagnosis of Current OCD, based on Diagnostic and Statistical Manual (DSM-IV) criteria, a Y-BOCS (Yale-Brown Obsessive-Compulsive Scale) score >=16"
1132,NCT02206945,11:14:chronic_disease,Principle OCD symptoms- Primary symptoms must be either Cleaning/Contamination or Checking; other symptoms okay
1133,NCT03143985,20:32:treatment,Patients requiring hemodialysis
1134,NCT02965508,",102:114:treatment","Patients must live in Manhattan, have access to a telephone 24 hours a day, 7 days a week, not be on hemodialysis, agree to open the door and allow access to the members of the team"
1135,NCT02570854,"11:23:treatment,",Receiving hemodialysis at least 2 times per week
1136,NCT02532621,"46:58:treatment,",has a reasonable expectation of remaining on hemodialysis for at least 6 months
1137,NCT02522871,16:28:treatment,Chronic use of hemodialysis
1138,NCT02468778,15:27:treatment,Subject is on hemodialysis
1139,NCT02433210,"11:23:treatment,",Stable on hemodialysis for more than 3 months
1140,NCT02378428,21:33:treatment,Patients who are on hemodialysis
1141,NCT02278198,1:13:treatment,hemodialysis
1142,NCT03126370,1:12:chronic_disease,Hepatitis B infection
1143,NCT02641093,1:12:chronic_disease,Hepatitis B
1144,NCT02635360,1:12:chronic_disease,Hepatitis B
1145,NCT02587962,8:19:chronic_disease,Active Hepatitis B (HBsAg reactive
1146,NCT02570854,12:23:chronic_disease,A positive Hepatitis B surface antigen test result
1147,NCT02520427,14:25:chronic_disease,Positive for Hepatitis B
1148,NCT02508038,1:12:chronic_disease,Hepatitis B surface antigen (HBsAg)
1149,NCT01880567,16:27:chronic_disease,positive serum Hepatitis B antibody
1150,NCT01306019,19:30:chronic_disease,Documented active Hepatitis B infection
1151,NCT03116685,1:4:chronic_disease,CKD-EPI formula will be used for adults
1152,NCT02945969,",,,339:342:chronic_disease,,","The investigators chose an upper eGFR limit slightly higher than the Kidney Disease Outcomes Quality Initiative (KDOQI) definition of moderately reduced glomerular filtration rate (GFR) to be more inclusive of patients with mild reduction in GFR but significant proteinuria. The lower eGFR limit was set to exclude patients with advanced CKD, where the potential effects of dietary sodium reduction on proteinuria may not be apparent or greatly alter CKD progression. The eGFR to define eligibility will be calculated using calibrated serum creatinine values and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) estimating equation"
1153,NCT02836574,123:126:chronic_disease,"The subject should have adequate, historical clinical data to provide a reasonable estimate of the rate of progression of CKD"
1154,NCT02820350,96:99:chronic_disease,Patients who have never seen a pediatric nephrologist will be assumed not to have pre-existing CKD
1155,NCT02587936,"1:4:chronic_disease,",CKD Inclusion Criteria (present at least ? 3 months apart)
1156,NCT02497300,"1:4:chronic_disease,,,,,",CKD (eGFR 25-60 mL/min/1.73m2) with urine albumin-to-creatinine ratio > 30 mg/g
1157,NCT02497300,"1:4:chronic_disease,,,,",CKD (eGFR > 60 mL/min/1.73m2) with urine albumin-to-creatinine ratio ? 300 mg/g
1158,NCT02411773,"8:11:chronic_disease,,",Severe CKD (estimated glomerular filtration rate (eGFR) < 15 cc/minute)
1159,NCT01530958,15:18:chronic_disease,Patients with CKD
1160,NCT03076021,"1:8:chronic_disease,,","Obesity, BMI ? 30 kg/m2"
1161,NCT03061903,"1:8:chronic_disease,,",Obesity (Body Mass Index (BMI) > 30)
1162,NCT02866279,"1:8:chronic_disease,,",Obesity (pre-pregnancy BMI >35)
1163,NCT02819440,"1:8:chronic_disease,,",Obesity (BMI ? 30 kg/m2)
1164,NCT02706249,"1:8:chronic_disease,,",Obesity (BMI ? 30)
1165,NCT02548351,"1:8:chronic_disease,,",Obesity (BMI ?30 kg/m2)
1166,NCT02473250,"1:8:chronic_disease,,",Obesity with weight >350 lbs
1167,NCT01614990,"1:8:chronic_disease,,",Obesity (body weight >140 Kg)
1168,NCT01026532,"1:8:chronic_disease,,",Obesity as defined by a Body Mass Index (BMI) >30
1169,NCT03029884,1:13:chronic_disease,Coagulopathy
1170,NCT03003390,1:13:chronic_disease,Coagulopathy
1171,NCT02983903,"1:13:chronic_disease,,,,,","Coagulopathy (platelet count < 50,000, INR > 1.5) detected on blood testing done within 3 weeks of the procedural visit"
1172,NCT02937402,"1:13:chronic_disease,,",Coagulopathy with international normalized ratio (INR) > 2.0 or
1173,NCT02937402,"1:13:treatment,,",Coagulopathy with platelets (Plt) < 10 k
1174,NCT02679560,"1:13:chronic_disease,,",Coagulopathy with INR >1.5
1175,NCT02473276,1:13:chronic_disease,Coagulopathy
1176,NCT01419561,"1:13:chronic_disease,,",Coagulopathy (PT or PTT >1.5 times upper limit of normal)
1177,NCT01187368,1:13:chronic_disease,Coagulopathy
1178,NCT02947347,1:19:chronic_disease,Measurable disease
1179,NCT02939183,"1:19:chronic_disease,",Measurable disease (assessed within 28 days prior to day 1)
1180,NCT02595996,1:19:chronic_disease,Measurable disease
1181,NCT02592707,1:19:chronic_disease,Measurable disease based on RECIST v1.1
1182,NCT02476786,1:19:chronic_disease,Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) by ultrasound or mammogram
1183,NCT02451553,1:19:chronic_disease,Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
1184,NCT02250157,1:19:chronic_disease,Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria
1185,NCT02091141,1:19:chronic_disease,Measurable disease by RECIST v1.1
1186,NCT01464034,1:19:cancer,Measurable disease
1187,NCT02901067,"1:17:chronic_disease,,","Thrombocytopenia (platelet count < 50,000)"
1188,NCT02474927,1:17:chronic_disease,Thrombocytopenia
1189,NCT02343549,"1:17:chronic_disease,,",Thrombocytopenia (platelet count < 100 x 103 )
1190,NCT02335905,"1:17:chronic_disease,","Thrombocytopenia (less than 50,000 platelets/mm^3)"
1191,NCT02234934,"1:17:chronic_disease,,","Thrombocytopenia (platelet count < 150,000/mm3)"
1192,NCT02226341,"1:17:chronic_disease,,","Thrombocytopenia (platelets < 50,000/mm3)"
1193,NCT02074436,"1:17:cancer,,",Thrombocytopenia with untransfused platelet counts < 20 x 10?/L in the out-patient or in the in-patient setting
1194,NCT01419561,"1:17:chronic_disease,,","Thrombocytopenia (platelets<100,000 cells/microL)"
1195,NCT01059786,"1:17:chronic_disease,,","Thrombocytopenia (Plt less than 100,000/microl)"
1196,NCT02706249,8:28:chronic_disease,Active peptic ulcer disease
1197,NCT02509546,8:28:chronic_disease,Active peptic ulcer disease
1198,NCT02464878,8:28:chronic_disease,Active peptic ulcer disease
1199,NCT02132598,8:28:chronic_disease,Active peptic ulcer disease
1200,NCT02078102,"49:69:chronic_disease,",Patients must not have nor had active or recent peptic ulcer disease within the past 6 months
1201,NCT01974609,22:42:chronic_disease,patients with active peptic ulcer disease (history of severe heartburn)
1202,NCT01639508,8:28:chronic_disease,active peptic ulcer disease
1203,NCT01553214,21:41:chronic_disease,"Active, symptomatic peptic ulcer disease"
1204,NCT01238120,"19:39:chronic_disease,",have a history of peptic ulcer disease within the last 12 months
1205,NCT02473354,18:37:chronic_disease,has a history of sickle cell disease [self-reported]
1206,NCT02312596,1:20:chronic_disease,sickle cell disease
1207,NCT02312518,1:20:chronic_disease,sickle cell disease
1208,NCT02186418,24:43:chronic_disease,"Confirmed diagnosis of sickle cell disease genotype Hb- S/beta-thalassemia or Hb-S/ beta + thalassemia disease or HbS/Hb-S, confirmed by beta-globin gene analysis and a hemoglobin separation method"
1209,NCT02186418,18:37:chronic_disease,Most adults with sickle cell disease will have compromised PFTs
1210,NCT02186418,8:27:chronic_disease,Severe sickle cell disease
1211,NCT02165007,22:41:chronic_disease,Patients with severe sickle cell disease
1212,NCT01891812,15:34:chronic_disease,Patients with sickle cell disease
1213,NCT01754298,14:33:chronic_disease,Diagnosis of sickle cell disease
1214,NCT03144921,8:22:chronic_disease,severe mental illness
1215,NCT03084640,48:62:chronic_disease,"Any concurrent uncontrolled illness, including mental illness or substance abuse, which in the opinion of the Investigator"
1216,NCT03026816,24:38:chronic_disease,Clinically significant mental illness
1217,NCT02826577,10:24:chronic_disease,Unstable mental illness
1218,NCT02799095,68:82:chronic_disease,"Subjects with any other concurrent uncontrolled illness, including mental illness or substance abuse, which may interfere with the ability of the subject to cooperate and participate in the study"
1219,NCT02680535,1:15:chronic_disease,mental illness
1220,NCT02437773,31:45:chronic_disease,No history of past or current mental illness
1221,NCT02155946,22:36:chronic_disease,No history of severe mental illness
1222,NCT03133013,16:41:chronic_disease,diagnosed with Major Depressive Disorder by a psychiatric specialist of this research according to MINI screening and DSM-5 criteria
1223,NCT03038620,"12:37:chronic_disease,",History of Major Depressive Disorder within the last 2 years
1224,NCT02734602,37:62:chronic_disease,"Meet DSM-IV diagnostic criteria for Major Depressive Disorder, and for a current depressive episode"
1225,NCT02674529,56:81:chronic_disease,Currently experiencing a depressive episode as part of Major Depressive Disorder
1226,NCT02389465,21:46:chronic_disease,DSM-IV criteria for Major Depressive Disorder
1227,NCT02357849,22:47:chronic_disease,"current diagnosis of Major Depressive Disorder, single episode or recurrent, severe without psychotic features"
1228,NCT02301260,24:49:chronic_disease,a current diagnosis of Major Depressive Disorder
1229,NCT02133898,"14:39:chronic_disease,",Diagnosis of Major Depressive Disorder based on Structured Clinical Interview for DSM-IV (SCID)
1230,NCT03122639,"1:4:chronic_disease,,",OSA is defined as apnea-hypopnea index (AHI) ?5 events/hour of sleep
1231,NCT03109210,"21:24:chronic_disease,,",have a diagnosis of OSA with an AHI > 5 on a diagnostic polysomnogram
1232,NCT02962557,"11:14:chronic_disease,,,",Suspected OSA will be defined as a patient with a screening questionnaire (STOP-Bang) score of 5-8 (A score consistent with a high risk of OSA)
1233,NCT02781701,"44:47:chronic_disease,,,",At home confirmation of moderate to severe OSA (AHI 15-60)
1234,NCT02413970,34:37:chronic_disease,Likely suffer moderate-to-severe OSA based on history and physical
1235,NCT02413970,"34:37:chronic_disease,,",have an established diagnosis of OSA (AHI >= 15) based on a prior sleep study
1236,NCT02202811,"20:23:chronic_disease,,",Moderate to severe OSA (AHI)>15
1237,NCT01738009,34:37:chronic_disease,Normal subjects or patients with OSA
1238,NCT03076021,7:21:chronic_disease,Known kidney disease
1239,NCT03034564,13:27:chronic_disease,Significant kidney disease history
1240,NCT02982772,1:15:chronic_disease,kidney disease
1241,NCT02914483,26:40:chronic_disease,chronic elevation due to kidney disease
1242,NCT02881515,12:26:chronic_disease,history of kidney disease
1243,NCT02682147,1:15:chronic_disease,kidney disease
1244,NCT02462161,1:15:chronic_disease,kidney disease
1245,NCT02411773,",,35:49:chronic_disease","Veterans 18-75 years old, without kidney disease, as study controls"
1246,NCT03066648,11:14:chronic_disease,High risk MDS
1247,NCT02649790,"25:28:chronic_disease,,,",Documented diagnosis of MDS with 5-19% myeloblasts
1248,NCT02649790,",33:36:cancer",IPSS low or intermediate-1 risk MDS
1249,NCT02530463,"15:18:cancer,",Patients with MDS (up to 20% blasts) of any risk as defined as
1250,NCT02131597,"13:16:cancer,,,,",higher risk MDS (International Prognostic Scoring System [IPSS] int-2 or high; or >= 10% blasts as defined by World Health Organization [WHO])
1251,NCT01861106,",68:71:chronic_disease,,","Clinical history of at least one life-threatening infection and/or MDS with International Prognostic Scoring System (IPSS) category of Intermediate-1, Intermediate-2 or High"
1252,NCT01861106,"31:34:cancer,,",The majority of patients with MDS will have less than 5% blasts
1253,NCT01349101,15:18:cancer,patients with MDS
1254,NCT03028831,1:19:chronic_disease,bleeding disorders
1255,NCT02914171,18:36:chronic_disease,Individuals with bleeding disorders
1256,NCT02703272,41:59:chronic_disease,Participants with inherited or acquired bleeding disorders
1257,NCT02553941,"7:25:chronic_disease,,","Known bleeding disorders, active bleeding disorders or clinical signs of bleeding (grade >= 2)"
1258,NCT02514083,7:25:chronic_disease,Known bleeding disorders
1259,NCT02366871,21:39:chronic_disease,Known or documented bleeding disorders
1260,NCT02203552,7:25:chronic_disease,Known bleeding disorders
1261,NCT01695967,1:19:chronic_disease,bleeding disorders
1262,NCT02987491,",,,,54:59:chronic_disease,,",Normal weight (body mass index [BMI] 18-26 kg/m2) or obese (BMI 30-46 kg/m2)
1263,NCT02577549,"32:37:chronic_disease,,","Not sufficiently overweight or obese, BMI < 27 kg/m2"
1264,NCT02465541,",15:20:chronic_disease,",Overweight or obese (> 25 kg/m^2)
1265,NCT02425566,1:6:chronic_disease,obese
1266,NCT02424929,19:24:chronic_disease,Patients that are obese or that have severe potential airway issues
1267,NCT02392897,"24:29:chronic_disease,","Normal, overweight and obese males and females"
1268,NCT02347527,12:17:chronic_disease,Overweight/obese adults
1269,NCT01421797,12:17:chronic_disease,Normal and obese
1270,NCT02764801,26:45:chronic_disease,with clinically unstable cardiac arrhythmias
1271,NCT02496208,24:43:chronic_disease,Clinically-significant cardiac arrhythmias
1272,NCT02208362,70:89:chronic_disease,Research participant requires pressor support and/or has symptomatic cardiac arrhythmias
1273,NCT02101736,24:43:chronic_disease,clinically-significant cardiac arrhythmias
1274,NCT01978509,16:35:chronic_disease,Risk of severe cardiac arrhythmias
1275,NCT01841333,"8:27:chronic_disease,",Active cardiac arrhythmias with rapid ventricular response (defined as heart rate greater than 100 beats/minute)
1276,NCT01822522,24:43:chronic_disease,Clinically-significant cardiac arrhythmias
1277,NCT01639508,24:43:chronic_disease,clinically-significant cardiac arrhythmias
1278,NCT02573493,"18:37:cancer,",History of prior invasive malignancy diagnosed within 3 years prior to study enrollment
1279,NCT02465268,"7:26:cancer,",Prior invasive malignancy unless disease free for ? 3 years
1280,NCT02237183,"47:66:cancer,",Participants must not have a current or prior invasive malignancy within the past 6 months
1281,NCT02122185,"19:38:cancer,,,",Concurrent active invasive malignancy or one previously diagnosed with a greater than 30% chance of recurrence in the next two years
1282,NCT02110992,7:26:cancer,Prior invasive malignancy
1283,NCT02080221,"10:29:cancer,",No prior invasive malignancy within the prior two years
1284,NCT01890590,"18:37:cancer,",Prior history of invasive malignancy within the last 2 years
1285,NCT01659203,"24:43:cancer,",History of a different invasive malignancy within the past 3 years
1286,NCT02416674,35:50:treatment,Strong motivation to proceed with transplantation
1287,NCT02327403,",17:32:treatment",?6 months after transplantation
1288,NCT01459107,116:131:treatment,Functionless or minimally functional hand desiring removal of functionless / minimally functional hand followed by transplantation
1289,NCT01453088,",,26:41:treatment",Age ?60 years at time of transplantation
1290,NCT01366612,45:60:treatment,Any stage of disease will be considered for transplantation
1291,NCT01241708,",,,29:44:treatment",Age: 18-75 years at time of transplantation
1292,NCT01054196,82:97:treatment,Patients must have an adequate number of CD34+ stem cells collected to allow for transplantation
1293,NCT00711373,68:83:treatment,severe concomitant diseases which would exclude the recipient from transplantation
1294,NCT03176979,",12:22:allergy_name",Women with gadolinium contrast allergy
1295,NCT02844465,12:22:allergy_name,Allergy to gadolinium
1296,NCT02776891,16:26:treatment,intolerance to gadolinium
1297,NCT02531880,12:22:allergy_name,Allergy to gadolinium
1298,NCT02251431,27:37:allergy_name,Allergy or intolerance to gadolinium
1299,NCT02124902,28:38:allergy_name,Prior allergic reaction to gadolinium-based MR contrast agents
1300,NCT01644591,50:60:allergy_name,Patients are excluded if there is any history of gadolinium allergy
1301,NCT03159754,17:29:treatment,Patients taking theophylline
1302,NCT02498301,1:13:treatment,theophylline
1303,NCT02495168,40:52:treatment,Once-a-day controlled-release forms of theophylline: 36 hours
1304,NCT02495168,23:35:treatment,Short-acting forms of theophylline: 12 hours
1305,NCT02495168,41:53:treatment,Twice-a-day controlled-release forms of theophylline: 24 hours
1306,NCT02479451,33:45:treatment,Patients currently treated with theophylline for clinical indication
1307,NCT02479451,28:40:allergy_name,Prior allergic reaction to theophylline
1308,NCT03153410,15:30:chronic_disease,Patients with thyroid disease
1309,NCT03073070,14:29:chronic_disease,uncontrolled thyroid disease
1310,NCT03035799,"14:29:chronic_disease,",Uncontrolled thyroid disease as indicated by an abnormal thyroid stimulating hormone (TSH) level
1311,NCT03007745,1:16:chronic_disease,thyroid disease
1312,NCT02272556,11:26:chronic_disease,Untreated thyroid disease
1313,NCT02169037,40:55:chronic_disease,"AF secondary to electrolyte imbalance, thyroid disease"
1314,NCT01614990,11:26:chronic_disease,untreated thyroid disease
1315,NCT03133013,1:19:chronic_disease,multiple sclerosis
1316,NCT03058796,1:19:chronic_disease,multiple sclerosis
1317,NCT03016351,1:19:chronic_disease,multiple sclerosis
1318,NCT02862938,26:44:chronic_disease,Patient has a history of multiple sclerosis
1319,NCT02694666,15:33:chronic_disease,Self-reported multiple sclerosis and confirmed by the physician
1320,NCT02329652,1:19:chronic_disease,multiple sclerosis
1321,NCT01326715,14:32:chronic_disease,Diagnosis of multiple sclerosis according to the current McDonald Criteria
1322,NCT03114891,12:15:allergy_name,Additional TMS contraindications
1323,NCT03037983,38:41:allergy_name,History of prior adverse reaction to TMS
1324,NCT02565199,24:27:allergy_name,Has a contradiction to TMS
1325,NCT02565199,",27:30:treatment",MEP cannot be evoked with TMS in the ECU muscle
1326,NCT02565199,49:52:treatment,The subjects must be comfortable when receiving TMS of all strengths
1327,NCT02544503,21:24:treatment,Contraindication to TMS
1328,NCT02479906,41:44:treatment,Subject has had previous treatment with TMS
1329,NCT03096288,1:24:chronic_disease,Hemodynamic instability
1330,NCT02973139,1:24:chronic_disease,Hemodynamic instability
1331,NCT02836899,"1:24:chronic_disease,,",Hemodynamic instability as defined by a systolic blood pressure <90 mmHg
1332,NCT02749968,"1:24:chronic_disease,,,,",Hemodynamic instability (defined as new intravenous vasopressor or inotrope requirement or mean arterial pressure < 55 mmHg)
1333,NCT02741180,1:24:chronic_disease,Hemodynamic instability
1334,NCT02464904,"1:24:chronic_disease,,,,","Hemodynamic instability with systolic blood pressure <90 mmHg or heart rate > 120 beats/min, unless deemed to be stable with these values by the surgical or interventional pulmonary attending physicians"
1335,NCT00871260,1:24:chronic_disease,Hemodynamic instability
1336,NCT03089853,",36:51:treatment",can be enrolled within 36 hours of hospitalization
1337,NCT03078907,"5:20:treatment,",Any hospitalization during the last 30 days prior to screening
1338,NCT02531295,"8:23:treatment,",Recent hospitalization in the last 90 days
1339,NCT02494141,"12:27:treatment,",History of hospitalization within the last 3 months
1340,NCT02408406,67:82:treatment,Current outpatient status (participation will be suspended during hospitalization)
1341,NCT02341300,",98:113:treatment,",Women with severe chronic illness and high likelihood of preterm birth and/or expected long-term hospitalizations during pregnancy
1342,NCT01705119,37:52:treatment,patient was not ambulatory prior to hospitalization
1343,NCT03069469,44:58:chronic_disease,History or presence of clinically relevant cardiovascular abnormalities
1344,NCT02469857,",,123:137:chronic_disease","(in any one or combination of the 5 major components of SOFA score with one organ component having a score of at least 2: cardiovascular, respiratory, renal, coagulation, CNS), measured as close as possible to the first debridement"
1345,NCT02397889,1:15:chronic_disease,cardiovascular
1346,NCT02343042,18:32:chronic_disease,"Active, unstable cardiovascular function"
1347,NCT02215096,24:38:chronic_disease,History or evidence of cardiovascular risk
1348,NCT02070549,24:38:chronic_disease,History or evidence of cardiovascular risk
1349,NCT01532687,45:59:chronic_disease,History of any one or more of the following cardiovascular conditions
1350,NCT03043807,"1:16:treatment,",hormone therapy was recently initiated (<90 days duration))
1351,NCT02907983,10:25:treatment,for whom hormone therapy is contraindicated
1352,NCT01886794,"8:23:treatment,,",Use of hormone therapy in postmenopausal women in the last 90 days
1353,NCT01570998,1:16:treatment,hormone therapy
1354,NCT01438073,42:57:treatment,able to undergo appropriate washout from hormone therapy
1355,NCT00914823,42:57:treatment,able to undergo appropriate washout from hormone therapy
1356,NCT00914823,30:45:treatment,able to undergo washout from hormone therapy
1357,NCT03018704,34:57:treatment,"current regular treatment with a psychotropic medication, including medications that, when combined with alcohol, present a risk of overdose"
1358,NCT02707887,"12:35:treatment,",The use of psychotropic medication for < 3 months
1359,NCT02483910,4:27:treatment,"On psychotropic medication, but regimen is not stable (Once stabilized, eligibility could be reconsidered.)"
1360,NCT02283333,"25:48:treatment,",Veterans starting a new psychotropic medication at baseline will be asked to wait 4 weeks for medication stabilization before starting the study
1361,NCT02046330,"29:52:treatment,",On a stable drug regimen of psychotropic medication for at least 6 weeks at the time of entry into the study
1362,NCT01986075,28:51:treatment,Currently being prescribed psychotropic medication by another physician
1363,NCT01964404,12:35:treatment,Taking any psychotropic medication
1364,NCT02947945,1:11:chronic_disease,"Neuropathy, mono or poly (motor deficit or nerve conduction abnormality)"
1365,NCT02828618,"22:32:chronic_disease,,",Neurologic function: Neuropathy (sensory and motor) less than or equal to CTCAE Grade 1
1366,NCT02366819,"1:11:chronic_disease,","Neuropathy, grade 2 or greater by NCI-CTCAE, v 4.0"
1367,NCT02269293,"22:32:chronic_disease,",Neurologic function: Neuropathy (sensory and motor) less than or equal to Grade 1
1368,NCT01690468,"1:11:chronic_disease,,",Neuropathy (sensory and motor) less than or equal to grade 1 per Common Toxicity Criteria (CTC) version 4
1369,NCT01591356,1:11:chronic_disease,Neuropathy (sensory and motor) =< to CTCAE grade 1
1370,NCT01419561,1:11:chronic_disease,Neuropathy with or without pain
1371,NCT02931110,"19:21:chronic_disease,,,,,,","For subjects with MM, measurable disease with serum monoclonal immunoglobulin protein (M-protein) ?1 g/dL, or urine M-protein protein ?200 mg/24 hours, or involved serum free light chain (SFLC) ?10 mg/dL"
1372,NCT02343042,95:97:cancer,"Histologically confirmed diagnosis, measurable disease and evidence of disease progression of MM"
1373,NCT02343042,13:15:cancer,"Symptomatic MM, based on IMWG guidelines"
1374,NCT02253316,13:15:cancer,Evidence of MM disease progression any time prior to enrollment
1375,NCT02253316,42:44:cancer,Progression from smoldering/asymptomatic MM to symptomatic MM
1376,NCT01572480,30:32:cancer,Patients with a diagnosis of MM as defined by the 2014 IMWH diagnostic criteria
1377,NCT00734877,43:45:cancer,Patients must have newly diagnosed active MM requiring treatment
1378,NCT02770547,1:22:chronic_disease,Peripheral neuropathy
1379,NCT02457832,1:22:chronic_disease,Peripheral neuropathy
1380,NCT02365766,"1:22:chronic_disease,,",Peripheral neuropathy of Grade 2-4
1381,NCT02287558,1:22:chronic_disease,"Peripheral neuropathy, as determined from neurologic consultation"
1382,NCT02177695,"1:22:chronic_disease,",Peripheral neuropathy >/= Grade 2
1383,NCT02064296,1:22:chronic_disease,Peripheral neuropathy of know cause that interferes with activities of daily living
1384,NCT01959698,"1:22:chronic_disease,",Peripheral neuropathy of grade 2 or greater severity as defined by the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
1385,NCT02682407,1:12:chronic_disease,hepatitis C infection
1386,NCT02578641,18:29:chronic_disease,Known history of hepatitis C
1387,NCT02412540,1:12:chronic_disease,hepatitis C
1388,NCT02004275,14:25:chronic_disease,Known active hepatitis C based on
1389,NCT01919619,1:12:chronic_disease,hepatitis C infection
1390,NCT01865162,1:12:chronic_disease,hepatitis C
1391,NCT01823198,28:39:chronic_disease,"Patients with a history of hepatitis C, but have a negative viral load, are eligible"
1392,NCT02615353,"1:16:chronic_disease,,,,",Type 2 diabetes: Fasting glucose ?126 mg/dl or 2-hour glucose ?200 mg/dl
1393,NCT02587936,1:16:chronic_disease,Type 2 diabetes included in problem list
1394,NCT02548351,1:16:chronic_disease,Type 2 diabetes diagnosed per 2013 American Diabetes Association criteria
1395,NCT02356848,",24:39:chronic_disease",Adults (21 years) with Type 2 diabetes
1396,NCT02157974,1:16:chronic_disease,Type 2 diabetes
1397,NCT00862433,",,,100:115:chronic_disease",Overweight (BMI greater than or equal to 27) with mild to moderate non-insulin dependent diabetes (Type 2 diabetes)
1398,NCT00739362,1:16:chronic_disease,Type 2 diabetes (according to the World Health Organization diagnostic criteria)
1399,NCT02536794,1:23:cancer,leptomeningeal disease
1400,NCT02439450,7:29:cancer,Known leptomeningeal disease
1401,NCT02091141,12:34:cancer,History of leptomeningeal disease
1402,NCT01903330,21:43:chronic_disease,Presence of diffuse leptomeningeal disease
1403,NCT01894061,15:37:cancer,Patients with leptomeningeal disease
1404,NCT01891318,34:56:cancer,Imaging or cytologic evidence of leptomeningeal disease
1405,NCT01644591,89:111:cancer,Patients are excluded if there is radiographic or cerebrospinal fluid (CSF) evidence of leptomeningeal disease
1406,NCT03162731,1:24:cancer,squamous cell carcinoma of the skin
1407,NCT03059355,1:24:cancer,squamous cell carcinoma
1408,NCT02582775,13:36:cancer,Evidence of squamous cell carcinoma
1409,NCT02158234,48:71:cancer,"Recurrence of previously pathologically proven squamous cell carcinoma of the head and neck, including original primary sites in the paranasal sinuses, nasal cavity, nasopharynx, oropharynx, oral cavity, larynx, hypopharynx, salivary glands, and/or involvement of cervical lymph nodes"
1410,NCT02106598,13:36:cancer,oral cavity squamous cell carcinoma
1411,NCT02101034,56:79:cancer,Histologically or cytologically confirmed diagnosis of squamous cell carcinoma of the head and neck
1412,NCT03151083,"16:24:chronic_disease,","Diagnosed with insomnia lasting 3 months by the PACT provider, as evidenced by referral by the provider for access to the SHUTiTM program"
1413,NCT03151083,",67:75:chronic_disease",Willing to participate in an internet-based self-help program for insomnia after the access to and requirements of the program are explained to them
1414,NCT03112902,1:9:chronic_disease,insomnia
1415,NCT03109210,",,67:75:chronic_disease",Insomnia Severity Index (ISI) score > 10 indicating at least mild insomnia
1416,NCT02774642,30:38:chronic_disease,Meet diagnostic criteria for insomnia
1417,NCT02535923,"27:35:chronic_disease,,",Self-reported symptoms of insomnia via an Insomnia Severity Index (ISI) score of 15 or greater
1418,NCT03133793,",,,57:59:chronic_disease",New York Heart Association (NYHA) Classification II-III HF
1419,NCT02589977,21:23:chronic_disease,acute decompensated HF
1420,NCT02589977,34:36:chronic_disease,physician-confirmed diagnosis of HF
1421,NCT02519283,18:20:chronic_disease,Prior history of HF
1422,NCT02145351,35:37:chronic_disease,Hospitalization for decompensated HF
1423,NCT02145351,"32:34:chronic_disease,,,",Previous clinical diagnosis of HF with current NYHA Class II-III symptoms
1424,NCT03104205,1:18:chronic_disease,Suicidal ideation
1425,NCT02910648,1:18:chronic_disease,Suicidal ideation in past year
1426,NCT02250664,1:18:chronic_disease,Suicidal ideation in the past month
1427,NCT02250534,1:18:chronic_disease,Suicidal ideation in the past month
1428,NCT02133898,1:18:chronic_disease,Suicidal ideation
1429,NCT01964261,1:18:chronic_disease,Suicidal ideation
1430,NCT03072381,18:27:allergy_name,known allergy to Lidocaine
1431,NCT03016351,1:10:allergy_name,Lidocaine allergy
1432,NCT02987491,1:10:allergy_name,Lidocaine allergy
1433,NCT02803359,12:21:allergy_name,Allergy to Lidocaine
1434,NCT02340650,13:22:allergy_name,Person with Lidocaine sensitivity
1435,NCT01842399,45:54:allergy_name,Allergy or intolerance to local anesthetic- Lidocaine
1436,NCT03039036,1:27:chronic_disease,hepatitis B or C infection
1437,NCT02953509,25:51:chronic_disease,Known active or chronic hepatitis B or C infection
1438,NCT02907918,7:33:chronic_disease,Known hepatitis B or C infection
1439,NCT02833805,8:34:chronic_disease,Active hepatitis B or C infection determined by serology and/or nucleic acid testing (NAT)
1440,NCT02776761,27:53:chronic_disease,Any confirmed evidence of hepatitis B or C infection
1441,NCT01572480,8:34:chronic_disease,Active hepatitis B or C infection
1442,NCT03009110,1:18:chronic_disease,Bleeding disorder
1443,NCT02940288,1:18:chronic_disease,Bleeding disorder
1444,NCT02622295,1:18:chronic_disease,Bleeding disorder
1445,NCT02490943,1:18:chronic_disease,Bleeding disorder
1446,NCT02414607,1:18:chronic_disease,Bleeding disorder
1447,NCT02254863,1:18:chronic_disease,Bleeding disorder
1448,NCT02985801,12:37:cancer,Underlying pancreatic adenocarcinoma
1449,NCT02843945,18:43:cancer,locally advanced pancreatic adenocarcinoma
1450,NCT02562716,59:84:cancer,Patients must have histologically or cytologically proven pancreatic adenocarcinoma
1451,NCT02311361,54:79:cancer,Patients must have histopathological confirmation of pancreatic adenocarcinoma prior to entering this study by the Laboratory of Pathology of the NCI to entering this study by the Laboratory of Pathology of the NCI prior to entering this study
1452,NCT02128100,43:68:cancer,Pathologic or clinical diagnosis of a new pancreatic adenocarcinoma
1453,NCT02047474,42:67:cancer,Pathologic or cytologic documentation of pancreatic adenocarcinoma
1454,NCT02943915,60:72:chronic_disease,"History of long bone fractures since the SCI, secondary to osteoporosis"
1455,NCT02589600,",13:25:chronic_disease,",Men because osteoporosis is less common in men
1456,NCT02589600,"1:13:chronic_disease,,","osteoporosis by axial bone density (spine, hip or forearm bone mineral density (BMD) T-score ? -2.5 SD)"
1457,NCT02446886,34:46:chronic_disease,Patients with a known history of osteoporosis or bone density values in the osteoporosis range at screening
1458,NCT02373644,8:20:chronic_disease,severe osteoporosis
1459,NCT02245841,15:27:chronic_disease,Patients with osteoporosis
1460,NCT02878044,32:46:cancer,Clinical diagnosis of low risk thyroid cancer
1461,NCT02747888,15:29:cancer,Families with thyroid cancer and a known genetic syndrome
1462,NCT02747888,70:84:cancer,Individual adult patient with current or previous known or suspected thyroid cancer or nodule(s) if they come from a family with a high suspicion of hereditary cancer
1463,NCT02564978,30:44:cancer,Participant has a history of thyroid cancer
1464,NCT02393690,"49:63:cancer,",It is pathologically proven to be involved with thyroid cancer (by cytology or pathology) and it measures >= 1 cm in the long axis
1465,NCT02278198,17:31:cancer,nown metastatic thyroid cancer
1466,NCT02833805,28:53:treatment,Previous administration of immunosuppressive therapy for SAA
1467,NCT02384954,31:56:treatment,No disease requiring systemic immunosuppressive therapy
1468,NCT02324582,"19:44:treatment,",any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment
1469,NCT02268253,11:36:treatment,receiving immunosuppressive therapy
1470,NCT02266745,1:26:treatment,immunosuppressive therapy
1471,NCT01087294,26:51:treatment,A trial of withdrawal of immunosuppressive therapy
1472,NCT02746458,14:32:chronic_disease,Diagnosis of sickle cell anemia
1473,NCT02286154,14:32:chronic_disease,Diagnosis of sickle cell anemia
1474,NCT02056470,1:19:chronic_disease,sickle cell anemia
1475,NCT01966367,",,55:73:chronic_disease,",Patient must be < or = 40 years of age. Patients with sickle cell anemia must be at least 2 years of age
1476,NCT01966367,63:81:chronic_disease,The following additional exclusion criteria for patients with sickle cell anemia the following exclusion criteria also apply
1477,NCT00737893,30:48:chronic_disease,The patient has a history of sickle cell anemia
1478,NCT02624258,1:19:chronic_disease,refractory disease who are unresponsive to
1479,NCT02530034,29:47:cancer,Patients must have relapsed/refractory disease
1480,NCT02519452,13:31:cancer,Relapsed or refractory disease
1481,NCT02394028,14:32:chronic_disease,"Intolerance, refractory disease"
1482,NCT01614197,83:101:chronic_disease,Second or greater relapse B-cell patients are eligible at time of relapse or with refractory disease
1483,NCT01349101,15:33:chronic_disease,Patients with refractory disease
1484,NCT02535312,31:40:treatment,Arm A dose level 4 (75 mg/m^2 cisplatin)
1485,NCT02535312,36:45:treatment,for whom the current dose level of cisplatin in combination with pemetrexed is appropriate
1486,NCT02466971,",,43:52:treatment",Creatinine =< 1.5 mg/dL to receive weekly cisplatin
1487,NCT02365766,"5:14:treatment,,,",The cisplatin dose will be split over two days for values between 50-59 mL/min
1488,NCT02158234,26:35:treatment,Medically fit to receive cisplatin
1489,NCT02094625,"9:18:treatment,,",Planned cisplatin dose to be infused over ?6 hours for ?2 days per cycle
1490,NCT02512718,"14:28:chronic_disease,,",Pathological hyperlipidemia (2 consecutive fasting triglyceride levels > 500 mg/dL)
1491,NCT02512718,"14:28:chronic_disease,,",pathological hyperlipidemia (2 consecutive fasting triglyceride levels > 500 mg/dL)
1492,NCT02393742,1:15:chronic_disease,hyperlipidemia
1493,NCT02302235,25:39:chronic_disease,History of uncontrolled hyperlipidemia
1494,NCT01627301,1:15:chronic_disease,hyperlipidemia
1495,NCT01625923,12:26:chronic_disease,History of hyperlipidemia
1496,NCT02210650,15:31:chronic_disease,Patients with systemic disease
1497,NCT01947673,13:29:chronic_disease,any serious systemic disease that might influence survival
1498,NCT01772329,"42:58:chronic_disease,,",any co-morbidity which results in severe systemic disease limiting function {as defined by the American Society of Anesthesiology (ASA) physical status classification > 3}
1499,NCT01627301,13:29:chronic_disease,any serious systemic disease
1500,NCT00338377,40:56:chronic_disease,Many patients present with concomitant systemic disease outside of the central nervous system
1501,NCT00147056,24:40:chronic_disease,Known life-threatening systemic disease
1502,NCT03175159,37:41:treatment,Self reports being 100% adherent to PrEP
1503,NCT03148171,",23:27:treatment,",Have had fewer than 3 PrEP clinical visits in the past 12 months
1504,NCT03132415,11:15:chronic_disease,Not be on PrEP at time of enrollment
1505,NCT03078153,"17:21:treatment,",Actively taking PrEP or having taken PrEP within 30 days of enrollment
1506,NCT03078153,"15:19:treatment,",Not a current PrEP user and have not taken PrEP in the last 30 days
1507,NCT03166371,1:15:chronic_disease,encephalopathy
1508,NCT02811263,20:34:chronic_disease,Sentinel event and encephalopathy occurred only after birth
1509,NCT02621944,"32:46:chronic_disease,,,",All infants must have signs of encephalopathy within 6 hours of age using the modified Sarnat scoring system
1510,NCT02146924,54:68:chronic_disease,Research participants without clinically significant encephalopathy/new focal deficits
1511,NCT01903330,",,,,,92:106:chronic_disease","blood pressure of > 150 mmHg systolic and > 100 mmHg diastolic, or history of hypertensive encephalopathy"
1512,NCT03153982,",,,,,,,304:315:treatment","Women (patients or partners of male patients) of childbearing potential (WOCBP) must practice acceptable methods of birth control to prevent pregnancy. All WOCBP must have a negative pregnancy test within 4 weeks prior to registration, and this must be repeated within 72 hours prior to first receiving ruxolitinib"
1513,NCT02876302,79:90:treatment,Because no dosing or adverse event data are currently available on the use of ruxolitinib in participants
1514,NCT02876302,16:27:treatment,The effects of ruxolitinib on the developing human fetus are unknown
1515,NCT02493530,81:92:treatment,"Patients with these diagnoses may be eligible, provided they are able to obtain ruxolitinib from commercial supply"
1516,NCT02098161,76:87:allergy_name,"Patients who are not candidates for, intolerant, or relapsed/refractory to ruxolitinib"
1517,NCT03135522,12:24:chronic_disease,History of lung disease
1518,NCT02995590,15:27:chronic_disease,No history of lung disease
1519,NCT02128802,13:25:chronic_disease,Significant lung disease
1520,NCT02013492,"27:39:chronic_disease,,,,","Patients with significant lung disease, an ejection fraction less than 40%, or a resting heart rate less than 60/min will not be enrolled"
1521,NCT01445821,"11:23:chronic_disease,,",End-stage lung disease characterized by TLC<45% of predicted value
1522,NCT03121352,",50:59:treatment",Subjects must have received no more than 2 prior therapies for this disease
1523,NCT02703272,26:35:treatment,has taken any disallowed therapies as noted in Section 8.2
1524,NCT02013492,52:61:treatment,Patients may have had any number of prior systemic therapies
1525,NCT01495637,87:96:treatment,DNR status or care team/family is considering plans for withdrawal of life-sustaining therapies
1526,NCT00338377,"57:66:treatment,","Patients who have been previously treated with other IT therapies are eligible, as long as there is at least a 2 week wash out period"
1527,NCT03104725,"1:3:chronic_disease,",PD diagnosed within the past 5 years
1528,NCT02231073,12:14:chronic_disease,Idiopathic PD subjects: Same as above and deep brain stimulation electrodes
1529,NCT01742182,"1:3:chronic_disease,,,",PD Hoehn and Yahr stage 2-4
1530,NCT01581580,31:33:chronic_disease,"Patients with tremor-dominant PD with Scans Without Evidence of Dopaminergic Effect (SWEDD) will be excluded based on clinical and historic information, including DaT functional imaging obtained during routine clinical evaluation of PD as needed"
1531,NCT01341080,",,83:85:chronic_disease,,",Subjects will have to be at least stage 2 on the Hoehn and Yahr staging system of PD and have a history of at least 1 fall or near fall in the last 6 months
1532,NCT03080142,22:45:treatment,Patients on systemic anticoagulation therapy
1533,NCT02278315,",,52:75:treatment","Platelet count < 150,000/uL with ongoing full-dose anticoagulation therapy"
1534,NCT02053363,9:32:treatment,Current anticoagulation therapy that cannot be interrupted
1535,NCT01187368,15:38:treatment,Intolerant of anticoagulation therapy
1536,NCT00737893,19:42:treatment,The patient is on anticoagulation therapy
1537,NCT03071393,18:39:chronic_disease,severe recurrent autonomic dysreflexia
1538,NCT02943915,14:35:chronic_disease,Uncontrolled autonomic dysreflexia
1539,NCT02329652,39:60:chronic_disease,subjects should not have a history of autonomic dysreflexia
1540,NCT02274116,11:32:chronic_disease,recurrent autonomic dysreflexia
1541,NCT02115685,15:36:chronic_disease,an episode of autonomic dysreflexia in the past year
1542,NCT03060096,1:26:cancer,non-melanoma skin cancers
1543,NCT02585973,1:26:cancer,non-melanoma skin cancers
1544,NCT02583893,1:26:cancer,non-melanoma skin cancers
1545,NCT02541903,21:46:cancer,effectively treated non-melanoma skin cancers
1546,NCT02217345,1:26:cancer,non-melanoma skin cancers
1547,NCT03053908,22:38:chronic_disease,life-long history of major depression
1548,NCT02837510,"28:44:chronic_disease,",subjects with a history of major depression but in remission for past 6 months are eligible
1549,NCT02620579,1:17:chronic_disease,major depression
1550,NCT02347995,11:27:chronic_disease,untreated major depression by clinical interview
1551,NCT02243813,",157:173:chronic_disease",Current or past history within the last 5 years of meeting DSM-5 criteria for alcohol or substance use disorder (excluding caffeine and nicotine) or severe major depression
1552,NCT03008408,12:26:chronic_disease,Documented cardiomyopathy
1553,NCT02624765,1:15:chronic_disease,cardiomyopathy
1554,NCT02488967,12:26:chronic_disease,Documented cardiomyopathy
1555,NCT02152254,18:32:chronic_disease,prior or current cardiomyopathy
1556,NCT01696734,1:15:chronic_disease,cardiomyopathy
1557,NCT03004287,22:42:cancer,Diagnosis of primary plasma cell leukemia
1558,NCT02343042,8:28:cancer,Active plasma cell leukemia
1559,NCT02334865,36:56:cancer,Patients with a known diagnosis of plasma cell leukemia
1560,NCT02004275,22:42:cancer,Primary or secondary plasma cell leukemia
1561,NCT01464034,22:42:cancer,Current diagnosis of plasma cell leukemia
1562,NCT02977299,"17:31:treatment,,,","currently on an antidepressant of adequate dose (as defined by the MGH ATRQ) and duration (at least 8 weeks), with the antidepressant dose being stable over the past four weeks, and with documented (in the MGH ATRQ) non-response (less than 50% improvement) to the current antidepressant"
1563,NCT02960763,",46:60:treatment",Failure to respond adequately to two or more antidepressant treatment trials of recommended dose and length
1564,NCT02669030,14:28:treatment,Currently on antidepressant
1565,NCT02562430,27:41:treatment,Only one failed one prior antidepressant in the current episode
1566,NCT02553161,23:37:treatment,a history of previous antidepressant exposure
1567,NCT02931110,1:16:chronic_disease,lymphadenopathy
1568,NCT02514083,42:57:chronic_disease,Massive nodes or clusters or progressive lymphadenopathy
1569,NCT02227199,27:42:chronic_disease,patients with evidence of lymphadenopathy in the neck must have a dedicated CT of neck
1570,NCT01750567,"16:31:chronic_disease,",ny increase in lymphadenopathy over best response that has persisted for more than 3 months
1571,NCT01419561,"12:27:chronic_disease,,",Pathologic lymphadenopathy (at least five discrete nodes each >1cm in their longest dimension)
1572,NCT02913430,",,31:46:cancer",ALP ? 5X ULN in patients with bone metastases
1573,NCT02699697,"26:41:cancer,",Radiographic evidence of bone metastases within 8 weeks of study
1574,NCT02479230,",,,83:98:cancer",Alkaline phosphatase < 2.5 upper limit of normal (ULN) (< 10 x ULN in presence of bone metastases)
1575,NCT02408861,45:60:cancer,Repeat imaging demonstrates no new sites of bone metastases
1576,NCT02101034,",,56:71:cancer,",Alkaline phosphatase ? 2.5 x IULN for patients without bone metastases and ? 5.0 x IULN for patients with bone metastases
1577,NCT02856412,1:17:chronic_disease,systemic illness affecting central nervous system (CNS) function
1578,NCT02634957,12:28:chronic_disease,History of systemic illness that could affect wound healing
1579,NCT02076906,34:50:chronic_disease,Clinically significant unrelated systemic illness
1580,NCT01996449,7:23:chronic_disease,other systemic illness
1581,NCT00670358,13:29:chronic_disease,"No comorbid systemic illness or other severe concurrent disease that, in the judgment of the investigator, would preclude study entry or significantly interfere with the proper assessment of safety and toxicity of the prescribed study regimen"
1582,NCT02816697,1:12:chronic_disease,Hypotension
1583,NCT02806570,"26:37:chronic_disease,,",Hemodynamic instability: Hypotension (systolic pressure <90 millimeter Mercury (mmHg)) or requirement for inotropic support or mechanical hemodynamic support
1584,NCT02507011,"1:12:chronic_disease,,",Hypotension defined as systolic blood pressure < 100 mmHg at the time of enrollment
1585,NCT02497300,"1:12:chronic_disease,,",Hypotension (office BP < 110/70 mm Hg)
1586,NCT02192398,"1:12:chronic_disease,,,,,,,",Hypotension (SBP < 90 mmHg and DBP < 60 mmHg for female or SBP < 100 mmHg and DBP < 60 mmHg for male; measured while in a sitting position) will be reviewed by a study physician
1587,NCT02762006,",,76:99:treatment",Mean QT interval corrected for heart rate (QTc) ?470 ms calculated from an electrocardiogram (ECG) using Fridericia's Correction (QTcF)
1588,NCT02525861,"80:103:treatment,","The participant has clinically significant abnormalities detected on a 12-lead electrocardiogram (ECG) performed at the time of screening. (Past records obtained within 26 weeks prior to screening may be used, if available.)"
1589,NCT02503722,87:110:treatment,"Any clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiogram (ECG)"
1590,NCT02402660,39:62:treatment,Has a clinically significant abnormal electrocardiogram (ECG)
1591,NCT00540761,"30:53:treatment,,,",defined as chest pain or new electrocardiogram (ECG) changes in the 12 hours prior to study entry and/or rising creatine kinase (CK) and CK-MB serum enzymes
1592,NCT02703220,1:16:treatment,antidepressants
1593,NCT02556606,",80:95:treatment","Participants have not responded to two or more adequate trials of FDA-approved antidepressants, determined by Antidepressant Treatment Response Questionnaire (ATRQ) criteria"
1594,NCT02466685,1:16:treatment,antidepressants
1595,NCT02233868,1:16:treatment,antidepressants
1596,NCT02046330,",93:108:treatment,",Adequate trials (equal or >6 weeks at the maximum recommended or tolerated dose) of primary antidepressants from at least 3 different classes
1597,NCT02665338,1:14:chronic_disease,Schizophrenia
1598,NCT02243813,90:103:chronic_disease,Current or past history of meeting Diagnostic and Statistics Manual (DSM)-5 criteria for Schizophrenia
1599,NCT02133898,1:14:chronic_disease,Schizophrenia
1600,NCT02128802,1:14:chronic_disease,Schizophrenia
1601,NCT02021578,1:14:chronic_disease,Schizophrenia (parent or child)
1602,NCT02592551,",56:75:treatment",Any unresolved toxicity (>CTCAE grade 2) from previous anti-cancer therapy
1603,NCT02576444,40:59:treatment,Concurrent administration of any other anti-cancer therapy
1604,NCT02401347,"5:24:treatment,",Any anti-cancer therapy within the past 21 days of the first day of treatment
1605,NCT02393690,",100:119:treatment",Unresolved toxicity > Common Terminology Criteria for Adverse Events (CTCAE) grade 2 from previous anti-cancer therapy
1606,NCT02199236,24:43:treatment,Patients on concurrent anti-cancer therapy other than that allowed in the study
1607,NCT02570321,42:62:chronic_disease,Participants who are decisionally and/or cognitively impaired
1608,NCT02352480,18:38:chronic_disease,Subjects who are cognitively impaired
1609,NCT02352467,18:38:chronic_disease,Subjects who are cognitively impaired
1610,NCT02352454,18:38:chronic_disease,Subjects who are cognitively impaired
1611,NCT02312518,18:38:chronic_disease,Subjects who are cognitively impaired and do not have a healthcare proxy
1612,NCT02551679,1:19:chronic_disease,Bleeding diathesis
1613,NCT02548104,1:19:chronic_disease,Bleeding diathesis
1614,NCT02535832,1:19:chronic_disease,Bleeding diathesis
1615,NCT02389465,1:19:chronic_disease,Bleeding diathesis
1616,NCT02056288,1:19:chronic_disease,Bleeding diathesis
1617,NCT02519322,80:83:treatment,"following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method"
1618,NCT02519322,49:52:treatment,this interval depends on the type and dosage of HRT
1619,NCT02056873,42:45:treatment,"(Subjects not required to participate in HRT but it will be highly encouraged, and must be completed prior to start of this study's protocol"
1620,NCT01943851,"80:83:treatment,","Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method"
1621,NCT01943851,34:37:treatment,"Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment"
1622,NCT02496585,14:42:chronic_disease,History of a gastrointestinal perforation
1623,NCT02120222,"1:29:chronic_disease,",gastrointestinal perforation within 28 days prior to beginning study treatment
1624,NCT02101736,1:29:chronic_disease,gastrointestinal perforation
1625,NCT02007239,11:39:chronic_disease,Suspected gastrointestinal perforation
1626,NCT01639508,1:29:chronic_disease,gastrointestinal perforation
1627,NCT02462161,1:38:chronic_disease,chronic obstructive pulmonary disease
1628,NCT02332928,1:38:chronic_disease,chronic obstructive pulmonary disease requiring oxygen replacement
1629,NCT02329652,1:38:chronic_disease,chronic obstructive pulmonary disease
1630,NCT02081404,18:55:chronic_disease,oxygen dependent chronic obstructive pulmonary disease
1631,NCT01341080,20:57:chronic_disease,Moderate or severe chronic obstructive pulmonary disease
1632,NCT02421315,35:54:chronic_disease,DSM-IV current diagnosis of major depressive disorder
1633,NCT02214667,1:20:chronic_disease,depressive disorder
1634,NCT02106052,15:34:chronic_disease,Current major depressive disorder
1635,NCT02021578,24:43:chronic_disease,Current diagnosis of a depressive disorder (child)
1636,NCT02021578,39:58:chronic_disease,Parent with a current or history of a depressive disorder within child's lif
1637,NCT02362308,13:35:treatment,status-post surgical sterilization
1638,NCT02341209,",93:115:treatment,,",WOCBP includes any female who has experienced menarche and who has not undergone successful surgical sterilization or is not postmenopausal (defined as amenorrhea ? 12 consecutive months without an alternative medical cause)
1639,NCT01904136,",,,125:147:treatment",Positive pregnancy test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization
1640,NCT01823198,",,,,136:158:treatment",Pregnancy: positive pregnancy test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization
1641,NCT01701986,",,166:188:treatment",Pregnancy (positive beta human chorionic gonadotropin [HCG] test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization) or currently breast-feeding
1642,NCT02343549,"15:26:treatment,,",Able to start bevacizumab at least 2 weeks but no more than 4 weeks from date of biopsy
1643,NCT02343549,44:55:allergy_name,Known hypersensitivity to any component of bevacizumab
1644,NCT02343549,39:50:allergy_name,Subjects meeting any of the following bevacizumab-specific contraindications
1645,NCT01903330,64:75:allergy_name,Known contraindication or hypersensitivity to any component of bevacizumab
1646,NCT01894061,16:27:treatment,The effects of bevacizumab on developing fetus or nursing infant are not known
1647,NCT03182907,41:44:chronic_disease,At screening has suspected or confirmed CDI
1648,NCT02667418,"18:21:chronic_disease,",second recurrent CDI episode occurring within 3 months of the first recurrent episode
1649,NCT01905709,",33:36:chronic_disease",At least two episodes of severe CDI resulting in hospitalization and associated with significant morbidity
1650,NCT01905709,36:39:chronic_disease,Subject has recurrent or relapsing CDI
1651,NCT03169543,1:15:chronic_disease,"Claustrophobic, or intolerant of the scanner environment"
1652,NCT02315950,1:15:chronic_disease,Claustrophobic
1653,NCT02095808,1:15:chronic_disease,Claustrophobic
1654,NCT02035085,1:15:chronic_disease,Claustrophobic
1655,NCT03152409,12:20:chronic_disease,History of GI bleed
1656,NCT03100461,9:17:chronic_disease,current GI bleed
1657,NCT02272998,"1:9:chronic_disease,",GI bleed within 30 days prior to registration on study
1658,NCT01918683,"8:16:chronic_disease,",Active GI bleed within 2 weeks of study enrollment
1659,NCT03146663,57:84:treatment,Disease that progressed while receiving initial line of platinum-based chemotherapy
1660,NCT03146663,"28:55:treatment,",Time from the last line of platinum-based chemotherapy of less than 6 months
1661,NCT02203513,",133:160:treatment",Patients should have recurrent platinum-resistant - defined as disease recurrence by imaging within 6 months of the last receipt of platinum-based chemotherapy
1662,NCT01941316,",66:93:treatment",Patients who progressed during or within one month of completing platinum-based chemotherapy
1663,NCT03141359,",,54:67:chronic_disease","Centrally located primary tumor < 2 cm from involved nodal disease which would result in significant overlap of radiation dose. Centrally located is defined as within or touching the zone of the proximal bronchial tree, which is a volume 2 cm in all directions around the proximal bronchial tree (carina, right and left main bronchi, right and left upper lobe bronchi, intermedius bronchus, right middle lobe bronchus, lingular bronchus right and left lower lobe bronchi)"
1664,NCT02977468,23:36:chronic_disease,Pathologically proven nodal disease at diagnosis is not allowed
1665,NCT02541565,17:30:cancer,Have measurable nodal disease
1666,NCT02353819,4:17:cancer,No nodal disease
1667,NCT03131960,12:30:chronic_disease,History of hemorrhagic stroke
1668,NCT02576301,16:34:chronic_disease,Any history of hemorrhagic stroke
1669,NCT02169739,1:19:chronic_disease,hemorrhagic stroke
1670,NCT02140554,10:28:chronic_disease,overt or hemorrhagic stroke
1671,NCT03125902,7:43:chronic_disease,Known central nervous system (CNS) disease
1672,NCT02530034,28:64:chronic_disease,Patients with known active central nervous system (CNS) disease
1673,NCT01701986,21:57:chronic_disease,Patient with active central nervous system (CNS) disease
1674,NCT00075387,35:71:chronic_disease,Subjects with rapidly progressing central nervous system (CNS) disease with associated neurological deterioration
1675,NCT03119467,"20:34:treatment,",Patients receiving cancer therapy within 3 weeks prior to Cycle1 Day1 (C1D1)
1676,NCT02538198,61:75:treatment,"has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months)"
1677,NCT01858168,65:79:treatment,Persistent clinically significant toxicities caused by previous cancer therapy
1678,NCT01625234,30:44:treatment,Patients currently receiving cancer therapy
1679,NCT03108950,8:23:chronic_disease,Active pressure ulcers
1680,NCT02978638,21:36:chronic_disease,"Active or recurrent pressure ulcers, particularly in sacral, ischial or trochanteric areas"
1681,NCT02533882,8:23:chronic_disease,Active pressure ulcers
1682,NCT02139436,",28:43:chronic_disease",current grade 2 or greater pressure ulcers at relevant contact sites
1683,NCT03085485,",59:76:chronic_disease",Clinically stable in the last 4 weeks with no evidence of COPD exacerbation
1684,NCT02178566,21:38:chronic_disease,Hospitalization for COPD exacerbation
1685,NCT02178566,24:41:chronic_disease,Use of antibiotics for COPD exacerbation
1686,NCT01742338,40:57:chronic_disease,re-admitted to the hospital with a new COPD exacerbation
1687,NCT03073785,5:14:cancer,All malignant disease must be able to be encompassed within a single irradiation field
1688,NCT02406599,",25:34:cancer","Women with non-palpable malignant lesions, requiring image guided localization"
1689,NCT02186418,25:34:cancer,Patients with an active malignant disease
1690,NCT02105545,20:29:cancer,Any patient with a malignant diagnosis at the time of diagnosis or relapse
1691,NCT03063892,1:27:chronic_disease,Myocardial infarction (MI) and/or stents within the past year
1692,NCT02343042,"1:27:chronic_disease,",Myocardial infarction (MI) within 3 months prior to C1D1
1693,NCT01684397,1:27:chronic_disease,Myocardial infarction (MI)
1694,NCT01620216,1:27:chronic_disease,Myocardial infarction (MI)
1695,NCT03058029,1:9:chronic_disease,Diabetic subjects
1696,NCT02490631,1:9:chronic_disease,Diabetic
1697,NCT02313428,1:9:chronic_disease,Diabetic
1698,NCT00085982,"1:9:chronic_disease,,",Diabetic symptoms with a random plasma glucose >= 200 mg/dL
1699,NCT03040726,"1:24:chronic_disease,,",Severe renal impairment (calculated creatinine clearance =< 29 cc/min)
1700,NCT03012815,"1:24:chronic_disease,,",Severe renal impairment (estimated CrCl < 30)
1701,NCT02950233,"1:24:chronic_disease,,",Severe renal impairment (creatinine clearance based GFR of <30ml/min)
1702,NCT01585402,"1:24:chronic_disease,,",Severe renal impairment (estimated creatinine clearance/eGFR of < 30ml/min calculated using CKD-EPI equation
1703,NCT03033498,29:42:chronic_disease,has a diagnosis of definite idiopathic PD
1704,NCT01742182,14:27:chronic_disease,Diagnosis of idiopathic PD as defined by the United Kingdom PD Society Brain Bank Criteria
1705,NCT01581580,30:43:chronic_disease,Have a clinical diagnosis of idiopathic PD
1706,NCT01581580,18:31:chronic_disease,The diagnosis of idiopathic PD will be based on the UK Brain Bank Criteria
1707,NCT03012815,"16:26:treatment,",Already taking gabapentin more than 300 mg three times a day
1708,NCT03012815,40:50:treatment,Patients receiving therapeutic dose of gabapentin (rather than continuation of home dose) prior to enrollment
1709,NCT02480114,14:24:treatment,Currently on gabapentin
1710,NCT02480114,24:34:treatment,Prior non-tolerance of gabapentin
1711,NCT02996227,1:16:chronic_disease,"Hepatic disease, e.g. twice the normal levels of liver enzymes"
1712,NCT02755116,1:16:chronic_disease,Hepatic disease
1713,NCT01895777,1:16:chronic_disease,Hepatic disease
1714,NCT01184547,1:16:chronic_disease,Hepatic disease
1715,NCT02971202,1:20:chronic_disease,severe hypoglycemia
1716,NCT02415556,12:31:chronic_disease,History of severe hypoglycemia
1717,NCT02251431,12:31:chronic_disease,History of severe hypoglycemia
1718,NCT01474889,"16:35:chronic_disease,",No episodes of severe hypoglycemia in the past 3 years
1719,NCT02945800,1:37:chronic_disease,symptomatic congestive heart failure
1720,NCT02857218,1:37:chronic_disease,symptomatic congestive heart failure
1721,NCT02843568,1:37:chronic_disease,symptomatic congestive heart failure
1722,NCT02159703,1:37:chronic_disease,symptomatic congestive heart failure
1723,NCT02931110,",10:21:chronic_disease",Grade ?2 bradycardia
1724,NCT02925923,19:30:chronic_disease,increased risk of bradycardia
1725,NCT02329652,8:19:chronic_disease,severe bradycardia
1726,NCT01696734,24:35:chronic_disease,clinically significant bradycardia
1727,NCT02923921,26:37:treatment,who were intolerant of a gemcitabine containing regimen
1728,NCT02533674,27:38:allergy_name,Known hypersensitivity to gemcitabine or any component of the formulation
1729,NCT02533674,43:54:treatment,Patients who have previously discontinued gemcitabine-containing regimens due to gemcitabine-related toxicity
1730,NCT02437370,43:54:treatment,Patients with a known hypersensitivity to gemcitabine (Arm B only)
1731,NCT02918864,8:24:chronic_disease,simple febrile seizures
1732,NCT02477839,25:41:chronic_disease,Subject has experienced febrile seizures exclusively
1733,NCT02477839,19:35:chronic_disease,The occurrence of febrile seizures in addition to partial-onset seizures
1734,NCT02418195,16:32:chronic_disease,only childhood febrile seizures
1735,NCT02905188,"1:14:chronic_disease,,",Heart failure of Class III-IV and / or C-D per NYHA Criteria
1736,NCT02508038,1:14:chronic_disease,Heart failure
1737,NCT02471833,1:14:chronic_disease,Heart failure
1738,NCT02095808,1:14:chronic_disease,Heart failure
1739,NCT02881242,"1:20:chronic_disease,",Uncontrolled angina within 3 months
1740,NCT02519322,"1:20:chronic_disease,",Uncontrolled angina within the 3 months prior to consent
1741,NCT02203695,"1:20:chronic_disease,",Uncontrolled angina within 3 months of Screening visit
1742,NCT01620216,1:20:chronic_disease,Uncontrolled angina at time of consent OR
1743,NCT02871349,7:18:chronic_disease,Major head trauma
1744,NCT02479906,"38:49:chronic_disease,",Subject has a history of significant head trauma with loss of consciousness for longer than 5 minutes
1745,NCT02469389,1:12:chronic_disease,head trauma with loss of consciousness
1746,NCT01782599,14:25:chronic_disease,a history of head trauma
1747,NCT02860000,40:62:cancer,"History of primary, operable ER+/HER2? invasive breast cancer"
1748,NCT02476786,68:90:cancer,"Newly diagnosed histologically or cytologically confirmed operable invasive breast cancer defined as cT1 or T2, N0-1, and M0"
1749,NCT02427581,39:61:cancer,Histologically confirmed diagnosis of invasive breast cancer
1750,NCT02422641,43:65:cancer,Histologically or cytologically confirmed invasive breast cancer
1751,NCT02851914,1:11:chronic_disease,Depression diagnosis by mental health provider
1752,NCT02726906,1:11:chronic_disease,Depression
1753,NCT02473250,"1:11:chronic_disease,,",Depression of sufficient severity to score at least 16 on the first 17 items of the Hamilton Depression Rating Scale
1754,NCT01581580,"1:11:chronic_disease,,",Depression or evidenced by self-report on the Beck Depression Inventory-2 (score above 20)
1755,NCT02822001,",54:70:treatment",Patients weighing ? 80 pounds who are not -intubated prior to surgery
1756,NCT02565966,",,13:29:treatment",3 - 4 weeks prior to surgery
1757,NCT02565966,",,,17:33:treatment",diet 3 -4 weeks prior to surgery
1758,NCT02561104,101:117:treatment,Study doctor will assess patient findings and determine how long RGP lens wear must be discontinued prior to surgery
1759,NCT02780401,",,177:198:treatment",Left ventricular ejection fraction (LVEF) results must be >= lower limit of normal (LLN) for institution performing based on results from the multi-gated acquisition (MUGA) or echocardiogram (ECHO) done at baseline
1760,NCT02465060,15:36:treatment,documented by echocardiogram (ECHO) (as clinically indicated)
1761,NCT01989585,",84:105:treatment",Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO)
1762,NCT00720785,",,53:74:treatment",Left ventricular ejection fraction less than 40% by echocardiogram (ECHO)
1763,NCT02740595,1:16:chronic_disease,Cardiac disease
1764,NCT02734888,1:16:chronic_disease,Cardiac disease
1765,NCT02323581,1:16:chronic_disease,Cardiac disease
1766,NCT02025426,"8:23:chronic_disease,",Severe Cardiac disease in pregnancy with marked functional limitations (NYHA Class III and IV)
1767,NCT02669173,1:23:treatment,cytotoxic chemotherapy
1768,NCT02346526,"21:43:treatment,",No intention to use cytotoxic chemotherapy within the next 6 months
1769,NCT02232516,",,83:105:treatment",with a cumulative illness rating scale (CIRS) score >= 6 OR deemed ineligible for cytotoxic chemotherapy by the treating investigator
1770,NCT02048722,"8:30:treatment,",Use of cytotoxic chemotherapy within 21 days of registration
1771,NCT02617589,24:27:cancer,Recurrent or secondary GBM
1772,NCT02359097,"27:30:cancer,","for presumed diagnosis of GBM, histological confirmation of GBM must be completed within 12 weeks of enrollment"
1773,NCT02343549,26:29:cancer,Pathological evidence of GBM using WHO classification criteria
1774,NCT01865162,"56:59:cancer,,",Measurable contrast-enhancing progressive or recurrent GBM by MRI imaging ? two weeks before screening
1775,NCT02587403,"21:51:treatment,",Participation in an investigational drug or device study that would impact the safety or scientific integrity of this study (in the opinion of the Investigator and with the approval of the Sponsor) within the past 6 weeks prior to enrollment into this trial
1776,NCT02366611,11:41:treatment,Use of an investigational drug or device
1777,NCT02169830,"21:51:treatment,",Patient has used an investigational drug or device in the the 3 months prior to screening
1778,NCT01464164,"24:54:treatment,",Treatment with another investigational drug or device <56 days pre-study entry
1779,NCT02573493,",,14:28:cancer",Arm 1: T2-T4 primary tumors
1780,NCT02573493,",,16:30:cancer",Arm 3: T2T1-T4 primary tumors
1781,NCT02573493,",,7:21:cancer",T2-T4 primary tumors
1782,NCT02427841,46:60:cancer,"Subjects with locally advanced, unresectable primary tumors"
1783,NCT02562040,1:19:chronic_disease,Bleeding disorders
1784,NCT02558010,1:19:chronic_disease,Bleeding disorders
1785,NCT02226159,1:19:chronic_disease,Bleeding disorders or other medical contraindications to the injection procedure
1786,NCT01850758,1:19:chronic_disease,Bleeding disorders
1787,NCT02551679,8:23:chronic_disease,Severe aortic stenosis
1788,NCT02468778,"24:39:chronic_disease,,",Documented presence of aortic stenosis (orifice area of 1.5cm2 or less)
1789,NCT02000115,"17:32:chronic_disease,,,","has symptomatic aortic stenosis as demonstrated by NYHA Functional Classification of II, III, or IV"
1790,NCT01791543,8:23:chronic_disease,Severe aortic stenosis
1791,NCT02506192,27:37:treatment,Known hypersensitivity to Prednisone
1792,NCT02474199,"1:11:treatment,",Prednisone: maximum dose of 5mg daily
1793,NCT02043548,1:11:treatment,Prednisone Tapering: Prednisone should be held constant without tapering or escalation (unless there is a serious adverse event or disease flare) until the subject has achieved the DOI
1794,NCT01940094,"1:11:treatment,,",Prednisone dose at time of enrollment of ? 5 mg/day and ? 20 mg/day
1795,NCT02496208,1:25:chronic_disease,Cardiovascular disorders
1796,NCT02132598,1:25:chronic_disease,Cardiovascular disorders
1797,NCT02101736,1:25:chronic_disease,Cardiovascular disorders
1798,NCT01822522,1:25:chronic_disease,Cardiovascular disorders
1799,NCT02474927,25:36:treatment,Previous intolerance to carfilzomib
1800,NCT02073097,",118:129:treatment",breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with carfilzomib
1801,NCT01572480,16:27:treatment,The effects of carfilzomib on a developing human fetus are unknown
1802,NCT01464034,44:55:treatment,Pts who have received prior treatment with carfilzomib (Phase II only)
1803,NCT02442323,40:49:cancer,undifferentiated/poorly differentiated carcinoma
1804,NCT02419495,73:82:cancer,"For the Arm B (paclitaxel) expansion cohort, patients must have ovarian carcinoma"
1805,NCT02128906,23:32:cancer,"poorly differentiated carcinoma of the oropharynx, larynx"
1806,NCT00906984,37:46:cancer,Confirmed diagnosis of intrahepatic carcinoma
1807,NCT02378428,106:123:treatment,"The presence of mixed response (MR), or no response (NR) following the completion of A3973 or equivalent induction therapy"
1808,NCT02378428,",,78:95:treatment",the presence of a partial response (PR) with high Curie score (>2) following induction therapy
1809,NCT02003222,83:100:treatment,"Patient should be human leukocyte antigen (HLA) typed (A, B, C, DR and DQ) during induction therapy phase or a written explanation for not undergoing HLA typing on the flow sheet"
1810,NCT01515527,",,58:75:treatment",Patients aged < 60 years who are unsuitable for standard induction therapy may be eligible after discussion with PI
1811,NCT02354547,",42:56:treatment",At least 7 days after the last dose of a biologic agent
1812,NCT02101736,",38:52:treatment",At least 14 days since completion of biologic agent
1813,NCT02030028,"28:42:treatment,",Have received at least are biologic agent for at least 6 months
1814,NCT02007239,"38:52:treatment,",Previous administration of any other biologic agent targeted at cytokine blockade within 5 days of enrollment
1815,NCT02324608,102:111:allergy_name,History of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab or other agents used in the study
1816,NCT02159495,104:113:allergy_name,History of allergic reactions attributed to compounds of similar chemical or biological composition to cetuximab
1817,NCT02128906,1:10:treatment,cetuximab may be harmful to the fetus or the nursing infant
1818,NCT01874860,",33:42:treatment",Receipt of at least one dose of cetuximab during the study time period
1819,NCT02262832,17:28:treatment,"Availability of metreleptin to the patient either as an approved drug, or through local compassionate use or expanded access programs"
1820,NCT02262806,17:28:treatment,"Availability of metreleptin to the patient either as an approved drug, or through local compassionate use or expanded access programs"
1821,NCT02262806,38:49:treatment,Previously or currently treated with metreleptin under NIH study 02-DK-0022 and/or NIH study 13-DK-0057
1822,NCT02262806,15:26:treatment,Withdrawal of metreleptin led to marked worsening of metabolic parameters
1823,NCT02167009,29:47:treatment,Is considered high risk for surgical treatment
1824,NCT02167009,9:27:treatment,Refuses surgical treatment
1825,NCT02021279,46:64:treatment,Subject is to planning to undergo concurrent surgical treatment of prolapse using mesh other than the MatriStem Pelvic Floor Matrix
1826,NCT01714596,"41:59:treatment,",patients with more than one instance of surgical treatment of infection and approximately 6 week course of antibiotics
1827,NCT02114229,",,,82:106:chronic_disease",Performance status defined by Karnofsky or Lansky > 30 (except for patients with posterior fossa syndrome)
1828,NCT02114229,",,,82:106:chronic_disease",Performance status defined by Karnofsky or Lansky > 60 (except for patients with posterior fossa syndrome)
1829,NCT01878617,12:36:chronic_disease,except for posterior fossa syndrome
1830,NCT01503086,82:106:chronic_disease,"motor, visual, or auditory handicap that prevents computer use (e.g., unresolved posterior fossa syndrome) are not eligible to participate in this trial"
1831,NCT01835626,108:118:treatment,Agreement not to donate blood or blood products during the study and for 7 months after discontinuation of vismodegib
1832,NCT01835626,",,,100:110:treatment",Verify the pregnancy status of females of reproductive potential within 7 days prior to initiating vismodegib
1833,NCT01835626,",89:99:treatment",agreement not to donate sperm during the study and for 3 months after the final dose of vismodegib
1834,NCT01835626,",90:100:treatment",agreement not to donate sperm during the study and for 7 months after discontinuation of vismodegib
1835,NCT03184389,48:76:treatment,Will not use non-cigarette tobacco products or nicotine replacement therapy during the study period
1836,NCT02927847,35:63:treatment,presence of contraindications for nicotine replacement therapy
1837,NCT02067975,16:44:treatment,Current use of nicotine replacement therapy or other nicotine products
1838,NCT03181048,1:17:treatment,Previous surgery about the hip
1839,NCT02532595,1:17:treatment,Previous surgery to the foot/ankle
1840,NCT02132130,1:17:treatment,Previous surgery in the study ear
1841,NCT03179163,10:18:treatment,taking a diuretic
1842,NCT02546583,",37:45:treatment",At least 6 hours since last dose of diuretic
1843,NCT02133885,"24:32:treatment,,,",one of which must be a diuretic (with no changes for a minimum of two weeks prior to screening) that is expected to be maintained without changes for at least 6-9 months
1844,NCT03170453,36:56:chronic_disease,"Presence of significant social and cognitive disability, based on the Cognitive Style and Social Cognition Eligibility Interview (Hogarty et al., 2004)"
1845,NCT02927639,13:33:chronic_disease,Significant cognitive disability
1846,NCT01983228,",58:78:chronic_disease",must be able to communicate effectively by telephone (no cognitive disability)
1847,NCT03164538,1:4:chronic_disease,T2D
1848,NCT03036254,14:17:chronic_disease,Diagnosis of T2D
1849,NCT02519543,23:26:chronic_disease,alcohol dependence or T2D
1850,NCT03153319,"12:15:chronic_disease,",History of HCT less than 2 years prior to enrollment
1851,NCT02509546,"21:24:treatment,",Expected to undergo HCT within 120 days of enrollment
1852,NCT02100891,"89:92:treatment,","Donors unable or unwilling to undergo marrow harvest or PBSC collection for the initial HCT, storage of autologous blood prior to marrow harvest (if applicable), or apheresis one week after marrow harvest"
1853,NCT03145181,"26:46:treatment,",Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less
1854,NCT02257424,30:50:treatment,Any number and type of prior anticancer therapies
1855,NCT02187848,47:67:treatment,non-resolution of toxicities induced by these anticancer therapies
1856,NCT03137121,48:65:cancer,Have histologically or cytologically-confirmed malignant disease in an advanced incurable stage
1857,NCT02338999,34:51:cancer,Current or previous diagnosis of malignant disease
1858,NCT01570998,"21:38:cancer,",Previous history of malignant disease does not preclude entry if the expectation of relapse-free survival at 10 years or greater
1859,NCT03131635,14:38:chronic_disease,"Diagnosis of Autism Spectrum Disorder based on Autism Diagnostic Interview Revised (ADI-R), Autism Diagnostic Observation Schedule (ADOS-2), DSM-5, and expert clinical opinion"
1860,NCT03020927,31:55:chronic_disease,have a community diagnosis of Autism Spectrum Disorder (as reported by parent)
1861,NCT01970345,25:49:chronic_disease,Meet DSM-5 criteria for Autism Spectrum Disorder confirmed by the Autism Diagnostic Interview-Revised (ADI-R)
1862,NCT03114501,",38:40:treatment,",going to receive at least 4 weeks of RT with at least 20 fractions
1863,NCT02533674,"23:25:treatment,,",Patients who have had RT in more than 35% of the bone marrow
1864,NCT02332928,29:31:treatment,Patients to be treated with RT for curative intent
1865,NCT03109041,"11:26:cancer,",Any other invasive cancer in the past 5 years
1866,NCT02494869,13:28:cancer,Any current invasive cancer diagnosis
1867,NCT02033616,"24:39:cancer,",Diagnosis of any other invasive cancer or other disease process which is considered to be life-threatening within the next five years
1868,NCT03104699,1:9:treatment,"Steroids with no or minimal systemic effect (topical, inhalation)"
1869,NCT02848417,1:9:treatment,Steroids
1870,NCT02393157,1:9:treatment,Steroids
1871,NCT03096288,1:26:chronic_disease,transient ischemic attack
1872,NCT02885649,"37:62:chronic_disease,",History of loss of consciousness or transient ischemic attack within twelve (12) months of enrollment
1873,NCT02844738,"16:41:chronic_disease,",Diagnosis of a transient ischemic attack in the 6 months prior to screening
1874,NCT03087799,30:33:chronic_disease,Meet diagnostic criteria for IBS
1875,NCT03087799,"23:26:chronic_disease,",Stable medication for IBS for at least 1 month
1876,NCT02079857,14:17:chronic_disease,Diagnosis of IBS based on ROME III criteria
1877,NCT03070535,54:72:treatment,Acid reflux is allowed if participant is on a stable medication regimen
1878,NCT02472834,90:108:treatment,"Willing and able to adhere to all study-related procedures, including adherence to study medication regimen"
1879,NCT02133872,11:29:treatment,On stable medication regimen
1880,NCT03060473,1:20:chronic_disease,placental abruption
1881,NCT02742454,67:86:chronic_disease,Medical emergency necessitating emergency delivery (e.g. complete placental abruption)
1882,NCT02438371,11:30:chronic_disease,suspected placental abruption
1883,NCT03057548,1:18:chronic_disease,Mental impairment precluding the patient from providing informed consent or completing appropriate follow-up
1884,NCT02494869,1:18:chronic_disease,Mental impairment leading to inability to cooperate
1885,NCT02166905,1:18:chronic_disease,Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study
1886,NCT03051282,27:37:chronic_disease,Subject with a history of angioedema
1887,NCT02277548,12:22:chronic_disease,History of angioedema
1888,NCT01568177,7:17:chronic_disease,known angioedema
1889,NCT03038620,",,47:67:chronic_disease",triglycerides > 150 mg/dL or on treatment for hypertriglyceridemia
1890,NCT02272998,19:39:chronic_disease,Have uncontrolled hypertriglyceridemia
1891,NCT01620216,14:34:chronic_disease,Uncontrolled hypertriglyceridemia
1892,NCT03029806,9:14:treatment,Chronic NSAID use
1893,NCT02358681,"15:20:treatment,",Receipt of an NSAID within six hours of study drug administration
1894,NCT01238120,"43:48:treatment,,,",Currently taking a consistent dosage of a NSAID at least 3 days a week for the last 3 months that is over 400mg daily
1895,NCT03017937,17:38:chronic_disease,Known increased intracranial pressure
1896,NCT01777035,10:31:cancer,Elevated intracranial pressure
1897,NCT01705119,22:43:chronic_disease,Evidence of elevated intracranial pressure
1898,NCT03015805,1:33:chronic_disease,Pervasive developmental disorder
1899,NCT02877875,1:33:chronic_disease,Pervasive developmental disorder
1900,NCT02418195,1:33:chronic_disease,Pervasive developmental disorder
1901,NCT03005574,1:17:chronic_disease,medical disorder with known effects on cognitive functioning
1902,NCT02891850,17:33:chronic_disease,"Patients with a medical disorder, condition, or history"
1903,NCT02500147,30:46:chronic_disease,Past or present history of a medical disorder or medication known to affect body composition
1904,NCT02981173,1:26:chronic_disease,Axis I psychotic disorder in first degree relative
1905,NCT02404194,21:46:chronic_disease,Lifetime history of Axis I psychotic disorder
1906,NCT02155699,25:50:chronic_disease,meeting criteria for an Axis I psychotic disorder
1907,NCT02953860,1:11:cancer,Metastatic
1908,NCT02080221,1:11:cancer,Metastatic advanced disease
1909,NCT01568255,1:11:cancer,Metastatic malignancy
1910,NCT02943590,20:32:treatment,Concomitant use of cyclosporine
1911,NCT02594111,1:13:treatment,cyclosporine
1912,NCT02245841,1:13:treatment,cyclosporine
1913,NCT02931110,1:9:treatment,apixaban
1914,NCT02406885,41:49:allergy_name,History of hypersensitivity reaction to apixaban
1915,NCT02366871,121:129:treatment,WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) apixaban plus 5 half-lives of study drug apixaban (2.5 days) plus 30 days (duration of ovulatory cycle) for a total of 32.5 days post-treatment completion
1916,NCT02925923,19:22:chronic_disease,troponin negative ACS
1917,NCT02519283,13:16:chronic_disease,Evidence of ACS based on ischemia on ECG or Troponin elevation
1918,NCT02469519,26:29:chronic_disease,Received first course of ACS at or prior to 31w6d gestation
1919,NCT02918981,14:18:allergy_name,Allergies to milk consumption
1920,NCT02778867,32:36:allergy_name,Have history of anaphylaxis to milk
1921,NCT01536522,5:9:allergy_name,Any milk allergies
1922,NCT02912572,45:53:allergy_name,"History of allergic reactions attributed to avelumab or any component in its formulations, or compounds of similar chemical or biologic composition to avelumab"
1923,NCT02912572,",62:70:treatment,",Participant must not be pregnant or breastfeeding given that avelumab is an agent with unknown effects in pregnancy and breastfeeding and the potential for teratogenesis
1924,NCT02912572,16:24:treatment,The effects of avelumab on the developing human fetus are unknown
1925,NCT02905370,1:10:chronic_disease,Pneumonia
1926,NCT02652247,1:10:chronic_disease,Pneumonia diagnosis at the time of ICU admission
1927,NCT02449980,1:10:chronic_disease,Pneumonia
1928,NCT02898597,18:30:chronic_disease,Having an active skin disease
1929,NCT02369770,8:20:chronic_disease,active skin disease with open wounds present below knee of treated limb
1930,NCT02359864,16:28:chronic_disease,Dermatological skin disease of the scalp
1931,NCT02875301,7:24:chronic_disease,other cardiac condition in the past year
1932,NCT02454010,"9:26:chronic_disease,",Serious cardiac condition within the last 6 months
1933,NCT02446236,11:28:chronic_disease,"Any other cardiac condition that, in the opinion of the treatment physician, would make this protocol unreasonably hazardous for the patient"
1934,NCT02865135,1:10:chronic_disease,mucositis
1935,NCT02727062,44:53:chronic_disease,Physical exam demonstrating no preexisting mucositis
1936,NCT02422641,8:17:chronic_disease,Active mucositis
1937,NCT02851472,",24:39:chronic_disease",Hypotensive for age or active bleeding
1938,NCT02575404,4:19:chronic_disease,No active bleeding
1939,NCT01925573,4:19:chronic_disease,"No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)"
1940,NCT02836574,"21:35:chronic_disease,,","individuals who are morbidly obese (defined as BMI greater than 45 kg/m2), have excessive fat surrounding the kidney, or who are otherwise at excessive risk for serious complications"
1941,NCT02501733,19:33:chronic_disease,Patients that are morbidly obese
1942,NCT02452203,"16:30:chronic_disease,,",Participant is morbidly obese (BMI > 40)
1943,NCT02826343,1:17:treatment,Liver transplant
1944,NCT02762266,1:17:treatment,Liver transplant
1945,NCT02522871,",,35:51:treatment",Registered male or female primary Liver transplant candidate
1946,NCT02819141,1:13:chronic_disease,Acute stroke
1947,NCT02409810,1:13:chronic_disease,Acute stroke
1948,NCT02145260,1:13:chronic_disease,Acute stroke
1949,NCT02806570,8:30:chronic_disease,Active bacterial endocarditis
1950,NCT02000115,"8:30:chronic_disease,",Active bacterial endocarditis within 6 months prior to the index procedure
1951,NCT01562626,18:40:chronic_disease,prior history of bacterial endocarditis
1952,NCT02783157,1:8:chronic_disease,Hepatic
1953,NCT01804634,1:8:chronic_disease,Hepatic
1954,NCT01505569,"1:8:chronic_disease,,,,,,","Hepatic: AST or ALT ? 2.5 x upper limits of normal (ULN), if hepatic involvement < 5 x ULN; bilirubin ? 2.0 x upper limits of normal (ULN)"
1955,NCT02750319,18:20:chronic_disease,History of prior AF
1956,NCT02347111,"1:3:chronic_disease,",AF symptoms present at least once per month
1957,NCT02169037,11:13:chronic_disease,sustained AF during the procedure
1958,NCT02734771,19:32:treatment,Prior exposure to anthracycline
1959,NCT02666378,25:38:treatment,Patients should receive anthracycline as part of the recommended treatment
1960,NCT02456857,",34:47:treatment",Received at least one dose of an anthracycline-based NACT
1961,NCT02710396,"11:36:treatment,,","Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., ? Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier"
1962,NCT02446457,"11:36:treatment,,,","Has had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events (AEs) due to agents administered more than 4 weeks earlier"
1963,NCT02437370,"11:36:treatment,,,","Has had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier"
1964,NCT02682407,19:35:treatment,Have a history of renal transplant
1965,NCT02213068,14:30:treatment,Recipient of renal transplant from living or deceased donor
1966,NCT02128802,10:26:treatment,Previous renal transplant
1967,NCT02670044,15:43:cancer,Patients with acute promyelocytic leukemia (French-American-British [FAB] class M3 AML)
1968,NCT02509546,14:42:cancer,Diagnosis of acute promyelocytic leukemia
1969,NCT02319369,20:48:cancer,Has a diagnosis of acute promyelocytic leukemia
1970,NCT02635360,1:19:cancer,Distant metastases
1971,NCT02207439,1:19:cancer,Distant metastases
1972,NCT01688388,1:19:cancer,Distant metastases
1973,NCT02594501,1:18:chronic_disease,Cardiogenic shock
1974,NCT02468778,"1:18:chronic_disease,,,,,",Cardiogenic shock (SBP <90 mmHg for >1 hour with either cool clammy skin OR oliguria OR altered sensorium AND cardiac index <2.2 L/min/m2)
1975,NCT02100722,1:18:chronic_disease,Cardiogenic shock and/or need for mechanical/pharmacologic hemodynamic support
1976,NCT02583893,53:75:cancer,Patients must have histologic evidence of high risk acute myeloid leukemia
1977,NCT02162420,"1:23:cancer,",acute myeloid leukemia with >30% blasts
1978,NCT01660607,11:33:cancer,High risk acute myeloid leukemia in CR1
1979,NCT02570672,1:18:cancer,"Active malignancy, non-skin"
1980,NCT01293214,1:18:cancer,Active malignancy
1981,NCT01140087,1:18:cancer,Active malignancy
1982,NCT02553941,"28:53:treatment,,","Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4.03), grade =< 1, or to the levels dictated in the inclusion/exclusion criteria"
1983,NCT02390752,85:110:treatment,Patients must have fully recovered (to Grade 1) from the acute toxic effects of all prior anti-cancer therapy
1984,NCT01532687,27:52:treatment,Any ongoing toxicity from prior anti-cancer therapy
1985,NCT02544503,8:20:chronic_disease,Normal neurological examination
1986,NCT02428205,7:19:chronic_disease,Other neurological diagnosis
1987,NCT01923662,",52:64:chronic_disease",Time post injury greater than six months to assure neurological and emotional stability
1988,NCT02535832,16:18:chronic_disease,Diagnosed with RA by a Rheumatologist and according to American College of Rheumatology 2010 criteria
1989,NCT02373644,1:3:chronic_disease,RA
1990,NCT02030028,1:3:chronic_disease,RA diagnosis by American College of Rheumatology criteria
1991,NCT02530034,1:29:cancer,acute myeloid leukemia (AML) by WHO classification
1992,NCT01823198,19:47:cancer,Treatment related acute myeloid leukemia (AML)
1993,NCT00719888,52:80:cancer,Very high risk pediatric/young adult patients with acute myeloid leukemia (AML)
1994,NCT02522494,14:38:chronic_disease,Diagnosis of type 2 diabetes mellitus
1995,NCT01967849,19:43:chronic_disease,family history of type 2 diabetes mellitus
1996,NCT01666665,14:38:chronic_disease,Pre Existing type 2 diabetes mellitus and receiving treatment
1997,NCT02515513,30:48:treatment,do not meet the criteria for surgical resection
1998,NCT01893307,10:28:treatment,Previous surgical resection
1999,NCT01835626,10:28:treatment,"Complete surgical resection is not possible or is deemed excessively morbid (e.g. invasion into cranial nerves or skull base, proximity to brain, spinal canal, or orbit)"
2000,NCT02512497,",,158:166:treatment",Hematopoetic Transplant Co-Morbidity Index (HCT-CI) >4 unless deemed clinically insignificant by primary investigator for patients receiving Time-Sequential Busulfan (total exposure 20000 umol-min
2001,NCT02338232,1:9:treatment,Busulfan 130 mg/m2 iv daily x 2 (reduced intensity) or 4 days
2002,NCT01951885,"1:9:treatment,,","Busulfan dose may be adjusted according to pharmacokinetics targeting a daily AUC of 5000 ?mol-min/L, per institution standard of practice"
2003,NCT02500381,"16:36:treatment,",Stable dose of oral corticosteroids for at least 24 weeks
2004,NCT01787682,26:46:treatment,Current use of long-term oral corticosteroids (CHF only)
2005,NCT01787682,"24:44:treatment,",Use of short course of oral corticosteroids within 4 weeks preceding first study day
2006,NCT02485639,14:37:chronic_disease,a history of Guillain-Barre syndrome
2007,NCT02418195,1:24:chronic_disease,Guillain-Barre syndrome (if active)
2008,NCT01967238,12:35:chronic_disease,History of Guillain-Barre syndrome
2009,NCT02477839,31:40:treatment,Subject has been treated with felbamate
2010,NCT02477839,"23:32:treatment,",Subjects treated with felbamate for <12 months
2011,NCT02477839,"23:32:treatment,",Subjects treated with felbamate for >=12 months prior to Visit 1
2012,NCT02470897,1:12:chronic_disease,Scleroderma
2013,NCT02429830,16:27:chronic_disease,Diagnosed with Scleroderma
2014,NCT02418195,1:12:chronic_disease,Scleroderma
2015,NCT02453373,5:29:chronic_disease,Any intracerebral hemorrhage
2016,NCT02329327,19:43:chronic_disease,A patient with an intracerebral hemorrhage
2017,NCT02174016,1:25:chronic_disease,intracerebral hemorrhage
2018,NCT02448173,"11:29:treatment,",Following curative resection patients must have a CEA within normal limits
2019,NCT02311361,64:82:treatment,Patients must have disease that is not amenable to potentially curative resection
2020,NCT01684904,71:89:treatment,Surgical consultation to confirm that patient will be able to undergo curative resection after completion of PCT prior to registration
2021,NCT02431897,12:37:chronic_disease,History of connective tissue disease
2022,NCT02159703,1:26:chronic_disease,connective tissue disease
2023,NCT01886794,12:37:chronic_disease,History of connective tissue disease
2024,NCT02412540,"1:13:treatment,",Liver biopsy for clinical indication to evaluate for NASH within 1 year of enrollment
2025,NCT01465100,1:13:treatment,"Liver biopsy shows significant fibrosis, defined by the Ishak Stage 5"
2026,NCT01461837,1:13:treatment,Liver biopsy is optional to assess for iron overload in chronically transfused patients
2027,NCT02403128,11:25:chronic_disease,Any other ocular disease responsible for decrease in vision
2028,NCT02403128,13:27:chronic_disease,Concomitant ocular disease that can cause increase in foveal thickness
2029,NCT01280669,17:31:chronic_disease,Any significant ocular disease that could compromise the visual outcome in the study eye
2030,NCT02393794,1:28:chronic_disease,Congenital long QT syndrome
2031,NCT01908777,1:28:chronic_disease,Congenital long QT syndrome
2032,NCT01582191,1:28:chronic_disease,Congenital long QT syndrome
2033,NCT02382549,1:35:treatment,Allergy desensitization injections
2034,NCT02358187,1:35:treatment,Allergy desensitization injections
2035,NCT01130077,1:35:treatment,Allergy desensitization injections
2036,NCT02366871,12:30:treatment,undergoing surgical debulking
2037,NCT01061515,73:91:treatment,Intraperitoneal ports may be placed during or at any time separate from surgical debulking
2038,NCT01061515,",72:90:treatment","Provided the patient has been allowed at least 4 weeks to recover from surgical debulking, no additional recovery time is required for port placement"
2039,NCT02343549,"12:29:chronic_disease,,","History of abdominal fistula, gastrointestinal perforation within 6 months prior to study enrollment"
2040,NCT02120222,12:29:chronic_disease,history of abdominal fistula
2041,NCT01639508,12:29:chronic_disease,history of abdominal fistula
2042,NCT02324582,1:28:treatment,Prior systemic chemotherapy
2043,NCT01261728,1:28:treatment,Prior systemic chemotherapy
2044,NCT00969111,1:28:treatment,Prior systemic chemotherapy for any reason
2045,NCT02314377,",,,,,,226:245:treatment,","Patients must not have proteinuria at screening as demonstrated by either 1) urine protein: creatinine (UPC) ratio > 1.0 at screening, OR 2) urine dipstick for proteinuria ? 2+ (patients discovered to have ?2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ? 1g of protein in 24 hours to be eligible)"
2046,NCT02138617,",,,48:67:treatment,,,",patients discovered to have ?2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ? 1g of protein in 24 hours
2047,NCT02020707,",,,50:69:treatment,,",patients discovered to have >= 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate =< 1 g of protein in 24 hours to be eligible
2048,NCT02301611,1:17:treatment,biologic therapy as clinically indicated
2049,NCT02120222,219:235:treatment,"If patient did not receive such agents, rationale for not treating the patients with the 629 agent must be cleared with the study PI (ie no V600e/k BRAF mutation or patient with autoimmunity, thus 630 not eligible for biologic therapy)"
2050,NCT00107289,",48:64:treatment",At least 2 weeks should have elapsed since any biologic therapy
2051,NCT02277613,41:67:treatment,Anticipated need for additional planned coronary revascularization procedure(s)
2052,NCT02121158,68:94:treatment,Clinical symptoms or findings that would make them a candidate for coronary revascularization
2053,NCT00673842,26:52:treatment,the specified time after coronary revascularization
2054,NCT02236000,"1:14:cancer,",Breast cancer must be determined by local testing to be human epidermal growth factor receptor 2 (HER2)-positive prior to study entry using American Society of Clinical Oncology (ASCO) - College of American Pathologists (CAP) HER2 test guidelines
2055,NCT01980823,"1:14:cancer,",Breast cancer is uncommon in patients less than this age
2056,NCT00948285,1:14:cancer,Breast cancer patients identified as conservation candidates by their surgeons
2057,NCT02204098,",28:31:treatment,","no menses for <1 year with FSH and estradiol levels in postmenopausal range, according to institutional standards"
2058,NCT01842399,"10:13:treatment,","If their FSH test is more than 20, they will be considered menopausal"
2059,NCT01842399,",,109:112:treatment",Women over 55 years old who haven't had a period for a year will be considered menopausal and do not need a FSH test
2060,NCT02159495,1:20:chronic_disease,Infectious diseases: no clinical evidence of uncontrolled active infectious process
2061,NCT02146924,1:20:chronic_disease,Infectious diseases criteria: no clinical evidence of uncontrolled active infectious process
2062,NCT02146924,1:20:chronic_disease,Infectious diseases: no clinical evidence of uncontrolled active infectious process
2063,NCT02122081,11:42:treatment,Receiving supplementary continuous oxygen
2064,NCT02100891,",,,,59:90:treatment","Pulmonary: DLCO <40% TLC <40%, FEV1 <40% and/or receiving supplementary continuous oxygen"
2065,NCT01366612,",,,,55:86:treatment","FVC, FEV1, or DLCO <50% of predicted and/or receiving supplementary continuous oxygen"
2066,NCT02072356,1:30:chronic_disease,Active uncontrolled infection
2067,NCT01618357,1:30:chronic_disease,Active uncontrolled infection
2068,NCT00716066,1:30:chronic_disease,Active uncontrolled infection
2069,NCT01966367,10:24:chronic_disease,Adequate renal function as determined by the institutional normal range
2070,NCT01853163,29:43:chronic_disease,patient has stable impaired renal function
2071,NCT01835626,10:24:chronic_disease,Adequate renal function
2072,NCT01877382,",29:43:treatment",within 3 weeks before study drug treatment
2073,NCT01620216,",59:73:treatment",a result is available within 2 weeks of starting on study drug treatment
2074,NCT00902720,1:15:treatment,drug treatment
2075,NCT01811368,15:44:chronic_disease,Uncorrectable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time
2076,NCT01453088,"13:42:chronic_disease,,,,",Evidence of hepatic synthetic dysfunction or total bilirubin > 2x or AST > 3x ULN
2077,NCT01366612,"13:42:chronic_disease,,,,","Evidence of hepatic synthetic dysfunction, or total bilirubin >2x or AST >3x UL"
2078,NCT01453088,1:18:chronic_disease,Organ dysfunction
2079,NCT01366612,1:18:chronic_disease,Organ dysfunction
2080,NCT00472329,1:18:chronic_disease,Organ dysfunction felt to be due to the conditioning for the first transplant
2081,NCT03188042,"21:36:chronic_disease,,",Medically diagnosed memory disorder or Telephone Interview for Cognitive Status-modified (TICS-m) score ? 27
2082,NCT02751866,",13:28:chronic_disease",age-related memory disorder
2083,NCT03186937,55:82:chronic_disease,Patients not able to swallow oral medications or with gastrointestinal conditions that may impact absorption of oral medications
2084,NCT02120222,7:34:chronic_disease,other gastrointestinal conditions with increased risk of perforation
2085,NCT03181867,20:54:treatment,Subjects receiving androgen deprivation therapy (ADT)
2086,NCT02663908,24:58:treatment,Indication to initiate androgen deprivation therapy (ADT)
2087,NCT03179397,1:9:chronic_disease,Aniridia
2088,NCT02332369,1:9:chronic_disease,Aniridia
2089,NCT03176784,23:37:allergy_name,had a reaction to the nicotine patch that prevented them from continuing to use it
2090,NCT02157610,22:36:treatment,Contraindication for nicotine patch use
2091,NCT03171168,31:47:chronic_disease,Patients suffering from acute septic arthritis
2092,NCT01420887,18:34:chronic_disease,Current or prior septic arthritis
2093,NCT03170401,9:36:chronic_disease,massive gastrointestinal hemorrhage
2094,NCT02053909,12:39:chronic_disease,History of gastrointestinal hemorrhage
2095,NCT03162731,",13:24:chronic_disease",men who are azoospermic do not require contraception
2096,NCT03016871,",,109:120:chronic_disease","women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception"
2097,NCT03155724,1:28:chronic_disease,Chronic atrial fibrillation
2098,NCT00291525,1:28:chronic_disease,Chronic atrial fibrillation
2099,NCT03153319,8:33:chronic_disease,Active graft versus host disease
2100,NCT01943851,35:60:chronic_disease,"there are no signs or symptoms of graft versus host disease, other than Grade 1 skin involvement"
2101,NCT03148795,1:26:chronic_disease,Gastrointestinal disorder affecting absorption
2102,NCT03093272,1:26:chronic_disease,Gastrointestinal disorder affecting absorption
2103,NCT03145298,1:23:treatment,prior organ transplant
2104,NCT01220583,4:26:treatment,No prior organ transplant
2105,NCT03143985,1:24:treatment,inhaled corticosteroids are permitted
2106,NCT02203695,1:24:treatment,inhaled corticosteroids
2107,NCT03136029,",24:57:treatment",Women currently taking hormone replacement therapy (HRT)
2108,NCT01532687,20:53:treatment,Subjects not using hormone replacement therapy (HRT) must have experienced total cessation of menses
2109,NCT03135522,1:12:chronic_disease,Sarcoidosis
2110,NCT02981082,1:12:chronic_disease,Sarcoidosis
2111,NCT03133793,8:42:treatment,Recent percutaneous coronary intervention
2112,NCT01275716,12:46:treatment,Undergoing percutaneous coronary intervention for any clinical indication
2113,NCT03130543,15:19:allergy_name,Patients with food allergies such that they cannot be on a milk or rice based diet
2114,NCT02589353,18:22:allergy_name,has a history of food allergy
2115,NCT03125902,10:33:chronic_disease,Negative hepatitis C virus (HCV) antibody test at screening
2116,NCT02120222,"26:49:chronic_disease,",known to be positive for hepatitis C virus (HCV) ribonucleic acid (RNA)
2117,NCT03119363,",,,71:75:treatment",Who are currently over age 18 and were at least age 16 at the time of ASCT
2118,NCT02362997,87:91:treatment,Participants who entered clinical remission with one of those agents and proceeded to ASCT without intervening relapse may be eligible after discussion with the Study Chair
2119,NCT03115463,22:55:chronic_disease,Prenatally diagnosed cyanotic congenital heart disease
2120,NCT02861950,1:34:chronic_disease,cyanotic congenital heart disease
2121,NCT03112863,"21:33:treatment,",Those who have used isotretinoin in the last 6 months
2122,NCT03076021,56:68:treatment,Patients with severe acne that are expected to receive isotretinoin for therapeutic reasons
2123,NCT03112590,31:53:chronic_disease,"Known current or a history of hepatitis B or C virus, including chronic and dormant states, unless disease has been treated and confirmed cleared"
2124,NCT02481310,39:61:chronic_disease,Patients who have a clinically active hepatitis B or C virus infection
2125,NCT03106220,"1:18:chronic_disease,",variceal bleeding in the previous 1 month
2126,NCT01360606,14:31:chronic_disease,A history of variceal bleeding where the varices have not been eradicated or decompressed by shunt placement
2127,NCT03101566,"27:51:treatment,",Must not have undergone a major surgical procedure < 4 weeks prior to registration
2128,NCT02530034,"27:51:treatment,",Patients who have had any major surgical procedure within 14 days of day 1
2129,NCT03096288,1:9:treatment,edoxaban
2130,NCT03088072,21:29:allergy_name,Hypersensitivity to edoxaban
2131,NCT03090607,8:26:treatment,Had an ablation procedure in the lower esophageal sphincter area
2132,NCT00584649,"74:92:treatment,","Any medical condition significantly increasing the risk of extending the ablation procedure or of X ray exposure, including pregnancy"
2133,NCT03088592,49:60:treatment,Medically cleared for undergoing anesthesia and DBS surgery
2134,NCT02056873,65:76:treatment,Those who improve significantly will be excluded from receiving DBS surgery)
2135,NCT03086369,9:33:cancer,Current hematologic malignancies
2136,NCT02091141,19:43:cancer,Participants with hematologic malignancies
2137,NCT03085485,62:68:treatment,Subjects taking moderate or strong inhibitors or inducers of CYP3A4
2138,NCT02857270,83:89:treatment,Currently using concomitant medications that are strong inhibitors or inducers of CYP3A4
2139,NCT03085004,1:6:chronic_disease,Cysts with the following high risk features
2140,NCT02634957,1:6:chronic_disease,Cysts
2141,NCT03078504,1:20:chronic_disease,unstable arrhythmia
2142,NCT02990481,1:20:chronic_disease,unstable arrhythmia
2143,NCT03074877,27:44:chronic_disease,Having moderate to severe mental disability (based on medical records)
2144,NCT01568918,17:34:chronic_disease,Patients with a mental disability
2145,NCT03071393,1:19:chronic_disease,Spinal cord injury affecting segments between C4-T12
2146,NCT01715571,1:19:chronic_disease,Spinal cord injury
2147,NCT03069716,12:34:chronic_disease,Functional class IV heart failure
2148,NCT02121158,",28:50:chronic_disease",New York Heart Association class IV heart failure
2149,NCT03060772,12:26:cancer,History of bladder cancer
2150,NCT02177695,23:37:cancer,Histologically proven bladder cancer
2151,NCT03059355,1:35:chronic_disease,Proliferative diabetic retinopathy
2152,NCT02911792,1:35:chronic_disease,Proliferative diabetic retinopathy
2153,NCT03058029,"1:18:treatment,",Blood transfusion within three (3) months prior to Screening Visit
2154,NCT02570854,"1:18:treatment,",Blood transfusion administered within 4 weeks prior to baseline
2155,NCT03058029,",103:122:treatment,",Thyroid hormones or preparations within one (1) month prior to Screening Visit [except stable dose of replacement therapy for at least two(2) months]
2156,NCT02271711,1:20:treatment,replacement therapy
2157,NCT03054519,"1:13:treatment,",gene therapy study so long as at least six months have passed since the final intervention administration
2158,NCT02140554,18:30:treatment,Prior receipt of gene therapy
2159,NCT03045341,1:22:chronic_disease,"Binge eating disorder (full criteria as described in the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 5th edition)"
2160,NCT02932748,1:22:chronic_disease,Binge eating disorder
2161,NCT03043794,10:20:treatment,Planning mastectomy
2162,NCT02511301,10:20:treatment,Previous mastectomy
2163,NCT03042689,1:31:chronic_disease,Active coronary artery disease
2164,NCT02048722,1:31:chronic_disease,Active coronary artery disease
2165,NCT03038269,1:16:chronic_disease,Visual problems (uncorrected by glasses/contact lenses)
2166,NCT02637349,1:16:chronic_disease,Visual problems preventing them from reading the assessment and reports
2167,NCT03036254,",35:39:treatment",Chest pathology incompatible with HBOT
2168,NCT03036254,33:37:treatment,Subjects with an indication for HBOT
2169,NCT03034564,1:10:treatment,modafinil
2170,NCT02131467,1:10:treatment,modafinil
2171,NCT03029442,1:30:chronic_disease,Cushing's disease or syndrome
2172,NCT01983475,1:30:chronic_disease,Cushing's disease or syndrome
2173,NCT03027388,74:84:treatment,Patients must be in adequate general medical health to safely tolerate a craniotomy
2174,NCT03027388,31:41:treatment,Patients unwilling to undergo craniotomy
2175,NCT03019367,1:14:chronic_disease,Cord prolapse
2176,NCT02478684,1:14:chronic_disease,Cord prolapse
2177,NCT03012815,12:22:treatment,Prescribed pregabalin
2178,NCT01511640,43:53:treatment,medical history that would contraindicate pregabalin administration
2179,NCT03008616,1:22:chronic_disease,Chronic renal disease
2180,NCT00904046,1:22:chronic_disease,Chronic renal disease
2181,NCT03007030,1:39:chronic_disease,Serious medical or psychiatric illness likely to interfere with participation in this clinical study
2182,NCT02734771,1:39:chronic_disease,Serious medical or psychiatric illness likely to interfere with participation in this clinical study
2183,NCT03005418,56:76:treatment,Known medical condition which would preclude long term antiplatelet therapy after resolution of acute injuries
2184,NCT02100722,"24:44:treatment,",Inability to take dual antiplatelet therapy for six months
2185,NCT02994940,21:36:chronic_disease,Patients with known G6PD deficiency
2186,NCT02466971,51:66:chronic_disease,Patients with self-reported or known diagnosis of G6PD deficiency
2187,NCT02993406,1:32:chronic_disease,transient ischemic attack (TIA)
2188,NCT02169739,33:64:chronic_disease,other prior cortical or retinal transient ischemic attack (TIA)
2189,NCT02990377,26:32:treatment,DSM-V moderate or severe opiate (heroin or OA)
2190,NCT01625923,9:15:treatment,Regular opiate use
2191,NCT02985801,8:29:chronic_disease,Common bile duct obstruction resulting in obstructive jaundice
2192,NCT02285101,",,,41:62:chronic_disease,,,,,,,,,,,","total bilirubin >2.0 mg/dL, evidence of bile duct obstruction, serum albumin <2.5 g/dL, serum ALT or AST >2.5 x upper limit of normal, serum creatinine ?1.5 mg/dL, ANC ?1.5 x 109/L, platelets <100 x 109/L, or INR >2.0"
2193,NCT02978885,",,,,,,132:147:treatment",forced expiratory volume 1 (FEV1)/forced vital capacity (FVC) <0.70 and FEV1 50-79% normal) undergoing Whipple procedures or other major surgeries
2194,NCT01686659,45:60:treatment,Adult patients undergoing one of the listed major surgeries associated with possibility of significant blood loss
2195,NCT02974257,"1:15:chronic_disease,,","Cardiac arrest occurring while admitted to the hospital, with sustained (>20 minutes) return of spontaneous circulation (ROSC)"
2196,NCT02934555,1:15:chronic_disease,Cardiac arrest defined by cessation of pulse requiring chest compressions
2197,NCT02967315,33:56:chronic_disease,Patients that present with free pulmonary insufficiency
2198,NCT02072356,13:36:chronic_disease,Evidence of pulmonary insufficiency
2199,NCT02955394,31:65:cancer,Current or previously treated brain or leptomeningeal metastases
2200,NCT02581215,40:74:cancer,Documented and/or symptomatic or known brain or leptomeningeal metastases
2201,NCT02947945,1:15:chronic_disease,Cardiomyopathy (established by echocardiography or MRI)
2202,NCT02496208,1:15:chronic_disease,Cardiomyopathy
2203,NCT02944825,",,115:128:chronic_disease",We anticipated enrolling a study population of approximately 60% men and 40% women based on a higher incidence of kidney stones among men in NHANES data
2204,NCT01968590,"12:25:chronic_disease,",history of kidney stones in last 5 years
2205,NCT02937402,50:82:chronic_disease,Inability to perform informed consent due to any medical or psychiatric condition
2206,NCT02834403,"5:37:chronic_disease,",Any medical or psychiatric condition that would prevent informed consent or limit expected survival to less than 4 weeks
2207,NCT02932280,15:52:cancer,Patients with primary central nervous system tumors
2208,NCT02354547,1:38:cancer,primary central nervous system tumors
2209,NCT02930018,"1:11:treatment,",Study drug intended to be administered within 60 minutes of the baseline/qualifying NCCT
2210,NCT02474667,"1:11:treatment,",Study drug can be administered starting within 30 hours after restoration of blood flow to the engrafted kidney
2211,NCT02925923,1:11:treatment,Dabigatran
2212,NCT02329327,1:11:treatment,Dabigatran
2213,NCT02924441,1:15:treatment,breast surgery
2214,NCT02540330,1:15:treatment,breast surgery which interrupts communication of the ductal systems with the nipple
2215,NCT02920086,1:20:chronic_disease,respiratory failure episode within the preceding year; forced expiratory volume in 1 sec <0.5 L
2216,NCT02469857,16:35:chronic_disease,a patient with respiratory failure such that an SaO2 of 80% cannot be achieved
2217,NCT02913495,23:45:allergy_name,A contraindication to progesterone treatment
2218,NCT02518594,"19:41:treatment,,",Planned or actual progesterone treatment of any type or form after 14 weeks 6 days during the current pregnancy
2219,NCT02912572,20:39:cancer,"POLE-mutated, i.e. endometrial cancers known to harbor mutations in the exonuclease domain (amino acid residues 268-471) of polymerase e (POLE) as determined by targeted sequencing or other next generation sequencing assay"
2220,NCT02912572,41:60:cancer,first cohort (MSI/POLE cohort) includes endometrial cancers
2221,NCT02911116,"24:40:treatment,",Participant received a live vaccination within the past six weeks
2222,NCT02108860,"3:19:treatment,",A live vaccination fewer than 3 months before enrollment
2223,NCT02905591,1:52:chronic_disease,Glucose-6-phosphate dehydrogenase (G6PD) deficiency
2224,NCT02905578,1:52:chronic_disease,Glucose-6-phosphate dehydrogenase (G6PD) deficiency
2225,NCT02905188,1:23:chronic_disease,Hepatic encephalopathy
2226,NCT01811368,1:23:chronic_disease,Hepatic encephalopathy
2227,NCT02900794,1:23:chronic_disease,Chronic rhinosinusitis as described by the guidelines published in the 2015 Clinical practice guideline (update)
2228,NCT02493257,1:23:chronic_disease,Chronic rhinosinusitis
2229,NCT02890485,12:24:treatment,History of knee surgery
2230,NCT02219581,30:42:treatment,Patients undergoing revision knee surgery
2231,NCT02876510,1:29:chronic_disease,gastrointestinal obstruction
2232,NCT02099591,22:50:chronic_disease,Signs or symptoms of gastrointestinal obstruction
2233,NCT02871726,26:43:treatment,Scheduled for an initial diagnostic biopsy
2234,NCT01925378,",92:109:treatment","have a satisfactory (readable, good quality) colposcopic evaluation at least 14 days after diagnostic biopsy"
2235,NCT02864160,1:20:chronic_disease,diabetic neuropathy
2236,NCT00065676,8:27:chronic_disease,severe diabetic neuropathy
2237,NCT02861417,22:36:treatment,Patients must have a haploidentical related donor or a fully matched related or unrelated donor
2238,NCT01758042,14:28:treatment,Existence of haploidentical first degree relative who passes standard donor evaluations for bone marrow and kidney donation
2239,NCT02857218,27:40:chronic_disease,Subjects with evidence of iron overload
2240,NCT02516670,16:29:chronic_disease,Has history of iron overload
2241,NCT02851303,41:54:treatment,"Primary substance exposure in-utero was buprenorphine, or was not opioids"
2242,NCT02187198,33:46:allergy_name,known allergy or intolerance to buprenorphine
2243,NCT02844751,29:43:chronic_disease,Patients with indication of Osteoarthritis
2244,NCT02844738,29:43:chronic_disease,Patients with indication of Osteoarthritis
2245,NCT02830360,7:28:chronic_disease,Prior Myocardial Infarction
2246,NCT02006069,1:22:chronic_disease,Myocardial Infarction
2247,NCT02826681,9:25:treatment,Planned elective surgery during the study year
2248,NCT02431897,19:35:treatment,Medically fit for elective surgery
2249,NCT02819141,"1:19:treatment,",General anesthesia within 12 hours prior to enrollment
2250,NCT02548104,1:19:treatment,General anesthesia
2251,NCT02811939,51:63:allergy_name,Individuals with a documented reaction/allergy to Pregnenolone
2252,NCT02576912,51:63:allergy_name,Individuals with a documented reaction/allergy to Pregnenolone
2253,NCT02807272,14:18:cancer,Diagnosis of CMML as defined by the World Health Organization (WHO) criteria
2254,NCT02566304,16:20:cancer,"A diagnosis of CMML, unless in morphologic CR"
2255,NCT02796209,",74:102:treatment",Previous history (within 14 days prior to enrollment) and current use of monoamine oxidase inhibitors
2256,NCT02784535,16:44:treatment,current use of monoamine oxidase inhibitors
2257,NCT02792036,31:49:chronic_disease,Participants must not have an invasive infection at time of protocol entry
2258,NCT01783535,31:49:chronic_disease,Participants must not have an invasive infection at time of protocol entry
2259,NCT02778282,7:30:chronic_disease,other organic mental disorder
2260,NCT00875342,9:32:chronic_disease,Current organic mental disorder
2261,NCT02770326,12:53:treatment,History of hematopoietic stem cell transplant (HSCT)
2262,NCT01685411,",,,58:99:treatment",<45 years of age who are at least 6 months after initial hematopoietic stem cell transplant (HSCT)
2263,NCT02762032,5:28:chronic_disease,Any dermatological disorder that may interfere with the accurate evaluation of the subject's skin
2264,NCT02341287,14:37:chronic_disease,History of a dermatological disorder
2265,NCT02746458,22:30:chronic_disease,Current diagnosis of acidosis
2266,NCT02174016,"8:16:chronic_disease,,",Severe acidosis (serum bicarbonate ? 17 mEq/L) resistant to correction
2267,NCT02742454,18:30:chronic_disease,Suspected severe fetal anemia
2268,NCT02122328,",,114:126:chronic_disease",Recipient twin with a middle cerebral artery peak systolic velocity > 1.5 multiples of the median (indicative of fetal anemia)
2269,NCT02740543,",,48:60:treatment",? 20% (PC20) after inhalation of < 16 mg/ml of methacholine)
2270,NCT01026532,",,,118:130:treatment,,,,,,","Women of child-bearing potential (WCBP) must have a negative urine pregnancy test (urine HCG) within 48 hours of the methacholine challenge at Visit 2, within 48 hours of the inhaled allergen challenge at V3 and on the day of the segmental allergen challenge on Visit 5. WCBP must agree to use a reliable method of birth control for the duration of the study (reliable methods of birth control can include abstinence, barrier methods, oral contraceptives, injection contraceptives or skin absorption contraceptives)"
2271,NCT02734602,1:27:chronic_disease,neurodegenerative disorder
2272,NCT02465034,14:40:chronic_disease,History of a neurodegenerative disorder
2273,NCT02724540,16:30:allergy_name,intolerance to contrast media
2274,NCT02169037,24:38:allergy_name,untreatable allergy to contrast media
2275,NCT02719327,27:31:allergy_name,Known hypersensitivity to fish
2276,NCT02176902,24:28:allergy_name,Patient has allergy to fish
2277,NCT02710331,1:17:chronic_disease,Hearing deficits
2278,NCT02407808,1:17:chronic_disease,Hearing deficits
2279,NCT02706249,20:58:chronic_disease,Known diagnosis of disseminated intravascular coagulation
2280,NCT02520011,31:69:chronic_disease,Have evidence of uncontrolled disseminated intravascular coagulation
2281,NCT02703090,1:19:chronic_disease,Neurologic disease
2282,NCT02495389,1:19:chronic_disease,Neurologic disease known to affect the lower urinary tract
2283,NCT02688647,"1:27:chronic_disease,,",Severe concomitant illness limiting life expectancy (< 1 year)
2284,NCT02578641,1:27:chronic_disease,Severe concomitant illness
2285,NCT02680574,1:26:chronic_disease,peripheral artery disease (aortic or lower extremity)
2286,NCT02393742,"20:45:chronic_disease,,",Moderate or severe peripheral artery disease (ankle-brachial index <0.7)(183)
2287,NCT02679560,12:32:chronic_disease,Concern or compartment syndrome
2288,NCT02015390,22:42:chronic_disease,Patients with active compartment syndrome
2289,NCT02667418,11:26:chronic_disease,incipient toxic megacolon
2290,NCT02463305,24:39:chronic_disease,Evidence or history of toxic megacolon
2291,NCT02665338,1:32:chronic_disease,increased intracranial pressure
2292,NCT02479906,44:75:chronic_disease,Any condition likely to be associated with increased intracranial pressure
2293,NCT02655614,126:135:treatment,"For participants participating in a designated drug-drug interaction (DDI) cohort in the MAD stage of the study, who require midazolam/caffeine administration: known allergy, religious prohibition, or other condition limiting midazolam or caffeine administration"
2294,NCT02556606,41:50:allergy_name,Past intolerance or hypersensitivity to midazolam
2295,NCT02642939,"13:35:chronic_disease,,,",significant ischemic heart disease; mean QTc interval > 480 msec on at least two separate electrocardiograms (ECGs) prior to study start
2296,NCT02037048,1:23:chronic_disease,ischemic heart disease are not eligible
2297,NCT02639065,4:24:cancer,in situ cervical cancer
2298,NCT02128230,4:24:cancer,in situ cervical cancer
2299,NCT02632422,1:29:chronic_disease,severe autonomic dysreflexia
2300,NCT02329652,1:29:chronic_disease,severe autonomic dysreflexia
2301,NCT02624765,8:12:chronic_disease,severe IUGR
2302,NCT02299414,11:15:chronic_disease,Suspected IUGR
2303,NCT02620449,"1:14:chronic_disease,,,,,",severe anemia (hemoglobin < 8 g/dl for women and < 9 g/dl for men)
2304,NCT02339233,"1:14:chronic_disease,,",severe anemia (Hgb<8 g/dL)
2305,NCT02607514,8:23:chronic_disease,Active suicidal intent within the past year (yes on item 4 or 5 on the Columbia-Suicide Severity Rating Scale)
2306,NCT00285935,20:35:chronic_disease,"No current, active suicidal intent"
2307,NCT02593526,",,,164:180:treatment",Expected geographic unavailability at a participating HD unit for >2 consecutive weeks or >4 weeks total during the next 6 months (excluding unavailability due to hospitalizations)
2308,NCT02495168,1:17:treatment,hospitalizations within the past year or during the Run-in Period
2309,NCT02593110,9:19:chronic_disease,current foot ulcer
2310,NCT02356848,25:35:chronic_disease,Patients with an active foot ulcer
2311,NCT02589977,1:20:chronic_disease,pericardial disease
2312,NCT02004275,27:46:chronic_disease,No clinically significant pericardial disease
2313,NCT02587936,8:27:treatment,Use of hypoglycemic agents
2314,NCT00065676,"28:47:treatment,,",Subjects will be taken off hypoglycemic agents for 3 to 7 days prior to each part of the study
2315,NCT02584309,1:36:treatment,Prior treatment with anthracyclines
2316,NCT02498613,1:36:treatment,Prior treatment with anthracyclines
2317,NCT02580604,",,,,,,194:219:treatment",Serum calcium <8.5 or >10.3 mg/dL Serum 25(OH)D <20 ng/mL; volunteers with abnormal serum 25(OH)D values may be re-considered for participation in the study if serum 25(OH)D is >20 ng/mL after vitamin D supplementation
2318,NCT01968590,"1:26:treatment,,",vitamin D supplementation in the last 3 months equal to or greater than 600IU per day
2319,NCT02576301,1:29:cancer,Acute promyelocytic leukemia
2320,NCT02074436,1:29:cancer,Acute promyelocytic leukemia
2321,NCT02574728,1:40:cancer,diffuse intrinsic pontine glioma (DIPG)
2322,NCT02502708,78:117:cancer,Patients with a radiographic diagnosis or histologically proven diagnosis of diffuse intrinsic pontine glioma (DIPG)
2323,NCT02573597,1:14:chronic_disease,Pre-eclampsia
2324,NCT02025426,1:14:chronic_disease,"Pre-eclampsia (mild, or severe)"
2325,NCT02572323,54:65:allergy_name,Known allergy/sensitivity or any hypersensitivity to tesamorelin
2326,NCT02572323,"8:19:treatment,",Use of tesamorelin in the last 6 months
2327,NCT02570854,"14:34:chronic_disease,,,,,","Uncontrolled renal osteodystrophy defined asthe coexistence of all of the following at screening (1) intact PTH ? 750 pg/mL, (2) serum phosphate above the upper limit of the lab normal range, and (3) calcium x phosphate product > 75 mg2/dL2 (6.05 mmol2/L2)"
2328,NCT02056470,1:21:chronic_disease,renal osteodystrophy
2329,NCT02566395,1:21:cancer,Non-Hodgkin lymphoma
2330,NCT02338232,1:21:cancer,Non-Hodgkin lymphoma
2331,NCT02565446,1:17:treatment,cochlear implant
2332,NCT02132130,28:44:treatment,Patients with a history of cochlear implant in the study ear
2333,NCT02563678,"16:33:treatment,",presenting for hyperbaric oxygen for acute carbon monoxide poisoning (up to 3 sessions)
2334,NCT01986205,22:39:treatment,Contraindications to hyperbaric oxygen
2335,NCT02562430,"20:29:treatment,",Concomitant use of trazodone (up to 200 mg daily)
2336,NCT02266329,45:54:treatment,Potential participants who have been taking trazodone will undergo a 2-week washout period before beginning the preliminary screening period
2337,NCT02561104,14:30:treatment,Referred for cataract surgery at Parkland Memorial Hospital
2338,NCT01988246,",,71:87:treatment",Central subfield macular thickness ? 320 ?m in the study eye prior to cataract surgery as determined by SD-OCT and confirmed by the reading center
2339,NCT02554786,",,,,105:120:treatment","Pre-bronchodilator ? 50% FEV1 of < 85 % of the predicted normal value for the patient after withholding bronchodilators at both Visit 101 and 102, according to ATS/ERS criteria"
2340,NCT01799538,23:38:treatment,Inability to withhold bronchodilators for 24 hours
2341,NCT02553447,31:64:treatment,Simultaneous participation in other therapeutic clinical trials will be allowed
2342,NCT02524275,31:64:treatment,Simultaneous participation in other therapeutic clinical trials will not be allowed
2343,NCT02547818,8:35:chronic_disease,Severe renal or hepatic impairment
2344,NCT01850355,12:39:chronic_disease,History of renal or hepatic impairment
2345,NCT02543983,13:25:treatment,Agree to be hospitalized
2346,NCT02516670,122:134:treatment,Patients who require frequent (several times a day) monitoring of their blood glucose or patients who have recently been hospitalized for glucose control
2347,NCT02542956,45:71:treatment,Participating in another study involving an investigational medication
2348,NCT00980538,",,,,,275:301:treatment","Girls, who are sexually active and able to become pregnant, not using safe and effective birth control methods, or not willing to continue practicing these birth control methods, during the trial and until 30 days after the end of the trial (or after the last intake of the investigational medication)"
2349,NCT02541903,1:25:cancer,ductal carcinoma in situ
2350,NCT01918644,23:47:cancer,appropriately treated ductal carcinoma in situ
2351,NCT02536170,26:51:chronic_disease,Established diagnosis of sickle cell disease (SCD); all genotypes
2352,NCT02140554,14:39:chronic_disease,"Diagnosis of sickle cell disease (SCD), with either ?S/?S or ?S/?0 or ?S/?+ genotype"
2353,NCT02534168,22:32:treatment,Pre-operative use of analgesics
2354,NCT02358681,"60:70:treatment,",Frequent use of drugs for headache (i.e. regular intake of analgesics for acute headaches on more than 10 days per month)
2355,NCT02531932,",,,125:135:treatment",Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of Everolimus
2356,NCT02327403,1:11:treatment,Everolimus
2357,NCT02526212,21:24:treatment,Currently receiving BMT at Montefiore community health center (CHC)
2358,NCT02526212,"10:13:treatment,",Received BMT for 12 or more weeks
2359,NCT02522468,1:25:cancer,Locally advanced disease
2360,NCT01835626,1:25:cancer,Locally advanced disease is considered to include involved lymph nodes of the neck
2361,NCT02519322,26:37:chronic_disease,"Subjects with history of myocarditis, regardless of etiology"
2362,NCT01568177,1:12:chronic_disease,myocarditis
2363,NCT02516670,6:29:chronic_disease,Have end stage renal disease
2364,NCT02293096,1:24:chronic_disease,end stage renal disease
2365,NCT02512497,1:30:treatment,Prior whole brain irradiation
2366,NCT01701986,1:30:treatment,Prior whole brain irradiation
2367,NCT02508311,1:16:chronic_disease,Hyperthyroidism
2368,NCT01983475,1:16:chronic_disease,Hyperthyroidism
2369,NCT02504866,3:30:treatment,A ventriculo-peritoneal shunt
2370,NCT02355002,1:28:treatment,ventriculo-peritoneal shunt
2371,NCT02503722,1:24:chronic_disease,malabsorption syndromes
2372,NCT01675154,9:32:chronic_disease,Chronic malabsorption syndromes
2373,NCT02501954,15:29:cancer,Patients with carcinosarcoma
2374,NCT01600040,1:15:cancer,carcinosarcoma
2375,NCT02501473,"15:71:treatment,",Has undergone prior allogeneic hematopoietic stem cell transplantation within the last 5 years
2376,NCT02332668,"1:57:treatment,",prior allogeneic hematopoietic stem cell transplantation within the last 5 years
2377,NCT02498535,"17:43:treatment,",Ongoing chronic inhaled antibiotic therapy for at least 3 months prior to (screening or baseline)
2378,NCT02498535,22:48:treatment,Willing to be off of inhaled antibiotic therapy from Day 1 to Day 15
2379,NCT02496585,22:43:chronic_disease,Diagnosis of diffuse radiation pneumonitis
2380,NCT02496585,",44:65:chronic_disease",Newly diagnosed clinical grade 2 or higher radiation pneumonitis according to CTCAE version 4.0 criteria
2381,NCT02495415,29:61:chronic_disease,Patients with an identified familial hyperlipidemia disorder
2382,NCT01553071,29:61:chronic_disease,Patients with an identified familial hyperlipidemia disorder
2383,NCT02494258,50:66:treatment,any investigational agent after the last dose of oral azacitidine administered as part of the parent oral azacitidine study
2384,NCT02494258,10:26:treatment,received oral azacitidine
2385,NCT02490943,"4:19:chronic_disease,",No MS exacerbation for 60 days prior to screening
2386,NCT02427997,"9:24:chronic_disease,","have no MS exacerbation within the preceding 4 weeks, as determined by interview and medical notes review"
2387,NCT02489019,24:46:treatment,Patients scheduled for cardiovascular surgery
2388,NCT02436070,10:32:treatment,Previous cardiovascular surgery
2389,NCT02487095,103:114:treatment,History of allergic reactions attributed to compounds of similar chemical or biologic composition to (study agent) or other agents used in study
2390,NCT02273362,",,,,112:123:treatment",Willingness to use adequate contraception to avoid pregnancy or impregnation until 2 weeks after discontinuing study agent
2391,NCT02484404,",19:60:treatment",with at least one prior line of platinum-based chemotherapy
2392,NCT02484404,",19:60:treatment",with at least one prior line of platinum-based chemotherapy are eligible
2393,NCT02479906,12:36:chronic_disease,History of cerebrovascular accident
2394,NCT02469857,"8:32:chronic_disease,",Recent cerebrovascular accident in the last 3 months
2395,NCT02476409,61:70:allergy_name,History of adverse reaction or clinical contraindication to tolvaptan
2396,NCT02476409,32:41:allergy_name,History of hypersensitivity to tolvaptan
2397,NCT02473250,"1:4:treatment,",ECT within the past 6 months
2398,NCT02046330,33:36:treatment,Refusal of an adequate trial of ECT
2399,NCT02471430,10:45:chronic_disease,Negative Hepatitis B surface antigen (HBsAg) or Negative HBV DNA PCR
2400,NCT02320292,1:36:chronic_disease,Hepatitis B surface antigen (HBsAg) positive
2401,NCT02466685,"31:56:treatment,",change in mood stabilizing or antidepressant medication or dose within 2 months prior to screening
2402,NCT02133898,"4:29:treatment,",No antidepressant medication in past 3 months
2403,NCT02464969,1:33:chronic_disease,Uncontrolled severe hypertension at the time of randomization
2404,NCT02369653,1:33:chronic_disease,Uncontrolled severe hypertension at enrollment
2405,NCT02460900,51:62:allergy_name,Previous allergic reaction or hypersensitivity to Varenicline (by participant report ever in lifetime)
2406,NCT02460900,"15:26:treatment,",Recent use of Varenicline (by participant report in the past 3 months)
2407,NCT02457845,63:85:treatment,Radiation: Patients must have received their last fraction of craniospinal radiation
2408,NCT01130077,42:64:treatment,Patients in Stratum F must have received craniospinal radiation
2409,NCT02451488,",72:78:treatment",All WOCBP must have a negative pregnancy test prior to first receiving GM-CSF
2410,NCT02033616,27:33:allergy_name,Known hypersensitivity to GM-CSF
2411,NCT02442297,",,,,202:220:treatment",Available autologous transduced T lymphocytes with greater than or equal to 15% expression of HER2 CAR determined by flow-cytometry and killing of HER2-positive targets greater than or equal to 20% in cytotoxicity assay
2412,NCT01953900,",,65:83:treatment",killing of GD2-positive targets greater than or equal to 20% in cytotoxicity assay
2413,NCT02442297,"1:13:treatment,",Temozolomide will be allowed up to 48 hours preinfusion
2414,NCT02340156,73:85:allergy_name,Have a history of hypersensitivity reaction to any of the components of Temozolomide
2415,NCT02436070,1:15:chronic_disease,Bronchiectasis
2416,NCT02434809,1:15:chronic_disease,Bronchiectasis in the region of the intended implantation
2417,NCT02429934,"22:40:chronic_disease,",Subjects with active glomerulonephritis (>3 g protein/24h and/or active urine sediment)
2418,NCT02418195,12:30:chronic_disease,Autoimmune glomerulonephritis
2419,NCT02426047,14:36:chronic_disease,Metabolic or mitochondrial disorder
2420,NCT01817751,7:29:chronic_disease,Known mitochondrial disorder caused by mutations in mitochondrial DNA polymerase ?
2421,NCT02421380,15:28:chronic_disease,patients with brain lesions
2422,NCT02339376,21:34:cancer,Rapidly progressive brain lesions
2423,NCT02418195,1:16:chronic_disease,Grave's disease
2424,NCT02152956,7:22:chronic_disease,prior Grave's disease now euthyroid clinically and by laboratory testing
2425,NCT02416206,14:30:cancer,Diagnosis of Multiple Myeloma
2426,NCT01947140,1:17:cancer,Multiple Myeloma patients specified in the protocol
2427,NCT02413970,54:58:treatment,"Subjects who have been prescribed, but refuse to try CPAP would be considered intolerant"
2428,NCT02261857,23:27:treatment,Inability to tolerate CPAP attributed to poor fit by a sleep clinician
2429,NCT02405078,"1:9:treatment,,,,",CT scans showing involvement of 1 or more clearly demarcated lesions with a long axis > 1.5 cm and short axis >= 1.0 cm
2430,NCT00975520,39:47:treatment,Inability to localise surgical bed on CT scans and/or surgical margins (cm) not known
2431,NCT02401347,14:31:chronic_disease,Known active hepatitis C virus
2432,NCT01676259,1:18:chronic_disease,hepatitis C virus
2433,NCT02397083,42:54:allergy_name,Known intolerance or hypersensitivity to progesterone or its excipients
2434,NCT02133573,"17:29:treatment,",Maternal use of progesterone within 30 days of enrollment
2435,NCT02389517,84:87:cancer,available deoxyribonucleic acid (DNA) sample will be used for calibration step for MRD evaluation by gene sequencing
2436,NCT02003222,1:4:chronic_disease,MRD results will be reported to the submitting institution
2437,NCT02379520,"69:83:treatment,,",Currently receiving any investigational agents or have received any tumor vaccines or T cell antibodies within previous 4 weeks
2438,NCT02354547,1:15:treatment,tumor vaccines
2439,NCT02373241,1:13:chronic_disease,Hyperkalemia
2440,NCT02169089,"1:13:chronic_disease,,",Hyperkalemia defined as serum K+? 5.1 meq/L at visit 0 (screening)
2441,NCT02369406,",,28:41:chronic_disease,",30-365 days after birth if HIV-infection diagnosed within 96 hours after birth
2442,NCT02369406,"1:14:chronic_disease,",HIV-infection documented within 42 days after birth
2443,NCT02366754,1:23:chronic_disease,Traumatic Brain Injury etiology
2444,NCT02249039,1:23:chronic_disease,Traumatic Brain Injury
2445,NCT02362308,1:18:chronic_disease,"Mental conditions rendering the subject unable to understand the nature, scope and possible consequences of the study"
2446,NCT02130687,1:18:chronic_disease,"Mental conditions rendering the subject unable to understand the nature, scope, or possible consequences of the study"
2447,NCT02354703,114:125:treatment,"As of Screen Visit, the subject is sharing a household with a subject randomized to any investigational trial of ondansetron"
2448,NCT02354703,60:71:allergy_name,History of severe or life-threatening adverse reactions to ondansetron
2449,NCT02353728,43:46:cancer,Documented diagnosis of Ph+ Chronic phase CML
2450,NCT00368355,1:4:cancer,CML
2451,NCT02352454,8:22:chronic_disease,Proven venous disease
2452,NCT02312518,35:49:chronic_disease,Medicare/Medicaid eligible Proven venous disease
2453,NCT02347111,1:25:chronic_disease,structural heart disease
2454,NCT02169037,1:25:chronic_disease,structural heart disease of clinical significance
2455,NCT02343042,46:55:treatment,"Prior exposure to a SINE compound, including selinexor"
2456,NCT02323880,51:60:treatment,Patients must not have received prior exposure to selinexor
2457,NCT02340650,17:32:chronic_disease,Patients having acute infection
2458,NCT01239160,14:29:chronic_disease,Diagnosis of acute infection
2459,NCT02338999,",47:56:treatment",Postmenopausal women who have not undergone a DEXA scan over the last year will undergo a DEXA scan at screening
2460,NCT02338999,",43:52:treatment,,",Postmenopausal women who have undergone a DEXA scan during the last year and have a T score better than -2.5 will be included without repeating the DEXA scan prior to enrollment
2461,NCT02332187,"18:26:treatment,,,,",Use of high dose pressors (more than 15 mcg/min of norepinephrine or more than 15 mg/kg/min of dopamine)
2462,NCT02145260,8:16:treatment,Use of pressors
2463,NCT02323880,",,,106:128:treatment","Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1"
2464,NCT02304458,",,,106:128:treatment,","Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1"
2465,NCT02323126,"1:13:cancer,",Tumor tissue for determination and/or confirmation of genetic pre-requisites (i.e. EGFR T790M positivity post progression on EGFR TKI for Group 1; cMet status for Group 2) must be provided for analysis
2466,NCT00887146,1:13:cancer,Tumor tissue must show co-deletion of chromosomes 1p and 19q; for eligibility
2467,NCT02317991,26:40:treatment,anticipation of need for major surgical procedure during the course of the study
2468,NCT01903330,26:40:treatment,Anticipation of need for major surgical procedure during the course of the study
2469,NCT02312596,1:11:chronic_disease,vasculitis
2470,NCT02312518,1:11:chronic_disease,vasculitis
2471,NCT02308904,",32:51:treatment,",History of at least 5 years of chronic transfusion (defined as ? 8 transfusions/year)
2472,NCT02140554,",,53:72:treatment",abnormal transcranial Doppler [?200 cm/sec] needing chronic transfusion
2473,NCT02302235,12:33:cancer,History of non-glioma malignancy
2474,NCT01865162,12:33:cancer,History of non-glioma malignancy
2475,NCT02287558,"1:22:chronic_disease,,,,","Hepatic insufficiency, bilirubin > 2.0 or transaminases > 3.0 x normal"
2476,NCT01970345,1:22:chronic_disease,Hepatic insufficiency
2477,NCT02271100,22:41:allergy_name,Contraindications to neuraxial analgesia
2478,NCT02121184,21:40:allergy_name,Contraindication to neuraxial analgesia
2479,NCT02266745,41:61:treatment,"Evaluable disease, either measurable on physical examination"
2480,NCT01220583,"9:29:treatment,",History/physical examination within 8 weeks prior to registration
2481,NCT02262806,1:21:chronic_disease,Psychiatric disorder impeding competence or compliance
2482,NCT00085982,1:21:chronic_disease,Psychiatric disorder impeding competence or compliance
2483,NCT02252588,13:26:chronic_disease,Presence of chronic cough and sputum will be defined by responses to the first two questions on the SGRQ. Subjects w
2484,NCT02252588,32:45:chronic_disease,Presence or high likelihood of chronic cough and sputum production
2485,NCT02250664,18:44:treatment,Currently taking anticonvulsant medications
2486,NCT02250534,18:44:treatment,Currently taking anticonvulsant medications
2487,NCT02234934,10:33:treatment,Abnormal electrocardiogram (EKG) indicating cardiac pathology
2488,NCT01409161,",48:71:treatment,",Fridericia corrected QT (QTcF) interval on the electrocardiogram (EKG) greater than 480 milliseconds
2489,NCT02233868,7:23:chronic_disease,"Major medical problems that can permanently impact brain function (e.g., CNS, cardiovascular, metabolic, autoimmune, endocrine) as determined by history and clinical exam"
2490,NCT02230189,29:45:chronic_disease,"Presence of past or current medical problems/other factors that may pose additional risks from participation or influence study results, as determined per study investigator"
2491,NCT02232516,1:33:cancer,Enteropathy-type T-cell lymphoma
2492,NCT01787409,1:33:cancer,Enteropathy-type T-cell lymphoma
2493,NCT02219711,28:50:cancer,Metastatic or unresectable solid tumor malignancy
2494,NCT01625234,65:87:cancer,Histologically or cytologically confirmed diagnosis of advanced solid tumor malignancy
2495,NCT02206945,1:22:chronic_disease,severe claustrophobia
2496,NCT00285935,"25:46:chronic_disease,,","No MRI exclusions (e.g. severe claustrophobia, metal implants, pacemakers, BMI >38)"
2497,NCT02194387,",20:32:treatment",Less than 3 months post-surgery
2498,NCT01101451,",53:65:treatment,",Patients should not be randomized less than 3 weeks post-surgery but will not be acceptable for randomization more than 8 weeks post-surgery
2499,NCT02189798,"18:44:chronic_disease,,,,,,,,","Up to a moderate sensorineural hearing loss in the low-to-mid frequencies (pure tone average ?65 dB for 125, 250, 500, and 1000 Hz) and a severe-to-profound sensorineural hearing loss in the high frequencies (pure tone average ? 70 dB HL for 2,000, 3000, 4,000, and 8,000 Hz) in the contralateral (non-implanted) ear"
2500,NCT02189798,"18:44:chronic_disease,,,","Up to a moderate sensorineural hearing loss in the low-to-mid frequencies (pure tone average ?65 dB for 125, 250, 500, and 1000 Hz) and a severe-to-profound sensorineural hearing loss in the high frequencies (pure tone average ? 70 dB HL for 2,000, 3000, 4,000, and 8,000 Hz) in the ear to be implanted"
2501,NCT02181257,",144:147:chronic_disease,",Frequent laboratory based spirometry defined as having had regular FEV1 measurements during the preceding six months prior to diagnosis of new BOS with no time interval between FEV1 measurements that exceeds 8 weeks
2502,NCT02181257,",60:63:chronic_disease",History of close FEV1 monitoring prior to diagnosis of new BOS defined as having had either of the two monitoring approaches
2503,NCT02172950,",,,61:84:chronic_disease,,",Males 0 to <18 years of who have been diagnosed with severe congenital hemophilia A (FVIII activity levels < 1%)
2504,NCT02172950,",,,,62:85:chronic_disease,,,,","Males 0 to <65 years age who have been diagnosed with severe congenital hemophilia A (FVIII activity levels < 1%), who have at least 50 EDs to any FVIII product, and who are not currently enrolled in a CSL-sponsored clinical study with rVIII-SingleChain"
2505,NCT02167009,12:30:treatment,History of pelvic irradiation
2506,NCT01868386,11:29:treatment,had prior pelvic irradiation
2507,NCT02159027,55:70:treatment,Unwillingness to stop from eating grapefruit or using St. John's wort
2508,NCT01959204,"8:23:treatment,,",Use of St. John's wort is prohibited from 28 days before dosing until 14 days after dosing
2509,NCT02152995,",,69:82:treatment",patients with controlled atrial fibrillation for > 30 days prior to randomization
2510,NCT01872975,",,61:74:treatment,",Pregnancy testing must be performed within 2 weeks prior to randomization according to institutional standards for women of childbearing potential
2511,NCT02148003,"21:24:treatment,",History of previous RFA at the same level(s) in the previous 12 months
2512,NCT02148003,"27:30:treatment,,",Patients who will undergo RFA of 3?4 lumbar facet medial branches on one side only
2513,NCT02143726,1:25:chronic_disease,Cerebrovascular accident
2514,NCT01626079,"1:25:chronic_disease,",Cerebrovascular accident within 30 days prior to subject registration
2515,NCT02133196,77:99:treatment,Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities
2516,NCT01967823,76:98:treatment,Patients who have decreased immunecompetence may be less responsive to the experimental treatment and more susceptible to its toxicities
2517,NCT02130687,",,49:61:treatment",2-hour plasma glucose ?200 mg/dL following 75gr oral glucose load
2518,NCT00085982,",,,85:97:treatment",2 hour plasma glucose >= 200 mg/dL following a 75 gram (1.75g/kg if less than 40kg) oral glucose load
2519,NCT02128230,74:93:treatment,Patients must be either untreated or have not had more than one cycle of systemic MM therapy
2520,NCT00734877,",74:93:treatment",Patients must be either untreated or have not had more than one cycle of systemic MM therapy
2521,NCT02124772,35:63:chronic_disease,History of or current evidence of retinal vein occlusion (RVO)
2522,NCT02070549,37:65:chronic_disease,History or current evidence/risk of retinal vein occlusion (RVO)
2523,NCT02111850,1:18:cancer,Metastatic cancer diagnosis will be confirmed by the Laboratory of Pathology at the NCI
2524,NCT02019641,"1:18:cancer,",Metastatic cancer with a life expectancy of less than one year
2525,NCT02101944,",13:31:chronic_disease,",> 200 mg of monoclonal protein in the urine on screening 24-hour electrophoresis
2526,NCT01415882,",14:32:chronic_disease,",>= 200 mg of monoclonal protein in the urine on 24 hour electrophoresis
2527,NCT02089607,1:19:chronic_disease,Saccular aneurysms deemed at significant risk for rupture based upon physician interpretation
2528,NCT01937949,1:19:chronic_disease,Saccular aneurysms deemed at significant risk for rupture based upon physician interpretation
2529,NCT02081404,1:25:chronic_disease,Eosinophilic esophagitis
2530,NCT01942018,1:25:chronic_disease,Eosinophilic esophagitis
2531,NCT02058095,40:55:treatment,Current or anticipated future need for nitrate therapy
2532,NCT01970176,40:55:treatment,Current or anticipated future need for nitrate therapy
2533,NCT02048722,14:25:treatment,Prior use of regorafenib
2534,NCT02048371,51:62:allergy_name,"Known or suspected allergy or hypersensitivity to regorafenib, or excipients of the formulations given during the course of this trial"
2535,NCT02036853,31:44:treatment,Concomitant administration of valproic acid
2536,NCT01817751,59:72:treatment,Any condition that would prohibit patient from initiating valproic acid
2537,NCT02021604,41:43:chronic_disease,Patients who do not have a diagnosis of HI
2538,NCT02021604,15:17:chronic_disease,Patients with HI attending the Cook Children's Congenital Hyperinsulinism Center and being treated by an Endocrinologist which may be the PI or a partner of this clinician
2539,NCT02013778,"8:21:chronic_disease,",Active GI hemorrhage within 2 weeks of study enrollment
2540,NCT01696734,"1:14:chronic_disease,",GI hemorrhage or obstruction experienced within the previous 6 weeks
2541,NCT01996865,33:48:allergy_name,Known sensitivity or allergy to murine products
2542,NCT01959698,30:45:allergy_name,No known hypersensitivity to murine products
2543,NCT01969643,38:49:allergy_name,Combination Arm: hypersensitivity to trastuzumab
2544,NCT01494662,14:25:treatment,Washout from trastuzumab
2545,NCT01964261,1:24:chronic_disease,Intellectual impairment
2546,NCT01581580,"1:24:chronic_disease,,",Intellectual impairment as determined by a score of less than 70 on the estimated General Ability Index (GAI)
2547,NCT01954173,30:40:treatment,Patients treated with simple cystectomy with macroscopically negative margins are eligible for this study
2548,NCT01730118,21:31:treatment,Status-post primary cystectomy with curative intent
2549,NCT01928576,24:48:cancer,Patients with advanced malignant hepatic tumors
2550,NCT01333046,24:48:cancer,Patients with advanced malignant hepatic tumors
2551,NCT01897259,27:39:chronic_disease,conservative treatment of tennis elbow is recommended as standard of care treatment
2552,NCT01897259,",133:145:chronic_disease","treatment by a health care profession (MD, physicians assistnat, therapist, or nurse practitioner) within the previous 6 months for tennis elbow"
2553,NCT01878617,",,,,214:233:cancer","Age greater than or equal to 3 years and less than 22 years of age at the time of diagnosis (may enroll on Strata W, S or N), OR (2) age is greater than or equal to 22 years and less than 40 years AND patient has SHH medulloblastoma (must enroll on Stratum S)"
2554,NCT01878617,",,,,141:160:cancer",?5 years at the time of remediation intervention consent or age is greater than or equal to 22 years and less than 40 years and patient has SHH medulloblastoma
2555,NCT01865162,16:44:treatment,? weeks from a non-nitrosourea chemotherapy (all [a-c] in order to allow recovery from the potential of severe toxicity related to these treatments)
2556,NCT01849146,",16:44:treatment",3 weeks from a non-nitrosourea chemotherapy
2557,NCT01823198,1:31:cancer,Chronic myeloid leukemia (CML)
2558,NCT01619761,1:31:cancer,Chronic myeloid leukemia (CML) second chronic phase or accelerated phase
2559,NCT01804634,5:8:chronic_disease,"For CMV seronegative recipients, a CMV seronegative donor"
2560,NCT00919503,290:293:chronic_disease,DONOR: Unrelated Umbilical Cord Blood: Any cord blood units that have not passed donor screening for infectious disease markers as recommended by NMDP will not be used unless a waiver is signed by the clinical attending allowing use of cord blood unit; cord blood units are presumed to be CMV negative regardless of serologic testing due to passive transmission of maternal CMV antibodies
2561,NCT01789333,15:24:chronic_disease,Patients with nystagmus or any other condition that is severe enough to prevent steady gaze during the treatment
2562,NCT01115283,37:46:chronic_disease,"any ocular pathological conditions, nystagmus"
2563,NCT01754857,27:38:allergy_name,Known hypersensitivity to thalidomide
2564,NCT01433965,27:38:allergy_name,Known hypersensitivity to thalidomide
2565,NCT01696734,18:29:allergy_name,Known allergy to domperidone
2566,NCT01696734,",,84:95:treatment,",have a negative urine pregnancy test within 30 days of the first administration of domperidone and must either commit to continued abstinence from heterosexual intercourse or use an effective method of birth control during the course of the study)
2567,NCT01659203,16:24:cancer,Other types of sarcomas
2568,NCT01449149,27:35:cancer,other soft tissue or bony sarcomas
2569,NCT01625923,12:30:chronic_disease,History of hyperprolactinemia
2570,NCT00914823,",,20:38:chronic_disease",Men and women with hyperprolactinemia
2571,NCT01568177,"7:26:chronic_disease,,",Prior non-cardiac illness with an estimated life expectancy < 4 years
2572,NCT00573027,"7:26:chronic_disease,,",Prior non-cardiac illness with an estimated life expectancy <4 years
2573,NCT01524536,43:55:chronic_disease,signs and/or symptoms attributable to the eosinophilia
2574,NCT00044304,31:43:chronic_disease,no secondary etiology for the eosinophilia despite careful clinical evaluation
2575,NCT01494662,53:83:chronic_disease,"In cohort 3, eligible patients must have measurable Central Nervous System disease"
2576,NCT01494662,53:83:chronic_disease,"In cohort 4, eligible patients must have measurable Central Nervous System disease"
2577,NCT01433965,1:31:chronic_disease,"Active, uncontrolled infection"
2578,NCT01187368,1:31:chronic_disease,"Active, uncontrolled infection"
2579,NCT01389024,",,51:68:treatment",Room air oxygen saturation <90% on the day of the MRI with sedation
2580,NCT01389024,",,107:124:treatment",Room air oxygen saturation greater than or equal to 5% below the participant's baseline on the day of the MRI with sedation
2581,NCT01042522,"1:31:chronic_disease,,",Neuropathy (sensory and motor) less than or equal to CTCAE grade 1
2582,NCT00492778,"1:31:chronic_disease,,",Neuropathy (sensory and motor) =< CTCAE v 3.0 grade 1
2583,NCT00501826,"13:15:chronic_disease,",patients in CR after =< 2 courses are also eligible
2584,NCT00357565,",20:22:treatment",>1 cycle to obtain CR
2585,NCT00004317,14:38:chronic_disease,Asymptomatic congenital toxoplasmosis
2586,NCT00004317,"14:38:chronic_disease,,",Infants with congenital toxoplasmosis Toxoplasma gondii confirmed prior to age 2.5 months
2587,NCT03188042,"1:21:chronic_disease,",Visual field defects present for at least 6 months
2588,NCT03187379,1:38:treatment,laparoscopic roux-en-y gastric bypass
2589,NCT03187379,8:31:treatment,use of EEA stapler anastomosis
2590,NCT03186872,1:30:chronic_disease,Personality pathology or PTSD (captured from DSM-V cross cutting symptoms inventory already being used as part of routine care screening in this clinic)
2591,NCT03185130,1:10:chronic_disease,Meningeal signs are present
2592,NCT03183102,12:40:chronic_disease,History of venous thromboembolic events
2593,NCT03182907,"17:44:treatment,",Has received an investigational study agent within the previous 30 days
2594,NCT03182075,1:34:chronic_disease,psychiatric or medical conditions that make participation unsafe
2595,NCT03181516,1:12:treatment,Amoxicillin
2596,NCT03181516,1:10:treatment,Cefoxitin
2597,NCT03181516,1:13:treatment,Erythromycin
2598,NCT03181516,1:13:allergy_name,Milk-protein allergy
2599,NCT03181516,1:21:treatment,Velosef (cephradine)
2600,NCT03181126,"1:16:treatment,",Steroid therapy for anti-neoplastic intent within 5 days
2601,NCT03180086,",25:56:treatment",women with a history of breast enlargement or reduction
2602,NCT03179397,1:24:chronic_disease,Iris Neovascularization
2603,NCT03179397,10:28:treatment,Previous refractive surgery
2604,NCT03179163,22:72:allergy_name,contraindication for all three pharmacotherapy drugs used in this study
2605,NCT03178383,20:58:cancer,"Have no history of breast, prostate, or colorectal cancer"
2606,NCT03176784,7:29:treatment,using Chantix or varenicline and not willing to stop for duration of the study
2607,NCT03175978,"1:35:treatment,",prior use of systemic methotrexate > 1 month prior to study entry is allowed
2608,NCT03171493,26:41:cancer,History of or concurrent non-invasive UC involving a portion of urinary tract outside of the bladder
2609,NCT03171168,"20:45:treatment,",Patient started on lipid lowering medication in last 3 months
2610,NCT03170518,"1:20:chronic_disease,",Severe hypoglycemia within 6 months prior to Day 1
2611,NCT03170453,1:31:chronic_disease,disruptive or violent behavior
2612,NCT03170375,1:31:chronic_disease,severely uncontrolled diabetes
2613,NCT03169881,1:30:chronic_disease,Congenital thrombotic disease
2614,NCT03168776,26:70:treatment,Current participation in another investigational drug or device study
2615,NCT03168776,22:64:treatment,contraindications to anti-platelet and/or anticoagulant therapy
2616,NCT03168347,40:59:treatment,Currently or previously managed with a biologic medication
2617,NCT03166371,"1:22:chronic_disease,,,,,,",Acute hepatic failure during current hospitalization with total serum bilirubin > 3.5 mg/dL or transaminase values [alanine transaminase (ALT) and/or aspartate transaminase (AST) values > 3-fold the upper limit of normal range]
2618,NCT03163901,14:53:chronic_disease,Diagnosis of mild to moderate traumatic brain injury
2619,NCT03160547,1:11:chronic_disease,Sarcopenia
2620,NCT03159936,"1:23:treatment,",Topical corticosteroid within the past 2 weeks
2621,NCT03159754,16:26:treatment,Patient taking tizanidine
2622,NCT03158974,1:16:treatment,Cytotoxic drugs
2623,NCT03158974,1:35:treatment,Oral or parenteral corticosteroids
2624,NCT03157492,",45:47:treatment",Greater than three years post-activation of CI
2625,NCT03154580,1:17:chronic_disease,Major depression that is not substance-induced)
2626,NCT03154476,1:25:chronic_disease,Severe renal dysfunction
2627,NCT03153969,"1:17:chronic_disease,",Cervical lesions must provide for a minimum of 1mm thickness of restorative material while maintaining natural tooth contour
2628,NCT03153969,12:32:chronic_disease,Teeth with periapical pathology
2629,NCT03153319,1:22:chronic_disease,Hepatitis B infection (active or chronic carrier)
2630,NCT03152409,10:30:chronic_disease,Comorbid autoimmune condition
2631,NCT03152058,"1:26:chronic_disease,",Type 1 or Type 2 diabetes antedating pregnancy
2632,NCT03151330,"27:45:treatment,",The subject has a planned cerclage placement for the current pregnancy
2633,NCT03150004,70:117:treatment,"In first or subsequent relapse or refractory status, with or without prior hematopoietic stem cell transplant (HSCT)"
2634,NCT03149783,7:30:treatment,other sodium channel blockers
2635,NCT03149549,21:58:treatment,Currently receiving anticoagulation therapy with warfarin
2636,NCT03148795,36:50:chronic_disease,Patients must have measurable soft tissue disease per RECIST 1.1
2637,NCT03148379,72:101:treatment,retained hardware in the knee that requires removal or interferes with Total Knee Arthroplasty (TKA) procedure
2638,NCT03146663,",23:61:treatment",Received fewer than 3 prior chemotherapy-containing regimens
2639,NCT03145298,"25:47:treatment,,",The subjects must be on PAH-specific therapies for at least 4 months and on a stable dose for at least 4 weeks prior to enrollment into study
2640,NCT03144921,47:59:chronic_disease,Exhibit changes in memory as specified on the AD8 dementia screening tool
2641,NCT03144206,10:42:treatment,Plan for post operative radiation therapy
2642,NCT03143153,11:28:cancer,"Must have esophageal cancer that cannot be operated on, or treated with definitive chemoradiation with curative intent, that is advanced, reoccurring or has spread out"
2643,NCT03140527,"1:24:chronic_disease,,,","Abnormal liver function as defined by aspartate aminotransferase (AST), alanine aminotransferase (ALT) or bilirubin > upper limit of the normal range"
2644,NCT03139227,"20:68:treatment,",Chronic use of any herbal or dietary supplement containing apigenin within the 3 months prior to entry on the study
2645,NCT03138733,"1:39:chronic_disease,,","Staphylococcus aureus bacteremia (SAB), based on at least one positive blood culture obtained within the 72 h prior to randomization"
2646,NCT03137771,1:21:cancer,Cutaneous metastasis of NSCLC
2647,NCT03137459,1:25:chronic_disease,"Severe visual impairment, defined as being unable to read large-print materials"
2648,NCT03137173,"12:44:treatment,",Use of any systemic antibacterial treatment within 14 days
2649,NCT03136029,1:28:chronic_disease,Peripheral Vascular Disease
2650,NCT03135990,9:45:chronic_disease,Current substance use disorder or dependence as primary diagnosis
2651,NCT03134274,6:21:chronic_disease,Have impaired vision that prevents them from reading instructions
2652,NCT03133793,1:28:chronic_disease,Severe cognitive impairment
2653,NCT03132636,1:33:treatment,Immunosuppressive corticosteroid doses
2654,NCT03131960,13:25:chronic_disease,Significant sensory loss
2655,NCT03130907,15:30:chronic_disease,Patients with solitary kidney
2656,NCT03129880,16:41:chronic_disease,Diagnosed with benign vocal fold lesions and/or hyper-function
2657,NCT03129542,1:23:chronic_disease,ischemic bowel disease
2658,NCT03128008,39:73:cancer,Histologic/cytologic documentation of non-small cell lung cancer (NSCLC)
2659,NCT03127722,36:65:treatment,Subjects who have had an attempted prior sterilization procedure
2660,NCT03125902,"34:57:chronic_disease,",previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for at least 2 weeks prior to randomization
2661,NCT03125226,1:17:treatment,Prior cystectomy
2662,NCT03123068,1:19:chronic_disease,Infectious disease within the last month
2663,NCT03122912,12:19:chronic_disease,History of keloids
2664,NCT03122145,24:30:allergy_name,Anyone with allergy to barium
2665,NCT03121586,1:11:treatment,Lurasidone
2666,NCT03121352,35:56:treatment,Patients who have participated in MK-3475 Merck studies
2667,NCT03120728,",55:68:treatment,,,,,,","Use of a non-hormonal form of contraception, such as: sterilization (tubal ligation, Essure), copper IUD (intrauterine device), barrier methods or abstinence"
2668,NCT03120728,12:37:chronic_disease,history of peripartum cardiomyopathy
2669,NCT03120585,56:76:treatment,Those neonates who are intubated for administration of exogenous surfactant but who are immediately extubated to non-invasive respiratory support after surfactant administration will remain eligible for study inclusion
2670,NCT03119363,"1:17:cancer,",Secondary cancer diagnosis (prior or current) within the past 5 years
2671,NCT03117751,",34:60:cancer",LLy participants must have < 25% tumor cells in bone marrow and peripheral blood by morphology and flow cytometry
2672,NCT03116997,7:20:chronic_disease,Known liver Disease
2673,NCT03116464,1:20:chronic_disease,Caregiver psychosis
2674,NCT03115359,1:29:treatment,Cognitive Behavioral Therapy training
2675,NCT03114501,26:29:cancer,Diagnosed with a primary HNC
2676,NCT03114020,"1:43:chronic_disease,",Upper or lower respiratory tract infection within 2 weeks prior to screening and baseline (day1)
2677,NCT03113825,"10:39:treatment,",Received systemic investigational drug within 6 weeks prior to AVB-620 administration or has received AVB-620 previously
2678,NCT03113760,33:54:treatment,Patients with genetic diagnosis of NLRC4-MAS mutation
2679,NCT03113695,",,,,,166:175:treatment",Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test within 10 - 14 days prior to and again within 24 hours prior to starting REVLIMID®
2680,NCT03113695,1:31:chronic_disease,fungal infections of nail beds
2681,NCT03112902,1:49:chronic_disease,rapid eye movement (REM)-sleep behavior disorder
2682,NCT03112824,1:7:treatment,SSRI's
2683,NCT03112720,37:52:treatment,Subjects already being treated with lidocaine patch or other vehicle for chronic pain
2684,NCT03112603,1:13:chronic_disease,Severe cGvHD
2685,NCT03111121,1:18:treatment,Microlaryngoscopy
2686,NCT03109210,"11:29:treatment,",change in thyroid medication dosage or received a new prescription for thyroid medication 3 months before the screening visit
2687,NCT03108820,9:21:chronic_disease,have an acute stroke upon admission
2688,NCT03107546,1:74:treatment,Previous surgery on the web that requires a subsequent syndactyly release
2689,NCT03106740,13:27:treatment,on a stable pain treatment
2690,NCT03105362,8:21:treatment,Stable GI medication regime
2691,NCT03105362,1:30:chronic_disease,microvillus inclusion disease
2692,NCT03104699,1:56:cancer,Efficacy Expansion Cohort (Second-Line Cervical Cancer)
2693,NCT03104699,"1:34:chronic_disease,",cerebral vascular accident/stroke (<6 months before enrollment)
2694,NCT03104699,1:35:cancer,minimal deviation/adenoma malignum
2695,NCT03104517,12:56:cancer,"History of cancer in pelvic organs, ureters, or kidneys"
2696,NCT03103646,40:50:treatment,Subject has previously been dosed with Lu AF35700
2697,NCT03101956,"1:13:treatment,",Knee surgery on the affected knee within the last 6 months
2698,NCT03101956,1:13:chronic_disease,Osteoporosis or recent fracture of the hip or spinal joints
2699,NCT03100539,"26:41:treatment,",Any massage professional massage therapy within the last 6 months
2700,NCT03100461,"1:12:treatment,",Colonoscopy within 10 years
2701,NCT03100370,26:49:treatment,No planned alteration in upper-extremity therapy or medication for muscle tone during the course of the study
2702,NCT03098082,1:27:chronic_disease,Stage 3 or 4 renal disease and/or oliguria
2703,NCT03096886,1:39:treatment,Centrally acting antiadrenergic agents
2704,NCT03096366,1:110:treatment,Anterior cruciate ligament (ACL) reconstruction with concomitant meniscus or cartilage restoration procedures
2705,NCT03096288,"4:82:treatment,","On therapy with clopidogrel (75mg od), with or without low-dose aspirin (81mg od), as per standard-of-care for at least 30 days"
2706,NCT03096288,1:22:treatment,vitamin K antagonists
2707,NCT03093272,1:37:cancer,Castration-resistant prostate cancer
2708,NCT03092011,70:73:chronic_disease,Babies being started on medication to control withdrawal symptoms of NAS
2709,NCT03090672,12:43:chronic_disease,History of severe traumatic brain injuries
2710,NCT03090607,21:84:chronic_disease,History of or known esophageal stricture or gross esophageal anatomic abnormalities
2711,NCT03089905,38:67:chronic_disease,Existing diagnosis of behavioural or neurodevelopmental disability
2712,NCT03089515,7:27:chronic_disease,Known prostate hyperplasia
2713,NCT03089515,1:25:chronic_disease,bladder-neck obstruction
2714,NCT03088709,1:29:cancer,Non-Hodgkin's Lymphoma (NHL)
2715,NCT03088072,20:35:chronic_disease,Moderate or severe mitral stenosis
2716,NCT03088033,1:32:treatment,treatment with intravenous (IV)
2717,NCT03086369,40:68:cancer,Have received first line treatment for metastatic pancreatic cancer
2718,NCT03085485,12:28:chronic_disease,Element of CFTR Dysfunction
2719,NCT03085433,",26:45:chronic_disease",Male partner with severe oligoasthenospermia
2720,NCT03085095,1:20:cancer,Metastases to brain per prior clinical evaluation
2721,NCT03084640,44:89:cancer,Histopathologically confirmed diagnosis of metastatic or unresectable malignant melanoma
2722,NCT03084640,34:57:treatment,"who have previously received any anti-PD-1/PD-L1 therapy, alone or in combination"
2723,NCT03081390,39:58:treatment,"Chronic use of medications, including oral contraceptives"
2724,NCT03080142,33:51:treatment,Patients scheduled for elective colorectal surgery with Dr. Linda Farkas
2725,NCT03079297,6:31:chronic_disease,Have Maple Syrup Urine Disease
2726,NCT03078907,"20:59:treatment,",Participation in a cardio-pulmonary rehabilitation program based on exercise training within 8 weeks prior to screening
2727,NCT03078530,15:38:chronic_disease,Veterans with psychological disorders will not be excluded but will be identified for sub-group analysis
2728,NCT03078023,",,40:68:treatment",Esophageal minimal diameter < 13 mm on structured barium esophagram
2729,NCT03077243,1:15:chronic_disease,Systemic lupus
2730,NCT03076658,22:35:treatment,without a history of spine surgery
2731,NCT03075306,92:99:chronic_disease,"Serious health condition precluding participation in weight management intervention (e.g., bulimia)"
2732,NCT03074240,",,39:62:treatment",Patients ? 18 years of age undergoing umbilical hernia repair
2733,NCT03073785,62:70:cancer,Patients with inoperable conditions with resectable disease (T1-2NoMo)
2734,NCT03073343,",,52:74:treatment",2-hour plasma glucose level of > 200mg/dL during a glucose tolerance test
2735,NCT03073070,12:39:chronic_disease,history of gastrointestinal blood loss
2736,NCT03072238,12:36:chronic_disease,History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias
2737,NCT03072238,12:31:chronic_disease,measurable soft tissue disease by computed tomography (CT)
2738,NCT03071393,8:35:chronic_disease,"severe musculoskeletal impairments, open wounds, or skin lesions that would limit participation in functional assessments"
2739,NCT03070899,13:38:chronic_disease,Undiagnosed abnormal uterine bleeding
2740,NCT03070145,1:19:chronic_disease,Moderate arthritis that does not preclude physical activity is not a reason for ineligibility
2741,NCT03069469,1:51:cancer,Diffuse-type Tenosynovial Giant Cell Tumor (DTGCT) patients
2742,NCT03068780,1:20:chronic_disease,junctional EB (JEB)
2743,NCT03067818,1:31:chronic_disease,Brainstem or cerebellar stroke
2744,NCT03065972,26:47:chronic_disease,Diagnosed with End-stage Renal Disease stage 4
2745,NCT03065465,"7:24:chronic_disease,,",Acute hypovolemic shock that is unresponsive to transfusion of 5 or more units of red blood cells (RBC's)
2746,NCT03065465,1:18:chronic_disease,anastomotic ulcer
2747,NCT03062462,14:52:chronic_disease,Diagnosed as respiratory or circulatory instability
2748,NCT03062111,1:19:chronic_disease,Neurogenic bladder
2749,NCT03061201,"1:20:chronic_disease,,",Severe hemophilia A (past evidence of circulating FVIII activity of < 1% normal)
2750,NCT03060772,12:34:chronic_disease,History of cirrhosis of the liver
2751,NCT03060473,61:71:allergy_name,Contraindication to any of the antibiotics used (allergy to macrolides)
2752,NCT03059888,48:60:treatment,History of inadequate response to conventional MG treatment
2753,NCT03059407,39:54:chronic_disease,or concern for immune system function/infectious risk that could be worsened by animal exposure
2754,NCT03059030,22:33:treatment,"Contraindications to angiography and selective visceral catheterization such as bleeding, diathesis or coagulopathy that is not correctable by usual therapy or hemostatic agents (e.g. closure device)"
2755,NCT03059004,13:27:chronic_disease,Evidence of osteoarthritic changes on imaging
2756,NCT03058952,1:32:chronic_disease,antisocial personality disorder
2757,NCT03058783,"1:20:cancer,",carcinoma of cervix effectively treated more than 5 years ago
2758,NCT03058029,12:41:treatment,History of abdominal radiation treatment
2759,NCT03057730,47:68:treatment,Healthy subjects with no contraindications to root coverage surgery
2760,NCT03056287,1:17:chronic_disease,Severe arthritis or other problems that limit passive range of motion
2761,NCT03055377,",60:81:chronic_disease",Must meet current (within last 30 days) DSM-5 criteria for cannabis use disorder
2762,NCT03054155,33:49:treatment,Patients unable to tolerate the laser treatments
2763,NCT03053908,10:32:chronic_disease,Subjects hypomotility disorders of the gastrointestinal tract including but not limited to Ileus
2764,NCT03053453,1:38:treatment,Contralateral Total Knee Arthroplasty
2765,NCT03053453,10:33:treatment,Revision Total Knee Arthroplasty
2766,NCT03053037,54:74:treatment,Confirmed restorability with crown restoration after root canal treatment or adequate existing full cuspal coverage restoration
2767,NCT03051347,42:56:chronic_disease,Any child with a potentially disfiguring skin condition or change in appearance related to disease/intervention will be considered eligible
2768,NCT03051282,"45:52:treatment,",habitual consumption of large quantities of ethanol (>3 drinks/day)
2769,NCT03049189,9:28:treatment,Planned alternative therapy (for the period of study participation)
2770,NCT03049189,1:47:chronic_disease,Somatostatin receptor positive (SSTR+) disease
2771,NCT03048448,"1:24:chronic_disease,,,",Mild hepatic impairment (Group 4): Child-Pugh Class A (5-6 points)
2772,NCT03045341,18:45:treatment,Currently taking anti-depressant medications
2773,NCT03043794,46:66:treatment,Planning breast conserving surgery including sentinel node biopsy
2774,NCT03042897,20:36:treatment,"Must agree to take progestin agents (i.e., oral agents or MIRENA intrauterine device [IUD] which are accepted treatments for low grade uterine malignancies to control their disease while the intervention is ongoing)"
2775,NCT03042689,1:47:chronic_disease,"Thrombotic, embolic, venous or arterial events"
2776,NCT03042689,1:26:cancer,superficial bladder tumor
2777,NCT03041844,"8:30:chronic_disease,,,,",Severe vascular insufficiency (ankle-brachial index lower than 0.75 or toe-brachial index below 0.5)
2778,NCT03040778,12:28:cancer,Absence of tumor in the jaw at the time of recruitment
2779,NCT03040778,21:57:chronic_disease,Patients with known hemorrhagic and coagulation disorder
2780,NCT03040778,1:29:chronic_disease,extensive retinal hemorrhage
2781,NCT03038867,"12:32:treatment,",use of any hormonal medications on a daily or intermittent basis during the preceding 3 months
2782,NCT03038620,40:78:allergy_name,Known or suspected hypersensitivity to trial product(s) or related product(s)
2783,NCT03038269,"1:24:treatment,","Botulinum toxin therapy in either upper extremity during last 2 months, or planned during study period"
2784,NCT03038269,"1:19:treatment,",Orthopedic surgery in affected arm within 2 years
2785,NCT03037983,33:37:treatment,Patients with prior exposure to rTMS
2786,NCT03037879,10:28:chronic_disease,Level of Spinal Cord Injury between C1 and T12
2787,NCT03037385,58:78:cancer,"have a pathologically documented, definitively diagnosed advanced solid tumor with an oncogenic RET mutation previously treated with SOC appropriate for the tumor type and not eligible for any of the other groups"
2788,NCT03036280,"38:55:chronic_disease,",has been hospitalized or treated for suicidal behavior in the past 5 years
2789,NCT03036098,44:57:treatment,Patients with disease that is suitable for local therapy administered
2790,NCT03035773,16:69:cancer,"Diagnosed with breast, colorectal, or prostate cancer (stages I-III)"
2791,NCT03034811,1:18:chronic_disease,Charcot's disease
2792,NCT03034564,4:23:chronic_disease,No supine hypertension (high blood pressure while laying down) judged to be of clinical significance by the investigator
2793,NCT03034564,1:17:chronic_disease,light headedness
2794,NCT03033498,",,60:74:treatment,",Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to initial study drug administration
2795,NCT03033212,1:22:chronic_disease,degenerative kyphosis
2796,NCT03033212,1:28:chronic_disease,intervertebral disc disease
2797,NCT03032432,13:52:chronic_disease,Evidence of symptomatic glenohumeral osteoarthritis
2798,NCT03030859,1:27:chronic_disease,cardiac or pulmonary edema
2799,NCT03029884,179:182:treatment,"Patients may be excluded from enrollment due to a condition that, in the judgment of the PI, significantly increases risk or reduces significantly the likelihood of benefit from DBS"
2800,NCT03029806,"1:13:treatment,",Decongestant use in the past 2 weeks
2801,NCT03028831,1:20:treatment,previous GI surgery resulting in disturbed gut function due to of loss of bowel or altered anatomy
2802,NCT03028012,1:28:chronic_disease,Gastrointestinal ulceration
2803,NCT03027388,"16:21:treatment,,,,,,,,,","The effects of LB100 on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately"
2804,NCT03023930,18:21:chronic_disease,ED patients with OUD
2805,NCT03023059,7:25:chronic_disease,Known retinal hemorrhage
2806,NCT03022292,1:39:chronic_disease,Prior retinal pigment epithelial (RPE) tear in study eye
2807,NCT03021538,37:41:treatment,Patients bridged to transplant with ECMO
2808,NCT03019367,1:17:chronic_disease,Bleeding Accreta
2809,NCT03018704,35:51:chronic_disease,"a current, clinically significant physical disease or abnormality"
2810,NCT03018704,1:34:chronic_disease,imminent suicide or violence risk
2811,NCT03017937,"8:32:chronic_disease,",Recent penetrating brain trauma (within 6 months)
2812,NCT03017118,1:45:treatment,Radiographic evidence of Eaton stage 1 and 2 only
2813,NCT03016130,1:30:treatment,Allogeneic or autologous HSCT for any indication
2814,NCT03015805,1:26:chronic_disease,Active psychotic disorder
2815,NCT03014687,1:17:chronic_disease,Active sinusitis
2816,NCT03013543,1:17:chronic_disease,Alström Syndrome
2817,NCT03013543,26:46:treatment,Inability to comply with QD injection regimen
2818,NCT03013543,1:29:chronic_disease,Smith-Magenis Syndrome (SMS)
2819,NCT03011801,"1:26:treatment,",Corticosteroid medication use during this pregnancy
2820,NCT03011567,",,57:75:treatment","Low platelet count (recorded measurement <50,000 during hospital admission)"
2821,NCT03010852,"1:15:treatment,",Oxygen therapy within the previous 30 days
2822,NCT03008616,1:23:chronic_disease,Active hepatic disease
2823,NCT03008616,1:35:chronic_disease,antiphospholipid antibody syndrome
2824,NCT03008070,78:117:allergy_name,Have a known hypersensitivity to any of the ingredients or excipients of the Investigational medicinal product (IMP)
2825,NCT03007745,1:24:chronic_disease,Cheyne-Stokes breathing
2826,NCT03007030,1:14:cancer,Positive CD30+ immunohistochemical expression
2827,NCT03006770,"1:20:treatment,",Concomitant therapy with a statin and an anti-platelet agent for at least 2 weeks prior to randomization
2828,NCT03006770,1:31:treatment,endovascular revascularization
2829,NCT03006302,12:29:chronic_disease,History of Seratonin Syndome
2830,NCT03005782,1:31:treatment,Prior treatment with any LAG-3 targeting biologic or small molecule
2831,NCT03004807,"14:35:chronic_disease,,",Uncontrolled stage II hypertension (blood pressure above 159/99 mm Hg)
2832,NCT03003780,19:50:chronic_disease,Clinical signs of unstable cardiovascular disease
2833,NCT03003689,1:33:chronic_disease,uncontrolled systemic conditions
2834,NCT03002389,1:27:chronic_disease,pulmonary vascular disease
2835,NCT03001830,8:26:chronic_disease,severe bleeding phenotype
2836,NCT03000439,19:81:treatment,Subjects who have previously failed treatment with more than two biologic DMARDs
2837,NCT02998021,1:16:chronic_disease,upper limb pain that interferes with the ability to propel or transfer
2838,NCT02995733,22:33:allergy_name,Known allergy to the ICS inhaler used in the study
2839,NCT02993900,1:36:cancer,Carcinoma of the vulva: Stage I-IVA or recurrence
2840,NCT02992275,",,66:84:chronic_disease,","Poorly controlled hypertension (>160/100); or patient report of: symptomatic angina at rest or during exercise, syncope without known resolution of cause, or a significant coronary event (such as a MI) in the past six months"
2841,NCT02991677,1:27:chronic_disease,Musculoskeletal conditions which preclude participation in an exercise training program
2842,NCT02991651,1:34:cancer,non-melanoma cutaneous malignancy
2843,NCT02991144,"18:96:treatment,",Participation in another investigational medicine study (including another gene transfer trial) within 3 months of Screening
2844,NCT02990481,1:29:cancer,Symptomatic brain metastases
2845,NCT02990377,32:52:treatment,Presenting for pain related to acute cancer therapy
2846,NCT02989597,1:21:chronic_disease,Severe heart disease
2847,NCT02988895,14:24:chronic_disease,Diagnosis of active CNV
2848,NCT02987491,"1:21:chronic_disease,,",Hypercholesterolemia (fasting LDL>140mg/dl)
2849,NCT02986087,1:24:chronic_disease,Placental abnormalities known at time of enrollment
2850,NCT02983903,1:20:treatment,Supplemental oxygen utilization at baseline
2851,NCT02983240,1:20:chronic_disease,Severe preeclampsia
2852,NCT02982564,"16:41:treatment,,",Have completed adjuvant curative therapy at least two months to 5 years prior to recruitment
2853,NCT02982226,1:16:chronic_disease,Fat Pad Atrophy
2854,NCT02981173,1:33:treatment,"lysergic acid diethylamide (LSD), or related compounds"
2855,NCT02981082,1:30:chronic_disease,Pulmonary venous hypertension
2856,NCT02979366,",61:76:treatment",already enrolled in the study who has received at least one S64315 infusion
2857,NCT02978443,38:88:treatment,Patients must be eligible to receive nivolumab in combination with ipilimumab treatment per institutional guidelines
2858,NCT02975869,16:51:cancer,A diagnosis of acute promyelocytic leukemia (APML)
2859,NCT02974686,4:61:treatment,On standard immunosuppression with tacrolimus and prednisone
2860,NCT02973425,"60:76:treatment,,",The Food and Drug Administration (FDA) advises caution for nicotine lozenge use among women who are pregnant
2861,NCT02971137,1:17:chronic_disease,Terminal Illness
2862,NCT02969187,10:33:treatment,Previous major abdominal surgery (possible adhesions and longer operation)
2863,NCT02969187,1:29:treatment,laparoscopic cholecystectomy
2864,NCT02968602,"1:25:chronic_disease,",Severe liver dysfunction (LFT 3X upper limit of normal)
2865,NCT02966665,12:51:treatment,History of percutaneous coronary revascularization
2866,NCT02965638,12:28:chronic_disease,Persistent fetal arrhythmia
2867,NCT02964741,35:56:chronic_disease,Presence of any other systemic or chronic pain disorder
2868,NCT02964182,1:8:treatment,Chantix
2869,NCT02962895,1:29:chronic_disease,Secondary Sjogren's syndrome
2870,NCT02960763,9:40:chronic_disease,Current Major Depressive Disorder (MDD)
2871,NCT02960113,22:55:treatment,Subjects who receive spinal and/or epidural anesthesia
2872,NCT02959671,1:42:chronic_disease,Mental/emotional/developmental disability
2873,NCT02956486,"12:48:chronic_disease,",History of transient ischemic attacks or stroke within 12 months of Screening
2874,NCT02955537,1:37:chronic_disease,Stage IV or V chronic kidney disease
2875,NCT02954185,1:24:chronic_disease,Neurological conditions
2876,NCT02953860,1:18:treatment,Vaginal estrogens are allowed if necessary for patient comfort
2877,NCT02953509,"1:18:cancer,",Second malignancy within the last 3 years
2878,NCT02953392,26:51:chronic_disease,Subjects presenting with maxillary sinus pathology
2879,NCT02952365,40:53:treatment,Subjects who have previously undergone LASIK surgery
2880,NCT02950337,1:22:chronic_disease,Chronic heart disease
2881,NCT02950337,1:46:chronic_disease,severely symptomatic congestive heart failure
2882,NCT02947945,1:17:chronic_disease,Palpable purpura
2883,NCT02947373,20:34:treatment,Patients receiving active therapy on an investigational trial at the time of enrollment should consult with the study chair regarding potential interactions with other study agents
2884,NCT02946892,"12:25:treatment,",The use of beta blockers within 2 months of randomization
2885,NCT02946892,1:22:chronic_disease,primary aldosteronism
2886,NCT02946658,20:43:chronic_disease,Prior Diagnosis of moderate to severe COPD
2887,NCT02945800,1:21:treatment,Stem Cell Transplant or Rescue: No evidence of active graft vs. host disease and 2 months must have elapsed from the start of protocol therapy since transplant
2888,NCT02944825,22:56:treatment,Patients who perform clean intermittent catheterization
2889,NCT02944825,1:19:treatment,ureteroscopy [URS]
2890,NCT02943915,"1:11:chronic_disease,,","Spasticity that prevents joint motion (severe stiffness or rigidity,) where both legs have a Modified Ashworth Score (MAS) score of 3 or higher for half or more of their proximal lower extremity muscles; proximal muscles include hip flexors/extensors/adductors and knee flexors/extensors"
2891,NCT02943590,35:38:cancer,All patients with newly diagnosed NHL
2892,NCT02943408,7:57:chronic_disease,other specified or unspecified depressive disorder (311)
2893,NCT02942095,1:33:cancer,Pancreatic ductal adenocarcinoma patient with KRAS point mutation at codon G12 or G13
2894,NCT02940288,1:26:treatment,Prosthetic cardiac valves
2895,NCT02939183,34:78:treatment,Currently receiving treatment in another investigational device or drug study
2896,NCT02937350,1:15:treatment,Gastric bypass
2897,NCT02933034,"19:27:chronic_disease,",have a history of torsades or prolonged QT/QTc interval
2898,NCT02932410,"16:40:treatment,","Treatment with i.v. or s.c. prostanoids within 4 weeks before randomization, unless given for vasoreactivity testing"
2899,NCT02932410,1:16:chronic_disease,schistosomiasis
2900,NCT02932280,1:13:cancer,Solid tumors must have a lesion evaluable by RECIST criteria version 1.1
2901,NCT02931110,1:29:chronic_disease,extranodal organ involvement
2902,NCT02931110,1:13:chronic_disease,organomegaly
2903,NCT02930018,139:151:treatment,Intent to use any endovascular device other than a stent retriever or clot aspiration device or intra-arterial medications as the initial thrombectomy approach
2904,NCT02929069,9:39:chronic_disease,Current suicidal or homicidal ideation
2905,NCT02928991,1:24:chronic_disease,Diamond-Blackfan Anemia
2906,NCT02928991,1:30:chronic_disease,Severe Congenital Neutropenia
2907,NCT02928991,25:34:chronic_disease,negative evaluation for dysplasia
2908,NCT02927301,"5:34:treatment,",Any prior therapy for lung cancer within 3 years
2909,NCT02926729,20:32:cancer,Patients that have complex DCIS
2910,NCT02926378,1:25:treatment,Magnetic dental implants - loss of magnetic hold to keep the implant in place
2911,NCT02926248,",41:60:treatment",Patients with less than 10 degrees of a flexion contracture
2912,NCT02925923,1:9:treatment,Edoxaban
2913,NCT02925923,"1:7:chronic_disease,,",NSTEMI as evidenced by elevation of troponin levels (Troponin > 0.034 ng/ml)
2914,NCT02925923,1:14:treatment,Telithormycin
2915,NCT02924402,22:54:allergy_name,Known intolerance to CD20 monoclonal antibody therapy
2916,NCT02924363,1:28:treatment,Ferromagnetic aneurysm clip
2917,NCT02924194,24:45:chronic_disease,currently uncontrolled visual hallucinations
2918,NCT02923011,33:72:allergy_name,Known intolerance or allergy to MR contrast agent (gadolinium chelates)
2919,NCT02922881,8:17:treatment,Use of biologics in present or in the past
2920,NCT02921022,"30:47:treatment,,",Patients with current use of megestrol acetate (use with 10 days of Day 1)
2921,NCT02920710,18:48:chronic_disease,Diagnosis of any underlying neurologic disorder that would potentially confound interpretation of the study results
2922,NCT02919436,12:19:allergy_name,Allergy to lactose
2923,NCT02918981,1:34:treatment,non-steroidal anti-inflammatories
2924,NCT02916472,11:28:treatment,completed primary treatment
2925,NCT02914834,1:29:treatment,concomitant physical therapy
2926,NCT02914483,1:19:chronic_disease,anginal equivalent symptoms at rest
2927,NCT02914171,26:37:treatment,Individuals with current IV inotrope requirements
2928,NCT02914171,11:34:chronic_disease,extensive extra-cardiac syndromes
2929,NCT02913430,"1:17:cancer,","Brain metastasis is allowed if previously treated, stable and off steroids for a minimum of 56 days"
2930,NCT02913430,33:84:treatment,There is no minimum duration of AI in the metastatic setting or neoadjuvant setting
2931,NCT02913404,76:102:treatment,Subjects will be of generally good health and will have decided to undergo ACL reconstruction surgery and agreed to participate in the study (following informed consent procedures)
2932,NCT02912572,1:27:chronic_disease,Grade 2 sensory neuropathy
2933,NCT02911792,1:124:treatment,"Ingestion of medications known to interfere with the renin-angiotensin system or renal function, including diuretic therapy"
2934,NCT02911467,37:54:chronic_disease,A history of clinically significant EKG abnormalities
2935,NCT02911467,31:58:chronic_disease,Patients with rate-controlled atrial fibrillation/flutter
2936,NCT02911467,",,70:90:treatment",willing to use adequate contraception for one month after undergoing HP pyruvate infusion
2937,NCT02910700,15:40:cancer,Patients with melanoma brain metastases are allowed
2938,NCT02910648,31:52:chronic_disease,Below the clinical cutoff for Restless Leg Syndrome
2939,NCT02908906,29:61:treatment,Treatment with any local or systemic anti-neoplastic therapy
2940,NCT02908841,1:34:treatment,Preoperative prophylactic heparin is not an exclusion criterion
2941,NCT02908841,1:43:treatment,robotic assisted laparoscopic hysterectomy
2942,NCT02907983,12:22:chronic_disease,history of neurologic deficit to the brachial plexus
2943,NCT02907983,1:47:treatment,serotonin selective reuptake inhibitors (SSRI) (2 weeks)
2944,NCT02905929,8:27:treatment,Use of insulin medications
2945,NCT02905591,1:13:treatment,amphetamines
2946,NCT02905578,1:36:chronic_disease,Metastatic or node positive disease
2947,NCT02905370,1:48:chronic_disease,Deep vein thrombosis/pulmonary embolus (DVT/PE)
2948,NCT02905370,1:14:chronic_disease,Heart Disease
2949,NCT02905370,1:22:treatment,Post-op bowel surgery
2950,NCT02903446,12:27:chronic_disease,History of Addison disease
2951,NCT02903446,7:20:chronic_disease,Other bone diseases which affect bone metabolism
2952,NCT02902952,"1:31:chronic_disease,,",Autism Spectrum Disorder (ASD) Diagnosis 6-12 years old
2953,NCT02901314,1:21:chronic_disease,cognitive conditions that limit ability to understand
2954,NCT02901067,"1:11:chronic_disease,,",Severe TBI; defined as AIS Head >3
2955,NCT02901041,1:12:treatment,anxiolytics
2956,NCT02900794,",,22:44:chronic_disease",age 18 or older with chronic rhinosinusitis as described by the guidelines published in the 2015 Clinical practice guideline (update)
2957,NCT02896751,"11:23:treatment,",On stable NIV settings for a minimum of 2 months
2958,NCT02895945,25:52:chronic_disease,Participant has another active coagulation disorder
2959,NCT02895945,1:13:chronic_disease,hemophilia A
2960,NCT02891850,10:60:chronic_disease,Relevant obstructive and restrictive or other lung diseases
2961,NCT02891447,43:73:allergy_name,"Subjects with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity"
2962,NCT02886572,"3:29:treatment,,",A contrast-enhanced MRI scan showing = or > 4 brain metastases
2963,NCT02885649,1:33:chronic_disease,Retroperitoneal/hilar adenopathy concerning for locally advanced disease
2964,NCT02881320,"1:121:treatment,",Stable antiretroviral regimen of 2 nucleoside reverse transcriptase inhibitors (NRTIs) in combination with a third agent for a minimum of 6 months prior to the screening visit
2965,NCT02879136,46:67:chronic_disease,Presence of signs and symptoms suggestive of atypical parkinsonism
2966,NCT02877134,1:35:treatment,Oral 5-aminosalicylic acid (5-ASA) compounds
2967,NCT02876302,1:26:treatment,Enlargement of the breast
2968,NCT02875405,1:34:chronic_disease,mitral or tricuspid valve disease
2969,NCT02875301,1:16:chronic_disease,Type I Diabetes
2970,NCT02875301,7:27:chronic_disease,other cardiovascular event
2971,NCT02872935,"1:11:treatment,",Antiemetic drug use in the 24 hours prior to cesarean delivery
2972,NCT02871349,1:17:chronic_disease,Bradyarrhythmias
2973,NCT02867124,33:39:allergy_name,History of allergic reaction to XR-NTX
2974,NCT02865135,1:38:chronic_disease,Active uncontrolled serious infection
2975,NCT02864147,27:70:treatment,Known hypersensitivity or prior intravaginal treatment with Imiquimod
2976,NCT02864147,1:31:chronic_disease,renal or hepatic insufficiency
2977,NCT02863809,1:18:treatment,Cornea transplant
2978,NCT02863809,48:62:treatment,No or minimal tear production with evidence of keratinization of the bulbar conjunctiva
2979,NCT02862938,"5:24:treatment,",Any intraocular surgery of the study eye within 12 weeks prior to the screening visit
2980,NCT02862938,"37:53:treatment,",Participant is likely to be offered glaucoma surgery within 6 months of screening
2981,NCT02861950,28:45:chronic_disease,abnormal caudal anatomy or spinal dysraphism
2982,NCT02860702,19:49:treatment,Infants requiring cardio-pulmonary resuscitation prior to surgical repair
2983,NCT02859142,8:28:chronic_disease,recent major cardiovascular event
2984,NCT02857218,45:72:cancer,"Pathologically confirmed, locally advanced, malignancy of the esophagus"
2985,NCT02857218,1:18:chronic_disease,severely agitated
2986,NCT02855554,1:38:chronic_disease,Hypertrophic cardiomyopathy (group 2)
2987,NCT02852538,1:22:chronic_disease,intellectual disorder
2988,NCT02851758,7:29:chronic_disease,Known mitochondria disorders
2989,NCT02851290,1:18:chronic_disease,Genetic syndromes
2990,NCT02849639,1:30:chronic_disease,Blockage of the urinary tract
2991,NCT02848417,1:19:treatment,Immunosuppressives
2992,NCT02848417,15:31:chronic_disease,Veterans with Gulf War Illness
2993,NCT02847689,1:42:chronic_disease,Cystic periventricular leukomalacia (PVL)
2994,NCT02847689,1:34:chronic_disease,Major sensori-neural hearing loss
2995,NCT02846532,34:65:treatment,Satisfactory initial post-Fontan transthoracic echocardiographic Screening
2996,NCT02845596,1:48:chronic_disease,Inherited bone marrow failure syndromes (IBMFS)
2997,NCT02844751,"1:18:cancer,",Neoplastic cancer within 5 years prior to screening
2998,NCT02843945,"1:6:treatment,",3DCRT (up to 56 Gy)
2999,NCT02843568,1:28:treatment,Prior thoracic radiotherapy
3000,NCT02842658,1:28:chronic_disease,Uncompensated heart failure
3001,NCT02841540,30:65:treatment,Participant is candidate for hematopoietic stem cell transplants at the time of enrollment
3002,NCT02839759,"14:35:treatment,",Prior use of hearing amplification within the past 10 years
3003,NCT02838797,2:30:chronic_disease,gastroesophageal reflux disease
3004,NCT02837510,1:27:treatment,Anti-psychotic medications
3005,NCT02837497,14:36:treatment,AND Received CPR in the ICU setting
3006,NCT02836899,1:25:treatment,Emergent cardiac surgery
3007,NCT02836574,19:39:chronic_disease,history of severe systemic reaction(s)
3008,NCT02834403,19:41:treatment,Concurrent use of potent CYP3A4 inducers
3009,NCT02834403,1:27:chronic_disease,Severe renal insufficiency
3010,NCT02833792,1:32:treatment,Prior treatment with stem cells
3011,NCT02832115,24:38:treatment,Likely need for use of nitroglycerine for non-study indication
3012,NCT02832115,7:17:treatment,known LIMA graft
3013,NCT02830074,"6:19:chronic_disease,",with chronic SCI/D (>3 months post injury)
3014,NCT02829268,"10:36:treatment,",received blood product transfusions within 90 days prior to screening
3015,NCT02828592,10:22:chronic_disease,markedly hypocellular
3016,NCT02826681,"13:29:treatment,",Subjects on sleep medication must be on a stable dose for at least 6 months prior screening
3017,NCT02826577,12:32:chronic_disease,History of heart irregularities
3018,NCT02824276,15:34:treatment,candidate for oral opioid therapy as assessed at the BWH Pain Management Center
3019,NCT02823665,1:25:chronic_disease,type 2 diabetes mellitis
3020,NCT02822378,1:10:treatment,denosumab at any time
3021,NCT02822378,"1:9:treatment,",tibolone within the past 3 months
3022,NCT02819843,67:83:chronic_disease,"Previously infected, with evidence of immunity and no evidence of active hepatitis"
3023,NCT02819635,1:19:treatment,biologic therapies in the opinion of the investigator
3024,NCT02819141,34:89:treatment,currently receiving a continuous intravenous infusion of a sedative/opioid medication(s)
3025,NCT02816736,22:47:treatment,patients who require chronic inotropic therapy
3026,NCT02815917,"8:35:treatment,","Use of dopaminergic CNS stimulants (prescription, over-the counter or recreational drugs) within 30 days of screening intake visit, as assessed by review of health history form and concomitant medication review at screening intake visit (from medical record and/or self-reported) that are deemed by a physician investigator to have a potential influence on the binding of [18F]FTP"
3027,NCT02811263,"11:59:chronic_disease,,",Receiving active or passive whole body cooling/hypothermia since < 6 hours of age
3028,NCT02808442,1:17:cancer,Burkitt leukemia
3029,NCT02807883,15:24:cancer,Patients with B-lineage
3030,NCT02807272,25:38:chronic_disease,Modification of Diet in Renal Disease formulas
3031,NCT02805504,21:37:treatment,Patients undergoing urologic surgery
3032,NCT02804230,"34:59:chronic_disease,",Patients with a known history of psychogenic non-epileptic spells in the last three years
3033,NCT02803359,29:65:treatment,Healthy Subjects undergoing thyroid or other open neck surgeries
3034,NCT02803359,1:33:chronic_disease,Laryngopharyngeal Reflux Disease
3035,NCT02803164,105:129:chronic_disease,Subject is scheduled to undergo surgical intervention(s) as part of the standard care for management of intra-thoracic infection
3036,NCT02801539,31:42:treatment,Able to complete a home-based RMT regimen
3037,NCT02801136,7:28:chronic_disease,Other serious mental health diagnoses
3038,NCT02798458,14:40:allergy_name,Allergies to components of the SmartBar
3039,NCT02798458,21:28:chronic_disease,Previous history of bezoars
3040,NCT02796391,1:30:treatment,"Clozapine (Clozaril, FazaClo)"
3041,NCT02796391,1:23:treatment,Irinotecan (Camptosar)
3042,NCT02796391,22:41:chronic_disease,significant unstable medical/psychiatric or substance use disorders
3043,NCT02796209,1:35:chronic_disease,Neurogenic Orthostatic Hypotension
3044,NCT02796209,1:12:treatment,delavirdine
3045,NCT02793921,36:49:cancer,"Diagnosed with Stage 0, 1, 2 or 3a Breast Cancer"
3046,NCT02793921,1:17:treatment,wound dehiscence
3047,NCT02792257,13:20:chronic_disease,Presence of Agit-AD as defined by the provisional criteria from the International Psychogeriatric Association (IPA)
3048,NCT02789111,1:31:chronic_disease,Chronic kidney disease stage 5
3049,NCT02783716,",84:103:treatment",Patients who are unwilling or unable to return for follow up visits 3 months after device implantation
3050,NCT02780401,1:23:chronic_disease,Dilated cardiomyopathy
3051,NCT02779556,1:22:chronic_disease,cognitive impairments
3052,NCT02778867,28:53:chronic_disease,Have been diagnosed with a GI malabsorption disorder
3053,NCT02778867,1:18:allergy_name,IgE-mediated food allergy
3054,NCT02778529,1:26:chronic_disease,Cervical SCI (C-5 to C-7)
3055,NCT02778282,1:33:chronic_disease,Substantial cognitive impairment
3056,NCT02776761,8:23:chronic_disease,single febrile seizure as a child
3057,NCT02775162,12:40:treatment,undergoing simultaneous transplantation of more than one organ
3058,NCT02774421,1:14:cancer,subependymoma
3059,NCT02772562,1:23:cancer,pN1 lymph node disease
3060,NCT02772302,1:26:chronic_disease,Minimally conscious state
3061,NCT02771626,16:45:treatment,Intolerance to prior anti-PD-1/PD-L1 therapy
3062,NCT02770547,1:32:treatment,Implanted cardiac defibrillator
3063,NCT02770326,1:22:chronic_disease,Gastrointestinal (GI) contraindications
3064,NCT02770326,1:24:chronic_disease,Small bowel obstruction
3065,NCT02769611,"1:26:treatment,",Resynchronization therapy initiated less than 90 days prior to enrollment
3066,NCT02768727,23:49:chronic_disease,Current or history of neuropsychiatric disorders
3067,NCT02766998,32:77:chronic_disease,all pre-natal diagnoses of any single ventricle circulation physiology (SVP)
3068,NCT02765633,"26:58:treatment,,",Participation in another investigational therapeutic drug or investigational therapeutic device trial within 30 days of starting study
3069,NCT02765282,34:58:chronic_disease,Clinical diagnosis of idiopathic Parkinson's disease (PD)
3070,NCT02764801,25:48:treatment,who have received prior radioembolization (Y90) of the lesion of interest
3071,NCT02763917,13:41:chronic_disease,Significant pulmonary or cardiac disease
3072,NCT02762825,"34:51:treatment,,",Referred by physician to CR with echocardiographic evidence of HFpEF defined as an ejection fraction ? 50 %
3073,NCT02762773,15:63:chronic_disease,Patients with pre-gestational or gestational diabetes mellitus
3074,NCT02762266,1:24:cancer,Extrahepatic metastases
3075,NCT02762266,"1:22:cancer,",Unifocal liver tumors not to exceed 7.5 cm in greatest axial dimension
3076,NCT02762032,1:20:treatment,Immunosuppressant's
3077,NCT02760498,69:88:allergy_name,Allergic reactions or acute hypersensitivity reaction attributed to antibody treatments
3078,NCT02759575,1:60:treatment,Prior radiation therapy to the larynx area or involved neck
3079,NCT02758847,1:15:chronic_disease,Acute thrombus in the target limb
3080,NCT02755896,1:28:cancer,"Stage 1 (pT1) breast cancer, excised with negative margins"
3081,NCT02755116,30:48:treatment,Patient scheduled to undergo ambulatory surgery under general anesthesia
3082,NCT02752191,25:28:chronic_disease,with known or suspected CHD with inconclusive echocardiographic exams
3083,NCT02750319,8:25:chronic_disease,not in cardiogenic shock
3084,NCT02748616,",,41:61:chronic_disease",Male and female patients with recurrent C. difficile colitis
3085,NCT02748070,22:46:treatment,scheduled to undergo endoscopic sinus surgery
3086,NCT02747238,10:26:treatment,Previous spinal surgeries
3087,NCT02746458,12:24:cancer,History of lymphotomies
3088,NCT02746458,1:30:chronic_disease,severe traumatic brain injury
3089,NCT02744677,15:34:chronic_disease,History of or active endocarditis
3090,NCT02744430,27:61:treatment,Patients already taking a beta-adrenergic agonist medication
3091,NCT02744391,"55:75:chronic_disease,",Diagnosis of substance abuse or dependence (excluding Tobacco Use Disorder) within the past 12 months
3092,NCT02743728,1:20:chronic_disease,Metabolic Disorders
3093,NCT02743494,16:43:cancer,Diagnosed with Stage IV resectable disease
3094,NCT02741791,1:8:chronic_disease,Suicide risk
3095,NCT02740543,"1:23:treatment,",Inhaled corticosteroid use in previous 1 month or more will be allowed
3096,NCT02740361,52:56:treatment,willingness to engage in self-administration of an iCBT intervention for 3 months and complete follow-up
3097,NCT02737930,1:21:chronic_disease,Premorbid depression
3098,NCT02734771,1:19:cancer,Composite lymphoma containing both indolent and large cell features will be included
3099,NCT02734134,15:30:chronic_disease,Patients with systemic sepsis who require emergent surgery
3100,NCT02730481,"10:13:treatment,,","Received IPs within 14 days or 5 half-lives of the first study dosing day, whichever is longer"
3101,NCT02727062,1:17:cancer,Laryngeal cancer
3102,NCT02726347,21:46:treatment,subjects who are on immune suppressive agents
3103,NCT02725177,",28:75:treatment",Recent (less than 4 weeks) intra-ocular or intra-orbital steroid injection
3104,NCT02724540,"12:31:cancer,,",Measurable metastasis to liver with at least one dimension ? 1.0 cm
3105,NCT02724540,1:10:treatment,sedatives
3106,NCT02723994,1:54:treatment,CRLF2 rearrangement with JAK1 or JAK2 mutation (JAK+)
3107,NCT02723994,1:27:chronic_disease,Trisomy 21 (Down syndrome)
3108,NCT02721303,12:29:treatment,Use of any weight loss drugs
3109,NCT02718001,25:57:chronic_disease,"Clinically significant, symptomatic mitral regurgitation"
3110,NCT02712736,22:54:chronic_disease,Patients with active inflammatory bowel disease (IBD) flares
3111,NCT02710396,24:57:chronic_disease,Has a known history of active TB (Bacillus Tuberculosis)
3112,NCT02709655,17:48:chronic_disease,"The patient has Major depressive disorder (MDD), diagnosed according to DSM-5"
3113,NCT02707471,",31:34:chronic_disease",within 12 months of beginning AET
3114,NCT02703272,16:66:chronic_disease,A diagnosis of post-transplant lymphoproliferative disease (PTLD)
3115,NCT02703220,7:56:treatment,other central nervous system (CNS) altering medications
3116,NCT02700451,",,22:42:treatment",Require 1 or 2 level lumbar spinal fusion through posterior or lateral approach
3117,NCT02698722,1:17:chronic_disease,Stage 4 or 5 CKD
3118,NCT02695043,29:55:chronic_disease,Trauma related intracranial neuroimaging abnormalities
3119,NCT02693990,16:40:treatment,The effects of proton radiation therapy on the developing human fetus are known to be teratogenic
3120,NCT02690116,1:15:chronic_disease,Hypothyroidism (fatigue-related factor)
3121,NCT02688647,"16:47:treatment,",Treatment with endothelin receptor antagonists within 4 weeks before study entry
3122,NCT02688309,"20:66:treatment,",Previous use of an anti-Vascular Endothelial Growth Factor (VEGF) drug within 1 month of study entry
3123,NCT02687906,10:23:chronic_disease,Signs of severe sepsis
3124,NCT02686528,20:45:chronic_disease,Index diagnosis of noninflammatory arthritis
3125,NCT02685605,1:21:chronic_disease,Supratentorial T1-Gd enhancing lesion(s) amenable to total resection
3126,NCT02682147,38:48:allergy_name,Prior history of hypersensitivity to Sildenafil
3127,NCT02680574,1:51:treatment,surgical or percutaneous intervention for coronary
3128,NCT02680535,"1:37:chronic_disease,,,,,,,,,","acute or chronic hepatic dysfunction as evidenced by clinically significant abnormalities in albumin, total protein, or prothrombin time, or evidence of hepatic injury with clinically important (> grade 1) changes in AST, ALT, ALP, bilirubin, or GGT values"
3129,NCT02680145,9:27:chronic_disease,Have an isolated rectocele
3130,NCT02678351,9:49:treatment,Planned prostatectomy with lymph node dissection
3131,NCT02674529,43:70:treatment,Have a medical condition that contradicts treatment with escitalopram
3132,NCT02672098,21:36:chronic_disease,Patients with known acute hepatitis
3133,NCT02670837,14:52:chronic_disease,Diagnosis of Dystrophic Epidermolysis Bullosa (DEB)
3134,NCT02670837,26:60:treatment,Skin Graft Donor (either hematopoietic cell transplantation donor for the EB patient [Arm A] or EB patient herself/himself [Arm B])
3135,NCT02669173,"39:61:chronic_disease,",Electrocardiogram without evidence of acute cardiac ischemia within 14 days prior study registration
3136,NCT02667418,",86:97:chronic_disease,",Current episode represents the first recurrent episode of CDI within 3 months of the primary CDI episode in a patient who has not had CDI in the 3 months prior to the primary episode
3137,NCT02667418,1:11:treatment,vancomycin
3138,NCT02665962,22:40:cancer,Newly diagnosed with Endometrial Cancer
3139,NCT02665338,1:17:chronic_disease,Major Depression
3140,NCT02664909,21:49:treatment,Patients undergoing hip hemiarthroplasty surgery for a displaced femoral neck fracture
3141,NCT02664168,48:86:treatment,Skin integrity issues that preclude the use of Negative Pressure Wound Therapy (NPWT)
3142,NCT02663908,"1:29:chronic_disease,",Acute cardiovascular disease in the previous 30 days
3143,NCT02663596,76:86:allergy_name,History of any moderate or severe hypersensitivity or allergic reaction to vancomcyin (a history of mild rash followed by uneventful re-exposure and/or red man syndrome is not a contraindication)
3144,NCT02660528,"1:32:chronic_disease,",Active drug or alcohol disorder in the last three months
3145,NCT02660528,1:10:chronic_disease,hypomania
3146,NCT02657993,"1:22:treatment,",Bone fracture/surgery of an extremity during the preceding 6 months
3147,NCT02656550,14:45:chronic_disease,Subject with Diabetes Mellitus Type I and II by medical history
3148,NCT02655614,"18:27:treatment,,,","Currently taking edaravone unless after completion of at least the second 14-day drug-treatment period, as long as Day 1 occurs during a drug-free period at least 24 hours after the last edaravone dose and at least 5 days prior to the first dose of the next cycle"
3149,NCT02650206,1:11:chronic_disease,Gallstones
3150,NCT02650206,31:55:cancer,Personal or family history of medullary thyroid cancer
3151,NCT02646930,13:62:treatment,Patients on monoclonal antibody preparations directed to TNF?
3152,NCT02646787,60:85:treatment,Any face/head/neck injuries that interfere with the use of Virtual Reality equipment
3153,NCT02645539,1:29:chronic_disease,Severe end-organ dysfunction or failure
3154,NCT02641093,1:15:cancer,Nasopharyngeal
3155,NCT02640950,"17:34:chronic_disease,",The patient has attempted suicide within the past 12 months prior to Screening
3156,NCT02640638,1:24:chronic_disease,Pregestational diabetes
3157,NCT02639390,19:54:treatment,Receiving oral or injected antispasticity medications during study treatment
3158,NCT02639065,1:24:chronic_disease,Ventricular arrhythmias requiring medication(s)
3159,NCT02638454,",,,,,,158:176:chronic_disease,,","10 subjects with Normal Muscle Mass and 10 subjects with Low Muscle Mass as determined by DXA scan (70-85 years of age cohort) Low Muscle Mass is defined as Class I Sarcopenia, Skeletal Muscle Index within 1 to 2 standard deviations from the sex-specific mean of young adults"
3160,NCT02638454,13:28:chronic_disease,Significant immune disorder
3161,NCT02636530,"1:21:treatment,",anti-resorptive drug use in the last 2 years
3162,NCT02635919,21:42:treatment,Recently prescribed varenicline (Chantix) with the intention to quit smoking in the next 3 months
3163,NCT02634957,15:55:chronic_disease,Patients with benign mid membranous vocal fold lesions
3164,NCT02634957,1:28:chronic_disease,Sub-epithelial fibrous mass
3165,NCT02632721,1:34:cancer,"Acute promyelocytic leukemia (APL, French-American-British (FAB) subtype M3), according to WHO classification"
3166,NCT02632422,1:24:chronic_disease,pulmonary complications
3167,NCT02629731,14:30:chronic_disease,diagnosis of ankle OA or PTTD [non-control subjects only]
3168,NCT02628535,28:49:treatment,"Patients with prior immune checkpoint inhibitors must have related toxicities reduced to Grade 0, 1, or baseline"
3169,NCT02624765,5:30:chronic_disease,Any maternal-fetal conditions associated with high odds of premature delivery or death
3170,NCT02624765,1:4:chronic_disease,SVT with fetal hydrops (irrespective of duration)
3171,NCT02624765,1:20:chronic_disease,sick sinus syndrome
3172,NCT02624518,1:23:treatment,Post-radiation therapy
3173,NCT02624258,",29:41:treatment,,",Are more than 6 months from transplant 6) Karnofsky performance status ? 50 at screening
3174,NCT02624258,",,81:98:chronic_disease,",Must have a minimum level of pulmonary reserve defined as ? Grade 1 dyspnea and pulse oxygenation > 94% on room air
3175,NCT02622295,1:30:treatment,Anti-osteoporosis medications
3176,NCT02622295,1:16:chronic_disease,Pressure ulcers
3177,NCT02620761,25:37:treatment,No previous exposure to indomethacin
3178,NCT02620579,21:44:treatment,previous history of upper-extremity surgery
3179,NCT02615873,24:32:treatment,Has a good response to Levodopa in the opinion of the investigator
3180,NCT02615249,"1:58:treatment,",Treatment with ultraviolet (UV) light (including tanning) during the 3 weeks prior to inclusion in this study
3181,NCT02613936,",21:49:chronic_disease",less than 1 week of post-traumatic amnesia (PTA)
3182,NCT02611063,1:24:chronic_disease,Active hemolytic anemia
3183,NCT02608840,10:41:chronic_disease,unstable medical or psychiatric disorder
3184,NCT02607748,17:33:chronic_disease,Patients in the asymptomatic CAD group
3185,NCT02606396,20:43:chronic_disease,Prior diagnosis of oropharyngeal dysphagia
3186,NCT02606045,45:49:chronic_disease,Willingness to comply with randomization to rVWF or TA study arms
3187,NCT02603757,"27:52:treatment,","Patients taking high-dose Vitamin D supplementation (50,000 IU weekly) prior to enrollment"
3188,NCT02600273,"1:19:chronic_disease,,",Acute intoxication as measured by breath alcohol level (BAL) > 0
3189,NCT02599922,13:32:chronic_disease,Evidence of degenerative myopia regardless of the refractive error in the study eye
3190,NCT02597985,1:21:chronic_disease,Advanced Parkinson's
3191,NCT02595866,1:25:chronic_disease,Active tuberculosis (TB)
3192,NCT02595372,1:22:treatment,Esomeprazole (Nexium)
3193,NCT02595372,7:28:chronic_disease,Prior osteoporotic fracture
3194,NCT02594384,1:27:cancer,mantle cell lymphoma (MCL)
3195,NCT02594111,8:32:treatment,Use of anti-inflammatory agents
3196,NCT02594111,1:10:treatment,ritonavir
3197,NCT02593526,6:28:treatment,Post kidney transplantation
3198,NCT02593123,1:22:cancer,Multiple myeloma (MM)
3199,NCT02593123,1:59:treatment,Previous therapy with rabbit anti-thymocyte globulin (ATG)
3200,NCT02593123,9:44:treatment,revious myeloablative autologous transplant is permitted but not required
3201,NCT02593110,18:38:treatment,Currently taking aliskiren (Tekturna)
3202,NCT02593110,"1:19:treatment,",orthopedic surgery during the past 3 months
3203,NCT02592707,65:89:treatment,Documentation of progressive disease based on RECIST v1.1 under prior anti-tumor therapy within 6 months of entry in the study (although the progression might have occurred more than 6 months before study entry)
3204,NCT02592551,1:17:chronic_disease,N3 nodal disease
3205,NCT02592551,23:26:cancer,Surgically resectable MPM with no disease extension beyond the ipsilateral hemithorax
3206,NCT02591147,39:49:treatment,"The approximal lesion detected in the radiograph has advanced dentine lesion (RB4, RC5, or RC6)"
3207,NCT02589977,1:15:chronic_disease,symptomatic HF
3208,NCT02589938,21:36:cancer,have a diagnosis of head/neck cance
3209,NCT02589353,69:91:chronic_disease,"has a history of taste or smell loss or other oral disorders (e.g., burning mouth syndrome)"
3210,NCT02589340,16:26:chronic_disease,Mild to Severe dyskinesia
3211,NCT02588612,",,,,89:114:chronic_disease",Corrected QT interval (QTc) >450 milliseconds (msec) or QTc >480 msec for subjects with Bundle Branch Block (BBB)
3212,NCT02588326,"1:16:chronic_disease,",Acute sinusitis within the last six weeks prior to enrollment
3213,NCT02588326,1:15:chronic_disease,ear infections
3214,NCT02588027,47:58:treatment,Patients with rotator cuff tears that require open repair
3215,NCT02587403,1:24:chronic_disease,Enterocutaneous fistula
3216,NCT02585973,1:20:chronic_disease,HPV/p16 (+) disease
3217,NCT02585791,19:51:chronic_disease,Other concomitant inflammatory pulmonary disorders
3218,NCT02584933,",,,,,211:230:treatment","Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 3 months afer stopping ceritinib treatment"
3219,NCT02584647,77:103:treatment,these patients are at increased risk of lethal infections when treated with marrow suppressive therapy
3220,NCT02584309,1:13:cancer,Fibrosarcoma
3221,NCT02584309,1:40:cancer,Malignant peripheral nerve sheath tumor
3222,NCT02584309,"1:23:chronic_disease,,",Systolic heart failure defined as left ventricular ejection fraction ? 45%
3223,NCT02584270,36:55:cancer,Patients with a new diagnosis of a T1/T2 tongue cancer
3224,NCT02584244,",82:101:chronic_disease",total bilirubin within normal institutional limits (except in cases of malignant biliary obstruction)
3225,NCT02583893,1:28:treatment,"Telithromycin (e.g., Ketek)"
3226,NCT02582957,1:15:chronic_disease,Lung contusion
3227,NCT02582827,12:31:chronic_disease,History of vascular neuropathy
3228,NCT02582775,16:19:chronic_disease,beta 3 laminin JEB mutants
3229,NCT02581982,25:73:cancer,Patients diagnosed with platinum-refractory metastatic urothelial cancer that is measureable based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1
3230,NCT02581384,"1:7:cancer,",Lesion larger than 3 cm in diameter
3231,NCT02581215,20:42:chronic_disease,Acute or sub-acute intestinal obstruction
3232,NCT02580604,12:37:chronic_disease,History of type 1 or type 2 diabetes
3233,NCT02579967,19:41:chronic_disease,Infection with an opportunistic organism
3234,NCT02579265,1:33:chronic_disease,Cyanotic congenital heart defect
3235,NCT02579265,1:15:chronic_disease,Meconium ileus
3236,NCT02579265,1:35:chronic_disease,spontaneous intestinal perforation
3237,NCT02579174,37:52:treatment,"Medical contraindication to undergo preoperative CT, or inability to tolerate preoperative CT"
3238,NCT02579096,"70:94:treatment,",Previous history of failure to reach target uric acid levels despite therapy with allopurinol at dose > 300 mg/day
3239,NCT02579044,58:107:allergy_name,Subjects who have known or suspected hypersensitivity to any of the excipients included in the formulation should not be treated
3240,NCT02578901,15:18:chronic_disease,Patients with DIC according to the patient's physician
3241,NCT02578641,1:34:cancer,Central nervous system metastasis
3242,NCT02578641,1:31:chronic_disease,Severe intercurrent infections
3243,NCT02578641,1:44:cancer,"superficial bladder tumors [Ta, Tis and T1]"
3244,NCT02577731,32:53:chronic_disease,Patients with any pre-existing hematological disease
3245,NCT02577549,12:21:chronic_disease,Not having knee pain
3246,NCT02577406,71:100:allergy_name,Subject has known or suspected to have hypersensitivity to any of the components of study treatment
3247,NCT02577406,1:30:chronic_disease,acute coronary syndrome (ACS)
3248,NCT02576444,48:62:cancer,"Patients with known germline BRCA mutations in breast cancers will be excluded from the study, however testing is not required for inclusion in the study"
3249,NCT02576431,47:89:treatment,Prior progression while receiving approved or investigational tyrosine kinase inhibitors targeting TRK
3250,NCT02574910,54:73:allergy_name,"Known allergies, hypersensitivity, or intolerance to abiraterone acetate or its excipients (refer to United States Prescribing Information)"
3251,NCT02574728,19:32:cancer,participants with pineal tumors and elevations of serum or cerebrospinal fluid (CSF) alpha-fetoprotein (AFP) or beta-human chorionic gonadotropin (beta-HCG)
3252,NCT02574650,10:47:treatment,Previous tricuspid valve repair or replacement
3253,NCT02574455,"21:39:cancer,",patients with other prior malignancies must have had at least a 3-year disease-free interval
3254,NCT02573883,16:41:treatment,Treatment with systemic immunomodulators
3255,NCT02573597,",35:59:treatment",Narcotics within 3 hours prior to labor epidural placement
3256,NCT02573376,9:22:chronic_disease,Chronic HCV infection as documented by quantifiable HCV RNA
3257,NCT02572791,",80:110:chronic_disease","Confirmed (i.e., culture-positive) active or recent (within the past 2 months) S. aureus cutaneous infections"
3258,NCT02570984,12:28:chronic_disease,History of hypoxic seizures during a wheezing episode
3259,NCT02570984,1:27:chronic_disease,major congenital anomalies
3260,NCT02570854,15:38:chronic_disease,Patients with Hepatitis C Virus (HCV) infection may be included if all other liver function eligibility criteria are met
3261,NCT02570321,14:31:chronic_disease,Impending or frank perforation at recruitment
3262,NCT02570256,1:18:chronic_disease,bilateral paresis
3263,NCT02568267,",56:81:treatment",At least 4 weeks must have elapsed since completion of antibody-directed therapy
3264,NCT02568267,1:25:treatment,Prior anticancer therapy
3265,NCT02567448,"20:31:treatment,",detached retina or eye surgery in the past three months
3266,NCT02567422,",,136:147:treatment",Pregnant women are excluded from this study because M6620 (VX-970) as a DNA-damage response (DDR) inhibitor may have the potential for teratogenic or abortifacient effects
3267,NCT02567266,20:52:chronic_disease,Adolescents with a current substance abuse disorder as determined using the ADIS-5-C/P
3268,NCT02566395,1:26:cancer,Acue myelogenous leukemia
3269,NCT02565901,25:52:treatment,Agree to participate in biopsy of metastatic lesion during the study at day 21
3270,NCT02565901,7:35:cancer,Known parenchymal brain metastasis
3271,NCT02565901,1:14:cancer,squamous cell histology
3272,NCT02565498,13:35:chronic_disease,Presence of regional nodal disease or unequivocal distant metastases
3273,NCT02565407,19:34:treatment,Regular intake of benzodiazepines
3274,NCT02564978,12:33:treatment,History of vitreoretinal surgery
3275,NCT02564978,1:18:chronic_disease,Pathologic myopia
3276,NCT02564978,",,111:122:treatment",The total area of GA lesions combined should be less than 7.0 MPS disc areas (DA) (17.78 mm(2)) as evident on FAF imaging
3277,NCT02564796,15:38:chronic_disease,Newborns with acyanotic heart disease
3278,NCT02564744,"51:75:chronic_disease,","For Part 2 and Part 3 of the study, patients with primary refractory DLBCL (defined as progression of disease within 24 weeks after first line of treatment)"
3279,NCT02564198,8:25:chronic_disease,Active non-healing wound or bone fracture
3280,NCT02563678,23:49:treatment,Medical clearance for hyperbaric oxygen exposure
3281,NCT02563574,9:38:chronic_disease,Current major psychiatric disturbance
3282,NCT02562755,12:25:chronic_disease,History of severe eczema (as determined by the Investigator) requiring medical treatment
3283,NCT02562430,5:38:treatment,Any investigational psychotropic drug within the last year
3284,NCT02562430,1:29:treatment,Monoamine oxidase inhibitors
3285,NCT02562235,1:19:chronic_disease,Hereditable (HPAH)
3286,NCT02562235,"1:32:chronic_disease,,","Pulmonary arterial hypertension confirmed by a RHC at any time prior to start of study, with mean pulmonary artery pressure (PAPmean) ?25 mmHg at rest"
3287,NCT02562040,"1:15:chronic_disease,,",Severe obesity (body mass index (BMI) z-score ?3)
3288,NCT02561988,1:13:chronic_disease,Eosinophilia and known positivity for the FIP1L1-PGDFRA fusion
3289,NCT02561988,",38:64:cancer",at least 1 C-finding attributable to systemic mastocytosis (SM)
3290,NCT02561104,1:9:chronic_disease,Hypotony
3291,NCT02560766,"12:50:chronic_disease,","History of suicidal behavior or suicidal ideation as indicated by the C-SSRS, administered at screening, and as per investigator's judgment"
3292,NCT02560623,33:53:treatment,Undergoing clinically indicated diagnostic endoscopy
3293,NCT02558972,"1:17:treatment,",Prior medication will be stopped for at least 2 weeks
3294,NCT02558010,1:18:chronic_disease,Seizure Disorders
3295,NCT02557321,",99:120:treatment",who have failed to achieve a complete or partial response within 24 weeks following initiation of checkpoint inhibition
3296,NCT02555280,"1:30:chronic_disease,,",Degenerative lumbar scoliosis (Cobb angle of greater than 25°)
3297,NCT02555280,",53:75:treatment",More than two contiguous vertebral levels requiring surgical decompression
3298,NCT02555280,28:53:chronic_disease,Patients with up to stable Grade I spondylolisthesis at two contiguous levels
3299,NCT02555280,45:76:treatment,Subject is currently involved in a study of another investigational product for similar purpose
3300,NCT02555280,1:14:chronic_disease,pars fracture
3301,NCT02555189,16:26:treatment,The effects of ribociclib on the developing human fetus at the recommended therapeutic dose are unknown
3302,NCT02554812,42:73:cancer,Histological or cytological diagnosis of advanced/metastatic solid tumor
3303,NCT02554383,"1:11:treatment,",Antibiotic use within 15 days
3304,NCT02554253,26:48:treatment,procedures not requiring cardiopulmonary bypass
3305,NCT02553642,",59:74:treatment,",Must have no evidence of progression for at least 4 weeks after treatment is complete and within 28 days prior to first dose of study drug administration
3306,NCT02553460,15:25:cancer,Patients with T-cell ALL
3307,NCT02553265,",30:56:chronic_disease",Male or female patients with familial dysautonomia (FD)
3308,NCT02553265,1:24:chronic_disease,Unstable blood pressure
3309,NCT02553161,45:63:chronic_disease,"has at least one first degree relative with Bipolar I Disorder, as assessed by the Structured Clinical Interview for DSM (SCID; First et al. 1995), the Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS-PL, Kaufman et al., 1997), and the Family History-Research Diagnostic Criteria (FH-RDC; Andreasen et al., 1977)"
3310,NCT02551679,1:22:chronic_disease,Hypercoagulable state
3311,NCT02551679,46:83:chronic_disease,Subject has hemodynamic indicators of severe peripheral arterial occlusive disease
3312,NCT02549937,1:32:treatment,Alanine aminotransaminase (ALT)
3313,NCT02549833,1:29:treatment,Prior radiation therapy (RT) after the initial diagnosis will be allowed
3314,NCT02548351,12:29:treatment,History of biliary diversion
3315,NCT02548104,1:16:treatment,revision of TKA
3316,NCT02547818,"1:17:chronic_disease,","Major depressive episode, as described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) within the past 6 months, which could lead to difficulty complying with the protocol"
3317,NCT02547818,41:67:treatment,Visual and auditory acuity adequate for neuropsychological testing
3318,NCT02547662,",,,,,,,,284:321:treatment,,","Females of childbearing potential (FCBP)* must have a negative serum pregnancy test with a sensitivity of at least 50 mIU/mL within 10-14 days prior to and again within 24 hours prior to prescribing pomalidomide for cycle 1 (prescriptions must be filled within 7 days as required by RevAssist [lenalidomide REMS program]), and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method"
3319,NCT02544880,10:41:treatment,Positive Antinuclear Antibody Test (ANA)
3320,NCT02544503,8:49:treatment,Use of central nervous system (CNS) active drugs that block plasticity
3321,NCT02543983,66:101:chronic_disease,"Participants who, in the investigator s judgment, pose a current homicidal risk or pose suicide risk that cannot be managed in a secure, voluntary inpatient setting"
3322,NCT02543944,1:31:chronic_disease,Wolff-Parkinson White syndrome
3323,NCT02543944,1:25:chronic_disease,wide complex tachycardia
3324,NCT02543723,14:18:treatment,New cycle of OCAs
3325,NCT02542657,",69:109:treatment",Disease that has progressed during or within 6 months of coming off therapy with bortezomib and lenalidomide (either sequentially or concurrent); progressive disease
3326,NCT02541903,43:47:chronic_disease,Histologically or cytologically confirmed PSCC
3327,NCT02541903,13:37:cancer,Previous or concomitant malignancies at other sites
3328,NCT02541565,",69:87:treatment",subjects must be planned to receive full course (6 cycles) of RCHOP chemoimmunotherapy as per clinical standard of care
3329,NCT02540330,1:48:treatment,Concurrent treatment with another anti-estrogen
3330,NCT02540330,13:29:chronic_disease,Presence of pleural effusion
3331,NCT02538484,1:9:chronic_disease,Cachexia
3332,NCT02538198,11:31:treatment,Permitted concurrent therapies
3333,NCT02536794,7:40:chronic_disease,Known active or chronic viral hepatitis
3334,NCT02536170,12:20:allergy_name,Allergy to arginine
3335,NCT02535832,1:23:chronic_disease,Untreated osteoporosis
3336,NCT02535312,",6:42:treatment",#ERROR!
3337,NCT02535312,1:22:treatment,intervening treatment is allowed
3338,NCT02534922,25:58:treatment,Subjects shall have had cytoreductive (debulking) surgery
3339,NCT02533674,54:72:treatment,Documented disease progression during or immediately after last therapy according to any of the aforementioned criteria
3340,NCT02533674,22:30:treatment,Prior treatment with PM060184
3341,NCT02533674,",36:58:treatment",at least four weeks since the last MAb-containing therapy
3342,NCT02532621,29:38:treatment,Subject is currently taking Aggrenox®
3343,NCT02532452,1:43:chronic_disease,Uncontrolled bacterial or fungal infection
3344,NCT02531880,25:48:treatment,On-going treatment with calcium-channel blocker
3345,NCT02531711,12:25:allergy_name,History of specific food allergies that would prevent adherence to study diet
3346,NCT02530463,25:34:treatment,Previously treated with HMA agent
3347,NCT02530073,",,77:109:treatment","Preterm labor, cervix shortened (<15 mm at enrollment or within 24 hours of FETO balloon insertion procedure) or uterine anomaly strongly predisposing to preterm labor, placenta previa"
3348,NCT02530034,1:38:cancer,chronic myelomonocytic leukemia (CMML)
3349,NCT02527421,55:66:allergy_name,Subjects who have a history of an adverse reaction to cosyntropin injection or similar test reagents
3350,NCT02527265,"17:43:treatment,","Exposure to any investigational product(s) in the past 3 months or 5 half-lives, whichever is more"
3351,NCT02525861,"12:46:treatment,,","Documented Alpha1-Proteinase Inhibitor (A1PI) genotype of Pi*Z/Z, Pi*Z/Null, Pi*Malton/Z, Pi*Null/Null, or other at-risk allelic combinations such as SZ (excluding MS and MZ) and an endogenous A1PI plasma levels of ?11 ?M"
3352,NCT02524379,"7:19:chronic_disease,","Acute cervical SCI with ASIA Impairment Scale grade A, B or C on admission"
3353,NCT02524379,"26:43:chronic_disease,",Unconsciousness or other mental impairment that prevents neurological assessment within the first 8 hours
3354,NCT02522715,"1:18:treatment,,,,",Aminoglutethimide; approximate half-life: 15 hours; washout period required: 4 days
3355,NCT02522715,1:16:treatment,Metastatic CRPC
3356,NCT02522468,1:20:treatment,Breast-conservation candidate
3357,NCT02521818,1:14:allergy_name,multiple food allergies
3358,NCT02521103,36:52:allergy_name,Patient has a known sensitivity to device materials
3359,NCT02520791,24:66:treatment,Relapsed or refractory post autologous cell transplantation (HCT)
3360,NCT02520778,32:39:allergy_name,History of hypersensitivity to AZD9291 (or drugs with a similar chemical structure or class to AZD9291) or any excipients of these agents
3361,NCT02520778,"27:35:treatment,",must discontinue previous EGFR-TKI at least 7 days prior to study enrollment
3362,NCT02520713,1:43:cancer,Infantile fibrosarcoma without NTRK fusion
3363,NCT02520713,1:25:cancer,Undifferentiated sarcoma
3364,NCT02520427,1:30:cancer,promyelocytic leukemia (APML)
3365,NCT02520011,"12:46:treatment,",Received a hematopoietic stem cell transplant within the previous 2 months
3366,NCT02519452,40:70:treatment,Participant has previously received an allogenic stem cell transplant
3367,NCT02519452,"1:19:chronic_disease,",Refractory disease is defined as less than (<) 25 percent (%) reduction in M-protein or progression of disease during treatment
3368,NCT02519348,19:42:treatment,Prior exposure to immune-mediated therapy
3369,NCT02519283,48:51:chronic_disease,"Patients deemed by emergency physician to have AHF, who they plan to discharge or hold for brief ED-based observation"
3370,NCT02518594,"13:58:chronic_disease,,",Evidence of severe IUGR (intrauterine growth restriction) (<5th percentile for gestational age) in either fetus
3371,NCT02518594,"1:31:chronic_disease,","Twin-twin transfusion syndrome, due to increased risk of adverse pregnancy outcome"
3372,NCT02516670,16:38:chronic_disease,Has history of calcium oxalate stones
3373,NCT02516241,37:65:treatment,Patients eligible or ineligible for cisplatin-based chemotherapy
3374,NCT02515708,1:22:treatment,Multiorgan transplant
3375,NCT02515110,12:57:treatment,History of ipsilateral or contralateral axillary surgery for any condition
3376,NCT02514915,",,79:106:treatment",Patients with a documented symptomatic lesion size smaller than 3cm requiring clinical surgical resection
3377,NCT02514083,",,88:105:chronic_disease",Total bilirubin greater than or equal to 1.5 times upper limit of normal unless due to Gilbert s disease
3378,NCT02513797,86:118:chronic_disease,Documented diagnosis of symptomatic continuous persistent or longstanding persistent non-valvular atrial fibrillation
3379,NCT02513797,1:33:chronic_disease,"Left atrial appendage morphology: Superior-posterior oriented left atrial appendage (i.e. superior C shape), that has Left atrial appendage distal apex extending posterior to the ostium of the appendage"
3380,NCT02512926,",46:49:treatment",At least 14 days must have elapsed for local XRT
3381,NCT02512718,1:16:chronic_disease,Lipid nephrosis
3382,NCT02512497,"1:23:chronic_disease,,","Congenital QT syndrome, QTc >500 ms"
3383,NCT02511301,33:40:cancer,Any biopsy or treatment for the BI-RADS category 4 or 5 abnormality
3384,NCT02510417,11:15:chronic_disease,Available VSTs
3385,NCT02509507,31:43:cancer,Subjects must have measurable liver tumors and lesions that are suitable for injection
3386,NCT02509260,1:31:treatment,enterocutaneous fistula repair
3387,NCT02509260,"30:40:treatment,",patients who had undergone a laparotomy within the preceding three months
3388,NCT02508467,14:38:treatment,has declined treatment with sorafenib
3389,NCT02508311,",,,50:60:chronic_disease",Neurological level of injury between T1-T6 (High Paraplegia)
3390,NCT02508038,84:104:chronic_disease,"Is free from risk factors for, and clinical evidence of, infection due to relevant communicable disease agents and diseases"
3391,NCT02508038,13:42:cancer,Relapsed or primary refractory metastatic
3392,NCT02508038,10:29:chronic_disease,signs of leukoencephalopathy
3393,NCT02507505,9:48:treatment,Planned surgical treatment via hemiarthroplasty
3394,NCT02507011,"1:20:treatment,",RVEF by cardiac MRI < 45%
3395,NCT02506192,1:16:chronic_disease,Crohn's Disease
3396,NCT02506192,1:27:chronic_disease,Inflammatory lung diseases
3397,NCT02506192,1:25:chronic_disease,acute Chronic Infections
3398,NCT02504866,12:32:chronic_disease,History of exercise intolerance
3399,NCT02503722,18:36:chronic_disease,Prior history of corneal ulceration
3400,NCT02503722,",136:160:treatment",patients should not consume food or beverages containing the fruit or juice of grapefruits or Seville oranges within 7 days before the first dose of study drug and throughout the study
3401,NCT02502799,"14:44:chronic_disease,,,",Diagnosis of autism spectrum disorder (ASD) with a severity level of 2 or 3
3402,NCT02501954,25:53:cancer,Patients with FIGO 2009 Stage IVB endometrial cancer
3403,NCT02501954,1:18:chronic_disease,Pelvic lymph node sampling
3404,NCT02501733,15:26:treatment,Patients with knee fusion to the affected joint
3405,NCT02501473,"12:30:treatment,",Received a live virus vaccine within 30 days of planned study start
3406,NCT02500407,"1:38:treatment,",Systemic immunosuppressive medication within 2 weeks prior to study drug
3407,NCT02498951,"1:32:treatment,",Vaccination with a live vaccine a minimum of 4 weeks prior to study enrollment
3408,NCT02498613,"30:57:cancer,",Patients with concomitant or prior invasive malignancies within the past 3 years
3409,NCT02498535,"17:31:treatment,","For subjects on cycled therapy, at least 2 cycles of drug need to have been completed prior to baseline"
3410,NCT02498301,"13:27:chronic_disease,",Subject has acute diarrhea within 7 days prior to enrollment
3411,NCT02498262,79:94:chronic_disease,Participants will include individuals that have suffered a moderate to severe traumatic brain
3412,NCT02497300,"1:25:chronic_disease,,",Diabetes mellitus type 2 with glycosylated hemoglobin ? 6.5%
3413,NCT02496611,12:26:chronic_disease,History of cholelithiasis
3414,NCT02496611,36:71:chronic_disease,Personal- and/or family history of multiple endocrine neoplasia type 2
3415,NCT02496585,1:17:cancer,Liver metastases
3416,NCT02496208,23:34:chronic_disease,appearance of one new bone lesion
3417,NCT02495545,133:143:treatment,Able to cooperate in the completion of a standardized neurological examination by ISNCSCI standards (includes patients who are on a ventilator)
3418,NCT02495415,"46:73:treatment,",Growth factor(s): Must not have received any hematopoetic growth factors within 7 days of study entry
3419,NCT02495415,37:49:allergy_name,Patients with documented allergy to egg products
3420,NCT02495389,13:32:treatment,Patients on current OAB therapy will undergo a two-week drug washout period prior to baseline assessment
3421,NCT02495168,"1:21:treatment,",Oral corticosteroids for 30 days
3422,NCT02495168,"49:54:treatment,",patients should be able to withhold all inhaled SABAs for at least 6 hours prior to lung function assessments on study visits
3423,NCT02494869,25:29:cancer,Cytologically confirmed LCIS
3424,NCT02494869,1:18:chronic_disease,Recurrent syncope
3425,NCT02494869,1:27:chronic_disease,Uncontrolled heart failure
3426,NCT02494141,20:39:treatment,Currently taking a curcumin supplement
3427,NCT02493530,1:23:treatment,bone marrow transplant
3428,NCT02493257,1:18:chronic_disease,Allergic rhinitis
3429,NCT02493257,1:31:treatment,Radiation to the head and neck
3430,NCT02490943,25:46:allergy_name,Any contraindication to warm or cold compress
3431,NCT02490631,1:28:chronic_disease,intradural spinal pathology
3432,NCT02489539,13:25:chronic_disease,Patient has body habitus or other medical condition which prevents adequate delineation of the aorta
3433,NCT02489045,15:44:chronic_disease,Patients with respiratory distress syndrome
3434,NCT02488967,"1:4:chronic_disease,,,,","ISH non-amplified with a ratio of HER2 to CEP17 < 2.0, and if reported, average HER2 gene copy number < 4 signals/cells"
3435,NCT02487797,12:53:treatment,History of prior cesarean section or uterine surgery
3436,NCT02487082,1:24:chronic_disease,Cardiovascular problems
3437,NCT02485639,32:43:treatment,who have not received seasonal flu vaccine for the current year (September - June)
3438,NCT02484404,43:47:cancer,Histologically or cytologically confirmed SCLC
3439,NCT02484404,23:34:treatment,Patients who have had prior PARPi are not eligible
3440,NCT02484404,28:50:treatment,Patients who have received radionuclide treatment
3441,NCT02484300,1:34:treatment,Prior or current use of melatonin
3442,NCT02483910,"21:105:treatment,",Currently receiving Direct Instruction Language for Learning (DI-LL) or participation in a DI-LL program in the past 2 years
3443,NCT02482376,17:35:cancer,Clinical T1N0M0 invasive carcinoma
3444,NCT02481765,16:41:chronic_disease,The subject is severely hearing impaired
3445,NCT02481310,1:19:treatment,Surgically sterile
3446,NCT02481245,21:44:chronic_disease,DSM IV diagnosis of Bipolar Disorder Type I
3447,NCT02481245,"45:66:treatment,",Taking an adequate dose of any FDA-approved anti-manic medication for at least two weeks prior to enrollment
3448,NCT02480036,1:21:treatment,Previous kyphoplasty in the same area
3449,NCT02479906,1:19:chronic_disease,Multiple sclerosis
3450,NCT02479698,1:50:cancer,Merkel polyoma-virus related Merkel cell tumor(s) with measurable disease on imaging per RECIST criteria
3451,NCT02479620,9:36:treatment,Planned major index limb amputation
3452,NCT02479230,36:69:treatment,There is no limit to the number of prior systemic treatment regimens
3453,NCT02477839,"5:15:treatment,",The VNS device must have been implanted for >=6 months prior to Visit 1
3454,NCT02476409,22:38:chronic_disease,Clinical evidence of digoxin toxicity
3455,NCT02476409,10:41:chronic_disease,Elevated jugular venous distension (JVD)
3456,NCT02476409,29:48:chronic_disease,Planned hospitalization for acute heart failure
3457,NCT02474927,8:31:chronic_disease,Active cytomegalovirus disease
3458,NCT02474667,29:53:treatment,"Patients may participate in another concurrent study only if that study is a non-interventional, observational investigation"
3459,NCT02474368,1:11:treatment,Amifostine
3460,NCT02474368,1:39:treatment,Granulocyte stimulating factor (G-CSF)
3461,NCT02474199,14:22:treatment,Confirmatory chest CT
3462,NCT02474199,1:31:chronic_disease,primary sclerosing cholangitis
3463,NCT02473536,"1:15:cancer,",Tumor thrombus must be ? level II
3464,NCT02473354,101:113:treatment,has completed the appropriate fasting periods for solids and liquids prior to the administration of remifentanil
3465,NCT02473250,18:44:treatment,Participation in nuclear medicine protocols in the last year
3466,NCT02473250,1:17:chronic_disease,blood dyscrasias
3467,NCT02473250,1:14:chronic_disease,hypersplenism
3468,NCT02472834,"20:46:treatment,",Taking any type of amino acid supplementation within the last 90 days
3469,NCT02472223,"6:50:chronic_disease,","Sex: Pink eye {adenoviral conjunctivitis (Ad-Cs)} occurs with equal prevalence in males and females, therefore we will recruit both genders"
3470,NCT02471911,",,,122:150:treatment",Women of childbearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test prior to selinexor treatment
3471,NCT02471430,27:37:chronic_disease,No clinically significant eye disease
3472,NCT02470897,",20:76:treatment",#ERROR!
3473,NCT02469857,1:36:chronic_disease,Idiopathic Thrombocytopenia Purpura
3474,NCT02469662,23:38:chronic_disease,Patient has a current major infection distant from the operative site
3475,NCT02469389,1:10:chronic_disease,anhedonia
3476,NCT02468778,"5:37:treatment,",Any prior coronary revascularization within the last 6 months
3477,NCT02468778,20:48:chronic_disease,intervention of an unprotected left main artery
3478,NCT02468024,15:46:cancer,Patients with non-peripheral (central) tumors are NOT eligible
3479,NCT02467478,1:52:treatment,Treatment with cytochrome p450 (CYP 3A4) inhibitors
3480,NCT02466971,32:58:cancer,Patient has another concurrent active invasive malignancy
3481,NCT02466750,"25:42:treatment,,",Have completed previous WEE vaccine study as a nonresponder (PRNT80 < 1:40)
3482,NCT02466685,1:24:treatment,atypical antipsychotics
3483,NCT02465541,10:35:cancer,No prior type I endometrial cancer diagnosis
3484,NCT02465060,9:24:treatment,Chronic inhaled steroid use
3485,NCT02465060,14:40:treatment,Stopping the anticoagulation for biopsy should be per site standard operating procedure (SOP)
3486,NCT02465034,22:55:treatment,Contraindications to Transcranial Magnetic Stimulation
3487,NCT02464904,58:77:treatment,Absence of or limited access to the pleural space during medical pleuroscopy
3488,NCT02464878,22:41:treatment,Islet donor-directed anti-HLA antibodies detected by Luminex Single Antigen/specificity bead assay including weakly reactive antibodies that would not be detected by a flow cross-match
3489,NCT02464878,1:23:chronic_disease,nail fungal infections
3490,NCT02464696,15:61:chronic_disease,Patients with acute chronic obstructive disease exacerbation as the primary etiology for respiratory failure
3491,NCT02464696,1:29:chronic_disease,Supraventricular tachycardia
3492,NCT02464436,"1:12:chronic_disease,,",High myopia (>6 diopters) in the study eye
3493,NCT02463305,1:32:treatment,Prior surgical bowel resections
3494,NCT02462590,29:47:chronic_disease,"primary diagnosis of severe acute pancreatitis, without reference to a Ranson score [Ranson 1974])"
3495,NCT02461927,28:68:chronic_disease,Current or past history of psychotic features or psychotic disorder
3496,NCT02460835,10:29:cancer,not have extrahepatic cancer
3497,NCT02460692,68:84:chronic_disease,Presence of another painful condition of greater severity than the neuropathic pain condition which is being studied
3498,NCT02458482,"98:128:treatment,",Patients who present from a referring facility or Primary Care Physician (PCP) and have received systemic corticosteroids (SCS) within one hour of initial AAIRS scoring will also be included
3499,NCT02457845,1:34:treatment,Autologous bone marrow transplant
3500,NCT02457832,1:18:treatment,Metallic implants
3501,NCT02457702,"35:45:treatment,",Significant weight loss or use of diet pills within previous 6 months
3502,NCT02454907,1:23:chronic_disease,Relapsing-remitting MS (2010 criteria)
3503,NCT02453373,"1:25:chronic_disease,,",Ischemic cortical stroke with NIHSS > _5_
3504,NCT02453373,12:35:chronic_disease,history of cold agglutinin disease
3505,NCT02452697,25:41:chronic_disease,Those with a history of cardiac problems or abnormal cardiac findings by physical examination should undergo a stress evaluation or be evaluated by a cardiologist and deemed eligible to donate
3506,NCT02452203,34:54:chronic_disease,Participant meets criteria for a DSM5 Axis-1 disorder
3507,NCT02451683,"1:16:chronic_disease,",Cervical injury at C8 or above
3508,NCT02451553,1:30:treatment,Prior treatment with afatinib
3509,NCT02451488,",,,122:149:treatment",who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and 2 weeks after cessation of the study drug
3510,NCT02451423,"1:23:chronic_disease,",BCG-refractory disease is defined as the absence of a complete response by 6 months in patients who have received induction
3511,NCT02451423,"20:33:chronic_disease,,",Patients with past HBV infection or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBc Ab] and absence of HBsAg) are eligible
3512,NCT02451423,20:44:treatment,maintenance OR two induction courses of BCG
3513,NCT02451215,1:31:cancer,Choroid plexus papilloma (CPP)
3514,NCT02451215,1:14:cancer,Ganglioglioma
3515,NCT02451215,1:11:cancer,Meningioma
3516,NCT02448381,44:68:cancer,"Subjects must have a clinical diagnosis of CTCL (mycosis fungoides), Stage IA, Stage IB, or Stage IIA"
3517,NCT02446457,",64:91:chronic_disease",Have measurable disease (>= 1.5 cm in the longest diameter for nodal or extranodal disease)
3518,NCT02446236,",,,,,,149:160:chronic_disease,","Platelets > 75,000/?L and absolute neutrophils count (ANC) > 1,000/?L within 14 days of study registration (unless the treating physician deems the neutropenia is related to bone marrow involvement, then an ANC of > 750/mm 3 is allowed)"
3519,NCT02445768,67:77:treatment,"exhibit contra-indications to enter the magnetic field of the 3T (pacemakers, metal parts in the body etc)"
3520,NCT02442622,1:23:chronic_disease,radial tunnel syndrome
3521,NCT02442323,1:26:cancer,papillary cystic neoplasm
3522,NCT02442102,33:53:cancer,"Head and/or neck disease (e.g., oropharyngeal cancer)"
3523,NCT02441101,"1:28:chronic_disease,",Acute Myocardial infarction within 6 months of entry into the study
3524,NCT02440581,"1:29:treatment,",Chronic maintenance dialysis of at least 3 months
3525,NCT02439450,21:85:treatment,Arm 6: Suitable for front line maintenance treatment with pembrolizumab ± pemetrexed per the current approved package inserts
3526,NCT02439450,1:19:treatment,fresh tumor biopsy at Week 10 when feasible
3527,NCT02438995,22:31:treatment,Previous exposure to Cetuximab
3528,NCT02437851,"1:12:cancer,",Anal cancer that cannot be completely excised with a >=1 mm clear margin from surrounding tissue or where excision to obtain a clear margin would compromise sphincter function or anal canal diameter
3529,NCT02437370,4:27:treatment,Be previously chemotherapy-treated
3530,NCT02437110,"5:17:treatment,",had neuroimaging within the last 18 months
3531,NCT02436070,1:20:chronic_disease,Sickle Cell disease
3532,NCT02435069,27:48:chronic_disease,children with preexisting electrolyte imbalance
3533,NCT02434809,32:38:allergy_name,History of hypersensitivity to nickel
3534,NCT02433977,"1:28:chronic_disease,",Respiratory tract infection within the last 4 weeks
3535,NCT02433158,15:29:treatment,Completion of Study B5201002
3536,NCT02431806,24:48:chronic_disease,Clinically significant cardiovascular disorders
3537,NCT02430077,",,,78:109:treatment",Hepatic steatosis (>5.6% hepatic triglyceride content) as demonstrated by 1H magnetic resonance spectroscopy
3538,NCT02430051,17:39:treatment,Prescription of anti-cholinergic drugs (which may alter EDA)
3539,NCT02429830,",,107:114:treatment",If the subject is of child bearing potential must have a negative pregnancy test within one week prior to implant and must agree to use effective means of birth control during the course of the study
3540,NCT02428205,1:18:chronic_disease,Major head trauma
3541,NCT02427841,"13:42:chronic_disease,",No baseline peripheral sensory neuropathy >= grade 2
3542,NCT02426476,36:53:treatment,an active prescription for certain heart medications
3543,NCT02426047,14:22:treatment,Prior use of betaquik® at any time for any duration
3544,NCT02424968,",,50:66:treatment",Patients must be beyond day 30 and before day 60 after transplant
3545,NCT02423863,",82:91:treatment",Contraception must be continued for at least 2 months following the last dose of poly-ICLC
3546,NCT02423863,1:14:cancer,Squamous head
3547,NCT02423525,31:75:treatment,Current or anticipated use of enzyme-inducing anti-epileptic drugs (EIAED)
3548,NCT02422641,1:16:cancer,Triple-negative patients will be defined per ASCO-CAP Guidelines (American Society of Clinical Oncology-College of American Pathologists)
3549,NCT02421341,",80:116:chronic_disease","Will be matched for age, gender, height and weight and will have no history of cardiovascular related abnormalities"
3550,NCT02421315,27:40:treatment,Positive urine screen for illicit drugs
3551,NCT02421276,"16:71:chronic_disease,,,",Diagnosed with idiopathic or secondary pulmonary arterial hypertension as defined by a mean pulmonary artery pressure > 25 mmHg at rest or > 30 mmHg with exercise
3552,NCT02419560,29:32:cancer,Subject is at high risk for TLS
3553,NCT02418195,1:17:chronic_disease,Anorexia nervosa
3554,NCT02418195,1:17:chronic_disease,Behcet's disease
3555,NCT02418195,1:24:chronic_disease,Hashimoto's thyroiditis
3556,NCT02418195,1:12:chronic_disease,Post-partum state
3557,NCT02418195,1:25:chronic_disease,Wegener's granulomatosis
3558,NCT02417701,15:79:treatment,Maintained on modern therapeutic regimens utilizing non-CYP-interactive agents
3559,NCT02416102,12:33:chronic_disease,History of renal artery stenosis
3560,NCT02415556,1:10:chronic_disease,Type 1 DM
3561,NCT02414269,"15:18:chronic_disease,,",Patients with MPD aged ?18 years
3562,NCT02414178,1:22:chronic_disease,Severe claustrophobia
3563,NCT02414139,",72:84:treatment","Patients with characterized EGFR mutations that predict sensitivity to EGFR therapy, including, but not limited to exon 19 deletions and exon 21 mutations"
3564,NCT02413047,1:28:treatment,Oral corticosteroid therapy
3565,NCT02412540,1:15:chronic_disease,Wilson disease
3566,NCT02411773,"1:20:chronic_disease,,",Metabolic Alkalosis (serum bicarbonate > 28 meq/L)
3567,NCT02410954,17:75:chronic_disease,Current or past Axis I Diagnostic and Statistical Manual (DSM-IV) disorder based on the MINI
3568,NCT02409810,1:20:chronic_disease,Acute liver failure
3569,NCT02408861,50:66:allergy_name,delayed-type hypersensitivity reaction caused by contact allergen
3570,NCT02408120,31:47:treatment,Subjects receiving continuous insulin infusion
3571,NCT02408120,1:24:treatment,non-insulin injectables
3572,NCT02407028,"1:34:treatment,",First hyperbaric oxygen treatment cannot be initiated within 24 hours of injury
3573,NCT02406885,20:27:treatment,Strong inducers of CYP 3A4
3574,NCT02406599,28:42:treatment,Patients for whom complete cavity shaving is planned (sites where this is the routine practice of the investigator will also be excluded from participation in the study)
3575,NCT02404870,44:57:allergy_name,"Have previous hypersensitivity reaction to canagliflozin (including but not limited to rash, raised red patches on your skin (hives), swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing)"
3576,NCT02404155,21:39:chronic_disease,DSM-IV diagnosis of Mental Retardation
3577,NCT02404155,1:19:chronic_disease,Sjogren's Syndrome
3578,NCT02403323,33:68:treatment,Patients previously enrolled in etrolizumab Phase III study GA29144 who meet the eligibility criteria for open-label etrolizumab as described in the protocol
3579,NCT02403128,",,31:50:treatment",CFT of 310 microns or more by spectral domain OCT or lipid in the center of the fovea
3580,NCT02402660,",148:177:treatment",At least one eye (called the primary study eye) must have at least one well-demarcated area of significantly reduced autofluorescence as imaged by fundus autofluorescence (FAF)
3581,NCT02402647,1:18:chronic_disease,Hoarding Disorder diagnosis outlined by the Diagnostic and Statistical Manual of Mental Disorders
3582,NCT02401347,52:59:allergy_name,Known hypersensitivity to any of the components of BMN 673
3583,NCT02401074,"1:38:chronic_disease,",Upper and lower respiratory infection within 1 month of screening
3584,NCT02400463,1:14:chronic_disease,Malabsorption
3585,NCT02400255,"8:18:chronic_disease,",Active GVHD grade ? 2
3586,NCT02398773,127:134:allergy_name,Patient must NOT have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-FES
3587,NCT02397889,12:23:chronic_disease,History of (hypo)mania
3588,NCT02397889,1:33:chronic_disease,gastro-esophageal reflux disease
3589,NCT02397083,"64:115:treatment,",Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosing
3590,NCT02395614,26:69:treatment,candidates for immediate breast reconstruction with tissue expanders
3591,NCT02395393,55:96:treatment,to be undergoing surveillance or clinically indicated bronchoscopies with transbronchial biopsy as part of their routine care
3592,NCT02394535,1:29:treatment,Prior abdominal radiotherapy
3593,NCT02394535,17:27:treatment,patients taking cimetidine must have this drug discontinued
3594,NCT02393885,59:86:treatment,A condition or congenital anomaly which prevents required surgical or catheter access
3595,NCT02393885,"1:38:chronic_disease,,,","Stroke/cerebrovascular accident (CVA) within previous six months, carotid artery stenosis greater than 80%"
3596,NCT02393742,",,34:37:chronic_disease",Body mass index (BMI) >40 kg/m2 (FMD measurements can be inaccurate in severely obese patients)
3597,NCT02393690,132:152:cancer,Modification of the RECIST v1.1 measurable disease criteria includes a change in the definition of what is considered a measurable malignant lymph node
3598,NCT02393157,1:31:cancer,CD20+ B-lymphoblastic lymphoma
3599,NCT02393157,32:71:treatment,Patients may not have received prior therapy with obinutuzumab (GA101)
3600,NCT02393157,1:24:treatment,Radiation Therapy (XRT)
3601,NCT02392286,"13:44:treatment,",Patients on systemic corticosteroid therapy currently or within the past 8 weeks
3602,NCT02390752,1:27:chronic_disease,Active untreated infection
3603,NCT02390752,",,167:174:treatment","Individuals who are pregnant or breast feeding or who become pregnant while enrolled on this trial will be excluded from participation, due to the unknown effects of PLX3397 on a growing fetus or newborn child"
3604,NCT02390752,65:83:treatment,Patients must have relapsed after or be refractory to effective standard therapies
3605,NCT02389959,36:79:chronic_disease,The patient carries a diagnosis of hereditary hemorrhagic telangiectasia (HHT)
3606,NCT02389517,",,72:103:treatment",Rate-corrected QT interval of electrocardiograph (QTc) > 470 msec on a 12-lead electrocardiogram (ECG) during screening
3607,NCT02388685,1:33:treatment,Lower extremity vascular surgery
3608,NCT02387905,25:40:chronic_disease,Patients who have frank mechanical pain
3609,NCT02385110,33:61:chronic_disease,"A documentation of diagnosis of hemophagocytic lymphocytosis, either newly diagnosed or relapsed/refractory by the treating physician and the PI in the patients chart"
3610,NCT02383927,1:24:chronic_disease,cerebro-vascular attack within the prior year
3611,NCT02382549,94:123:chronic_disease,Participants classified according to the New York Heart Association classification as having Class III or IV heart disease
3612,NCT02382549,30:62:cancer,"Participants with measurable stage IIIB, IIIC, or IV melanoma that have clinical or radiological evidence of disease"
3613,NCT02382419,42:60:allergy_name,Any known allergy or hypersensitivity to vaginal lubricants or any component of study product
3614,NCT02379156,1:26:chronic_disease,Untreated thyroid disease
3615,NCT02378714,",,,,95:141:chronic_disease",systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg after two readings or symptomatic uncontrolled stage II hypertension
3616,NCT02378428,88:105:treatment,Patients with disease of any major organ system that would compromise their ability to withstand therapy
3617,NCT02376153,1:18:treatment,Acetabular repair with instrumentation
3618,NCT02374333,18:41:chronic_disease,Any uncontrolled active medical disorder that would preclude participation as outlined
3619,NCT02374333,16:36:treatment,relapsed after prior autologous SCT
3620,NCT02374021,54:79:chronic_disease,"Prior patient reported, physician diagnosed clinical cardiovascular (CV) event"
3621,NCT02374021,1:16:chronic_disease,macular disease
3622,NCT02373644,1:17:treatment,ASIS distraction
3623,NCT02373644,1:19:treatment,Sacral compression
3624,NCT02370693,"13:42:chronic_disease,",Patient has Grade 2 peripheral neuropathy by history within 14 days before enrollment
3625,NCT02370095,"1:29:chronic_disease,,,",Severe chronic liver disease (Child-Pugh Score 11-15)
3626,NCT02370056,7:22:treatment,total proctocolectomy
3627,NCT02369770,1:32:chronic_disease,Severe cardiovascular disorders that interfere with ability to perform moderate movement exercises
3628,NCT02367196,7:59:chronic_disease,"Known chronic, active hepatitis B or C (HBV/HCV) infection"
3629,NCT02367040,"1:24:cancer,,",Follicular lymphoma(FL) grade1-2-3a
3630,NCT02366871,1:26:chronic_disease,Active bleeding condition
3631,NCT02366871,1:13:chronic_disease,haemophilias
3632,NCT02366871,1:21:chronic_disease,protein C deficiency
3633,NCT02366819,1:25:cancer,gross peritoneal disease
3634,NCT02365766,"1:17:chronic_disease,",Hearing impaired ?grade 2 as assessed by treating physician (may or may not be enrolled in a monitoring program)
3635,NCT02365467,16:65:chronic_disease,Subject has an acute dissection of the descending thoracic aorta
3636,NCT02365467,"19:51:chronic_disease,",Subject has had a cerebral vascular accident (CVA) within 3 months
3637,NCT02365467,"3:20:chronic_disease,,,",a fusiform aneurysm with a diameter of ? 5.5 cm OR is > 2 times the diameter of the non-aneurysmal thoracic aorta
3638,NCT02362308,22:37:chronic_disease,Previously diagnosed type 1 Diabetes
3639,NCT02362308,1:17:chronic_disease,"Type II Diabetes, as defined by ADA criteria"
3640,NCT02361554,",70:80:treatment","Subject is able to read English, understand and cooperate with study procedures, and has signed a written informed consent form prior to any study procedures"
3641,NCT02360579,21:53:treatment,Patients who are on chronic systemic steroid therapy for any reason
3642,NCT02359864,"15:25:treatment,,",Patient has a MMSE score of between 10-20
3643,NCT02359825,43:63:treatment,unlikely to complete the normal regime of occupational therapy
3644,NCT02359097,42:57:treatment,Subjects who have a contraindication for 3 tesla (T) MRI
3645,NCT02358187,",20:29:treatment",Interleukins (e.g. Proleukin®)
3646,NCT02357784,7:37:chronic_disease,has > Stage II pelvic organ prolapse
3647,NCT02356861,5:40:chronic_disease,"Had Gulf War Veterans' Illnesses (GWVI), but did not answer 'Yes' to the following questions: 1) Difficulty concentrating and/or 2) Difficulty remembering recent information"
3648,NCT02356705,23:47:treatment,scheduled for a minor Ear/Nose/Throat surgical procedure requiring mask anesthesia
3649,NCT02356653,1:10:cancer,Lymphomas
3650,NCT02355912,23:40:chronic_disease,cognitive deficits or visual impairment that would impair their ability to give informed consent or impair their ability to follow simple instructions during the experiments
3651,NCT02355535,1:54:treatment,Prior allogeneic bone marrow or organ transplantation
3652,NCT02355002,1:17:treatment,vagal stimulator
3653,NCT02354703,12:28:chronic_disease,History of Long QT Syndrome or a first-degree biological family member with this condition
3654,NCT02354547,",41:70:treatment",At least 21 days after the last dose of myelosuppressive chemotherapy
3655,NCT02353819,1:15:cancer,Adenocarcinoma of the prostate
3656,NCT02353728,1:34:chronic_disease,Complete left bundle branch block
3657,NCT02353728,8:35:treatment,Use of ventricular-paced pacemaker
3658,NCT02351544,63:81:chronic_disease,"Patients deemed by the authors or the neurologist to not have migraine headaches, but an alternative diagnosis"
3659,NCT02350764,",,87:98:treatment,",Exception is made for patients with EGFR or ALK re-arrangements who must have stopped TKI therapy at least 7 days prior to C1D1
3660,NCT02349958,21:36:chronic_disease,"Patients with known extra-abdominal disease, or unresected bulky abdominal retroperitoneal lymph nodes"
3661,NCT02349867,1:20:chronic_disease,Arterial thrombotic
3662,NCT02347995,29:49:chronic_disease,hemodynamically significant valvular dysfunction
3663,NCT02347891,1:16:chronic_disease,Dermatomyositis patients that do not meet the MMT criteria
3664,NCT02347891,15:39:treatment,Have received treatment with Belimumab at any time prior to Screening
3665,NCT02347111,"1:28:treatment,",Cardiac or thoracic surgery within the previous 6 months
3666,NCT02347111,",20:24:treatment",Received 2 or more AADs in past
3667,NCT02346526,1:19:chronic_disease,Fecal incontinence
3668,NCT02346253,"51:69:treatment,","Clinically negative lymph nodes as established by abdomino-pelvic CT, no more than 90 days prior toregistration"
3669,NCT02346201,30:54:chronic_disease,"Currently meets criteria for Major Depressive Episode, by Diagnostic Statistical Manual of Mental Disorder - IV (TR) criteria"
3670,NCT02343549,18:30:treatment,Have undergone a brain biopsy via stereotactic or open technique
3671,NCT02343549,13:38:chronic_disease,Significant liver function impairment
3672,NCT02343549,1:7:chronic_disease,nausea
3673,NCT02343042,"1:54:treatment,",Treatment with an investigational anti-cancer therapy within 3 weeks prior to C1D1
3674,NCT02342782,45:113:allergy_name,History of allergic reactions attributed to compounds of similar chemical or biologic composition to basiliximab
3675,NCT02342782,1:40:chronic_disease,psychosocial circumstances or illnesses that preclude protocol participation (to be determined by P.I.)
3676,NCT02341209,"75:95:treatment,,",The subject has resolution of all clinically significant toxic effects of prior cancer therapy to Grade ?1 by the National Cancer Institute Common Terminology Criteria for Adverse Events
3677,NCT02340156,22:42:cancer,Histology other than astrocytoma grade IV
3678,NCT02340156,1:11:treatment,Urinalysis: No clinically significant abnormalities
3679,NCT02339948,42:71:treatment,Tissue for diagnosis must be obtained by transrectal ultrasound biopsy
3680,NCT02339922,56:74:cancer,Patients must have a diagnosis of one of the following B-NHL malignancies
3681,NCT02339233,1:12:chronic_disease,hypovolemia
3682,NCT02338999,27:31:allergy_name,Known hypersensitivity to TZDs
3683,NCT02338232,1:35:cancer,Acute myeloid or lymphoid leukemia in remission
3684,NCT02338232,1:29:treatment,Regimens for transplantation
3685,NCT02335905,33:44:allergy_name,Has had an allergic reaction to ceftaroline in the past
3686,NCT02335671,36:64:cancer,Participants with prior history of ipsilateral breast carcinoma
3687,NCT02335242,"47:69:chronic_disease,",Be required to have the clinical diagnosis of lymphatic malformation that appears to be over 3 cm in greatest diameter in order to be evaluated for entry
3688,NCT02335242,1:17:treatment,"Organic nitrates in any form, either regularly or intermittently"
3689,NCT02333227,28:39:treatment,Willing to chew 1 piece of xylitol gum for 10 minutes after the morning and evening meal (intervention sites)
3690,NCT02332928,"35:44:treatment,",Subjects who are currently taking melatonin must discontinue melatonin for 5 days before enrolling in the study
3691,NCT02332863,1:5:allergy_name,Gold allergy
3692,NCT02332850,1:15:treatment,prior surgical procedures
3693,NCT02332668,",,,42:47:cancer",between 3 years and <18 years of age for rrcHL participants
3694,NCT02332369,1:21:chronic_disease,Congenital cataracts
3695,NCT02332369,1:7:chronic_disease,Iritis
3696,NCT02332369,1:19:chronic_disease,Retinal detachment
3697,NCT02332291,"1:26:treatment,",Electroconvulsive therapy in last 6 months
3698,NCT02332187,"8:37:treatment,",Use of neuromuscular blocking agents within the 48 hours preceding testing
3699,NCT02329652,1:43:chronic_disease,diabetes with peripheral nerve involvement
3700,NCT02328313,35:79:treatment,Scheduled to begin an appropriate adjuvant or neoadjuvant chemotherapy regimen as defined by NCCN guidelines (www.nccn.org)
3701,NCT02327403,11:15:chronic_disease,recurrent FSGS
3702,NCT02327312,1:12:chronic_disease,choroiditis
3703,NCT02324582,1:31:chronic_disease,active urinary tract infection
3704,NCT02324582,10:32:treatment,targeted small molecule therapy
3705,NCT02324439,1:15:chronic_disease,Renal function
3706,NCT02324387,15:45:treatment,scheduled for neoadjuvant chemotherapy (NAC)
3707,NCT02323880,57:64:treatment,Parts B and C: Patients must have measurable disease on imaging
3708,NCT02323581,31:72:treatment,Suitable arterial anatomy for endovascular TAAA repair with TAAA device
3709,NCT02323126,1:67:treatment,Previous treatment with a c-MET inhibitor or HGF-targeting therapy (applies only to Group 2)
3710,NCT02323100,8:52:treatment,Taking pancreatic enzyme replacement therapy (PERT)
3711,NCT02321501,1:38:treatment,enzyme-inducing anticonvulsive agents
3712,NCT02320292,4:18:cancer,No leukemic phase
3713,NCT02319369,37:62:treatment,Is able and willing to provide bone marrow biopsies/aspirates as requested by the protocol
3714,NCT02319369,23:92:treatment,receiving concomitant treatment with a strong inhibitor or inducer of cytochrome P450 3A4/5
3715,NCT02317991,",30:64:treatment",Patients must have < Grade 2 pre-existing peripheral neuropathy (per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v 4.03)
3716,NCT02317523,"27:36:chronic_disease,,",Neither the caregiver nor Alzheimer's patient can be diagnosed with a terminal illness with a life expectancy of less than 1 year
3717,NCT02316886,"51:76:treatment,",Contraindication to or planned discontinuation of dual antiplatelet therapy within 1 year
3718,NCT02316275,9:35:treatment,Planned mid-urethral sling surgery
3719,NCT02315612,74:104:treatment,"In view of the PI and the primary oncologist, there must be no available alternative curative therapies"
3720,NCT02314221,"1:13:chronic_disease,,",Brain injury with score on mini-mental status examination less than 26
3721,NCT02314221,8:34:chronic_disease,"Severe concurrent medical disease, illness or condition"
3722,NCT02313428,18:40:treatment,"Able to complete Topical Oxygen Therapy 4 day/week for 16 weeks (must be able to remove existing wound dressing and apply TO2 Boot/treatment, and then re-dress wound)"
3723,NCT02313428,1:11:chronic_disease,Foot Ulcer
3724,NCT02312596,"10:48:treatment,",Received another investigational device or drug within 30 days of enrollment
3725,NCT02312245,1:27:treatment,Vaccines and immunotherapy All of these exceptions should be confirmed with the Principal Investigator (PI) prior to registration
3726,NCT02311621,20:36:chronic_disease,Presence of active severe infection
3727,NCT02311621,",17:40:treatment",? 12 weeks from prior I131 MIBG therapy
3728,NCT02311361,1:18:cancer,Malignant ascites that is clinically detectable by physical examination or is symptomatic
3729,NCT02310633,1:51:chronic_disease,Moderate to Severe Traumatic Brain Injury (M-STBI) (blast and blunt)
3730,NCT02310399,1:26:chronic_disease,Cochlear nerve deficiency
3731,NCT02310399,73:111:treatment,Loss or lack of benefit from appropriate CI without the possibility for revision or contralateral implantation
3732,NCT02310399,14:30:chronic_disease,Severe inner ear malformation
3733,NCT02309892,38:57:cancer,Histologic evidence of predominantly squamous cell NSCLC
3734,NCT02307565,12:40:chronic_disease,History of Traumatic Brain Injury (TBI)
3735,NCT02307058,15:25:chronic_disease,Subjects with T3 disease based on digital rectal exam (DRE)
3736,NCT02305537,1:12:chronic_disease,Agoraphobia
3737,NCT02304458,24:60:cancer,Part D6: Patients with relapsed or refractory neuroblastoma (MIBG evaluable disease without RECIST measurable lesion)
3738,NCT02304458,",48:67:chronic_disease",Serum lipase =< ULN at baseline; patients with glucose intolerance should be on a stable regimen and be monitored
3739,NCT02302235,15:29:treatment,non-cytotoxic hormonal agent
3740,NCT02301611,"1:13:treatment,,",Vaccinations initiated between 3 weeks and 3 months from completion of SoC multi-modality cancer care
3741,NCT02299414,7:26:chronic_disease,Known major fetal anomaly
3742,NCT02298504,30:42:chronic_disease,Pediatric patients with deep dental decay in primary molars
3743,NCT02296684,15:24:cancer,Patients with sinonasal SCCAs
3744,NCT02293096,1:23:chronic_disease,end stage liver disease
3745,NCT02291978,15:39:chronic_disease,Patients with inflammatory arthritides
3746,NCT02290951,1:37:treatment,Allogeneic stem cell transplantation
3747,NCT02290028,10:15:treatment,Standard CRT-D indication according to clinical routine
3748,NCT02287337,1:44:treatment,Prior surgery to the neck or thoracic spine
3749,NCT02285101,"8:31:treatment,",Use of investigational drug(s) within 4 weeks of enrollment
3750,NCT02281409,12:26:cancer,metastatic gastric cancer
3751,NCT02278315,",,97:109:treatment",25% increase in bone marrow plasma cell percentage from lowest response value during (or after) last therapy
3752,NCT02278315,",,47:69:treatment","Platelet count < 100,000/uL without full-dose anticogulation therapy"
3753,NCT02278250,",23:53:treatment",More than 6 cycles of prior therapy with carboplatin
3754,NCT02277613,14:61:chronic_disease,Diagnosis of non-ST elevation myocardial infarction (NSTEMI)
3755,NCT02276443,",,69:96:chronic_disease",Patients who have history of PR prolongation (grade 2 or higher) or atrioventricular (AV) block
3756,NCT02273375,47:71:cancer,Histologically confirmed diagnosis of primary non-small cell carcinoma of the lung
3757,NCT02273375,1:66:treatment,Pre-operative (neo-adjuvant) platinum based or other chemotherapy is not permissible
3758,NCT02273362,19:43:treatment,An indication for surgical liver resection
3759,NCT02272998,28:43:cancer,Patients with an inherited cancer syndrome or a medical history suggestive of an inherited cancer syndrome remain eligible
3760,NCT02272556,1:19:chronic_disease,Bleeding Disorders
3761,NCT02272218,"1:35:treatment,,",anterior-posterior (AP) radiograph of both knees with K-L grade < 2
3762,NCT02272049,12:24:chronic_disease,History of heart defect
3763,NCT02271711,1:25:cancer,Extra-cranial metastasis
3764,NCT02270970,"1:23:chronic_disease,",Herpes zoster outbreak within three months of dosing
3765,NCT02270619,1:36:treatment,non-steroid anti-inflammatory drugs
3766,NCT02269293,46:58:treatment,Patients must be willing and able to swallow oral tablets
3767,NCT02268448,18:66:chronic_disease,Known history of central or peripheral nervous system dysfunction
3768,NCT02268253,",,,67:79:treatment,",Serum albumin ?3.2 g/dL (or ?32 g/L) in the absence of receipt of (IV) albumin within the previous 72 hours
3769,NCT02266784,32:48:chronic_disease,Has a primary diagnosis of any Axis II Disorder
3770,NCT02266329,26:67:treatment,Current participation in transcranial magnetic stimulation studies
3771,NCT02266329,1:31:chronic_disease,Structural brain abnormalities on any prior imaging with associated clinically evident manifestations
3772,NCT02265315,"8:26:treatment,",Stable medication therapy for at least 3 months
3773,NCT02264678,22:45:treatment,Contra-indicated for treatment with olaparib
3774,NCT02264678,1:38:cancer,head and neck squamous cell carcinoma
3775,NCT02262832,1:26:chronic_disease,Generalized lipodystrophy (either congenital or acquired)
3776,NCT02261558,6:15:cancer,past cancer(s)
3777,NCT02261519,"15:35:treatment,",The subject's anti-EPS medications dose or regimen has changed within 2 weeks prior to screening
3778,NCT02260856,49:63:treatment,Skeletally immature requiring isolated complete epiphysiodesis of the distal femur and/or proximal tibia
3779,NCT02259621,1:25:cancer,Squamous or non-squamous histology
3780,NCT02257424,"37:71:treatment,",Patients must not receive any other investigational anticancer therapy during the period on study or the four weeks prior to entry
3781,NCT02255383,1:24:chronic_disease,Neuropathic arthropathy
3782,NCT02255383,73:107:treatment,the salvage of previously failed surgical attempts that did not include partial or total knee arthroplasty of the ipsilateral knee
3783,NCT02254863,16:35:treatment,Requirement of ventilatory support
3784,NCT02253316,1:22:chronic_disease,secondary amyloidosis
3785,NCT02252432,15:42:treatment,scheduled for elective lumbar laminectomy
3786,NCT02251431,1:27:chronic_disease,Collagen vascular diseases
3787,NCT02251431,1:22:treatment,Renal transplantation
3788,NCT02249520,40:49:treatment,Outpatient undergoing standard-of-care 18FDG-PET at S. Mark Taper Foundation Imaging Center at CSMC
3789,NCT02249039,1:9:chronic_disease,Asphyxia
3790,NCT02245841,1:5:treatment,IVIG
3791,NCT02245841,1:31:chronic_disease,amyopathic dermatomyositis(AD)
3792,NCT02245841,1:22:treatment,mycophenolate mofetil
3793,NCT02244814,16:36:chronic_disease,diagnosed with Gestational diabetes according to the criteria established by the American College of Obstetricians and Gynecologists
3794,NCT02243813,23:52:treatment,Agree not to take any Pro-re-nata (PRN) medications on the mornings of drug sessions
3795,NCT02243631,1:5:chronic_disease,CPPD diagnosed by Ryan /McCarty criteria
3796,NCT02242526,"1:9:chronic_disease,,",Upper GI with a documented hiatal hernia greater than 5cm
3797,NCT02240498,45:48:treatment,Approval by the primary care team to pursue PDT and discuss enrollment with the patient
3798,NCT02240498,1:10:chronic_disease,abscesses not amenable to safe percutaneous image-guided drainage
3799,NCT02236377,8:30:chronic_disease,recent parasuicidal behaviors
3800,NCT02236013,16:45:chronic_disease,Subject has an active uncontrolled infection
3801,NCT02236000,52:77:chronic_disease,other disease or condition significantly affecting gastrointestinal function
3802,NCT02234934,13:37:cancer,Evidence of active malignant disease
3803,NCT02234934,"9:22:treatment,,",Resting O2 saturation by pulse oximetry < 90% on room air
3804,NCT02234557,1:45:chronic_disease,Comorbid oppositional defiant disorder (ODD) and simple phobias are permitted
3805,NCT02234193,22:53:treatment,scheduled to undergo elective abdominoplasty surgery at MGH
3806,NCT02233868,1:19:treatment,antianginal agents
3807,NCT02233868,1:15:treatment,antihistamines (sedating)
3808,NCT02232516,1:38:cancer,Adult T-cell lymphoma/leukemia (ATLL)
3809,NCT02232516,1:17:cancer,NK-cell leukemia
3810,NCT02232516,1:37:cancer,T-cell granular lymphocytic leukemia
3811,NCT02232516,1:44:cancer,anaplastic large cell kinase (ALK)-negative
3812,NCT02232165,1:22:chronic_disease,"Central cord syndrome, defined as ASIA C or D with mean lower extremity score greater than upper extremity score"
3813,NCT02230605,9:33:treatment,Planned postoperative intubation
3814,NCT02229565,11:40:cancer,Suspected malignancy of prostate cancer
3815,NCT02226341,1:23:chronic_disease,Active lupus nephritis
3816,NCT02226159,20:40:chronic_disease,Active progressive neurological deficit
3817,NCT02225548,21:38:chronic_disease,Subject with active peptic ulceration
3818,NCT02223520,29:38:chronic_disease,Parent(s) test positive for S. aureus at screening
3819,NCT02222545,24:35:treatment,Have a positive direct Coombs test
3820,NCT02219711,1:19:treatment,Standard treatment is not available
3821,NCT02219581,21:53:treatment,Patients undergoing primary total joint arthroplasty of the knee
3822,NCT02219555,38:60:chronic_disease,patient have a clinical diagnosis of carpal tunnel syndrome
3823,NCT02217709,1:42:treatment,Post-primary androgen-deprivation therapy
3824,NCT02216227,25:34:allergy_name,Documented allergies to mupirocin
3825,NCT02215096,"1:24:treatment,,","Investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to enrollment"
3826,NCT02214667,1:26:chronic_disease,schizophreniform disorder
3827,NCT02214550,20:52:cancer,presence of active pelvic or abdominal malignancies (primary or metastatic)
3828,NCT02213068,1:4:chronic_disease,EBV seropositive
3829,NCT02213068,17:31:chronic_disease,Recipients with EBV serostatus negative or unknown
3830,NCT02210650,1:28:chronic_disease,primary hyperparathyroidism
3831,NCT02210078,"15:32:chronic_disease,,",Patients with active acute GVHD grades II-IV
3832,NCT02209636,11:28:treatment,Not using phosphate binders
3833,NCT02208362,",,162:173:treatment",Research participant does not require supplemental oxygen to keep saturation greater than 95% and/or does not have presence of any radiographic abnormalities on chest x-ray that are progressive
3834,NCT02207465,1:17:cancer,Nodal metastases beyond the field of resection Borderline resectable
3835,NCT02207465,19:39:chronic_disease,Unreconstructible SMV/portal occlusion
3836,NCT02207439,",,,,,208:225:treatment","women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, during study, until 1 month after completion of the final FMISO PET/CT scan"
3837,NCT02204956,1:43:treatment,Mini-Mental State Examination (MMSE: [45])
3838,NCT02204098,1:22:treatment,Investigational agent
3839,NCT02203903,"4:29:treatment,","No investigational therapies (under IND, not extensively studied in the current clinical context) within the last 28 days"
3840,NCT02203513,21:25:cancer,A family history of HBOC is defined by NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian guideline
3841,NCT02203513,19:48:chronic_disease,Stable persistent grade 2 peripheral neuropathy may be allowed as determined on a case-by-case basis at the discretion of the PI
3842,NCT02202369,36:56:treatment,Subjects undergoing a single level lumbar decompression and fusion
3843,NCT02200445,16:43:allergy_name,Allergy to any component of the study drug
3844,NCT02199236,"17:34:treatment,,,,","Able to receive HDR brachytherapy ANC ? 1.5 cells/mm3 and PLT ?100,000/mm3"
3845,NCT02196038,",57:61:chronic_disease","In the hospital setting >24 hours for the management of ADHF, or diagnosed with ADHF after being hospitalized for another reason"
3846,NCT02195232,20:64:chronic_disease,Known diagnosis of disseminated intravascular coagulation (DIC)
3847,NCT02193932,1:20:chronic_disease,"Refractory epilepsy cases, referred by the service of Neurology"
3848,NCT02193490,13:30:allergy_name,Allergic to Deoxyribonuclease eye drops or any similar products
3849,NCT02192398,",,,27:41:treatment","VAS score of 4-8, despite opioid therapy"
3850,NCT02192359,48:100:treatment,Prospective participant is unable to undergo a magnetic resonance imaging (MRI) with contrast agent
3851,NCT02189889,32:35:allergy_name,have known hypersensitivity to EPO or any of its components
3852,NCT02189798,90:117:treatment,"Unrealistic expectations regarding potential benefits, risks and limitations inherent to implant surgical procedures as determined by the investigator"
3853,NCT02188745,1:23:chronic_disease,deep venous thrombosis
3854,NCT02187848,22:46:allergy_name,Known intolerance to infused protein products
3855,NCT02187198,11:31:treatment,ever used heroin intravenously
3856,NCT02186418,",,124:137:treatment",All participants of reproductive potential must agree to a contraceptive method for a period of no less than one year post gene transfer
3857,NCT02184520,1:21:chronic_disease,Acute mental illness or substance abuse
3858,NCT02181478,16:55:treatment,Candidates for reduced intensity conditioning regimens
3859,NCT02181257,1:8:chronic_disease,Aphakia or absence of ocular lenses
3860,NCT02180412,87:108:chronic_disease,Diagnosis of acute porphyria documented by a substantial increase in urinary or serum porphobilinogen (PBG)
3861,NCT02180412,"1:19:treatment,",Therapy with hemin within 7 days prior to enrollment in this study
3862,NCT02179853,"11:26:treatment,",Use of an IL-1 antagonist within the 3 months prior to enrollment
3863,NCT02178566,35:47:allergy_name,Known hypersensitivity to inhaled nitric oxide
3864,NCT02177838,8:53:treatment,use of highly active anti-retroviral therapy (HAART) is allowed
3865,NCT02177695,24:76:treatment,have tumor tissue from transurethral resection of the bladder tumor (TURBT) available for submission that is sufficient for COXEN testing and must agree to submission of 20 (10 micron) slides plus 2 (5 micron) slides from the start and end of the 20 slides for a total of 22 unstained slides
3866,NCT02176967,20:45:cancer,Only patients with MYCN non-amplified tumors
3867,NCT02176902,27:46:treatment,Patient elects to undergo active surveillance
3868,NCT02176161,1:28:treatment,oral glucocorticoid therapy
3869,NCT02174016,12:38:chronic_disease,History of inborn error of metabolism
3870,NCT02172651,21:43:cancer,History of prior or synchronous malignancy
3871,NCT02171104,1:21:chronic_disease,Adrenoleukodystrophy with cerebral involvement
3872,NCT02171104,1:23:chronic_disease,CoA-Oxidase Deficiency
3873,NCT02171104,1:33:chronic_disease,Glycoprotein Metabolic Disorders
3874,NCT02171104,1:33:chronic_disease,MPS VI (Maroteaux-Lamy syndrome)
3875,NCT02171104,1:32:chronic_disease,Mucopolysaccharidosis Disorders
3876,NCT02171104,1:22:chronic_disease,Peroxisomal Disorders
3877,NCT02169830,18:27:treatment,Patient is using marijuana for medical or other uses
3878,NCT02169739,"10:24:chronic_disease,",Clinical lacunar stroke syndrome within the past 6 months
3879,NCT02169089,1:41:chronic_disease,Class III or IV Congestive Heart Failure
3880,NCT02169089,1:27:chronic_disease,Primary Hyperaldosteronism
3881,NCT02169037,9:32:chronic_disease,extreme left atrial enlargement
3882,NCT02169037,"1:21:treatment,,",oral anticoagulation required for those subjects who have a score of two or more based on the following criteria (CHAD score)
3883,NCT02167958,1:16:cancer,Acute Leukemias in 2nd or subsequent remission
3884,NCT02167022,1:11:chronic_disease,spastic CP confirmed by a pediatric neurologist or pediatric rehabilitation specialist
3885,NCT02167009,",60:89:treatment",Patient has a prostate size larger than 90g as measured by transrectal ultrasound (TRUS)
3886,NCT02166905,"18:82:treatment,",Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dosing of study drug
3887,NCT02165449,"15:43:treatment,",No changes in antidepressant medication(s) in the past one (1) month
3888,NCT02164734,18:21:chronic_disease,Mild-to-moderate RDS
3889,NCT02163317,"42:84:treatment,",have a history/physical examination with digital rectal examination of the prostate within 90 days prior to screening
3890,NCT02162420,1:56:chronic_disease,Dyskeratosis Congenita (DC) with evidence of BM failure
3891,NCT02162420,17:49:chronic_disease,With or without clonal cytogenetic abnormalities
3892,NCT02162420,1:17:cancer,oral leukoplakia
3893,NCT02162420,1:22:treatment,transfusion dependent
3894,NCT02161211,1:33:chronic_disease,cognitive or physical impairment that precludes study participation
3895,NCT02160288,28:43:chronic_disease,Presence of full thickness rectal prolapse
3896,NCT02159703,75:89:cancer,Presence of close (2 mm) or positive margins PNI on TORS resection of the primary cancer
3897,NCT02159560,21:45:treatment,Contraindication to epidural catheterization
3898,NCT02159495,104:138:treatment,"Related donor selection will be conducted in accordance with City of Hope's Department of Hematology & Hematopoietic Cell Transplantation criteria and, in the case of unrelated donor from a transplant center, will comply with the National Marrow Donor Program's (NMDP) donor selection standards"
3899,NCT02159027,1:17:cancer,"Kaposi's sarcoma restricted to the skin, unless subject considered cured"
3900,NCT02158858,",,44:70:treatment",ANC ? 1 x 10^9/L without the assistance of granulocyte growth factors
3901,NCT02158858,38:40:cancer,Patients with confirmed diagnosis of MF
3902,NCT02158793,112:130:treatment,"Willingness to participate in ongoing psychiatric, psychological and social work evaluations prior to and post-transplant surgery"
3903,NCT02155699,7:24:chronic_disease,other physical disorder that could affect brain functioning
3904,NCT02152995,18:39:treatment,Current use of a prohibited medication
3905,NCT02152995,",30:54:treatment",The presence of at least one fluorodeoxyglucose (FDG) avid lesion
3906,NCT02152995,",35:54:treatment",thyroid-stimulating hormone [TSH] suppressive therapy
3907,NCT02152956,38:60:treatment,patients with relapsed disease after flotetuzumab treatment
3908,NCT02150967,1:20:treatment,BGJ398/infigratinib (all cohorts)
3909,NCT02148796,49:63:allergy_name,Participant has known sensitivity to any of the study products and any of the ingredients to be administered
3910,NCT02148796,1:38:chronic_disease,chronic gastroesophageal reflux (GER) requiring medical treatment
3911,NCT02148263,13:54:treatment,Able to use Opti-Free PureMoist contact lens solution
3912,NCT02148003,41:56:chronic_disease,Subjects who have an active systemic or local infection
3913,NCT02145351,9:33:chronic_disease,Chronic stable exertional angina
3914,NCT02145260,"1:11:chronic_disease,",Chronic HD (>90 days)
3915,NCT02143830,1:31:cancer,Myelodysplastic Syndrome (MDS)
3916,NCT02143726,21:85:treatment,Chronic concomitant treatment with strong inhibitors of cytochrome P450 3A4 (CYP3A4)
3917,NCT02143726,"13:37:treatment,",Patients on strong CYP3A4 inhibitors must discontinue the drug for 14 days prior to registration on the study
3918,NCT02143726,",43:61:treatment",who have received greater than 600 mCi of radioactive iodine in their lifetime
3919,NCT02141919,42:61:treatment,Subjects must not have received previous abdominal radiation
3920,NCT02141074,"36:59:treatment,",Previously untreated or exposed to FIX containing products less than or equal to 3 exposure days (5 previous exposures to blood components is acceptable)
3921,NCT02140554,"18:69:treatment,",Participation in another clinical study with an investigational drug within 30 days of Screening
3922,NCT02140255,"1:19:chronic_disease,","Maternal infection must be confirmed, with confirmatory results available within 10 business days of enrollment"
3923,NCT02139436,1:30:chronic_disease,peripheral nerve compressions or rotator cuff tears that limit ability to row
3924,NCT02138669,1:24:treatment,isotretinoin (Accutane)
3925,NCT02138617,20:37:treatment,Willing to undergo UGT1A1 genotyping
3926,NCT02138214,1:9:cancer,T4 tumor
3927,NCT02135874,15:42:cancer,Patients with active secondary malignancy will not be eligible unless approved by the principal investigator
3928,NCT02135588,1:39:chronic_disease,Traumatic hemorrhagic pleural effusion
3929,NCT02134392,48:52:allergy_name,Recent ingestion of a potential allergen (e.g. nuts) where recipient has a known allergy to this (these) agent(s)
3930,NCT02134392,1:23:chronic_disease,electrolyte imbalances on basic metabolic panel
3931,NCT02133898,1:32:treatment,Electroconvulsive Therapy (ECT) failure in past
3932,NCT02133885,",49:73:chronic_disease",More than one in-patient hospitalization for an anti-hypertensive crisis within the year
3933,NCT02133573,",,,,110:130:treatment",History of preterm birth or short cervix (defined as cervical length ? 25 mm at 18-24 weeks GA necessitating progesterone therapy
3934,NCT02133196,",16:44:treatment",Greater than 2 invasive thoracic procedures
3935,NCT02132130,77:101:treatment,Abnormal vital signs and/or ECG that suggest potential contraindication for planned study anesthesia
3936,NCT02132130,1:18:chronic_disease,Meniere's Disease
3937,NCT02132130,1:25:chronic_disease,central auditory lesions
3938,NCT02131467,21:31:allergy_name,Hypersensitivity to perampanel
3939,NCT02131467,1:11:treatment,nevirapine
3940,NCT02131389,5:22:chronic_disease,Has hip joint disease related to one or more
3941,NCT02130687,16:29:treatment,Treatment with lithium salts
3942,NCT02128906,47:67:cancer,Patients with a history of curatively-treated non-HNSCC malignancy
3943,NCT02128230,53:66:chronic_disease,lower levels are explained by extensive bone marrow plasmacytosis
3944,NCT02127398,1:19:chronic_disease,Short gut syndrome requiring total parenteral nutrition
3945,NCT02125786,1:31:treatment,Prior craniospinal irradiation
3946,NCT02124772,16:29:treatment,"Any prohibited medication(s), currently used or expected to be required"
3947,NCT02124772,68:95:treatment,Must have a disease that is relapsed/refractory to all potentially curative standard treatment regimens
3948,NCT02124174,1:35:chronic_disease,Active and uncontrolled infections will cause patients to be excluded
3949,NCT02122328,1:22:chronic_disease,Dandy-Walker syndrome
3950,NCT02122328,1:18:chronic_disease,holoprosencephaly
3951,NCT02122185,",,,,79:107:cancer",carcinoembryonic antigen (CEA) ratio > 25 OR CA125 =< 250 with no evidence of gastrointestinal (GI) cancer
3952,NCT02122081,"29:103:treatment,",Interval between completing treatment with a hypomethylating agent or other non-cytotoxic chemotherapy and the start of conditioning regimen must be at least 10 days
3953,NCT02121158,45:61:chronic_disease,Irreversible brain damage from pre-existing cerebral disease
3954,NCT02121158,12:20:chronic_disease,documented prior MI
3955,NCT02120222,1:20:chronic_disease,Serious psychiatric or medical conditions that could interfere with treatment
3956,NCT02115685,1:27:chronic_disease,bladder or other infection
3957,NCT02115295,",,,,,,133:153:cancer,,,,,","Adequate organ function as defined below: liver function (bilirubin </=2mg/dL, AST and/or ALT </=3 x ULN- or <5 x ULN if related to leukemic involvement), kidney function (creatinine </=1.5 x ULN ), known cardiac ejection fraction of > or = 45% within the past 6 months"
3958,NCT02111850,1:9:treatment,Serology
3959,NCT02110992,1:37:cancer,Primary tumors of the salivary gland
3960,NCT02110069,"1:26:chronic_disease,,,,","Kasabach Merritt Syndrome defined at a platelet counts less than 50,000 K/µl and/or fibrinogen level < 100 mg/dl at the time of diagnosis"
3961,NCT02109627,1:42:cancer,Acute promyelocytic leukemia (FAB M3 AML)
3962,NCT02109081,",,65:90:chronic_disease",MMSE score of ? 20 out of 30 on preoperative testing (more than mild cognitive impairment) or delirium on preoperative CAM testing
3963,NCT02108860,"1:34:treatment,,",Treatment with methylprednisolone 1000 mg within 28 days prior to enrollment
3964,NCT02107703,"32:84:treatment,",approved Receptor activator of nuclear factor kappa-B (RANK) ligand targeted agents <7 days prior to randomization
3965,NCT02106988,43:65:treatment,with active infections requiring specific anti-infective therapy are not eligible until all signs of infections are resolved
3966,NCT02106598,1:28:chronic_disease,chronic renal insufficiency
3967,NCT02106052,24:58:chronic_disease,History of significant developmental or learning disorder that may affect participation and confound interpretation of study results
3968,NCT02105766,",,103:113:treatment,",Red cell alloimmunization/ Transfusion dependent/ Total hemoglobin increases less than 1g/dL while on hydroxurea (hydroxurea for at least 6 months)
3969,NCT02105545,30:44:cancer,Subjects for whom sufficient cancer tissues are not available to meet the objectives of the study
3970,NCT02101944,",,,,134:159:treatment",Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL prior to starting therapy and prior to beginning another cycle
3971,NCT02101944,13:44:cancer,Presence of clonal bone marrow plasma cells
3972,NCT02101853,60:88:treatment,No waiting period for patients who relapse while receiving standard maintenance therapy
3973,NCT02101736,"31:51:chronic_disease,",Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
3974,NCT02101736,1:23:cancer,Plexiform neurofibroma that is progressive OR causing significant morbidity
3975,NCT02100956,"1:17:chronic_disease,",Neuropathic pain for > 6 months
3976,NCT02100891,30:50:treatment,Patients who have received a prior allogeneic HCT are ineligible
3977,NCT02099240,67:98:treatment,Isolation of an organism from bone culture that is susceptible to intravenous and oral antibiotic
3978,NCT02099058,17:42:treatment,Subjects in the combination therapy Arm E
3979,NCT02098252,16:25:chronic_disease,patient with a brain AVM
3980,NCT02095808,"46:81:cancer,,","Patients must have suspicious or known to be malignant solitary pulmonary nodule,5cm or less in size"
3981,NCT02095678,61:75:treatment,Patients with ferromagnetic or otherwise non-MRI compatible aneurysm clips
3982,NCT02094794,43:72:treatment,"All candidates for this study must have a human leukocyte antigen (HLA) (A, B, C, DR) identical siblings who is willing to donate bone marrow or primed blood stem cells or a 10/10 allele matched unrelated donor"
3983,NCT02094118,28:53:treatment,No plan for placement of a pulmonary artery catheter
3984,NCT02092324,15:39:chronic_disease,Subjects with end stage renal function
3985,NCT02091999,8:29:chronic_disease,Active Hepatitis C infection
3986,NCT02091999,28:80:treatment,Subject must have received prior treatment with a CPI in the metastatic setting
3987,NCT02091141,42:83:allergy_name,Known allergy or hypersensitivity to any component of the atezolizumab formulation
3988,NCT02091141,1:90:treatment,Previous treatment with atezolizumab or another programmed death-1 (PD-1)/PD-L1 inhibitor
3989,NCT02089607,31:54:treatment,"In such a situation, multiple extra-anatomic bypasses may be necessary"
3990,NCT02089607,24:38:chronic_disease,Left (or right) common carotid artery
3991,NCT02089607,46:66:chronic_disease,Presence of concomitant thoracoabdominal and aortic arch aneurysm meeting one of the above-mentioned criteria
3992,NCT02089607,"1:33:chronic_disease,,",Thoracoabdominal aortic aneurysm with a diameter ? 5.5 cm or 2 times the normal aortic diameter
3993,NCT02088554,1:47:chronic_disease,Hypertrophic obstructive cardiomyopathy (HOCM)
3994,NCT02088554,"15:55:chronic_disease,,","Patient has a non-cardiac major or progressive disease, with a life expectancy of less than 2 years"
3995,NCT02088554,1:16:cancer,Terminal cancer
3996,NCT02086448,14:37:chronic_disease,diagnosis of pregestational diabetes
3997,NCT02081404,1:24:treatment,Chronic anticoagulation
3998,NCT02081404,18:36:treatment,Prior history of esophageal surgery
3999,NCT02079857,48:71:treatment,Individuals currently receiving other types of complementary therapies
4000,NCT02078102,33:65:treatment,Patients must not have received prior bone seeking radionuclides
4001,NCT02076906,1:20:cancer,Lesion in the skull
4002,NCT02076906,22:55:treatment,The last dose of all myelosuppressive anticancer drugs
4003,NCT02075671,23:45:chronic_disease,Clinical diagnosis of papulopustular rosacea based on physician evaluation
4004,NCT02075671,"8:31:treatment,",Use of topical corticosteroids (on the face) 1 month prior to Visit 1
4005,NCT02074631,22:37:cancer,History of a primary bone malignancy involving the lumbar spine
4006,NCT02074436,"1:35:treatment,",Hematopoietic stem cell transplant recipient within 100 days post-transplant
4007,NCT02073292,1:28:chronic_disease,Systemic or local infection
4008,NCT02070549,1:18:cancer,Colorectal cancer patients
4009,NCT02069899,38:45:treatment,Having received at least one dose of NI-0501
4010,NCT02067819,100:115:treatment,"Other dental health problems that might interfere with the assessment, installation, or wearing of orthotic device"
4011,NCT02064296,"1:12:treatment,",Acupuncture within last 6-months
4012,NCT02064036,32:49:allergy_name,Prior allergic reaction to the hormones involved in this protocol
4013,NCT02063438,10:21:treatment,Previous thoracotomy on the operative side
4014,NCT02061293,6:10:chronic_disease,with SCID (DSM-IV) diagnosis of alcohol dependence who
4015,NCT02059239,1:28:treatment,Prior autologous transplant
4016,NCT02058095,1:40:chronic_disease,Obstructive Hypertrophic cardiomyopathy
4017,NCT02058095,1:10:treatment,Terazosin
4018,NCT02057133,156:217:treatment,"Have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study (for example, history of major surgical resection involving the stomach or small bowel)"
4019,NCT02056873,"43:69:treatment,,",Must be at minimum a single trial with an alpha-2 adrenergic agonist (0.1-0.3 mg/day)
4020,NCT02056470,16:32:treatment,Previous major knee replacement of the affected knee joint
4021,NCT02055053,20:44:chronic_disease,with unilateral or bilateral inguinal herna for laparoscopic repair
4022,NCT02053792,21:47:treatment,Currently receiving IV immunomodulating agents
4023,NCT02053792,36:64:treatment,Never previously been treated with FIX clotting factor products
4024,NCT02053792,20:104:treatment,subjects requiring major non-emergency surgery who have not previously completed a CSL-sponsored rIX-FP lead-in study
4025,NCT02053363,8:30:chronic_disease,Active intravascular clotting
4026,NCT02050347,"11:64:treatment,,",Available allogeneic activated peripheral blood T cell products with >=15% expression of CD19.CAR-CD28? determined by flow cytometry (cell dose is based on total cell numbers and not individual antileukemic cell numbers)
4027,NCT02050113,1:22:chronic_disease,Anaphylactic reaction to contrast that cannot be adequately pre-medicated
4028,NCT02050113,"12:22:treatment,,",For use of Zenith TX2: diameter >38 mm or <24 mm (for proximal and distal neck diameter)
4029,NCT02048722,26:38:cancer,Histologically confirmed angiosarcoma
4030,NCT02048332,",42:60:treatment",Recipient must be at least 28 days after stem cell infusion
4031,NCT02046330,1:32:chronic_disease,"Major Depression Disorder (MDD) diagnosed by Structured Clinical Interview for DSM-IV (SCID I/DSM-IV), judged to be of disabling severity"
4032,NCT02043548,",20:30:treatment",2 week washout for etanercept
4033,NCT02042222,70:89:treatment,"A decision by the subject's family and primary clinician to initiate hydroxyurea therapy, made independently of recruitment for the study (not applicable for the biological arm patients)"
4034,NCT02041936,29:50:treatment,Unable to be treated with a muscle blockade agent
4035,NCT02040610,"1:41:cancer,",Clinical stage T1-T2c (AJCC 7th edition) within 90 days of registration
4036,NCT02038257,12:26:chronic_disease,History of koebnerization (new patches of vitiligo at sites of injury or trauma)
4037,NCT02037048,27:39:cancer,Patients with evidence of clinical T4b (unresectable)
4038,NCT02036853,31:43:treatment,Patients are able to tolerate triheptanoin if they have been (or are currently being) treated with this medication
4039,NCT02035137,24:42:treatment,They have had previous I-131 MIBG therapy
4040,NCT02033616,82:107:cancer,"Successful establishment of an autologous epithelial ovarian, fallopian tube, or primary peritoneal cancer cell line by AIVITA Biomedical, Inc"
4041,NCT02031250,14:33:treatment,referred for definitive chemo?RT
4042,NCT02030015,33:42:allergy_name,Subjects who have an allergy to miglustat or any of the components within the drug product
4043,NCT02025465,"9:36:chronic_disease,,",Current Atrioventricular (AV) block (2nd or 3rd degree)
4044,NCT02021604,",96:121:treatment",Nursing mothers who are unwilling to discontinue breastfeeding their infant for 48 hours after Fluorodopa F 18 injection
4045,NCT02021279,26:45:cancer,"Subject has a history of pelvic organ cancer (e.g. uterine, ovarian, bladder, or cervical)"
4046,NCT02020707,45:72:cancer,histologic proof of surgically unresectable stage IV malignant melanoma
4047,NCT02020018,1:12:treatment,Thoracotomy
4048,NCT02019641,25:40:treatment,Active participation in ILD drug trials
4049,NCT02019641,13:41:chronic_disease,Significant hepatic or renal dysfunction
4050,NCT02016781,27:34:treatment,"No intent to proceed with alloHCT using donor sources not specified in this protocol, including human leukocyte antigen (HLA)-mismatched related or unrelated donors"
4051,NCT02016781,1:17:treatment,Prior autologous
4052,NCT02016781,1:56:chronic_disease,Refractory cytopenia with multilineage dysplasia (RCMD)
4053,NCT02015390,28:45:allergy_name,Known allergic reaction to titanium implants
4054,NCT02013492,63:85:cancer,Patients must have histologically-proven locally-recurrent or metastatic solid tumor
4055,NCT02013154,1:46:treatment,Previously treated with an anti-DKK-1 therapy
4056,NCT02012296,",44:96:treatment",a minimum washout of 28 days for any other anticancer therapy prior to first dose of study drug is required (only applicable for phase I)
4057,NCT02011971,18:36:treatment,Use of centrally active medications
4058,NCT02008656,1:24:cancer,Recurrent rectal cancer
4059,NCT02007239,13:44:chronic_disease,Evidence of cytokine release syndrome (CRS)
4060,NCT02007239,"29:49:treatment,",must be planned to initiate HLH-directed therapy within 24 hours of study enrollment
4061,NCT02004275,2:5:chronic_disease,#NAME?
4062,NCT02004275,1:27:chronic_disease,Pomalidomide naive disease
4063,NCT02004028,18:40:chronic_disease,Known history of malignant hypertension
4064,NCT02003222,1:27:treatment,ALLOGENEIC TRANSPLANTATION
4065,NCT02003222,8:39:cancer,Mature B ALL (Burkitt's-like leukemia)
4066,NCT02003222,"11:42:treatment,",pre-study bone marrow biopsy and aspirate must be completed =< 1 week prior to registration
4067,NCT02000115,5:46:chronic_disease,has senile degenerative aortic valve stenosis with echocardiographically derived criteria
4068,NCT01996449,1:14:treatment,phenylephrine
4069,NCT01994382,1:22:cancer,Burkitt-like Lymphoma
4070,NCT01994382,1:19:cancer,Richter's syndrome
4071,NCT01993810,"46:74:treatment,",non-operable disease will be determined by a multi-disciplinary treatment team within 60 days prior to registration
4072,NCT01990495,"24:42:treatment,",undergoing maintenance hemodialysis (MHD) for at least three months and without other active/uncontrolled disease will be studied
4073,NCT01990209,15:46:cancer,Patients with metastases limited to the bones
4074,NCT01989585,16:26:treatment,Miscellaneous: conivaptan
4075,NCT01989507,49:69:treatment,actively quitting smoking or current use of any nicotine replacement or other smoking cessation treatment
4076,NCT01988246,28:47:treatment,Patients who have received corneal transplants in the study eye
4077,NCT01983475,"1:37:treatment,",Anabolic or Steroid hormonal therapy; within the past year and longer than six months
4078,NCT01980043,1:71:treatment,Previous Abdominal Surgeries including abdominal wall repair with mesh
4079,NCT01978509,1:16:chronic_disease,Toxic megacolon
4080,NCT01976429,12:36:treatment,history of ossicular reconstruction
4081,NCT01974609,32:63:chronic_disease,patients with other medical or psychological health conditions that preclude then from receiving either intervention or returning for follow-up visits
4082,NCT01973283,37:52:chronic_disease,Patient is considered a significant risk of suicide
4083,NCT01972113,21:70:chronic_disease,Subjects presenting chronic degenerative and/or inflammatory diseases
4084,NCT01970306,26:33:chronic_disease,Pathologically confirmed Gastric
4085,NCT01969643,"18:39:cancer,","Combination Arm: HER2-positive disease and received at least 2 prior cytotoxic regimens in the incurable, unresectable, LA/MBC setting (not enrolling new patients)"
4086,NCT01968590,1:31:treatment,anti-epileptic medical therapy
4087,NCT01968590,"1:26:treatment,",oral or IV glucocorticoid use for over 3 months
4088,NCT01967238,1:4:allergy_name,Egg allergy
4089,NCT01966367,42:65:cancer,Additional eligibility for patients with non-malignant disorders receiving reduced intensity conditioning
4090,NCT01964859,11:27:chronic_disease,An active nonhealing wound
4091,NCT01964261,1:28:chronic_disease,High cervical spinal lesion
4092,NCT01962415,",,,,,,323:356:treatment","A 4/6, 5/6 or 6/6 HLA matched related or unrelated UCB unit available that will deliver a pre-cryopreservation total nucleated cell dose of ? 3 x 10e7 cells/kg, or double unit grafts, each cord blood unit delivering at least 2 x 10e7 cells/kg OR an 8 of 8 or 7 of 8 HLA allele level matched unrelated donor bone marrow or peripheral blood progenitor graft"
4093,NCT01962415,1:8:chronic_disease,Chediak
4094,NCT01962415,1:51:chronic_disease,Congenital Amegakaryocytic Thrombocytopenia (CAMT)
4095,NCT01962415,2:16:chronic_disease,Gaucher Disease
4096,NCT01962415,1:24:chronic_disease,Hurler syndrome (MPS I)
4097,NCT01962415,1:17:chronic_disease,Leukodystrophies
4098,NCT01962415,1:15:chronic_disease,Omenn Syndrome
4099,NCT01962415,"1:29:treatment,,,,,,",Pulmonary evaluation testing demonstrating CVC or FEV1/FVC of ? 50% of predicted for age and/or resting pulse oximeter ? 92% on room air or clearance by the pediatric or adult pulmonologist
4100,NCT01962415,1:26:chronic_disease,Sickle cell disease (SCD)
4101,NCT01962415,1:19:chronic_disease,alpha mannosidosis
4102,NCT01961557,16:41:chronic_disease,Diagnosed with knee extension deficiency as indicated by a crouched posture during gait lacking
4103,NCT01959698,7:40:treatment,Prior high-dose chemotherapy (HDC)-ASCT
4104,NCT01954576,166:176:cancer,"Because the genetic analyses described in Section 8.0 will be performed under HRPO# 201111001 (Analysis of Histological, Genomic, Molecular, and Clinical Factors in CNS Cancer: the Neuro-Oncology Group), for patients enrolling in this trial at WUSM, it is required that WUSM patients must also enroll in HRPO# 201111001. The genetic analyses for UF patients will take place at WUSM under the auspices of this protocol"
4105,NCT01954173,1:38:treatment,Prior radiation therapy to the pelvis
4106,NCT01953900,1:30:chronic_disease,Severe intercurrent infection
4107,NCT01953575,28:56:chronic_disease,Medical conditions such as severe heart or lung disease that preclude safe performance of endoscopy
4108,NCT01953263,15:31:chronic_disease,Patients with vaginal prolapse beyond introitus
4109,NCT01952730,27:95:cancer,Histologically documented hepatic colorectal cancer metastasis with resectable hepatic lesions
4110,NCT01951885,1:15:cancer,Myelodysplasia
4111,NCT01950351,"1:21:cancer,",Clinical stage T1-2b (American Joint Committee on Cancer [AJCC] 7th edition) and PSA
4112,NCT01947140,68:83:cancer,Patients must have histologically confirmed relapsed or refractory T-Cell Lymphoma (as defined by WHO criteria)
4113,NCT01945814,15:41:chronic_disease,Patients with Grade 3 hyperbilirubinemia
4114,NCT01943851,",51:70:cancer",Consult the GSK Medical Monitor if unsure whether second malignancies meet requirements specified above
4115,NCT01942018,1:22:cancer,Esophageal malignancy
4116,NCT01942018,76:93:chronic_disease,Mechanical obstruction to esophageal outflow or infiltrative esophageal or gastric disorders
4117,NCT01941316,"36:58:chronic_disease,",All other required tests to assess non-measurable disease must be performed within 42 days prior to enrollment
4118,NCT01941316,1:17:treatment,Prior irinotecan
4119,NCT01940757,",39:75:treatment,",Pregnancy as determined by a positive urine human choriogonadotropin (hCG) (if female)
4120,NCT01937884,"25:44:treatment,",Anticipate placement of central venous line within 24 hours of admission
4121,NCT01937884,9:29:treatment,Require artificial nutrition
4122,NCT01931202,1:17:chronic_disease,Anxiety Disorder
4123,NCT01925573,1:18:chronic_disease,Blood coagulation parameters
4124,NCT01925131,",22:29:treatment",Patient is in second salvage or more
4125,NCT01925131,1:26:treatment,Pretreatment cytogenetics must be performed on all patients
4126,NCT01925131,15:32:cancer,patients with bilineal leukemia are excluded
4127,NCT01921634,1:22:treatment,Previous appendectomy
4128,NCT01920061,",4:78:treatment",>2 prior regimens containing cytotoxic chemotherapy in the metastatic setting
4129,NCT01919619,20:54:cancer,adequately treated basal or squamous cell skin cancer
4130,NCT01918683,10:43:treatment,Complete obstruction of portal venous flow to the segment of liver that includes the target lesion
4131,NCT01918644,13:41:cancer,early stage invasive carcinoma of breast
4132,NCT01917929,16:72:treatment,Patient has an existing total hip replacement on the contralateral side
4133,NCT01915095,"1:12:chronic_disease,",Chronic SCI ( 6 months of injury)
4134,NCT01913106,13:31:cancer,Symptomatic metastasis disease
4135,NCT01910818,",184:197:chronic_disease","The scars must be deemed stable for a period of 3 months or have a suitable contralateral control before initiation of treatment. This will be determined by objective measurements of scar erythema, pliability, induration, thickness at enrollment and again at 3 months"
4136,NCT01908777,1:48:cancer,Central nervous system or meningeal involvement
4137,NCT01908777,1:49:cancer,Primary cutaneous anaplastic large cell lymphoma
4138,NCT01906385,9:28:treatment,"Planned stereotactic biopsy as standard of care (ie, for confirmation of disease progression)"
4139,NCT01904136,"1:41:chronic_disease,",Central nervous system (CNS) involvement within 3 months
4140,NCT01902810,"12:42:chronic_disease,,",History of Congestive Heart Failure (CHF) (ejection fraction < 20%)
4141,NCT01901562,6:32:chronic_disease,Have bilateral nipple discharge
4142,NCT01898793,1:32:cancer,Isolated extramedullary relapse (phase II only)
4143,NCT01896999,",51:61:treatment,,",all females of childbearing potential must have a blood test or urine study within 24 hours prior to enrollment to rule out pregnancy
4144,NCT01895881,20:48:cancer,Known or suspected estrogen-dependent neoplasia
4145,NCT01895777,"1:13:treatment,,","Transfusions during the screening period are allowed, provided that a satisfactory hemoglobin or platelet level is attained prior to visit 2"
4146,NCT01894061,",53:100:treatment",3 weeks must have elapsed since the completion of a non-nitrosourea-containing chemotherapy regimen
4147,NCT01893554,31:34:chronic_disease,Currently enrolled in another RSV study
4148,NCT01893307,1:53:cancer,"Distant Metastases (Stage IV C, any T, any N and M1)"
4149,NCT01891812,1:20:chronic_disease,developmental delay
4150,NCT01890590,1:48:treatment,Prior upper abdominal external beam irradiation
4151,NCT01884740,",,136:150:treatment,,",Females of childbearing potential and fertile men will be informed as to the potential risk of procreation while participating in this research trial and will be advised that they must use effective contraception during and for a period of three months after the treatment period
4152,NCT01884740,1:40:cancer,anaplastic mixed oligoastrocytoma (AOA)
4153,NCT01883076,",71:104:treatment","Any condition requiring urgent, or unplanned procedure within 15 days prior to Stage II surgical repair"
4154,NCT01882153,111:128:chronic_disease,Receiving or will receive a parent delivered intervention to alleviate symptoms related to their diagnosis of autistic disorder
4155,NCT01877382,18:59:cancer,Has a history of primary central nervous system malignancy
4156,NCT01876511,28:49:cancer,Patients with MSI positive non-colorectal cancer
4157,NCT01876511,5:160:treatment,"had prior treatment with anti-PD-1 (anti-programmed cell death protein 1), anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX-40, anti-CD40, or anti-CTLA-4 antibodies"
4158,NCT01872975,1:21:treatment,Sentinel node biopsy alone
4159,NCT01871727,93:110:treatment,A shorter washout may be allowed if participant is experiencing progressive disease despite ongoing treatment
4160,NCT01871727,13:42:chronic_disease,Significant pulmonary symptoms or disease
4161,NCT01869114,",122:131:treatment",Pregnant or lactating patients are ineligible for this study due to the unknown human fetal or teratogenic toxicities of rapamycin
4162,NCT01865162,1:29:treatment,non-cytotoxic hormonal agent
4163,NCT01864265,"11:20:chronic_disease,,",Must have active RA with a DAS28 ?3.2
4164,NCT01864109,19:47:chronic_disease,in the absence of hepatic involvement of tumor
4165,NCT01859819,1:26:cancer,B-Lymphoblastic lymphomas
4166,NCT01858168,26:41:cancer,Histologically confirmed Ewing's sarcoma
4167,NCT01853163,26:56:treatment,Patient scheduled for an orthopaedic surgical procedure
4168,NCT01851694,1:31:treatment,Prior lung or liver transplant
4169,NCT01850758,11:14:chronic_disease,A massive ACL tear or one that includes more than 2/3'rds of the ligament that's retracted
4170,NCT01850355,28:43:chronic_disease,DSM-IV-TR PDD diagnoses of Rett's disorder
4171,NCT01849146,",,53:70:treatment",Pregnant women are excluded from this study because AZD1775 (MK-1775) has potential for teratogenic or abortifacients effects
4172,NCT01842399,1:13:treatment,Amphetamines
4173,NCT01841957,15:33:treatment,Candidate for topical anesthesia
4174,NCT01841333,"5:34:treatment,,","For non-myeloablative transplants, ?50% CD3 donor chimerism at screening"
4175,NCT01836354,1:4:chronic_disease,TIA based on a clinical definition of focal neurologic deficits consistent with a single vascular territory of the brain
4176,NCT01835626,",87:110:treatment","Recent (within 4 weeks of Registration), current, or planned participation in another experimental drug study"
4177,NCT01829958,1:21:chronic_disease,Ureteral compression
4178,NCT01823198,46:71:treatment,Failed to achieve a cytogenetic remission to tyrosine kinase inhibitor treatment or has a cytogenetic relapse
4179,NCT01822522,23:42:cancer,The participant has a primary brain tumor
4180,NCT01822522,25:46:chronic_disease,participants with known hepatitis B infection should be screened for active disease prior to study participation
4181,NCT01819480,21:34:cancer,Diagnosis of either oropharyngeal
4182,NCT01817751,18:38:chronic_disease,Known history of retinitis pigmentosa
4183,NCT01815359,1:45:chronic_disease,Restrictive or obstructive pulmonary disease that would limit study compliance or place the patient at unacceptable risk for participation in the study
4184,NCT01812174,21:51:chronic_disease,"Patients who have a noncardiac progressive disease, which in the investigator's experience produces an unacceptable increased risk to the patient"
4185,NCT01811368,"1:24:chronic_disease,,",Chronic viral hepatitis with total serum bilirubin > 3 mg/dL
4186,NCT01811368,36:64:chronic_disease,Patients with any of the following liver function abnormalities
4187,NCT01810588,35:71:cancer,Previously Relapsed or refractory acute leukemia (myeloid or lymphoid)
4188,NCT01809002,1:22:chronic_disease,Peripheral Neuropathy
4189,NCT01807897,"24:45:chronic_disease,","Physician diagnosis of chronic heart failure, American Heart Association Stage C-D"
4190,NCT01807091,27:57:treatment,The benefits/risks of the induction chemotherapy regimen will be reviewed
4191,NCT01804634,52:66:treatment,Patients who relapse after either single or tandem autologous BMT are eligible
4192,NCT01804465,14:132:treatment,A history of prior treatment with ipilimumab or prior cluster of differentiation 137 (CD137) agonist or CTLA-4 inhibitor or agonist
4193,NCT01802346,19:31:treatment,Concurrent use of somatostatin
4194,NCT01799538,14:17:chronic_disease,Diagnosis of LAM
4195,NCT01799538,1:14:treatment,tissue biopsy
4196,NCT01795313,"1:16:treatment,",Tetanus vaccine during therapy or within 1 week prior to enrollment
4197,NCT01794793,48:75:treatment,"Patient has been permanently discontinued from pasireotide study treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason"
4198,NCT01794559,24:50:chronic_disease,primary diagnosis of a DSM-IV depressive disorder
4199,NCT01791543,12:37:allergy_name,Allergy to radiographic contrast dye
4200,NCT01791543,1:23:chronic_disease,Ventricular arrhythmia is recurrent and symptomatic
4201,NCT01787682,"54:81:chronic_disease,,,","Clinically stable condition and not suffering from a respiratory tract infection or exacerbation of their disease (defined as a combination of increased cough, sputum purulence, shortness of breath, systemic symptoms such as fever, and a decrease in FEV1 > 10% compared with values when clinically stable in the preceding year) at least 4 weeks prior to the first test day"
4202,NCT01787682,"8:64:treatment,",Use of protein or amino acid containing nutritional supplements within 5 days of first study day
4203,NCT01787409,13:38:cancer,Dim surface immunoglobulin expression
4204,NCT01787409,26:100:treatment,patients can begin their chemotherapy while awaiting vitamin D results and treatment arm assignment
4205,NCT01782599,"19:53:treatment,,",Be willing to use Nicotine Replacement Therapy (NRT) and the e-cigarette for a period of 2 to 3 weeks
4206,NCT01776190,59:70:treatment,You will need to participate in four physician visits and blood draws
4207,NCT01774019,57:78:treatment,"Surgically altered biliary tract anatomy, not including prior cholecystectomy"
4208,NCT01773707,38:51:chronic_disease,Have serological evidence of current CMV infection
4209,NCT01773395,34:97:allergy_name,History of allergic reactions to compounds of similar chemical or biologic composition to GM-CSF
4210,NCT01766297,7:32:cancer,Known BRCA 1 or BRCA 2 mutation
4211,NCT01766297,39:55:cancer,Patient does not have microscopically multifocal tumor
4212,NCT01760655,",16:41:chronic_disease",Greater than 3 cytogenetic abnormalities or any one of the following cytogenetic abnormalities
4213,NCT01760005,"24:74:treatment,",Have been exposed to a monoclonal antibody targeting beta amyloid peptide within the past six months
4214,NCT01757418,9:17:treatment,current estrogen use
4215,NCT01756040,8:16:chronic_disease,Severe asphyxia
4216,NCT01754779,1:15:chronic_disease,Hypercalciuric CaP stone formers
4217,NCT01754298,14:18:chronic_disease,Diagnosis of JOCD
4218,NCT01753986,18:53:treatment,Participation in Batterer Intervention Program in RI
4219,NCT01750567,24:39:chronic_disease,Patient with confirmed del11q mutation may be included if untreated
4220,NCT01742299,48:66:treatment,"Patient has been permanently discontinued from imatinib treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason"
4221,NCT01737502,1:25:cancer,Non-melanoma skin cancer
4222,NCT01737502,1:26:cancer,localized prostate cancer
4223,NCT01734512,1:22:cancer,Pilocytic Astrocytoma - 90600112
4224,NCT01730794,1:10:chronic_disease,Hypoxemic or hypercapnic acute respiratory failure
4225,NCT01726257,30:43:treatment,Anatomic eligibility for the Nellix System per the instructions
4226,NCT01726257,1:12:chronic_disease,Psychiatric or other condition that may interfere with the study
4227,NCT01720836,1:15:cancer,Stage IA(T1NO)
4228,NCT01716806,",56:78:treatment",Measurable disease of at least 1.5 cm as documented by radiographic technique
4229,NCT01714596,48:59:treatment,Cultures positive in thio only after operative debridement
4230,NCT01714596,124:155:treatment,"Patients who, based upon the clinical judgment of the treating clinician, are NOT equally suited for treatment with either oral or intravenous antibiotics (i.e., those for whom there is a clinical treatment preference)"
4231,NCT01712308,"27:57:treatment,",Use of any MPN-associated myelofibrosis-directed therapy within 2 weeks prior to study day 1
4232,NCT01705119,9:32:treatment,who are mechanically ventilated
4233,NCT01703117,1:20:chronic_disease,Lactose intolerance
4234,NCT01703117,6:30:chronic_disease,with mild Alzheimer's disease determined after neurological and neuropsychological evaluation following the National Institute on Aging - Alzheimer's disease Association criteria that recently revisited the NINCDS-ADRDA criteria
4235,NCT01697865,1:18:chronic_disease,Advanced dementia
4236,NCT01697371,1:23:chronic_disease,Active liver infection
4237,NCT01697293,"1:24:treatment,,",Electrocardiogram (ECG) corrected QT (QTC) < 450 msec
4238,NCT01696734,"24:45:chronic_disease,,,,,,,,,",Clinically significant electrolyte disorders including sodium < 130 or > 145 and/or potassium < 3.0 or > 5.5 and/or magnesium < 1.6 or > 2.6
4239,NCT01696734,1:12:chronic_disease,heart block
4240,NCT01695967,1:23:chronic_disease,craniofacial anomalies
4241,NCT01690468,",,97:146:cancer",Patients must be disease-free of prior invasive malignancies for >2 years with the exception of basal cell or squamous cell carcinoma of the skin
4242,NCT01688388,27:39:cancer,Any hormonal receptor and HER-2 status
4243,NCT01684904,1:22:treatment,Endoscopic ultrasound
4244,NCT01684397,13:46:chronic_disease,Symptomatic peripheral arterial disease (PAD)
4245,NCT01681589,13:33:chronic_disease,Presence of focal motor deficits in the upper extremities
4246,NCT01676753,43:82:allergy_name,Patient has known hypersensitivity to the components of study drug or its analogs
4247,NCT01676259,18:28:allergy_name,Known allergy to sesame oil
4248,NCT01676259,13:49:chronic_disease,symptomatic peripheral arterial vascular disease
4249,NCT01672138,27:44:treatment,Patients undergoing first catheter ablation for drug-refractory Persistent (PerAF) or long-standing persistent AF (LSPAF)
4250,NCT01668602,1:20:chronic_disease,Orthopedic problems in the lower limbs or spine (or other medical conditions) that limit walking
4251,NCT01666665,1:26:chronic_disease,Acute or chronic acidosis (lactic or any other metabolic type)
4252,NCT01666080,1:16:treatment,Transplantation using sufficiently matched related donors (such as matched siblings) or unrelated donors
4253,NCT01660607,1:29:chronic_disease,Myeloproliferative syndromes
4254,NCT01660607,1:15:chronic_disease,hepatitis C ab
4255,NCT01659203,23:73:cancer,Histologically proven primary soft tissue sarcoma of the retroperitoneum
4256,NCT01653093,8:43:treatment,in the perioperative liver transplantation period
4257,NCT01652092,1:19:chronic_disease,Griscelli Syndrome
4258,NCT01652092,1:21:chronic_disease,Reticular dysgenesis
4259,NCT01648023,"1:44:chronic_disease,","Active bacterial, viral or fungal infection within 72 hours of study entry"
4260,NCT01648023,84:101:treatment,that would place the patient at undue risk and that would preclude the safe use of chemoembolization or would interfere with study participation
4261,NCT01647321,23:63:chronic_disease,clinical diagnosis of secondary progressive multiple sclerosis
4262,NCT01643460,",,77:101:treatment",Patients referred between January 2009 and February 2016 to EUS at IUMC for pancreatic cyst ablation and with no contraindications for anticipated safe and successful performance of the procedure
4263,NCT01639508,1:15:treatment,ROS1 infustion
4264,NCT01631617,1:18:chronic_disease,Atopic Dermatitis Patients
4265,NCT01631617,1:22:chronic_disease,chronic skin diseases
4266,NCT01626079,61:77:treatment,Insufficient mobile leaflet available for grasping with the MitraClip device
4267,NCT01626079,",,,63:76:treatment","New York Heart Association (NYHA) Functional Class II, III or ambulatory IV"
4268,NCT01626079,44:47:treatment,Subjects who have any contraindications to CPX and are not capable of performing CPX per investigator's assessment should not be registered in the CPX Sub-study
4269,NCT01626079,",,70:74:treatment",a greater than 100% increase or greater than 50% decrease in dose of GDMT
4270,NCT01625234,15:33:cancer,Patients with primary CNS tumors
4271,NCT01624090,",47:76:treatment",At least 3 half-lives must have elapsed since monoclonal antibody treatment
4272,NCT01624090,1:13:treatment,Dipyridamole
4273,NCT01624090,36:68:chronic_disease,Patients with any of the following pulmonary function abnormalities
4274,NCT01624090,1:14:treatment,Valproic acid
4275,NCT01622868,7:11:treatment,Prior WBRT
4276,NCT01620216,1:10:treatment,Sorafenib
4277,NCT01617161,",95:125:treatment,",Must have complete history and physical examination within 45 days of study entry and digital rectal examination of prostate within 180 days of study entry
4278,NCT01614990,",54:69:treatment,,","Co-administration of drugs that prolong QT interval, CYP3A4 inducers, QTc equal to or greater than 450ms at screening"
4279,NCT01614197,",64:73:treatment",At least 3 half-lives must have elapsed after the last dose of GVHD meds
4280,NCT01614197,108:119:treatment,Patients with known optic nerve and/or retinal involvement (because it may not be possible to safely delay irradiation) are not eligible
4281,NCT01604512,25:56:treatment,Any contraindication to gadolinium intravenous contrast as per standard Department of Radiology contrast guidelines
4282,NCT01600040,1:32:cancer,uterine papillary serous cancer
4283,NCT01597518,"21:41:treatment,",Able to receive the Investigational Drug within 12 hours of injury
4284,NCT01597518,21:42:chronic_disease,Injury arising from penetrating mechanism
4285,NCT01597518,1:20:treatment,Phenylpropanolamine
4286,NCT01597518,1:9:treatment,Zileuton
4287,NCT01595529,14:35:chronic_disease,A child with phenylketonuria (PKU)
4288,NCT01595529,"15:39:treatment,",Enrollment in another antibiotic study less than 30 days prior to enrollment visit
4289,NCT01595529,1:15:chronic_disease,hydronephrosis
4290,NCT01591356,",,,,,,,,319:343:treatment","Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study and for at least 3 months after completion of EphA2 siRNA-DOPC therapy"
4291,NCT01589263,12:36:chronic_disease,History of bladder calculi (stones)
4292,NCT01589263,",45:90:treatment","This decision can be based on PSA velocity, previous TRUS (transrectal ultrasound) biopsy, percent free PSA, or other clinical estimations in keeping with sound urologic care"
4293,NCT01584076,7:29:chronic_disease,Known psychological problems
4294,NCT01584076,12:51:treatment,history of prior amblyopia treatment with patching
4295,NCT01581580,19:42:treatment,good benefit from dopaminergic medication but associated with insufficient duration of action or unacceptable side-effects
4296,NCT01573754,12:41:chronic_disease,Documented porphyria cutanea tarda (PCT)
4297,NCT01572480,"1:14:treatment,",Immunoparesis with reduction of 2 uninvolved immunoglobulin isotypes
4298,NCT01570998,1:11:cancer,High grade
4299,NCT01570998,1:14:cancer,Node positive patients
4300,NCT01570816,1:22:chronic_disease,autoimmune deficiency
4301,NCT01568918,1:29:treatment,Cervical Anterior Corpectomy
4302,NCT01568918,1:21:treatment,Cervical Laminectomy
4303,NCT01568918,1:18:treatment,Lumbar Discectomy (METRx or Open)
4304,NCT01568918,1:29:treatment,Lumbar Posterolateral Fusion
4305,NCT01568255,1:15:chronic_disease,Myopathic pain that cannot be attributed to other medical conditions
4306,NCT01568177,1:17:chronic_disease,esophageal spasm
4307,NCT01562626,1:5:treatment,5-FC
4308,NCT01562626,1:21:chronic_disease,patent foramen ovale
4309,NCT01555905,19:40:chronic_disease,No diagnosis of a neuromusuclar disease
4310,NCT01555554,13:33:treatment,They are on beta blocker therapy at the time of the preoperative baseline assessment
4311,NCT01554371,62:86:cancer,Patient must have histologically or cytologically documented solid tumor malignancies
4312,NCT01553942,8:22:chronic_disease,"Active hepatitis B, C"
4313,NCT01553214,1:16:treatment,Lithium therapy
4314,NCT01547429,1:18:chronic_disease,Mentally retarded patients
4315,NCT01543490,13:24:chronic_disease,symptomatic blepharitis
4316,NCT01539109,1:37:treatment,Concurrent upper limb rehabilitation
4317,NCT01538966,21:37:chronic_disease,"The patient has any mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study, and/or evidence of an uncooperative attitude"
4318,NCT01532687,5:37:treatment,Any prior treatment with gemcitabine
4319,NCT01532687,1:24:treatment,Injectable progesterone
4320,NCT01532687,1:38:treatment,prior to the first dose of study drug and for the duration of the study
4321,NCT01530958,1:19:chronic_disease,impaired cognition
4322,NCT01525901,1:13:chronic_disease,valvulopathy
4323,NCT01522768,61:70:treatment,Known or suspected active drug or alcohol abuse. Restricted Therapies
4324,NCT01512888,25:32:chronic_disease,A clinical diagnosis of SCID-X1 documented in the medical record
4325,NCT01508390,48:61:treatment,Must be able to tolerate the confinement of an MRI procedure
4326,NCT01505569,1:15:cancer,Hepatoblastoma - metastatic at time of diagnosis and/or relapsed after therapy
4327,NCT01505569,"17:27:cancer,,",Other High Risk CNS Tumors - to be approved by 2 or more physicians (at least one oncologist and one BMT physician)
4328,NCT01505569,1:27:cancer,"extraneural metastases, M4"
4329,NCT01505062,",,140:149:treatment",agree to use an effective form of contraception such as the contraceptive pill or intra uterine device for at least three months following SAR421869 administration
4330,NCT01504373,1:33:treatment,Uncuffed endotracheal tube (ETT)
4331,NCT01500551,1:11:chronic_disease,Infections
4332,NCT01495637,27:44:chronic_disease,"presence of a new, severe neurologic injury at the time of enrollment which, in the opinion of the treating physician, is highly likely to lead to a diagnosis of brain death"
4333,NCT01494662,68:89:treatment,These patients may include those who have received or not received previous treatment(s) for their CNS
4334,NCT01481974,6:31:chronic_disease,Have fulminant hepatic failure
4335,NCT01474889,"8:14:treatment,,",Use of RT-CGM (continuous glucose monitor) within last 4 weeks
4336,NCT01465100,7:34:chronic_disease,Known biopterin synthesis defects
4337,NCT01464164,1:4:chronic_disease,DBA diagnosed
4338,NCT01464034,143:158:chronic_disease,"Pts in whom the required program of oral and intravenous fluid hydration is contraindicated, e.g. due to pre-existing pulmonary, cardiac, or renal impairment"
4339,NCT01461837,1:33:chronic_disease,Hemoglobin S Beta0/+ thalassemia
4340,NCT01459107,158:185:treatment,"Conditions that, in the opinion of the study team, may impact the immunomodulatory protocol potentially exposing the recipient to an unacceptable risk under immunosuppressive treatment"
4341,NCT01459107,75:108:treatment,Patient agrees to comply with the protocol and states a dedication to the immunomodulatory treatment regime
4342,NCT01459107,1:45:chronic_disease,Type I (insulin-dependent) diabetes mellitus
4343,NCT01449149,1:19:cancer,cutaneous squamous
4344,NCT01445821,"9:30:chronic_disease,,",Diffuse cutaneous scleroderma with involvement proximal to the elbow or knee and a Rodnan score (see Appendix V) of > 14
4345,NCT01444209,36:74:treatment,Patients who are unable to undergo placement of a stereotactic head frame
4346,NCT01436968,21:75:treatment,Planning to undergo standard prostate-only external beam radiation therapy
4347,NCT01433315,41:68:treatment,those taking any medications other than non-sedating antihistamines or oral contraceptives
4348,NCT01430390,1:19:chronic_disease,cardiac conditions
4349,NCT01422746,24:56:chronic_disease,Significant history of cardiac or pulmonary dysfunction
4350,NCT01421810,"10:43:treatment,",Abnormal thyroid stimulating hormone (TSH) for age
4351,NCT01421095,",41:61:treatment",A minimum of 1 year since completion of gonoadotoxic therapy
4352,NCT01421095,1:24:treatment,unilateral oophorectomy
4353,NCT01419561,"19:33:chronic_disease,","Exposure risk for KSHV infection (including being a first or second generation immigrant from an endemic area, or male-to-male sexual activity) or evidence of KSHV infection"
4354,NCT01415882,",69:97:treatment","Recovered (i.e., < grade 1 toxicity) from the reversible effects of prior antineoplastic therapy"
4355,NCT01407809,1:18:chronic_disease,Visual field loss
4356,NCT01389024,41:54:allergy_name,"Allergy or previous adverse reaction to pentobarbital, if used at the participating center"
4357,NCT01389024,",47:63:chronic_disease",Participants whose MRI show a silent or overt cerebral infarct
4358,NCT01379573,81:84:chronic_disease,"Identification of any of the following structural lesions considered causal for CHB, i.e., those that could account for block because of fibrous disruption between the atrium and AV node or due to absence of the penetrating bundles of the AV node"
4359,NCT01379573,1:12:chronic_disease,heterotaxia
4360,NCT01373099,49:70:treatment,Infection of a revision as opposed to a primary total hip arthroplast
4361,NCT01367444,"5:28:treatment,",Any injectable intravitreal treatment to the treated eye or intravitreal device in the treated eye within 6 months prior to screening
4362,NCT01367444,",,,107:131:treatment",Males must agree with their partner to use two forms of contraception for at least three months following SAR422459 administration
4363,NCT01367444,",,,,114:123:treatment",Reduction in macular mean sensitivity of ?5 dB or reduction in hill of vision by >14 dB-sr as assessed by static perimetry
4364,NCT01366612,1:29:chronic_disease,chronic myelogenous leukemia
4365,NCT01360606,"11:29:cancer,","Extensive liver tumor burden, defined as more than 75% of the liver"
4366,NCT01356290,27:59:allergy_name,Known hypersensitivity to any of the drugs in the protocol
4367,NCT01345344,1:30:chronic_disease,comorbid acute pain condition
4368,NCT01333046,15:44:chronic_disease,Patients with severe intercurrent infection
4369,NCT01326715,93:116:treatment,"Evidence of abnormal permeability of the brain or cerebrospinal fluid, based on a screening gadolinium-enhacned MRI scancan"
4370,NCT01313533,1:17:chronic_disease,Comorbid illness making 2 year survival unlikely
4371,NCT01312857,1:30:treatment,Prior treatment with HAI FUDR
4372,NCT01293214,"24:64:treatment,",Willing to comply with extensive post-transplant rehabilitation for a minimum of two years
4373,NCT01280669,"1:20:treatment,",Intraocular surgery within 90 days prior to Day 0 in the study eye
4374,NCT01270724,15:21:cancer,Patients with ICGCTs who are newly diagnosed
4375,NCT01261728,9:85:treatment,Ongoing treatment with therapeutic doses of warfarin or low molecular weight heparin
4376,NCT01261728,1:27:treatment,prior intravesical therapy
4377,NCT01245712,30:56:treatment,Treatment plan that includes regional nodal irradiation
4378,NCT01243931,"109:112:treatment,",Patients with vision primarily limited by superficial opacities and irregularities that could be removed by PTK while leaving at least 250 µm
4379,NCT01238120,",57:80:treatment,",Be scheduled to receive at least 2 additional cycles of oral or IV chemotherapy over the 42-day study period
4380,NCT01220583,15:48:treatment,No concurrent erythropoiesis-stimulating agents
4381,NCT01189786,",,45:57:chronic_disease","Active, acute GvHD > grade II or extensive, chronic GvHD"
4382,NCT01189786,"1:22:chronic_disease,,,","Pulmonary dysfunction (FEV1, FVC or DLCO 40% of predicted or 3 SD below normal)"
4383,NCT01187368,1:33:chronic_disease,Severe right ventricular failure
4384,NCT01185210,"53:61:treatment,,,,",positive breath test after ingestion of 25 grams of fructose defined as either (a) ? 20 ppm rise of breath H2/CH4/both over baseline values or a successive rise of ? 5 ppm over baseline and in 3 consecutive breath samples
4385,NCT01185132,"1:4:chronic_disease,,",PTV to ipsilateral breast ratio (IBR) ? 25 %
4386,NCT01184547,1:10:chronic_disease,Arthritis
4387,NCT01175044,12:27:allergy_name,Allergy to povidone iodine
4388,NCT01174121,24:49:treatment,Refractory to approved standard systemic therapy
4389,NCT01140087,30:55:treatment,Willing and able to continue immunosuppression regimen as directed by treating physician
4390,NCT01128816,15:45:treatment,Presence of a left-ventricular assist device
4391,NCT01087294,",,140:160:treatment",Donors greater than or equal to 18 years of age must be the same individual whose cells were used as the source for the patient s original stem cell transplant
4392,NCT01072370,19:38:chronic_disease,Presence of known chromosomal anomaly
4393,NCT01061515,62:75:treatment,"Appropriate studies will be undertaken in patients receiving HAART therapy, when indicated"
4394,NCT01059786,"1:11:treatment,",cladribine for 6 months prior to study entry
4395,NCT01050855,1:34:chronic_disease,Severe combined immune deficiency
4396,NCT01045148,13:36:cancer,Evidence of distant metastases (M1)
4397,NCT01037790,",,,158:174:treatment",Sexually active subjects (male and female) must use accepted methods of contraception during the course of the study and for 3 months after the last dose of protocol drug(s)
4398,NCT01028846,1:21:chronic_disease,hypercholesterolemia
4399,NCT01011777,1:30:chronic_disease,Grade V vesicoureteral reflux (Grade IV findings plus loss of the papillary impression and ureteral tortuosity)
4400,NCT01011777,"136:151:treatment,",Urinalysis and urine culture demonstrating either no bacterial growth or growth of an organism that can be treated with an appropriate oral antibiotic for 7 days preoperatively
4401,NCT00980538,79:82:allergy_name,Previously demonstrated clinically significant allergy or hypersensitivity to ETR or to any of the excipients of ETR
4402,NCT00975520,26:54:cancer,Histologically confirmed neurotropic primary melanoma
4403,NCT00969332,1:36:treatment,Extracorporeal Membrane Oxygenation
4404,NCT00967785,29:48:chronic_disease,Signs or symptoms of active microbial infection
4405,NCT00967577,28:47:allergy_name,Prior allergic reaction to Gadolinium contrast
4406,NCT00959140,"1:14:treatment,",chest CT scan within 14 days of registration
4407,NCT00930228,10:13:treatment,Abnormal TSH
4408,NCT00929006,12:37:chronic_disease,Persistent liver panel abnormalities
4409,NCT00926237,"1:9:chronic_disease,",Tinnitus present for at least 6 months and severe enough to seek medical attention
4410,NCT00924027,81:96:cancer,Patients who can not undergo resection because of poor lung function or distant lung metastasis
4411,NCT00919503,382:399:treatment,DONOR: HLA-matched sibling cord blood exclusions: Any cord blood units that have not passed donor screening for infectious disease markers as recommended by the National Marrow Donor Project (NMDP) will not be used unless a waiver is signed by the clinical attending allowing use of cord blood unit; cord blood units are presumed to be cytomegalovirus (CMV) negative regardless of serologic testing due to passive transmission of maternal CMV antibodies
4412,NCT00914823,"17:34:chronic_disease,",Patients with a macroprolactinoma confirmed on MRI imaging
4413,NCT00914628,21:39:treatment,Contraindication to haploidentical HCT as defined by the Investigator
4414,NCT00909909,1:31:cancer,Colloidal (mucinous) carcinoma
4415,NCT00909909,4:31:cancer,No Paget disease of the nipple
4416,NCT00909909,1:18:cancer,Tubular carcinoma
4417,NCT00904046,"1:18:treatment,",Thiazolidinedione use in the preceding 18 months
4418,NCT00896493,1:17:chronic_disease,HIV seronegative
4419,NCT00887146,70:82:treatment,Tissue must have been determined to have local 1p/9q co-deletion and IDH mutation prior to submission for central path review
4420,NCT00881660,18:21:chronic_disease,Extremely Severe CDH
4421,NCT00881660,46:60:chronic_disease,Suspicion of major recognized syndrome (e.g. Fryns syndrome) on ultrasound or MRI
4422,NCT00871260,1:41:chronic_disease,Acute ST-elevation myocardial infarction
4423,NCT00862433,1:18:treatment,Insulin treatment
4424,NCT00857207,12:42:chronic_disease,History of pre-morbid learning disability
4425,NCT00840047,",17:26:treatment,",More than 6 MET PET scans within the previous 12 months
4426,NCT00819208,1:11:cancer,T4 lesions
4427,NCT00799864,34:75:chronic_disease,Patient has any currently active Acquired Immunodeficiency Syndrome (AIDS) defining illness
4428,NCT00788164,1:9:chronic_disease,Impetigo
4429,NCT00788164,15:51:cancer,No concurrent adenocarcinoma in situ of the cervix
4430,NCT00788164,21:47:chronic_disease,Proven or suspected immunosuppressive disorder
4431,NCT00788164,1:25:cancer,nonmelanoma skin lesions
4432,NCT00737893,1:48:chronic_disease,Nonarteritic Anterior Ischemic Optic Neuropathy
4433,NCT00737893,49:92:allergy_name,The patient has contraindications to the use of phosphodiesterase type 5 (PDE 5) inhibitors
4434,NCT00737893,18:23:chronic_disease,condition called NAION
4435,NCT00720785,1:29:chronic_disease,Active Hepatitis B infection (Hep B surface antigen positive)
4436,NCT00720785,",,81:91:treatment","Peripheral neuropathy of grade greater than 1, which would require reduction of bortezomib dose"
4437,NCT00720785,1:32:cancer,metastatic epithelial neoplasms
4438,NCT00719888,"87:117:cancer,","Conditioning regimen selection should be based on the underlying disease, presence of minimum residual disease (MRD), age, co-morbidities, attending physician, and site preference"
4439,NCT00719888,",,42:73:treatment",blasts must be < 10% by a representative bone marrow aspirate morphology
4440,NCT00719888,90:107:treatment,to be eligible in first chronic phase (CP1) patient must have failed or be intolerant to imatinib mesylate
4441,NCT00716066,1:34:chronic_disease,Lambert-Eaton myasthenic syndrome
4442,NCT00716066,73:106:chronic_disease,Patients must satisfy the criteria for a diagnosis of one of the severe neurological autoimmune disorders outlined
4443,NCT00716066,1:22:chronic_disease,Stiff Person Syndrome
4444,NCT00715611,",,42:72:cancer",at the participating site of stage I-III malignant pleural mesothelioma
4445,NCT00713492,"25:56:treatment,",Daily or regular use of prescription or OTC medications known to interact with alcohol in the 2-week period prior to assessment
4446,NCT00711373,35:57:chronic_disease,No serious co-existing medical or psycho-social problems
4447,NCT00703105,28:53:treatment,Patients who have received prior anti-tumor vaccines are ineligible
4448,NCT00678145,1:13:chronic_disease,Heart attack
4449,NCT00673842,1:33:treatment,Cardiac Resynchronization device
4450,NCT00673842,1:30:treatment,cardiac resynchronization ICD
4451,NCT00670358,1:37:chronic_disease,Psychiatric illness/social situation that would preclude compliance with study requirements
4452,NCT00632853,10:46:treatment,No prior mediastinal or thoracic radiotherapy
4453,NCT00630253,",,,44:66:chronic_disease,","In patients 18-60 years of age, moderately severe aplastic anemia is defined as having at least one"
4454,NCT00625417,1:19:treatment,radical mastectomy
4455,NCT00594217,",12:35:chronic_disease",Women with abnormal renal function
4456,NCT00540761,1:21:chronic_disease,Kidney insufficiency
4457,NCT00539162,8:30:cancer,Active non-ovarian malignancy
4458,NCT00488696,1:29:chronic_disease,Free rupture of the aneurysm
4459,NCT00483249,1:17:chronic_disease,Aortic aneurysms
4460,NCT00472329,32:62:treatment,Any patient who has rejected a previous allogeneic transplant (related or unrelated) rejection based on chimerism data from peripheral blood specimens showing loss of donor T Cells
4461,NCT00467987,8:20:treatment,Use of testosterone in the past
4462,NCT00409435,"30:44:treatment,",Patients must not have taken pyridostigmine in the past month
4463,NCT00391170,24:41:chronic_disease,Clinically significant oral chronic GVHD at the time of the screening
4464,NCT00383656,"22:37:treatment,",who have not been on gonadal steroid preparations for at least 1 month
4465,NCT00358657,"15:41:chronic_disease,,","Patients with metabolic storage diseases who have severe central nervous system (CNS) involvement of disease, defined as intelligence quotient (IQ) score < 70"
4466,NCT00357565,"1:25:treatment,",Myeloablative transplant within the last 6 months
4467,NCT00351611,30:50:treatment,patients currently receiving pregabalin treatment
4468,NCT00338065,15:39:chronic_disease,Patients with normal-pressure glaucoma
4469,NCT00293475,56:66:treatment,cytology (analysis from cerebral spinal fluid [CSF] or vitrectomy)
4470,NCT00291525,1:28:treatment,Concomitant cardiac surgery
4471,NCT00291525,1:20:chronic_disease,Neurological events
4472,NCT00291525,",17:45:treatment",Women receiving estrogen replacement therapy
4473,NCT00285935,"4:12:treatment,",No vaccines for at least 4 weeks prior to baseline blood draw (including the flu shot)
4474,NCT00230607,24:38:treatment,agree to adhere to the Fabry Registry recommended schedule of assessments for medical history
4475,NCT00209235,70:94:chronic_disease,the growth hormone sufficient participants must meet the criteria of idiopathic short stature or SGA indication
4476,NCT00186927,23:26:chronic_disease,household member with URI
4477,NCT00147056,43:58:treatment,Able to communicate sensations during the ExAblate MRGFUS procedure
4478,NCT00147056,13:37:chronic_disease,Symptomatic coronary artery stenosis
4479,NCT00085982,25:50:chronic_disease,"Clinically significant, severe insulin resistance"
4480,NCT00085982,56:71:treatment,The inclusion criteria should include any patient with extreme insulin resistance who has appropriately low leptin levels
4481,NCT00044304,1:23:chronic_disease,dysplastic eosinophils on peripheral smear
4482,NCT00001651,79:93:treatment,"Adequate venous access in the arms for blood drawing and 5 day infusions, and lymphapheresis"
4483,NCT00001337,1:31:cancer,mediastinal gray zone lymphoma
4484,NCT02990481,"29:32:chronic_disease,34:45:chronic_disease,47:58:chronic_disease","Known active infection with HIV, hepatitis B, hepatitis C"
4485,NCT02654236,"34:45:chronic_disease,47:58:chronic_disease,63:66:chronic_disease","Known co-existing infection with hepatitis C, hepatitis B, or HIV"
4486,NCT02648282,"42:45:chronic_disease,47:58:chronic_disease,63:74:chronic_disease","who have known history of infection with HIV, hepatitis B, or hepatitis C"
4487,NCT02579967,"1:4:chronic_disease,15:26:chronic_disease,63:74:chronic_disease","HIV negative, hepatitis B virus surface antigen negative, and hepatitis C virus antibody negative"
4488,NCT02574455,"22:25:chronic_disease,36:47:chronic_disease,61:72:chronic_disease","Patients known to be HIV positive, hepatitis B positive, or hepatitis C positive"
4489,NCT02281409,"26:29:chronic_disease,31:42:chronic_disease,44:55:chronic_disease","An existing diagnosis of HIV, hepatitis B, hepatitis C, or any current laboratory findings or clinical signs and symptoms that suggest these conditions"
4490,NCT02278315,"18:21:chronic_disease,23:34:chronic_disease,38:49:chronic_disease","Known history of HIV, hepatitis C or hepatitis B infection"
4491,NCT01876511,"51:54:chronic_disease,56:67:chronic_disease,72:83:chronic_disease","Patients who have known history of infection with HIV, hepatitis B, or hepatitis C"
4492,NCT01087294,"16:19:chronic_disease,30:41:chronic_disease,72:83:chronic_disease","Donors must be HIV negative, hepatitis B surface antigen negative, and hepatitis C antibody negative"
4493,NCT03152058,",12:15:chronic_disease,17:28:chronic_disease,32:43:chronic_disease","Women with HIV, Hepatitis B or Hepatitis C positive status"
4494,NCT03113760,"39:42:chronic_disease,44:55:chronic_disease,59:70:chronic_disease","Positive test for or prior history of HIV, Hepatitis B or Hepatitis C (serology)"
4495,NCT02465268,"1:4:chronic_disease,6:17:chronic_disease,22:33:chronic_disease","HIV, Hepatitis B, or Hepatitis C seropositive"
4496,NCT02311621,"10:13:chronic_disease,36:47:chronic_disease,68:79:chronic_disease,","Negative HIV antigen and antibody, Hepatitis B surface antigen and Hepatitis C antibody within 3 months prior to enrollment"
4497,NCT01883076,"49:52:chronic_disease,54:65:chronic_disease,71:82:chronic_disease","Mother's serology test results are negative for HIV, Hepatitis B, and Hepatitis C"
4498,NCT01087294,"18:21:chronic_disease,32:43:chronic_disease,65:76:chronic_disease","Patients must be HIV negative, Hepatitis B surface antigen, and Hepatitis C antibody negative"
4499,NCT02542202,"1:16:chronic_disease,20:36:chronic_disease,47:70:treatment",Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
4500,NCT02470897,"1:16:chronic_disease,20:36:chronic_disease,47:70:treatment",Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
4501,NCT01622868,"1:16:chronic_disease,20:36:chronic_disease,47:70:treatment",Acute bacterial or fungal infection requiring intravenous antibiotics at the time of study entry
4502,NCT01617161,"1:16:chronic_disease,20:36:chronic_disease,47:70:treatment",Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
4503,NCT01220583,"1:16:chronic_disease,20:36:chronic_disease,47:70:treatment",Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
4504,NCT02547662,"7:36:chronic_disease,40:52:treatment,115:123:treatment",Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing
4505,NCT02481310,"27:56:chronic_disease,60:72:treatment,135:143:treatment",Patients who have a known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing
4506,NCT02389517,"7:36:chronic_disease,40:52:treatment,115:123:treatment",Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing
4507,NCT02339922,"7:36:chronic_disease,40:52:treatment,115:123:treatment",Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing
4508,NCT02346253,"7:16:chronic_disease,20:36:chronic_disease,47:70:treatment",Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
4509,NCT02163317,"7:16:chronic_disease,20:36:chronic_disease,47:70:treatment",Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
4510,NCT01972919,"7:16:chronic_disease,20:36:chronic_disease,47:70:treatment",Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
4511,NCT01954173,"7:16:chronic_disease,20:36:chronic_disease,47:70:treatment",Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
4512,NCT03121352,"28:48:chronic_disease,90:106:chronic_disease,120:144:chronic_disease,146:170:chronic_disease,172:190:chronic_disease,195:232:chronic_disease","Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
4513,NCT02985554,"14:34:chronic_disease,77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
4514,NCT01494662,"14:34:chronic_disease,76:92:chronic_disease,106:130:chronic_disease,132:156:chronic_disease,158:176:chronic_disease,181:218:chronic_disease","Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
4515,NCT02880215,"17:35:chronic_disease,37:53:chronic_disease,58:71:chronic_disease","current or past psychotic disorder, bipolar disorder, or schizophrenia"
4516,NCT02502799,"14:30:chronic_disease,32:45:chronic_disease,60:78:chronic_disease","Diagnosis of bipolar disorder, schizophrenia, and/or other psychotic disorder"
4517,NCT01986075,"26:42:chronic_disease,44:57:chronic_disease,65:83:chronic_disease","Meets DSM-V criteria for bipolar disorder, schizophrenia or any psychotic disorder other than transient psychosis due to drug abuse"
4518,NCT02592551,"28:54:chronic_disease,62:77:chronic_disease,79:97:chronic_disease","Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)"
4519,NCT02532231,"28:54:chronic_disease,63:78:chronic_disease,83:101:chronic_disease",Patients with a history of inflammatory bowel disease such as Crohn's disease and ulcerative colitis
4520,NCT01950351,"8:34:chronic_disease,36:51:chronic_disease,55:73:chronic_disease",active inflammatory bowel disease (Crohn's disease or ulcerative colitis)
4521,NCT02512497,"1:26:chronic_disease,30:56:chronic_disease,62:77:treatment",Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes
4522,NCT02393794,"1:26:chronic_disease,30:56:chronic_disease,62:77:treatment",Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes
4523,NCT01908777,"1:26:chronic_disease,30:56:chronic_disease,62:77:treatment",Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes
4524,NCT02451683,"41:50:chronic_disease,52:66:chronic_disease,70:88:chronic_disease","Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease"
4525,NCT02446210,"41:50:chronic_disease,52:66:chronic_disease,70:88:chronic_disease","Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease"
4526,NCT01915095,"41:50:chronic_disease,52:66:chronic_disease,70:88:chronic_disease","Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease"
4527,NCT02312596,"1:18:treatment,20:32:treatment,34:49:treatment,57:82:treatment,","Radiation therapy, chemotherapy, chronic steroid use or immunosuppressive therapy within 30 days of enrollment"
4528,NCT02312570,",,,106:123:treatment,125:137:treatment,139:164:treatment,168:183:treatment,","WBC >13,000/cm3 or < 5, 000 cm3, or electrolytes that are outside the host institution's range of normal Radiation therapy, chemotherapy, immunosuppressive therapy or chronic steroid use within 30 days of enrollment"
4529,NCT02312518,",,,,268:285:treatment,287:299:treatment,301:326:treatment,330:345:treatment,","Presence of additional abnormal lab values obtained within 7 days prior to the Day 0 visit determined to be clinically significant by the investigator including: WBC >13,000/cm3 or < 5, 000 cm3, or electrolytes that are outside the host institution's range of normal Radiation therapy, chemotherapy, immunosuppressive therapy or chronic steroid use within 30 days of enrollment"
4530,NCT01928576,"79:90:treatment,96:106:treatment,114:123:treatment,,","Because no dosing or adverse event data are currently available on the use of azacitidine with entinostat, or of Nivolumab, in patients <18 years of age, children are excluded from this study"
4531,NCT01928576,"102:112:allergy_name,114:125:allergy_name,130:139:allergy_name","History of allergic reactions attributed to compounds of similar chemical or biologic composition to entinostat, azacitidine, or Nivolumab"
4532,NCT01928576,"16:26:treatment,28:39:treatment,45:54:treatment","The effects of entinostat, azacitidine, and Nivolumab, on the developing human fetus are unknown"
4533,NCT03110354,"24:31:chronic_disease,33:46:chronic_disease,51:68:chronic_disease","Has substance abuse or medical, psychological, or social conditions that, in the opinion of the Investigator, may interfere with the subject's participation in the clinical study or evaluation of the clinical study results"
4534,NCT01360606,"18:25:chronic_disease,27:40:chronic_disease,44:61:chronic_disease","Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results"
4535,NCT03043794,"75:80:chronic_disease,82:102:chronic_disease,104:115:chronic_disease","Medical conditions that may increase risk for poor cosmetic outcome (i.e. Lupus, rheumatoid arthritis, scleroderma"
4536,NCT02482376,"75:80:chronic_disease,82:102:chronic_disease,104:115:chronic_disease","Medical conditions that may increase risk for poor cosmetic outcome (i.e. Lupus, rheumatoid arthritis, scleroderma)"
4537,NCT03008408,"30:50:treatment,,146:158:treatment,160:177:treatment,179:201:treatment","Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc"
4538,NCT02321501,"30:50:treatment,,118:130:treatment,132:149:treatment,151:173:treatment","Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks including chemotherapy, radiation therapy, antibody based therapy, etc"
4539,NCT02910700,"75:84:allergy_name,86:96:allergy_name,101:111:allergy_name","History of allergy or adverse drug reaction to the study drug components (nivolumab, dabrafenib, or trametinib) or drugs of similar chemical or biologic composition"
4540,NCT02910700,"68:77:treatment,79:89:treatment,95:105:treatment","breastfeeding should be discontinued if the mother is treated with nivolumab, dabrafenib, and trametinib"
4541,NCT02833805,"14:23:chronic_disease,25:30:chronic_disease,35:51:chronic_disease","Uncontrolled bacterial, viral, or fungal infection"
4542,NCT01966367,"14:23:chronic_disease,25:30:chronic_disease,34:50:chronic_disease","Uncontrolled bacterial, viral or fungal infection in the past month"
4543,NCT02695433,"12:25:chronic_disease,27:38:chronic_disease,40:45:chronic_disease,47:63:chronic_disease,67:82:chronic_disease","History of heart disease, respiratory, renal, gastrointestinal or hepatic disease"
4544,NCT02695433,"12:25:chronic_disease,27:38:chronic_disease,40:45:chronic_disease,47:63:chronic_disease,68:83:chronic_disease","history of heart disease, respiratory, renal, gastrointestinal, or hepatic disease"
4545,NCT02646787,"15:23:chronic_disease,25:34:chronic_disease,50:72:chronic_disease","Demonstrating delirium, psychosis or any form of Organic Brain Disorder and associated memory problems"
4546,NCT02646787,"19:27:chronic_disease,29:38:chronic_disease,54:76:chronic_disease","Not demonstrating delirium, psychosis or any form of Organic Brain Disorder"
4547,NCT02581982,"14:53:cancer,61:85:cancer,120:136:cancer,,273:288:treatment,418:426:treatment,","Known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment; this exception does not include carcinomatous meningitis which is excluded regardless of clinical stability"
4548,NCT02541565,"18:57:cancer,65:89:cancer,124:140:cancer,,277:292:treatment,422:430:treatment","Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids"
4549,NCT02576444,"1:14:treatment,7:14:treatment,,53:68:treatment","Major surgery within 3 weeks prior to first dose of study treatment, and patients must have recovered from the effects of surgery"
4550,NCT02451553,"1:14:treatment,7:14:treatment,,46:61:treatment",Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study
4551,NCT02553941,"5:29:chronic_disease,31:48:chronic_disease,53:77:chronic_disease","Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk"
4552,NCT02309580,"5:29:chronic_disease,31:48:chronic_disease,53:77:chronic_disease","Any life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject's safety or put the study outcomes at undue risk"
4553,NCT02547662,"34:59:chronic_disease,71:90:chronic_disease,92:116:chronic_disease,118:124:chronic_disease,129:150:chronic_disease,","Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure, angina, or myocardial infarction within the past 6 months"
4554,NCT01415882,"34:59:chronic_disease,71:90:chronic_disease,92:116:chronic_disease,118:124:chronic_disease,129:150:chronic_disease,","Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure, angina, or myocardial infarction within the past 6 months"
4555,NCT02542202,"1:51:chronic_disease,61:80:chronic_disease,121:134:treatment,",Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration
4556,NCT01954173,"1:51:chronic_disease,61:80:chronic_disease,121:134:treatment",Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
4557,NCT02532452,"40:48:treatment,40:47:treatment,,63:73:treatment",Clinical status must allow tapering of steroids to < 0.5mg/kg prednisone or other steroid equivalent
4558,NCT02048332,"40:47:treatment,40:48:treatment,61:71:treatment",Clinical status must allow tapering of steroids to 0.5mg/kg prednisone or other steroid equivalent
4559,NCT02520778,"91:107:chronic_disease,121:145:chronic_disease,147:162:chronic_disease,173:191:chronic_disease,193:217:chronic_disease,241:248:treatment,259:281:treatment,285:311:chronic_disease,315:334:chronic_disease","Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, gastrointestinal disease limiting absorption of AZD9291 such as a malabsorption syndrome or inflammatory bowel disease or psychiatric illness/social situations that would limit compliance with study requirements"
4560,NCT02496663,"77:93:chronic_disease,107:131:chronic_disease,133:148:chronic_disease,159:177:chronic_disease,179:203:chronic_disease,227:234:treatment,245:267:chronic_disease,271:297:chronic_disease,301:320:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, gastrointestinal disease limiting absorption of AZD9291 such as a malabsorption syndrome or inflammatory bowel disease or psychiatric illness/social situations that would limit compliance with study requirements"
4561,NCT02516670,"1:22:chronic_disease,24:34:treatment,36:46:treatment","Gastrointestinal (GI): cimetidine, aprepitant"
4562,NCT01822522,"1:22:chronic_disease,24:34:treatment,36:46:treatment","Gastrointestinal (GI): cimetidine, aprepitant"
4563,NCT02512497,"8:30:chronic_disease,32:37:chronic_disease,41:58:chronic_disease","Active uncontrolled bacterial, viral or fungal infections"
4564,NCT02105766,"13:35:chronic_disease,37:42:chronic_disease,47:64:chronic_disease,","Evidence of uncontrolled bacterial, viral, or fungal infections (currently taking medication and progression of clinical symptoms) within one month prior to starting the conditioning regimen"
4565,NCT02496208,"12:37:chronic_disease,,,,,,131:165:treatment,156:165:treatment,","Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mmHg systolic, or > 90 mmHg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment"
4566,NCT02132598,"12:37:chronic_disease,,,,116:150:treatment,141:150:treatment,","Concurrent uncontrolled hypertension defined as sustained BP > 140 mm Hg systolic, or > 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment"
4567,NCT02484937,"49:62:chronic_disease,64:80:chronic_disease,85:102:chronic_disease","Significant psychiatric history: a diagnosis of schizophrenia, bipolar disorder, or severe depression"
4568,NCT02341963,"49:62:chronic_disease,64:80:chronic_disease,85:102:chronic_disease","Significant psychiatric history; a diagnosis of schizophrenia, bipolar disorder, or severe depression"
4569,NCT02466009,"1:14:chronic_disease,25:29:treatment,34:53:treatment",Renal failure requiring hemo- or peritoneal dialysis
4570,NCT02459119,"1:14:chronic_disease,25:29:treatment,33:52:treatment",Renal failure requiring hemo-or peritoneal dialysis
4571,NCT02429557,"13:20:chronic_disease,22:27:chronic_disease,31:46:chronic_disease","Significant cardiac, renal or hepatic illness, or with contraindications to administration of pressor agents or external abdominal compression"
4572,NCT02417415,"13:20:chronic_disease,22:27:chronic_disease,31:46:chronic_disease","Significant cardiac, renal or hepatic illness"
4573,NCT02408861,"48:57:treatment,62:65:chronic_disease,62:75:chronic_disease,87:113:treatment","Participants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications when clinically indicated, and should be under the care of a physician experienced in HIV management"
4574,NCT01822522,"62:71:treatment,76:79:treatment,76:89:chronic_disease,101:127:treatment","Participating participants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications, when clinically indicated and should be under the care of a physician experienced in HIV management"
4575,NCT02393690,"21:42:treatment,74:83:treatment,92:108:cancer",Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
4576,NCT02312245,"21:42:treatment,74:83:treatment,92:108:cancer",Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
4577,NCT02382549,"22:29:treatment,32:39:treatment,42:50:treatment","Growth factors (e.g. Procrit®, Aranesp®, Neulasta®)"
4578,NCT02358187,"22:29:treatment,32:39:treatment,42:50:treatment","Growth factors (e.g. Procrit®, Aranesp®, Neulasta®)"
4579,NCT02352480,"35:51:allergy_name,53:69:allergy_name,71:79:allergy_name,81:94:allergy_name,103:129:allergy_name","Subjects known to be sensitive to Aurix components (calcium chloride, thrombin, ascorbic acid) and/or materials of bovine origin"
4580,NCT02352467,"35:51:allergy_name,53:69:allergy_name,71:79:allergy_name,81:94:allergy_name,103:129:allergy_name","Subjects known to be sensitive to Aurix components (calcium chloride, thrombin, ascorbic acid) and/or materials of bovine origin"
4581,NCT02323945,"12:20:chronic_disease,22:34:chronic_disease,43:51:chronic_disease","History of seizures, brain injury, and/or epilepsy"
4582,NCT02323698,"12:20:chronic_disease,22:34:chronic_disease,43:51:chronic_disease","History of seizures, brain injury, and/or epilepsy"
4583,NCT02315196,"13:29:chronic_disease,37:52:chronic_disease,54:71:chronic_disease","Significant vascular disease (e.g., aortic aneurysm, aortic dissection)"
4584,NCT02314377,"36:52:chronic_disease,60:75:chronic_disease,77:94:chronic_disease","Patients must not have significant vascular disease (e.g., aortic aneurysm, aortic dissection)"
4585,NCT02302235,"1:20:cancer,22:45:cancer,47:50:cancer","Astrocytoma grade 4 (glioblastoma multiforme, GBM, histologically confirmed, WHO criteria)"
4586,NCT01865162,"1:20:cancer,22:45:cancer,47:50:cancer","Astrocytoma grade 4 (glioblastoma multiforme, GBM, histologically confirmed, WHO criteria)"
4587,NCT02192398,"17:39:treatment,49:61:treatment,78:89:chronic_disease,97:108:treatment","Subjects are on antihypertensive drugs (e.g., a beta-blocker) that result in hypotension and/or bradycardia as defined above"
4588,NCT01681264,"17:39:treatment,49:61:treatment,78:89:chronic_disease,97:108:chronic_disease","Subjects are on antihypertensive drugs (e.g., a beta-blocker) that result in hypotension and/or bradycardia as defined above"
4589,NCT02163317,"1:38:chronic_disease,61:80:chronic_disease,121:134:treatment",Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
4590,NCT01622868,"1:38:chronic_disease,61:80:chronic_disease,121:134:treatment",Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of study entry
4591,NCT02133196,"1:8:cancer,37:62:treatment,,107:116:treatment",Lesions that have been treated with stereotactic radiosurgery must be clinically stable for 1 month after treatment for the patient
4592,NCT01967823,"1:8:cancer,37:62:treatment,,107:116:treatment",Lesions that have been treated with stereotactic radiosurgery must be clinically stable for 1 month after treatment for the patient to be eligible
4593,NCT02101736,"1:27:chronic_disease,39:57:chronic_disease,62:77:chronic_disease,80:94:chronic_disease,96:109:chronic_disease,123:134:chronic_disease,138:150:chronic_disease","inflammatory bowel disease (including ulcerative colitis and Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis"
4594,NCT01639508,"1:27:chronic_disease,39:57:chronic_disease,62:77:chronic_disease,80:94:chronic_disease,96:109:chronic_disease,123:134:chronic_disease,138:150:chronic_disease","inflammatory bowel disease (including ulcerative colitis and Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis"
4595,NCT01993810,"1:19:treatment,47:53:cancer,86:103:treatment",Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
4596,NCT01972919,"1:19:treatment,47:53:cancer,86:103:treatment",Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
4597,NCT01896999,"22:32:cancer,59:83:cancer,85:111:cancer","No evidence of prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical carcinoma"
4598,NCT01415752,"22:32:cancer,59:83:cancer,85:111:cancer,","No evidence of prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical carcinoma, or any surgically or radiation-cured malignancy continuously disease free for ? 5 years so as not to interfere with interpretation of radiographic response"
4599,NCT01795313,"20:27:chronic_disease,29:45:chronic_disease,47:56:chronic_disease,61:80:chronic_disease","must have no overt cardiac, gastrointestinal, pulmonary, or psychiatric disease"
4600,NCT01130077,"10:17:chronic_disease,19:35:chronic_disease,37:46:chronic_disease,50:69:chronic_disease","No overt cardiac, gastrointestinal, pulmonary or psychiatric disease"
4601,NCT01438073,"17:32:chronic_disease,34:43:chronic_disease,47:51:chronic_disease",no evidence for androgen excess (hirsutism or acne)
4602,NCT00914823,"17:32:chronic_disease,34:43:chronic_disease,47:51:chronic_disease",no evidence for androgen excess (hirsutism or acne)
4603,NCT03188185,"14:49:treatment,,96:99:treatment,122:149:treatment",Has received electroconvulsive therapy treatment within the last 2 years or within the current MDE or failed a course of electroconvulsive treatment at any time
4604,NCT03188042,"10:28:chronic_disease,36:44:chronic_disease,63:83:chronic_disease","Unstable medical conditions (e.g., diabetes, diabetes causing diabetic retinopathy)"
4605,NCT03183128,"32:44:treatment,46:58:treatment,63:81:treatment,86:103:cancer","Concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for active malignancy (subjects on maintenance chemotherapy may only be enrolled after consultation with the study medical monitor)"
4606,NCT03182751,"18:33:chronic_disease,35:57:chronic_disease,59:84:chronic_disease,86:110:chronic_disease,112:147:chronic_disease,149:167:chronic_disease","Known history of Factor V Leiden, protein C/S deficiency, prothrombin gene mutation, anti-thrombin deficiency, anti-phospholipid antibody syndrome, lupus anticoagulan"
4607,NCT03181516,"12:25:chronic_disease,37:51:chronic_disease,55:70:chronic_disease,76:94:treatment,98:108:treatment","History of heart disease, including valvulopathies or cardiac surgery, any implantable device or prosthetic"
4608,NCT03179995,"20:32:cancer,45:66:treatment,,143:156:chronic_disease,191:200:chronic_disease,201:222:chronic_disease","Patients must have liver tumors requiring a major liver resection, defined as removing at least three anatomical segments in patients without liver disease and two segments in patients with cirrhosis/fibrosis of the liver"
4609,NCT03179397,"38:54:chronic_disease,61:81:chronic_disease,91:108:chronic_disease,,",Subjects with diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal disorders) that are predicted to cause future acuity losses to a level worse than 0.2 LogMAR (20/32)
4610,NCT03178617,"22:36:cancer,28:36:cancer,43:77:cancer,74:76:cancer,79:107:cancer,,,","Children treated for acute leukemia (e.g. acute lymphoblastic leukemia [ALL], acute myeloid leukemia [AML]), LL, or other types of leukemia (if treated intensively) aged 5-12 years and their parents/caregivers"
4611,NCT03176784,"18:28:treatment,30:35:treatment,40:50:treatment","currently taking Wellbutrin, Zyban, or Buproprion (Contrave is a weight-loss drug that has Wellbutrin in it) for reasons other than to quit smoking"
4612,NCT03175978,"14:17:cancer,18:22:cancer,62:78:treatment,71:78:treatment",Diagnosis of MDS/CMML that is refractory to or intolerant to standard therapy and is no longer likely to respond to such therapy (at least one line of therapy)
4613,NCT03171493,"37:49:treatment,,83:99:treatment,,133:150:treatment",Any of the following prior therapy: Chemotherapy ? 3 weeks prior to registration. Biologic therapy ? 4 weeks prior to registration. Radiation therapy ? 3 weeks prior to registration
4614,NCT03171480,"1:23:treatment,55:82:chronic_disease,110:162:chronic_disease,167:213:chronic_disease,215:240:chronic_disease,242:271:chronic_disease,273:301:chronic_disease,306:362:chronic_disease,379:390:chronic_disease,405:424:chronic_disease","Isosorbide mononitrate should not be used in cases of acute myocardial infarction with low filling pressure, acute circulatory failure (shock, vascular collapse), or hypertrophic obstructive cardiomyopathy (HOCM), constrictive pericarditis, low cardiac filling pressures, aortic/mitral valve stenosis and diseases associated with a raised intra-cranial pressure e.g following a head trauma and including cerebral hemorrhage"
4615,NCT03170375,"12:27:chronic_disease,38:45:treatment,66:78:chronic_disease,96:105:treatment","unoperated aortic aneurysm for which surgery is indicated, prior hyperkalemia requiring urgent treatment"
4616,NCT03168971,"24:30:cancer,32:40:cancer,42:50:cancer,52:56:cancer,61:81:cancer,103:112:treatment,","Confirmed diagnosis of breast, lymphoma, prostate, lung, or gynecological cancer, currently on active treatment or within six months of completion of treatment"
4617,NCT03166371,"16:22:cancer,,79:89:cancer,93:128:cancer,132:147:cancer",Current active cancer or recently (within 6 months) treated cancer other than basal cell or squamous cell carcinoma of the skin or prostate cancer
4618,NCT03165227,"1:10:treatment,16:32:treatment,40:68:treatment,70:78:treatment,82:91:treatment","Treatment with SGLT2 inhibitors and/or phosphodiesterase inhibitors, nitrates or riociguat, from screening (Visit 1) or within 5 half-lives before randomisation whatever is earlier"
4619,NCT03162731,"5:18:treatment,24:33:treatment,35:45:treatment,47:67:treatment","Any prior therapy with anti-PD-1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways"
4620,NCT03162731,"1:27:cancer,31:54:cancer,86:102:treatment",superficial bladder cancer or in situ cervical cancer that has undergone potentially curative therapy
4621,NCT03161028,"1:27:chronic_disease,19:27:chronic_disease,58:83:treatment",Insulin-dependent diabetes or diabetes not controlled on oral diabetes medications
4622,NCT03157167,"11:23:cancer,24:36:chronic_disease,42:47:chronic_disease",Confirmed cutaneous KS/oral lesions with edema
4623,NCT03154580,"1:18:chronic_disease,25:34:chronic_disease,36:46:chronic_disease,48:64:chronic_disease","Systemic diseases (e.g. hepatitis, autoimmune, Cushing syndrome)"
4624,NCT03153982,"9:25:chronic_disease,36:55:treatment,59:77:treatment",Current active infection requiring systemic antibiotic or antifungal therapy
4625,NCT03153982,"8:25:treatment,84:95:treatment,127:137:treatment,139:153:treatment,155:165:treatment,167:176:treatment,178:190:treatment,192:204:treatment,206:215:treatment,217:227:treatment,229:239:treatment,241:251:treatment,253:265:treatment,267:276:treatment,278:288:treatment,290:300:treatment,302:315:treatment,320:332:treatment","Strong CYP3A4 inhibitors: (Patients must discontinue drug 7 days prior to starting ruxolitinib), including but not limited to boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, or voriconazole. In addition, patients will be instructed to avoid grapefruit or grapefruit juice, starfruit, or seville oranges"
4626,NCT03153410,"40:46:allergy_name,48:58:allergy_name,60:64:treatment,66:74:allergy_name,75:84:allergy_name,86:104:allergy_name,106:113:allergy_name,132:137:allergy_name,151:185:allergy_name","Known or suspected hypersensitivity to GM-CSF, hetastarch, corn, dimethyl sulfoxide, fetal bovine serum, trypsin (porcine origin), yeast or any other component of GVAX pancreas vaccine"
4627,NCT03153319,"1:26:chronic_disease,34:46:chronic_disease,48:63:chronic_disease","Hematologic abnormalities (e.g., pancytopenia, aplastic anemia)"
4628,NCT03151434,"83:91:allergy_name,93:104:allergy_name,106:117:allergy_name","Known allergy or other contraindications to the study medications , which include dilaudid, bupivacaine, ropivacaine"
4629,NCT03148795,"11:35:chronic_disease,39:60:chronic_disease,82:91:chronic_disease,326:343:chronic_disease","Any other acute or chronic medical or psychiatric condition (concurrent disease, infection, or comorbidity) that interferes with ability to participate in the study, causes undue risk, or complicates the interpretation of data, in the opinion of the investigator or sponsor, including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study"
4630,NCT03148795,"40:52:treatment,56:67:treatment,,83:105:treatment,107:119:treatment,127:146:treatment,147:157:treatment,167:176:treatment,180:195:cancer,213:232:treatment,241:265:cancer,269:292:cancer","Documented disease progression (either radiographic or biochemical) on at least 1 novel hormonal therapy (enzalutamide and/or abiraterone acetate/prednisone) for the treatment of metastatic CRPC, irrespective of prior NHT treatment for non castrate prostate cancer or nonmetastatic (M0) CRPC"
4631,NCT03146663,"1:19:treatment,21:30:treatment,107:121:treatment,123:137:treatment,141:154:treatment,","Prior chemotherapy, radiation (other than short cycle of radiation to reduce bone pain), treatment with a VEGF inhibitor, PARP inhibitor or immunotherapy within 21 days of first receipt of study drug"
4632,NCT03145298,"14:17:chronic_disease,29:33:chronic_disease,35:39:chronic_disease,41:48:chronic_disease,52:59:chronic_disease","Diagnosis of PAH other than IPAH, HPAH, PAH-CTD or PAH-HIV"
4633,NCT03145181,"1:24:treatment,74:90:treatment,92:110:treatment,115:153:treatment,165:204:treatment,,","Prior antitumor therapy as follows, before the first dose of study drug: Targeted therapy, epigenetic therapy, or treatment with an investigational drug or used an invasive investigational medical device within 21 days or at least 5 half-lives, whichever is less"
4634,NCT03144245,"1:10:chronic_disease,12:17:chronic_disease,19:26:chronic_disease,28:44:chronic_disease,46:58:chronic_disease,62:81:chronic_disease","Pulmonary, renal, hepatic, gastrointestinal, neurological or psychiatric disease that would limit compliance with study requirements"
4635,NCT03143985,"24:46:chronic_disease,74:120:chronic_disease,122:146:chronic_disease,164:179:chronic_disease,192:213:chronic_disease,217:223:chronic_disease,,288:299:chronic_disease","Clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association (NYHA) Class 3 or 4, congestive heart failure, uncontrolled or unstable angina, history of myocardial infarction or stroke within 6 months prior to study entry, or clinically significant arrhythmias not controlled by medication"
4636,NCT03143985,"1:26:treatment,28:40:treatment,42:50:treatment,59:71:treatment,77:90:treatment,,128:145:treatment,153:162:treatment,","Prior anti-cancer therapy (chemotherapy, targeted agents, radiotherapy, and immunotherapy) within the prior 21 days except for alkylating agents (e.g., melphalan) within the prior 28 days"
4637,NCT03143894,",,86:114:treatment,126:133:treatment,135:152:treatment,157:183:treatment","Treatment Status: At least 6 months and no more than 5 years after the conclusion of active breast cancer therapy, including surgery, radiation therapy and (neo)adjuvant chemotherapy, if administered"
4638,NCT03141359,"23:38:treatment,98:115:treatment,178:187:treatment,201:211:cancer",Subjects who have had prior radiation to the region of the chest that would result in overlap of radiation therapy fields and determined by the treating physician to impede the treatment of the study malignancy
4639,NCT03140527,"1:7:cancer,,43:66:cancer,72:88:treatment,,134:158:cancer",cancer within the past 5 years (excluding cervical cancer in situ with curative therapy for at least one year prior to screening and non-melanoma skin cancer)
4640,NCT03139227,"19:28:treatment,30:40:treatment,56:76:treatment","Concurrent use of tamoxifen, raloxifene, or any of the aromatase inhibitors"
4641,NCT03138733,"1:10:treatment,39:58:treatment,60:92:treatment,,",Treatment with potentially effective (anti-staphylococcal) systemic antibacterial treatment for more than 48 h within the 7 days prior to randomization
4642,NCT03137771,"43:56:treatment,78:86:treatment,106:124:chronic_disease,149:167:treatment,,197:212:treatment,214:238:treatment,243:266:treatment","Patients who received prior non-induction pembrolizumab, patients on chronic steroids or who have active autoimmune disease for which they received systemic treatment in the previous 2 years with corticosteroids, disease modifying agents, or immunosuppressive drugs"
4643,NCT03137758,"10:32:treatment,55:59:cancer,63:67:cancer,,",received cytotoxic chemotherapy for either metastatic HSPC or CRPC within the last 12 weeks or other investigational agents within 4 weeks
4644,NCT03137498,"32:41:allergy_name,45:64:allergy_name,68:76:allergy_name,78:82:allergy_name,84:91:allergy_name,93:102:allergy_name","Reported/documented allergy to lidocaine OR ketorolac (Toradol) OR morphine, corn, aspirin, ibuprofen"
4645,NCT03137121,"12:23:chronic_disease,30:46:cancer,48:64:chronic_disease","History of CNS disease (e.g. brain metastases, seizure disorder)"
4646,NCT03135990,"33:75:chronic_disease,83:115:chronic_disease,119:144:chronic_disease",A prior or present diagnosis of receptive and expressive language disorder and/or pervasive developmental disorder or severe mental retardation
4647,NCT03135171,"10:19:treatment,25:36:treatment,46:110:treatment,122:132:treatment,134:146:treatment,148:158:treatment,160:169:treatment,171:181:treatment,183:191:treatment,","Previous treatment with tocilizumab or other cytokine-targeted biologic disease modifying antirheumatic drugs (including adalimumab, certolizumab, etanercept, golimumab, infliximab, anakinra) within 3 months of enrollment"
4648,NCT03133013,"12:22:treatment,38:48:treatment,50:62:treatment,64:71:treatment,73:79:treatment,91:99:treatment","Prescribed interferon regularly with stimulants, opioid drugs (Ritalin, Opioid, etc.) and steroids"
4649,NCT03131635,"1:17:treatment,25:50:treatment,53:67:treatment,69:95:treatment,99:125:treatment,","Stable treatment (e.g., applied behavior analysis), speech therapy, psychotropic medication(s) or biomedical intervention(s) for at least 1 month prior to baseline measurements with no anticipated changes during study participation"
4650,NCT03131037,"1:30:treatment,61:92:treatment,101:118:treatment",Prior bone marrow transplants (including stem cells) except autologous stem cell transplant without immunosuppression is NOT considered an exclusion
4651,NCT03130218,"8:31:chronic_disease,40:46:chronic_disease,50:94:chronic_disease",Severe reactive airway disease such as asthma or chronic obstructive pulmonary disease (COPD)
4652,NCT03126370,"18:21:treatment,28:37:treatment,42:79:treatment,109:118:treatment,122:125:chronic_disease",Have been taking TDF and a ritonavir- or cobicistat-boosted protease inhibitor as part of standard care for treatment of HIV
4653,NCT03125902,"1:24:chronic_disease,55:62:treatment,70:79:treatment",Spinal cord compression not definitively treated with surgery and/or radiation
4654,NCT03124355,"37:57:chronic_disease,65:76:chronic_disease,78:89:treatment","Medical conditions that can explain postural tachycardia (e.g., dehydration, medications)"
4655,NCT03123783,"55:80:treatment,99:118:cancer,122:127:cancer",History of life-threatening toxicity related to prior anti-PD-1/PD-L1 treatment for subjects with metastatic melanoma or NSCLC
4656,NCT03123198,"92:105:chronic_disease,126:134:chronic_disease,167:197:treatment","Clients who need mental health services not available at the DBT-RU, such as treatment for schizophrenia or life-threatening anorexia, or who are currently obtaining optimum professional treatment that should not be ended"
4657,NCT03123055,"32:61:chronic_disease,63:83:chronic_disease,98:109:chronic_disease,111:133:chronic_disease","Participants with a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on the Screening chest CT scan"
4658,NCT03122912,"10:15:treatment,44:51:treatment,79:85:treatment,",Frequent NSAID use (not including low dose aspirin) and not willing to go off NSAIDS for 3 weeks prior to enrollment and to end of study
4659,NCT03122691,"12:34:chronic_disease,55:64:chronic_disease,66:91:chronic_disease","History of xerostomia (dry mouth), or the presence of mucositis, gum infection or bleeding, or other significant oral cavity disease or disorder that in the investigator's opinion may affect the collection of oral fluid samples"
4660,NCT03121352,"45:116:allergy_name,118:129:allergy_name,131:144:allergy_name,149:161:allergy_name","History of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-paclitaxel, carboplatin, pembrolizumab, or other agents used in this study"
4661,NCT03120728,"71:97:treatment,99:107:treatment,109:118:treatment,120:133:treatment","Use of medications that interact with contraceptive steroid hormones: anti-epileptic medications, rifampin, rifabutin, fosamprenavir, etc"
4662,NCT03119363,"24:41:chronic_disease,80:86:chronic_disease,105:115:treatment,,","Confounding underlying medical illnesses which may cause fatigue (e.g., severe Anemia not controlled by medication, per self-report corroborated by medical chart review (e.g., Hb<10gm/dl)"
4663,NCT03118973,"1:17:chronic_disease,19:31:chronic_disease,59:83:treatment","Thrombocytopenia, coagulopathy, or indication for ongoing anti-coagulation therapy"
4664,NCT03116685,"18:41:chronic_disease,28:41:chronic_disease,69:86:treatment,98:123:chronic_disease,132:147:chronic_disease,157:183:chronic_disease,188:208:chronic_disease","The existence of secondary hyperoxaluria, e.g. hyperoxaluria due to bariatric surgery or chronic gastrointestinal diseases such as cystic fibrosis, chronic inflammatory bowel disease and short-bowel syndrome"
4665,NCT03115398,"14:46:cancer,48:68:cancer,70:74:cancer,76:98:cancer,103:117:cancer","Diagnosis of invasive malignancy of the brain, head and neck region, lung, gastrointestinal tract, or uterine cervix"
4666,NCT03114020,",,84:103:treatment,105:123:treatment,125:148:treatment,153:156:treatment,","men who are sexually active must agree to use an adequate method of contraception (oral contraceptives, depot progesterone, condom plus spermicidal, or IUD) during the study and for 1 month after the final dose of study drug"
4667,NCT03113825,"1:24:treatment,28:44:treatment,57:70:cancer,,95:110:treatment",Prior neoadjuvant chemo or biologic therapy for current breast cancer within 4 weeks prior to planned surgery [Period 1]
4668,NCT03112863,"29:37:treatment,41:59:treatment,,123:140:chronic_disease,150:176:treatment,178:192:treatment,194:215:treatment,232:251:treatment","Those who have had a recent surgical or cosmetic procedure in the last 3 months that can affect facial wrinkles or facial hyperpigmentation, such as botulinum toxin injections, chemical peels, laser based therapies to the face, or face lift surgeries"
4669,NCT03112603,"205:239:treatment,250:268:treatment,270:297:treatment,299:340:treatment,342:352:treatment,354:363:treatment,365:376:treatment,378:386:treatment,388:397:treatment","must accept to be treated with only one of the following BAT options on Cycle 1 Day 1 (additions and changes are allowed during the course of the study, but only with BAT from the following BAT options): extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, ibrutinib"
4670,NCT03112590,"31:54:treatment,75:86:treatment,91:101:treatment",Must be candidates to receive paclitaxel chemotherapy in combination with trastuzumab and pertuzumab
4671,NCT03112174,"26:29:cancer,230:270:treatment,275:306:treatment","Pathologically confirmed MCL (in tumor tissue), with documentation of either overexpression of cyclin D1 in association with other relevant markers (eg, CD19, CD20, PAX5, CD5) or evidence of t(11;14) as assessed by cytogenetics, fluorescent in situ hybridization (FISH), or polymerase chain reaction (PCR)"
4672,NCT03110354,"32:50:cancer,59:70:cancer,74:82:cancer,96:105:treatment",Has a second concurrent active primary malignancy such as solid tumor or lymphoma under active treatment
4673,NCT03110107,"19:43:cancer,48:54:cancer,60:74:cancer","Participants with primary CNS malignancies, or tumors with CNS metastases as the only site of disease, will be excluded"
4674,NCT03109210,"11:31:chronic_disease,39:55:chronic_disease,122:132:treatment","untreated psychiatric disorder (e.g., major depression) found on structured interviews as these conditions have specific treatments and it would be inappropriate not to offer those treatments"
4675,NCT03104725,"14:34:chronic_disease,49:58:treatment,66:77:treatment",History of a post-spinal headache that required treatment with a blood patch
4676,NCT03104699,"1:14:treatment,24:98:treatment,107:116:treatment,118:128:treatment,133:190:treatment","Prior therapy with any antibody/drug targeting T-cell co-regulatory proteins (immune checkpoints) such as anti-PD-1, anti-PD-L1, or anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibodies"
4677,NCT03104699,"15:58:cancer,78:87:treatment,93:154:treatment","subjects with castration-resistant prostate cancer (CRPC), who may remain on treatment with luteinizing hormone-releasing hormone agonists or antagonists"
4678,NCT03101566,"12:28:treatment,,,82:92:treatment,144:162:chronic_disease","Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease"
4679,NCT03101566,"32:56:treatment,58:70:treatment,74:90:treatment,105:131:cancer",Patients may not have received prior systemic treatment (chemotherapy or targeted therapy) for advanced BTC (biliary tract cancer)
4680,NCT03100435,"36:57:allergy_name,67:104:chronic_disease,108:126:chronic_disease","Subjects with contraindications to wearing a mouth guard, such as chronic obstructive pulmonary disease or severe sleep apnea"
4681,NCT03097588,"125:135:allergy_name,137:149:allergy_name,151:164:allergy_name","Subjects with known hypersensitivity or other allergic reactions attributed to compounds of similar biologic composition to netupitant, palonosetron, dexamethasone, or other agents used in the study"
4682,NCT03095118,"27:52:treatment,63:79:treatment,81:84:treatment,86:98:treatment,100:110:treatment,114:126:treatment,","Patients who had received immunosuppressive therapy including cyclophosphamide, MMF, cyclosporine, tacrolimus or azathioprine in the last 3 months"
4683,NCT03093909,"77:93:chronic_disease,95:106:chronic_disease,119:134:chronic_disease,136:155:chronic_disease,157:193:chronic_disease,195:219:chronic_disease,221:239:chronic_disease,244:281:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, bradycardia, related to cardiac disease, bundle branch block, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
4684,NCT03093272,"1:10:treatment,16:35:treatment,40:44:chronic_disease",Treatment with abiraterone acetate for CRPC in the past is required
4685,NCT03092635,"16:32:cancer,82:90:treatment,94:118:treatment","Treated stable brain metastases are allowed, as long as patient does not require steroids or anti-seizure medications"
4686,NCT03090607,"12:31:chronic_disease,33:46:chronic_disease,83:119:treatment","History of heartburn-like pain, regurgitation, or both prior to the initiation of proton pump inhibitor (PPIs) therapy"
4687,NCT03089554,"14:34:chronic_disease,77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease,253:269:treatment","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with targeted therapy, in the opinion of the treating physician"
4688,NCT03088072,"1:11:chronic_disease,16:30:chronic_disease,44:64:chronic_disease","AV fistula, or pseudoaneurysm), or serious pericardial effusion)"
4689,NCT03088033,"13:15:chronic_disease,34:43:treatment,49:58:treatment,",Symptoms of HF requiring current treatment with diuretics for > 30 days
4690,NCT03087903,"15:40:chronic_disease,54:88:treatment,100:131:treatment",Patients with hormone sensitive disease who received prior androgen deprivation therapy as part of primary/salvage local treatment
4691,NCT03085485,"24:35:chronic_disease,46:70:treatment,74:98:chronic_disease",Clinically significant arrhythmias requiring anti-arrhythmic agent(s) or conduction abnormalities that in the opinion of the investigator that affect patient safety
4692,NCT03085095,"118:125:treatment,127:144:treatment,146:157:treatment,212:240:treatment","Evidence of biochemical (PSA) or clinical relapse following local primary intervention with curative intent, such as surgery, radiation therapy, cryotherapy, or high-frequency ultrasound and not a candidate for salvage treatment by surgery"
4693,NCT03084640,"21:36:chronic_disease,,109:121:chronic_disease,123:138:chronic_disease,140:166:chronic_disease,170:200:chronic_disease","Severe uncontrolled cardiac disease within 6 months of screening, including but not limited to uncontrolled hypertension; unstable angina; myocardial infarction (MI) or cerebrovascular accident (CVA)"
4694,NCT03079297,"1:24:treatment,26:29:treatment,34:38:treatment,49:81:treatment","Vagus nerve stimulation, ECT, or rTMS, or other somatic antidepressant treatment during current episode"
4695,NCT03078530,"32:46:chronic_disease,58:66:chronic_disease,71:77:chronic_disease",Normal gross appearance of the colonic mucosa other than erythema and polyps
4696,NCT03078192,"27:30:chronic_disease,32:59:chronic_disease,63:75:chronic_disease,77:114:chronic_disease,118:143:chronic_disease,148:153:chronic_disease","Either has a diagnosis of PAH, isolated left heart disease or lung disease (chronic obstructive pulmonary disease or interstitial lung disease) or CTEPH using established clinical criteria"
4697,NCT03077412,"12:33:treatment,35:50:treatment,64:73:treatment,77:86:treatment,114:121:treatment","History of total proctocolectomy, total colectomy, presence of ileostomy or colostomy, or likely requirement for surgery during the study"
4698,NCT03077243,"1:38:chronic_disease,61:80:chronic_disease,127:134:treatment",Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
4699,NCT03076034,"12:31:cancer,33:60:chronic_disease,62:77:chronic_disease,79:95:cancer","History of skeletal metastasis, primary hyperparathyroidism, Paget's disease, multiple myeloma"
4700,NCT03075826,"14:26:treatment,62:73:treatment,91:103:treatment,,",have had any chemotherapy (investigational or FDA approved) (hydroxyurea is permitted) or radiotherapy within 2 weeks prior to study entry or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier
4701,NCT03073785,"1:23:cancer,67:81:cancer,90:116:cancer,131:148:chronic_disease,171:186:cancer","T 1-2N+MO or T3-4 NxMo, or borderline resectable and unresectable adenocarcinoma without distant metastatic disease or resectable T3-4 NxMo disease or M1 with controlled distant disease"
4702,NCT03073343,"13:26:chronic_disease,38:71:chronic_disease,75:104:chronic_disease",Evidence of liver disease other than non-alcoholic fatty liver disease or non-alcoholic steatohepatitis
4703,NCT03072238,"21:35:chronic_disease,37:46:chronic_disease,51:72:chronic_disease","Any other diseases, cardiovascular, pulmonary, or metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the participants at high risk from treatment complications"
4704,NCT03072238,"27:66:cancer,93:119:treatment,123:138:treatment",Known untreated or active central nervous system (CNS) metastases (progressing or requiring anticonvulsant medications or corticosteroids for symptomatic control)
4705,NCT03072238,"1:33:treatment,56:72:treatment,80:92:treatment,94:103:treatment","Prior treatment with abiraterone or other known potent CYP17 inhibitors (e.g., ketoconazole, orteronel) or investigational agents that block androgen synthesis"
4706,NCT03072238,"1:25:chronic_disease,40:77:chronic_disease,79:107:chronic_disease","structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy)"
4707,NCT03071692,"1:16:chronic_disease,8:16:chronic_disease,,,,,,,,,,409:418:treatment","Type 2 diabetes of longer than 12 weeks duration documented in medical records, for example: local laboratory evidence through medical record review of elevated HbA1c (? 6.5% [48 mmol/mol]), elevated plasma glucose (fasting ? 126 mg/dL [7.0 mmol/L], 2-hour ? 200 mg/dL [11.1 mmol/L] during oral glucose tolerance testing, or random value ? 200 mg/dL with classic symptoms, or currently taking medication for treatment of diabetes; AND either"
4708,NCT03070535,"17:42:chronic_disease,61:81:treatment,85:92:treatment","Diabetes: Known type 1 or Type 2 diabetes, currently taking diabetic medications or insulin"
4709,NCT03070535,"7:26:chronic_disease,37:64:chronic_disease,66:90:chronic_disease,96:110:chronic_disease","Major digestive disorders including inflammatory bowel diseases, irritable bowel syndrome, and celiac disease"
4710,NCT03070535,"8:16:treatment,18:30:treatment,47:74:treatment","Use of estrogen, testosterone, and continuous corticosteroid replacements will be excluded, as these may have effects on study outcomes"
4711,NCT03070340,"28:38:allergy_name,111:114:treatment,179:193:treatment",Known allergic reaction to gadolinium; patient may be eligible if the referring physician determines that the MRI is medically necessary and if the patient is willing to undergo pre-medication for contrast allergy
4712,NCT03070145,"24:39:chronic_disease,48:69:chronic_disease,71:105:chronic_disease,111:125:chronic_disease","Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement"
4713,NCT03069469,"7:35:chronic_disease,44:55:chronic_disease,64:75:chronic_disease,87:123:chronic_disease","Known human immunodeficiency virus, active hepatitis B, active hepatitis C, or active mycobacterium tuberculosis infection"
4714,NCT03068442,"24:38:chronic_disease,50:69:chronic_disease,110:130:chronic_disease,134:151:cancer,153:165:chronic_disease,,","Other known sources of cardioembolism, including atrial fibrillation, mechanical heart valve, left atrial or ventricular thrombus or intracardiac mass, endocarditis, EF <30%"
4715,NCT03067051,",,,,134:154:treatment,156:173:chronic_disease,188:197:treatment",history of CTCAE v4 grade 3 or greater or persistent (>1 separate episode or symptoms lasting more than 3 months after initiation of medical intervention) grade 2 proctitis attributed to radiation
4716,NCT03061201,",23:37:chronic_disease,41:53:treatment,91:102:chronic_disease,119:140:chronic_disease",Presence of > grade 2 liver fibrosis on elastography for subjects with history of treated Hepatitis C or suspicion of chronic liver disease
4717,NCT03059888,"61:71:chronic_disease,135:146:chronic_disease,148:159:chronic_disease,163:166:chronic_disease","Subject has evidence of active or latent bacterial or viral infections, including positive infectious disease laboratory test result (Hepatitis B, Hepatitis C or HIV)"
4718,NCT03059030,"56:71:allergy_name,73:82:allergy_name,84:93:allergy_name,97:105:allergy_name","History of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically"
4719,NCT03058679,",25:40:treatment,,,88:98:treatment,102:112:treatment",Start or change dose of corticosteroids within 1 week of screening or a dose >20mg/day prednisone or equivalent
4720,NCT03058146,"12:33:chronic_disease,35:56:chronic_disease,58:64:chronic_disease","History of major vascular events (myocardial infarction, stroke, etc)"
4721,NCT03058029,"1:7:chronic_disease,9:24:treatment,29:50:chronic_disease,","Angina, coronary bypass, or myocardial infarction within six(6)months prior to Screening Visit"
4722,NCT03056339,"23:49:treatment,59:77:treatment,,130:158:treatment",Patients may continue tyrosine kinase inhibitors or other targeted therapies until at least two weeks prior to administration of lymphodepleting chemotherapy
4723,NCT03056287,"12:36:chronic_disease,38:66:chronic_disease,68:95:chronic_disease,97:119:chronic_disease,121:127:chronic_disease,131:138:chronic_disease","history of congestive heart failure, unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during ADL's"
4724,NCT03053453,"7:31:treatment,40:63:treatment,67:76:treatment",Prior ipsilateral knee surgery such as ligament reconstruction or osteotomy
4725,NCT03050801,"13:31:chronic_disease,35:55:chronic_disease,69:72:chronic_disease,103:109:chronic_disease,111:128:chronic_disease,130:147:chronic_disease,149:162:chronic_disease,166:182:chronic_disease","Any current major neurological or psychiatric disorder unrelated to TBI, such as (but not limited to) stroke, Parkinson disease, Alzheimer disease, schizophrenia or major depression"
4726,NCT03049189,"1:6:chronic_disease,8:15:chronic_disease,17:31:chronic_disease,36:68:chronic_disease","Renal, hepatic, cardiovascular, or haematological organ dysfunction, potentially interfering with the safety of the study treatments"
4727,NCT03046017,"38:50:treatment,65:82:treatment,84:98:treatment,100:114:chronic_disease,,150:162:treatment","Presence of any contraindications to MRI scanning. For example: cardiac pacemaker, metal implants, claustrophobia, pregnancy, cannot lie still in an fMRI scanner"
4728,NCT03043807,"1:14:treatment,21:33:treatment,35:45:treatment","Antiandrogens (e.g. bicalutamide, nilutamide)"
4729,NCT03043794,"20:25:cancer,29:61:treatment,57:60:treatment","Clearly demarcated tumor on magnetic resonance imaging (MRI), as determined by treating physician (MRI may be done after enrollment if not done prior)"
4730,NCT03042767,"1:41:chronic_disease,65:77:treatment,81:84:treatment",Nonalcoholic fatty liver disease (NAFLD) diagnosis confirmed by liver biopsy or MRI
4731,NCT03042689,"1:14:cancer,32:43:treatment,71:78:treatment",myelofibrosis that have failed ruxolitinib or are ineligible for this therapy
4732,NCT03040726,"23:39:treatment,43:58:treatment,63:74:treatment",Expected to use other 5HT3 antagonists or NK1 antagonists for prophylaxis during the study
4733,NCT03040726,"1:21:treatment,23:30:treatment,32:48:treatment,54:70:treatment,,","Total (T.) bilirubin, albumin, prothrombin time, and serum creatinine tests can be done within 14 days of study enrollment (only if not performed in the last 14 days)"
4734,NCT03038620,"18:46:chronic_disease,54:67:chronic_disease,69:85:chronic_disease","History of other severe psychiatric disorders, e.g., schizophrenia, bipolar disorder"
4735,NCT03037931,"1:28:chronic_disease,30:53:chronic_disease,55:80:chronic_disease,85:91:chronic_disease,","Acute myocardial infarction, acute coronary syndrome, transient ischemic attack, or stroke within 30 days of enrollment"
4736,NCT03037931,",41:73:treatment,75:90:treatment,95:112:treatment","the recent receipt (within 3 months) of erythropoietin stimulating agent, IV iron therapy, or blood transfusion"
4737,NCT03037385,"58:107:cancer,73:78:cancer,132:135:treatment","have a pathologically documented, definitively diagnosed advanced solid tumor with an oncogenic RET fusion previously treated with SOC appropriate for the tumor type and not eligible for any of the other groups"
4738,NCT03036098,"1:16:treatment,25:33:treatment,35:44:treatment,46:55:treatment,57:67:treatment,72:91:treatment,146:167:treatment,171:190:treatment","Prior treatment with an anti-PD1, anti-PDL1, anti-PDL2, anti-CD137, or anti-CTLA4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways"
4739,NCT03035474,",,50:66:treatment,68:95:treatment,97:130:treatment,132:158:treatment,163:186:treatment","LVEF ? 40% based on last local measurement using echocardiography, multigated acquisition scan, computed tomography (CT) scanning, magnetic resonance imaging, or ventricular angiography"
4740,NCT03034772,"43:55:treatment,63:74:chronic_disease,76:103:chronic_disease,105:142:chronic_disease,144:167:chronic_disease,169:175:chronic_disease","Any contraindication for topical use of a beta-blocker (e.g., bradycardia, decompensated heart failure, chronic obstructive pulmonary disease, reactive airway disease, asthma, etc.)"
4741,NCT03034213,"7:24:cancer,44:56:treatment,,,156:176:cancer,178:201:cancer,206:229:cancer","Known active malignancy present and/or had chemotherapy 12 weeks prior to screening or planned chemotherapy within 12 weeks of treatment with exception of basal cell carcinoma, squamous cell carcinoma, or prostate cancer in situ"
4742,NCT03033212,"7:21:treatment,32:43:treatment,44:54:treatment",Prior spinal surgery excluding laminectomy/discectomy
4743,NCT03030118,"28:62:chronic_disease,64:75:chronic_disease,80:91:chronic_disease","Evidence of infection with human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C"
4744,NCT03029884,"1:18:chronic_disease,,,39:84:chronic_disease,86:117:chronic_disease,119:132:chronic_disease,134:150:chronic_disease,152:187:chronic_disease","Active depression (BDI > 20) or other untreated or uncontrolled psychiatric illness (active general anxiety disorder, schizophrenia, bipolar disorder, obsessive-compulsive disorder (OCD)"
4745,NCT03029884,"1:4:treatment,,58:65:treatment,74:78:chronic_disease,80:86:chronic_disease,88:98:chronic_disease","MRI done within one year not showing contraindication to surgery such as mass, lesion, hemorrhage or other abnormality near target"
4746,NCT03029806,"15:27:chronic_disease,29:37:chronic_disease,39:45:chronic_disease,47:70:chronic_disease,72:86:chronic_disease,88:94:cancer,96:111:chronic_disease,113:125:chronic_disease,130:146:treatment,","No history of hypertension, diabetes, stroke, coronary artery disease, kidney disease, cancer, thyroid disease, preeclampsia, or hospitalizations in 6 months"
4747,NCT03028350,"12:57:treatment,88:109:treatment,,148:157:treatment",Any use of nonsteroidal anti-inflammatory drugs (NSAIDs) or any drug that inhibits the cyclooxygenase enzyme in the last two weeks before starting treatment
4748,NCT03027388,"27:45:treatment,49:65:treatment,,143:159:treatment","Patients may not have had prior chemotherapy or biologic therapy in the 4 weeks prior to study entry. For patients who have been treated with targeted therapy, 5 half-lives of that therapy (or 28 days, whichever is shorter) must have passed prior to enrollment in the study"
4749,NCT03025139,"20:27:treatment,29:38:treatment,47:70:treatment,","Have completed all surgery, radiation, and/or chemotherapy treatments at least 6 months previously"
4750,NCT03023449,"12:37:chronic_disease,46:52:chronic_disease,56:93:chronic_disease",History of chronic pulmonary disease such as asthma or chronic obstructive pulmonary disease
4751,NCT03022292,"5:39:treatment,85:146:treatment,148:174:treatment,176:193:treatment,195:219:treatment,221:247:treatment,249:272:treatment,288:336:treatment","Any prior treatment of neovascular AMD in the eye proposed for enrollment including previous anti-vascular endothelial factor (anti-VEGF) therapy, photodynamic therapy (PDT), radiation therapy, corticosteroid treatment, surgical treatment for CNV, thermal laser treatment, and any other prior intravitreal treatment for neovascular AMD (except minerals and vitamins)"
4752,NCT03021538,"1:16:chronic_disease,17:31:chronic_disease,42:51:chronic_disease,115:127:treatment",Cystic fibrosis/bronchiectasis/resistant infection patients where surgeon will need to remove both lungs prior to implantation
4753,NCT03019133,"11:31:chronic_disease,33:43:chronic_disease,45:72:chronic_disease,74:84:chronic_disease,86:107:chronic_disease,117:131:chronic_disease","Untreated sleep apnea disorder, narcolepsy, REM sleep behavior disorder, parasomnia, restless leg syndrome or other sleep disorder"
4754,NCT03016871,"34:44:cancer,,97:115:treatment,119:139:cancer,143:178:cancer,183:201:cancer,206:230:cancer,237:253:treatment","Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy"
4755,NCT03016130,"1:35:cancer,49:81:treatment,89:100:treatment,102:111:treatment,113:129:treatment,,","Acute lymphoblastic leukemia (ALL) receiving an intensive induction chemotherapy (e.g., HyperCVAD±R, CALGB9251, Larsons protocol) with an expected duration of neutropenia of ?7 days"
4756,NCT03013543,"14:27:chronic_disease,29:45:chronic_disease,47:67:chronic_disease,234:258:chronic_disease","Diagnosis of schizophrenia, bipolar disorder, personality disorder or other Diagnostic and Statistical Manual of Mental Disorders (DSM-III) disorders that the investigator believes will interfere significantly with study compliance. Neurocognitive disorders affecting ability to consent will not be disqualifying as long as an appropriate guardian able to give consent has been appointed"
4757,NCT03011567,"1:10:chronic_disease,12:34:chronic_disease,36:65:chronic_disease","Hemolysis, Elevated Liver Enzymes, Low Platelet (HELLP) Syndrome"
4758,NCT03009981,"58:72:treatment,,97:107:treatment,108:120:treatment",Any chronic medical condition requiring a higher dose of corticosteroid than equivalent of 5 mg prednisone/prednisolone once daily
4759,NCT03009981,"1:35:treatment,80:92:treatment,94:104:treatment,106:115:treatment,145:160:cancer","Prior androgen deprivation therapy and/or first generation anti-androgen (e.g. bicalutamide, nilutamide, flutamide) for biochemically recurrent prostate cancer"
4760,NCT03008408,"12:36:chronic_disease,48:69:chronic_disease,71:86:chronic_disease,88:119:chronic_disease,121:141:chronic_disease,171:183:chronic_disease,","History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis within 6 months prior to screening"
4761,NCT03008408,"18:42:chronic_disease,53:76:chronic_disease,80:94:chronic_disease,107:122:chronic_disease,173:184:chronic_disease","Risk factors for Torsades de Pointe (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia"
4762,NCT03008070,"24:44:chronic_disease,65:87:chronic_disease,105:126:chronic_disease","History of, or current cardiac dysrhythmias and/or a history of cardiovascular disease event, including myocardial infarction, except patients with only well controlled hypertension"
4763,NCT03007745,"10:19:treatment,25:49:treatment,51:68:treatment,73:76:chronic_disease,96:115:treatment","Previous treatment with positive airway pressure, non-nasal surgery for OSA, or current use of supplemental oxygen"
4764,NCT03006302,"1:13:treatment,15:24:treatment,29:54:treatment,","Chemotherapy, radiation, or biological cancer therapy within 14 days of study treatment"
4765,NCT03006302,"1:33:treatment,35:44:treatment,46:56:treatment,61:71:treatment,81:94:treatment","Prior treatment with anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti PD-L2, or with IDO inhibitor"
4766,NCT03004807,"1:35:treatment,47:62:chronic_disease,129:144:chronic_disease,156:170:chronic_disease,172:188:chronic_disease,190:208:chronic_disease,210:219:chronic_disease,239:261:chronic_disease","Bariatric (gastric bypass) surgery or serious chronic illness that might affect absorption of multivitamins or minerals such as Crohn's disease, unmanaged celiac disease, chronic diarrhea, ulcerative colitis, gastritis, or a diagnosis of malabsorption syndrome"
4767,NCT03004807,"1:14:chronic_disease,18:40:chronic_disease,60:68:chronic_disease","psychological or neurological disorders, or a diagnosis of dementia"
4768,NCT03003689,"49:62:chronic_disease,64:97:chronic_disease,99:124:chronic_disease,126:144:chronic_disease","significant chronic oral soft tissue pathology (lichen planus, Benign Mucous Membrane Pemphigoid, Steven Johnson's Syndrome, Sjogren's Syndrome, etc.)"
4769,NCT03001882,"27:75:cancer,84:117:treatment,127:142:treatment,159:177:cancer","Histologically confirmed, stage IV or recurrent non-small cell lung cancer with no prior systemic anticancer therapy given as primary therapy for advanced or metastatic disease"
4770,NCT03001765,"34:52:chronic_disease,56:70:chronic_disease,72:85:chronic_disease,87:90:chronic_disease","Previous documented diagnosis of cardiac arrhythmia by holter monitor, event monitor, ECG"
4771,NCT03000257,"34:60:chronic_disease,62:73:chronic_disease,84:107:cancer","Participant has known history or inflammatory bowel disease, pneumonitis, or known uncontrolled metastases to the central nervous system (CNS) (with certain exceptions)"
4772,NCT02996227,"1:15:treatment,56:64:treatment,68:78:treatment",Anticoagulants considered to be a contraindication for epidural or TAP blocks
4773,NCT02995590,"12:14:chronic_disease,16:22:chronic_disease,48:60:chronic_disease","History of MI, stroke and/or poorly controlled hypertension"
4774,NCT02995330,"1:14:treatment,36:52:treatment,70:82:treatment,84:94:treatment,96:105:treatment,107:119:treatment,121:132:treatment,134:146:treatment,148:155:treatment","Prior therapy with one second line hormonal therapy is allowed (i.e. bicalutamide, nilutamide, flutamide, ketoconazole, abiraterone, enzalutamide, ARN-509)"
4775,NCT02994043,"55:76:chronic_disease,88:111:chronic_disease,113:127:chronic_disease,133:142:chronic_disease","Currently taking any medications for the treatment of psychiatric disorders, including substance use disorders, mood disorders, and psychosis"
4776,NCT02992275,"22:41:allergy_name,80:92:chronic_disease,96:112:chronic_disease,133:141:chronic_disease,154:179:chronic_disease","Contraindications to resistance training, including a self-reported history of intracranial or retinal bleeding in the last year or Diabetes with active proliferative retinopathy"
4777,NCT02991248,"24:54:chronic_disease,61:82:chronic_disease,86:124:chronic_disease",concomitant central or peripheral neurological injury (e.g. traumatic head injury or peripheral nerve damage in lower limbs)
4778,NCT02990481,"1:6:cancer,53:65:treatment,126:144:treatment",Tumor progression after receiving standard/approved chemotherapy or where there is no approved therapy or not amendable to a curative treatment
4779,NCT02988960,"21:32:treatment,60:71:cancer,95:113:treatment,104:113:treatment",Participants in all monotherapy arms must have an advanced solid tumor that has progressed on standard therapies known to provide clinical benefit or the participants are intolerant to such therapies
4780,NCT02988895,"45:67:treatment,69:91:treatment,96:126:treatment","increase the risk of structural damage from retrobulbar anesthesia, sub-Tenon's anesthesia, or retrobulbar device positioning"
4781,NCT02985554,"43:47:chronic_disease,,80:95:chronic_disease,108:113:chronic_disease","Patients who have disease relapse, active GVHD or history of more than Stage 1 skin acute GVHD, history of cGVHD"
4782,NCT02985554,"15:39:cancer,47:66:treatment,111:115:chronic_disease,,148:163:chronic_disease","Patients with hematologic malignancies status post allogeneic SCT without evidence of disease relapse, active GVHD or history of more than Stage I skin acute GVHD"
4783,NCT02985554,"1:50:cancer,51:98:cancer,99:124:cancer,148:176:cancer,,257:299:cancer,303:320:cancer,358:368:treatment,379:407:cancer,468:485:treatment","Refractory acute myelogenous or lymphoid leukemia Relapsed acute myelogenous or lymphoid leukemia Myelodysplastic syndromes with 5% or more blasts Chronic myelogenous leukemia in chronic phase 3 or more, blast phase presently, or second accelerated phase, Recurrent or refractory malignant lymphoma or Hodgkin's disease with less than a partial response at transplant High risk chronic lymphocytic leukemia defined as no response or stable disease to the most recent treatment regimen"
4784,NCT02983240,"22:31:allergy_name,104:126:chronic_disease,132:160:chronic_disease,162:190:chronic_disease,192:205:chronic_disease","Contraindication for tocolysis e.g. premature rupture of the amniotic membranes allowing for ascending intrauterine infection with group B streptococcus or GBS (beta hemolytic streptococcus, S. agalactiae) or other micro-organisms"
4785,NCT02981173,"8:26:chronic_disease,33:46:chronic_disease,48:57:chronic_disease,59:84:chronic_disease","Axis I psychotic disorder (e.g. schizophrenia, bipolar I, depression with psychosis)"
4786,NCT02979574,"1:23:chronic_disease,37:60:treatment,67:87:chronic_disease",Inflammatory arthritis that require disease modifying drugs (e.g. rheumatoid arthritis)
4787,NCT02978443,"28:44:cancer,81:88:treatment,92:101:treatment,,175:183:treatment,187:195:treatment",Patients with a history of brain metastases must have completed treatment (i.e. surgery or radiation) 1 month prior to enrollment and have no evidence of disease or edema on brain CT or head MRI
4788,NCT02977468,"9:41:cancer,43:78:cancer,80:98:cancer,106:126:cancer,158:174:treatment","include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, DCIS of the breast, or in situ cervical cancer that has undergone potentially curative therapy"
4789,NCT02974686,"21:31:allergy_name,33:42:allergy_name,53:75:allergy_name","Hypersensitivity to everolimus, sirolimus, or other rapamycin deriviatives"
4790,NCT02972840,"13:35:chronic_disease,60:83:chronic_disease,85:109:chronic_disease,114:135:chronic_disease,,188:216:chronic_disease,,","Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of first dose of study drug, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or corrected QT interval (QTc) > 480 msec (calculated using Friderica's formula: QT/RR0.33) at screening"
4791,NCT02967315,"122:154:chronic_disease,215:238:chronic_disease,256:278:chronic_disease","Patients who have lesions predisposing to chronic volume overload (i.e. patients with significant residual postoperative ventricular septal defects (VSD), or large aorto-pulmonary collaterals or more than moderate tricuspid insufficiency) since all these hemodynamic conditions can influence the late function of the right ventricle and potentially affect the response of the right side of the heart in changes in volume status"
4792,NCT02966444,"12:21:chronic_disease,25:42:chronic_disease,44:70:chronic_disease","Reports of metabolic or endocrine disease, gastrointestinal disorders, or history of medical or surgical events"
4793,NCT02963831,"9:26:chronic_disease,48:55:chronic_disease,81:113:chronic_disease,,171:208:treatment","Ongoing bowel perforation or presence of bowel fistula or abscess or history of small or large bowel obstruction within 3 months of registration, including subjects with palliative gastric drainage catheters"
4794,NCT02963831,"1:40:treatment,,110:130:treatment,132:184:treatment,186:224:treatment,228:272:treatment","Treatment with an investigational agent within 4 weeks of starting study treatment or prior treatment with a checkpoint inhibitor (cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) antibodies)"
4795,NCT02962128,"8:15:treatment,,32:38:treatment,42:62:treatment","use of aspirin (>100 mg /day), NSAIDS or oral corticosteroids"
4796,NCT02960555,"1:16:treatment,42:53:treatment,55:70:treatment,72:83:treatment,85:96:treatment,98:109:treatment","Bisphosphonates are permitted, including pamidronate, zoledronic acid, alendronate, ibandronate, risedronate"
4797,NCT02960113,",38:50:chronic_disease,52:65:chronic_disease,56:65:chronic_disease","Current history of pregnancy induced hypertension, pre-eclampsia, or eclampsia"
4798,NCT02958462,"1:25:chronic_disease,31:49:cancer,66:86:cancer,88:118:chronic_disease","Marrow failure syndromes with myeloid malignancy predisposition- telomere dysfunction, chromosomal breakage disorders, etc"
4799,NCT02956486,"13:33:chronic_disease,85:111:treatment,115:139:treatment",Any chronic inflammatory disease that is not adequately controlled or that requires systemic immunosuppressive or immunomodulatory therapy
4800,NCT02955537,"1:8:treatment,19:25:chronic_disease,29:38:chronic_disease",Steroid dependent asthma or emphysema
4801,NCT02953860,"5:13:treatment,16:28:treatment,19:28:treatment,40:52:treatment,","two biopsies - pretreatment as regards enzalutamide, and during treatment at 4 weeks"
4802,NCT02951455,"1:14:chronic_disease,16:26:chronic_disease,52:68:chronic_disease,74:83:chronic_disease","schizophrenia, depression with psychotic features, bipolar disorder, any psychosis"
4803,NCT02949726,"55:68:cancer,87:124:treatment,129:148:treatment,175:187:treatment,189:199:treatment,203:228:treatment","Participants must have been clinically diagnosed with breast cancer and scheduled for axillary lymph node dissection (ALND) and radiation treatment at MD Anderson (receiving chemotherapy, mastectomy or breast-conserving surgery"
4804,NCT02947945,"30:42:treatment,44:56:treatment,61:82:treatment,","Subjects who have received a methotrexate, azathioprine, or mycophenolate mofetil induction regimen may be included if on a stable dose for at least 4 weeks prior to visit 1"
4805,NCT02947165,"15:38:treatment,,129:162:treatment,203:215:treatment",Resistance to anti-PD-1/PD-L1 therapy is defined as: Documented progressive disease occurring while on/or within 6 months after anti-PD-1 and/or anti-PD-L1 agent (single or combination) received as the last therapy prior to enrollment
4806,NCT02946892,"29:40:treatment,,76:90:treatment,92:116:treatment,118:132:treatment,134:147:treatment,149:161:treatment,163:173:treatment,175:184:treatment,186:196:treatment,198:209:treatment,211:218:treatment,223:247:treatment","Use of any of the following medications within two weeks of randomization: MAO inhibitors, Calcium channel blockers, alpha blockers, beta blockers, disopyramide, flecainide, encainide, moricizine, propafenone, sotalol, or beta adrenergic agonists"
4807,NCT02946268,"31:58:treatment,104:136:treatment,138:151:treatment,153:169:treatment,175:201:treatment","Patients scheduled to undergo unilateral shoulder surgery at Duke University Medical Center, including arthroscopic rotator cuff repair, acromioplasty, hemiarthroplasty, and total shoulder replacement"
4808,NCT02945800,"1:30:treatment,23:30:treatment,55:84:treatment,",Myelosuppressive chemotherapy: Must not have received myelosuppressive chemotherapy within 3 weeks of protocol therapy on this study
4809,NCT02945293,"50:65:treatment,67:75:treatment,77:85:treatment,87:102:treatment,104:112:treatment","Medications that may alter oxycodone metabolism: St. John's wort, Dilantin, tegretol, corticosteroids, rifampin"
4810,NCT02942095,"80:118:allergy_name,123:133:allergy_name,140:165:allergy_name","Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO)"
4811,NCT02940288,"46:53:treatment,,85:97:treatment,123:135:treatment",Patients will be withdrawn from the study if surgery time exceeds 90 minutes or the laparoscopic procedure turned into an open surgery
4812,NCT02938559,"17:33:chronic_disease,64:74:chronic_disease,102:104:treatment","Evidence of any medical disorder or condition that could cause depression, preclude participation in CT, or is associated with memory problems, that is not currently stabilized and/or managed under the care of a physician"
4813,NCT02937402,"1:20:chronic_disease,,50:74:treatment,78:91:treatment,95:117:treatment,",Respiratory failure requiring greater than 6 Lpm supplemental oxygen (O2) by nasal cannula or mechanical ventilation within the past six weeks
4814,NCT02932280,"21:46:chronic_disease,52:60:chronic_disease,87:102:chronic_disease,104:117:chronic_disease,","Significant chronic gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption, or Grade ? 2 National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events Version 4.0 [CTCAE v.4.0] diarrhea of any etiology at baseline)"
4815,NCT02931110,"19:24:cancer,26:28:cancer,30:33:cancer,35:37:cancer,42:45:cancer,46:49:cancer,,","For subjects with DLBCL, FL, MCL, HL, or CLL/SLL: presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ?1 lesion that measures ?2.0 cm in the longest dimension [LD] and ?1.0 cm in the longest perpendicular dimension [LPD] as assessed by computed tomography [CT])"
4816,NCT02930018,"71:93:chronic_disease,127:150:treatment,203:228:treatment","Clinical history, past imaging or clinical judgment suggests that the intracranial occlusion is chronic or there is suspected intracranial dissection such that there is a predicted lack of success with endovascular intervention"
4817,NCT02929589,"85:94:allergy_name,96:105:allergy_name,110:134:allergy_name","Those patients who are allergic to, refuse to take, or are otherwise unable to take oxycodone, ibuprofen, or acetaminophen medication orally for post-operative pain management"
4818,NCT02926378,"10:19:treatment,21:34:treatment,55:68:treatment","having a pacemaker, defibrillator or wires other than sternal wires"
4819,NCT02926248,"1:13:treatment,15:26:treatment,28:39:treatment,41:52:treatment,54:62:treatment,64:75:treatment,77:84:treatment","atorvastatin, fluvastatin, pravastatin, simvastatin, fibrates, gemfibrozil, digoxin"
4820,NCT02924402,"25:34:chronic_disease,36:41:chronic_disease,43:82:chronic_disease,","Evidence of any serious bacterial, viral, parasitic or systemic fungal infections within the 30 days prior to study entry"
4821,NCT02924194,"59:70:treatment,63:70:treatment,76:85:chronic_disease,87:99:chronic_disease","Subjects with any medical contraindications to undergoing DBS surgery (eg, infection, coagulopathy, or significant cardiac or other medical risk factors for surgery)"
4822,NCT02923921,"28:45:treatment,77:87:treatment,89:97:treatment,99:109:treatment","Prior history of receiving immune modulators including, but not limited to, anti-CTLA4, anti-PD1, anti-PD-L1"
4823,NCT02922881,"1:18:treatment,8:18:treatment,20:23:treatment,24:28:treatment,",Stable medication (IMM/5ASA) use or no medication use for the past 6 weeks
4824,NCT02920788,"55:81:chronic_disease,93:103:chronic_disease,108:112:chronic_disease","Eligible participants may have other co-morbid stable neuropsychiatric disorders, including depression and PTSD"
4825,NCT02919436,"12:25:chronic_disease,27:43:chronic_disease,47:64:cancer","History of spinal trauma, spinal infection or spinal cord tumor"
4826,NCT02916524,"18:29:treatment,106:118:treatment,120:128:treatment,130:159:treatment","Currently taking medications that are known to exert significant effects on cognitive processes, such as neuroleptics, steroids, anticholinesterase inhibitors, etc"
4827,NCT02915744,"1:14:treatment,36:47:treatment,39:47:treatment,66:84:treatment,94:107:treatment,111:117:treatment,123:135:treatment,137:156:treatment","prior therapy (administered in the neoadjuvant, adjuvant, and/or metastatic setting) with an anthracycline, a taxane, and capecitabine (prior anthracycline can be omitted if not medically appropriate or contraindicated for the patient)"
4828,NCT02914509,"25:44:chronic_disease,,,98:117:chronic_disease,126:143:chronic_disease,181:206:chronic_disease",Documented diagnosis of ocular hypertension with an open angle of Schaffer Grade 3 or greater or open-angle glaucoma without pseudoexfoliation or pigment dispersion or evidence of traumatic angle recession
4829,NCT02913430,"40:51:treatment,59:67:treatment,69:81:treatment,85:103:treatment","Patients must have previously received palbociclib in the adjuvant, neo-adjuvant or metastatic setting"
4830,NCT02912572,"1:11:treatment,13:20:treatment,22:38:treatment,43:67:treatment,73:98:treatment","Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection)"
4831,NCT02912572,"8:24:chronic_disease,81:98:chronic_disease,,149:157:chronic_disease,,213:239:chronic_disease","Severe gastrointestinal conditions such as clinical or radiological evidence of bowel obstruction within 4 weeks prior to study entry, uncontrolled diarrhea in the last 4 weeks prior to enrollment, or history of inflammatory bowel disease"
4832,NCT02911831,"32:43:treatment,45:57:treatment,59:83:treatment,85:95:treatment,97:117:treatment,119:129:treatment,131:146:treatment","Can be previously treated with Depo-Lupron, Depo-Provera, Oral Contraceptive pills, Mirena IUD, endometrial ablation, myomectomy, oral progestins"
4833,NCT02911831,"72:88:chronic_disease,102:126:chronic_disease,128:151:chronic_disease,153:177:chronic_disease,179:197:chronic_disease,202:221:chronic_disease","Uncontrolled current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, subarachnoid hemorrhage, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
4834,NCT02911467,"13:29:chronic_disease,63:72:treatment,89:101:treatment",Patients on anti-coagulation they must be able to safely stop treatment for purposes of tumor biopsy
4835,NCT02910700,"38:55:chronic_disease,59:76:chronic_disease,88:114:chronic_disease",Known history of a positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection
4836,NCT02909387,"13:22:chronic_disease,26:33:chronic_disease,55:60:treatment",Is severely depressed or anxious as determined by the PHQ-4
4837,NCT02907983,"1:11:treatment,13:22:treatment,64:84:treatment","pregabalin, clonidine, selective estrogen receptor modulators, aromatase inhibitors, tissue selective estrogen complexes"
4838,NCT02905578,"1:4:chronic_disease,37:44:treatment,88:108:treatment,123:140:treatment",HIV positive individuals undergoing therapy due to known drug:drug interaction between antiretroviral drugs and high-dose ascorbate therapy
4839,NCT02901314,"38:49:chronic_disease,61:69:chronic_disease,71:84:chronic_disease,92:104:chronic_disease","adhere to self-care recommendations (Alzheimer's condition, dementia, schizophrenia, other neurological history that impairs memory)"
4840,NCT02900794,"21:37:chronic_disease,39:58:chronic_disease,60:81:chronic_disease","Patients with known immunodeficiency, ciliary dysfunction, uncontrolled diabetes"
4841,NCT02893982,"21:47:treatment,,108:127:treatment,132:140:treatment,,",Patients who are on anticoagulation medication that may not be safely held for the procedure (? 5 days for antiplatelet agents and warfarin; ? 24 hours for low-molecular weight heparin formulations) will be excluded
4842,NCT02891564,"8:26:treatment,30:55:treatment,81:96:treatment",use of psychotropic drugs or cholinesterase inhibitors other than mild doses of benzodiazepines
4843,NCT02890979,"32:53:cancer,64:71:chronic_disease,88:126:chronic_disease",Subjects with risk factors for esophageal malignancy including Barrett?s esophagus and gastroesophageal reflux disease (GERD)
4844,NCT02885649,"83:104:chronic_disease,106:129:treatment,131:146:chronic_disease,148:167:chronic_disease,188:212:chronic_disease,217:241:chronic_disease,","Any unstable, serious co-existing medical conditions including but not limited to myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within twelve (12) months prior to screening"
4845,NCT02881242,"5:18:treatment,20:42:treatment,44:78:treatment,44:56:treatment,80:96:treatment,101:114:treatment,,","Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 30 days of enrollment and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days of enrollment"
4846,NCT02879136,"99:109:chronic_disease,111:124:chronic_disease,134:155:chronic_disease","Concomitant conditions that may affect significantly the evaluation of balance or gait, including orthopedic, rheumatologic or other neurological diseases"
4847,NCT02877394,"16:25:treatment,27:34:treatment,36:42:treatment,44:49:treatment,51:69:treatment,72:83:treatment,85:97:treatment,103:115:treatment,,","Current use of laxatives (MiraLax, Ex-lax, senna, herbal supplements), linaclotide, lubiprostone, and prucalopride to treat constipation- patients using these medications will be eligible to participate if they can discontinue the medication at least 3 days (72 hrs.) before the date of screening and are willing to stay off them till the study is complete"
4848,NCT02877134,"1:12:treatment,37:46:treatment,50:65:chronic_disease",Antibiotics being used as a primary treatment of Crohn's disease
4849,NCT02877134,"1:21:treatment,,,112:122:treatment,136:163:treatment","Oral corticosteroids at a prednisone-equivalent dose at or below 40 milligram per day (mg/day), or 9 mg/day of budesonide, or 5 mg/day beclomethasone dipropionate"
4850,NCT02876302,"32:39:cancer,,103:126:cancer,132:181:cancer","Individuals with the following cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin"
4851,NCT02876302,",,53:63:treatment,65:76:treatment,82:98:treatment","Pregnant women are excluded from this study because paclitaxel, doxorubicin, and cyclophosphamide have the potential for teratogenic or abortifacient effects"
4852,NCT02873598,",,82:103:treatment,123:133:treatment,137:148:treatment,153:167:treatment,,","Completion of at least 3 months, but no more than 6 months of standard induction chemotherapy for LAPC, which may include FOLFIRINOX or gemcitabine and nab-paclitaxel, preferably within 2-4 weeks but no longer than 8 weeks"
4853,NCT02867696,"17:35:chronic_disease,37:43:chronic_disease,58:68:chronic_disease,114:140:chronic_disease,142:173:treatment,177:188:treatment,196:217:chronic_disease,244:267:treatment","Reports current congestive failure, angina, uncontrolled arrhythmia, symptoms indicative of increased risk of an acute cardiovascular event, coronary artery bypass grafting or angioplasty, prior myocardial infarction, and conditions requiring anticoagulation therapy (deep vein thrombosis)"
4854,NCT02865135,"1:17:chronic_disease,25:28:chronic_disease,63:88:treatment,134:149:treatment","Active hepatitis, known HIV, or other condition that requires immunosuppressive therapy, including current use of high dose systemic corticosteroids"
4855,NCT02865135,"14:53:cancer,66:77:cancer,163:178:treatment","Uncontrolled central nervous system (CNS) metastases (i.e. known CNS lesions that are radiographically unstable, symptomatic and/or requiring escalating doses of corticosteroids)"
4856,NCT02864862,"8:29:chronic_disease,31:43:chronic_disease,57:76:treatment","severe parafunctional habits, malocclusion or intent of orthodontic therapy in the future"
4857,NCT02864147,"13:33:cancer,45:48:chronic_disease,66:88:treatment",evidence of endocervical disease defined as CIN 2/3 diagnosed on endocervical curettage
4858,NCT02862938,"17:45:chronic_disease,,71:91:chronic_disease,113:133:chronic_disease","Participant has choroidal neovascularization secondary to age related macular degeneration or any other type of retinal degeneration that may interfere with the study procedures, evaluations and outcome assessments"
4859,NCT02861417,"29:51:cancer,56:82:cancer,87:111:cancer,116:152:chronic_disease,157:181:cancer,186:214:cancer,219:241:cancer,246:264:cancer,269:285:cancer",Diagnoses to be included a) Acute myeloid leukemia; b) Acute lymphocytic leukemia; c) Chronic myeloid leukemia; d) Chronic lymphoproliferative disorder; e) Myelodysplastic syndrome; f) Myeloproliferative syndromes; g) Non-Hodgkin's lymphoma; h) Hodgkin's Lymphoma; i) Multiple myeloma
4860,NCT02860000,",114:125:treatment,,148:177:treatment,197:234:treatment,239:271:treatment","A non-nodal lesion is considered measurable if its longest diameter can be accurately measured as >= 2.0 cm with chest x-ray, or as >= 1.0 cm with computed tomography (CT) scan, CT component of a positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI)"
4861,NCT02860000,"1:10:treatment,39:54:treatment,84:103:treatment,104:113:treatment,115:128:treatment,132:145:treatment,150:158:treatment,160:169:treatment,171:182:treatment,186:201:treatment,","Treatment with clinically significant enzyme inducers, such as the enzyme-inducing antiepileptic drugs phenytoin, carbamazepine or phenobarbital, or rifampin, rifabutin, rifapentine or St. John's wort =< 14 days prior to registration"
4862,NCT02857218,"15:23:cancer,27:57:cancer,126:135:treatment,147:188:treatment,201:214:treatment","Subjects with cervical or Siewert 3 esophageal carcinoma, that are recommended by the multi-disciplinary tumor board to have treatment other than tri-modality chemo-radiation therapy (RT) followed by esophagectomy"
4863,NCT02851407,"37:58:treatment,81:90:treatment,94:97:chronic_disease",Patient is using or plans to use an investigational agent for the prevention or treatment of VOD
4864,NCT02849457,"18:43:treatment,54:64:treatment,72:102:treatment,113:124:treatment","Has received any anticonvulsant medication including vigabatrin, other anti-seizure therapeutic agent including cannabidiol"
4865,NCT02845453,"26:42:chronic_disease,46:84:chronic_disease,108:125:chronic_disease",Meets DSM-5 criteria for bipolar disorder or disruptive mood dysregulation disorder or DSM IV criteria for mood disorder NOS
4866,NCT02844504,"77:83:treatment,85:95:treatment,97:108:treatment,112:127:treatment","Current medication believed to affect cognitive/psychomotor function (i.e., opioid, analgesics, anxiolytics or antidepressants)"
4867,NCT02843568,"25:51:cancer,55:70:cancer,78:89:cancer",Histologic diagnosis of non-small cell lung cancer or lung metastasis from a solid tumor
4868,NCT02841540,"19:23:chronic_disease,,71:78:treatment,80:91:treatment,97:124:treatment",Participants with CMML must have been treated with at least one prior therapy (hydroxyurea or a hypomethylating agent [HMA])
4869,NCT02838797,"24:37:treatment,39:56:treatment,58:88:treatment,90:129:treatment,135:145:treatment,414:430:treatment,435:454:chronic_disease","participants may be on oral levodopa, dopamine agonists, monoamine oxidase-B inhibitors, catechol-O-methyltransferase inhibitors, and amantadine, but doses must have remained stable for 28 days prior to enrollment and should be anticipated to remain stable throughout the study, participants may have deep brain stimulation (though stimulator settings must be expected to remain constant throughout the study) or ablative surgery for Parkinson's Disease"
4870,NCT02837510,"47:56:chronic_disease,58:74:chronic_disease,76:89:chronic_disease,99:115:chronic_disease","Self-reported history or current diagnosis of psychosis, bipolar disorder, schizophrenia, current major depression"
4871,NCT02836574,"1:24:treatment,9:24:treatment,29:61:treatment,,182:188:chronic_disease","inhaled corticosteroids and chronic low-dose corticosteroids (less than or equal to 7.5 mg per day) are permitted as are brief pulsed corticosteroids for intermittent symptoms (eg, asthma)"
4872,NCT02835729,"1:26:chronic_disease,31:62:chronic_disease,95:122:chronic_disease,126:134:chronic_disease",Active autoimmune disease and chronic inflammatory conditions requiring concurrent use of any systemic immunosuppressants or steroids
4873,NCT02834403,"12:33:chronic_disease,35:41:chronic_disease,43:65:chronic_disease,70:104:chronic_disease,","History of myocardial infarction, stroke, ventricular arrhythmia, or symptomatic conduction abnormality within the past 12 months"
4874,NCT02833792,"12:24:chronic_disease,26:34:chronic_disease,39:62:chronic_disease","History of intracranial, subdural, or subarachnoid hemorrhage"
4875,NCT02832167,"25:32:treatment,34:42:treatment,44:52:treatment,54:63:treatment,68:86:treatment","Prior treatment with an antiPD1, antiPDL1, antiPDL2, antiCD137, or antiCTLA4 antibody, or any other antibody or drug specifically targeting Tcell co-stimulation or checkpoint pathways"
4876,NCT02830360,"22:24:chronic_disease,61:71:treatment,73:80:treatment,93:133:treatment,","One of the following VT events while not being treated with amiodarone, sotalol, or another class I or class III antiarrhythmic drug) within the last 6 months"
4877,NCT02826681,",61:64:chronic_disease,71:78:treatment,80:117:treatment,119:135:treatment,137:172:treatment,177:208:treatment","Current (past 4 weeks) use of drugs that may cause or treat RLS, e.g. opioids, calcium channel alpha-2-delta ligands, anti-depressants, dopaminergic agonist or antagonists, or centrally-acting antihistamines"
4878,NCT02826681,"26:36:treatment,39:42:treatment,46:52:treatment,59:73:treatment",Previously randomized to Injectafer® (FCM or VIT-45) in a clinical trial
4879,NCT02824276,"13:21:chronic_disease,23:31:chronic_disease,33:42:chronic_disease,53:73:chronic_disease","evidence of delirium, dementia, psychosis, or other cognitive impairment preventing completion of study procedures"
4880,NCT02820350,"1:4:chronic_disease,40:60:chronic_disease,62:86:chronic_disease,88:102:chronic_disease,104:138:treatment,140:152:treatment,157:182:treatment","AKI occurring in the setting of burns, obstructive uropathy, scleroderma renal crisis, atheroembolism, functional or surgical nephrectomy, cyclosporine, or tacrolimus nephrotoxicity"
4881,NCT02820350,"34:55:chronic_disease,63:67:chronic_disease,79:112:treatment,179:207:chronic_disease,,","Presence of preexisting advanced chronic renal failure (i.e., ESRD) requiring chronic renal replacement therapy prior to this episode of acute kidney injury or with pre-existing chronic kidney disease (CKD) defined as a eGFR<30ml/min/1.73m2"
4882,NCT02819843,"7:24:chronic_disease,49:72:chronic_disease,76:102:chronic_disease",Known severe congenital or acquired cellular or humoral immunodeficient or immunocompromised patients
4883,NCT02819440,"16:32:treatment,34:44:treatment,46:55:treatment,57:67:treatment","Current use of PDE-5 inhibitors (sildenafil, tadalafil, vardenafil)"
4884,NCT02819141,",,104:112:treatment,114:127:treatment,129:137:treatment,139:147:treatment,149:158:treatment,160:168:treatment,170:179:treatment,181:189:treatment,191:202:treatment,204:219:treatment","received at least one intravenous bolus dose of a sedative/opioid medication in the previous 24 hours (fentanyl, hydromorphone, ketamine, morphine, midazolam, diazepam, lorazepam, propofol, haloperidol, dexmedetomidine)"
4885,NCT02818972,"47:73:chronic_disease,85:106:chronic_disease,118:141:chronic_disease,150:174:chronic_disease,176:182:chronic_disease,190:216:chronic_disease,241:258:chronic_disease,270:283:chronic_disease","Subjects with disease, for example: suspected connective tissue disorder, specified coagulation disorders, specified coronary artery disease, severe congestive heart failure, stroke and/or Myocardial Infarction (MI) as specified, specified pulmonary disease, specified renal failure"
4886,NCT02815917,"12:49:chronic_disease,51:67:chronic_disease,69:82:chronic_disease,86:104:chronic_disease","History of Post-Traumatic Stress Disorder (PTSD), bipolar disorder, schizophrenia or psychotic disorder as assessed by medical record review and/or self-reported"
4887,NCT02813889,"32:39:chronic_disease,41:51:chronic_disease,55:77:chronic_disease","have no history of significant cardiac, orthopedic or neurological condition"
4888,NCT02811679,"25:40:treatment,33:40:treatment,,,139:200:treatment",Subjects who respond to initial therapy for greater than one year must have had at least 2 prior lines of therapy including one line with chemoimmunotherapy including an anti-CD20 monoclonal antibody
4889,NCT02810704,"137:144:treatment,146:154:treatment,159:170:treatment","Concurrently enrolled in another active interventional clinical trial testing a drug or intervention known or believed to interact with aspirin, warfarin, or rivaroxaban"
4890,NCT02809677,"1:27:chronic_disease,37:43:chronic_disease,45:61:chronic_disease,63:76:chronic_disease","severe psychiatric illness, such as autism, bipolar disorder, schizophrenia or current drug/alcohol abuse/dependence"
4891,NCT02807272,"9:18:treatment,27:43:treatment,48:52:cancer",Ongoing treatment with an anticancer agent for CMML not contemplated in this protocol
4892,NCT02806570,"18:25:allergy_name,27:36:allergy_name,41:53:allergy_name","Known allergy to nitinol, polyester, or polyethylene"
4893,NCT02802176,"1:29:chronic_disease,52:60:chronic_disease,64:76:chronic_disease",Uncontrolled chronic disease (such as uncontrolled diabetes or hypertension)
4894,NCT02799095,"52:70:treatment,72:85:treatment,93:126:treatment,128:140:treatment,144:151:treatment","Subjects must be recovered from the effects of any prior chemotherapy, immunotherapy, other prior systemic anticancer therapy, radiotherapy or surgery"
4895,NCT02797795,"5:17:treatment,19:48:treatment,50:81:treatment,83:108:treatment,,138:148:treatment,230:253:treatment,","Any chemotherapy, immunomodulatory drug therapy, antineoplastic hormonal therapy, immunosuppressive therapy, corticosteroids > 20 mg/day prednisone or equivalent (unless administered to prevent contrast material reactions during radiographic procedures), or growth factor treatment (e.g., erythropoietin) within 14 days before first NEV801 dose"
4896,NCT02792582,"1:16:treatment,22:38:treatment,42:63:treatment",Prior treatment with intracystic P-32 or intracystic bleomycin
4897,NCT02786251,"81:110:treatment,112:128:treatment,133:147:treatment,188:209:chronic_disease","Conditions that render subject unable to complete all testing procedures (e.g., severe ambulatory impairments, limb amputations, or metal implants that interfere with imaging procedures; coagulation disorders)"
4898,NCT02783716,"26:31:treatment,35:40:treatment,45:63:chronic_disease,,,,,,,","Patients recommended for CRT-P or CRT-D for heart failure (HF) according to current American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Rhythm Society (HRS) guidelines of Left Ventricle Ejection Fraction (LVEF)<35%, Left Bundle Branch Block (LBBB)>120 ms, New York Heart Association (NYHA) Class II-III)"
4899,NCT02780401,"15:29:cancer,31:44:cancer,46:73:cancer","Patients with non-metastatic, node positive, HER2 negative breast cancer, confirmed by pathology report, who are in remission and defined as having no evidence of disease (NED)"
4900,NCT02778282,"45:59:chronic_disease,61:68:chronic_disease,70:75:chronic_disease,77:88:chronic_disease,90:99:chronic_disease,101:113:chronic_disease,118:139:chronic_disease,170:179:treatment,","Serious unstable medical illness including, cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease such that hospitalization for treatment of that illness is likely within the next 3 months"
4901,NCT02776761,"28:45:chronic_disease,49:74:chronic_disease,86:130:chronic_disease","Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection"
4902,NCT02775162,"47:62:treatment,64:78:treatment,80:97:treatment,99:124:treatment","requiring all of the following at the time of transplantation: oxygen therapy, inotropic support, renal replacement therapy"
4903,NCT02772562,"61:82:allergy_name,91:137:allergy_name,142:159:allergy_name","Prior history of serious toxicity or a systemic reaction to vaccinia immunization such as myopericarditis progressive vaccinia infection, or eczema vaccinatum"
4904,NCT02771626,"25:43:treatment,56:71:treatment,,87:97:treatment,119:157:treatment,",Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other systemic immunosuppressive medications within 2 weeks
4905,NCT02770547,"1:23:chronic_disease,,,37:74:treatment,78:82:treatment,86:109:treatment",Chronic kidney disease (eGFR <30 by Modification of Diet in Renal Disease or Mayo or Cockcroft-Gault formula)
4906,NCT02769611,",,,19:32:chronic_disease,19:37:chronic_disease,48:85:chronic_disease,,,189:205:treatment,209:220:treatment,",NYHA Class III-IV heart failure (HF) confirmed left ventricular systolic dysfunction with left ventricular ejection fraction (LVEF) <40% as assessed by noninvasive imaging studies such as echocardiography or cardiac MRI within the last 6 months admitted with decompensated heart failure and almost ready for clinical discharge
4907,NCT02763033,"1:17:chronic_disease,60:116:treatment,147:159:chronic_disease",Active infection is defined as a stool sample positive for Clostridium difficile toxin via EIA (enzyme immunoassay) and either symptoms (frequent loose stools)
4908,NCT02762006,"13:22:treatment,28:41:treatment,50:60:cancer,71:79:cancer,81:99:treatment,101:117:chronic_disease","No previous treatment with immunotherapy for any malignancy including cytokine, anti-tumor vaccine, T-cell activator, co-stimulator or immune checkpoint inhibitor"
4909,NCT02760498,"16:50:chronic_disease,58:82:chronic_disease,88:105:chronic_disease,109:126:chronic_disease",Infection with human immunodeficiency virus (HIV) and/or chronic/active infection with hepatitis B virus or hepatitis C virus
4910,NCT02759120,"32:45:allergy_name,50:62:allergy_name,64:76:allergy_name","Allergy or intolerance to both tetracyclines AND trimethoprim, sulfonamides or their combination"
4911,NCT02755896,"29:60:cancer,68:88:treatment,114:151:cancer",Presence of a proportion of Ductal Carcinoma in-situ (DCIS) in the core biopsy specimen which is compatible with extensive intraductal component (EIC)
4912,NCT02753283,"10:43:treatment,45:55:treatment,60:90:treatment,182:191:treatment","Those on hormone replacement therapy (HRT), raloxifene, or prescribed protective hip pads by their Primary Care Physician (PCP) will be allowed to participate and continue on these therapies"
4913,NCT02747888,"15:29:cancer,46:62:chronic_disease,88:95:cancer,146:162:chronic_disease","Families with thyroid cancer and a suspected genetic syndrome (e.g. multiple childhood cancers in the family, multiple primary cancers, multiple endocrinopathies, etc.)"
4914,NCT02744391,"23:42:chronic_disease,44:61:chronic_disease,66:68:chronic_disease","Diagnosis of probable Alzheimer's Disease, Vascular Dementia, or PD"
4915,NCT02744391,"38:55:chronic_disease,57:75:chronic_disease,77:103:chronic_disease,118:140:chronic_disease,185:208:chronic_disease","Presence of a clinically significant brain abnormality, significant anemia, insulin dependent diabetes, a history of cardiovascular disease, or uncontrolled/untreated risk factors for coronary artery disease"
4916,NCT02742454,"43:57:chronic_disease,59:89:chronic_disease,91:121:chronic_disease","Life-threatening condition of fetus (e.g. severe hydrops, lethal chromosomal abnormality, severe congenital malformation)"
4917,NCT02740361,"1:39:chronic_disease,48:56:chronic_disease,60:66:chronic_disease",substantial neurocognitive impairments such as dementia or autism
4918,NCT02739620,"11:22:treatment,26:47:treatment,64:73:treatment",receiving neoadjuvant or adjuvant chemotherapy with or without radiation
4919,NCT02737202,"10:21:chronic_disease,23:28:chronic_disease,30:37:chronic_disease,39:59:chronic_disease,63:81:chronic_disease,,","Advanced hematologic, renal, hepatic, non-LAM lung disease or metabolic diseases; or BMI of >35"
4920,NCT02734771,",28:51:chronic_disease,,,93:107:treatment,111:146:treatment",New York Heart Association class III heart failure or ejection fraction of less than 30% on echocardiogram or Multi Gated Acquisition Scan (MUGA)
4921,NCT02734134,"48:62:treatment,64:80:treatment,85:117:treatment","Resistant organisms not sensitive to available IV antibiotics, oral antibiotics, or heat stable antibiotic additives to bone cement with documented elution characteristics"
4922,NCT02728050,"1:4:cancer,16:50:cancer,,170:186:cancer",AML other than acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) or variants according to the 2008 World Health Organization (WHO) classification; patients with biphenotypic AML
4923,NCT02727972,"14:31:chronic_disease,56:70:treatment,80:88:treatment,90:97:treatment,99:106:treatment,108:115:treatment","history of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto)"
4924,NCT02725177,"21:31:cancer,55:85:cancer,89:116:cancer,121:147:cancer,","Have any history of malignancy, except fully resected cutaneous squamous cell cancer or cutaneous basal cell cancer, or cervical carcinoma in-situ with a minimum of 5 years period without recurrence"
4925,NCT02724540,",44:62:treatment,64:68:treatment,70:78:treatment,82:89:treatment,119:148:treatment","Patients must be at least one month beyond prior chemotherapy, PRRT, ablation or surgery, and have recovered from all therapy-associated toxicities"
4926,NCT02721381,"24:36:chronic_disease,44:56:chronic_disease,60:77:chronic_disease","history of significant brain injury, known neurological or genetic condition"
4927,NCT02712736,"15:18:chronic_disease,33:49:treatment,51:58:treatment,67:79:treatment","patients with PSC, confirmed by laboratory tests, imaging, and/or liver biopsy"
4928,NCT02706353,"43:71:cancer,76:92:cancer,99:114:cancer","Histologically or cytologically confirmed malignant melanoma from skin, or mucosal melanoma (i.e. ocular melanoma subjects are not eligible)"
4929,NCT02706249,"79:101:cancer,103:111:cancer,115:131:cancer","Participants must have histologically or cytologically confirmed diagnosis of solid tumor malignancy, lymphoma or multiple myeloma"
4930,NCT02703220,"27:45:chronic_disease,117:145:chronic_disease,146:166:chronic_disease,,","Patients with significant pulmonary diseases by history and abnormal pulmonary function testing, including moderate obstructive/restrictive lung/chest wall disorders with resting oxygen saturation of <96% or on supplemental oxygen"
4931,NCT02701998,"42:56:chronic_disease,58:67:chronic_disease,72:89:chronic_disease","No major signs or symptoms suggestive of cardiovascular, pulmonary, or metabolic disease (as determined by attending physician)"
4932,NCT02699697,"1:11:cancer,19:24:cancer,26:31:cancer,33:37:cancer,55:64:treatment","Metastases to the skull, hands, feet are not eligible treatment sites"
4933,NCT02693080,"21:25:treatment,49:59:cancer,74:100:cancer,104:119:cancer","Patients undergoing SABR for the treatment of a lung tumor, inclusive of non-small cell lung cancer or lung metastases"
4934,NCT02688647,"51:54:chronic_disease,51:64:chronic_disease,,129:136:treatment",Documented sustained improvement of the subject's IPF condition up to 12 months before study entry with or without IPF-specific therapy
4935,NCT02688647,"1:19:treatment,,59:73:treatment,77:87:treatment,89:99:treatment,104:113:treatment","Systemic treatment within 4 weeks before study entry with cyclosporine A or tacrolimus, everolimus, or sirolimus (calcineurin or mammalian target of rapamycin inhibitors)"
4936,NCT02687906,"25:40:chronic_disease,73:94:chronic_disease,98:120:chronic_disease","Evidence of significant hepatic disease or dysfunction, including known acute viral hepatitis or hepatic encephalopathy"
4937,NCT02682407,"22:26:chronic_disease,28:43:chronic_disease,45:47:chronic_disease,52:69:chronic_disease,80:101:chronic_disease","Have a diagnosis of: IgAN, Lupus Nephritis, MN, or C3 Glomerulopathy including Dense Deposit Disease"
4938,NCT02681614,"90:106:chronic_disease,108:144:chronic_disease,146:170:chronic_disease,172:190:chronic_disease,195:232:chronic_disease","Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
4939,NCT02679560,"8:34:treatment,36:47:treatment,49:59:treatment,61:70:treatment,72:92:treatment,98:125:treatment,127:138:treatment,140:148:treatment,150:158:treatment","Use of direct thrombin inhibitors (bivalirudin, argatroban, desirudin, dabigatran etexilate), or direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban)"
4940,NCT02672098,"43:55:cancer,86:96:cancer,98:125:cancer,130:156:cancer","Histologic types feature would be serous, endometrioid, clear cell, undifferentiated carcinomas, transitional cell carcinoma, or mixed epithelial carcinoma  No End organ function"
4941,NCT02670044,"14:37:chronic_disease,39:74:chronic_disease,96:99:chronic_disease,101:111:cancer,113:129:chronic_disease,134:163:chronic_disease","Positive for hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg) and known history of HIV, malignancy, active infection and cardiovascular diseases (CVs)"
4942,NCT02669173,"1:24:cancer,32:47:chronic_disease,49:70:chronic_disease,72:78:chronic_disease,","Arterial ischemic event (e.g., unstable angina, myocardial infarction, stroke) within 6 months of study entry"
4943,NCT02668744,"5:13:chronic_disease,15:24:chronic_disease,29:53:chronic_disease","Any physical, cognitive, or psychological disability that would prevent participation in the study"
4944,NCT02665962,"26:45:cancer,,103:119:treatment,132:154:treatment,158:167:treatment","Diagnosed with any other invasive malignancy currently, in the last five years or expected to undergo active treatment with either cytotoxic chemotherapy or radiation during the 6 week caloric restriction period"
4945,NCT02664909,"8:16:treatment,18:28:treatment,30:41:treatment,43:51:treatment,57:76:treatment","taking Warfarin, Dabigatran, Rivaroxaban, Apixaban, and Fresh Frozen Plasma"
4946,NCT02661386,"1:14:treatment,29:36:treatment,40:46:treatment",Anticoagulant usage such as heparin or Plavix
4947,NCT02660528,"18:44:chronic_disease,58:68:chronic_disease,70:80:chronic_disease,82:91:chronic_disease,97:111:chronic_disease","Patients with an active or recent infection, for example cellulitis, bacteremia, pneumonia, and pyelonephritis"
4948,NCT02657993,"16:31:treatment,44:48:treatment,50:66:treatment,71:100:treatment,","Current use of corticosteroids, defined as oral, intravenous (IV), or injections of corticosteroids in the past 4 weeks"
4949,NCT02656706,"7:17:cancer,,80:87:cancer,129:163:cancer,165:191:cancer,196:229:cancer","Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast"
4950,NCT02649790,"20:65:treatment,69:126:treatment,,155:159:treatment",Patients receiving granulocyte-colony stimulating factor (G-CSF) or granulocyte macrophage-colony stimulating factor (GM-CSF) within the 3 weeks prior to C1D1
4951,NCT02648282,"15:26:treatment,30:41:treatment,43:51:treatment,58:70:treatment,,",have received mFOLFIRINOX or Gemcitabine/ Abraxane based chemotherapy for 4 cycles with last dose of therapy between 2-5 weeks of study enrollment
4952,NCT02645539,"51:55:treatment,57:64:treatment,66:91:treatment,100:111:treatment","Currently receiving circulatory support including ECMO, Impella, TandemLife or equivalents; or any durable VAD"
4953,NCT02642939,"84:94:cancer,96:106:cancer,110:118:cancer,120:125:cancer","Histological or cytological documented diagnosis of locally advanced, recurrent or metastatic (Stage IIIB or Stage IV) NSCLC"
4954,NCT02640950,"12:23:chronic_disease,25:33:chronic_disease,37:53:chronic_disease,55:86:treatment","History of head injury, epilepsy or seizure disorder, non-removable metallic implants or objects in or around the head"
4955,NCT02639546,"1:6:cancer,17:32:treatment,93:109:treatment",Tumor for which prior treatment has proven to be ineffective or intolerable or for which no standard therapy exists
4956,NCT02639065,"20:59:treatment,52:59:treatment,69:94:treatment,",Patients receiving chronic systemic corticosteroid therapy or other immunosuppressive therapy within 28 days prior to registration for protocol therapy
4957,NCT02639065,"1:9:chronic_disease,30:36:chronic_disease,37:42:chronic_disease,59:87:treatment,91:115:treatment,117:131:chronic_disease,163:172:chronic_disease,,233:249:chronic_disease,254:272:chronic_disease","vitiligo, resolved childhood asthma/atopy, requirement of intermittent bronchodilators or local steroid injections, hypothyroidism stable on hormone replacement, psoriasis not requiring systemic treatment (within the past 2 years), Graves's disease and Sjogren's syndrome"
4958,NCT02635893,"78:97:chronic_disease,106:121:chronic_disease,123:135:chronic_disease,139:162:chronic_disease","Ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida or herniated cervical disk"
4959,NCT02633163,"1:14:chronic_disease,,46:55:chronic_disease,85:96:treatment,100:125:treatment,",Herpes zoster within the past 90 days or any infection requiring hospitalization or intravenous or intramuscular antibiotics within the past 60 days
4960,NCT02633111,"1:38:cancer,71:106:cancer,111:138:cancer",De novo diffuse large B-cell lymphoma (including all subtypes such as primary mediastinal B-cell lymphoma and T-cell rich B-cell lymphoma)
4961,NCT02632422,"1:26:chronic_disease,55:63:chronic_disease,65:83:chronic_disease,87:108:chronic_disease","severe concurrent illness or pain, including unhealed decubiti, severe neuropathic or chronic pain syndrome, infection (e.g. bladder)"
4962,NCT02628535,",85:94:chronic_disease,96:107:chronic_disease,188:204:chronic_disease,227:241:treatment,,286:307:chronic_disease","Clinically significant pulmonary compromise within 28 days of first dose, including pneumonia, pneumonitis, requirement for supplemental oxygen). use to maintain adequate oxygenation, or pleural effusion sufficient to warrant pleurocentesis or any history of ? Grade 3 drug induced or radiation pneumonitis"
4963,NCT02627495,"10:28:chronic_disease,35:56:chronic_disease,58:86:chronic_disease,88:101:chronic_disease,105:142:chronic_disease","Unstable medical conditions (e.g. uncontrolled diabetes, uncompensated cardiac issues, heart failure or chronic obstructive pulmonary disease)"
4964,NCT02624258,"15:17:chronic_disease,36:54:treatment,72:86:treatment",subjects with HL with no available curative treatment options (such as autologous SCT)
4965,NCT02616185,"8:46:treatment,53:65:treatment,67:78:treatment,140:144:cancer","Failed prior therapy with a secondary hormone (e.g. enzalutamide, abiraterone) with documented progressive disease (post-secondary hormone CRPC)"
4966,NCT02616185,"26:45:treatment,56:84:treatment,86:112:cancer",Progressive disease post-surgical castration or during androgen suppression therapy (pre-secondary hormone CRPC)
4967,NCT02615249,"41:61:treatment,63:72:treatment,76:82:treatment,","Participation in a clinical trial of an investigational drug, treatment or device during this study or 3 weeks prior to inclusion in this study"
4968,NCT02611063,"64:74:cancer,75:137:treatment,142:163:treatment",All patients must have undergone appropriate staging for their malignancy prior to transplantation including bone marrow aspirate/biopsy and radiographic scanning if indicated
4969,NCT02610374,"1:25:chronic_disease,34:50:chronic_disease,64:74:cancer,89:110:treatment",Active chronic infection such as hepatitis B or C or an active malignancy that requires systemic chemotherapy
4970,NCT02608125,"73:94:chronic_disease,96:102:chronic_disease,104:112:chronic_disease,121:130:chronic_disease","Patients with other major uncontrolled medical conditions, e.g., recent myocardial infarction, stroke, diabetes, active hepatitis"
4971,NCT02607748,"1:17:chronic_disease,56:88:treatment,,148:151:chronic_disease,,","Asymptomatic CAD group: 40 patients who have undergone Coronary Artery Calcium scanning within 6 months prior to the imaging visit, matched to the ACS patients for age, gender, and CAC score"
4972,NCT02606305,"8:26:chronic_disease,37:53:treatment,,71:78:treatment,83:96:treatment",Active autoimmune disease requiring systemic therapy in past 2 years (IMGN853 and pembrolizumab only)
4973,NCT02606045,"1:10:treatment,16:21:treatment,23:38:treatment,40:51:treatment,53:59:treatment,64:97:treatment,","Treatment with DDAVP, cryoprecipitate, whole blood, plasma and plasma derivatives containing VWF within 5 days of study"
4974,NCT02600897,"16:45:treatment,50:75:treatment,88:100:treatment,102:113:treatment,118:129:treatment,,148:168:treatment,,186:189:treatment,193:216:treatment,,236:248:treatment,249:261:treatment,262:277:treatment,278:309:treatment,","Current use of systemic immunosuppressant(s), or prior anti-cancer therapy to include: lenalidomide, fludarabine, or alemtuzumab within 12 months; radioimmunoconjugate within 12 weeks; mAb or antibody-drug conjugate within 4 weeks; or radiotherapy/chemotherapy/hormone therapy/targeted small-molecule therapy within 2 weeks prior to Day 1 of Cycle 1"
4975,NCT02595866,"12:23:chronic_disease,47:68:treatment,197:210:chronic_disease","A positive hepatitis B serology indicative of previous immunization (i.e., hepatitis B surface antibody [HBsAb] positive and hepatitis B core antibody [HBcAb] negative), or a fully resolved acute HBV infection"
4976,NCT02595372,"1:11:treatment,13:21:treatment,23:30:treatment","Omeprazole (Prilosec, Zegerid)"
4977,NCT02594501,",,52:58:chronic_disease,62:77:chronic_disease,81:87:chronic_disease,96:106:chronic_disease,131:151:treatment,168:187:chronic_disease,,,",Patients older than age 18 with ischemic symptoms (stable or unstable angina or NSTEMI without thrombosis of the target lesion on coronary angiography) or evidence of myocardial ischemia in the presence of ? 50% de novo stenosis located in native coronary vessels (max. 2 lesions in one or 2 separate vessels)
4978,NCT02594384,"15:20:cancer,122:142:treatment,146:168:treatment","Patients with DLBCL: Cancer progression after transplant, or be unwilling, unable or not an appropriate candidate for an autologous stem cell or bone marrow transplant"
4979,NCT02593110,"1:8:treatment,35:52:treatment,54:80:treatment","Surgery including lower extremity revascularization, coronary revascularization with stenting"
4980,NCT02592707,"27:32:allergy_name,37:41:allergy_name,46:50:allergy_name,68:94:allergy_name","Known hypersensitivity to 177Lu, to DOTA, to JR11 or to any of the excipients of 177Lu-OPS201"
4981,NCT02592551,"5:8:cancer,20:30:cancer,39:50:cancer","Any MPM histology (epithelial, mixed, sarcomatoid)"
4982,NCT02592551,"23:31:treatment,,119:127:treatment,131:150:treatment",Receipt of drugs with laxative properties and herbal or natural remedies for constipation within 90 days of receiving MEDI4736 or MEDI + tremelimumab
4983,NCT02592551,"77:93:chronic_disease,107:131:chronic_disease,146:158:chronic_disease,160:184:chronic_disease,186:204:chronic_disease,213:233:chronic_disease,237:246:chronic_disease,255:273:chronic_disease,322:350:chronic_disease,352:363:chronic_disease,367:401:chronic_disease,406:443:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent"
4984,NCT02592473,"15:39:chronic_disease,,52:63:chronic_disease,68:89:chronic_disease","Patients with urinary tract infections (> 2/year), prostatitis, or interstitial cystitis"
4985,NCT02589938,"12:22:chronic_disease,24:41:chronic_disease,95:114:treatment","History of xerostomia, Sjogren's disease or other illness known to affect salivation prior to head/neck radiation"
4986,NCT02589522,",,,61:64:treatment,71:94:chronic_disease,,,,154:194:treatment,247:251:treatment","Patients with 1-3 brain metastases, each < 3 cm by contrast MRI, with stable systemic disease and ECOG score of 0-2, who would otherwise be eligible for SRS/stereotactic radiation therapy (SRT) alone should not be enrolled into this study unless WBRT is recommended due to any medical reasons or logistic limitations as determined by the treating physician"
4987,NCT02589353,"13:25:chronic_disease,27:39:chronic_disease,44:53:chronic_disease","has current oral lesions, canker sores, or piercings"
4988,NCT02588612,"9:40:chronic_disease,64:82:chronic_disease,86:109:chronic_disease,111:127:cancer,148:169:chronic_disease,275:282:chronic_disease,284:298:chronic_disease,300:312:chronic_disease,314:329:chronic_disease,331:360:chronic_disease,385:394:chronic_disease","Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease per Investigator assessment). Stable chronic liver disease should generally be defined by the absence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice or cirrhosis"
4989,NCT02588612,"1:26:treatment,,51:64:treatment,66:98:treatment,,223:243:treatment,,294:340:treatment",Investigational treatment within 4 weeks prior to leukapheresis; experimental anti-cancer vaccine within 2 months prior to leukapheresis in the absence of response or in the opinion of the Investigator is responding to an experimental vaccine given within 6 months prior to leukapheresis; any prior gene therapy using an integrating vector
4990,NCT02588612,"74:77:treatment,175:185:treatment,196:226:treatment","Subjects with known epidermal growth factor receptor (EGFR) mutations or ALK or ROS1 gene rearrangements must have failed (disease progression [PD] or unacceptable toxicity) prior EGFR or ALK or ROS1 tyrosine kinase inhibitor, respectively (PD or unacceptable toxicity)"
4991,NCT02588326,"16:29:treatment,82:104:chronic_disease,106:115:chronic_disease,117:133:chronic_disease,165:177:chronic_disease","Any history of nasal surgery or known clinically relevant abnormalities, such as rhinitis medicamentosa, polyposis, septum deviation with clinical symptoms, recent nasal trauma, or nasal structural abnormalities"
4992,NCT02588326,"13:21:chronic_disease,23:32:chronic_disease,34:55:chronic_disease,59:68:cancer,81:91:cancer","Presence of glaucoma, cataracts, ocular herpes simplex or carcinoma (other than basal cell)"
4993,NCT02588326,"12:36:treatment,64:84:treatment,86:94:treatment,","Use of any topically applied agents to the nasal mucosa (i.e., antibacterial creams, Vaseline) within 30 days of enrollment"
4994,NCT02587962,"62:88:cancer,145:153:cancer,157:167:cancer,186:193:treatment,290:302:cancer,311:337:cancer","Patients must have histologically or cytologically confirmed carcinoma of the esophagus including the gastroesophageal junction that is locally advanced or metastatic with no available therapy options that are known to provide clinical benefit per institutional standard of care. (various solid tumors cohort, gastroesophageal carcinoma group only)"
4995,NCT02587962,"62:74:cancer,132:139:treatment,236:248:cancer","Patients must have histologically or cytologically confirmed mesothelioma that is locally advanced or metastatic with no available therapy options that are known to provide clinical benefit per institutional standard of care. (various solid tumors cohort, mesothelioma group only)"
4996,NCT02587962,"1:32:treatment,34:44:treatment,46:56:treatment,58:68:treatment,73:130:treatment","Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody"
4997,NCT02587598,"10:44:treatment,,102:112:treatment,,133:144:treatment,148:160:treatment,,186:196:treatment,200:220:treatment","Received non-biologic anticancer medication within 5 half-lives prior to receiving the first dose of study drug (within 6 weeks for mitomycin-C or nitrosoureas), within 28 days for any antibodies or biological therapies"
4998,NCT02585973,"1:7:treatment,15:38:cancer,40:46:cancer,48:59:cancer,64:75:cancer,,","Biopsy proven HNSCC of the oropharynx, larynx, hypopharynx, or oral cavity Stage III-IVB as defined by American Joint Committee on Cancer (AJCC) T0-T4, N0 - N3, M0"
4999,NCT02585973,",69:78:treatment,80:97:treatment,101:122:treatment","Receiving or less than 21 days since receiving any other concurrent cytotoxic, biologic agent(s) or investigational agent"
5000,NCT02585791,"15:36:chronic_disease,58:78:treatment,86:97:treatment,",Subjects with respiratory infection that required use of oral corticosteroids and/or antibiotics within the prior 3 months
5001,NCT02584647,"1:4:chronic_disease,38:60:treatment,139:146:treatment",HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with PLX3397
5002,NCT02584647,",,53:60:treatment,65:74:treatment,109:120:treatment,124:137:treatment",Pregnant women are excluded from this study because PLX3397 and sirolimus are agents with the potential for teratogenic or abortifacient effects
5003,NCT02584647,"15:30:treatment,32:52:treatment,58:73:treatment","These include anticonvulsants, mycin antimicrobials, and antiretrovirals"
5004,NCT02584309,"7:10:chronic_disease,37:59:treatment,89:134:treatment",Known HIV-positivity on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with dexrazoxane
5005,NCT02584309,"1:8:treatment,24:42:cancer,49:61:treatment",Surgery for primary or metastatic disease after chemotherapy following a response is allowed
5006,NCT02584244,"34:52:treatment,62:68:cancer,78:103:treatment,107:123:treatment","Subjects previously treated with systemic therapies to treat cancer, such as neo-adjuvant chemotherapy or hormonal therapy"
5007,NCT02583893,"22:32:cancer,,,104:120:cancer,133:147:cancer,152:169:cancer","Previously untreated non-M3 AML age >60 with no evidence of favorable karyotype defined by presence of t(8;21)(q22;q22) [AML1-ETO], inv16(p13;q22), or t(16;16)(p13;q22) [CBF?;MYH11] by cytogenetics, FISH, or RT-PCR"
5008,NCT02583789,"8:28:chronic_disease,65:67:chronic_disease,,,161:188:treatment,",Active Raynaud's Phenomenon defined as patients with refractory RP having four or more RP attacks per week in the 2 weeks before inclusion in the study despite treatment with vasodilators for at least 3 months
5009,NCT02583360,"1:13:chronic_disease,15:21:chronic_disease,25:46:chronic_disease","Craniofacial, airway or foregut malformations"
5010,NCT02582957,"13:23:cancer,,,,135:156:chronic_disease,,,,216:225:treatment","Presence of malignancy or other irreversible disease or condition for which the six month mortality is estimated to exceed 50% (e.g., chronic liver disease with a Child-Pugh Score of 10-15, malignancy refractory to treatment) as this could affect the clinical course and cloud interpretation of the endpoints"
5011,NCT02582905,",,,,,51:60:chronic_disease,51:58:chronic_disease,64:75:chronic_disease,79:103:chronic_disease",Outpatient men and women age 18-70 years old with bipolar I or II disorder or schizoaffective disorder (bipolar type)
5012,NCT02582827,"18:25:chronic_disease,29:40:chronic_disease,136:143:treatment",Any uncontrolled medical or psychiatric risk factors that would contraindicate the use or impair the ability of the patient to receive therapy per protocol or that may impose excessive risk to the patient
5013,NCT02582827,",44:65:chronic_disease,69:77:chronic_disease,81:105:chronic_disease",History (within prior 24 months) of either myocardial infarction or unstable or poorly controlled angina
5014,NCT02582827,"24:51:chronic_disease,83:104:treatment,108:123:treatment,136:143:treatment",History of symptomatic peripheral vascular disease (venous or arterial) requiring surgical intervention or chronic therapy (other than aspirin)
5015,NCT02582827,"20:47:treatment,54:62:treatment,85:92:treatment,103:116:treatment,141:159:chronic_disease,161:168:treatment","Patients requiring therapeutic anticoagulation (e.g. warfarin, low-molecular weight heparin, or other anticoagulant) or with history of any bleeding diathesis. Aspirin or low-dose warfarin for catheter maintenance is allowed"
5016,NCT02582775,"29:31:chronic_disease,49:57:chronic_disease,59:66:chronic_disease,68:76:chronic_disease,78:85:chronic_disease,89:106:chronic_disease,111:171:treatment,175:216:treatment","Diagnosis of severe form of EB characterized by collagen, laminin, integrin, keratin or plakin deficiency (by immunofluorescence staining with protein specific antibodies or Western blotting and by mutation analysis)"
5017,NCT02581982,"21:34:allergy_name,47:57:treatment,59:69:treatment","Hypersensitivity to pembrolizumab, any of its excipients, paclitaxel, or any of its excipients"
5018,NCT02581787,"21:39:treatment,30:39:treatment,41:53:treatment,55:71:treatment,76:89:treatment","No prior receipt of systemic treatment (chemotherapy, targeted therapy, or immunotherapy) for the lesion under consideration of treatment"
5019,NCT02581215,"1:10:chronic_disease,,52:61:chronic_disease,93:115:chronic_disease,139:146:chronic_disease,272:281:treatment,287:296:treatment,304:316:treatment",Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) with a history of hepatic encephalopathy or clinical meaningful ascites resulting from cirrhosis; clinically meaningful ascites is defined as ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis
5020,NCT02581215,"1:17:treatment,21:37:treatment,41:63:treatment",Prior autologous or allogeneic organ or tissue transplantation
5021,NCT02581215,"36:50:cancer,70:91:cancer,93:111:cancer,113:120:cancer,124:132:cancer","Subjects with histology other than adenocarcinoma; Examples include: neuroendocrine tumors, acinar cell cancer, sarcoma or lymphoma of the pancreas"
5022,NCT02580162,"11:26:chronic_disease,34:50:chronic_disease,52:67:chronic_disease,69:90:chronic_disease","Diagnosed eating disorder (i.e., anorexia nervosa, bulimia nervosa, binge eating disorder) in either parent (participating and nonparticipating) and/or the participating child"
5023,NCT02579967,"52:70:chronic_disease,72:77:chronic_disease,79:113:chronic_disease,114:144:chronic_disease,146:156:chronic_disease,158:170:chronic_disease,175:190:chronic_disease","Evidence of immune dysregulation, as manifested by autoimmune disease, atopy, hemophagocytic lymphohistiocytosis/macrophage activation syndrome, granulomas, splenomegaly, or lymphadenopathy"
5024,NCT02579967,"40:60:treatment,68:96:treatment,131:138:chronic_disease",MagT1 mutation and active need to take anti-platelet agents and/or therapeutic anti-coagulation that cannot be interrupted during aplasia
5025,NCT02579967,"31:55:chronic_disease,71:87:chronic_disease,89:109:chronic_disease,114:124:cancer,137:164:cancer,175:198:cancer","Related donors: No history of opportunistic infections, autoimmunity, hemoglobinopathy, red cell enzymopathy, or malignancy, apart from nonmelanomatous skin cancer or healed cervical cancer in situ"
5026,NCT02579096,"60:84:treatment,86:96:treatment,98:106:treatment,110:125:treatment","Patients who are not candidates for any of the recommended prophylactic medications (colchicine, naprosyn or glucocorticoids)"
5027,NCT02579044,"45:56:treatment,51:83:treatment,75:83:chronic_disease","Other than the drugs used in this protocol, other drugs targeted to treat progeria are excluded"
5028,NCT02578901,"45:66:treatment,68:86:treatment,88:111:treatment,121:141:treatment","Subjects enrolled in other trials involving platelet transfusions, anti-fibrinolytics, platelet growth factors or other pro-coagulant agents"
5029,NCT02578901,"23:35:treatment,37:50:treatment,55:94:treatment","Undergoing or planned chemotherapy, immunotherapy, or hematopoietic stem cell transplantation"
5030,NCT02578732,"15:31:chronic_disease,54:65:treatment,194:197:chronic_disease,199:210:chronic_disease,215:226:chronic_disease","Patients with active infection or fever (patients on antibiotics for infection or patients getting over a cold or seasonal virus are not excluded), or known historical or active infection with HIV, hepatitis B, or hepatitis C"
5031,NCT02577731,"33:55:chronic_disease,57:63:cancer,76:79:chronic_disease,95:120:chronic_disease","Pre-existing conditions such as pathological fractures, cancer, history of HIV, or history of connective tissue disease"
5032,NCT02577406,"27:80:treatment,86:90:treatment,92:103:treatment,107:117:treatment","Refractory to or relapsed after second- or third-line low-intensity AML therapy (eg, LDAC, azacitidine or decitabine)"
5033,NCT02577406,"67:75:cancer,97:105:chronic_disease,107:116:chronic_disease,122:129:chronic_disease,133:138:chronic_disease,147:185:chronic_disease","Subject has immediately life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation"
5034,NCT02577406,"32:47:chronic_disease,,86:101:treatment,,,,163:187:chronic_disease","Subject has significant active cardiac disease within 6 months prior to the start of study treatment, including New York Heart Association (NYHA) class III or IV congestive heart failure"
5035,NCT02577406,"84:96:treatment,100:133:treatment,154:164:treatment","Subjects with degenerative and toxic encephalopathies, especially after the use of methotrexate or treatment with ionizing radiation, should not receive cytarabine"
5036,NCT02577367,"31:42:treatment,87:101:treatment,103:113:treatment,115:125:treatment,127:134:treatment,136:144:treatment,146:156:treatment,161:169:treatment","Concomitant administration of medications that affect thyroid function test including Cholestyramine, Sucralfate, Amiodarone, Lithium, Dopamine, Dobutamine and Dilantin at enrollment"
5037,NCT02576444,"1:18:chronic_disease,91:125:chronic_disease,144:161:treatment","Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV) and are receiving antiviral therapy (testing is not part of the protocol)"
5038,NCT02576444,"28:58:treatment,77:103:chronic_disease,147:163:treatment",Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication
5039,NCT02576444,"30:36:cancer,65:89:cancer,110:125:cancer,127:133:cancer,135:141:cancer,143:148:cancer,150:154:cancer,159:167:cancer,,210:222:cancer,","Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated stage I cancers (cervix, breast, colon, lung, or prostate as examples) or other advanced (> Stage I)solid tumors curatively treated with no evidence of disease for ? 5 years"
5040,NCT02576431,"30:39:chronic_disease,41:46:chronic_disease,51:67:chronic_disease,78:100:chronic_disease,111:127:chronic_disease","Active uncontrolled systemic bacterial, viral, or fungal infection, unstable cardiovascular disease, or other systemic disease that would limit compliance with study procedures"
5041,NCT02575404,"15:50:cancer,60:69:treatment,75:88:treatment",Patients with metastatic or unresectable melanoma for whom treatment with pembrolizumab is indicated
5042,NCT02574910,"11:44:chronic_disease,140:152:chronic_disease,157:169:chronic_disease,","Confirmed classic 21-hydroxylase deficiency evident by genotype groups A, A1 or B or clinical course (e.g., adrenal crisis with documented hyperkalemia and hyponatremia, at diagnosis or during a later evaluation; ambiguous genitalia in females)"
5043,NCT02574455,",25:40:treatment,42:54:treatment,56:77:treatment,88:114:treatment,116:133:treatment,135:148:treatment,156:173:treatment,178:191:treatment","At least 2 weeks beyond prior treatment (chemotherapy, investigational drugs including small molecular inhibitors, endocrine therapy, immunotherapy and/or radiation therapy) or major surgery"
5044,NCT02573883,"1:17:chronic_disease,8:17:chronic_disease,19:26:chronic_disease,28:34:chronic_disease,36:55:chronic_disease,57:71:chronic_disease","vulvar infection (candida, herpes, bacterial vaginosis, trichomoniasis or other infection)"
5045,NCT02573493,"66:101:chronic_disease,103:139:chronic_disease,141:165:chronic_disease,167:185:chronic_disease,190:235:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active serious infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or serious psychiatric illness/social situations that would limit compliance with study requirements"
5046,NCT02573376,"12:31:treatment,36:48:treatment,86:95:chronic_disease","Receipt of prior HCV treatment and radiographic, histologic, or clinical evidence of cirrhosis"
5047,NCT02573246,"23:30:chronic_disease,86:107:chronic_disease,144:150:chronic_disease,173:183:treatment,223:233:treatment,235:243:treatment,245:253:treatment","Has increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure (such as after large infarctions or trauma), or currently taking medication that lowers the seizure threshold (e.g Wellbutrin, Adderall, Clozaril)"
5048,NCT02573246,"1:26:chronic_disease,7:26:chronic_disease,28:58:chronic_disease,60:74:chronic_disease,76:87:chronic_disease,89:112:chronic_disease,96:112:chronic_disease,114:129:chronic_disease,131:159:chronic_disease,161:190:chronic_disease,192:208:chronic_disease,210:230:chronic_disease,232:249:chronic_disease,251:275:chronic_disease,340:369:chronic_disease,371:392:chronic_disease,394:414:chronic_disease,416:440:chronic_disease,442:461:chronic_disease,463:479:chronic_disease,481:496:chronic_disease,498:519:chronic_disease,521:552:chronic_disease,532:552:chronic_disease,554:587:chronic_disease,589:620:chronic_disease,622:653:chronic_disease,655:684:chronic_disease,686:715:chronic_disease,717:749:chronic_disease,751:780:chronic_disease,782:812:chronic_disease,814:855:chronic_disease","major depressive disorder, persistent depressive disorder, panic disorder, agoraphobia, social anxiety disorder, specific phobia, generalized anxiety disorder, obsessive-compulsive disorder, trichotillomania, excoriation disorder, hoarding disorder, body dysmorphic disorder, other specified, or unspecified obsessive-compulsive disorder, posttraumatic stress disorder, acute stress disorder, adjustment disorders, somatic symptom disorder, conversion disorder, anorexia nervosa, bulimia nervosa, binge-eating disorder, borderline personality disorder, narcissistic personality disorder, histrionic personality disorder, antisocial personality disorder, paranoid personality disorder, schizoid personality disorder, schizotypal personality disorder, avoidant personality disorder, dependent personality disorder, obsessive-compulsive personality disorder, personality disorder unspecified, depressive disorder unspecified, anxiety disorder unspecified"
5049,NCT02572323,"8:18:cancer,30:35:cancer,39:59:cancer",Active malignancy other than basal or squamous skin cancer
5050,NCT02572323,"1:23:treatment,55:104:treatment,,,160:163:chronic_disease,",Antiretroviral therapy: Patient currently receiving a combination antiretroviral therapy (cART) regimen ?12 weeks with no interruptions longer than 7 days and HIV <500 copies/ml during that time
5051,NCT02572323,"26:30:treatment,32:49:treatment,98:115:treatment,125:133:treatment,135:146:treatment,148:156:treatment","active or planned use of rhGH, anabolic steroids (other than replacement doses of testosterone), anti-TNFa therapy or other biologic (tocilizumab, Xelijanz, etc.)"
5052,NCT02570984,"1:11:treatment,15:41:treatment,53:68:treatment",Prior IVIG or systemic immunosuppressant other than corticosteroids
5053,NCT02570854,"1:14:chronic_disease,15:26:chronic_disease,,,51:73:treatment,75:88:treatment,113:138:chronic_disease","Liver disease/dysfunction (Child-Pugh score ? 6), prior liver transplant, heart failure (NYHA Class III or IV); gastrointestinal bleeding"
5054,NCT02570672,"1:13:chronic_disease,23:35:treatment,,,137:145:chronic_disease,","Pre-diabetic based on oral glucose tolerance test with 2 hour values of 140 - 199 mg/dL after an oral glucose load, and no diagnosis of diabetes in the past 12 months"
5055,NCT02568267,"1:16:treatment,34:53:treatment,55:59:treatment,64:78:treatment,100:106:cancer","Prior treatment with approved or investigational Trk, ROS1, or ALK inhibitors in patients who have tumors that harbor those respective gene rearrangements"
5056,NCT02567448,"1:21:chronic_disease,34:49:chronic_disease,39:49:chronic_disease,56:69:chronic_disease,71:87:chronic_disease,107:133:chronic_disease","psychiatric disorder, other than mild depression; e.g. schizophrenia, bipolar disorder, major depression, panic or anxiety disorders"
5057,NCT02567422,"13:23:treatment,37:55:treatment,90:99:treatment",Patients on tacrolimus or any other immunosuppressants with significant interaction with cisplatin
5058,NCT02567266,",,145:161:chronic_disease,169:197:chronic_disease,199:212:chronic_disease,214:230:chronic_disease,232:259:chronic_disease,264:283:chronic_disease,291:316:chronic_disease,318:348:chronic_disease,357:376:chronic_disease","Evidence of clinically significant symptoms will be defined as a Clinical Severity Rating (CSR) greater than or equal to 4 on any DSM-5 defined anxiety disorder (e.g., generalized anxiety disorder, social phobia, selective mutism, separation anxiety disorder) or depressive disorder (e.g., major depressive disorder, persistent depressive disorder), or an adjustment disorder with depressed mood, anxiety, or mixed anxiety and depressed mood"
5059,NCT02567227,"39:57:chronic_disease,65:84:chronic_disease,88:91:chronic_disease","Presence of progressive, degenerative neurologic disease (e.g., Parkinson's disease or ALS)"
5060,NCT02566304,"1:3:chronic_disease,7:11:chronic_disease,43:53:treatment,66:75:treatment",RA or RARS or isolated 5q- can proceed to transplant without any treatment
5061,NCT02565901,"24:37:chronic_disease,54:75:chronic_disease,80:106:chronic_disease,,129:154:chronic_disease,,,","Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) class II-IV heart disease"
5062,NCT02565901,"1:16:treatment,20:29:treatment,91:100:treatment",bisphosphonates or denosumab should not be initiated after registration and during active treatment
5063,NCT02565446,"29:36:treatment,52:65:chronic_disease,76:104:treatment,112:128:treatment,130:154:treatment,156:190:treatment,196:233:treatment,267:279:treatment","Current or prior history of therapy for underlying liver disease including interferon-based medications, other antiviral agents, immunomodulatory therapy, biologic response modifier therapy, and complementary/alternative medications including (but not encompassing) milk thistle"
5064,NCT02564978,"21:55:chronic_disease,51:54:chronic_disease,112:122:treatment",Current evidence of choroidal neovascularization (CNV) as determined by the treating physician or a history of treatments for CNV
5065,NCT02564978,"1:39:chronic_disease,5:39:chronic_disease,,61:72:chronic_disease,76:90:chronic_disease","non-proliferative diabetic retinopathy involving 10 or more hemorrhages or microaneurysms, or active proliferative diabetic retinopathy"
5066,NCT02564744,",53:69:treatment,62:69:treatment,,116:137:treatment,,268:280:treatment,286:332:treatment","Participants who received at least only one line of previous therapy and achieved either complete response (CR) or partial response (PR) for at least 24 weeks (from the last day of the last cycle) after their first line of therapy, but are not eligible for high dose chemotherapy with autologous stem cell transplantation (HD-ASCT)"
5067,NCT02563678,"1:11:treatment,29:37:chronic_disease,48:57:chronic_disease",Hyperbaric patients without diabetes or active infection
5068,NCT02562755,"16:19:cancer,21:57:cancer,75:134:chronic_disease",Advanced stage HCC (Barcelona Clinic Liver Cancer [BCLC] Stage C or B per American Association for the Study of Liver Disease [AASLD] guidelines)
5069,NCT02562755,"1:36:chronic_disease,54:65:treatment,69:77:treatment","significant coronary artery disease (e.g., requiring angioplasty or stenting)"
5070,NCT02562716,"10:20:cancer,62:67:cancer,72:85:cancer,87:98:cancer,92:98:cancer,100:123:cancer,125:166:cancer,227:236:treatment,","No prior malignancy is allowed except for adequately treated basal (or squamous cell) skin cancer, in situ cervical cancer, in situ breast (ductal or lobular) cancer, or other cancer for which the patient has been disease and treatment-free for two years"
5071,NCT02562430,"44:53:treatment,72:80:chronic_disease,95:140:chronic_disease,","Subjects with medical contraindications to bupropion (e.g., history of seizures, uncontrolled electrolyte imbalance due to eating disorders, etc.) unless stable for 8 weeks prior to screening and there will be no changes during participation in the study"
5072,NCT02562430,"21:35:treatment,111:120:treatment,124:131:treatment","currently taking an antidepressant as defined by the MGH-ATRQ, in the current episode and are willing to take bupropion or placebo as augmentation, since we are using subjects as their own controls and we are comparing changes within subjects"
5073,NCT02562235,"14:17:chronic_disease,31:64:treatment,60:63:treatment,,157:170:treatment",Diagnosis of PAH confirmed by right heart catheterization (RHC) at any time prior to enrolment (for patients with closed shunts - RHC no less than 4 months after surgery)
5074,NCT02562235,"8:44:chronic_disease,46:52:chronic_disease,58:67:chronic_disease","Severe congenital abnormalities of the lung, thorax, and diaphragm"
5075,NCT02562066,"1:39:treatment,52:75:treatment,78:84:treatment,89:105:treatment,","Treatment with an investigational drug (other than amifampridine phosphate), device, or biological agent within 30 days before Screening or while participating in this study"
5076,NCT02562040,"1:33:chronic_disease,42:57:chronic_disease,63:87:chronic_disease","Severe cardiopulmonary disorders such as cystic fibrosis, and congenital heart disease"
5077,NCT02561988,",,100:119:chronic_disease,123:151:chronic_disease,160:166:treatment,206:229:chronic_disease",alkaline phosphatase (> 2.5 × ULN) with 1 of the following present: ascites or clinically relevant portal hypertension or liver mast cell infiltration that is biopsy-proven or no other identified cause of abnormal liver function
5078,NCT02561104,"91:100:treatment,120:140:chronic_disease,151:169:chronic_disease,171:194:chronic_disease,196:205:chronic_disease,207:226:chronic_disease","Subject eyes will lack other pre?existing ocular pathology or condition that may confound treatment effects, including diabetic retinopathy, previous retinal detachment, iris neovascularization, amblyopia, optic nerve atrophy or recurrent severe anterior or posterior segment inflammation of unknown etiology"
5079,NCT02560766,"19:30:chronic_disease,56:79:chronic_disease,90:124:chronic_disease","Positive test for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody at screening"
5080,NCT02560623,"32:40:treatment,42:62:treatment,64:87:treatment,89:100:treatment,102:126:treatment","Patients with prior history of ablation (photodynamic therapy, radiofrequency ablation, cryotherapy, argon plasma coagulation)"
5081,NCT02557321,"24:29:chronic_disease,33:56:chronic_disease,58:82:chronic_disease,84:89:chronic_disease,91:107:chronic_disease,109:118:chronic_disease,120:133:chronic_disease,135:144:chronic_disease,149:181:chronic_disease","Clinically significant acute or unstable cardiovascular, cerebrovascular (stroke), renal, gastrointestinal, pulmonary, immunological, endocrine, or central nervous system disorders"
5082,NCT02557321,"37:48:chronic_disease,52:65:treatment,,89:111:treatment,119:136:treatment",there is no evidence of progressive CNS disease on brain imaging at least 90 days after treatment with surgery and/or radiation therapy
5083,NCT02556619,"28:49:treatment,51:60:treatment,80:83:treatment,85:103:treatment,105:113:treatment,117:137:treatment","Child-Pugh C, eligible for systemic chemotherapy (Sorafenib), not eligible for TXP, surgical resection, ablation or locoregional therapy"
5084,NCT02556606,"12:25:chronic_disease,27:51:chronic_disease,59:77:chronic_disease,82:98:chronic_disease","History of schizophrenia, schizoaffective disorder or any psychotic disorder, or bipolar disorder"
5085,NCT02556606,"72:83:chronic_disease,189:211:chronic_disease,229:241:chronic_disease,281:299:chronic_disease","Serious, unstable medical illnesses including respiratory [obstructive sleep apnea, or history of difficulty with airway management during previous anesthetics], cardiovascular [including ischemic heart disease and uncontrolled hypertension], and neurologic [including history of severe head injury]"
5086,NCT02555280,"20:43:treatment,112:120:treatment,139:155:treatment","Chronically taking medications or any drug known to potentially interfere with bone/soft tissue healing (e.g., steroids), not including a medrol dose pack"
5087,NCT02555280,"1:11:chronic_disease,43:53:chronic_disease,157:196:treatment","Osteopenia: A screening questionnaire for osteopenia, SCORE (Simple Calculated Osteoporosis Risk Estimation), will be used to screen patients who require a DEXA (dual-energy x-ray absorptiometry) bone mineral density measurement"
5088,NCT02555189,"5:11:treatment,13:24:treatment,29:45:treatment,53:60:treatment,62:74:treatment,76:88:treatment,177:190:treatment,192:199:treatment,204:213:treatment","All herbal, alternative and food supplements (i.e., PC-Spes, Saw Palmetto, St John Wort, etc.). They must be discontinued prior to enrollment. Patients may continue on a daily Multi-Vitamin, calcium and Vitamin D"
5089,NCT02555189,"1:23:treatment,35:38:treatment,40:51:treatment,57:71:treatment,90:118:treatment","Hormonal-acting agents (including DES, aldosterone, and spironolactone but not including GnRH agonists or antagonists) are forbidden during the trial and must be stopped prior to enrollment. No washout period will be required for any of these agents"
5090,NCT02555189,"32:40:treatment,67:80:treatment,85:94:treatment,96:107:treatment","Patient is currently receiving warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or otherwise"
5091,NCT02555189,"29:44:treatment,48:57:treatment,,144:154:treatment",Patients on stable doses of bisphosphonates or denosumab which have been started no less than 4 weeks prior to enrollment may continue on this medication
5092,NCT02555189,"23:46:treatment,35:46:treatment,48:61:treatment,63:91:treatment,93:107:treatment,109:133:treatment,135:147:treatment","Use of any prohibited concomitant medications: immunotherapy, 5 alpha reductase inhibitors, spironolactone, diethylstilbestrol (DES), ketoconazole, newer medications targeting ARs"
5093,NCT02554903,"1:35:treatment,43:51:treatment,53:65:treatment,70:82:treatment,,126:135:treatment","Treatment with inhaled prostanoids (e.g., iloprost, epoprostenol) or nitric oxide within 24 h prior to Baseline RHC or study treatment initiation"
5094,NCT02554812,"49:61:cancer,63:68:cancer,70:75:cancer,77:85:cancer,111:127:treatment","Combination B: Phase 1b, patients with advanced solid tumors (NSCLC, SCCHN, melanoma) that have progressed on standard therapy or for which no standard therapy is available, and Phase 2, patients with NSCLC, melanoma, or SCCHN"
5095,NCT02554786,"31:34:treatment,50:54:treatment,76:82:chronic_disease,,",have used medium or high dose ICS or low dose of LABA/ICS combinations for asthma for at least 3 months and at stable doses for at least 1 month prior to Visit 1
5096,NCT02554253,"9:24:treatment,17:24:treatment,,89:115:treatment,129:157:treatment","Complex cardiac surgery will be defined as surgery involving more than one heart valve, redo-sternotomy procedures, or combined valvular and CABG procedures"
5097,NCT02553941,"10:64:treatment,66:77:treatment,79:112:treatment","Requires treatment with a strong cytochrome P450 (CYP) family 3, subfamily A, polypeptide 4/5 (3A4/5) inhibitor"
5098,NCT02553642,"65:77:treatment,79:95:treatment,97:120:treatment,128:141:treatment,143:160:treatment,164:177:treatment,189:207:treatment,,269:278:treatment","At the time of day 1 of the study, patients must have completed chemotherapy, targeted therapy, investigational therapy, other immunotherapy, radiation therapy or major surgery (requiring general anesthesia) at least 28 days before administration of the first dose of nivolumab"
5099,NCT02553642,"57:81:treatment,,95:105:treatment,,149:159:treatment",Must have no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration
5100,NCT02553642,"55:60:cancer,68:95:treatment,144:156:treatment",Subjects must consent to allow for the acquisition of tumor sample prior to starting treatment on study (in most cases patients will require a tumor biopsy)
5101,NCT02553642,"90:121:cancer,101:121:cancer,297:311:cancer","Subjects with histologically or cytologically confirmed locally advanced/unresectable or metastatic urothelial carcinoma (including mixed histologies of urothelial carcinoma with elements of other subtypes) of the renal pelvis, ureter, bladder or urethra (referred to broadly in this protocol as bladder cancer)"
5102,NCT02553642,"30:42:treatment,51:60:treatment,64:74:cancer,,221:232:treatment,236:257:treatment","The subject actively refuses chemotherapy for the treatment of metastatic or locally advanced disease considered as standard treatment for this disease stage (i.e. a patient who has relapsed >1 year after treatment with neoadjuvant or adjuvant chemotherapy), despite being informed by the investigator about the treatment options"
5103,NCT02553265,"18:32:treatment,34:45:treatment,47:58:treatment,62:85:treatment","Patients taking: metoclopramide, domperidone, risperidone or other dopamine blockers"
5104,NCT02552953,",14:32:treatment,,47:58:treatment,63:74:treatment,78:91:treatment,93:128:treatment,130:147:treatment","4 weeks from prior chemotherapy ( 6 weeks for mitomycin C and nitrosourea) , immunotherapy, investigational anti-cancer therapy, radiation therapy; and have recovered from prior toxicities"
5105,NCT02551679,"58:74:chronic_disease,121:137:treatment,195:215:treatment","Subjects who, in the opinion of the investigator, have a vascular disease prognosis that indicates they would require a major amputation in a time frame shortly after administration of the IMP (investigational drug or placebo)"
5106,NCT02549937,"19:29:treatment,38:47:chronic_disease,61:74:chronic_disease,90:106:treatment,119:143:chronic_disease,223:246:treatment","Inability to take medication orally, dysphagia or an active gastric ulcer resulting from previous surgery or a severe gastrointestinal disease,or any other condition that investigators believe may affect absorption of the investigational product"
5107,NCT02549937,"1:16:treatment,20:40:treatment,,81:96:treatment,,110:124:treatment",Strong inducers or inhibitors of CYP3A4 within 2 weeks before the first dose of study treatment (3 weeks for St John?s Wort)
5108,NCT02549937,"8:23:chronic_disease,36:67:treatment,,,,109:133:chronic_disease,135:158:chronic_disease,169:178:treatment,,","severe/unstable angina pectoris or coronary artery bypass grafting, New York Heart Association Class III/IV congestive heart failure, ventricular arrhythmias requiring treatment or left ventricular ejection fraction (LVEF) < 50%"
5109,NCT02549833,"53:59:cancer,75:86:cancer,88:105:cancer,110:126:cancer,191:200:treatment,237:243:treatment","must have newly diagnosed or recurrent WHO grade II glioma (defined as an astrocytoma, oligodendroglioma, or oligoastrocytoma) that is to be histologically confirmed by clinically indicated resection. If patients have already undergone biopsy and have pathological diagnosis of WHO grade II glioma, pathology must be reviewed and confirmed at UCSF"
5110,NCT02548351,"86:90:treatment,91:101:treatment,105:114:treatment,","For subjects with a historical biopsy, is either not taking or is on stable doses of TZDs/glitazones or vitamin E for 6 months before Day 1"
5111,NCT02547818,"22:29:treatment,81:96:treatment,115:121:chronic_disease",Chronic daily use of aspirin exceeding standard of care guidelines for low dose aspirin therapy for prevention of stroke and/or other recommended uses
5112,NCT02547662,"19:47:chronic_disease,70:94:treatment,91:93:treatment,98:130:treatment,156:193:treatment,,,",For patients with extramedullary disease (EMD) measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) or the CT portion of the positron emission tomography (PET)/CT: must have at least one lesion that has a single diameter of >= 2 cm; skin lesions can be used if the area is >= 2 cm in at least one diameter and measured with a ruler
5113,NCT02547662,",43:55:treatment,,,,213:222:treatment,294:315:treatment",at least 28 days before she starts taking pomalidomide FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy; patient must follow pregnancy testing requirements as outlined in the POMALYST REMS program
5114,NCT02544880,"86:96:cancer,103:106:chronic_disease,110:127:treatment",Immunosuppression or immunocompromised for reasons not directly related to patient's malignancy (e.g. HIV or kidney transplant)
5115,NCT02544880,"1:16:treatment,34:47:treatment,55:67:treatment,105:114:treatment,118:142:cancer,144:154:cancer,156:167:cancer,171:177:cancer","Prior radiation, with or without prior surgery and/or chemotherapy, to the head and neck for definitive treatment of HNSCC of the oral cavity, oropharynx, hypopharynx or larynx with previously documented complete clinical or radiographic response to initial treatment"
5116,NCT02544880,"8:23:treatment,32:53:treatment,55:74:treatment,80:108:treatment,","Use of PDE5 inhibitors such as vardenafil (Levitra®), Tadalafil (Cialis®), and sildenafil citrate (Viagra®) ?15-days prior to (intended) enrollment"
5117,NCT02544373,"1:24:chronic_disease,36:38:chronic_disease,84:103:chronic_disease,105:134:chronic_disease,146:152:chronic_disease","Nervous system diseases other than MS that may predispose subjects to OSA (such as Parkinson's disease, amyotrophic lateral sclerosis, or recent stroke)"
5118,NCT02544373,"9:12:chronic_disease,37:63:chronic_disease,,,112:129:chronic_disease","extreme OSA accompanied by signs of cardiopulmonary compromise (RDI>60 respiratory events per hour with severe nocturnal hypoxia or unstable ECG rhythms on PSG), will be excluded unless they are randomized to immediate PAP arm"
5119,NCT02543983,"87:99:chronic_disease,101:109:chronic_disease,133:144:treatment","Presence of medical illness likely to alter brain morphology and/or physiology (e.g., hypertension, diabetes) even if controlled by medications"
5120,NCT02543944,"6:22:chronic_disease,26:42:chronic_disease,53:76:chronic_disease",have major depression or anxiety disorder requiring psychoactive medication (as determined by physician)
5121,NCT02543866,"38:71:treatment,101:120:treatment,129:136:treatment,138:143:treatment,148:164:treatment,168:192:treatment","Patients with past or current use of systemic immunosuppressive agents will be excluded. Receipt of non-systemic agents such as inhaled, nasal, or topical steroids or immune-modulating agents"
5122,NCT02542657,"1:14:chronic_disease,,,70:77:cancer,112:126:treatment",Hypercalcemia (corrected serum calcium > 11.5 mg/dL) attributable to myeloma (e.g. not due to omitted doses of bisphosphonate)
5123,NCT02542202,"23:33:cancer,45:65:cancer,73:97:cancer",Known active invasive malignancy except for renal cell carcinoma and/or non-melanoma skin cancer
5124,NCT02542202,"40:53:cancer,79:98:treatment,103:120:treatment",Patients who have an intact unresected primary tumor should be considered for radical nephrectomy and primary resection prior to enrollment in the study
5125,NCT02541903,"8:19:chronic_disease,20:29:chronic_disease,54:62:chronic_disease,54:59:chronic_disease,",Active hepatitis B infection (defined as presence of Hep BsAg and/ or Hep B DNA)
5126,NCT02541565,"20:36:chronic_disease,53:77:treatment,99:124:treatment,,172:181:treatment",Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment
5127,NCT02541565,"1:33:cancer,35:70:cancer,78:98:cancer,130:146:treatment","basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy"
5128,NCT02540330,"27:56:cancer,60:84:cancer,95:105:treatment",Pathological diagnosis of Invasive Ductal Breast Cancer or Ductal Carcinoma in Situ requiring mastectomy
5129,NCT02540330,"27:38:allergy_name,86:96:allergy_name,98:105:allergy_name,107:121:allergy_name,127:142:allergy_name","known hypersensitivity to fulvestrant or any of its formulation components including castor oil, alcohol, benzyl alcohol, and benzyl benzoate"
5130,NCT02539160,"1:13:treatment,15:27:treatment,29:41:treatment,43:57:treatment,59:69:treatment,71:80:treatment,82:92:treatment,94:104:treatment,106:115:treatment,117:127:treatment,132:145:treatment","ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin"
5131,NCT02538198,"77:86:chronic_disease,90:109:chronic_disease,110:127:chronic_disease",Uncontrolled intercurrent illness including but not limited to uncontrolled infection or psychiatric illness/social situations that would compromise compliance with study requirements
5132,NCT02536846,"11:28:chronic_disease,43:55:chronic_disease,64:75:chronic_disease,77:100:chronic_disease,102:120:chronic_disease,122:130:chronic_disease,132:148:chronic_disease,176:197:chronic_disease,199:219:chronic_disease,271:284:allergy_name","Diagnosis diabetes mellitus, uncontrolled hypertension, severe hypotension, coronary artery disease, metabolic syndrome, glaucoma, liver impairment, decreased renal function, respiratory disorders, peptic ulcer disease (absolute and relative contraindications to use of antipsychotic drugs)"
5133,NCT02536794,"5:10:cancer,41:82:treatment,102:115:cancer",the tumor must be non-gene amplified by fluorescence in situ hybridization (FISH) performed upon the primary tumor
5134,NCT02535832,"24:31:chronic_disease,33:40:chronic_disease,44:60:chronic_disease","Clinically significant hepatic, cardiac or renal impairment"
5135,NCT02535325,"51:61:treatment,107:138:chronic_disease,146:168:chronic_disease,178:211:treatment","Ability to swallow and retain orally-administered medication and does not have any clinically significant gastro-intestinal abnormalities (e.g., malabsorption syndrome or major resection of the stomach or bowel)"
5136,NCT02535312,"12:24:treatment,28:40:treatment,132:146:chronic_disease,377:388:treatment","documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by ultrasound; tubal ligation must be confirmed with medical records of the actual procedure otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit though 4 months after the last dose of study drugs"
5137,NCT02535286,"5:18:treatment,20:32:treatment,36:49:treatment,","Any major surgery, chemotherapy or immunotherapy within the last 14 days"
5138,NCT02534922,"27:39:cancer,67:84:cancer,102:139:cancer","Have any other concurrent malignancies, except adequately treated in situ carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin"
5139,NCT02534922,"44:69:cancer,71:96:cancer,100:121:cancer,163:176:cancer","Subjects must have recurrent or persistent epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. Histologic confirmation of the original primary tumor is required"
5140,NCT02533674,"1:16:treatment,22:52:treatment,75:91:treatment,,","Prior treatment with gemcitabine-containing therapy for advanced disease (adjuvant therapy is allowed, provided not more than six cycles were administered and relapse occurred more than six months after the last drug administration)"
5141,NCT02532595,"159:180:chronic_disease,182:190:chronic_disease,194:212:chronic_disease,214:224:chronic_disease,226:245:chronic_disease,249:276:chronic_disease","Vascular or sensory disturbances in the lower leg which include but is not limited to injury to the nerve root or peripheral nerve in the affected lower leg, inflammatory diseases, bleeding or clotting disorders, lymphedema, peripheral vascular or peripheral arterial disease"
5142,NCT02532231,"35:59:treatment,75:87:treatment,91:102:treatment",Patients with history of previous immunomodulatory therapy (not including lenalidomide or thalidomide)
5143,NCT02531932,"1:40:chronic_disease,44:68:chronic_disease,116:126:treatment,134:152:chronic_disease,185:193:chronic_disease,195:217:chronic_disease,221:242:treatment","Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of Everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)"
5144,NCT02531932,"43:53:allergy_name,63:73:allergy_name,75:84:allergy_name,86:98:allergy_name","Patients with a known hypersensitivity to Everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients"
5145,NCT02531932,"20:43:cancer,47:52:cancer,56:92:cancer",adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin
5146,NCT02531880,"29:41:cancer,42:48:chronic_disease,117:125:treatment","Brain abnormality such as a brain tumor, stroke, brain damage from head trauma or blood vessel abnormalities, on an MRI scan"
5147,NCT02531711,"12:22:chronic_disease,24:41:cancer,43:60:chronic_disease,98:106:treatment","History of vasculitis, intracranial mass, clotting disorder (including medication-induced, e.g., warfarin)"
5148,NCT02531295,"22:44:chronic_disease,83:92:chronic_disease,110:132:chronic_disease,152:178:chronic_disease,195:212:treatment,216:267:treatment,273:291:chronic_disease","Any known history of liver-related diseases including but not limited to: hepatic cirrhosis of decompensated chronic liver diseases; clinically active hepatitis B or C infection as evidenced by clinical jaundice or Grade 2 or higher liver function test abnormalities; any hepatic impairment, regardless of the graded liver function test abnormalities"
5149,NCT02530463,"1:16:treatment,28:52:treatment,56:94:treatment",Current therapy with other systemic anti-neoplastic or anti-neoplastic investigational agents
5150,NCT02530463,"31:38:treatment,54:64:treatment,,91:121:treatment",Patients who are on high dose steroid (equivalent of prednisone more than 10 mg a day) or immune suppression medications
5151,NCT02530034,"30:38:treatment,42:67:treatment,78:100:cancer",Patients receiving any other standard or investigational treatment for their hematologic malignancy other than supportive care
5152,NCT02530034,"1:14:cancer,21:57:chronic_disease,59:65:chronic_disease,69:75:chronic_disease,,254:295:treatment","high-risk MDS (i.e. refractory anemia with excess blasts [RAEB-1 or RAEB-2] by World Health Organization [WHO] classification, or any WHO subset with International Prognostic Scoring System [IPSS] intermediate-2 or high, or any patients that has failed prior therapy with hypomethylating agents)"
5153,NCT02527564,"68:97:treatment,99:118:treatment,120:164:treatment,166:193:treatment","Clinically significant abnormalities on baseline laboratory tests (comprehensive metabolic panel, fasting lipid panel, Complete Blood Count (CBC) with differential, thyroid stimulating hormone)"
5154,NCT02527421,"34:54:chronic_disease,56:73:chronic_disease,77:101:chronic_disease,129:145:cancer","Subjects with a known history of acute adrenal crisis, Addison's disease or decreased adrenal output, low pituitary function or pituitary tumors"
5155,NCT02527421,"1:33:treatment,41:53:treatment,55:67:treatment,69:80:treatment","systemic antipsoriatic treatment (e.g., methotrexate, cyclosporine, hydroxyurea),"
5156,NCT02527265,"1:28:chronic_disease,19:28:chronic_disease,,100:109:treatment,",Respiratory tract infection within 30 days before screening or between screening and initiation of treatment period; subject may return 4 weeks after resolution of the infection for rescreening
5157,NCT02526511,"15:33:cancer,52:69:treatment,77:99:treatment,185:194:treatment",Patients with metastatic disease may have received prior nephrectomy and/or prior systemic therapy (no limit on number); their baseline pMRI would be performed prior to starting a new treatment
5158,NCT02525861,"57:68:allergy_name,128:140:treatment,141:155:treatment,165:182:allergy_name,184:193:allergy_name,195:218:allergy_name","Known history of allergic/hypersensitivity reactions to medications used during and for perioperative care associated with the bronchoscopy/BAL procedures, such as local anesthetics, sedatives, pain control medication"
5159,NCT02525861,"48:55:chronic_disease,57:68:chronic_disease,73:90:chronic_disease,141:156:chronic_disease,158:183:chronic_disease","The participant has any clinically significant medical, psychiatric, or cognitive illness, or any other uncontrolled medical condition (eg, unstable angina, transient ischemic attack) that, in the opinion of the investigator, would impede the participant's ability to comply with the study procedures, pose increased risk to the participant's safety, or confound the interpretation of study results"
5160,NCT02525861,"43:53:cancer,,176:186:cancer,190:225:cancer,227:258:cancer,270:285:cancer,300:309:treatment","The participant is experiencing an active malignancy or has a history of malignancy within 5 years prior to screening, with the exception of the following: adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or stable prostate cancer not requiring treatment"
5161,NCT02525692,",41:56:treatment,58:70:treatment,72:84:treatment,93:100:treatment,131:139:chronic_disease","All adverse events Grade > 1 related to prior therapies (chemotherapy, radiotherapy, and/or surgery) must be resolved, except for alopecia"
5162,NCT02525692,"27:44:treatment,60:104:treatment,134:143:treatment,","Concomitant use of potent CYP3A4/5 inducers, which include enzyme inducing antiepileptic drugs (EIAEDs) (see Appendix B), during the treatment phase of the study and within 2 weeks prior to starting treatment"
5163,NCT02525692,"18:37:chronic_disease,48:67:chronic_disease,69:85:chronic_disease,89:100:chronic_disease,112:130:treatment,189:192:chronic_disease","Known history of cardiac arrhythmias including atrial fibrillation, tachyarrhythmias or bradycardia. Receiving therapeutic agents known to prolong QT interval will be excluded. History of CHF"
5164,NCT02525692,"1:7:cancer,82:102:treatment,169:176:cancer,169:175:cancer","Tumors with isocitrate dehydrogenase 1 (IDH1) or IDH2 mutations as determined by immunohistochemistry for the IDH1 R132H variant or by direct sequencing. IDH1/2-mutant gliomas have a markedly longer overall survival rate compared to those with IDH1/2-wildtype glioma (Parsons et al., 2008; Yan et al., 2009), indicating IDH1/2-mutant gliomas have a distinct natural history"
5165,NCT02525029,"9:31:chronic_disease,52:67:treatment,89:114:treatment",Current thromboembolic disease requiring full-dose anticoagulation - patients receiving pharmacologic prophylaxis for thromboembolic disease will be eligible
5166,NCT02525029,"16:26:chronic_disease,,44:68:treatment,,89:99:treatment",Progression of acute GVHD within 3 days of systemic corticosteroids of at least 2 mg/kg prednisone or equivalent
5167,NCT02524275,"7:17:cancer,49:59:cancer,63:98:cancer,103:117:cancer","Prior malignancy, except for adequately treated basal cell or squamous cell carcinoma of the skin, or thyroid cancer"
5168,NCT02523443,"21:35:treatment,36:57:treatment,64:77:treatment",Patients taking any opioid agonist/antagonist medication (i.e. Buprenorphine)
5169,NCT02522715,",52:81:treatment,85:111:treatment,115:127:treatment,","Must have appropriate wash out (> 6 half-lives) of androgen receptor antagonists, 5 alpha reductase inhibitors or ketoconazole prior to the start of cycle 1; if the agent is not in the table below, the washout should be 2 weeks"
5170,NCT02522715,"57:78:chronic_disease,80:103:chronic_disease,111:132:chronic_disease","clinical signs suggestive of high or imminent risks for pathological fracture, spinal cord compression and/or cauda equina syndrome"
5171,NCT02522715,"23:35:treatment,39:46:treatment,56:84:treatment",may not have received enzalutamide or ARN-509 (another androgen receptor antagonist) in the past
5172,NCT02521493,"14:24:chronic_disease,,103:106:cancer,,218:248:cancer",Patients has cytopenias and/or bone marrow blasts but does not meet the criteria for the diagnosis of AML (WHO Myeloid Neoplasm classification) because of < 20% marrow blasts and meets the criteria for a diagnosis of myelodysplastic syndrome (MDS)
5173,NCT02520791,"39:56:chronic_disease,95:101:chronic_disease,105:124:chronic_disease,323:332:chronic_disease,365:374:chronic_disease,520:549:treatment","All potential patients must undergo a tuberculosis (TB) test prior to study entry to rule out active or latent tuberculosis (either purified protein derivative [PPD] or QuantiFERON-TB Gold, whichever is preferred and available at the institution); patients with a history of TB (even if treated), or evidence of active or latent TB, are excluded; the diagnosis of active TB is defined per current guidelines; patients with a positive TB test (e.g. PPD or QuantiFERON-TB Gold) will be excluded; patients with history of Bacille-Calmette-Guerin (BCG) vaccination will be tested with QuantiFERON-TB Gold test in order to rule out exposure to TB"
5174,NCT02520791,"13:29:chronic_disease,33:53:chronic_disease,33:44:chronic_disease,55:77:chronic_disease,97:108:chronic_disease,134:144:chronic_disease,153:166:chronic_disease,249:277:treatment,330:341:treatment,","Evidence of active infection by hepatitis B and/or C; active viral infection by hepatitis B and hepatitis C could be associated with cytopenias (due to hypersplenism or due to the active virus itself), which could add further risk when a potential immunosuppressive medication is used; for patients with hepatitis B treated with anti-virals to undetectable viral load, and for patients with hepatitis C with undetectable ribonucleic acid (RNA) levels and no evidence of liver damage, enrollment may be considered"
5175,NCT02520791,"24:40:treatment,48:65:treatment,69:85:treatment,91:138:treatment,","Patients not receiving systemic therapy (i.e., systemic steroids or biologic therapy with disease modifying anti-rheumatic drugs [DMARDs]) within 2 years"
5176,NCT02520778,"118:151:chronic_disease,153:177:chronic_disease,179:204:chronic_disease","Any clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiogram (ECG) (e.g., complete left bundle branch block, third degree heart block, second degree heart block)"
5177,NCT02520778,"15:49:chronic_disease,53:75:treatment,120:161:treatment",Patients with human immunodeficiency virus (HIV) on antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with AZD9291
5178,NCT02520778,"11:26:treatment,30:51:treatment,84:100:chronic_disease,106:116:treatment",receiving anticoagulation or anti-platelet therapy are excluded due to the risk of thrombocytopenia with navitoclax
5179,NCT02520427,"1:18:treatment,20:32:treatment,34:50:treatment,52:78:treatment,80:96:treatment,101:122:treatment,,","Antitumor therapy (chemotherapy, antibody therapy, molecular-targeted therapy, retinoid therapy, or investigational agent) within 14 days or 5 half-lives of day 1"
5180,NCT02520011,",,62:78:chronic_disease,80:89:chronic_disease,94:102:cancer","Have a total bilirubin level ?2.0 mg/dL (unless secondary to Gilbert syndrome, hemolysis, or leukemia)"
5181,NCT02520011,",32:49:treatment,54:57:cancer,59:81:treatment,93:111:treatment,185:196:treatment",Received more than 2 cycles of induction therapy for AML. Investigational agents as part of front-line therapy for AML may by acceptable following discussion with the Medical Monitor. Hydroxyurea is permitted (see #5 below)
5182,NCT02519452,"6:27:treatment,78:87:treatment,89:128:treatment,137:156:treatment,158:170:treatment,172:187:treatment","Each prior line of therapy may consist of one or more agents and may include induction, hematopoietic stem cell transplantation, and/or maintenance therapy. Radiotherapy, bisphosphonates"
5183,NCT02519348,"16:28:treatment,30:43:treatment,48:76:treatment,81:87:cancer,88:97:treatment","Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment"
5184,NCT02519348,"1:23:chronic_disease,9:23:chronic_disease,,65:76:treatment",Hepatic encephalopathy within past 12 months or requirement for medications to prevent or control encephalopathy
5185,NCT02519322,"16:30:treatment,32:40:treatment,42:49:treatment,51:77:treatment","Current use of anticoagulants (warfarin, heparin, direct thrombin inhibitors) at therapeutic levels"
5186,NCT02519322,",,53:89:treatment,105:134:treatment,,156:172:treatment",Left ventricular ejection fraction (LVEF) >= 50% by transthoracic echocardiography (TTE) (preferred) or multigated acquisition (MUGA) within 6 months from first study drug administration
5187,NCT02519322,"7:17:cancer,,93:101:cancer,122:129:cancer,171:176:cancer,180:205:cancer,207:233:cancer,238:271:cancer,273:279:cancer,284:290:cancer,320:327:treatment,329:338:treatment","Prior malignancy active within the previous 3 years except for patient's prior diagnosis of melanoma and locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast with local control measures (surgery, radiation)"
5188,NCT02519322,",,52:70:chronic_disease,,123:126:cancer,,147:168:treatment",Total bilirubin =< 1.5 X ULN (except subjects with Gilbert's syndrome who must have normal direct bilirubin) [3 mg/dL for HCC] (within 28 days of first study treatment)
5189,NCT02519322,",,,117:126:treatment,134:144:treatment,193:203:treatment",men who are sexually active with WOCBP must continue contraception for 33 weeks (90 days plus the time required for nivolumab and/or relatlimab to undergo 5 half-lives) after the last dose of study drug
5190,NCT02518594,"12:24:allergy_name,26:34:allergy_name,57:67:treatment,79:86:allergy_name,90:100:allergy_name,122:129:allergy_name","Allergy to progesterone, silicone, or excipients in the study drug, including peanuts or peanut oil in the study drug or placebo"
5191,NCT02518594,"7:24:chronic_disease,44:57:chronic_disease,94:110:treatment",Known liver dysfunction or disease because liver disease is a contraindication to the active study medication
5192,NCT02517307,"24:29:chronic_disease,31:36:chronic_disease,38:41:chronic_disease,45:60:chronic_disease,,,109:138:chronic_disease","confirmed diagnosis of VLCAD, LCHAD, TFP or MCAD deficiency or same gender, age and BMI as a subject with a fatty acid oxidation disorder"
5193,NCT02516969,"1:22:cancer,68:87:cancer,89:102:cancer,104:126:cancer","extra-nodal extension (patient with other high-risk features gross perinueral invasion, bone invasion, angiolyphatic invasion, or a constellation of these factors may be eligible based on case-by-case basis at discretion of principal investigator)"
5194,NCT02516813,"58:71:treatment,75:94:treatment,103:145:treatment,103:111:treatment,138:145:chronic_disease,149:165:chronic_disease","History of any other significant medical disease such as major gastric or small bowel surgery, recent drainage of significant volumes of ascites or pleural effusion (as per Investigator's judgement) or a psychiatric condition that might impair the subject's well-being or preclude full participation in the trial"
5195,NCT02516813,"1:9:treatment,,78:84:cancer,178:187:treatment,208:213:cancer,258:277:cancer","Prior RT to the same region within 12 months (Phase Ia, Arm A; subjects with tumors localized in the head and neck region or thorax) or at any time previously (Phase Ia, Arm B; treatment-naïve subjects with SCCHN and Phase Ib; treatment-naïve subjects with Stage III A/B NSCLC or SCCHN)"
5196,NCT02516813,"30:40:treatment,44:66:treatment,,115:130:treatment",Subjects currently receiving H2-blocker or proton pump inhibitors (or unable to stop at least 5 days prior to the first treatment)
5197,NCT02516696,"17:38:chronic_disease,,,,,132:145:chronic_disease,,,190:209:chronic_disease,231:254:chronic_disease,295:303:chronic_disease","Subject has had myocardial infarction within 6 months prior to enrollment , or NYHA(New York Hospital Association) Class III or IV heart failure (see APPENDIX VI), Ejection Fraction < 35%, uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia or active conduction system abnormalities"
5198,NCT02516696,"16:52:treatment,,91:106:treatment,118:133:treatment,,194:207:treatment",Subject has no prior anti-myeloma treatment therapy within 14 days prior to initiation of study treatment except for corticosteroids with a maximum allowed dosage equivalent to three pulses of dexamethasone (40mg daily for 4 days equals one pulse)
5199,NCT02516670,"25:59:chronic_disease,55:58:chronic_disease,82:93:chronic_disease,98:119:chronic_disease","Have a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies), hepatitis B, or hepatitis C infection"
5200,NCT02516670,"10:28:treatment,33:51:cancer,55:91:cancer,116:141:cancer,","Have had prior chemotherapy for metastatic disease in castration-resistant prostate cancer (prior chemotherapy for hormone-sensitive disease, more than twelve months prior to registration, is acceptable)"
5201,NCT02516332,"28:35:chronic_disease,,,,188:203:chronic_disease,205:219:chronic_disease,224:238:chronic_disease","Patients also will have an anxiety symptom severity score of at least 8 on the Hospital Anxiety and Depression-Anxiety scale (HADS-A) or a DSM-5 diagnosis of an Anxiety Disorder, such as General Anxiety, Social Anxiety, or Panic Disorder"
5202,NCT02516241,"28:38:chronic_disease,42:64:chronic_disease,130:138:chronic_disease,142:150:chronic_disease,167:181:chronic_disease,197:215:chronic_disease,227:246:treatment,298:314:treatment,,446:460:chronic_disease","Active or prior documented autoimmune or inflammatory disorders. The following are exceptions to this criterion:  Patients with vitiligo or alopecia  Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement  Any chronic skin condition that does not require systemic therapy  Patients without active disease in the last 3 years may be included but only after consultation with AstraZeneca  Patients with celiac disease controlled by diet alone may be included but only after consultation with AstraZeneca"
5203,NCT02516241,"19:42:treatment,80:137:treatment,139:148:treatment,150:160:treatment,165:186:treatment,198:229:treatment,243:268:treatment,272:285:treatment,","Prior exposure to immune-mediated therapy, including but not limited to, other anti cytotoxic T-lymphocyte-associated protein 4 (CTLA 4), anti-PD-1, anti-PD-L1, or anti-PD-L2 antibodies, including therapeutic anticancer vaccines. Prior local intervesical chemotherapy or immunotherapy is allowed if completed at least 28 days prior to the initiation of study treatment"
5204,NCT02515110,"32:44:treatment,49:60:cancer,64:100:cancer,119:137:cancer,151:173:treatment","Any history, not including the index cancer, of ipsilateral or contralateral invasive breast cancer or ipsilateral or contralateral DCIS treated with radiation therapy (RT)"
5205,NCT02515110,"23:43:cancer,47:82:cancer,91:109:cancer,110:132:treatment",complete resection of basal cell carcinoma or squamous cell carcinoma of the skin and any in situ malignancy after curative therapy
5206,NCT02514083,"42:64:chronic_disease,101:112:chronic_disease,114:151:chronic_disease,236:257:chronic_disease,261:276:chronic_disease,281:304:chronic_disease,","Currently active, clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, Class 3 or 4 congestive heart failure as defined by New York Heart Association Functional Classification, or a history of myocardial infarction or unstable angina, or acute coronary syndrome within 6 months of screening"
5207,NCT02514083,"1:25:chronic_disease,27:44:chronic_disease,48:72:chronic_disease,197:206:treatment,211:222:treatment","Life-threatening illness, medical condition or organ system dysfunction which, in the investigator s opinion, could compromise the subject s safety, interfere with the absorption or metabolism of ibrutinib and fludarabine, or put the study outcomes at undue risk"
5208,NCT02514083,"32:66:treatment,74:86:treatment,108:117:treatment,153:162:treatment",Subjects who received a strong cytochrome P450 (CYP) 3A inhibitor within 7 days prior to the first dose of ibrutinib or subjects who require continuous treatment with a strong CYP3A inhibitor
5209,NCT02514070,"33:37:allergy_name,39:48:allergy_name,52:83:allergy_name","Known sensitivity or allergy to fish, shellfish or omega-3 fatty acids supplements"
5210,NCT02514070,"32:43:treatment,,111:131:treatment,133:155:treatment,157:181:treatment,183:191:treatment,193:200:treatment,204:210:treatment","Subjects taking supplements or medications that affect lipoproteins for at least the past six weeks including fish oil supplements, bile-acid sequestrants, plant sterol supplements, fibrates, statins or Niacin"
5211,NCT02513797,"25:31:treatment,33:52:treatment,73:92:treatment,103:115:treatment,117:128:treatment,137:155:treatment","Any contraindication to suture, endovascular device, or other minimally invasive techniques including percutaneous, transseptal, and/or sub-xiphoid access"
5212,NCT02513797,"23:40:chronic_disease,42:65:chronic_disease,73:90:chronic_disease,100:140:treatment,","Documented history of cardiogenic shock, hemodynamic instability or any medical condition in which intra-aortic balloon pump (IABP) therapy is clinically indicated within 3 months prior to the planned study intervention"
5213,NCT02513485,"1:18:chronic_disease,25:41:chronic_disease,45:83:chronic_disease",Chronic infection (e.g. hepatitis B or C or Human Immunodeficiency Virus infection)
5214,NCT02513485,"1:26:treatment,28:39:treatment,48:67:treatment,69:85:treatment,106:120:chronic_disease","Embedded metallic objects, prosthetics made of paramagnetic metals, aneurysmal clips and/or a history of claustrophobia"
5215,NCT02512926,",39:54:treatment,,70:76:treatment,82:87:treatment,98:131:treatment,142:145:chronic_disease","At least 90 days must have elapsed if prior radiation to ?50% of the pelvis, the spine, or other substantial bone marrow radiation including TBI"
5216,NCT02512926,",103:125:chronic_disease,132:141:cancer,143:155:chronic_disease","Patients must meet the WHO classification with ? 5% blasts in the bone marrow or must have definitive extramedullary disease (e.g. chloromas, skin lesions)"
5217,NCT02512718,"8:14:chronic_disease,16:34:chronic_disease,38:46:chronic_disease","Recent stroke, cardiac infarction or embolism"
5218,NCT02512497,"21:46:cancer,48:73:cancer,75:104:cancer,106:139:cancer,144:170:cancer,172:202:cancer,212:248:treatment","Diagnosis of either Cutaneous T-Cell Lymphoma; T-Prolymphocytic Leukemia; T-Large Granulocytic Leukemia; T-Lymphoblastic Leukemia/lymphoma; or Peripheral T-Cell Lymphoma, Natural Killer/T-cell lymphoma for whom allogeneic stem cell transplantation is indicated"
5219,NCT02512445,"20:40:chronic_disease,48:59:chronic_disease,76:98:chronic_disease,110:128:chronic_disease","Moderate or severe cognitive impairment, acute suicidality, current severe substance use disorder, unmanaged psychosis or mania"
5220,NCT02510456,"13:56:treatment,61:79:treatment,83:105:cancer,130:154:treatment",Planned for primary systemic (neoadjuvant) chemotherapy and surgical resection of residual primary tumor following completion of neoadjuvant chemotherapy
5221,NCT02509546,"1:12:cancer,35:37:treatment,55:62:treatment",De novo AML who have not achieved CR after 2 lines of therapy
5222,NCT02509507,"9:12:cancer,56:79:chronic_disease,83:116:chronic_disease","For non-HCC, there must not be acute or chronic active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection"
5223,NCT02509507,"30:69:cancer,74:98:cancer,106:120:cancer,158:177:cancer,187:192:cancer,194:197:cancer,212:220:cancer","Subjects must either have no central nervous system (CNS) metastasis, or carcinomatous meningitis, or if CNS metastasis is present, must have stable treated cerebral metastases from BC, NSCLC, RCC, CRC, GEC, or melanoma"
5224,NCT02509507,"16:30:treatment,113:123:cancer,128:148:treatment",expected other cancer therapy while on study with the exception of local radiation to the site of bone or other metastasis for palliative treatment
5225,NCT02508038,"1:4:treatment,9:24:chronic_disease,26:33:treatment",NAT for West Nile Virus (WNV-PCR)
5226,NCT02508038,"21:41:chronic_disease,55:61:cancer,69:78:treatment,",Significant serious intercurrent illness unrelated to cancer or its treatment not covered by other exclusion criteria expected to significantly increase the risk of HSCT
5227,NCT02507232,"31:46:treatment,48:60:treatment,62:74:treatment,85:110:treatment,127:138:cancer","Disease that has not received prior radiation, radiosurgery, chemotherapy, or other investigational treatment directed at the brain tumor at any time. Previous surgical procedures"
5228,NCT02507232,"8:29:chronic_disease,8:15:chronic_disease,,,,93:116:chronic_disease","Severe cardiac insufficiency (NYHA III or IV), with uncontrolled and/or unstable cardiac or coronary artery disease"
5229,NCT02506192,"16:26:treatment,30:45:treatment,37:45:treatment,58:65:treatment",Chronic use of Prednisone or Corticosteroids (occasional inhaled use of steroids acceptable)
5230,NCT02506192,"1:15:chronic_disease,17:28:chronic_disease,,53:62:treatment",Kidney Disease (Hep B and C ok if after 6 months of treatment)
5231,NCT02505035,"1:9:chronic_disease,53:95:treatment,,120:136:treatment,",Dementia admitted from a long-term care facility or prior placement of a surgical feeding tube or 2 or more additional hospitalizations in the past 12 months
5232,NCT02504489,"37:46:treatment,63:83:treatment,84:102:treatment,110:122:treatment,124:140:treatment,142:160:treatment,165:178:treatment,183:204:cancer,208:237:cancer","Disease progression during or after treatment with one or two treatment regimen(s) Treatment regimens can be chemotherapy, targeted therapy, biological therapy, or immunotherapy for advanced (Stage IIIB) or metastatic disease (Stage IV)"
5233,NCT02503722,"1:25:chronic_disease,58:74:treatment,123:129:chronic_disease,134:142:chronic_disease,144:177:chronic_disease","Gastrointestinal disease limiting the ability to swallow oral medications or absorb oral medications including refractory nausea and vomiting, chronic gastrointestinal diseases, inflammatory bowel disease"
5234,NCT02503722,"20:44:treatment,53:55:treatment,59:72:treatment,84:92:treatment,96:132:treatment,,191:201:treatment","Patients receiving systemic corticosteroids (either IV or oral steroids, excluding inhalers or low-dose hormone replacement therapy) within 1 week before administration of the first dose of study drug"
5235,NCT02503722,"1:10:treatment,,61:78:treatment,61:70:treatment,138:146:chronic_disease",Radiation: A minimum of 14 days must have elapsed following radiation therapy and resolution of all radiation induced toxicity excluding alopecia
5236,NCT02503722,"34:43:treatment,45:54:treatment,58:66:treatment,75:102:treatment","have progression of disease with erlotinib, gefitinib or afatinib as last previous systemic treatment"
5237,NCT02503709,",,,,,112:137:treatment,166:183:chronic_disease,217:240:chronic_disease","Consistent corrected QT (QTc) > 450 msec for men and > 470 msec for women by Fridericia formula, on 3 separate electrocardiograms (ECGs); patients with a history of long QTc syndrome or personal or family history of ventricular arrhythmias will be excluded"
5238,NCT02503709,"16:37:treatment,,,,,,,,,,,,786:836:treatment,895:929:treatment","The effects of onalespib and AT7519M on the developing human fetus are unknown; for this reason, women of childbearing potential and male patients with partners of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry, for the duration of study participation, and for 2 months after completion of study; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; women of childbearing potential enrolling on study must have a negative pregnancy test within 72 hours of enrollment in order to be eligible; because there is an unknown but potential risk to nursing infants secondary to treatment of the mother with onalespib and AT7519M, breastfeeding should be discontinued while the mother is treated with onalespib and AT7519M"
5239,NCT02503358,"40:56:chronic_disease,100:116:chronic_disease,125:143:chronic_disease,147:163:treatment,201:212:chronic_disease,214:225:chronic_disease,230:263:chronic_disease","Any evidence of severe or uncontrolled systemic disease, including, but not limited to, ongoing or active infection, active bleeding diatheses or renal transplant, including any patient known to have hepatitis B, hepatitis C, or human immunodeficiency virus (HIV"
5240,NCT02503358,",,113:122:treatment,,,203:224:treatment,238:252:treatment","Males of child bearing potential must agree to practice effective barrier contraception during the entire study treatment period and through 6 months) after the last dose of study drug, (includes males surgically sterilized (i.e. status post vasectomy)"
5241,NCT02502708,"44:61:cancer,86:96:cancer,98:113:cancer,124:160:cancer","histologically proven initial diagnosis of high-grade glioma (WHO grade III and IV), ependymoma, medulloblastoma, or other primary central nervous system tumor"
5242,NCT02502006,"1:12:chronic_disease,14:22:chronic_disease,26:41:chronic_disease","coagulation, bleeding or blood disorders"
5243,NCT02501954,"1:8:treatment,30:42:treatment,47:77:treatment",Surgery must have included a hysterectomy and bilateral salpingooophorectomy
5244,NCT02501473,"1:4:treatment,48:58:chronic_disease,62:70:chronic_disease",ECG without evidence of clinically significant arrhythmia or ischemia
5245,NCT02501473,"12:17:cancer,42:64:treatment,85:94:treatment",Measurable tumor mass(es) accessible for intratumoral injection must be present for treatment and assessment of response
5246,NCT02501473,"13:31:chronic_disease,65:76:chronic_disease,100:108:chronic_disease,110:118:chronic_disease,120:134:chronic_disease,264:271:treatment","Significant autoimmune disease, including active non-infectious pneumonitis, with the exception of alopecia, vitiligo, hypothyroidism or other conditions that have never been clinically active or were transient and have completely resolved and require no ongoing therapy"
5247,NCT02501096,"9:35:cancer,81:210:treatment,234:245:treatment,276:297:treatment,307:316:treatment","For the renal cell carcinoma (RCC) cohort, participants must have progressed on treatment with an anti- programmed death receptor-1 /programmed death receptor-ligand 1 monoclonal antibody (anti-PD-1/PD-L1 mAb) administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies"
5248,NCT02501096,"47:57:cancer,67:78:cancer,112:121:treatment,136:145:treatment",Histologically and/or cytologically confirmed metastatic selected solid tumor types that have progressed after treatment with approved therapies or for which there are no standard effective therapies available
5249,NCT02501096,"41:75:chronic_disease,77:88:chronic_disease,93:104:chronic_disease","Participant is known to be positive for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C"
5250,NCT02501096,"9:25:cancer,27:32:cancer,36:71:cancer,76:108:cancer,112:118:cancer","treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the bladder or cervix"
5251,NCT02500602,"25:35:treatment,37:51:treatment,56:84:treatment,","Subjects on maintenance anxiolytic, antidepressant, or mood stabilizing medications which have been initiated during the past four weeks"
5252,NCT02500407,"1:43:treatment,,69:79:treatment,88:108:treatment,112:139:treatment","Autologous stem cell transplantation (SCT) within 100 days prior to study drug, or any prior allogeneic SCT or solid organ transplantation"
5253,NCT02500381,"21:30:treatment,46:68:treatment,81:92:treatment,",Current or previous treatment with any other experimental treatment (other than deflazacort) within 12 weeks prior to Week 1
5254,NCT02500147,"6:31:chronic_disease,39:56:chronic_disease,58:79:chronic_disease,81:95:chronic_disease,99:109:chronic_disease","With clinical hyperandrogenism and/or hyperandrogenemia, menstrual dysfunction (oligomenorrhea or amenorrhea)"
5255,NCT02498613,"3:27:treatment,29:40:treatment,,107:116:treatment,118:153:treatment","A major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib (percutaneous/endobronchial biopsies are allowed)"
5256,NCT02498613,"28:39:treatment,96:111:treatment,113:121:treatment,123:134:treatment,136:158:treatment","Participants receiving any medications or substances that are strong inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) are ineligible"
5257,NCT02498613,"23:35:treatment,39:41:treatment,,79:91:treatment,","Patients who have had chemotherapy or RT within 3 weeks prior to start of the study agents, or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier"
5258,NCT02498613,"46:62:treatment,,,119:136:treatment,140:171:treatment,180:188:treatment",The lesions have improved or remained stable radiographically and clinically for at least 6 weeks after completion of brain irradiation or stereotactic brain radiosurgery and off steroids for at least 6 weeks
5259,NCT02498613,"11:20:treatment,17:20:treatment,25:27:treatment,97:102:cancer,98:102:cancer,104:108:cancer","screening brain MRI (or CT if MRI contraindicated) will be required for patients with recurrent NSCLC, TNBC, or SCLC; brain MRI (or CT if MRI contraindicated) is required for PDAC if clinically suspected by patient's symptoms or neurological exam"
5260,NCT02498535,"10:34:treatment,43:56:treatment,106:115:treatment,117:127:treatment,129:139:treatment,143:150:treatment","Use of a nitric oxide donor agent such as nitroglycerin or drugs known to increase methemoglobin such as lidocaine, prilocaine, benzocaine or dapsone at screening"
5261,NCT02496663,"129:153:chronic_disease,155:179:chronic_disease,181:206:chronic_disease","Any clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiography (ECG) (e.g., complete left bundle branch block, third degree heart block, second degree heart block)"
5262,NCT02496663,"35:47:treatment,,62:74:treatment,,105:116:treatment",Patients must have completed last chemotherapy >= 3 weeks or radiotherapy >= 2 weeks prior to receiving study drugs
5263,NCT02496663,"4:13:treatment,49:57:treatment,,65:76:treatment,78:88:treatment,90:97:treatment,190:199:treatment,201:210:treatment,212:220:treatment,","be treatment naïve to 3rd generation and beyond EGFR-TKI (i.e., osimertinib, poziotinib, TAK-778) and EGFR monoclonal antibody; patient who received 1st or 2nd generation EGFR-TKI (such as erlotinib, gefitinib, afatinib) are eligible provided that they did not achieve a response to treatment or they did not have a duration of treatment on EGFR-TKI of 6 months or more"
5264,NCT02496663,"66:73:treatment,75:86:treatment,88:95:treatment","have progression of disease on a 3rd generation EGFR-TKI such as AZD9291, rociletinib, HM61713"
5265,NCT02496611,"1:8:chronic_disease,25:41:chronic_disease,43:62:chronic_disease",Obesity associated with genetic disorder (monogenetic obesity)
5266,NCT02496585,"1:14:treatment,16:25:treatment,27:35:treatment,44:62:treatment","Pembrolizumab, Nivolumab, Afatinib and all hormonal therapies"
5267,NCT02496208,",51:67:treatment,60:67:treatment,88:106:treatment,188:208:cancer,334:356:treatment",Patients must have either progressed on least one standard therapy or there must be no standard treatment that has been shown to prolong survival for the patient's disease (patients with urothelial carcinoma who are cisplatin-ineligible may receive protocol therapy as a first line therapy); patients may have received any number of prior cytotoxic agents
5268,NCT02496208,"9:26:chronic_disease,27:32:chronic_disease,,87:102:treatment",Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment
5269,NCT02496208,"29:34:cancer,77:86:cancer,88:95:cancer,97:117:cancer,119:125:cancer,129:133:cancer,155:167:cancer,171:190:cancer,,231:243:treatment","The subject has evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib"
5270,NCT02496208,"22:43:treatment,72:86:treatment,95:103:treatment,132:140:treatment,144:164:treatment,166:173:treatment,,194:211:treatment,,227:291:treatment","The subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, thrombin or factor Xa inhibitors; aspirin (up to 325 mg/day), low-dose warfarin (=< 1 mg/day), prophylactic and therapeutic low molecular weight heparin (LMWH)"
5271,NCT02495545,"8:18:cancer,,103:135:cancer,139:174:cancer,223:262:cancer,","Active malignancy or history of invasive malignancy within the last five years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitely treated. Patients with carcinoma in situ of the uterine cervix treated definitely more than 1 year prior to enrollment may enter the study"
5272,NCT02495415,"41:62:treatment,51:55:treatment,78:94:treatment,119:131:cancer","For patients with persistent disease, a biopsy of bone marrow, or bone, or a soft tissue site, must have demonstrated viable tumor"
5273,NCT02495415,"72:90:treatment,92:105:treatment,110:128:treatment","patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study"
5274,NCT02495168,"17:30:treatment,102:108:chronic_disease,129:151:treatment",Patients taking medication(s) (either daily or as needed) with the potential to affect the course of asthma or to interact with sympathomimetic amines
5275,NCT02495168,"24:42:treatment,44:47:treatment,52:57:treatment",Willing to discontinue asthma medications (ICS and LABAs) during the Run-in Period and for the remainder of the study
5276,NCT02494869,"1:36:chronic_disease,109:118:chronic_disease,120:133:chronic_disease,135:149:chronic_disease","Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e. infection, renal failure, thyrotoxicosis)"
5277,NCT02494141,"59:62:treatment,80:94:chronic_disease,96:104:treatment","Inability to cooperate with/clinical contraindication for MRI including severe claustrophobia, implants, devices, or non-removable body piercings"
5278,NCT02493530,"22:45:treatment,38:45:treatment,57:103:treatment,,126:141:treatment,,191:202:treatment",Patient has received wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) ? 28 days or limited field radiation for palliation ? 14 days prior to starting trial medications or has not recovered from side effects of such therapy
5279,NCT02489591,"1:27:chronic_disease,29:37:chronic_disease,39:49:chronic_disease,51:70:chronic_disease,74:84:chronic_disease","Concurrent sleep disorders (insomnia, narcolepsy, central sleep apnea or parasomnia)"
5280,NCT02489045,"22:31:chronic_disease,33:53:chronic_disease,71:87:chronic_disease","Patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli"
5281,NCT02488967,"26:36:treatment,106:120:cancer,125:156:cancer","For patients who undergo lumpectomy, the margins of the resected specimen must be histologically free of invasive tumor and ductal carcinoma in situ (DCIS) as determined by the local pathologist"
5282,NCT02488967,",,137:146:treatment,148:159:treatment,164:172:treatment,,242:260:cancer","Patients with alkaline phosphatase that is > ULN but =< 2.5 x ULN or unexplained bone pain are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET scan performed within 90 days prior to randomization does not demonstrate metastatic disease"
5283,NCT02487095,"30:34:cancer,39:71:cancer,146:155:treatment","Histological confirmation of SCLC, or extrapulmonary small cell cancer. Although NCI confirmation of pathology is not required prior to starting treatment, every effort will be made to obtain outside pathology to be reviewed by an NCI pathologist"
5284,NCT02487095,"40:44:cancer,46:51:cancer,53:67:cancer,69:84:cancer,90:112:cancer","Subjects with histologically confirmed SCLC, NSCLC, ovarian cancer, cervical cancer, and neuroendocrine cancers"
5285,NCT02485639,"38:42:allergy_name,38:41:allergy_name,51:66:allergy_name,107:120:allergy_name","known hypersensitivity or allergy to eggs, egg or chicken protein, report of allergy to components of the study vaccine or other components of the study vaccine"
5286,NCT02484404,"24:51:chronic_disease,35:51:chronic_disease,99:114:chronic_disease,118:143:chronic_disease","Clinically significant peripheral vascular disease or vascular disease, including rapidly growing aortic aneurysm or abdominal aortic aneurysm"
5287,NCT02484404,"86:93:cancer,95:109:cancer,114:139:cancer","Patients must have histologically or cytologically confirmed persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer"
5288,NCT02484404,"38:53:cancer,57:82:treatment,87:113:cancer",Patients who have had progression of prostate cancer on prior docetaxel treatment for castrate sensitive disease are ineligible
5289,NCT02484404,"7:25:chronic_disease,36:55:chronic_disease,60:74:chronic_disease,116:125:treatment,131:145:treatment","Prior cardiac arrhythmia including atrial fibrillation and atrial flutter, or requiring concurrent use of drugs or biologics with pro-arrhythmic potential"
5290,NCT02484300,"8:37:treatment,39:83:treatment,85:99:treatment,164:172:treatment,183:225:treatment,228:265:treatment,303:322:treatment,324:332:treatment,340:352:treatment","Use of serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, ACE inhibitors or any drugs which interfere with the renin-Angiotensin system, Losartan (or other Angiotensin II type 1 receptor antagonists), non-specific calcium channel blockers (L channel specific are acceptable), anti-inflammatories, vitamins or any antioxidants"
5291,NCT02484248,"1:10:treatment,16:31:treatment,35:55:treatment,",treatment with corticosteroids or oral cromolyn sodium in the four weeks prior to enrollment
5292,NCT02482376,",14:20:treatment,41:65:cancer,69:101:cancer",Women with a biopsy proven diagnosis of ductal carcinoma in situ or invasive carcinoma of the breast
5293,NCT02481310,"1:38:cancer,92:118:cancer,114:117:cancer,134:158:treatment","Diffuse large b-cell lymphoma (DLBCL) (including transformation from a previously indolent non-Hodgkin lymphoma [NHL], so long as no prior systemic treatment was given for the indolent NHL)"
5294,NCT02481245,"22:39:chronic_disease,22:38:chronic_disease,103:112:treatment",Primary diagnosis of anxiety disorders or patients where the anxiety disorder is the primary focus of treatment
5295,NCT02480036,"14:29:chronic_disease,72:88:chronic_disease,102:126:chronic_disease,128:152:chronic_disease,154:172:chronic_disease,177:214:chronic_disease","Uncontrolled medical illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5296,NCT02479698,"5:22:chronic_disease,12:21:chronic_disease,70:89:treatment,137:149:treatment",For fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment
5297,NCT02479230,"31:38:chronic_disease,42:64:chronic_disease,158:168:treatment","Other severe acute or chronic medical or psychiatric conditions, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study"
5298,NCT02477839,"13:21:chronic_disease,49:65:chronic_disease,93:118:chronic_disease,120:141:cancer,145:163:chronic_disease",Subject has epilepsy secondary to a progressing cerebral disease or any other progressively neurodegenerative disease (malignant brain tumor or Rasmussen Syndrome)
5299,NCT02477826,"23:40:chronic_disease,44:61:chronic_disease,65:99:chronic_disease,111:137:chronic_disease",Any positive test for hepatitis B virus or hepatitis C virus or human immunodeficiency virus (HIV) indicating acute or chronic infection
5300,NCT02476786,"20:30:cancer,,71:90:treatment,100:106:cancer",A history of other malignancy ? 5 years previous which would preclude endocrine treatment of their cancer
5301,NCT02475707,"5:13:cancer,112:126:treatment,132:147:treatment",Any leukemia-specific marker (such as t(12;21); t(9;22) or t(4;11)) documented in the patient's leukemia cells pre-transplant on a post-transplant evaluation
5302,NCT02474667,"74:89:treatment,99:114:treatment,142:167:treatment",Has measurable donor-specific antibody or positive cross-match requiring desensitization prior to transplantation or deviation from standard immunosuppressive therapy
5303,NCT02474368,"1:4:chronic_disease,41:63:treatment,128:153:treatment,155:159:treatment,164:190:treatment","HIV-positive individuals on combination antiretroviral therapy are ineligible because of the potential for interaction between conventional radiotherapy, SBRT and antiretroviral medications"
5304,NCT02474199,"1:28:treatment,,,82:90:treatment,,116:124:treatment",Mycophenolate mofetil (MMF): maximum dose of 500 mg administered twice daily for Cellcept or 360mg twice daily for Myfortic
5305,NCT02474173,"15:30:treatment,35:59:cancer,46:59:cancer,161:177:treatment",Any number of prior therapies for metastatic breast cancer is allowed; patients with weakly estrogen receptor positive breast cancer who received any number of endocrine agents for metastatic breast cancer
5306,NCT02474173,"16:23:treatment,95:105:treatment,,,,,312:327:treatment,,,,,,,,","The effects of AT13387 on the developing human fetus are unknown; for this reason and because paclitaxel are known to be teratogenic; women of child-bearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation and 3 months after completion of study treatment administration; adequate contraception includes methods such as oral contraceptives, double barrier method (condom plus spermicide or diaphragm), or abstaining from sexual intercourse; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately"
5307,NCT02473250,"10:18:chronic_disease,132:142:treatment,146:155:treatment","Actively suicidal, as defined by expressing ideation with a plan for suicide or develops suicidal ideation that requires immediate medication or treatment intervention"
5308,NCT02473250,"26:36:treatment,41:51:treatment,92:108:treatment,,143:152:treatment,","Previous failed trial of fluoxetine and citalopram by themselves or in combination with an anti-manic agent, defined as at least six weeks of treatment at the dose of 20 mg per day or more"
5309,NCT02471911,"29:41:cancer,54:70:cancer,,121:131:cancer,133:168:cancer,173:204:cancer,208:214:cancer","Patients who have had prior malignancies (other than B-cell lymphomas) for ?5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast"
5310,NCT02471430,"15:24:chronic_disease,26:32:chronic_disease,34:39:chronic_disease,43:62:chronic_disease,73:104:treatment","Presence of a bacterial, fungal, viral or protozoal infection requiring systemic anti-infective therapy"
5311,NCT02470897,"18:25:treatment,27:40:treatment,45:56:treatment,61:76:cancer",Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer
5312,NCT02469857,"31:43:treatment,47:77:treatment,87:118:treatment,123:129:cancer,134:155:cancer",Receiving or about to receive chemotherapy or biologic anti-cancer treatment although hormonal manipulation therapies for breast and prostate malignancies are permitted
5313,NCT02469129,"15:21:treatment,42:84:cancer,70:76:cancer,116:127:cancer,181:208:treatment,212:230:treatment,269:276:cancer,278:285:cancer,291:309:cancer","Patients with biopsy-proven diagnosis of head and neck squamous cell cancer (HNSCC) or any histopathologic type of lung cancer or any other type of cancer that can be treated with platinum-based chemotherapy as first-line therapy (which includes but is not limited to ovarian, gastric, and pancreatic cancers)"
5314,NCT02468778,"8:35:chronic_disease,68:85:treatment,130:152:treatment","Severe peripheral vascular disease that will preclude the use of a 14F access sheath, which is required for the insertion of the HeartMate PHP catheter"
5315,NCT02468453,"34:43:treatment,55:61:cancer,86:97:cancer,156:173:chronic_disease,187:231:cancer","Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including actinic keratosis, presence of malignant or pre-malignant pigmented lesions"
5316,NCT02468453,"21:58:chronic_disease,60:76:chronic_disease,78:89:chronic_disease,99:117:chronic_disease,124:144:chronic_disease,146:151:chronic_disease","Subject has a known collagen (connective tissue) disorder, vascular disease, scleroderma or other autoimmune disease (i.e. rheumatoid arthritis, lupus)"
5317,NCT02468453,"31:40:treatment,42:54:treatment,58:102:treatment,,122:131:treatment","Subject has systemically used retinoids, antioxidants or medical grade of skin nourishing supplements within 2 months of treatment or during the study"
5318,NCT02468453,"75:92:chronic_disease,94:117:chronic_disease,132:154:chronic_disease","Subject is suffering from significant concurrent illness, such as such as cardiac disorders, diabetes (type I or II), or pertinent neurological disorders"
5319,NCT02467478,"10:24:chronic_disease,28:43:chronic_disease,,131:164:chronic_disease",Previous cardiovascular or cerebrovascular event within 6 months of screening or active or clinically significant coronary and/or Peripheral Vascular Disease (PVD)
5320,NCT02466971,"30:51:treatment,60:69:treatment,73:79:cancer",Patient is receiving another investigational agent for the treatment of cancer
5321,NCT02466750,"32:39:treatment,43:66:treatment,,85:100:treatment",Have administration of another vaccine or investigational product within 28 days of WEE vaccination
5322,NCT02466685,"25:47:treatment,55:62:treatment,64:73:treatment,78:86:treatment,","Individuals receiving a single mood stabilizer (e.g., lithium. valproate, or lamictal) are allowed if a stable dose has been maintained for at least 2 months prior to screening"
5323,NCT02466009,"1:17:chronic_disease,21:28:chronic_disease,65:80:chronic_disease","Pleural effusion or ascites that causes respiratory compromise, grade 2 dyspnea"
5324,NCT02465541,"23:83:cancer,85:99:cancer,121:142:treatment,147:156:treatment","Previous diagnosis of grade 1 or 2, stage I or II endometrioid endometrial cancers (type I cancers) as confirmed during surgical intervention for treatment"
5325,NCT02465268,"21:50:treatment,54:59:cancer,,170:173:treatment",Must have undergone definitive surgical resection of tumor with less than approximately 3cm x 3cm residual enhancing tumor as product of longest perpendicular planes by MRI
5326,NCT02465060,"92:105:chronic_disease,118:134:chronic_disease,174:198:chronic_disease","No factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death"
5327,NCT02465060,"27:40:treatment,,86:94:chronic_disease,99:110:chronic_disease,124:133:treatment",all adverse events due to prior therapy have resolved to a grade 1 or better (except alopecia and lymphopenia) by start of treatment
5328,NCT02464878,"3:20:treatment,34:49:chronic_disease,,,91:110:chronic_disease",A kidney transplant patient with type 1 diabetes who has an HbA1c < 7.5 and no history of severe hypoglycemia
5329,NCT02464878,"24:40:chronic_disease,51:62:chronic_disease,64:75:chronic_disease,77:80:chronic_disease,85:102:chronic_disease","Presence or history of active infection including hepatitis B, hepatitis C, HIV, or tuberculosis (TB)"
5330,NCT02464696,"1:17:treatment,21:28:treatment,,85:92:cancer,96:130:cancer,134:147:cancer,174:199:chronic_disease",Chest radiograph or CT scan within </= 3 months prior to study enrollment rules out primary or metastatic malignancy in the lungs or pleural space as a significant cause of respiratory insufficiency
5331,NCT02464436,"1:17:treatment,38:52:treatment,,236:245:treatment",Cataract surgery in the study eye or ocular surgery in either eye (which in the opinion of the investigator may have an impact on patient safety or the integrity of data from the study eye) during the study or within 3 months prior to treatment
5332,NCT02464436,"15:25:cancer,34:58:cancer,60:84:cancer,89:103:cancer","No history of malignancy, except non-melanoma skin cancer; pre-malignant conditions and cancer in situ"
5333,NCT02463305,"34:39:chronic_disease,41:48:chronic_disease,50:57:chronic_disease,59:68:chronic_disease,72:82:cancer,128:156:treatment,160:181:treatment","Concomitant major comorbidities (renal, hepatic, cardiac, pulmonary or malignancy) to include any medical conditions requiring therapeutic anti-coagulation or anti-platelet therapy"
5334,NCT02462590,"22:44:chronic_disease,68:91:chronic_disease,93:117:chronic_disease,139:163:chronic_disease,176:209:chronic_disease,215:259:treatment,261:304:treatment,327:339:chronic_disease,351:371:treatment,379:398:treatment,406:428:treatment,501:527:treatment,529:553:treatment,556:605:treatment,607:617:treatment,621:635:treatment,651:685:treatment,687:720:treatment,724:771:treatment,807:829:treatment,831:867:treatment,871:890:treatment,923:944:treatment,948:969:treatment","Patients at risk for endovascular infection (previously documented rheumatic heart disease, congenital valve disease, surgically repaired congenital heart disease, unrepaired cyanotic congenital heart disease, any intracardiac repair with prosthetic material [mechanical or bio-prosthetic cardiac valves], previous or current endocarditis, permanent endovascular devices (e.g., endovascular grafts [e.g., aortic aneurysm repair, stents involving large arteries such as aorta, femorals and carotids], inferior vena cava filters, dialysis vascular grafts), tunnelled (not short-term) hemodialysis catheters, pacemakers or defibrillators. Patients with temporary central venous catheters, central venous dialysis catheters or peripherally inserted central catheters (PICCs) are not excluded and patients with coronary artery stents, coronary artery bypass grafts (CABG) or neurovascular coils are not excluded; patients with mitral valve prolapse or bicuspid aortic valve"
5335,NCT02461927,"42:50:allergy_name,52:61:allergy_name,63:73:allergy_name,78:87:allergy_name","Unstable medical condition or allergy to ketamine, midazolam, naltrexone, or lorazepam---clinically determined by a physician"
5336,NCT02460783,"22:24:treatment,34:42:treatment,44:56:treatment","Contraindications to LP, such as Coumadin, coagulopathy"
5337,NCT02459769,"16:31:treatment,33:45:treatment,54:63:treatment","have completed primary surgery, chemotherapy, and/or radiation"
5338,NCT02459119,"1:24:treatment,117:129:treatment,,293:312:chronic_disease","Prior radiation therapy is allowed as long as the irradiated area was not the sole source of measurable disease and radiotherapy was completed with recovery from toxicity, at least three weeks prior to enrollment. If the irradiated area is the only site of disease, there must be evidence of progressive disease"
5339,NCT02459119,"103:110:treatment,127:149:treatment,168:173:treatment,177:190:treatment",Wounds must be completely healed prior to study entry and patients recovered from all toxicities from surgery. Placement of a vascular access device is not considered major or minor surgery in this regard
5340,NCT02458482,"42:62:chronic_disease,70:79:chronic_disease,81:96:chronic_disease,98:109:allergy_name","other medical conditions contributing to respiratory distress (e.g., pneumonia, cystic fibrosis, anaphylaxis)"
5341,NCT02457845,",,96:111:treatment,127:137:cancer,153:173:treatment,",>24 Gy) or total body irradiation ? 3 months prior to study entry. Patients must have received focal radiation to symptomatic metastatic sites or local palliative radiation > 4 weeks prior to study entry
5342,NCT02457845,"47:56:treatment,83:101:treatment,103:116:treatment,120:138:treatment","Patients must have fully recovered from acute treatment related toxicities of all prior chemotherapy, immunotherapy or radiotherapy prior to entering this study"
5343,NCT02456857,"42:59:allergy_name,66:75:allergy_name,77:89:allergy_name","Known intolerance or hypersensitivity to rapamycin analogs (e.g. sirolimus, temsirolimus)"
5344,NCT02456857,"7:14:treatment,20:31:treatment,33:54:treatment,59:69:treatment","Prior therapy with bevacizumab, liposomal doxorubicin, or everolimus"
5345,NCT02455193,"13:40:chronic_disease,48:73:chronic_disease,82:102:chronic_disease","Significant endocrine/metabolic disease (e.g., uncontrolled hypertension, severe hypertriglyceridemia)"
5346,NCT02454010,",34:46:treatment,,110:122:treatment,124:137:treatment,141:163:treatment,","At least 4 weeks beyond the last chemotherapy (or ? 5 half-lives for targeted agents, whichever is shorter), radiotherapy, major surgery or experimental treatment and recovered from all acute toxicities (? Grade 1)"
5347,NCT02453373,"16:37:chronic_disease,44:52:chronic_disease,56:82:chronic_disease",A history of a brain vascular lesion (e.G. aneurism or arteriovenous malformation)
5348,NCT02453373,"8:32:chronic_disease,44:46:chronic_disease,50:52:chronic_disease,80:91:chronic_disease,,,140:151:treatment",severe ventricular dysrhythmias (sustained VT or VF) ) which cause significant hypotension (SBP ? 120 mmHg requiring more than two pressor medications)
5349,NCT02452697,"29:33:chronic_disease,62:69:treatment,86:111:treatment,",Patients with treated acute GVHD must be on a stable dose of therapy (no increase in immunosuppressive therapy for the 2 weeks before planned NK cell-enriched DLIs)
5350,NCT02452268,"1:22:treatment,26:43:treatment,45:58:treatment,60:72:treatment,74:87:treatment,89:107:treatment,111:132:treatment,,191:202:treatment,206:220:treatment,224:236:treatment,240:251:treatment,","Prior IL-15 treatment or cytotoxic therapy, immunotherapy, radiotherapy, major surgery, antitumor vaccines or monoclonal antibodies in the 4 weeks prior or for checkpoint inhibitors such as anti-CTLA-4 or anti PD1/PD-L1 or nitrosoureas or mitomycin C for 6 weeks prior to C1D1"
5351,NCT02452203,"1:4:treatment,34:51:treatment,53:97:treatment,99:120:treatment,122:132:treatment,134:171:treatment,173:184:treatment,186:209:treatment,211:240:treatment,242:252:treatment,254:285:treatment,290:323:treatment,399:410:treatment,,,545:563:treatment,","MRI contraindications including: cardiac pacemaker, metal fragments in eyes/skin/body (shrapnel), aortic/aneurysm clips, prosthesis, by-pass surgery/coronary artery clips, hearing aid, heart valve replacement, shunt (ventricular or spinal), electrodes, metal plates/pins/screws/ wires, or neuro/bio-stimulators (TENS unit), persons who have ever been a professional metal worker/welder, history of eye surgery/eyes washed out because of metal, vision problems uncorrectable with lenses, inability to lie still on one's back for 60-120 minutes; prior neurosurgery; tattoos or cosmetic makeup with metal dyes, unwillingness to remove body piercings, and pregnancy"
5352,NCT02452008,"23:41:chronic_disease,42:68:chronic_disease,81:99:chronic_disease,104:119:chronic_disease,122:142:chronic_disease,165:174:chronic_disease,176:187:chronic_disease,190:223:chronic_disease,235:245:chronic_disease,253:277:chronic_disease,280:283:chronic_disease,287:303:chronic_disease,349:372:chronic_disease,374:391:chronic_disease,393:411:chronic_disease","Have a history of any autoimmune disease:inflammatory bowel disease, (including ulcerative colitis and Crohn's Disease), rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythmatosus (SLE) autoimmune vasculitis (e.g., Wegener's Granulomatosis), CNS or motor neuropathy considered to be of autoimmune origin (e.g., Guillian-Barre Syndrome, Myasthenia Gravis, Multiple Sclerosis)"
5353,NCT02452008,"1:19:treatment,24:34:cancer,46:82:cancer",Prior chemotherapy for metastatic disease in castration-resistant prostate cancer
5354,NCT02451683,"9:25:chronic_disease,31:56:chronic_disease,78:97:chronic_disease,106:121:chronic_disease,123:135:chronic_disease,139:162:chronic_disease","Ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida or herniated cervical disk"
5355,NCT02451553,"1:31:chronic_disease,87:102:treatment,124:153:treatment,155:180:treatment,210:230:chronic_disease,234:250:chronic_disease","Gastrointestinal tract disease or any other reasons resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, active peptic ulcer disease or chronic diarrhea"
5356,NCT02451553,"1:13:treatment,6:13:treatment,,64:73:treatment,102:115:cancer,",Radiotherapy within 4 weeks prior to therapy except palliative radiation to target organs other than primary tumor may be allowed up to 2 weeks prior to registration
5357,NCT02451488,"1:28:chronic_disease,34:37:chronic_disease,39:50:chronic_disease,54:65:chronic_disease","Active or chronic infection with HIV, hepatitis B or hepatitis C"
5358,NCT02451488,",92:114:treatment,116:128:treatment,132:154:treatment",WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy or bilateral oophorectomy) or is not postmenopausal
5359,NCT02451423,"12:33:chronic_disease,12:21:treatment,58:66:chronic_disease",History of radiation pneumonitis in the radiation field (fibrosis) is permitted
5360,NCT02451423,"45:83:treatment,110:123:treatment,128:134:chronic_disease","Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled in the study after discussion with and approval by the Study Chair"
5361,NCT02451423,"8:17:chronic_disease,8:18:chronic_disease,,136:146:chronic_disease,158:167:chronic_disease","Severe infections within 4 weeks prior to Cycle 1, Day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia"
5362,NCT02451423,"12:35:treatment,40:58:treatment,66:81:treatment,86:107:chronic_disease","The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone for adrenal insufficiency) is allowed"
5363,NCT02451423,"95:126:cancer,128:133:cancer,137:162:cancer,174:189:cancer,250:274:cancer","death treated with expected curative outcome (such as, but not limited to, adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated with curative intent and absence of PSA relapse, or ductal carcinoma in situ of the breast treated surgically with curative intent)"
5364,NCT02448381,"73:82:chronic_disease,84:112:chronic_disease,114:132:chronic_disease,134:155:chronic_disease,157:185:chronic_disease,189:206:treatment,","History of sun hypersensitivity and photosensitive dermatoses including porphyria, systemic lupus erythematosus, Sjögren's syndrome, xeroderma pigmentosum, polymorphous light eruptions or radiation therapy within 30 days of enrolling"
5365,NCT02448173,"30:42:cancer,44:57:cancer,59:72:cancer","Patients must have Stage II (IIA = T3N0M0, IIB = T4aN0M0, IIC = T4bN0M0) disease"
5366,NCT02446886,"13:34:chronic_disease,46:50:chronic_disease,54:58:chronic_disease",Progressive neurological disorder other than RRMS or SPMS
5367,NCT02446457,"11:29:chronic_disease,92:103:chronic_disease,111:134:chronic_disease,","Has known active hepatitis B (e.g., hepatitis B virus surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] qualitative is detected)"
5368,NCT02446457,"11:35:treatment,57:82:treatment,,124:139:treatment",receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment
5369,NCT02446457,"26:45:cancer,,93:115:treatment,130:139:treatment,150:174:treatment","with histologic proof of follicular lymphoma grade 1, 2, or 3a relapsing after at least one prior systemic therapy that included rituximab (or other monoclonal CD20 antibody)"
5370,NCT02446236,"14:21:treatment,,,46:75:treatment,112:140:treatment",Able to take aspirin (81 or 325 mg) daily as prophylactic anti-coagulation (patients intolerant to ASA may use low molecular weight heparin)
5371,NCT02446210,"81:88:chronic_disease,128:142:treatment,144:153:treatment,158:183:treatment","Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold such as antipsychotic drugs (chlorpromazine, clozapine) or tricyclic antidepressants"
5372,NCT02445339,"22:37:treatment,76:85:treatment,95:122:chronic_disease",Currently prescribed pharmacotherapy for alcohol dependence (not including treatment of acute alcohol withdrawal syndrome)
5373,NCT02442102,"6:17:treatment,21:50:treatment,66:73:treatment,",Ever tracheotomy or prior endotracheal intubation other than for surgery (? 1 year)
5374,NCT02441140,"1:31:treatment,35:47:treatment,71:88:treatment",Prior bilateral tubal ligation or hysterectomy (as this would prevent chromopertubation)
5375,NCT02441062,"1:45:treatment,,78:81:treatment,82:89:treatment",Peptide receptor radionuclide therapy (PRRT) within 4 weeks of Ga-68 DOTATOC PET/CT scan
5376,NCT02440581,"1:31:chronic_disease,72:81:chronic_disease,85:94:chronic_disease",Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia
5377,NCT02440581,",85:100:treatment,105:117:treatment,145:155:treatment,157:174:treatment,182:195:treatment","Treatment within last 6 months with drugs that may affect bone metabolism including bisphosphonates and teriparatide (except for treatment with calcitriol, vitamin D analogs and/or calcimimetics)"
5378,NCT02439450,"1:31:chronic_disease,35:53:chronic_disease,72:77:cancer,89:103:treatment","severe/uncontrolled infections or concurrent illness, unrelated to the tumor, requiring active therapy"
5379,NCT02438995,"51:85:cancer,87:110:cancer,122:143:cancer,148:172:cancer","Patients with a documented diagnosis of recurrent head and neck squamous cell cancer (squamous cell carcinoma, including nasopharyngeal cancer, or adenoid cystic carcinoma)"
5380,NCT02437851,"17:22:cancer,26:39:chronic_disease,43:52:chronic_disease",Concurrent anal canal or perianal HSIL or condyloma that in the judgment of the clinician cannot be cleared or can only be cleared with undue morbidity to the patient
5381,NCT02437851,"16:37:treatment,49:56:treatment,60:106:treatment,134:153:treatment",Ongoing use of anticoagulant therapy other than aspirin or non-steroidal anti-inflammatory drugs (NSAIDS) that cannot be stopped for surgical procedures
5382,NCT02437812,"16:34:cancer,36:50:cancer,55:80:cancer","Advanced stage epithelial ovarian, fallopian tube, or primary peritoneal cancer"
5383,NCT02437370,"24:34:cancer,74:83:treatment,104:136:cancer,138:173:cancer,178:201:cancer,233:249:treatment,","Has a known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy; free of disease for more than 5 years"
5384,NCT02437370,"18:29:chronic_disease,86:97:chronic_disease,105:128:chronic_disease","Has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected)"
5385,NCT02437110,"10:29:chronic_disease,41:50:chronic_disease,64:80:chronic_disease,",Unstable psychiatric illness defined as psychosis or untreated major depression within 90 days of the screening visit
5386,NCT02435992,"18:30:treatment,32:46:treatment,51:63:treatment","Can be receiving azathioprine, mercaptopurine, or methotrexate, but treatment will be stopped prior to randomization"
5387,NCT02434809,"35:45:treatment,47:61:treatment,67:86:treatment,112:136:treatment","Active implanted devices, such as pacemakers, defibrillators, and drug infusion pumps since the effects of the Calypso System operation on these devices are unknown"
5388,NCT02433977,"1:17:treatment,28:34:chronic_disease,45:58:treatment,60:78:treatment",Systemic steroid dependent asthma (no daily oral steroids- short term therapy for asthma exacerbation is permitted)
5389,NCT02433626,"9:16:cancer,18:32:cancer,34:52:cancer,54:65:cancer,70:85:cancer","Part 1: Ovarian, fallopian tube, primary peritoneal, endometrial, or cervical cancer"
5390,NCT02433158,"45:68:chronic_disease,120:134:treatment,155:165:treatment,241:251:treatment",Occurrence of any severe and/or generalized cutaneous manifestation or any other adverse event during participation in Study B5201002 that was related to study drug and which would therefore make it inappropriate for the subject to receive rivipansel in the current study
5391,NCT02431806,"33:48:chronic_disease,60:63:chronic_disease,93:102:treatment",DSM-IV-TR-based diagnosis of an axis I disorder other than MDD that is the primary focus of treatment
5392,NCT02430077,"62:75:chronic_disease,101:130:chronic_disease,140:163:chronic_disease,165:185:chronic_disease,187:212:chronic_disease,214:233:chronic_disease,245:259:chronic_disease,268:284:chronic_disease,286:301:chronic_disease,305:335:chronic_disease","Laboratory or other histologic findings highly suggestive of liver disease due to causes other than non-alcoholic steatohepatitis, such as chronic viral hepatitis, autoimmune hepatitis, primary biliary cirrhosis, biliary obstruction or genetic liver diseases such as Wilson's disease, hemochromatosis or alpha-1-antitrypsin deficiency"
5393,NCT02430077,"33:45:treatment,47:61:treatment,65:74:treatment","surgical sterilization, such as hysterectomy, tubal ligation or vasectomy"
5394,NCT02429934,"15:31:chronic_disease,42:46:treatment,50:64:treatment,,99:115:treatment",Subjects with active infection requiring oral or IV antibiotics within one month of first dose of study medication
5395,NCT02429830,"19:47:chronic_disease,75:84:chronic_disease,86:106:chronic_disease,111:135:chronic_disease,139:155:chronic_disease","Diagnosed with an esophageal motility disorder such as but not limited to achalasia, nutcracker esophagus, or diffuse esophageal spasm or hypertensive LES"
5396,NCT02429830,"24:34:cancer,38:52:cancer,56:91:treatment,95:118:treatment,123:127:chronic_disease,151:169:treatment",Suspected or confirmed esophageal or gastric cancer or prior gastric or esophageal surgery or endoscopic intervention for GERD (with the exception of sleeve gastrectomy)
5397,NCT02429349,"34:41:cancer,60:78:cancer,87:95:cancer,100:120:cancer","include, but are not limited to, cancers with high risk of ovarian metastasis such as leukemia and non-Hodgkin lymphoma"
5398,NCT02427997,"13:34:treatment,57:65:treatment,,114:131:treatment,,163:180:treatment,","have stable MS disease treatments (e.g., last intake of steroids occurred at least 50 days before the enrolment, MS-specific drugs stable from at least 3 months, symptomatic drugs stable from at least 1 month before the enrolment)"
5399,NCT02427841,"18:21:chronic_disease,25:27:chronic_disease,96:117:treatment",Occlusion of the SMV or PV with insufficient normal vein above and below with which to perform venous reconstruction
5400,NCT02427581,"10:22:treatment,24:36:treatment,41:57:treatment,,83:107:treatment","Received chemotherapy, radiotherapy, or biologic therapy within the last 30 days (neoadjuvant chemotherapy excluded)"
5401,NCT02426476,"14:36:chronic_disease,38:54:treatment,56:78:treatment,","a history of ischemic heart disease, heart transplant, cardiovascular surgery within 1 year"
5402,NCT02425904,"45:80:treatment,96:99:chronic_disease,126:135:treatment,141:155:treatment,157:160:chronic_disease,226:257:treatment","In stratum 1, patients must have failed one prior systemic chemotherapy regimen. In stratum 2, RDD patients must have failed treatment with corticosteroid. ECD patients who have confirmed BRAF V600E mutation must have failed treatment with a BRAF inhibitor or are not considered to be eligible for such treatment"
5403,NCT02425904,"28:80:treatment,156:162:chronic_disease,164:173:chronic_disease,184:193:chronic_disease,208:234:chronic_disease,251:260:chronic_disease","Patients with a history of prior hematopoietic stem cell transplantation (HSCT), elevated conjugated serum bilirubin at study entry, uncontrolled systemic fungal, bacterial, or other infection, a history of hepatitis B or C infection or a history of cirrhosis"
5404,NCT02424968,"30:41:chronic_disease,43:54:chronic_disease,72:83:chronic_disease,94:127:chronic_disease,138:182:chronic_disease","Must not be seropositive for HIV 1 and 2, hepatitis B surface antigen, hepatitis C antibody, human T-lymphotropic virus (HTLV) antibody, cytomegalovirus (CMV) immunoglobulin M (IgM), or rapid plasma reagin (RPR) (Treponema)"
5405,NCT02424955,"22:33:cancer,37:47:cancer,62:103:treatment",Patient with primary liver tumor or metastasis scheduled for Stereotactic Ablative Radiotherapy (SABR)
5406,NCT02423863,"1:21:cancer,36:41:cancer,143:148:chronic_disease,177:196:treatment",Head and neck cancer patients with tumor invading major blood vessels for whom there may be a risk of blockage or bleeding if inflammation or edema is transiently increased by Hiltonol injections
5407,NCT02423772,"12:19:treatment,28:37:treatment,41:53:chronic_disease,",Prescribed opioids for the treatment of chronic pain for the past 90 days or longer
5408,NCT02423525,"81:106:chronic_disease,108:132:chronic_disease,,,,193:208:chronic_disease,230:240:chronic_disease,245:266:chronic_disease,","History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of 3 or 4, unstable angina or poorly controlled arrhythmia, or myocardial infarction within 6 months prior to enrollment"
5409,NCT02422641,"1:11:treatment,15:44:treatment,46:58:treatment,60:72:treatment,76:102:treatment,129:142:cancer","Concurrent or planned systemic chemotherapy, radiotherapy, new hormonal or anti-HER2 directed therapy directed at management of breast cancer"
5410,NCT02422641,"1:16:cancer,18:29:cancer,31:42:cancer,48:61:cancer","TRIPLE NEGATIVE (ER-negative, PR-negative, and HER2-negative disease)"
5411,NCT02421315,"41:44:treatment,61:74:treatment,79:103:treatment","Individuals who are currently receiving CBT, other forms of psychotherapy, or psychotropic medications"
5412,NCT02419495,"28:43:cancer,37:43:cancer,,97:102:cancer,106:141:cancer",Diagnosis or recurrence of invasive cancer other than the present cancer within 3 years (except basal or squamous cell carcinoma of the skin that has been definitively treated)
5413,NCT02419495,"35:55:chronic_disease,158:181:chronic_disease,218:256:chronic_disease,260:310:chronic_disease,311:343:chronic_disease,370:400:chronic_disease,,,453:479:chronic_disease,","Unstable cardiovascular function: symptomatic ischemia (chest pain of cardiac origin), or uncontrolled clinically significant conduction abnormalities (e.g. ventricular tachycardia on antiarrhythmics are excluded and 1st degree atrioventricular [AV] block or asymptomatic left anterior fascicular block [LAFB]/right bundle branch block [RBBB] will not be excluded), or congestive heart failure (CHF) of New York Heart Association (NYHA) class >= 3, or myocardial infarction (MI) within 3 months of consent date"
5414,NCT02419495,"20:52:treatment,,89:99:treatment,129:154:treatment,,200:209:treatment",subjects receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or other form of immunosuppressive therapy within 7 days before the first dose of study treatment
5415,NCT02418195,"1:4:chronic_disease,26:41:chronic_disease,51:68:chronic_disease","MDD Participants without Suicide Attempt, without SUicidal Ideation"
5416,NCT02417701,"10:53:treatment,94:105:treatment,,155:165:treatment",Patients receiving histamine H2 receptor antagonists before enrollment must stop using these medications for at least 24 hours before their first dose of study drug
5417,NCT02416102,"13:29:chronic_disease,41:45:chronic_disease,50:68:chronic_disease,78:92:chronic_disease,97:103:chronic_disease","Concomitant airway disorders other than COPD and chronic bronchitis, such as bronchiectasis and asthma (history and reversible airflow obstruction by American Thoracic Society (ATS) criteria)"
5418,NCT02415660,"126:155:chronic_disease,162:171:chronic_disease,173:190:chronic_disease,192:207:chronic_disease,212:247:chronic_disease","Signs and symptoms consistent with nerve root compression (i.e. diminished upper extremity strength, sensation or reflexes), cervical artery insufficiency (i.e. nystagmus, gait disturbances, Horner Syndrome) or upper cervical ligament instability (i.e. Sharp-Purser, alar ligament, transverse ligament tests)"
5419,NCT02415556,"23:27:chronic_disease,43:75:chronic_disease,,,,,186:198:chronic_disease",Safety substudy in 20 IDDM patients only: Insulin-treated type 2 diabetics with a C-peptide of <0.8 ng/mLd and fasting blood glucose >150 mg/dL will be excluded even without history of hypoglycemia during finger stick measurements
5420,NCT02415387,",,,49:62:cancer,,,120:144:treatment,156:186:treatment,188:197:treatment,199:219:treatment","Women who have been diagnosed with stage I-IIIA breast cancer will be recruited 1-10 years after the completion of all primary cancer treatment except for longer-term hormonal therapies (tamoxifen, aromatase inhibitors)"
5421,NCT02414269,"41:53:treatment,55:67:treatment,72:91:treatment,","All acute toxic effects of any previous radiotherapy, chemotherapy, or surgical procedures must have resolved to grade I or lower according to CTCAE (version 4.0)"
5422,NCT02414269,"1:13:treatment,15:31:treatment,43:68:treatment,73:85:treatment,","Chemotherapy, targeted therapy (such as a tyrosine kinase inhibitor) or radiotherapy must have been completed at least 14 days prior to administration of T cells"
5423,NCT02414178,"22:25:treatment,27:33:treatment,37:39:treatment,46:72:treatment","Contraindications to PET, PET-CT or MR (e.g. electronic medical devices, inability to lie still for long periods) that make it unsafe for the individual to participate"
5424,NCT02413047,"16:26:chronic_disease,30:55:chronic_disease,63:95:chronic_disease,97:141:chronic_disease,143:164:treatment","Any identified congenital or acquired immunodeficiency (e.g., common variable immunodeficiency, human immunodeficiency virus [HIV] infection, organ transplantation)"
5425,NCT02412540,"1:28:chronic_disease,64:67:treatment,91:94:chronic_disease,106:139:chronic_disease,","Active psychiatric disorder that would prevent eligibility for WLS or impede adherence to CLI, including clinically significant depression (hospitalization or suicidal ideation) in past 12 months"
5426,NCT02411656,"13:23:cancer,36:49:cancer,58:78:cancer,82:117:cancer,130:145:cancer,177:193:treatment","Has a known malignancy (other than breast cancer) except basal cell carcinoma or squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy"
5427,NCT02411656,"18:57:cancer,65:89:cancer,124:140:cancer,254:262:treatment,,298:307:treatment","Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate if they are stable, and have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment"
5428,NCT02411318,"24:40:chronic_disease,46:52:cancer,54:63:chronic_disease,65:78:chronic_disease,80:85:chronic_disease,87:94:chronic_disease,96:119:chronic_disease,129:151:chronic_disease,153:167:chronic_disease,169:179:chronic_disease,181:194:chronic_disease,199:223:chronic_disease","History of significant systemic disease (eg. cancer, infection, hematological, renal, hepatic, coronary artery disease or other cardiovascular disease, endocrinologic, neurologic, rheumatologic, or gastrointestinal disease)"
5429,NCT02409316,"53:60:treatment,64:70:treatment,82:95:cancer,99:110:cancer,130:157:treatment,159:176:treatment","History of ER+ pathology (ER+ may be confirmed from surgery or biopsy of primary breast cancer or lymph nodes, and/or surgery or biopsy of a metastatic site, metastatic biopsy is not required)"
5430,NCT02408861,"1:4:chronic_disease,1:16:chronic_disease,68:82:treatment,127:168:treatment","HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme linked immunosorbent assay [ELISA], test kit, and confirmed by Western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status"
5431,NCT02408861,",,,97:114:chronic_disease,123:133:treatment,138:147:treatment,169:187:chronic_disease,,,",Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) =< 3 x ULN for subjects with Gilbert's disease or with atazanavir- or indinavir-induced unconjugated hyperbilirubinemia without aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevation and must have a total bilirubin less than 3.0 mg/dL (within 2 weeks prior to enrollment)
5432,NCT02408861,"23:37:cancer,,174:198:treatment,200:208:treatment,213:244:treatment","for participants with Kaposi sarcoma, the following apply: at least five measurable cutaneous KS lesions or any number of lesions with systemic unresectable disease with no previous local radiation, surgical, or intralesional cytotoxic therapy that would prevent response assessment"
5433,NCT02407171,"5:13:cancer,27:32:cancer,55:78:treatment,108:126:treatment","For melanoma patients and NSCLC patients treated with prior anti-PD-1 therapy, patients must have received prior PD-1 therapy and have progressed (irPD) by irRC"
5434,NCT02407171,"10:58:treatment,16:25:treatment,65:72:treatment,",have had prior treatments with Tyrosine Kinase Inhibitors (e.g. Tarceva) require only a 72-hour washout period prior to starting protocol treatment
5435,NCT02407028,"31:58:treatment,,115:125:treatment,126:137:treatment,151:165:treatment",Ability to initiate the first hyperbaric oxygen treatment within 8 hours of admission in patients not requiring a craniotomy/craniectomy or any other major surgical procedure OR
5436,NCT02405078,"5:17:treatment,19:31:treatment,33:46:treatment,48:56:treatment,61:84:treatment,89:98:treatment,102:110:cancer,","Any chemotherapy, radiotherapy, immunotherapy, biologic, or investigational therapy for treatment of lymphoma within 14 days prior to treatment"
5437,NCT02404870,"17:32:chronic_disease,36:57:chronic_disease,100:109:chronic_disease,126:135:treatment","Past history of eating disorder or psychiatric disorders, including severe depression, anxiety, or psychosis or presently on treatment with medications for any of these conditions"
5438,NCT02404155,"46:54:chronic_disease,56:64:chronic_disease,66:73:chronic_disease,75:81:chronic_disease,83:97:chronic_disease","Documented nutritional deficiencies (such as Beriberi, Pellagra, Rickets, Scurvy, Keshan Disease)"
5439,NCT02403193,"22:38:chronic_disease,42:58:chronic_disease,146:155:treatment",Serious uncontrolled medical disorder or active infection that in the investigator's opinion would impair the patient's ability to receive study treatment
5440,NCT02402660,"26:41:chronic_disease,211:227:treatment,,254:288:chronic_disease","Has active or historical ocular disorder in the primary study eye that, in the opinion of the investigator, may confound assessment of the retina morphologically or functionally (this could include for example cataract surgery within the past 6 months, choroidal neovascularization (CNV)"
5441,NCT02402088,"25:42:chronic_disease,51:63:chronic_disease,65:79:chronic_disease,81:90:chronic_disease,92:97:chronic_disease,99:104:chronic_disease,106:123:chronic_disease,137:148:treatment","Any significant current medical condition such as neurological, cardiovascular, endocrine, renal, liver, thyroid pathology; subjects on medications for any medical condition"
5442,NCT02401347,"20:36:cancer,60:84:treatment,88:125:treatment,191:206:treatment,215:225:treatment,",Adequately treated brain metastases documented by baseline computed tomography (CT) or magnetic resonance imaging (MRI) scan that have not progressed since previous scans and do not require corticosteroids (except prednisone ? 5 mg/day or equivalent) for management of CNS symptoms
5443,NCT02401347,"30:41:treatment,45:54:treatment,,137:155:treatment","If prior platinum agent (eg, carboplatin or cisplatin) has been administered, no evidence of progression, or within 8 weeks of stopping platinum treatment"
5444,NCT02401074,"8:21:treatment,29:36:treatment,38:49:treatment,59:73:treatment,74:82:treatment,84:91:treatment,93:100:treatment,,135:147:treatment","Use of anti-platelet (i.e., aspirin, clopidogrel, etc) or anti-coagulant(coumadin, heparin, Xarelto®, etc) medication 5 days prior to bronchoscopy"
5445,NCT02401035,"8:13:treatment,15:25:treatment,27:38:treatment,43:60:treatment,66:86:treatment,,118:141:treatment","Use of H2RAs, sucralfate, misoprostol, or prokinetic agents, and bismuth preparations within 1 day (24 hours) before investigational product dosing on Day 1"
5446,NCT02400463,"34:44:cancer,154:162:treatment,166:191:treatment",Patients with a prior history of malignancy are eligible if their malignancy has been definitely treated or is in remission and does not require ongoing adjuvant or cancer-directed therapies
5447,NCT02400255,"1:64:treatment,71:103:treatment,105:128:treatment,133:190:treatment","First allogeneic hematopoietic stem cell transplantation (HSCT) using myeloablative conditioning (MAC), non-myeloablative (NMA), or reduced-intensity conditioning (RIC) preparative regimens"
5448,NCT02400255,"13:28:chronic_disease,,,,79:94:chronic_disease,103:113:treatment",Significant cardiac disease (New York Heart Association classes III or IV) or unstable angina despite medication
5449,NCT02398773,",61:73:treatment,78:88:cancer,,152:194:treatment",Patient must NOT have a history of > 1 line of administered chemotherapy for metastatic disease and must be off chemotherapy for a minimum of 2 weeks; prior chemotherapy in the adjuvant setting is allowed
5450,NCT02398240,"4:43:treatment,75:98:treatment,,114:147:cancer",No prior Hodgkin lymphoma directed therapy is allowed except for emergent mediastinal irradiation (<1000cGy) for superior vena cava (SVC) syndrome
5451,NCT02397889,"25:43:chronic_disease,54:67:chronic_disease,71:95:chronic_disease",diagnosis of a lifetime psychotic disorder including schizophrenia or schizoaffective disorder
5452,NCT02397083,"21:42:chronic_disease,55:65:chronic_disease,118:128:treatment,159:169:treatment,191:207:treatment,228:236:treatment,270:292:chronic_disease,298:325:chronic_disease","Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus (e.g., inability to take oral medication or a requirement for intravenous [IV] alimentation, prior surgical procedures affecting absorption, malabsorption syndrome, and active peptic ulcer disease)"
5453,NCT02397083,"81:105:chronic_disease,119:143:chronic_disease,145:166:chronic_disease,,197:207:treatment,230:248:chronic_disease,286:301:chronic_disease,,,,393:399:chronic_disease,422:451:chronic_disease,471:482:treatment,485:498:chronic_disease,507:516:chronic_disease,599:610:chronic_disease,715:732:chronic_disease,780:802:chronic_disease,,,,,971:989:chronic_disease","Patients who have any severe and/or uncontrolled medical conditions such as: a) unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction =< 6 months prior to start of everolimus, serious uncontrolled cardiac arrhythmia, or any other clinically significant cardiac disease; b) symptomatic congestive heart failure of New York Heart Association class III or IV; c) active (acute or chronic) or uncontrolled severe infection (not responding to antibiotics), liver disease such as cirrhosis, decompensated liver disease, and active and chronic hepatitis (i.e. quantifiable hepatitis B virus-deoxyribonucleic acid [HBV-DNA] and/or positive hepatitis B surface antigen [HbsAg], quantifiable hepatitis C virus-ribonucleic acid [HCV-RNA]); d) known severely impaired lung function (spirometry and diffusing capacity of the lung for carbon monoxide [DLCO] 50% or less of normal and oxygen [O2] saturation 88% or less at rest on room air); e) active, bleeding diathesis"
5454,NCT02394704,"5:32:treatment,34:43:treatment,45:75:treatment,86:131:treatment","Any implanted electrical device (pacemaker, vagus nerve stimulator implant, etc.) or prior treatment with a vagus nerve stimulator"
5455,NCT02394535,"13:21:treatment,41:48:treatment,,83:95:treatment",Patients on Coumadin must be changed to Lovenox at least 1 week prior to starting capecitabine
5456,NCT02394535,"1:11:treatment,35:51:treatment,75:85:treatment",ranitidine or a drug from another anti-ulcer class can be substituted for cimetidine
5457,NCT02394028,"28:46:allergy_name,134:136:allergy_name,140:150:allergy_name",intolerance to one or more anti-TNF therapies are eligible to participate in the study provided they are intolerant or refractory to CS or IS therapy
5458,NCT02393885,"19:32:cancer,34:48:cancer,52:63:cancer","Has the following atrial myxoma, mural thrombus or mural tumor"
5459,NCT02393885,"37:56:chronic_disease,92:103:chronic_disease,115:139:chronic_disease,143:157:chronic_disease","Uncorrected, reversible cause(s) of atrial fibrillation, or is currently being treated for arrhythmias other than atrial fibrillation (AF) or atrial flutter"
5460,NCT02393794,"1:18:treatment,23:32:treatment,42:60:cancer",IV bisphosphonate and denosumab for bony metastatic disease is allowed
5461,NCT02393794,"52:69:treatment,94:117:cancer,168:180:treatment,207:223:treatment","Participants who have previously been treated with endocrine therapy only, and later develop triple negative disease are eligible as long as they have had one line of chemotherapy in either the advanced or adjuvant setting"
5462,NCT02393794,"26:45:treatment,56:68:treatment,70:83:treatment,85:93:treatment,95:111:treatment,120:143:treatment","Subject has received any anti-cancer therapy including chemotherapy, immunotherapy, biologic, targeted therapy, or any investigational therapy"
5463,NCT02393794,"43:48:cancer,52:75:cancer,77:105:cancer,129:144:cancer,154:161:cancer,162:175:cancer","with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer or prior ovarian/breast cancer in patients with BRCA associated breast cancer"
5464,NCT02393690,"19:64:treatment,66:69:treatment,74:88:treatment,117:126:treatment,173:184:allergy_name,186:214:allergy_name,223:239:allergy_name","Prior exposure to mitogen-activated protein kinase kinase (MEK), RAS, or RAF inhibitors (note: previous exposure to sorafenib is allowed) OR history of hypersensitivity to selumetinib, thyrotropin alpha (Thyrogen), or any excipient agents"
5465,NCT02393690,"1:10:cancer,15:41:cancer,56:79:cancer,115:129:cancer,,206:225:cancer,227:241:cancer","medullary and anaplastic thyroid cancers are excluded; Hurthle cell carcinomas are excluded (defined as having an invasive tumor composed of > 75% oncocytic [Hurthle] cells lacking the nuclear features of papillary carcinoma, tumor necrosis, and marked mitotic activity)"
5466,NCT02392572,"41:79:cancer,64:79:cancer,83:96:cancer","For Arm E, in addition to patients with relapsed or refractory acute leukemias or high-risk MDS, patients with untreated high-risk MDS or acute leukemias"
5467,NCT02392572,"4:13:treatment,19:42:treatment,74:86:treatment,91:101:treatment",No treatment with immunosuppressive drugs with the exception of low dose cyclosporine and tacrolimus
5468,NCT02392572,"14:34:chronic_disease,65:87:chronic_disease,101:125:chronic_disease,,,,186:204:chronic_disease,209:228:chronic_disease,229:246:chronic_disease","Uncontrolled intercurrent illness including, but not limited to uncontrolled infection, symptomatic congestive heart failure (New York Heart Association class III and IV), uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5469,NCT02392286,"8:21:chronic_disease,37:46:chronic_disease,55:74:chronic_disease","severe liver disease (decompensated cirrhosis, active alcoholic hepatitis)"
5470,NCT02391402,"24:35:chronic_disease,78:94:chronic_disease,99:118:chronic_disease,159:169:treatment",Individuals with other psychiatric diagnoses will not be excluded except for bipolar disorder and psychotic disorders (requirement to refrain from additional treatments might be harmful)
5471,NCT02390752,"5:8:cancer,24:48:treatment,83:96:treatment","For NF1 PN there is no standard medical therapy, and therefore no requirement for prior therapy"
5472,NCT02390752,",59:100:treatment,107:117:treatment,,174:187:treatment","Others: greater than or equal to 7 days from last dose of short active hematopoietic growth factors, i.e. filgrastim, greater than or equal to 14 days for long-acting, i.e. pegfilgrastim"
5473,NCT02390752,",39:60:treatment,62:84:treatment,89:107:treatment,111:121:cancer","greater than or equal to 14 days from whole brain radiation, craniospinal radiation, or targeted radiation to CNS tumors"
5474,NCT02389517,"12:37:chronic_disease,46:78:chronic_disease,89:123:chronic_disease","Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive"
5475,NCT02389465,"24:46:chronic_disease,187:202:treatment,206:227:chronic_disease,,253:268:chronic_disease,270:340:chronic_disease,362:406:chronic_disease,440:464:chronic_disease,477:500:chronic_disease,502:534:chronic_disease,,,591:606:chronic_disease,626:632:chronic_disease","Clinically significant cardiovascular disease that will be assessed on a case-by-case basis. Clinically significant cardiovascular disease usually includes one or more of the following: cardiac surgery or myocardial infarction within the last 4 weeks; unstable angina; acute decompensated congestive heart failure or class IV heart failure; current significant cardiac arrhythmia or conduction disturbance, particularly those resulting in ventricular fibrillation, or causing syncope or near syncope; uncontrolled high blood pressure; QTc greater than 450msec (by history for subjects with cardiac disease); documented prior stroke"
5476,NCT02389465,"76:86:allergy_name,90:102:allergy_name,114:123:allergy_name,125:132:allergy_name,143:149:allergy_name,218:230:allergy_name","Known history of relevant severe drug allergy or hypersensitivity (e.g. to Citalopram or Escitalopram, and/or to celecoxib, aspirin, or other NSAIDs only for Phase 2; known demonstration of allergic-type reactions to sulfonamides)"
5477,NCT02389309,"1:11:treatment,13:20:treatment,22:31:treatment,33:43:treatment","Amiodarone, sotalol, ibutilide, dofetilide"
5478,NCT02389309,"1:15:treatment,17:28:treatment,30:42:treatment,44:56:treatment,58:66:treatment","Chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide"
5479,NCT02389309,"28:52:treatment,54:65:treatment,67:89:treatment,122:130:treatment,194:207:treatment,,343:352:treatment","Inducers and Inhibitors of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4): patients required to be on any CYP3A4/5 inhibitors or inducers will be excluded (with the exception of dexamethasone, but all efforts should be made to reduce the dose of dexamethasone); patients must discontinue drug at least 7 days prior to starting dasatinib"
5480,NCT02389309,"34:57:chronic_disease,,97:122:chronic_disease,135:158:chronic_disease,165:188:treatment","Patients with evidence of recent intratumoral hemorrhage (within 3 months of study enrollment), gastrointestinal bleeding, history of coronary artery disease or on anticoagulation therapy"
5481,NCT02389309,"1:8:treatment,,37:44:treatment,95:127:treatment",Surgery: at least 2 weeks following surgery including brain and spine provided post-operative magnetic resonance imaging (MRI) shows no active bleeding
5482,NCT02389309,"1:16:treatment,29:38:treatment,42:54:treatment",prior treatment with either dasatinib or temsirolimus
5483,NCT02388685,"27:30:treatment,32:50:treatment,52:65:treatment,67:102:treatment,104:115:treatment,119:136:treatment,138:152:chronic_disease","Known contraindication to MRI (intracardiac pacer, defibrillator, certain intracranial aneurysm clips, intraocular or cochlear implants, claustrophobia, etc.)"
5484,NCT02387216,"73:87:cancer,112:130:cancer,,,192:199:treatment","Patients with a diagnosis of cytologically or histologically documented adenocarcinoma of the lung with either metastatic disease (stage IV), Stage IIIB or Stage IIIC disease not amenable to surgery with curative intent"
5485,NCT02384954,"69:78:treatment,102:111:treatment,,301:308:treatment","Anti-CD20 mAb-sensitive disease is defined by a response to a prior rituximab-containing (or another treatment of an anti-CD20 monoclonal antibody) regimen, and relapse more than 6 months from the last administration of rituximab-containing (or another treatment of an anti-CD20 antibody-containing) therapy"
5486,NCT02383979,"1:32:chronic_disease,105:124:chronic_disease,128:146:chronic_disease","primary central nervous disease such as status post cerebral vascular accident with persistent deficit, Alzheimer's disease or Multiple Sclerosis"
5487,NCT02382549,"1:17:treatment,25:32:treatment,34:42:treatment,44:53:treatment,74:97:treatment","Inhaled steroids (e.g.: Advair®, Flovent®, Azmacort®) are not permitted. Topical corticosteroids are acceptable"
5488,NCT02382549,"27:36:cancer,38:43:cancer,45:69:cancer,77:101:cancer","participants may have had cutaneous, uveal, mucosal primary melanoma, or an unknown primary melanoma"
5489,NCT02382419,"1:75:cancer,90:120:chronic_disease,206:229:treatment","Normal Pap or Atypical Squamous Cells of Undetermined Significance (ASCUS) Pap test with HPV deoxyribonucleic acid (DNA) negative by reflex testing via Hybrid Capture 2 (Digene Corp., Gaithersburg, MD), a standard clinical assay within clinically acceptable screening guidelines (American Cancer Society [ACS]/American Society for Colposcopy and Cervical Pathology [ASCCP] 2012 Screening Guidelines)"
5490,NCT02379520,"16:22:cancer,61:64:chronic_disease,95:101:treatment",Diagnosis of a cancer for which the presence of a high risk HPV type has been documented in a biopsy sample
5491,NCT02378428,"18:65:treatment,58:65:treatment,,,106:123:treatment,106:115:treatment","Patients for who CEM (carboplatin, etoposide, melphalan) therapy is administered within 30 days prior to 131I-MIBG therapy or for whom this therapy is planned within 30 days following administration of 131I-MIBG"
5492,NCT02376205,"39:67:treatment,72:86:treatment,91:104:chronic_disease,108:118:chronic_disease",Patients undergoing one- or two-level anterior cervical discectomy and fusion surgery for radiculopathy or myelopathy symptoms
5493,NCT02374333,"1:13:chronic_disease,37:44:treatment,110:122:chronic_disease","CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity"
5494,NCT02374021,",,,55:76:treatment,78:87:treatment,89:116:treatment,118:151:treatment","2 or more high dose radiation scans in the past year (CT scan with contrast, angiogram, SPECT nuclear medicine scan, myocardial/cardiac perfusion scan)"
5495,NCT02374021,"7:51:chronic_disease,58:84:chronic_disease,86:97:chronic_disease","other autoimmune and chronic inflammatory diseases (i.e. inflammatory bowel disease, sarcoidosis)"
5496,NCT02372006,"29:36:chronic_disease,39:46:chronic_disease,48:53:chronic_disease,55:78:chronic_disease,80:83:chronic_disease,85:94:chronic_disease","known pre-existing relevant cardiac , hepatic, renal, bone marrow dysfunction, ILD, keratitis"
5497,NCT02369900,"13:24:treatment,26:34:treatment,36:46:treatment,50:59:treatment","Infusion of epinephrine, dopamine, dobutamine or milrinone at time of enrollment"
5498,NCT02369653,"18:29:cancer,31:54:cancer,59:89:cancer","New diagnosis of de novo ALL, lymphomas (T or B cell), or mixed-phenotype acute leukemia"
5499,NCT02369458,"14:24:cancer,47:57:cancer,61:96:cancer,143:174:cancer","Other active malignancy with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only, carcinoma in situ of the cervix, or synchronous H&N primaries"
5500,NCT02367196,"35:47:cancer,41:46:cancer,53:75:cancer,77:93:cancer,95:108:cancer","High grade, rapidly proliferative solid tumors (eg, small cell lung cancer, germ cell tumors, neuroblastoma) with extensive tumor burden"
5501,NCT02367040,"1:28:cancer,29:58:cancer,60:63:cancer,64:66:cancer",Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM)
5502,NCT02366871,"20:54:treatment,56:62:treatment,64:68:treatment","Concomitant use of dual strong inhibitors or inducers (CYP3A4, P-gp)"
5503,NCT02366871,"16:23:chronic_disease,24:29:chronic_disease,30:49:chronic_disease",no significant cardiac/renal/hepatic dysfunction
5504,NCT02366819,"17:27:treatment,29:39:treatment,44:71:treatment,73:81:treatment,83:94:treatment,96:118:treatment","Patients taking substrates, inhibitors, or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) should be encouraged to switch to alternative drugs whenever possible, given the potential for drug-drug interactions with irinotecan"
5505,NCT02366754,"6:33:treatment,37:50:treatment,52:68:treatment,72:88:treatment","Have implanted cardiac pacemaker or defibrillator, cochlear implant or nerve stimulator"
5506,NCT02366611,",,,33:57:cancer,72:100:treatment,104:121:treatment",Patients with AJCC stage III-IV head and neck malignancy scheduled for definitive radiation therapy or chemoradiotherapy
5507,NCT02365766,"14:54:treatment,63:68:treatment,72:78:treatment,",Has received therapy with hematopoietic growth factor such as G-CSF or GM-CSF in the 14 days prior to registration
5508,NCT02365467,"15:40:chronic_disease,47:64:chronic_disease,66:85:chronic_disease","Subject has a connective tissue disease (e.g. Marfan's syndrome, medial degeneration)"
5509,NCT02365467,"13:36:chronic_disease,42:57:chronic_disease,83:92:treatment",Subject has coronary artery disease with unstable angina and who has not received treatment
5510,NCT02365090,"1:14:chronic_disease,32:43:chronic_disease,37:43:chronic_disease,54:77:chronic_disease","Anisometropic (with or without microtropia) or fully accommodative esotropia (no tropia present with glasses),"
5511,NCT02362997,"39:62:treatment,74:86:treatment,88:100:treatment,104:117:treatment,125:129:treatment","Participants cannot have received any anti-neoplastic therapy (including radiotherapy, chemotherapy or immunotherapy) after ASCT"
5512,NCT02362997,"19:27:chronic_disease,48:54:chronic_disease,58:63:chronic_disease,65:79:chronic_disease,84:102:chronic_disease,143:162:treatment,184:199:treatment,201:225:treatment,230:273:treatment,","Participants with vitiligo, resolved childhood asthma or atopy, hypothyroidism, or Sjogren's syndrome, as well as participants requiring only intranasal steroids, intermittent use of bronchodilators, local steroid injections, or physiologic replacement doses of prednisone (? 10 mg/d) are not excluded from this study"
5513,NCT02362308,"20:58:allergy_name,65:75:allergy_name,77:95:allergy_name,97:104:allergy_name,113:140:allergy_name","Prior allergies to medications used in the study protocol (e.g. L-arginine, potassium chloride, insulin), or to drugs within the same class"
5514,NCT02361554,"34:53:treatment,69:78:treatment,,,169:183:treatment,",Adequate trials of two different antipsychotic drugs (not including clozapine) belonging to different classes of at least 12 weeks equivalent to at least 500 mg/day of chlorpromazine within the previous 5 years
5515,NCT02360579,"1:18:treatment,26:46:treatment,52:64:treatment","Antibiotics (ABX) of the aminoglycoside group (ie, streptomycin, gentamicin); except those who are skin-test negative for gentamicin hypersensitivity"
5516,NCT02360579,"1:29:treatment,74:81:cancer,101:104:cancer,112:140:cancer,,","Palliative radiation therapy is permitted so long as it does not involve lesions being selected for TIL, or as target or non-target lesions. Washout is not required if all related toxicities have resolved to ? Grade 1 as per CTCAE v4.03"
5517,NCT02360579,"39:55:chronic_disease,65:112:chronic_disease,117:158:chronic_disease",Patients who have any form of primary immunodeficiency (such as severe combined immunodeficiency disease [SCID] and acquired immunodeficiency syndrome [AIDS])
5518,NCT02360579,"1:17:treatment,19:27:treatment,37:51:treatment",Targeted therapy: MEK/BRAF or other targeted agent
5519,NCT02359253,"24:30:cancer,32:40:cancer,44:55:cancer","First focal unilateral lesion, ischemic or hemorrhagic"
5520,NCT02358850,"23:42:chronic_disease,44:51:chronic_disease,53:64:chronic_disease","Surgical indications: Chronic tonsillitis, Snoring, Sleep apnea"
5521,NCT02358187,",57:88:treatment,92:127:treatment,,170:207:treatment",Patients must be at least 3 weeks from the last dose of standard cytotoxic chemotherapy or myelosuppressive biological therapy and at least 1 week from the last dose of non-myelosuppressive biologic therapy
5522,NCT02356861,"15:40:chronic_disease,49:84:chronic_disease,86:97:chronic_disease,99:107:chronic_disease","Presence of a neurodegenerative disease such as Amyotrophic Lateral Sclerosis (ALS), Parkinson's, Dementia"
5523,NCT02355535,"23:34:cancer,38:60:cancer,73:81:cancer,123:139:treatment",Diagnosis of advanced solid tumor or hematologic malignancy (limited to lymphoma) that has failed or become intolerant to standard therapy
5524,NCT02355535,"23:45:treatment,33:45:treatment,47:65:treatment,67:94:treatment,114:130:treatment,,159:170:treatment,,210:219:treatment","May not have received cytotoxic chemotherapy, targeted therapies, biologic response modifiers, chemotherapy, and hormonal therapy within the last 3 weeks, or nitrosureas within the last 6 weeks prior to study treatment"
5525,NCT02355002,"22:36:chronic_disease,45:61:chronic_disease,63:73:chronic_disease,75:86:chronic_disease","Diagnosis of primary sleep disorder such as primary insomnia, narcolepsy, sleep apnea, shift work sleep disorder and others"
5526,NCT02354703,"51:58:treatment,60:67:treatment,69:81:treatment,83:95:treatment,100:115:treatment,174:184:treatment","At the Screen Visit, the subject's urine contains opiates, cocaine, amphetamines, barbiturates, or benzodiazepines that cannot be explained by appropriate use of prescribed medication"
5527,NCT02354703,"40:53:chronic_disease,55:71:chronic_disease,82:100:chronic_disease,139:164:chronic_disease,166:196:chronic_disease,198:212:chronic_disease,214:229:chronic_disease","The subject has a current diagnosis of schizophrenia, bipolar disorder, or other psychotic disorder, or a non-psychotic diagnosis such as major depressive disorder, post-traumatic stress disorder, panic disorder, eating disorder, or substance use disorder"
5528,NCT02353819,"60:83:treatment,87:111:treatment,114:128:treatment,133:143:treatment,","Clinically negative lymph nodes as established by imaging (abdominal and pelvic CT or abdominal and pelvic MRI), nodal sampling, or dissection within 90 days prior to registration"
5529,NCT02353819,"8:33:treatment,,72:81:treatment,85:100:cancer",Use of previous hormonal therapy for up to 9 months is allowed for the treatment of prostate cancer as well as for prostate volume reduction
5530,NCT02353728,"1:26:chronic_disease,32:45:chronic_disease,46:65:chronic_disease",Right bundle branch block plus left anterior/posterior hemiblock
5531,NCT02352025,"63:81:chronic_disease,83:102:chronic_disease,106:122:chronic_disease","As judged by the investigator, severe uncontrolled concurrent medical conditions, psychiatric illness or social condition that would limit compliance with study requirements"
5532,NCT02351544,"67:89:treatment,107:124:chronic_disease,115:124:chronic_disease","Those patients are included because there is no consensus whether surgical decompression is effective for chronic migraines only, or for chronic and episodic migraines. One of the goals of this trial is to determine this"
5533,NCT02350764,"35:63:treatment,84:93:treatment,98:122:treatment",Patients may not have intervening systemic anti-cancer therapy between the time of resection and treatment with nivolumab
5534,NCT02350764,"20:71:treatment,,85:95:treatment,,139:149:treatment",no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration
5535,NCT02349958,",61:66:treatment,73:106:treatment,111:123:treatment,158:162:treatment","These patients would ordinarily choose to have 12 cycles of Taxol given after standard first-line surgery and chemotherapy, and instead choose one course of IPHC as their CC"
5536,NCT02349867,"14:23:treatment,36:46:cancer,,99:117:treatment,121:141:cancer,145:180:cancer,189:204:cancer,218:233:cancer,240:256:treatment","Diagnosis or treatment for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, any in situ malignancy, or low-risk prostate cancer after curative therapy"
5537,NCT02349867,"1:8:chronic_disease,10:23:chronic_disease,28:45:chronic_disease","Medical, psychological, or social conditions"
5538,NCT02349867,"26:47:chronic_disease,51:75:chronic_disease,87:113:chronic_disease,126:140:treatment,158:167:treatment",embolic events such as a myocardial infarction or cerebrovascular accident (including transient ischemic attacks) within the 6 months prior to initiation of treatment
5539,NCT02347891,"8:41:treatment,43:57:treatment,59:69:treatment,71:83:treatment,88:109:treatment,","Use of parenteral (IV or IM) antibiotics (antibacterials, antivirals, anti-fungals, or anti parasitic agents) within 60 days of Day"
5540,NCT02346526,"29:33:cancer,,48:67:cancer,71:80:treatment,89:93:cancer,95:100:cancer,109:125:cancer,127:148:cancer","Bone-predominant metastatic CRPC: at least two skeletal metastases on bone scan with no lung, liver, and/or brain metastasis (lymph node metastasis is allowed)"
5541,NCT02346253,"12:33:treatment,35:68:treatment,73:75:treatment,80:95:cancer","History of radical prostatectomy, external beam radiotherapy (EBRT), or BT for prostate cancer"
5542,NCT02346201,"8:17:treatment,,,28:37:treatment,,,234:249:treatment,","Use of trazodone > 50mg or lorazepam > 0.5mg or for indications other than sleeping difficulties within the 30 days preceding randomization or a period of time equal to 5 half-lives of drug, whichever period of time is longer. Other benzodiazepines are prohibited in the past 30 days or within 5 half-lives, whichever period of time is longer"
5543,NCT02344355,"1:8:treatment,,36:43:treatment,47:53:treatment",Therapy must begin ? 5 weeks after surgery or biopsy
5544,NCT02343549,"41:53:allergy_name,90:94:allergy_name,98:106:allergy_name",History of hypersensitivity reaction to temozolomide or a history of hypersensitivity to DTIC or hydrogel
5545,NCT02343042,"24:26:chronic_disease,,,78:97:treatment,105:116:cancer","Documented evidence of PD after achieving at least SD for ? 1 cycle during a previous MM regimen (i.e., relapsed MM)"
5546,NCT02343042,"20:55:treatment,67:87:treatment,89:100:treatment,102:147:treatment,149:205:treatment,211:231:treatment,239:250:treatment,254:265:treatment","Patients receiving hematopoietic growth factor support, including erythropoietin (EPO), darbepoetin, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophagecolony stimulating factor (GM-CSF), and platelet stimulators (e.g., eltrombopag or romiplostim) may continue to do so"
5547,NCT02343042,"14:30:chronic_disease,41:63:treatment,65:75:treatment,80:91:treatment,","Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose"
5548,NCT02342782,"1:24:chronic_disease,25:40:chronic_disease,44:71:chronic_disease",Active hepatitis B or C viral infection or hepatitis B surface antigen positive
5549,NCT02342782,"1:22:treatment,10:22:treatment,26:35:treatment,,87:91:treatment,100:124:treatment,148:177:treatment","Systemic chemotherapy or radiation cannot have been given within 4 weeks prior to the Y-90 dose of radioimmunotherapy (RIT), with the exception of single agent cyclophosphamide priming chemotherapy administered for mobilization"
5550,NCT02341963,"25:64:treatment,66:97:treatment,99:130:treatment,132:159:treatment,161:193:treatment,195:209:treatment","Due to undergo elective major amputation of the lower extremity (above the knee amputation (AKA), below the knee amputation (BKA), total knee amputation (TKA), transmetatarsal amputation (TMA), toe amputation) from all causes"
5551,NCT02340156,"22:31:chronic_disease,43:60:chronic_disease,72:88:treatment","Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy"
5552,NCT02340156,"1:19:treatment,34:37:cancer,43:64:treatment,75:90:treatment,94:105:treatment",Prior chemotherapy for recurrent GBM with nitrosourea compounds including Gliadel® wafers or bevacizumab
5553,NCT02339922,"31:49:chronic_disease,64:75:chronic_disease,79:80:chronic_disease,81:96:chronic_disease,107:141:chronic_disease","Known ongoing or known active systemic infection, known active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive"
5554,NCT02339922,"1:21:treatment,23:35:treatment,37:47:treatment,49:58:treatment,61:73:treatment,75:95:treatment,97:118:treatment,120:130:treatment,132:143:treatment,146:172:treatment,174:183:treatment,185:198:treatment,200:210:treatment,213:224:treatment,226:241:treatment,297:302:cancer","anti-CD20 antibodies (obinutuzumab, ofatumumab, rituximab); lenalidomide; ibritumomab tiuxetan; proteasome inhibitors (bortezomib, carfilzomib); tyrosine kinase inhibitors (ibrutinib, acalabrutinib, idelalisib); alemtuzumab; corticosteroids unless given for an indication other than treating the B-NHL"
5555,NCT02339233,"1:15:chronic_disease,17:28:chronic_disease,30:37:chronic_disease,41:54:chronic_disease","cardiovascular, respiratory, bladder or renal disease unrelated to SCI"
5556,NCT02338999,"23:36:chronic_disease,38:51:chronic_disease,53:56:chronic_disease,60:62:chronic_disease,,","Patients with current heart failure (NYHA class II, III or IV) and/or a left ventricular ejection fraction of <45% by echocardiogram at screening"
5557,NCT02338999,"1:11:cancer,15:50:cancer,29:38:cancer",basal cell or squamous cell carcinoma of the skin with complete excision and clear borders or adequately treated in situ carcinoma of the cervix
5558,NCT02338232,"21:34:chronic_disease,45:61:chronic_disease,72:97:treatment,102:115:chronic_disease","Subjects with known heart failure, advanced renal impairment requiring renal replacement therapy, or liver failure"
5559,NCT02336451,"13:38:chronic_disease,42:52:chronic_disease,100:109:treatment,117:136:chronic_disease,182:204:chronic_disease","Patient has impairment of GI function or GI disease that may significantly alter the absorption of ceritinib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome)"
5560,NCT02336451,"27:43:cancer,49:54:cancer,69:92:treatment,113:142:cancer","Patients must have active brain metastases from NSCLC, confirmed by Gadolinium-enhanced MRI without concomitant leptomeningeal carcinomatosis"
5561,NCT02335905,",,25:38:chronic_disease,75:91:treatment,97:107:treatment,154:172:treatment",One to three site(s) of osteomyelitis with expectation that transition to oral antibiotics from IV therapy will be likely prior to discharge to complete antibiotic therapy
5562,NCT02335242,"17:20:treatment,53:75:cancer,,,161:171:treatment","Have a required MRI examination to confirm that the lymphatic malformation is present and is greater than 3 cm in diameter in order for the subjects to receive medication, which happens during the initial screening evaluation portion of the trial"
5563,NCT02335242,"202:258:chronic_disease,299:307:chronic_disease,309:321:chronic_disease,323:346:chronic_disease,351:365:chronic_disease,384:397:chronic_disease,399:414:chronic_disease,419:434:chronic_disease","any significant cardiovascular risk factors and any condition which requires participants to use nitric oxide donors or nitrates in any form, underlying anatomic or vascular risk factor for developing non-arteritic anterior ischemic optic neuropathy (NAION) including low ocular cup to disc ratio, diabetes, hypertension, coronary artery disease, or hyperlipidemia Participants with Down syndrome, Turner syndrome and Noonan syndrome will be considered on a case-by-case basis"
5564,NCT02334865,"27:38:allergy_name,40:52:allergy_name,54:85:allergy_name,90:147:allergy_name","Known hypersensitivity to thalidomide, lenalidomide, Keyhole Limpet Hemocyanin (KLH), or granulocyte colony-macrophage stimulating factor (GM-CSF)"
5565,NCT02333162,"1:29:cancer,44:74:cancer,93:137:treatment",acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS) undergoing second allogeneic (allo)-stem cell transplant (SCT) using the same donor or different donor for disease relapse
5566,NCT02332850,"14:16:cancer,38:60:treatment,66:86:treatment",Diagnosis of MM and documentation of treatment with an IMiD® and proteasome inhibitor
5567,NCT02332668,"10:18:cancer,71:82:cancer,86:94:cancer","Advanced melanoma or PD-L1-positive advanced, relapsed, or refractory solid tumor or lymphoma"
5568,NCT02332668,"1:20:treatment,30:39:treatment,41:48:treatment,53:99:treatment,104:111:chronic_disease,115:138:chronic_disease","replacement therapy (such as thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is acceptable"
5569,NCT02331095,"89:91:chronic_disease,141:159:treatment,161:170:treatment,188:207:treatment,209:219:treatment,221:247:treatment","A diagnosis of proximal DVT (proximal to and including popliteal vein), with or without PE, confirmed by objective imaging studies, such as Doppler ultrasound, venograms (for DVT) and/or computer tomography, angiograms, ventilation-perfusion scan (for PE)"
5570,NCT02329327,"1:23:chronic_disease,25:46:chronic_disease,48:92:chronic_disease,122:147:chronic_disease,149:173:chronic_disease,200:227:chronic_disease,","venous thromboembolism, myocardial infarction, disseminated intravascular coagulation (DIC), cerebral vascular accident, transient ischemic attack, unstable angina pectoris hospitalization or severe peripheral vascular disease within 2 weeks prior to screening"
5571,NCT02324582,",19:38:treatment,40:43:treatment,48:73:treatment","Less than 14 days post bladder biopsy, TUR, or traumatic catheterization"
5572,NCT02324439,"1:9:treatment,66:79:chronic_disease,81:116:chronic_disease,118:127:chronic_disease,129:143:chronic_disease,147:152:chronic_disease,154:183:chronic_disease","Flaxseed supplementation may be contraindicated in patients with acute abdomen, esophageal stricture or perforation, dysphagia, GI obstruction or ileus, acute intestinal inflammation or unexplained abdominal pain. Patients with any of these conditions will be excluded from this trial as the high fiber content of flaxseed may make these conditions worse"
5573,NCT02324439,"44:68:chronic_disease,78:96:chronic_disease,181:195:treatment",Patients with a diagnosis of/problems with von Willebrand's disease or other bleeding disorders (as flaxseed may slow blood clotting; the risk of bruising or bleeding in people on anticoagulants or with bleeding disorders may be a concern)
5574,NCT02323880,"1:16:treatment,69:82:treatment,,132:146:treatment","Corticosteroids: If used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid"
5575,NCT02323880,"21:51:cancer,122:134:treatment,195:216:treatment",Patients with known bone marrow metastatic disease will be eligible for study if they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions)
5576,NCT02323880,"51:61:cancer,129:146:cancer,140:145:cancer,148:169:cancer,188:201:cancer","patients must have had histologic verification of malignancy at original diagnosis or relapse except in patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of cerebrospinal fluid (CSF) or serum tumor markers including alpha-fetoprotein or beta-human chorionic gonadotropin (HCG)"
5577,NCT02323581,"20:45:chronic_disease,53:59:chronic_disease,63:84:chronic_disease","Known degenerative connective tissue disease, e.g., Marfan or Ehler-Danlos Syndrome"
5578,NCT02323191,"39:59:chronic_disease,161:183:chronic_disease,193:251:chronic_disease,253:274:chronic_disease,,310:321:chronic_disease,326:341:chronic_disease,346:363:chronic_disease,375:404:chronic_disease,432:444:chronic_disease","Evidence of significant, uncontrolled concomitant diseases, which could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina) or pulmonary disease (including obstructive pulmonary disease and history of symptomatic bronchospasm)"
5579,NCT02323191,"23:35:treatment,37:49:treatment,61:82:treatment,94:107:treatment,","Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy that have not regressed to Grade <=1 severity (Common Terminology Criteria for Adverse Events [CTCAE] v4.03, or later versions)"
5580,NCT02323126,"25:42:treatment,59:69:treatment,,129:145:treatment,153:165:treatment","require emergent use of systemic steroids, chronic use of prednisone (greater than 10mg or an equivalent steroid dose daily) or emergent surgery and/or radiotherapy"
5581,NCT02323100,"16:36:treatment,38:58:treatment,81:115:treatment,","Current use of ivacaftor (Kalydeco), lumacaftor/ivacaftor combination, or other corrector or potentiator (Symdeko) less than 30 days from Screening"
5582,NCT02321501,"14:19:cancer,47:86:cancer,158:166:treatment,",ALK-positive NSCLC patients with asymptomatic central nervous system (CNS) metastases who are neurologically stable or have not required increasing doses of steroids within the 2 week prior to study entry to manage CNS symptoms
5583,NCT02321501,"1:23:cancer,38:52:cancer,87:94:treatment,",Non-ALK-positive NSCLC patients with CNS metastasis should have completed a course of therapy would be eligible for the study provided they are clinically stable for 1 month
5584,NCT02321501,"95:115:treatment,,131:146:treatment,155:169:treatment",Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosing (except ALK inhibitors)
5585,NCT02321501,"14:31:chronic_disease,,,90:97:treatment,132:156:chronic_disease,160:182:chronic_disease,226:248:treatment","Uncontrolled diabetes mellitus as defined by hemoglobin A1c (HbA1c) >8% despite adequate therapy. Patients with a known history of impaired fasting glucose or diabetes mellitus (DM) may be included, however blood glucose and antidiabetic treatment must be monitored closely throughout the trial and adjusted as necessary"
5586,NCT02320292,"14:24:cancer,35:44:treatment,106:114:cancer",Active other malignancy requiring treatment that would interfere with the assessments of response of the lymphoma to protocol treatment and would interfere with follow-up assessments through year 5
5587,NCT02320292,"18:23:chronic_disease,34:42:treatment,60:68:treatment","Subjects who are HBsAg negative, anti-HBs positive, and/or anti-HBc positive, but viral DNA negative are eligible"
5588,NCT02319369,"93:99:chronic_disease,104:112:chronic_disease,114:127:chronic_disease,156:171:treatment,180:212:chronic_disease","Has any condition that would preclude adequate absorption of DS-3032b, including refractory nausea and vomiting, malabsorption, biliary shunt, significant bowel resection, and/or graft-versus-host disease (GVHD) affecting the gut"
5589,NCT02319369,"14:23:treatment,42:52:cancer,,109:120:treatment,,191:200:treatment","received any therapies intended to treat malignancy within 14 days of first receipt of DS-3032b [except for hydroxyurea, which must be discontinued at least 48 hours (Day -2) prior to study treatment]"
5590,NCT02317991,"108:117:treatment,160:191:chronic_disease,193:209:chronic_disease,211:234:chronic_disease,242:264:chronic_disease,304:317:chronic_disease,321:334:chronic_disease","Patients with other concurrent severe and/or uncontrolled medical disease which could compromise safety of treatment as so judged by treating physician (i.e., severely impaired lung function, severe infection, ventricular arrhythmias active ischemic heart disease, known active vasculitis of any cause, chronic liver or renal disease)"
5591,NCT02315612,"5:22:treatment,24:41:treatment,,115:128:treatment,","For radiation therapy: Radiation therapy must have been completed at least 3 weeks prior to enrollment (including CNS radiation), with the exception that there is no time restriction if the volume of bone marrow treated is less than 10% and also the subject has measurable/evaluable disease outside the radiation port"
5592,NCT02315612,"51:63:treatment,65:76:treatment,78:95:treatment,97:114:treatment,121:146:treatment,165:172:cancer,","Patients who are on standard ALL maintenance type chemotherapy (vincristine, 6- mercaptopurine, oral methotrexate, or a tyrosine kinase inhibitor for patients with Ph+ ALL) may be enrolled provided that chemotherapy is discontinued at least 1"
5593,NCT02315612,"46:58:cancer,46:49:chronic_disease,60:86:cancer,75:86:chronic_disease,158:174:treatment","Subjects with radiologically-detected active CNS lymphoma, leptomeningeal CNS disease or isolated CNS disease which are eligible for definitive CNS directed radiationtherapy"
5594,NCT02315196,"1:20:treatment,56:62:treatment,,149:167:cancer","Computed tomography of the chest, abdomen, and pelvis (CT CAP) and bone scan performed within 30 days prior to study entry and does not demonstrate metastatic disease"
5595,NCT02315196,"1:24:chronic_disease,26:38:chronic_disease,40:67:chronic_disease,72:101:chronic_disease,","Nervous system disorder (paresthesias, peripheral motor neuropathy, or peripheral sensory neuropathy) >= grade 2, per the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)"
5596,NCT02315196,"1:26:cancer,16:26:cancer,39:53:cancer,60:91:cancer,112:150:cancer,","Second primary malignancy except most situ carcinoma (e.g. in situ carcinoma of the cervix, adequately treated non-melanomatous carcinoma of the skin) or other malignancy treated at least 5 years previously with no evidence of recurrence"
5597,NCT02315196,"28:47:treatment,49:61:treatment,66:82:treatment","patients who have received corneal transplants, cadaver skin, or bone transplants are eligible"
5598,NCT02314377,"24:35:treatment,45:69:treatment,81:118:treatment,,143:154:treatment","Patients must not have core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to bevacizumab"
5599,NCT02314221,"1:19:chronic_disease,21:27:chronic_disease,29:43:chronic_disease,45:74:chronic_disease,76:98:chronic_disease,100:112:chronic_disease,114:133:chronic_disease","Multiple sclerosis, Stroke, Cerebral Palsy, Amyotrophic lateral sclerosis, Traumatic Brain injury, Spina bifida, Parkinson's disease"
5600,NCT02312596,"8:25:chronic_disease,43:51:treatment,56:80:treatment,122:132:chronic_disease,157:167:chronic_disease,176:182:chronic_disease","Active Charcot's disease as determined by clinical and radiographic examination of a non-diabetic pathophysiology (e.g., rheumatoid, radiation-related, and vasculitis related ulcers)"
5601,NCT02312596,"1:6:chronic_disease,39:60:treatment,68:72:treatment","Ulcer expected to be treated with any advanced therapeutics (e.g., HBOT)"
5602,NCT02312570,"1:24:chronic_disease,25:30:chronic_disease,25:31:chronic_disease,164:172:chronic_disease,174:184:chronic_disease,186:195:treatment,197:207:chronic_disease,209:234:chronic_disease,236:242:chronic_disease,247:264:chronic_disease","Stage I pressure ulcers Ulcers that are unstageable or of deep tissue morphology that have yet to become an open wound Ulcer not of PU pathophysiology (e.g., pure diabetic, vasculitic, radiation, rheumatoid, collagen vascular disease, venous, or arterial etiology)"
5603,NCT02312518,"88:106:treatment,124:129:chronic_disease,162:196:treatment","Subject requires or is anticipated to require interventions directed at improvement of arterial perfusion to affected area Ulcer expected to be treated with any advanced therapeutics (e.g., HBOT)"
5604,NCT02312245,"1:19:cancer,23:41:cancer,43:61:cancer,65:86:cancer","Platinum resistant or refractory ovarian, primary peritoneal or fallopian tube cancer of any subtype"
5605,NCT02311361,"22:48:chronic_disease,50:57:chronic_disease,59:66:chronic_disease,69:92:chronic_disease,94:108:chronic_disease,137:153:chronic_disease","Active or history of inflammatory bowel disease (colitis, Crohn s), irritable bowel disease, celiac disease, or other serious, chronic, gastrointestinal conditions associated with diarrhea"
5606,NCT02311361,"1:11:treatment,13:20:treatment,26:42:treatment","Intranasal, inhaled, and topical steroids"
5607,NCT02310464,"56:63:cancer,65:69:cancer,71:81:cancer,85:98:cancer","Histologically or cytologically confirmed diagnosis of gastric, lung, colorectal or breast cancer on file"
5608,NCT02310464,"32:53:treatment,55:83:treatment,105:131:cancer","Patients who have not received standard chemotherapy, hormonal or targeted therapy for their underlying advanced/metastatic cancer"
5609,NCT02310464,"15:32:chronic_disease,40:47:chronic_disease,56:66:cancer,78:90:chronic_disease,","Subjects with pleural effusions and/or ascites, due to malignancy, requiring paracentesis every 2 weeks or more frequently"
5610,NCT02310399,"27:46:chronic_disease,48:61:chronic_disease,63:76:chronic_disease","Patients with evidence of Chiari malformation, hydrocephalus, spina bifid a"
5611,NCT02309580,"42:64:chronic_disease,87:97:chronic_disease,,,114:138:chronic_disease,","Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification"
5612,NCT02309580,"8:17:chronic_disease,40:64:treatment,,118:128:treatment",Recent infection requiring intravenous anti-infective treatment that was completed ?14 days before the first dose of study drug
5613,NCT02308904,"25:30:treatment,32:35:treatment,39:51:treatment,","Liver iron evaluated by SQUID, MRI or liver biopsy within 12 months prior to enrollment in the study"
5614,NCT02308202,"66:80:treatment,82:92:treatment,94:99:treatment,101:108:treatment,113:138:treatment","Have evidence of untreated or unstable medical illness including neuroendocrine, autoimmune, renal, hepatic, or active infectious disease"
5615,NCT02307565,"1:23:chronic_disease,35:38:chronic_disease,40:59:chronic_disease,61:69:chronic_disease,71:77:chronic_disease,79:97:chronic_disease,99:118:chronic_disease","Neurological condition other than SCI (Alzheimer's disease, dementia, stroke, multiple sclerosis, Parkinson's disease, etc.)"
5616,NCT02304458,"1:64:treatment,73:151:treatment,83:91:treatment,,196:228:chronic_disease,252:269:treatment","Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: >= 100 days after infusion, no evidence of graft versus host disease (GVHD) and no requirement for immunosuppression"
5617,NCT02304458,"1:13:treatment,15:25:treatment,15:26:treatment,31:40:treatment,,119:131:treatment","Interleukins, interferons and cytokines (other than hematopoietic growth factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors)"
5618,NCT02304458,"28:58:chronic_disease,96:118:chronic_disease,134:151:treatment",Patients with a history of congestive heart failure (CHF) or are at risk because of underlying cardiovascular disease or exposure to cardiotoxic drugs must have adequate cardiac function as clinically indicated
5619,NCT02303977,"1:11:cancer,38:52:cancer,53:79:cancer",Histologic or cytologic diagnosis of adenocarcinoma non-small cell lung cancer
5620,NCT02302235,"96:103:chronic_disease,114:123:chronic_disease,127:149:chronic_disease,151:156:chronic_disease,160:173:chronic_disease,191:204:chronic_disease,206:219:chronic_disease,221:234:chronic_disease,236:257:chronic_disease,265:298:chronic_disease,300:309:chronic_disease,311:331:chronic_disease,336:348:chronic_disease","Any systemic illness or unstable medical condition that might pose additional risk, including: cardiac, unstable metabolic or endocrine disturbances, renal or liver disease, past history of renal calculi, hyperuricemia, hypercalcemia, mitochondrial disease, known disorder of fatty acid metabolism, porphyria, carnitine deficiency and pancreatitis"
5621,NCT02301611,"13:29:cancer,36:43:treatment,52:70:treatment",Evidence of residual disease after surgery and SoC adjuvant therapies
5622,NCT02301546,"1:17:chronic_disease,68:84:chronic_disease,86:108:chronic_disease","systemic illness that are thought to be affecting cognition (e.g., seizure disorder, demyelinating disorder, etc.)"
5623,NCT02299414,"21:30:treatment,34:44:treatment,56:72:allergy_name",Contraindication to labetalol or nifedipine (e.g. know hypersensitivity)
5624,NCT02296684,"13:26:treatment,75:82:treatment,84:89:treatment,91:98:treatment,100:109:treatment,110:130:treatment,132:144:treatment,146:152:treatment,154:184:treatment,190:205:treatment","Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine"
5625,NCT02296684,"1:70:treatment,75:141:treatment,153:163:treatment","Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)"
5626,NCT02296684,"24:30:cancer,47:54:treatment,56:66:cancer,70:105:cancer,155:186:cancer","previous head and neck cancer treated only by surgery, basal cell or squamous cell carcinoma of the skin which were treated with local resection only, or carcinoma in situ of the cervix"
5627,NCT02291978,"1:21:treatment,36:61:treatment,66:95:treatment,108:124:treatment,134:141:treatment,143:150:treatment,152:164:treatment,170:193:treatment","Conservative therapy is defined as systemic pain medications and anti-inflammatory medications, as well as physical therapy, such as massage, heating, hydrotherapy, and strengthening exercises"
5628,NCT02291978,"27:52:chronic_disease,56:59:treatment,97:115:chronic_disease,124:142:chronic_disease","Patients with evidence of lumbosacral radiculopathy on MRI or physical exam findings, including radicular leg pain, or any neurologic deficit at or below the segmental level of the highest facet to be treated, including subjects with impaired sphincter control"
5629,NCT02291848,"28:38:treatment,42:55:treatment,,78:93:treatment",If patient has received an autologous or syngeneic SCT they must be >90 days post-transplant (Group A)
5630,NCT02291523,"12:22:chronic_disease,36:58:treatment,68:85:chronic_disease,87:96:chronic_disease","Concurrent infections that require anti-microbial therapy (such as abdominal abscess, pneumonia, etc"
5631,NCT02290951,"1:4:cancer,28:43:treatment,52:78:treatment",NHL patients must have had prior treatment with an anti-CD20 antibody therapy
5632,NCT02287558,"26:47:chronic_disease,54:64:chronic_disease,75:88:chronic_disease","Inherited or significant acquired coagulopathy (i.e. hemophilia, advanced liver disease)"
5633,NCT02286687,"109:120:treatment,122:134:treatment,136:152:chronic_disease,154:167:chronic_disease","Any medical condition or diagnosis that would likely impair absorption of an orally administered drug (e.g. gastrectomy, ileal bypass, chronic diarrhea, gastroparesis)"
5634,NCT02286687,"12:42:chronic_disease,44:65:chronic_disease,69:84:chronic_disease,,130:137:treatment","History of cerebrovascular accident (CVA), myocardial infarction or unstable angina within the previous 6 months before starting therapy"
5635,NCT02286687,"192:206:chronic_disease,316:322:cancer,326:340:cancer","Patients must have one of the following: somatic mutations or deletions in BRCA1 or BRCA2; genomic alterations in other BRCA pathway genes (subcohorts: a. ATM, b. PALB2, c. other genes, e.g. Fanconi Anemia genes, ARID1A, MER11, RAD50, NBS1, ATR; amplification of EMSY); or germline mutation in BRCA1 or BRCA 2 (not breast or ovarian cancer)"
5636,NCT02285101,"11:24:chronic_disease,51:58:chronic_disease,60:77:chronic_disease,82:96:chronic_disease","Advancing liver failure indicated by uncontrolled ascites, pleural effusions, or encephalopathy"
5637,NCT02285101,"13:20:chronic_disease,22:27:chronic_disease,31:54:chronic_disease","Significant hepatic, renal or bone marrow dysfunction indicated by"
5638,NCT02281409,"53:59:cancer,67:92:chronic_disease,94:111:chronic_disease,","Any concomitant serious physical illness other than cancer (i.e., immune deficiency disease, bleeding disorder, etc.) within 1 year prior to dosing"
5639,NCT02278315,"1:18:treatment,20:32:treatment,34:47:treatment,49:72:treatment,76:90:treatment,,143:161:treatment","Radiation therapy, chemotherapy, immunotherapy, investigational therapy or corticosteroid use within 2 weeks of or after eligibility-defining bone marrow biopsy"
5640,NCT02278250,"84:95:cancer,110:126:treatment,,232:258:treatment,300:311:treatment,327:338:treatment,357:366:treatment","Participants with one histologically or cytologically confirmed malignant advanced solid tumor, for which no standard therapy is available which may convey clinical benefit and/or participants must have progressed after at least 1 prior chemotherapy regimen in the metastatic setting, and for which carboplatin (for Part B1), gemcitabine (for Part B2), or cisplatin (for Part B3) would be considered standard of care"
5641,NCT02277548,"56:72:treatment,74:84:treatment,89:99:treatment","Has another painful condition requiring chronic use of opioid analgesic, gabapentin, or pregabalin"
5642,NCT02276716,"17:31:treatment,41:49:treatment,51:58:treatment,60:67:treatment,69:83:treatment,85:96:treatment,100:111:treatment","Patients taking anticoagulants, such as warfarin, heparin, aspirin, pentoxifylline, clopidogrel or ticlopidine"
5643,NCT02276443,"27:39:treatment,45:51:treatment,59:72:treatment",Patients not eligible for chemotherapy with taxane and/or anthracycline based chemotherapy regimens
5644,NCT02276443,"21:27:treatment,31:38:treatment,52:57:cancer,96:109:cancer,,,",patient can undergo biopsy or surgery of a primary tumor site for suspected or proven invasive breast cancer of clinical stage I to III
5645,NCT02273375,"12:21:treatment,33:54:treatment,58:77:treatment",Concurrent treatment with other investigational drugs or anti-cancer therapy
5646,NCT02273375,"23:40:chronic_disease,71:96:treatment,113:119:chronic_disease",Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RA
5647,NCT02273375,"7:19:cancer,,102:111:treatment,223:233:cancer","other malignancies curatively treated with no evidence of disease for ? 5 years following the end of treatment and which, in the opinion of the treating physician, do not have a substantial risk of recurrence of the prior malignancy"
5648,NCT02273362,"1:9:treatment,34:46:treatment,50:69:treatment",Surgical cohort (cohort A only): percutaneous or transjugular biopsy incomplete or not performed
5649,NCT02273362,"7:22:treatment,31:41:treatment,43:52:treatment,54:65:treatment,67:76:treatment,78:91:treatment,93:106:treatment,112:127:treatment","se of CYP3A4 inducers such as rifampicin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, and St. John's wort"
5650,NCT02272998,"81:103:cancer,115:139:cancer,161:189:treatment",Patients with histologically or cytologically confirmed diagnosis of refractory metastatic solid tumor or chronic hematological malignancy who are eligible for investigational drug therapy
5651,NCT02272998,"31:57:chronic_disease,59:65:chronic_disease,67:98:chronic_disease,100:115:chronic_disease,119:146:chronic_disease","any patient with a history of myocardial infarction (MI), stroke, transient ischemic attack (TIA), unstable angina or peripheral vascular disease will not be eligible"
5652,NCT02272218,"38:49:treatment,50:66:treatment,103:110:treatment,115:130:treatment","has not yet tried to treat pain with oral NSAIDs/COX-2 inhibitors (unless medical contraindications), Tylenol, or topical therapy"
5653,NCT02271919,",28:50:chronic_disease,52:74:chronic_disease,76:82:chronic_disease,84:90:chronic_disease,92:104:chronic_disease","History (last 3 months) of abnormal heart rhythms, cardiovascular disease (stroke, angina, heart attack) may result in ineligibility; these conditions will be evaluated on a case by case basis by the study physician"
5654,NCT02271919,"9:20:treatment,30:40:chronic_disease,,62:98:treatment,103:125:treatment","certain medications to treat depression (last 14 days), i.e. monoamine oxidase inhibitors (MAOIs) and Elavil (Amitriptyline)"
5655,NCT02270970,"5:31:treatment,73:90:treatment,81:90:treatment",any immune suppressive therapy being taken despite option for immediate steroid treatment and later treatment rescues as needed
5656,NCT02270450,"33:50:chronic_disease,54:67:chronic_disease,96:114:treatment,118:129:chronic_disease,",Patients must not have signs of bowel perforation or acute abdomen as evidenced by free air on radiologic imaging or peritonitis on physical exam within 2 days prior to registration
5657,NCT02269293,",41:54:treatment,62:72:treatment,74:85:treatment,87:98:treatment,100:127:treatment,138:153:treatment","At least 4 weeks must have lapsed since major surgery (e.g., laparotomy, laparoscopy, thoracotomy, video assisted thoracoscopy) prior to study treatment initiation"
5658,NCT02269293,"64:75:chronic_disease,87:106:cancer,108:116:chronic_disease,147:163:chronic_disease,171:187:chronic_disease,203:227:chronic_disease,229:232:chronic_disease,234:240:chronic_disease,","Patients with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures which are not controlled, any brain metastases and/or epidural disease, or history of cerebrovascular accident (CVA, stroke) within six months prior to the first date of study treatment"
5659,NCT02268448,"16:40:treatment,52:59:treatment,61:76:treatment,81:101:treatment","Current use of chronic pain medications (including opioids, antidepressants and anti-epileptic drugs)"
5660,NCT02268253,",64:85:treatment,143:151:chronic_disease,153:159:chronic_disease,165:172:chronic_disease","has persistent clinically significant toxicities Grade ?2 from previous chemotherapy not readily controlled by supportive measures (excluding alopecia, nausea, and fatigue)"
5661,NCT02268253,"14:26:chronic_disease,53:64:chronic_disease,83:93:treatment",uncontrolled hypertension or clinically significant arrhythmias not controlled by medication)
5662,NCT02267772,"22:35:allergy_name,102:118:chronic_disease,120:140:chronic_disease,154:174:chronic_disease,182:194:chronic_disease,196:206:chronic_disease,,","contraindications to acetaminophen including reported elevated liver function tests, hepatic injury, hepatic disorder, active liver disease, alcoholism, chronic malnutrition, known coagulapathy, hemorrhage, creatinine > 1.0, or known allergy or hypersensitivity to acetaminophen"
5663,NCT02266745,"14:38:chronic_disease,,,,99:120:chronic_disease,122:146:chronic_disease,148:195:treatment,197:222:chronic_disease,227:245:chronic_disease,,285:295:treatment","Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3 months prior to initiation of study drug"
5664,NCT02266719,"1:11:chronic_disease,15:29:chronic_disease,,,44:77:chronic_disease,",Juxtarenal or suprarenal AAA and type I-IV thoracoabdominal aortic aneurysms with diameter ?5.0 cm in diameter or 2 times the normal aortic diameter
5665,NCT02266719,"1:26:chronic_disease,99:137:treatment,141:160:treatment","Thoracic aortic aneurysms that extend into the arch, with the exception of those patients who had prior open surgical aortic replacement or endovascular repair, where a surgical graft or an endograft has been extended proximal and/or near the celiac artery (functional type IV) that would serve as landing zone for the investigational endograft"
5666,NCT02266329,"8:29:treatment,39:50:treatment,54:71:treatment,83:94:treatment,",Use of prescribed stimulants (such as amphetamine or dextroamphetamine containing medications) within 2 weeks of beginning the preliminary screening period through the end of study involvement
5667,NCT02265874,"38:56:chronic_disease,69:80:treatment,84:107:treatment",patients with extensive irreversible pulmonary fibrosis (based upon lung biopsy or high resolution CT scan criterion)
5668,NCT02264236,"34:56:chronic_disease,58:81:chronic_disease,85:101:cancer","Existing diagnosis or history of leptomeningeal disease, spinal cord compression or brain metastases unless"
5669,NCT02263729,"6:23:chronic_disease,25:39:chronic_disease,41:46:chronic_disease,50:57:chronic_disease","Have diabetes mellitus, cardiovascular, renal or hepatic co-morbidities"
5670,NCT02262806,"7:20:chronic_disease,7:10:chronic_disease,39:52:chronic_disease",Known HIV infection or HIV-associated lipodystrophy
5671,NCT02261519,"12:20:chronic_disease,22:39:chronic_disease,48:68:chronic_disease,80:99:chronic_disease","History of epilepsy, major head trauma, or any neurological illness other than Tourette's syndrome which might impair the subject's cognition or psychiatric functioning per the investigator's judgment"
5672,NCT02261519,"40:53:chronic_disease,,196:209:chronic_disease,214:233:chronic_disease","Physician confirmed DSM-V diagnosis of schizophrenia for the past 2 years based on subject's history and confirmed by psychiatric evaluation and MINI International Neuropsychiatric Interview For Schizophrenia and Psychotic Disorders, version 7.0 (MINI, Version 7.0)"
5673,NCT02259621,"1:28:treatment,33:58:treatment,,73:83:treatment,135:153:chronic_disease",Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
5674,NCT02259504,"27:50:treatment,58:67:treatment,82:90:chronic_disease",Use (current or prior) of liquid embolic material in the treatment of the target aneurysm
5675,NCT02257424,"165:185:treatment,,,,,,,278:299:treatment,306:314:treatment,339:356:treatment,379:394:treatment,403:439:treatment,441:448:treatment,454:464:treatment","Current use of a prohibited medication as described in Section 6.3.8 of the protocol for Potential for Drug-Drug Interaction: apply moisturizing creams frequently, topical keratolytics (e.g. urea 20-40 % cream, salicylic acid 6%, tazarotene 0.1% cream, fluorouracil 5% cream), clobetasol propionate 0.05% ointment for erythematous areas, topical lidocaine 2%, and / or systemic pain medication such as nonsteroidal anti-inflammatory drugs, codeine, and pregabalin for pain"
5676,NCT02257424,"20:80:treatment,87:96:treatment,98:111:treatment,113:126:treatment,128:137:treatment,141:154:treatment,,197:206:treatment","Patients receiving cytochrome P450 enzyme-inducing anticonvulsant drugs (EIADs) (i.e. phenytoin, carbamazepine, Phenobarbital, primidone or oxcarbazepine) within 4 weeks of the start of the study treatment"
5677,NCT02257138,"16:33:chronic_disease,203:218:chronic_disease,229:246:chronic_disease","Any coexisting medical condition that in the judgment of the treating physician is likely to interfere with study procedures or results including uncontrolled severe infections, as well as uncontrolled cardiac disease, or other organ dysfunction"
5678,NCT02256631,"21:40:treatment,,117:122:treatment,124:131:treatment,136:141:treatment,142:147:treatment","Any requirement for supplemental oxygen beyond 24 hours of life or requiring supplemental oxygen at the time of the VRC01, VRC01LS, or VRC07-523LS dose"
5679,NCT02255383,"1:21:chronic_disease,23:37:chronic_disease,39:58:chronic_disease,60:73:chronic_disease","rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis"
5680,NCT02254863,"22:34:treatment,36:65:treatment,70:92:treatment","receiving concurrent radiotherapy, immunosuppressive medications, or cytotoxic chemotherapy"
5681,NCT02253316,"1:10:chronic_disease,21:48:treatment,66:75:chronic_disease,,115:124:treatment",Infection requiring systemic antibiotic therapy or other serious infection within 14 days prior to start of study treatment
5682,NCT02253316,",37:44:treatment,56:72:treatment,77:93:cancer,,,142:157:treatment",Received at least two cycles of any regimen as initial systemic therapy for multiple myeloma and are within 2-16 months of the first dose of initial therapy
5683,NCT02252432,"47:62:treatment,64:73:treatment,75:87:treatment,89:101:treatment,104:129:treatment,131:138:treatment,140:150:treatment,152:161:treatment,163:173:treatment,176:187:treatment,189:201:treatment,203:219:treatment,221:244:treatment,246:271:treatment","Drugs known to cause prolonged qT: class (IA) antiarrhythmics (quinidine, procainamide, disopyramide), class III antiarrhythmics (sotalol, dofetilide, ibutilide, amiodarone), haloperidol, thioridazine, arsenic trioxide, HIV protease inhibitors, tricyclic antidepressants"
5684,NCT02252432,"1:25:chronic_disease,27:45:chronic_disease,47:64:chronic_disease","Restrictive lung disease (pulmonary fibrosis, myasthenia gravis)"
5685,NCT02252081,"12:21:treatment,33:51:treatment,72:81:treatment,85:103:chronic_disease,",History of metformin use or any insulin sensitizer or any drug for the treatment of metabolic syndrome over the last one year
5686,NCT02251431,"39:47:treatment,51:89:treatment,95:114:treatment,116:154:treatment,156:178:treatment,183:195:treatment","Patient has ever been treated with an approved or investigational GLP-1 receptor agonist e.g. BYETTA (exenatide), BYDUREON (Exenatide extended-release), VICTOZA (liraglutide), or taspoglutide"
5687,NCT02250664,"11:31:treatment,33:42:treatment,52:69:treatment","Have used nicotine replacement, bupropion or other pharmacotherapies as cessation aids in the past month"
5688,NCT02250157,"27:37:allergy_name,41:62:allergy_name,78:106:allergy_name","Allergy or sensitivity to irinotecan or cranberry-grape juice, or any of the irinotecan tablet excipients"
5689,NCT02250157,"77:93:chronic_disease,107:131:chronic_disease,133:154:chronic_disease,,181:205:chronic_disease,207:225:chronic_disease,227:252:chronic_disease,277:295:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease requiring oxygen, known bleeding disorders, or any concomitant illness or social situation that would limit compliance with study requirements"
5690,NCT02244814,"1:13:chronic_disease,15:28:chronic_disease,30:44:chronic_disease,46:67:chronic_disease,69:81:chronic_disease,83:90:treatment,107:119:chronic_disease,121:139:chronic_disease,144:175:chronic_disease","hypertension, renal disease, thrombophilias, rheumatologic disease, preeclampsia, steroid use, history of pancreatitis, infectious disease, or intrauterine growth restriction"
5691,NCT02243813,"45:58:chronic_disease,60:78:chronic_disease,140:164:chronic_disease","Have a first or second-degree relative with Schizophrenia, Psychotic Disorder (unless substance induced or due to a medical condition), or Bipolar I or II Disorder"
5692,NCT02240498,"63:74:chronic_disease,76:87:chronic_disease,102:114:chronic_disease","All patients with clinical symptoms (ex: fever, chills, pain, tachycardia, hypotension), laboratory (leukocytosis) and radiologic findings (thick walled, rim-enhancing collection with gas bubbles or air-fluid levels) compatible with an abscess that requires image-guided percutaneous drainage"
5693,NCT02237183,"17:28:chronic_disease,44:56:treatment,60:88:treatment,,","Due to risk for hypotension in patients on vasodilators or antihypertensive medications, participants must not have blood pressure < 95 mm Hg systolic"
5694,NCT02236013,"1:20:treatment,25:42:chronic_disease,48:59:treatment,",Emergency treatment for hyperleukocytosis with hydroxyurea for ? 10 days
5695,NCT02236000,"15:45:treatment,,96:114:treatment,137:153:treatment",Chronic daily treatment with corticosteroids with a dose of greater than or equal to 10 mg/day methylprednisolone equivalent (excluding inhaled steroids)
5696,NCT02235857,"1:20:chronic_disease,42:53:chronic_disease,55:70:chronic_disease,72:110:chronic_disease,115:131:chronic_disease","Cardiac impairments such as uncontrolled arrhyth¬mia, unstable angina, decompensated congestive heart failure, or valvular disease"
5697,NCT02235857,"21:36:allergy_name,38:45:allergy_name,50:64:allergy_name","Hypersensitivity to dextran sulfate, heparin, or ethylene oxide"
5698,NCT02234934,"8:23:chronic_disease,56:80:chronic_disease,82:90:chronic_disease,92:103:chronic_disease","Active cardiac disease, including clinical evidence of congestive heart failure, cyanosis, hypotension"
5699,NCT02234934,"22:56:chronic_disease,60:71:chronic_disease,98:109:chronic_disease,136:139:chronic_disease,141:151:chronic_disease,153:168:chronic_disease,172:185:chronic_disease","No co-infection with Human Immunodeficiency Virus (HIV) or hepatitis B virus (HBsAg positive) or hepatitis C virus (HCV RNA positive), CMV, adenovirus, parvovirus B 19 or toxoplasmosis"
5700,NCT02234557,",28:36:chronic_disease,38:52:chronic_disease,54:76:chronic_disease,78:95:chronic_disease","neurologic disorder (e.g., epilepsy, cerebral palsy, traumatic brain injury, Tourette Syndrome)"
5701,NCT02233868,"48:68:chronic_disease,159:174:treatment,192:221:treatment,","Current or past DSM-IV or DSM-5 diagnosis of a psychiatric disorder (other than alcohol in AD participants and nicotine/caffeine use disorders) that required hospitalization (any length), or chronic medication management (more than 4 weeks) and that could impact brain function at the time of the study as determined by history and clinical exam"
5702,NCT02233868,"1:25:treatment,14:24:treatment,77:87:treatment,104:115:treatment,,187:213:treatment,215:238:treatment,240:264:treatment,284:297:treatment,299:322:treatment","psychoactive medications or medication that may affect study results (e.g., analgesics [non narcotic], antibiotics (must finish course at least 24 hours prior to a scheduled procedure), antidiarrheal preparations, anti-inflammatory drugs (systemic corticosteroids are exclusionary), antinauseants, cough/cold preparations) (self-report, medical history)"
5703,NCT02232516,"33:55:treatment,48:55:treatment,60:64:cancer,77:92:treatment,","Patients must not have received prior systemic therapy for PTCL (except for corticosteroids for 10 or fewer days at any dose, no washout period required as long as they discontinue prior to starting study therapy)"
5704,NCT02232165,"10:17:chronic_disease,19:28:chronic_disease,30:37:chronic_disease,41:54:chronic_disease","Advanced cardiac, pulmonary, hepatic or liver disease"
5705,NCT02231073,"32:43:chronic_disease,45:62:chronic_disease,68:88:chronic_disease,102:108:chronic_disease,110:120:chronic_disease,122:132:chronic_disease,136:162:chronic_disease","at least one of the following: rest tremor, muscular rigidity, and postural instability not cause by visual, vestibular, cerebellar or proprioceptive dysfunction"
5706,NCT02227199,"111:135:treatment,137:169:treatment,171:189:treatment,213:224:treatment,,,,,,419:458:treatment,,","Patients must have measurable disease defined as lesions that can be accurately measured in two dimensions by computed tomography (CT), magnetic resonance imaging (MRI), medical photograph (skin or oral lesion), plain x-ray, or other conventional technique and a greatest transverse diameter of 1 cm or greater; or palpable lesions with both diameters >= 2 cm; further, at least 1 of these lesions must be positive by positron emission tomography (PET) scan (i.e., Deauville score of 4 or more)"
5707,NCT02226159,"73:76:treatment,77:79:treatment,92:110:chronic_disease",Deemed to be good operative candidates by spine surgeons (patients with MRI/CT findings of neural compression with concordant symptoms) and had agreed to possible operative intervention
5708,NCT02225548,"27:48:chronic_disease,50:56:chronic_disease,77:87:chronic_disease,","Subject with a history of myocardial infarction, stroke or life-threatening arrhythmia within 6 months prior to screening"
5709,NCT02225548,"37:66:chronic_disease,87:95:chronic_disease,104:122:chronic_disease,124:140:cancer,146:154:cancer","Subject with clinically significant chronic hematological disease which could lead to priapism such as sickle cell anemia, multiple myeloma, and leukemia"
5710,NCT02222545,"29:33:chronic_disease,46:50:treatment,62:65:chronic_disease,69:72:chronic_disease","Have a diagnosis of primary aHUS, persistent HSCT-associated TMA or TTP"
5711,NCT02217709,"24:29:chronic_disease,33:58:chronic_disease,60:73:chronic_disease,75:91:chronic_disease,100:116:chronic_disease,127:142:treatment","Known prior history of mania or major psychiatric illness (schizophrenia, bipolar disorder, severe major depression requiring hospitalization, etc.)"
5712,NCT02216227,"9:28:treatment,32:50:treatment,71:83:treatment,87:98:treatment",Undergo cardiac transplants or cardiac procedures performed using the percutaneous or thoracotomy approach
5713,NCT02215096,"36:53:chronic_disease,87:98:chronic_disease,100:107:chronic_disease,109:114:chronic_disease,118:133:chronic_disease","Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal or cardiac disease)"
5714,NCT02215096,"1:21:cancer,16:21:cancer,65:71:treatment",PTEN deficient tumor as documented from archival or fresh (from biopsy) tumor tissue analyzed by GlaxoSmithKline selected laboratory
5715,NCT02215096,"12:33:chronic_disease,35:59:chronic_disease,71:86:chronic_disease,89:109:treatment,111:119:treatment,124:139:treatment,,185:214:chronic_disease,,,","history of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, stenting, or bypass grafting within the past 6 months prior to enrolment, Class III or IV heart failure as defined by the New York Heart Association functional classification system, LVEF below 50%"
5716,NCT02213913,"1:16:cancer,22:62:treatment,36:56:treatment,209:213:cancer,216:219:cancer,245:257:treatment","B-cell lymphoma with comprehensive immunohistochemistry (IHC) panel establishing lineage (CD20, CD3) and cell of origin (CD10, BCL6 and MUM1) in addition to proliferative/prognostic markers (Ki-67, C-myc and BCL2). DHL will be identified using cytogenetics and/or immunohistochemistry"
5717,NCT02213913,"29:43:chronic_disease,47:62:chronic_disease,96:114:chronic_disease,116:139:chronic_disease,164:167:cancer,178:199:chronic_disease","Subjects who have currently active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver involvement with NHL or stable chronic liver disease per investigator assessment)"
5718,NCT02213497,"52:63:chronic_disease,65:70:chronic_disease,72:79:chronic_disease,84:102:chronic_disease","Patients must be surgical candidates with adequate hematologic, renal, hepatic and pulmonary function"
5719,NCT02213289,",,,68:82:treatment,84:93:treatment,98:109:treatment","Cardiac Ejection Fraction >50% (for HER2+ patients) as assessed by echocardiogram, MUGA scan, or cardiac MRI"
5720,NCT02213289,"27:54:treatment,47:54:treatment,59:70:treatment,75:96:cancer,",Patients who have started first line mFOLFOX6 therapy (+/-trastuzumab for HER2 amplified tumors) may be considered for trial participation if they have received no more than 4 doses of therapy at the time of consent and screening
5721,NCT02209636,"12:23:treatment,99:109:treatment,125:138:treatment","Not taking medications that interact with agents administered during experimental sessions (e.g., sildenafil interacts with nitroglycerin)"
5722,NCT02208362,"74:90:chronic_disease,132:143:chronic_disease,147:148:chronic_disease,239:253:treatment","Research participants with any uncontrolled illness including ongoing or active infection; research participants with known active hepatitis B or C infection; research participants with any signs or symptoms of active infection, positive blood cultures or radiological evidence of infections"
5723,NCT02207439,"1:16:treatment,1:17:treatment,19:32:treatment,34:47:treatment,65:74:treatment,76:94:treatment,95:104:treatment,106:121:treatment,123:133:treatment,135:145:treatment,147:156:treatment,158:165:treatment,167:187:treatment,189:201:treatment,203:215:treatment,217:236:treatment,238:250:treatment,251:261:treatment,263:272:treatment,274:292:treatment,294:303:treatment,305:323:treatment,324:341:treatment,343:363:treatment,364:376:treatment,378:411:treatment,413:427:treatment,429:438:treatment","Anti-Convulsants: carbamazepine, Phenobarbital, Anti-Convulsant:phenytoin, Anti-Mycobacterial:rifabutin, PDE5 Inhibitors: sildenafil, vardenafil, tadalafil, HMG-CoA: Reductase Inhibitors: atorvastatin, rosuvastatin, Immuno-suppressants: cyclosporine,tacrolimus, sirolimus, Narcotic Analgesic: methadone, Oral Contraceptive:ethinyl estradiol, Macrolide Antibiotic:azithromycin, Inhaled/nasal steroid fluticasone, Antidepressant: trazodone"
5724,NCT02207439,"1:38:treatment,40:68:treatment,70:80:treatment,81:92:treatment,94:105:treatment,106:114:treatment,116:138:treatment,140:158:treatment,160:169:treatment,171:180:treatment","St.John's wort (hypericum perforatum), HMG-CoA Reductase Inhibitors: lovastatin,simvastatin, Neuroleptic:pimozide, Proton Pump Inhibitors, Sedative/Hypnotics: midazolam, triazolam"
5725,NCT02204098,"20:49:treatment,74:84:treatment,96:129:treatment,131:148:treatment,153:175:treatment","Current use of any electronic stimulation device, such as cardiac demand pacemakers, automatic implantable cardiac defibrillator, nerve stimulators, or deep brain stimulators"
5726,NCT02203903,"20:28:cancer,32:48:cancer,52:66:treatment","Evidence of active leukemia or lymphoma disease by flow cytometry, morphology, or cytogenetic evaluation within the marrow or extramedullary sites"
5727,NCT02203695,"25:38:treatment,40:60:treatment,65:88:treatment","Concurrent use of other antiandrogens, estrogen-like agents, or 5a-reductase inhibitors"
5728,NCT02203552,"25:57:treatment,58:73:treatment,103:122:treatment,136:145:treatment,157:171:chronic_disease","Any contraindication to magnetic resonance imaging (MRI)/PET examination including but not limited to ferromagnetic metal in the body, pacemaker, or severe claustrophobia"
5729,NCT02203552,"23:39:chronic_disease,43:59:chronic_disease,69:87:cancer",Reported diagnosis of major depression or anxiety disorder prior to breast cancer (BC) diagnosis
5730,NCT02203513,"46:52:cancer,60:70:cancer,74:101:cancer,103:128:cancer,137:158:cancer","For Cohorts 1-3, 5 and 6: patients must have breast and/or epithelial or endometrioid ovarian cancer, primary peritoneal cancer, and/or fallopian tube cancer histologically or cytologically confirmed at the NCI that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective"
5731,NCT02203513,",40:56:treatment,58:70:treatment,72:88:treatment,94:111:treatment,116:138:treatment,,152:163:treatment","Patients must be at least 4 weeks from previous therapy (chemotherapy, hormonal therapy, and radiation therapy, or investigational agents; 6 weeks for mitomycin C)"
5732,NCT02203513,"14:34:chronic_disease,78:102:chronic_disease,113:128:chronic_disease,138:148:chronic_disease,173:184:chronic_disease,188:198:chronic_disease,,250:269:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, clinically significant GI bleeding or hemoptysis within 28 days prior to the start of the study, or psychiatric illness/social situations that would limit compliance with study requirements"
5733,NCT02201992,"34:61:treatment,65:82:treatment,,,120:129:treatment,134:146:treatment",Patients must have completed any prior adjuvant chemotherapy or radiation therapy 2 or more weeks (6 or more weeks for mitomycin and nitrosoureas) prior to randomization and be adequately recovered at the time of randomization
5734,NCT02200445,",59:79:treatment,154:174:treatment,176:199:treatment,201:213:treatment,221:237:treatment,244:282:treatment","Failure to tolerate or failure to respond to at least one conventional therapy with the intention of inducing or maintaining remission (examples include oral corticosteroids, oral 5-aminosalicylates, azathioprine and/or 6-mercaptopurine, or a tumor necrosis factor (TNF) antagonist"
5735,NCT02200445,"27:35:treatment,37:47:treatment,51:63:treatment,81:96:chronic_disease,98:116:chronic_disease,118:129:chronic_disease,131:137:chronic_disease,142:177:chronic_disease","Requirement for immediate surgical, endoscopic or radiological intervention for toxic megacolon, massive hemorrhage, perforation, sepsis, or intra-abdominal or perianal abscess"
5736,NCT02195232,"22:28:treatment,32:45:treatment,63:78:chronic_disease",Known intolerance of niacin or ascorbic acid (including known G6PD deficiency)
5737,NCT02194738,"31:50:treatment,52:57:treatment,62:75:treatment,86:97:cancer",No patients who have received neoadjuvant therapy (chemo- or radio-therapy) for this lung cancer
5738,NCT02193373,"5:27:treatment,,86:120:treatment,122:129:treatment,133:144:treatment","Any manipulative therapies within the previous 7 days (including but not limited to: osteopathic manipulative treatment, massage or acupuncture)"
5739,NCT02193191,"15:33:chronic_disease,35:46:chronic_disease,51:64:chronic_disease","Patients with active hepatitis B, hepatitis C, or HIV infection"
5740,NCT02192398,"31:53:chronic_disease,60:70:chronic_disease,,,105:128:chronic_disease,145:151:chronic_disease,154:181:chronic_disease,183:196:chronic_disease,198:217:chronic_disease,233:240:chronic_disease","Has known pre-existing severe cardiovascular disease (i.e. arrhythmia - prolonged QT interval > 440ms), cerebrovascular disease/accident (i.e., stroke), hepatic or renal impairment, CNS condition, metabolic condition, or history of syncope"
5741,NCT02192398,"17:28:treatment,43:62:treatment,66:81:treatment,117:130:treatment,132:153:treatment,155:171:treatment,173:186:treatment,188:202:treatment,204:231:treatment,233:257:treatment,259:282:treatment,284:306:treatment,312:331:treatment","Subjects are on medications that serve as CYP3A4/5 inhibitors or CYP3A4 inducers including, but are not limited to, valproic acid, macrolide antibiotics, antifungal drugs, St. John wort, ACE inhibitors, nefazodone (antidepressant), calcium channel blockers, H2-receptor antagonists, anti-HIV or AIDS drugs, and antiepileptic drugs"
5742,NCT02192359,",,57:63:cancer,75:87:cancer,89:111:cancer,113:124:cancer,126:154:cancer,159:186:cancer,246:261:cancer,314:331:cancer","Histologically-confirmed diagnosis of a grade III or IV glioma (including glioblastoma, anaplastic astrocytoma, gliosarcoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma), or has a prior, histologically-confirmed, diagnosis of a grade II glioma and now has radiographic findings consistent with a high-grade glioma (grade III or IV)"
5743,NCT02192359,"31:37:treatment,47:55:treatment,57:68:treatment,70:79:treatment,84:96:treatment,,131:146:treatment","Use of drugs known to inhibit UGT1A1, such as atazanir, gemfibrozil, indinavir, or ketoconazole, within 2 weeks prior to start of study treatment"
5744,NCT02191488,"61:78:cancer,72:78:cancer,104:114:cancer,119:129:cancer","Preoperative diagnosis of either presumed first-time low or high grade glioma, or recurrent glioma, or metastasis, or meningioma"
5745,NCT02191098,",,,51:64:chronic_disease,81:109:chronic_disease,86:108:chronic_disease,186:205:chronic_disease","NYHA (New York Heart Association) Class III or IV heart failure, uncontrollable supraventricular arrhythmias, any history of a ventricular arrhythmia, or other clinical signs of severe cardiac dysfunction"
5746,NCT02189889,"1:16:chronic_disease,44:47:treatment,67:75:chronic_disease",unstable angina (defined by chest pain and EKG changes indicating ischemia at rest)
5747,NCT02189798,"29:65:treatment,71:99:treatment,148:167:treatment",unilaterally implanted with HiRes90K Advantage cochlear implant with HiFocus Mid-Scala electrode and fit with an ear-level sound processor (i.e. Naída family device)
5748,NCT02188745,"38:51:treatment,60:68:treatment,73:89:treatment,116:129:treatment,131:141:treatment,156:171:treatment,208:224:treatment","Combination regimens that include an anti-estrogen and any biologic, or targeted therapy, are permitted (e.g., any CDK inhibitor, everolimus, or any other novel biologics), and are considered to be a single hormonal therapy based regimen"
5749,NCT02188745,"15:43:cancer,,,,72:85:cancer,104:115:treatment","Patients with bone-only metastatic disease with a history of ER+/HER2- breast cancer are eligible, and bone biopsy is not required, providing their primary cancer is consistent with the above-described ER and HER2 criteria"
5750,NCT02188121,"18:42:treatment,72:78:treatment,82:85:treatment,","Receiving active cardiovascular treatment, defined as receiving both a statin or ARB in the past three months"
5751,NCT02188121,"1:14:chronic_disease,16:40:chronic_disease,42:58:chronic_disease,60:85:chronic_disease,90:99:chronic_disease","schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, or psychosis NOS (chart diagnosis)"
5752,NCT02187848,"1:30:treatment,32:35:treatment,39:67:treatment",Prior maytansinoid treatments (DM1 or DM4 antibody drug conjugates)
5753,NCT02187198,"44:55:chronic_disease,65:76:chronic_disease,84:98:chronic_disease,100:105:chronic_disease,107:116:chronic_disease,121:138:chronic_disease,149:172:treatment","serious unstable medical illness including bradycardia or other arrhythmias, major cardiovascular, renal, endocrine, or hepatic disorders for which buprenorphine treatment is contraindicated or which at the determination of the MD is medically dangerous"
5754,NCT02186418,"21:41:treatment,55:61:chronic_disease,67:92:chronic_disease,228:251:treatment","Patients who are on chronic transfusions for clinical stroke with MRA cerebral vasculopathy will be excluded since patients in the SWITCH study who were randomized to the hydroxyurea arm had recurrent stroke, while none in the chronic transfusion arm"
5755,NCT02186418,"34:56:chronic_disease,58:61:chronic_disease,72:95:treatment","Patients with medical history of pulmonary hypertension, PHT proved by cardiac catheterization"
5756,NCT02184520,"21:43:treatment,47:67:treatment,,86:93:treatment",Participation in an investigational device or drug clinical trials within 30 days of surgery
5757,NCT02181478,"1:32:cancer,34:56:cancer,58:80:cancer,190:196:treatment","Myelodysplastic syndromes (MDS), Intermediate-1 (INT-1), intermediate-2 (INT-2) or high Revised International Prognostic Scoring System (IPSS-R) score that has failed at least 1 first line therap"
5758,NCT02181257,",81:122:chronic_disease,161:164:chronic_disease,173:182:chronic_disease,184:197:chronic_disease","Patients whose decline in lung function (FEV1) is related to either Restrictive Chronic Lung Allograft Dysfunction (CLAD) or other causes that do not represent BOS such as pneumonia, heart failure, etc"
5759,NCT02180412,"9:24:chronic_disease,128:137:treatment,151:163:treatment","Type of acute porphyria confirmed by additional testing (in addition to increased PBG), which may be completed before or after treatment begins using pretreatment samples"
5760,NCT02178709,"21:24:allergy_name,26:37:allergy_name,48:63:allergy_name,66:76:allergy_name,90:100:allergy_name","Hypersensitivity to 5FU, oxaliplatin (or other platinum agents), irinotecan (or to their excipients)"
5761,NCT02178709,"20:28:cancer,32:56:cancer,66:76:cancer,80:110:cancer,112:138:cancer,155:200:cancer,215:230:cancer","adequately treated cervical or vulvar carcinoma in situ, treated basal cell or squamous carcinoma of the skin, superficial bladder tumors (Ta, Tis & T1), ductal carcinoma in situ (DCIS) of the breast and low grade prostate cancer"
5762,NCT02177838,"32:48:treatment,59:76:cancer,88:100:treatment,102:119:treatment,124:131:treatment","Patients may not have received previous therapy for their head and neck SCC, including chemotherapy, radiation therapy, or surgery beyond biopsy"
5763,NCT02177695,"20:59:cancer,53:59:cancer,61:84:cancer,105:125:cancer,","adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years"
5764,NCT02176967,"48:64:cancer,80:93:cancer,249:269:cancer",Patients must have newly diagnosed v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) non-amplified neuroblastoma (International Classification of Diseases for Oncology [ICD-O] morphology 9500/3) or MYCN non-amplified ganglioneuroblastoma verified by histology
5765,NCT02176161,"35:53:chronic_disease,83:104:chronic_disease,106:129:treatment,131:146:chronic_disease,148:167:chronic_disease,188:212:chronic_disease,217:241:chronic_disease,","any unstable, serious co-existing medical conditions including but not limited to myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within 6 months prior to screening"
5766,NCT02174549,"1:22:treatment,31:49:treatment,51:74:treatment,79:96:treatment,120:125:cancer,146:161:treatment,204:207:treatment,213:226:treatment,","Prior local therapies such as surgical resection, radiofrequency ablation, or alcohol injection are allowed as long as tumor progresses from the prior treatment and the patients are still candidates for TAE. All prior therapy must be at least 4 weeks prior to enrollment and free from treatment-related toxicity"
5767,NCT02172651,"25:44:treatment,56:75:treatment,77:92:treatment,94:111:treatment,113:126:treatment,131:153:treatment","Concurrent use of other anti-cancer therapy, including chemotherapy agents, targeted agents, biological agents, immunotherapy, or investigational agents not otherwise specified in this protocol"
5768,NCT02172651,"4:27:treatment,31:49:treatment,98:105:cancer,107:109:cancer,114:130:cancer","No prior radiation therapy or systemic treatment is allowed for patients undergoing resection of stage I, II, or III colon cancer"
5769,NCT02172651,"25:35:chronic_disease,168:179:chronic_disease,183:184:chronic_disease,205:220:treatment","Participants with these infections are ineligible because they are at increased risk of significant complications in the perioperative period, particularly for active hepatitis B or C patients undergoing liver resection"
5770,NCT02172651,"16:34:treatment,42:61:treatment,82:95:chronic_disease,171:194:chronic_disease","Regular use of thiazide diuretics (i.e., hydrochlorothiazide), which can lead to hypercalcemia, and unwillingness or inability to discontinue or switch to an alternative anti-hypertensive agent"
5771,NCT02171429,"22:31:chronic_disease,42:51:treatment,57:85:treatment,,123:139:treatment,",Any major episode of infection requiring treatment with intravenous (IV) antibiotics within 8 weeks prior to screening or oral antibiotics within 4 weeks prior to screening
5772,NCT02171104,"72:81:chronic_disease,83:94:chronic_disease,149:169:chronic_disease,306:322:chronic_disease,324:342:chronic_disease,344:358:chronic_disease,360:377:chronic_disease,379:395:chronic_disease","Patients will also be considered who have other life-threatening, rare lysosomal, peroxisomal or other similar inherited disorders characterized by white matter disease or other neurologic manifestations for which there is rationale that transplantation would be of benefit, such as certain patients with Wolman's disease, GM1 gangliosidosis, I-cell disease, Tay-Sachs disease, Sandhoff disease or others"
5773,NCT02169830,"1:11:treatment,13:42:treatment,44:51:treatment","Topiramate: acetazolamide (kidney stones), digoxin"
5774,NCT02169739,"10:23:chronic_disease,41:56:treatment,75:82:treatment",No major cardioembolic source requiring anticoagulation or other specific therapy
5775,NCT02169089,"1:24:chronic_disease,26:51:chronic_disease,53:56:chronic_disease,60:82:chronic_disease,,111:148:treatment,","Acute coronary syndrome, Transient ischemic attack, CVA or critical limb ischemia during the last 6 months or coronary/peripheral revascularization within the last 3 months"
5776,NCT02169089,"19:26:treatment,32:39:treatment,41:49:treatment,51:64:treatment,66:70:treatment,72:81:treatment,83:93:treatment","Initiation of new therapy with statins, ACEI/ARB, anti-oxidants, CCBs, diuretics, ? blockers"
5777,NCT02169037,"1:23:chronic_disease,50:58:treatment,80:105:chronic_disease,111:132:chronic_disease","acquired heart disease that may increase risk of ablation, such as significant ventricular septal defect post myocardial infarction"
5778,NCT02169037,"24:52:chronic_disease,54:70:chronic_disease,74:95:chronic_disease","history of significant blood clotting abnormalities, systemic thrombi or systemic embolization"
5779,NCT02167958,"25:42:treatment,83:113:cancer,145:151:cancer,158:166:cancer",Greater than 1 cycle of induction therapy required to achieve remission Preceding myelodysplastic syndrome (MDS) Presence of Flt3 abnormalities FAB M6 or M7 leukemia
5780,NCT02167009,"12:33:treatment,35:49:treatment,54:71:treatment","History of open prostate surgery, radiofrequency, or microwave therapy"
5781,NCT02166905,"13:31:treatment,91:106:treatment,108:122:treatment,126:163:treatment,169:201:treatment","Concomitant systemic treatment with chronic use (based on the investigator's judgment) of corticosteroids, anti-histamine or non-steroidal anti-inflammatory drugs, and other platelet inhibitory agents"
5782,NCT02166905,"28:61:treatment,54:61:treatment,97:107:treatment,111:122:treatment,,219:225:treatment,",Patients may have received previous NY-ESO-1 vaccine therapy; patients who received maintenance paclitaxel or bevacizumab are eligible for enrollment provided they have discontinued therapy (at least 4 weeks for prior taxane or prior bevacizumab) prior to randomization and recovered from toxicities to less than grade 2
5783,NCT02166190,"1:18:cancer,22:40:cancer,56:74:treatment",Pancreatic cancer or cholangiocarcinoma unsuitable for surgical resection
5784,NCT02164422,"1:4:treatment,94:105:chronic_disease,129:139:treatment,147:160:treatment,173:181:chronic_disease,183:199:chronic_disease,201:239:chronic_disease,244:258:chronic_disease,","EKG evidence at baseline screening of any clinically significant conduction abnormalities or arrhythmias; known intolerance for guanfacine or any alpha blocker; history of fainting, syncopal attacks, heart failure or myocardial infarction, or impaired liver as indicated by aspartate aminotransferase (AST)"
5785,NCT02163434,"117:134:chronic_disease,136:148:chronic_disease,150:163:chronic_disease,168:188:chronic_disease","Felt by the patient's obstetrician or emergency room attending physician not to have other medical problems such as bowel obstruction, pancreatitis, biliary colic, or peptic ulcer disease that could be contributing to the patient's symptoms"
5786,NCT02162810,"31:39:treatment,55:62:treatment,,127:140:allergy_name",All patients currently taking steroids at the time of surgery or during the six-week recovery period as well as patients with betamethasone hypersensitivity
5787,NCT02162420,"17:22:treatment,26:32:treatment,36:50:treatment",requirement for G-CSF or GM-CSF or erythropoietin
5788,NCT02159703,"13:15:chronic_disease,19:29:chronic_disease,33:48:treatment",Presence of N0 or N1 disease in neck dissection
5789,NCT02159495,"99:123:treatment,131:154:treatment,,,306:321:treatment",Research participant with central nervous system (CNS) leukemic involvement that is refractory to intrathecal chemotherapy and/or cranio-spinal radiation but effectively treated to completion remission (< 5 white blood cell[WBC]/mm^3 and no blast in cerebrospinal fluid [CSF]) is eligible to proceed with lymphodepletion
5790,NCT02159495,"27:47:treatment,60:83:chronic_disease,90:121:treatment","in the case of a positive hepatitis C antibody result, the hepatitis C virus (HCV) viral polymerase chain reaction (PCR) will have to be performed and the results should be negative"
5791,NCT02159027,"33:44:chronic_disease,60:81:chronic_disease,85:103:chronic_disease,116:139:chronic_disease,166:169:chronic_disease,251:277:chronic_disease","Learning disability, history of head injury with prolonged loss of consciousness or cognitive sequelae, history of opportunistic infection of the brain or other non-HIV etiologies that, in the judgment of the investigator, can explain the subjects's mild to moderate cognitive performance"
5792,NCT02157974,"10:24:chronic_disease,28:37:chronic_disease,49:53:chronic_disease",Cause of oligomenorrhea or hirsutism other than PCOS
5793,NCT02153229,"15:24:chronic_disease,48:57:allergy_name,61:85:allergy_name",Patients with porphyria or hypersensitivity to porphyrin or porphyrin-like compounds
5794,NCT02152995,"126:140:cancer,134:139:cancer,142:155:cancer,177:187:cancer,196:209:cancer,267:274:cancer","COHORT A: Confirmation in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) has an neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) or Kirsten rat sarcoma viral oncogene homolog (KRAS) or Harvey rat sarcoma viral oncogene homolog (HRAS) mutation at G12, G13, or Q61; this group of patients will also be referred to as RAS MUT"
5795,NCT02152995,",,235:258:treatment,,279:293:treatment,295:327:treatment,332:340:treatment","Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm with spiral CT scan, magnetic resonance imaging (MRI), or calipers by clinical exam"
5796,NCT02152956,"25:37:treatment,39:61:treatment,66:90:treatment,","Previous treatment with radiotherapy, cytotoxic chemotherapy, or immunotherapeutic agents in the 4 weeks prior to study drug administration (Cycle 1 Day 1)"
5797,NCT02152254,"28:34:chronic_disease,39:47:chronic_disease,59:84:chronic_disease,92:118:chronic_disease","The patient has refractory nausea and vomiting or chronic gastrointestinal diseases (e.g., inflammatory bowel disease)"
5798,NCT02151175,"19:27:chronic_disease,57:74:chronic_disease,90:110:chronic_disease","Subjects who have seizures secondary to drugs, alcohol, metabolic illness or progressive degenerative disease"
5799,NCT02148796,"44:80:chronic_disease,95:105:treatment,110:132:treatment",Participants may not have a history of any life-threatening respiratory illness that required intubation and mechanical ventilation
5800,NCT02146924,"32:48:treatment,50:61:treatment,63:72:treatment,74:83:treatment,87:98:treatment","Any known contraindications to cyclophosphamide, fludarabine, etoposide, cetuximab or tocilizumab"
5801,NCT02146924,"39:52:treatment,70:88:treatment,90:103:treatment,107:116:treatment,","If research participant is undergoing leukapheresis the last dose of prior chemotherapy, immunotherapy or radiation must be at least 2 weeks before the leukapheresis procedure"
5802,NCT02146924,"45:52:chronic_disease,74:90:chronic_disease,104:128:chronic_disease,130:154:chronic_disease,156:174:chronic_disease,194:211:chronic_disease,215:234:chronic_disease,235:252:chronic_disease","Research participants with any uncontrolled illness including ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, poorly controlled pulmonary disease or psychiatric illness/social situations that would limit compliance with study requirements"
5803,NCT02145351,"1:39:treatment,55:57:chronic_disease,69:92:chronic_disease,96:112:treatment,,,,,,,,,239:254:treatment,259:266:chronic_disease,,,","Chronic treatment with a loop diuretic for control of HF symptoms + left atrial enlargement on echocardiography or E/e' ratio (?14 average, ?15 septal ) on echocardiography, Resting PCWP >15 mm Hg or LV end-diastolic pressure >18 mmHg at catheterization for dyspnea and/or exercise PCWP/LV end-diastolic pressure >25 mmHg, or Elevated NT-proBNP level (?300 pg/ml )"
5804,NCT02143726,"13:37:treatment,43:61:cancer,65:107:treatment,,",Presence of fluorodeoxyglucose (FDG) avid metastatic lesions on positron emission tomography (PET)/CT scan (standardized uptake values [SUV]max > 5 of any single lesion)
5805,NCT02141919,"36:64:treatment,80:83:treatment,87:99:treatment",Subjects may not have received any treatment for the renal mass before such as RFA or cryoablation
5806,NCT02140554,"37:45:treatment,60:78:treatment,99:125:treatment","any contraindications to the use of busulfan and any other medicinal products required during the myeloablative conditioning, including hypersensitivity to the active substances or to any of the excipients"
5807,NCT02139280,"1:31:treatment,33:54:treatment,56:89:treatment","immunomodulatory drugs (IMiDs), proteasome inhibitors, monoclonal antibodies or steroids"
5808,NCT02138617,"1:16:treatment,22:32:treatment,40:51:treatment",Prior treatment with irinotecan and/or bevacizumab
5809,NCT02138214,"1:29:chronic_disease,76:94:chronic_disease,98:115:chronic_disease","Chronic neurologic condition which affects voice or swallow (for instance, multiple sclerosis or Parkinson disease)"
5810,NCT02134392,"100:115:chronic_disease,117:129:chronic_disease,130:165:chronic_disease,167:196:treatment,223:239:chronic_disease","Considerations for Increased Risk of Adverse Events Should Be Given to patients with decompensated liver cirrhosis, advanced HIV/acquired immune deficiency syndrome, recent bone marrow transplant, or other cause of severe immunodeficiency"
5811,NCT02134392,"7:29:chronic_disease,36:60:chronic_disease,62:74:chronic_disease","other chronic pain syndromes (e.g. chronic fatigue syndrome, fibromyalgia)"
5812,NCT02133196,"12:33:cancer,50:76:cancer,107:130:cancer,132:155:cancer,160:175:cancer,","Measurable metastatic (stage IV) or unresectable non-small cell lung cancer (including but not limited to squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinomas) with at least one lesion that is resectable for TIL generation"
5813,NCT02132598,"1:27:chronic_disease,39:57:chronic_disease,62:77:chronic_disease,80:94:chronic_disease,96:109:chronic_disease,123:134:chronic_disease,138:150:chronic_disease","Inflammatory bowel disease (including ulcerative colitis and Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis"
5814,NCT02132598,"11:17:cancer,43:99:treatment,101:132:treatment,138:170:treatment","Patients' tumors must undergo testing for Epidermal Growth Factor Receptor (EGFR) exon 19 deletion, EGFR exon 21 L858R substitution, and anaplastic lymphoma kinase (ALK) rearrangements"
5815,NCT02132598,"35:74:chronic_disease,85:88:treatment,92:125:treatment",The subject has evidence of acute intracranial or intratumoral hemorrhage either by MRI or computerized tomography (CT) scan
5816,NCT02132598,"26:48:treatment,60:98:treatment,103:118:treatment,126:135:treatment,139:149:treatment,161:192:treatment,,213:225:treatment,227:238:treatment,,285:294:treatment","The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies; including investigational biologic agents) within 3 weeks, or nitrosoureas/ mitomycin C within 6 weeks before the first dose of study treatment"
5817,NCT02132598,"40:43:treatment,40:48:treatment,52:71:treatment,,148:160:treatment",The subject must have a baseline brain MRI scan or CT scan of the head (in patients unable to obtain an MRI) within 14 days prior to first dose of cabozantinib
5818,NCT02131805,"1:4:cancer,5:8:cancer,26:32:chronic_disease","BCC/SCC in area prone to trauma (including, but not limited to the skin overlying the tibia, dorsum of hands and elbow)"
5819,NCT02131597,"5:17:treatment,10:17:treatment,,134:153:chronic_disease","Off chemotherapy for 2 weeks prior to entering this study with no toxic effects of that therapy, unless there is evidence of rapidly progressive disease"
5820,NCT02131597,"1:16:chronic_disease,18:27:chronic_disease,29:34:chronic_disease,45:54:chronic_disease,186:197:treatment,207:216:treatment","systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)"
5821,NCT02131389,"1:27:chronic_disease,40:54:chronic_disease,58:82:chronic_disease","Degenerative joint disease, (including osteoarthritis or post-traumatic arthritis)"
5822,NCT02131389,"19:41:chronic_disease,48:68:chronic_disease,70:99:chronic_disease,101:120:chronic_disease,122:150:chronic_disease","Is suffering from inflammatory arthritis (e.g. rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, etc.)"
5823,NCT02129348,"31:44:chronic_disease,46:70:chronic_disease,78:87:chronic_disease,92:110:chronic_disease","Current clinical diagnosis of schizophrenia, schizoaffective disorder, other psychosis, or bipolar 1 disorder (DSM-IV TR criteria)"
5824,NCT02128906,"19:32:treatment,95:100:cancer,108:121:cancer","Diagnostic simple tonsillectomy is permitted, provided patient has RECIST-measurable residual tumor and/or nodal disease"
5825,NCT02128906,"28:40:treatment,44:53:treatment,89:109:cancer","Patients may have received chemotherapy or radiation for a previous, curatively treated non-HNSCC malignancy"
5826,NCT02128230,"19:31:chronic_disease,33:50:chronic_disease,88:107:chronic_disease,164:173:treatment","Poorly controlled hypertension, diabetes mellitus, or other serious medical illness or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol"
5827,NCT02124902,"14:34:chronic_disease,66:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:201:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
5828,NCT02124772,"1:19:chronic_disease,23:46:chronic_disease,51:67:cancer","Gilbert's syndrome or asymptomatic gallstones, or liver metastases"
5829,NCT02124772,"1:14:treatment,44:50:cancer,52:83:cancer,89:116:cancer","Prior therapy: The subject's disease (i.e. cancer, neurofibromatosis type 1 [NF-1] with plexiform neurofibroma [PN]"
5830,NCT02124772,",,61:75:treatment,120:138:chronic_disease,139:147:chronic_disease","abnormal cardiac valve morphology (>=grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis]"
5831,NCT02122185,"19:43:treatment,65:86:treatment,108:134:treatment,144:152:treatment,161:175:cancer,179:192:treatment,196:224:treatment",Subjects for whom neoadjuvant chemotherapy followed by interval cytoreductive surgery is planned must have fine needle aspirate (FNA) or other cytology showing adenocarcinoma OR core biopsies OR surgically directed biopsies showing adenocarcinoma
5832,NCT02122185,"20:44:treatment,37:44:treatment,54:80:treatment",subjects receiving neoadjuvant chemotherapy for whom interval debulking surgery (assuming adequate response to therapy) is not planned
5833,NCT02122185,"20:45:treatment,38:45:treatment,,,133:154:treatment,156:163:treatment,168:183:treatment","ubjects undergoing primary debulking surgery must have stage III or IV disease and have undergone surgery to include, at a minimum, removal of the uterus, ovaries and fallopian tubes"
5834,NCT02122081,"24:33:treatment,43:46:cancer,48:51:cancer,55:58:cancer,68:83:treatment","For patients receiving treatment of their AML, MDS or ALL prior to transplantation"
5835,NCT02121158,"24:39:chronic_disease,46:52:cancer,54:60:chronic_disease,62:75:chronic_disease,","Any disease other than cardiac disease (e.g. cancer, uremia, liver failure), associated with a likelihood of survival less than 1 year"
5836,NCT02120222,"3:7:treatment,15:28:treatment,33:38:cancer,,,85:95:cancer",a BRAF and/or MEK inhibitor (if tumor contains the V600E or V600K mutation) for 628 metastatic disease
5837,NCT02115295,"55:81:cancer,83:111:cancer,115:118:cancer","For Salvage cohort: Patients with previously treated, relapsed or refractory AML, Acute Biphenotypic Leukemia, or CML in Myeloid Blast Phase are eligible"
5838,NCT02114229,"22:30:treatment,34:48:treatment,83:96:treatment",Intermittent uses of antacids or H2 antagonists are allowed while patients are on dexamethasone
5839,NCT02114229,"4:31:treatment,33:50:treatment,54:66:treatment,90:105:treatment",No previous anticancer therapy (radiation therapy or chemotherapy) other than the use of corticosteroids
5840,NCT02114229,"44:65:treatment,67:80:treatment,85:103:treatment","Requirement for constant administration of proton-pump inhibitor, H2 antagonist, or pancreatic enzymes"
5841,NCT02112617,"32:44:treatment,,99:116:treatment,197:222:treatment",Patients will be ineligible if chemotherapy was completed ? 1 year from the planned start date of radiation therapy or if the patient is referred for radiation therapy after a relapse following a regimen with chemotherapy alone
5842,NCT02111850,"24:30:chronic_disease,38:61:chronic_disease,92:111:chronic_disease,113:136:chronic_disease,161:172:chronic_disease,194:216:chronic_disease","Clinically significant atrial and or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second or third degree heart block or have a history of ischemic heart disease, or chest pain"
5843,NCT02111850,"39:49:treatment,70:81:chronic_disease,101:112:treatment,125:141:treatment",Patients who have previously received ipilimumab and have documented GI toxicity must have a normal colonoscopy with normal colonic biopsies
5844,NCT02109627,"1:11:treatment,15:36:treatment,41:44:cancer,50:72:treatment,,116:141:treatment,147:151:chronic_disease,",Allogeneic or autologous transplant for AML with infusion of stem cells within 90 days of study entry or on active immunosuppressive therapy for (GVHD) within 2 weeks before study entry
5845,NCT02109627,"14:17:chronic_disease,19:30:chronic_disease,34:35:chronic_disease,39:48:chronic_disease","Known active HIV, hepatitis B or C or infection"
5846,NCT02109627,"23:44:treatment,48:58:treatment,60:68:treatment,72:98:treatment,","Prior exposure to the investigational agent or anti-c-Met, anti-HGF or anti-VEGF directed therapy within six months prior to study entry"
5847,NCT02108860,"36:71:treatment,73:76:treatment,78:81:treatment,83:85:treatment,","Initiation or dose increase of the maintenance immunosuppressive agent (MTX, AZA, MA) within 3 months prior to screening"
5848,NCT02108860,"26:38:chronic_disease,68:87:chronic_disease,171:181:treatment,253:256:treatment,266:273:treatment,","Subjects with a positive tuberculosis screening test indicative of latent tuberculosis will be eligible for the study if they have no evidence of current tuberculosis on chest xray at screening and they are actively being treated for tuberculosis with INH or other therapy for latent tuberculosis given according to local health authority guidelines (e.g., CDC) that has been given for at least 4 weeks prior to randomization (Day 1)"
5849,NCT02107703,"13:22:chronic_disease,26:42:chronic_disease,58:73:chronic_disease","Have active bacterial or fungal infection, or detectable viral infection"
5850,NCT02107703,"15:48:treatment,61:72:treatment,74:95:treatment,98:109:treatment,111:121:treatment,130:146:treatment,207:249:treatment","Have received prior treatment with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy), fulvestrant, everolimus, or any CDK4/6 inhibitor. For the endocrine naïve cohort: In addition, have received treatment with any prior endocrine therapy"
5851,NCT02107703,"24:42:cancer,117:126:treatment,142:154:treatment,161:180:treatment,184:212:treatment",presented de novo with metastatic disease and then relapsed with radiologic evidence of progression after receiving treatment with either an antiestrogen or an aromatase inhibitor as first line endocrine therapy for metastatic disease
5852,NCT02106988,"51:63:treatment,65:75:treatment,81:88:treatment","willingness to accept supportive measures such as transfusions, filgrastim, and Epoetin"
5853,NCT02106650,"16:42:cancer,53:57:chronic_disease,62:66:cancer,88:97:treatment",diagnosed with hematological malignancies including PTCL and CTCL and are eligible for treatment with a dose of 30 mg/m^2
5854,NCT02106598,"49:54:cancer,66:83:cancer,88:105:cancer","Residual clinically or radiographically evident tumor, including primary cutaneous and mucosal melanomas"
5855,NCT02106052,"1:13:chronic_disease,14:35:chronic_disease,47:49:chronic_disease,89:108:chronic_disease,110:121:chronic_disease,123:129:chronic_disease,131:134:chronic_disease,136:153:chronic_disease,155:167:chronic_disease,169:191:chronic_disease,203:216:chronic_disease","Neurological/psychological disease other than MS that may impact cognitive status, e.g. Alzheimer's disease, Parkinson's, stroke, TIA, Vascular Dementia, Huntington's, traumatic brain injury or chronic CNS infection"
5856,NCT02105766,"16:34:treatment,143:167:chronic_disease,171:186:chronic_disease,206:212:chronic_disease","Fit to receive filgrastim (G-CSF) and to give peripheral blood stem cells (blood counts and blood pressure within DTM standards no history of congestive heart failure or unstable angina, and no history of stroke)"
5857,NCT02104349,"28:41:treatment,53:79:treatment,81:118:treatment,120:141:treatment","Patients that will undergo spine surgery including: single level lumbar fusion, posterior cervical laminectomy fusion, cervical laminaplasty"
5858,NCT02101944,"1:22:chronic_disease,28:42:chronic_disease,44:56:chronic_disease,58:72:chronic_disease,74:104:chronic_disease,110:139:chronic_disease","Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein), and skin changes (POEMS) syndrome"
5859,NCT02101853,"45:74:chronic_disease,76:89:chronic_disease,91:105:chronic_disease,107:128:chronic_disease,130:144:chronic_disease,146:163:chronic_disease,165:183:chronic_disease,203:231:chronic_disease","Patients known to have one of the following concomitant genetic syndromes: Down syndrome, Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome"
5860,NCT02101853,"32:44:allergy_name,46:56:allergy_name,61:111:allergy_name","Patients with known allergy to mitoxantrone, cytarabine, or both etoposide and etoposide phosphate (Etopophos)"
5861,NCT02101736,"8:20:chronic_disease,57:66:treatment,72:84:treatment,88:105:treatment",Active optic glioma or other low-grade glioma requiring treatment with chemotherapy or radiation therapy
5862,NCT02101736,"39:54:chronic_disease,111:132:chronic_disease,147:159:chronic_disease,168:177:chronic_disease,179:198:chronic_disease,200:230:chronic_disease,239:264:chronic_disease","Concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (e.g. uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, chronic liver or renal disease, active upper GI tract ulceration)"
5863,NCT02101736,"1:17:cancer,19:58:cancer,69:79:cancer,90:99:treatment,","Malignant glioma, malignant peripheral nerve sheath tumor, or other malignancy requiring treatment in the last 12 months"
5864,NCT02101034,"24:27:chronic_disease,36:41:cancer,54:59:cancer",Arm 3: disease must be HPV-related SCCHN (defined as OPSCC or unknown primary presenting with a neck mass that is either p16 positive or HPV ISH or PCR positive)
5865,NCT02101034,"27:40:treatment,45:63:cancer,86:95:treatment","Phase I only: any (or no) prior therapy for metastatic disease is allowed, including cetuximab"
5866,NCT02101034,"15:28:chronic_disease,33:55:treatment,90:105:treatment","patients with HIV infection and antiretroviral therapy are not excluded, as there are no pharmacokinetic tests being performed"
5867,NCT02100891,"11:33:cancer,29:32:cancer,105:110:cancer,173:180:treatment,196:225:treatment,227:238:treatment,244:264:treatment,272:279:treatment,283:295:treatment","High-Risk Rhabdomyosarcoma (RMS) or Intermediate Risk Alveolar RMS recurring as more than loco-regional tumor: Must have progressed on or recurred after standard frontline therapy which includes chemotherapy with vincristine, actinomycin, and cyclophosphamide AND either surgery or radiotherapy"
5868,NCT02099591,"22:33:chronic_disease,37:53:chronic_disease,68:76:chronic_disease",History of prolonged neutropenia or thrombocytopenia with clinical sequelae
5869,NCT02099058,"22:40:treatment,51:63:treatment,65:82:treatment,84:97:treatment,99:107:treatment,116:139:treatment,,170:184:treatment,,226:234:treatment","Subject has received anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within a period of 21 days or herbal therapy within 7 days prior to the first dose of ABBV-399"
5870,NCT02099058,"17:49:treatment,78:87:treatment,92:101:treatment","Subjects in the combination therapy arms A and D must be eligible to receive erlotinib, or nivolumab per most current prescribing information, or at the discretion of the Investigator"
5871,NCT02098876,"80:90:allergy_name,92:103:allergy_name,105:111:allergy_name,113:121:allergy_name,123:129:allergy_name,131:139:allergy_name,141:149:allergy_name,151:158:allergy_name,163:178:allergy_name","hypersensitivity or contraindication to device materials and their degradants, everolimus, zotarolimus, cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers"
5872,NCT02098161,"38:120:treatment,38:47:treatment,96:120:treatment,122:133:treatment,135:161:treatment,152:157:treatment,238:249:treatment,251:284:treatment","Patients who are currently receiving treatment with agents that are metabolized solely through cytochrome P450 family 3, subfamily A, polypeptide 4/5 (CYP3A4/5) and have a narrow therapeutic index or are strong cytochrome P450 family 3, subfamily C, polypeptide 8 (CYP2C8) inhibitors; or are receiving treatment with agents that carry a risk for QT prolongation and are CYP3A substrates"
5873,NCT02095184,"23:32:treatment,36:46:treatment,82:95:cancer,156:165:treatment,,203:215:treatment",Patients who received tamoxifen or raloxifene or another agent for prevention of breast cancer may be included as long as the patient has discontinued the treatment at least one month prior to baseline study biopsy
5874,NCT02094625,"50:57:treatment,172:181:treatment,200:209:treatment,213:240:treatment,246:286:treatment","Are anticipated to be able to comply with end-of-therapy audiology assessment (note that hearing assessments are performed per routine clinical care in children receiving cisplatin and consist of an audiogram or auditory brainstem response, and distortion-product otoacoustic emissions"
5875,NCT02094625,"52:66:cancer,68:83:cancer,85:97:cancer","Most common but not exclusive diagnoses consist of hepatoblastoma, medulloblastoma, osteosarcoma"
5876,NCT02092324,"34:68:chronic_disease,72:98:chronic_disease,102:103:chronic_disease",Subjects with known diagnosis of human immunodeficiency virus (HIV) or chronic active Hepatitis B or C
5877,NCT02091999,"21:53:treatment,58:74:chronic_disease,76:81:chronic_disease,83:92:chronic_disease,97:103:chronic_disease,134:152:treatment","Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of first dose of enfortumab vedotin"
5878,NCT02091999,"26:78:cancer,86:107:cancer,109:121:cancer,123:129:cancer,134:141:cancer","Histologically confirmed Transitional Cell Carcinoma of the Urothelium (TCCU) (i.e., cancer of the bladder, renal pelvis, ureter, or urethra"
5879,NCT02091999,"104:129:cancer,131:152:cancer,157:185:cancer,,268:295:treatment","Subjects with recurrent disease or histologically or cytologically confirmed Stage III/IV diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma who have previously progressed while receiving or within 6 months of completing a platinum-containing regimen"
5880,NCT02091999,"4:18:treatment,22:43:treatment,,92:110:treatment",no red blood cell or platelet transfusions are allowed within 14 days of the first dose of enfortumab vedotin
5881,NCT02091141,"53:71:treatment,64:71:treatment,73:80:treatment,85:97:treatment,,","All non-hematological adverse events related to any prior chemotherapy, surgery, or radiotherapy must have resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade less than or equal to (?) 2 prior to starting therapy"
5882,NCT02091141,"31:47:treatment,,,102:117:treatment,108:117:treatment","For patients enrolling in the atezolizumab arm, ECOG score must be documented within 7 days prior to first treatment and confirmation of ECOG PS must be entered into the interactive web response system [IWRS] prior to initiation of treatment"
5883,NCT02091141,"1:25:treatment,,95:104:treatment,136:160:treatment","Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the course of the study"
5884,NCT02091141,"10:44:chronic_disease,58:81:chronic_disease,93:123:chronic_disease,144:156:chronic_disease","Positive human immunodeficiency virus (HIV) test, active hepatitis B virus (HBV) infection, active hepatitis C virus (HCV) infection or active tuberculosis"
5885,NCT02091141,"1:14:chronic_disease,16:24:chronic_disease,26:38:chronic_disease","Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol"
5886,NCT02091141,"33:46:chronic_disease,87:102:treatment,137:147:treatment","Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude absorption of vismodegib"
5887,NCT02089607,"18:25:treatment,74:80:chronic_disease,85:113:chronic_disease,130:179:treatment,183:206:treatment","Examples include therapy directed to reduce rates of spinal cord injury, stroke and contrast-induced nephropathy associated with implantation of fenestrated-branched stent-grafts or advanced imaging trials designed to reduce radiation exposure during repair"
5888,NCT02089607,"26:66:treatment,115:155:treatment,166:191:treatment,217:232:treatment,254:269:treatment,317:357:treatment,378:395:chronic_disease,397:425:chronic_disease","Participation in another investigational clinical or device trial, with the exception of participation in another investigational endovascular stent-graft protocol, percutaneous aortic valve protocol, or concomitant clinical trials designed to evaluate medical therapy strategies to reduce perioperative risk during fenestrated-branched endovascular repair, including risks of renal dysfunction, contrast-induced nephropathy, neurologic, spinal cord or cardiac complications, and/or use of advanced imaging to reduce radiation exposure during implantation of these devices"
5889,NCT02088554,"31:57:chronic_disease,79:108:chronic_disease,124:140:treatment",Patient has greater than mild mitral valve regurgitation or greater than mild tricuspid valve regurgitation as assessed by echocardiography
5890,NCT02087826,"31:44:chronic_disease,56:70:chronic_disease,101:123:treatment","Conditions causing intestinal malabsorption, including celiac disease or a history of intestinal or gastric bypass surgery"
5891,NCT02085941,"23:27:cancer,29:33:cancer,37:58:cancer","must have an advanced head, neck or spine malignant tumor that would potentially benefit from a minimally invasive procedure"
5892,NCT02080221,"30:40:cancer,73:82:treatment,,134:147:cancer,164:179:cancer","patients with an early stage malignancy that is not expected to require treatment in the next 2 years (such as early stage, resected breast cancer or asymptomatic prostate cancer)"
5893,NCT02078102,"68:89:cancer,93:121:cancer,150:181:treatment","Patients must have a previously documented histologic diagnosis of multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL), and be eligible to undergo autologous PBSC transplantation on institutional protocols"
5894,NCT02076906,"10:29:treatment,31:43:treatment,45:63:treatment,65:82:treatment,104:118:treatment,109:118:treatment","No other anti-cancer therapy (chemotherapy, biological therapy, radiation therapy) is permitted during HIFU treatment and post treatment follow up for tolerability"
5895,NCT02076906,"15:21:cancer,90:97:treatment,147:156:treatment",The patient's cancer must have relapsed after or failed to respond to frontline curative therapy and there must not be other potentially curative treatment options available
5896,NCT02074631,"1:41:treatment,46:68:cancer,75:83:cancer,85:93:cancer,104:107:cancer,109:112:cancer,114:117:cancer,119:122:cancer,120:122:cancer,151:175:cancer,184:193:cancer,201:207:cancer,261:300:chronic_disease","Allogeneic hematopoietic cell transplant for hematologic malignancy (i.e. leukemia, lymphoma including ALL, AML, CML, NHL, HL) in complete remission; myelodysplastic syndrome (active dysplasia and/or blasts are permitted, but must not have active leukemia) or idiopathic severe aplastic anemia (SAA)"
5897,NCT02074631,"38:52:chronic_disease,78:106:chronic_disease,108:126:chronic_disease,128:144:chronic_disease,149:166:chronic_disease","Other indications for HCT, including Fanconi anemia, other form of inherited bone marrow failure diseases, metabolic disorder, hemoglobinopathy, or immune deficiency"
5898,NCT02074436,"1:23:chronic_disease,41:67:cancer,107:150:treatment,178:192:chronic_disease,",Acute thrombocytopenia in patients with hematological malignancies who are in remission and are receiving myelosuppressive consolidation chemotherapy that is expected to induce marrow aplasia for at least 2 weeks
5899,NCT02074436,"49:54:treatment,56:78:treatment,82:113:treatment,","Subjects receiving procoagulant agent including DDAVP, recombinant factor VII or prothrombin complex concentrate within 24 hours of enrollment"
5900,NCT02073097,"7:19:cancer,,74:97:cancer,101:106:cancer,110:146:cancer,160:175:cancer,182:198:treatment","Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin, or low-risk prostate cancer after curative therapy"
5901,NCT02072356,"14:37:cancer,67:70:cancer,235:241:cancer,254:259:cancer,276:299:treatment","Diagnosis of intrahepatic malignancy including but not limited to HCC; the histopathology confirmation criterion may be waived in patients with a radiographically identifiable liver mass, known laboratory or clinical risk factors for cancer or elevated tumor markers such as alpha-fetoprotein (AFP) and clinical findings"
5902,NCT02072148,"24:34:chronic_disease,38:59:chronic_disease,70:78:chronic_disease,82:90:chronic_disease",History of significant neurologic or psychiatric disorders including dementia or seizures
5903,NCT02072148,"10:25:chronic_disease,34:43:treatment,45:66:chronic_disease","Unstable cardiac disease despite treatment, myocardial infarction with months prior to study entry"
5904,NCT02070549,"1:42:treatment,12:21:treatment,27:42:treatment,121:134:treatment,192:204:chronic_disease,251:263:chronic_disease","Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis"
5905,NCT02070549,"64:80:cancer,89:99:cancer,126:168:treatment",Patients must have a histologically or cytologically confirmed solid malignancy that is metastatic or unresectable for which standard curative or palliative treatments do not exist or are no longer effective
5906,NCT02070549,"14:35:treatment,,,,168:178:treatment,234:260:treatment,268:317:treatment","Use of other investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of trametinib and during the study; patients previously treated with v-raf murine sarcoma (RAF) and/or mitogen-activated protein kinase (MEK) inhibitors"
5907,NCT02068092,"14:46:cancer,48:63:treatment,68:87:cancer","Diagnosis of lobular carcinoma in situ (LCIS), atypical ductal, or lobular hyperplasia"
5908,NCT02068092,"1:28:treatment,21:28:treatment,,93:119:treatment",Prior anticoagulant therapy use is allowed provided therapy is discontinued at least 7 days prior to the breast biopsy in order to reduce the risk of bleeding
5909,NCT02067975,"15:37:chronic_disease,39:57:chronic_disease,102:111:treatment","History of an organic brain disorder; mental retardation; or a medical condition, whose pathology or treatment could alter cognition"
5910,NCT02064673,"1:4:cancer,8:10:cancer,14:35:cancer",T3b or T4 or node positive disease
5911,NCT02064296,"22:27:treatment,29:33:treatment,38:52:treatment","Contraindications to fcMRI, fMRI, or 1H-MRS methods"
5912,NCT02064296,"1:29:chronic_disease,39:52:chronic_disease,60:70:chronic_disease,76:93:chronic_disease,","Severe psychiatric illnesses (current schizophrenia, major depression with suicidal ideation, substance abuse within two years)"
5913,NCT02064296,"46:57:treatment,61:70:treatment,97:99:chronic_disease",Willing to limit the introduction of any new medications or treatment modalities for control of FM symptoms during the study
5914,NCT02064036,"1:25:treatment,27:40:treatment,45:56:treatment,61:75:cancer",Previous radical surgery (prostatectomy) or cryosurgery for prostate cance
5915,NCT02064036,"8:19:treatment,35:45:treatment,47:52:treatment,",Use of dutasteride or dutasteride/tamsulosin (Jalyn) within 90 days prior to registration
5916,NCT02061553,"9:32:chronic_disease,49:66:chronic_disease,68:75:chronic_disease,,,","Current psychiatric instability, including very severe depression/ anxiety as indicated by PHQ-9 or GAD-7 ?20"
5917,NCT02061293,"1:8:treatment,10:25:treatment,27:33:treatment,38:46:treatment,","Cocaine, psychostimulant, opioid, or cannabis dependence (past 12 months)"
5918,NCT02061293,"14:24:treatment,69:86:treatment,94:109:treatment,111:125:treatment,127:143:treatment,145:155:treatment,178:190:treatment,194:213:treatment,215:222:treatment,224:239:treatment","Need to take medication with significant potential to interact with study medications (e.g., antidepressants, antipsychotics, psychostimulants, treatments for addictions, other dopaminergic or serotonergic agents, lithium, anticonvulsants)"
5919,NCT02058095,"13:28:treatment,33:53:chronic_disease,86:96:treatment",Patients on PDEV inhibition for erectile dysfunction who are not willing to stop the medication for the duration of the study
5920,NCT02057133,"13:22:treatment,25:34:treatment,56:78:treatment,119:151:treatment,156:174:chronic_disease","For Part A (LY2835219 + letrozole): Except for ongoing therapy with letrozole, the participant must not have received prior systemic endocrine therapy for metastatic disease"
5921,NCT02057133,"25:35:treatment,38:48:treatment,86:118:treatment,111:118:treatment,,137:169:treatment,171:182:treatment,184:193:treatment,199:217:cancer","For Part E (LY2835219 + exemestane + everolimus): The participant must have received prior systemic endocrine therapy with at least one nonsteroidal aromatase inhibitor (anastrozole, letrozole) for metastatic disease and may be receiving ongoing therapy with either exemestane or exemestane + everolimus"
5922,NCT02057133,"14:25:treatment,28:39:treatment,42:52:treatment,,101:121:treatment,126:144:cancer",For Part H: (abemaciclib + trastuzumab + pertuzumab): The participant must have received at least 1 chemotherapy regimen for metastatic disease
5923,NCT02057133,"6:45:cancer,58:70:treatment,,144:153:treatment",Have central nervous system (CNS) metastasis with either radiotherapy or development of neurological changes ?14 days prior to receiving study treatment
5924,NCT02056873,"50:53:treatment,57:79:cancer,120:140:treatment","Any previous neurological intervention including DBS or ablative brain lesions, any metal in the head, and any type of implanted stimulator"
5925,NCT02056873,"39:62:chronic_disease,64:77:chronic_disease,79:93:chronic_disease,103:123:chronic_disease,125:146:chronic_disease,192:199:treatment","Severe medical co-morbidity including cardiovascular disorder, lung disorder, kidney disease, chronic neurological disease, hematological disease, or frailty that impacts tolerability of the surgery as judged by the screening physicians"
5926,NCT02056470,"95:113:chronic_disease,115:120:chronic_disease,122:140:chronic_disease","Other significant disabling problems from the muscular-skeletal system than in the knees (i.e muscular dystrophy, polio, nueropathic joints)"
5927,NCT02053246,"11:13:chronic_disease,33:46:chronic_disease,57:82:chronic_disease,84:103:chronic_disease,108:119:chronic_disease","Causes of PH other than that of heart failure, such as: chronic thromboembolic PH, sickle-cell disease, or sarcoidosis"
5928,NCT02050347,"18:33:treatment,,50:60:treatment,80:87:treatment,91:95:chronic_disease",Currently taking corticosteroids (>0.5 mg/kg/day prednisone or equivalent) for therapy of GVHD
5929,NCT02050113,"1:7:chronic_disease,11:30:chronic_disease,,,101:116:treatment","Aortic or aortoiliac aneurysm with a history of growth ?1.0 cm per year, or clinical indication for aneurysm repair based on symptoms"
5930,NCT02050113,"10:31:chronic_disease,33:56:chronic_disease,61:82:chronic_disease","Previous myocardial infarction, coronary artery disease, or coronary artery stent"
5931,NCT02048852,"10:26:chronic_disease,68:91:chronic_disease,100:120:chronic_disease,122:128:chronic_disease,132:146:chronic_disease,148:164:chronic_disease,325:341:chronic_disease","unstable medical problems which may include but are not limited to immune system disorders, severe respiratory diseases, kidney or liver diseases, thyroid problems, substance abuse or dependence that would limit patients ability to follow experimental protocol (based on history and drug and alcohol questionaires) or other heart conditions"
5932,NCT02048722,"20:43:cancer,53:73:cancer,78:103:cancer","Exceptions include cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor"
5933,NCT02048722,"1:20:chronic_disease,32:50:treatment,75:85:treatment",Progressive disease under last palliative therapy with a history of prior ifosfamide
5934,NCT02048722,"1:12:treatment,16:30:treatment,35:47:cancer",doxorubicin or taxane therapy for angiosarcoma
5935,NCT02048371,",14:44:treatment,53:60:cancer,72:83:treatment,75:83:treatment","At least one prior line of systemic therapy for the sarcoma diagnosis (neoadjuvant, adjuvant or metastatic disease)"
5936,NCT02048371,"39:51:treatment,44:51:treatment,,,,138:162:treatment,",Patients who have received wide field radiotherapy ? 28 days (defined as > 50% of volume of pelvis bones or equivalent) or limited field radiation for palliation < 14 days prior to study registration or those patients who have not recovered adequately from side effects of such therapy
5937,NCT02048371,"72:96:chronic_disease,108:134:chronic_disease,136:156:chronic_disease,160:178:chronic_disease,,207:222:treatment","Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatment"
5938,NCT02047474,"16:21:cancer,264:288:treatment,285:287:treatment,295:314:treatment,319:351:treatment,391:394:treatment","No evidence of tumor extension to superior mesenteric artery, hepatic artery, celiac axis, aorta, or inferior vena cava, and no evidence of occlusion or encasement of the superior mesenteric vein or superior mesenteric vein/portal vein confluence, as assessed by computed tomography (CT) using pancreatic protocol (or magnetic resonance imaging [MRI] in patients who cannot undergo CT) and EUS"
5939,NCT02047474,"23:35:treatment,,54:66:cancer,78:95:cancer",Patients who received chemotherapy > 5 years ago for malignancies other than pancreatic cancer are eligible
5940,NCT02046330,",128:142:treatment,,201:208:treatment,210:212:treatment,214:224:treatment,226:238:treatment,240:255:treatment,257:266:treatment,273:302:treatment","adequate trials ( equal>4 weeks at the usually recommended or maximum tolerated dose) of augmentation/combination of a primary antidepressant using at least 2 different augmenting/combination agents (lithium, T3, stimulants, neuroleptics, anticonvulsants, buspirone, or a second primary antidepressant)"
5941,NCT02044120,"44:75:treatment,,126:137:treatment,139:155:treatment,157:167:treatment,169:178:treatment","Patients must have received as a minimum a first line chemotherapy regimen consisting of at least 2 of the following agents: doxorubicin, cyclophosphamide, ifosfamide, etoposide"
5942,NCT02043548,",21:32:treatment,34:38:treatment,42:58:treatment","3 month washout for leflunomide, IVIg or cyclophosphamide"
5943,NCT02043548,"20:37:cancer,39:51:cancer,,101:127:cancer,132:144:cancer,153:158:cancer,163:186:cancer,202:233:cancer,","Evidence of active malignant disease, malignancies diagnosed within the previous 5 years (including hematological malignancies and solid tumors, except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has been excised and cured), or breast cancer diagnosed within the previous 10 years unless related to primary disease under investigation"
5944,NCT02043548,"1:14:treatment,26:39:treatment,,86:99:treatment,",Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization
5945,NCT02043548,"51:53:chronic_disease,55:65:chronic_disease,67:79:chronic_disease,83:98:chronic_disease,120:154:treatment,161:176:treatment,178:186:treatment,188:197:treatment,199:210:treatment,204:206:chronic_disease,212:223:treatment","Subjects must either have the classic rash(es) of DM (heliotrope, Gottron sign or Gottron papules), possess one of the myositis-associated autoantibodies (e.g. anti-synthetase, anti-SRP, anti-Mi-2, anti-PM-Scl, anti TIF1-? etc.), or have the diagnosis of PM agreed upon by a 3-member Adjudication Committee consisting of a rheumatologist, neurologist and neuromuscular pathologist"
5946,NCT02041936,"19:31:treatment,36:52:treatment,,89:98:treatment,108:124:treatment",Inability to stop antiplatelet and coumadin therapy for 7 days prior to and 7 days post treatment with the NanoKnife System
5947,NCT02040610,"7:23:treatment,25:37:treatment,43:58:cancer",Prior systemic therapy (chemotherapy) for prostate cancer
5948,NCT02037048,"46:60:cancer,62:85:cancer,87:107:cancer,109:128:cancer,130:138:cancer,140:147:cancer","Patients with any other diagnosis except for adenocarcinoma (squamous cell carcinoma, small cell carcinoma, mixed adenosquamous, lymphoma, sarcoma, etc.) will be ineligible"
5949,NCT02036268,"22:29:treatment,104:113:treatment,117:126:treatment,133:160:cancer",Scheduled to undergo surgery at IU Health North Hospital that will results in a temporary or permanent colostomy or ileostomy for a benign or malignant disease process
5950,NCT02033941,"1:21:chronic_disease,32:51:chronic_disease,53:69:chronic_disease,74:98:chronic_disease,","Major mental illness including psychotic disorders, bipolar disorder, or major depressive episode that is not in remission for less than 12 months"
5951,NCT02033616,"53:126:cancer,128:142:cancer,155:172:cancer,189:207:treatment,250:271:treatment,291:307:treatment,315:330:treatment","Patients must previously have been staged as having stage III [intraperitoneal (IP)] or Stage IV (distant metastatic) ovarian, fallopian tube, or primary peritoneal cancer, have undergone surgical debulking, and have initiated or completed standard adjuvant chemotherapy, which may include intravenous (IV) and/or IP chemotherapy using standard regimens"
5952,NCT02031250,"30:40:cancer,48:50:cancer,52:73:cancer,83:111:chronic_disease",Locally/regionally advanced (stage T3?4 and/or N3) nasopharyngeal cancer which is EBV (?) (Epstein?Barr Virus)
5953,NCT02027948,"37:49:treatment,71:88:treatment,,,,124:134:cancer,138:170:cancer",Patients who will receive induction chemotherapy followed by combined chemoradiotherapy at MSKCC for localized stage I-III esophageal or gastroesophageal junction cancer
5954,NCT02025023,"1:9:chronic_disease,,58:67:treatment,71:79:treatment,84:93:treatment",Chalazia present for less than one month and no previous injection or incision and curettage
5955,NCT02021279,"24:49:chronic_disease,57:68:chronic_disease,70:103:chronic_disease,105:121:chronic_disease,123:137:chronic_disease,139:151:chronic_disease,153:165:chronic_disease,169:191:chronic_disease","Subject has a systemic connective tissue disease (e.g., scleroderma, systemic lupus erythematous (SLE), Marfans syndrome, Ehlers Danhlos, collagenosis, polymyositis or polymyalgia rheumatica)"
5956,NCT02021279,"19:36:treatment,62:79:treatment,83:109:treatment,","Subject has taken systemic steroids (within the last month), immunosuppressive or immunomodulatory treatment (within the last 3 months)"
5957,NCT02020707,"5:23:cancer,49:68:chronic_disease,,111:121:treatment,125:139:treatment",For gynecologic cancer cohort only recurrent or progressive disease within 30 days of the last dose of weekly paclitaxel or nab-paclitaxel
5958,NCT02020707,"12:25:chronic_disease,34:43:chronic_disease,45:69:chronic_disease,71:99:chronic_disease,103:119:chronic_disease","History of liver disease such as cirrhosis, chronic active hepatitis, chronic persistent hepatitis or hepatitis B or C"
5959,NCT02020707,"27:45:cancer,54:66:cancer,68:74:cancer,76:86:cancer,88:96:cancer,98:106:cancer,108:125:cancer,127:143:cancer,145:150:cancer,156:170:cancer,215:231:cancer","allowable histologies for endometrial cancer include endometrioid, serous, clear cell, mucinous, squamous, transitional cell, undifferentiated, mixed, and carcinosarcoma (this is considered a poorly differentiated epithelial tumor)"
5960,NCT02020564,"24:43:chronic_disease,58:74:chronic_disease,76:89:chronic_disease,94:103:chronic_disease,131:156:chronic_disease,158:171:chronic_disease,173:181:chronic_disease,183:199:chronic_disease","history of significant pyschiatric illness (for example, bipolar disorder, schizophrenia, or pyschosis) or a current diagnosis of Major Depressive Disorder, Schizophrenia, Epilepsy, Bipolar Disorder"
5961,NCT02019641,"124:133:chronic_disease,135:149:chronic_disease,151:163:chronic_disease,165:180:chronic_disease","Other medical conditions that would impair aerobic capacity or the ability to engage in physical activity, including other pulmonary, cardiovascular, neurological, musculoskeletal or metabolic conditions"
5962,NCT02016781,"1:7:cancer,21:37:treatment,46:58:treatment,59:76:treatment,",Cancer treated with curative surgery without chemotherapy/radiation therapy > 5 years previously will be allowed
5963,NCT02016430,"18:38:treatment,42:51:treatment,60:75:treatment,79:85:treatment",Having undergone bariatric procedures or surgeries such as gastric banding or bypass
5964,NCT02016235,"54:88:chronic_disease,110:129:chronic_disease,,,164:180:chronic_disease,199:217:treatment,219:234:treatment,239:248:treatment,","Exclusion criteria include history of symptomatic or asymptomatic kidney stone disease; primary or secondary hyperparathyroidism; estimated GFR <40 ml/min/1.73m2, chronic diarrhea states; intake of thiazide diuretics, glucocorticoids, or estrogens within one month of the study"
5965,NCT02013492,",36:61:cancer,,,179:207:treatment,211:243:treatment,262:271:chronic_disease,275:299:chronic_disease","At least one solid liver lesion or vascular tumor thrombosis (involving portal vein, IVC and/or hepatic vein) > 1 cm with arterial enhancement and delayed washout on multiphasic computerized tomography (CT) or magnetic resonance imaging (MRI) in the setting of cirrhosis or chronic hepatitis B or C without cirrhosis"
5966,NCT02013336,"43:56:cancer,58:74:cancer,76:89:cancer,94:106:cancer","Histologically or cytologically-confirmed Ewing sarcoma, rhabdomyosarcoma, neuroblastoma, or osteosarcoma"
5967,NCT02013154,"31:49:chronic_disease,82:90:chronic_disease,92:109:chronic_disease,114:123:chronic_disease,138:156:treatment","History of known or suspected autoimmune disease with the specific exceptions of vitiligo, atopic dermatitis, or psoriasis not requiring systemic treatment"
5968,NCT02013154,"1:48:treatment,50:100:treatment,217:230:treatment,327:333:treatment","Prior treatment anti- programmed death-1 (PD-1)/ anti-PD-ligand 1 (PD-L1) monoclonal antibody (mAb) is permitted in patients provided the patient's disease is primary refractory, and the patient is not intolerant of pembrolizumab. Patients who are not eligible to receive pembrolizumab will be allowed to receive single agent DKN-01"
5969,NCT02013154,"1:10:treatment,16:37:treatment,54:63:treatment,",Treatment with low dose chemotherapy concurrent with radiation within 14 days prior to study entry
5970,NCT02012296,"1:42:treatment,58:82:treatment,84:95:treatment,97:119:treatment,123:147:treatment,149:160:treatment,162:184:treatment","Concurrent therapy with strong inhibitors or inducers of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) or cytochrome P450 family 2, subfamily C, polypeptide 8 (CYP2C8) due to concerning possible drug-drug interactions"
5971,NCT02011971,"1:22:chronic_disease,30:38:chronic_disease,40:48:chronic_disease,50:63:chronic_disease,65:78:cancer,80:90:chronic_disease","Major medical disease (e.g., epilepsy, diabetes, heart disease, active cancer, depression)"
5972,NCT02008656,"10:32:treatment,44:56:treatment,58:67:treatment,69:87:treatment,78:87:treatment,89:105:treatment,107:120:treatment,122:134:treatment,136:151:treatment,153:176:treatment,178:211:treatment,213:224:treatment,226:261:treatment,271:289:treatment","No other experimental therapies (including chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, matrix metalloprotease inhibitors, thalidomide, anti-VEGF/Flk-1 monoclonal antibody or other experimental drugs) of any kind are permitted while the patient is receiving study treatment"
5973,NCT02008656,"18:32:treatment,37:56:chronic_disease,131:152:treatment","patients who are anticoagulated for atrial fibrillation or other conditions may participate, provided they are on stable doses of anticoagulant therapy"
5974,NCT02007239,"1:20:treatment,,54:62:treatment,,77:87:treatment,116:127:treatment,129:143:treatment,145:154:treatment,159:170:treatment","Vasoactive infusion for at least 12 hours, including dopamine ?5mcg/kg/min, dobutamine?5mcg/kg/min, or any dose of epinephrine, norepinephrine, milrinone, or vasopressin"
5975,NCT02004275,"24:59:treatment,47:59:treatment,61:71:treatment,76:89:treatment,175:201:treatment,,320:328:treatment","A patient who receives induction therapy with lenalidomide, bortezomib and dexamethasone and achieves a PR or better but subsequently progresses on continued lenalidomide or lenalidomide-dexamethasone would be eligible provided the progression occurs 60 days or more after discontinuation of the bortezomib; similarly, ixazomib exposure is allowed provided they meet the definition of proteasome inhibitor sensitive disease"
5976,NCT02004275,"1:13:treatment,14:32:cancer,,122:150:treatment",Lenalidomide-refractory disease is defined as disease progression on or progression within 60 days of the last dose of a lenalidomide-based treatment
5977,NCT02004275,"18:37:chronic_disease,43:54:treatment,58:80:treatment",Prior history of erythema multiforme with thalidomide or lenalidomide treatment
5978,NCT02004275,"21:28:cancer,62:75:treatment,77:79:treatment",relapsed disease is myeloma that has previously responded to prior therapy (MR or better) and subsequently progressed
5979,NCT02004028,"27:39:treatment,43:55:treatment,118:130:cancer",Participants who have had chemotherapy or radiotherapy any time prior to entering the study or at any prior time for mesothelioma. Patients receiving chemotherapy type drugs for benign conditions can participate in this trial
5980,NCT02004028,"24:46:chronic_disease,58:76:chronic_disease,80:95:chronic_disease,,127:136:treatment,,,192:216:chronic_disease,226:237:chronic_disease,248:272:treatment,297:316:chronic_disease,321:340:chronic_disease","Uncontrolled or severe cardiovascular disease, including myocardial infarct or unstable angina within 6 months prior to study treatment, New York Heart Association (NYHA) Class II or greater congestive heart failure, serious arrhythmias requiring medication for treatment, clinically significant pericardial disease, or cardiac amyloidosis"
5981,NCT02003222,"15:57:chronic_disease,,,,139:196:treatment,255:263:cancer",No history of acquired immune deficiency syndrome (AIDS)-related complications other than a history of low CD4+ T-cell count (< 200/mm^3) prior to initiation of combination antiretroviral therapy; on study CD4+ T-cell count may not be informative due to leukemia and should not be used as an exclusion criterion if low
5982,NCT02003222,"115:123:chronic_disease,125:132:chronic_disease,134:141:chronic_disease,143:150:chronic_disease,152:158:chronic_disease,167:181:chronic_disease,183:191:chronic_disease,193:212:chronic_disease,214:232:chronic_disease,234:256:chronic_disease,258:267:chronic_disease,290:307:chronic_disease","Patient must not have a history or presence of clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia; Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis, or other significant CNS abnormalities"
5983,NCT02000115,"49:56:allergy_name,58:65:allergy_name,67:87:allergy_name,92:112:allergy_name,132:146:allergy_name","A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine (Ticlid), or clopidogrel (Plavix), or sensitivity to contrast media which cannot be adequately premedicated"
5984,NCT02000115,"31:48:cancer,50:58:chronic_disease,62:72:chronic_disease","Echocardiographic evidence of intracardiac mass, thrombus or vegetation"
5985,NCT02000115,"1:20:chronic_disease,,,53:76:chronic_disease,95:103:treatment",Renal insufficiency (creatinine > 3.0 mg/dL) and/or end stage renal disease requiring chronic dialysis
5986,NCT01999179,"1:23:cancer,13:23:cancer,35:47:treatment,49:56:treatment,58:67:treatment,71:87:treatment","solid tumor malignancy undergoing chemotherapy, surgery, radiation or hormonal therapy for malignancy"
5987,NCT01996865,"17:32:treatment,,62:71:treatment,,132:142:treatment","Subjects taking corticosteroids during the last 1 week prior treatment, unless administered at a dose equivalent to < 20 mg/day of prednisone"
5988,NCT01994538,"52:55:chronic_disease,73:89:chronic_disease,91:121:chronic_disease","Symptoms thought more likely to be caused by a non-UTI diagnosis (e.g., urinary calculus, sexually transmitted infection, etc.)"
5989,NCT01994382,"32:35:chronic_disease,36:46:chronic_disease,48:55:chronic_disease,70:77:chronic_disease",Known carrier or infection for HIV/Hep B or C. HCV ab+ must be PCR-. HBV ab+ must be HBsAg- or undetectable DNA
5990,NCT01994382,",,70:73:cancer,74:77:cancer,81:108:cancer,110:115:cancer,117:119:cancer,121:124:cancer,126:129:cancer,131:157:cancer","Specific Patient at least 18yrs of age with histologically confirmed CLL/SLL or B-cell Non-Hodgkin lymphoma (DLBCL, FL, MCL, MZL, lymphoplasmacytic lymphoma)"
5991,NCT01993810,"1:27:treatment,28:62:treatment,63:92:treatment,",Fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/computed tomography (CT) scan for staging within 60 days prior to registration
5992,NCT01993810,"1:28:treatment,43:49:cancer,,76:98:treatment,,124:140:treatment","Prior systemic chemotherapy for the study cancer, if more than 4 cycles of induction chemotherapy or more than 6 months of targeted therapy"
5993,NCT01993719,"18:21:chronic_disease,50:59:treatment,146:162:chronic_disease",Seronegative for HIV antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus are less responsive to the experimental treatment and more susceptible to its toxicities.)
5994,NCT01992861,"36:53:treatment,70:98:treatment,103:118:cancer",Patients who will undergo standard radiation therapy with concurrent cisplatin-based chemotherapy for cervical cancer
5995,NCT01990209,",,,217:226:treatment,,274:284:treatment,332:367:treatment,","Female patients who are not of child-bearing potential and female patients of child-bearing potential who agree to use adequate contraceptive measures or abstain from heterosexual intercourse during the entire study treatment period and for 4 months after the last dose of study drug, who are not breastfeeding, and who have had a negative serum/urine pregnancy test ?7 days prior to dosing"
5996,NCT01990209,"1:26:treatment,,55:64:treatment,68:93:treatment,",Major surgical procedures ?28 days of beginning study treatment or minor surgical procedures ?7 days
5997,NCT01990209,"20:36:cancer,58:65:cancer,,116:128:treatment,132:177:treatment",Previously treated brain metastases are allowed provided lesions are stable for at least 3 months as documented by head CT scan or magnetic resonance imaging (MRI) of the brain
5998,NCT01989585,",,62:76:treatment,126:139:chronic_disease,140:148:chronic_disease","Abnormal cardiac valve morphology (>= grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study); subjects with moderate valvular thickening should not be entered on study"
5999,NCT01989585,"1:16:treatment,18:31:treatment,33:46:treatment,48:61:treatment,63:72:treatment,76:87:treatment","Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin, s-mephenytoin"
6000,NCT01989585,"29:39:treatment,55:66:treatment,70:88:treatment",Current use of a prohibited medication; the following medications or non-drug therapies are prohibited
6001,NCT01989585,"102:112:allergy_name,114:124:allergy_name,129:139:allergy_name,161:186:allergy_name","History of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax, dabrafenib, or trametinib, or excipients or to dimethyl sulfoxide (DMSO)"
6002,NCT01989585,"7:26:treatment,42:51:treatment,60:78:treatment",Other anti-cancer therapy while on study treatment; (note: megestrol [Megace] if used as an appetite stimulant is allowed)
6003,NCT01989585,"23:36:treatment,38:50:treatment,54:66:treatment,,109:119:treatment,124:158:treatment,196:223:treatment,240:256:treatment,261:276:treatment,,325:335:treatment,343:353:treatment,355:376:treatment,,460:469:treatment,471:480:treatment,","Patients who have had immunotherapy, chemotherapy or radiotherapy within 14 days prior to the first dose of navitoclax, or prior systemic anti-cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or vaccine therapy) within the last 3 weeks prior to first dose of dabrafenib and/or trametinib; chemotherapy regimens without delayed toxicity within the last 2 weeks preceding the first dose of study treatment; biologics will not be allowed within 30 days prior to, or during, navitoclax administration"
6004,NCT01989585,"1:14:treatment,7:14:treatment,160:181:treatment,189:202:treatment,204:220:treatment,210:220:treatment,","Prior therapy is allowed; for patients enrolled in the Phase I portion of the study, patients may have received any number of prior lines of therapy including treatment with a BRAF and/or MEK inhibitor; prior navitoclax use will not be allowed, unless the patient received < 7 days of navitoclax lead-in on this or another study and had to stop for reasons other than toxicity or disease progression"
6005,NCT01989585,",152:180:treatment,189:197:chronic_disease,234:247:treatment,254:265:chronic_disease,266:280:chronic_disease,282:303:chronic_disease,305:317:chronic_disease,329:348:treatment","Unresolved toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v. 5.0) grade 2 or higher from previous anti-cancer therapy, except alopecia or an endocrine toxicity related to immunotherapy (e.g. thyroiditis/hypothyroidism, adrenal insufficiency, hypophysitis) requiring replacement therapy, at the time of randomization"
6006,NCT01989507,"7:18:treatment,46:56:treatment,58:71:treatment,73:84:treatment,86:110:treatment,112:122:treatment","other medications that could affect smoking (naltrexone, buprenorphine, acamprosate, anti-seizure medications, disulfiram)"
6007,NCT01988246,"54:87:treatment,95:109:treatment,111:129:treatment","Planned multiple procedures for study eye during the cataract/IOL implantation surgery (e.g., trabeculectomy, corneal transplant)"
6008,NCT01988246,"8:25:treatment,27:33:treatment,35:72:treatment,75:91:treatment,,115:122:treatment,160:167:treatment,","Use of systemic steroids, NSAIDS (non-steroidal anti-inflammatory drugs), anti-VEGF agents within 7 days prior to surgery (through study exit). Daily doses of aspirin, up to 325 mg, will be permitted"
6009,NCT01986205,",161:169:chronic_disease,281:291:chronic_disease,293:300:chronic_disease,302:323:chronic_disease","At least 3 of the following persistent symptoms from the injury: headaches, dizziness or balance problems, blurred vision, tiredness/fatigue or sleep problems, seizures, remembering things or solving problems, managing stress or emotional upsets, controlling temper/irritability, depression, anxiety, post-traumatic stress, or ringing in the ears"
6010,NCT01986205,"7:27:chronic_disease,31:58:chronic_disease,68:86:chronic_disease",Major psychiatric disorder or degenerative mental disease (such as multiple sclerosis)
6011,NCT01986075,"1:28:chronic_disease,78:103:chronic_disease,105:120:chronic_disease,122:143:chronic_disease","Unstable physical disorders which might make participation hazardous such as uncontrolled hypertension, acute hepatitis, uncontrolled diabetes"
6012,NCT01983475,"45:59:treatment,45:60:treatment,,71:81:treatment,,250:259:chronic_disease","Any patient receiving moderate or high dose corticosteroids (>40 mg/d prednisone or an equivalent dose of other corticosteroid) for longer than one week, not including drug administered in an attempt to preserve neurological function at the time of acute SCI"
6013,NCT01983462,"12:26:chronic_disease,28:46:chronic_disease,48:57:chronic_disease,66:104:chronic_disease,109:127:chronic_disease","History of gastric ulcers, bleeding disorders, dyspepsia, severe gastroesophageal reflux disease (GERD), or metabolic acidosis"
6014,NCT01983462,"24:33:treatment,,185:197:treatment,232:246:treatment,251:270:treatment","If currently receiving treatment with or taking any of the following supplements, be willing and able to discontinue taking them for 2 weeks prior and throughout the treatment period: Vitamin C, E or other multivitamins containing vitamin C or E; or omega-3 fatty acids"
6015,NCT01983462,"8:44:treatment,52:59:treatment,61:68:treatment,70:78:treatment,83:91:treatment,94:110:treatment,118:128:treatment,130:139:treatment,144:155:treatment,158:165:treatment","Taking Phosphodiesterase (PDE) 5 inhibitors (e.g., Viagra®, Cialis®, Levitra®, or Revatio®); PDE 3 inhibitors (e.g., cilostazol, milrinone, or vesnarinone); lithium"
6016,NCT01983462,"30:39:treatment,41:50:treatment,52:59:treatment,68:86:treatment,88:95:treatment,97:104:treatment,106:111:treatment","Taking diabetic medications (Metformin, glyburide, insulin, etc.), thiazolidinediones (Avandia, Rezulin, Actos)"
6017,NCT01983462,"12:35:treatment,39:69:treatment,,128:149:treatment","Use of any investigational product or investigational medical device within 30 days prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments"
6018,NCT01980823,"56:70:treatment,72:75:chronic_disease,76:95:treatment,101:113:treatment,150:162:treatment","Strong Cytochrome P450 3A4 (abbreviated CYP3A4) (e.g., clarithromycin, HIV protease inhibitors, and itraconazole), given potential interactions with atorvastatin"
6019,NCT01976585,"1:11:cancer,47:82:cancer,90:132:cancer","basal cell or completely excised non-invasive squamous cell carcinoma of the skin, or in situ squamous cell carcinoma of the cervix"
6020,NCT01976169,"1:6:cancer,15:19:cancer,33:35:treatment",Tumor must be HER2-positive and RB-proficient
6021,NCT01974609,"93:103:chronic_disease,105:137:chronic_disease,139:164:chronic_disease,166:179:chronic_disease,181:194:chronic_disease","those with a history or symptoms of any significant medical problem in the last year (i.e., arrhythmia, impaired cardiovascular function, gastrointestinal bleeding, liver disease, renal disease)"
6022,NCT01973270,"20:31:treatment,33:48:treatment,67:76:treatment","Being treated with benztropine, diphenhydramine, or high doses of clozapine"
6023,NCT01970345,"19:38:treatment,19:29:treatment,,143:148:treatment","Must be on stable medication regimens for at least three months prior to enrollment, assuming the concomitant medication is safe for use with IGF-1"
6024,NCT01970176,"15:35:chronic_disease,71:87:chronic_disease,99:124:chronic_disease","Patients with retinitis pigmentosa, previous diagnosis of nonischemic optic neuropathy, untreated proliferative retinopathy or unexplained visual disturbance"
6025,NCT01968590,"14:29:chronic_disease,31:46:chronic_disease,48:67:chronic_disease","diagnosis of Paget's disease, hyperthyroidism, hyperparathyroidism, or other medical condition that affects bone health"
6026,NCT01968109,"1:44:cancer,48:60:cancer,66:80:cancer",Primary central nervous system (CNS) tumors or solid tumors with CNS metastases as the only site of active disease
6027,NCT01967823,"12:29:treatment,47:57:cancer,93:102:treatment","Definitive radiation therapy for unresectable meningioma, or for recurrent meningioma after resection"
6028,NCT01967823,"39:49:treatment,101:112:treatment,125:141:treatment",Patients who have previously received ipilimumab and have documented GI toxicity must have a normal colonoscopy with normal colonic biopsies
6029,NCT01967238,"100:108:chronic_disease,110:133:chronic_disease,135:156:chronic_disease,158:168:cancer","Any clinically significant acute or chronic medical condition requiring care of a physician (e.g., diabetes, coronary artery disease, rheumatologic illness, malignancy, substance abuse) that, in the opinion of the investigator, would preclude participation"
6030,NCT01967238,"14:31:treatment,,74:86:treatment,91:112:treatment,",Received the influenza vaccine less than 1 month ago and/or received the pneumococcal and meningococcal vaccine less than 4 years ago
6031,NCT01964859,"16:29:chronic_disease,55:61:chronic_disease,63:72:chronic_disease,74:87:chronic_disease","Having current skin diseases (i.e. extreme and active eczema, psoriasis, lichen planus) that the investigator feels is not safe for study participation"
6032,NCT01964261,"1:18:chronic_disease,30:50:chronic_disease,68:78:chronic_disease","Psychotic illness or chronic psychiatric disorder, including major depression if untreated"
6033,NCT01959698,"1:36:chronic_disease,47:80:chronic_disease,91:127:chronic_disease","Hepatitis B surface antigen (HBsAg) negative, hepatitis B core antibody (HBcAb) negative, hepatitis B surface antibody (HBsAb) positive patients"
6034,NCT01959698,",,55:68:chronic_disease,70:89:chronic_disease,111:134:chronic_disease,159:178:chronic_disease,183:203:treatment,222:230:chronic_disease","New York Heart Association (NYHA) class II or greater heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically significant pericardial disease, or electrocardiographic evidence of acute ischemia"
6035,NCT01959698,"15:20:treatment,35:40:treatment,65:70:treatment,93:116:chronic_disease,117:144:treatment","Patients with HBsAg negative, but HBcAb positive (regardless of HBsAb status) should have a hepatitis B virus (HBV) deoxyribonucleic acid (DNA) testing done and protocol"
6036,NCT01959425,"5:20:treatment,,59:94:treatment,114:128:treatment,130:139:treatment,145:157:treatment,161:207:treatment","Any cardiac surgery within the past 60 days (2 months) or valvular cardiac surgical procedure at any time (i.e., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve)"
6037,NCT01959425,"1:18:chronic_disease,27:56:chronic_disease,58:70:chronic_disease,74:78:chronic_disease","pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or COPD) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms"
6038,NCT01959204,"80:94:chronic_disease,96:107:chronic_disease,109:114:chronic_disease,116:132:chronic_disease,134:145:chronic_disease,147:158:chronic_disease,160:169:chronic_disease,174:194:chronic_disease,198:217:chronic_disease","Has the presence or history of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (except for the condition for which the procedure is being performed) as determined by the clinical investigator"
6039,NCT01956084,"60:63:chronic_disease,73:82:cancer,86:108:cancer,112:165:chronic_disease,169:186:cancer,187:201:cancer,247:258:chronic_disease,329:343:treatment","Any patient, regardless of age or sex, with a diagnosis of EBV positive Hodgkin's or non-Hodgkin's Lymphoma or EBV (associated)-T/NK-LPD lymphoproliferative disease or Lymphoepithelioma/leiomyosarcoma regardless of histological subtype or Severe Chronic EBV and in remission (group A) or with detectable disease (group B) after allogeneic SCT"
6040,NCT01954576,"11:21:cancer,43:55:treatment,,189:199:cancer,203:238:cancer,288:319:cancer","Any other malignancy that required active chemotherapy within the previous 12 months prior to registration and the disease is not currently progressing and/or metastatic. The exception is basal cell or squamous cell carcinoma of the skin, which were treated with local resection only or carcinoma in situ of the cervix"
6041,NCT01954576,"26:44:cancer,26:29:cancer,70:81:cancer,83:97:cancer,99:113:cancer,115:141:cancer,152:165:cancer,245:261:cancer","Histologically confirmed GBM (WHO grade IV); rare GBM variants (e.g. gliosarcoma, giant cell GBM, small cell GBM, GBM with oligodendroglioma features, GBM with PNET features) are allowed. Patients will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of GBM is made"
6042,NCT01954576,"10:22:treatment,,38:40:treatment,45:70:treatment,82:91:treatment",Received radiotherapy of at least 45 Gy and temozolomide chemotherapy as initial treatment for GBM
6043,NCT01954316,"15:27:treatment,29:41:treatment,43:61:treatment,65:90:treatment,,127:138:treatment,142:153:treatment,184:194:treatment,248:264:treatment","Have received radiotherapy, chemotherapy, biological therapy or investigational treatment less than four weeks (six weeks for nitrosourea or mitomycin C) prior to first dose of study medication or have not recovered from all acute toxicities from prior treatments"
6044,NCT01953588,"38:56:cancer,58:75:treatment,130:156:chronic_disease","Clinical or radiographic evidence of metastatic disease. Metastatic workup is not required, but is recommended for patients with clinical stage III disease"
6045,NCT01953575,"15:18:chronic_disease,31:40:chronic_disease,,134:151:treatment,,192:221:treatment","Patients with EoE, defined as dysphagia with histologic finding of greater than or equal to 15 eosinophils per high powered field on esophageal biopsy despite at least 6 weeks of twice daily proton pump inhibitor therapy"
6046,NCT01953263,"24:43:chronic_disease,55:73:chronic_disease,75:93:chronic_disease,98:122:chronic_disease,124:139:chronic_disease,141:162:chronic_disease,164:178:chronic_disease,180:194:cancer,196:210:chronic_disease,218:234:chronic_disease","Patients with abnormal urologic conditions, including post-void residual, urethral stricture and bladder neck contracture, spastic bladder, vesicoureteral reflux, bladder stones, bladder tumors, hydronephrosis, other renal impairment"
6047,NCT01951885,"27:34:chronic_disease,49:68:chronic_disease,156:163:treatment","Patients with any medical illness or concurrent psychiatric illness which, in the investigators' opinion, cannot be adequately controlled with appropriate therapy"
6048,NCT01950351,"1:38:chronic_disease,61:80:chronic_disease,121:134:treatment",chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
6049,NCT01950234,"1:22:treatment,11:22:treatment,44:59:treatment,61:70:treatment,72:83:treatment,85:95:treatment,99:116:treatment","Stimulant medications for fatigue (such as methylphenidate, modafinil, armodafinil, amantadine or dextroamphetamine) will be permitted, but subjects will be asked to not take these medications on study visit days until all study procedures/assessments are completed"
6050,NCT01950234,"1:54:treatment,97:112:treatment,114:118:treatment,120:132:treatment,134:155:treatment,157:169:treatment,173:184:treatment,,211:224:treatment","Treatment with non-cytotoxic immunosuppressive agents (including but not necessarily limited to corticosteroids, ACTH, azathioprine, mycophenolate mofetil, methotrexate or natalizumab) within 3 months prior to randomization"
6051,NCT01947140,"13:25:treatment,29:41:treatment,,70:81:treatment,85:96:treatment",Exposure to chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier
6052,NCT01946074,"17:36:treatment,64:72:treatment,77:94:treatment","Subjects in the combination therapy cohorts who are to receive ABBV-181, an anti-PD1 antibody, must also meet other criteria described in the Protocol"
6053,NCT01943851,"104:134:chronic_disease,150:160:chronic_disease,169:191:chronic_disease,195:210:treatment",Able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels
6054,NCT01943851,"36:53:chronic_disease,87:98:chronic_disease,100:107:chronic_disease,109:114:chronic_disease,116:131:chronic_disease,159:176:chronic_disease","Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal, cardiac disease, or clinically significant bleeding episodes)"
6055,NCT01943851,"43:46:cancer,48:50:cancer,55:58:cancer","In Part 1 and, Part 2, subjects must have AML, MM, or NHL"
6056,NCT01943851,"8:22:treatment,30:38:treatment,40:47:treatment,,","Use of anticoagulants (e.g., warfarin, heparin) at therapeutic levels within 7 days prior to the first dose of GSK525762"
6057,NCT01941316,"21:37:chronic_disease,48:57:treatment,59:79:treatment,81:91:treatment,96:107:treatment,","Must not have acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to enrollment"
6058,NCT01941316,"21:37:cancer,87:103:cancer,128:137:treatment,153:155:treatment,159:175:treatment,,227:249:treatment","Patients with known brain metastases are eligible only if he/she has been treated for brain metastasis, are asymptomatic after treatment, have a stable CT or MRI of the brain within 28 days of enrollment and are not receiving corticosteroid therapy to control symptoms from brain metastasis"
6059,NCT01940094,"74:84:treatment,,121:165:chronic_disease,167:173:chronic_disease,175:196:chronic_disease","Comorbid condition that has moderate likelihood of requiring a course of prednisone within one year of enrollment (e.g. chronic obstructive pulmonary disease (COPD), asthma, adrenal insufficiency)"
6060,NCT01931202,"12:21:chronic_disease,23:41:chronic_disease,43:48:chronic_disease,53:69:chronic_disease","History of psychosis, psychotic disorder, mania, or bipolar disorder"
6061,NCT01928589,"38:75:treatment,77:85:treatment,87:125:treatment,127:161:treatment,176:215:treatment,255:267:treatment,269:285:treatment,289:300:treatment,460:486:treatment,,,546:561:treatment,,,,,721:737:treatment,,839:856:treatment","Recommended regimens are as follows: Cyclophosphamide and Doxorubicin (AC); Taxotere, Doxorubicin and Cyclophosphamide (TAC); Taxotere and Cyclophosphamide (TC); or Taxotere, Carboplatin and Trastuzamab (TCH) prior to registration. The use of additional chemotherapy, hormonal therapy or Trastuzumab after the initial regimen is at the discretion of the Medical Oncologist. Other primary regimens are possible but the PI must be notified prior to enrollment. Partial breast irradiation must be scheduled to begin less than 71 days from the last breast surgical procedure. ECOG performance status ? 1. Women of child-bearing potential must have a negative (urine or blood) pregnancy test within 6 weeks prior to start of protocol therapy. Women of childbearing potential must also use effective non-hormonal contraception while undergoing radiation therapy. Ability to understand and the willingness to sign a written informed consent document"
6062,NCT01928576,"39:59:treatment,68:86:treatment,115:134:treatment","Patients must be willing to undergo a pre-treatment biopsy, either core needle biopsy or equivalent amount or via excisional specimen"
6063,NCT01928576,"23:76:treatment,69:76:treatment,78:91:treatment,99:116:treatment,145:163:cancer,,223:259:treatment",Patients who received adjuvant or neoadjuvant platinum-doublet chemotherapy (after surgery and/or radiation therapy) and developed recurrent or metastatic disease within 6 months of completing therapy are eligible and the adjuvant or neoadjuvant chemotherapy will count as a line of therapy as above
6064,NCT01928576,"1:29:treatment,31:41:treatment,43:53:treatment,55:65:treatment,67:97:treatment,195:224:treatment,228:250:treatment","Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody therapies, any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, DNA methyltransferase therapy or HDAC inhibitor therapy"
6065,NCT01928576,"24:49:treatment,69:97:treatment,90:97:treatment,104:137:treatment","subject who received a tyrosine kinase inhibitor after failure of a prior platinum-based therapy, that tyrosine kinase inhibitor therapy would count as an additional line of therapy"
6066,NCT01925573,"23:37:treatment,45:53:treatment,57:68:treatment","Patients on full-dose anticoagulants (e.g., warfarin or LMW heparin)"
6067,NCT01925573,"12:31:chronic_disease,35:62:chronic_disease,64:70:chronic_disease,72:75:chronic_disease,89:116:chronic_disease","history of hypertensive crisis or hypertensive encephalopathy, stroke, TIA, symptomatic peripheral vascular disease"
6068,NCT01925378,"23:40:chronic_disease,65:68:chronic_disease,108:123:cancer",Patients with a known immunocompromised condition or a positive HIV test. Patients with a prior history of cervical cancer
6069,NCT01925131,"63:66:cancer,91:100:treatment,,178:204:treatment",Patients known to have Philadelphia chromosome positive (Ph+) ALL must have either failed treatment or been intolerant to treatment with at least two second or third generation tyrosine kinase inhibitors
6070,NCT01925131,"37:49:treatment,51:73:treatment,88:101:treatment,","Patients must not have received any chemotherapy, investigational agents, or undergone major surgery within 14 days prior to registration"
6071,NCT01925131,"111:118:treatment,,,210:222:treatment,224:246:treatment,250:274:treatment","in addition to routine contraceptive methods, effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation"
6072,NCT01920737,"24:39:chronic_disease,90:109:chronic_disease,114:131:chronic_disease","Clinically significant cardiac disease (NY Heart Association Class III or IV), including chronic arrhythmias, or pulmonary disease"
6073,NCT01920737,"15:49:chronic_disease,53:56:cancer,86:107:treatment,113:130:treatment,138:162:treatment",Patients with central nervous system involvement by ALL are eligible and may receive concomitant treatment with radiation therapy and/or intrathecal chemotherapy in accordance with standard medical practice
6074,NCT01920061,"15:19:cancer,44:64:treatment,72:82:cancer",Patients with TNBC with no prior cytotoxic chemotherapy therapy in the metastatic setting
6075,NCT01919619,"1:12:chronic_disease,8:12:chronic_disease,,49:59:treatment",Active GVHD or recent GVHD and still on > 10 mg prednisone (or equivalent)
6076,NCT01918683,"1:32:treatment,34:37:treatment,42:58:treatment","Prior TACE to the target lesion, RFA, or liver transplant"
6077,NCT01918644,"23:32:cancer,34:41:cancer,45:60:cancer","Patients with primary ampullary, biliary or duodenal cancer"
6078,NCT01913106,"15:31:chronic_disease,33:38:chronic_disease,40:49:chronic_disease,54:71:chronic_disease,82:89:treatment","Patients with acute infections (viral, bacterial, or fungal infections requiring therapy)"
6079,NCT01912612,"18:22:treatment,24:28:treatment,33:44:treatment,56:66:treatment,72:81:treatment,85:110:chronic_disease,114:142:chronic_disease,241:252:treatment","Currently taking SSRI, SNRI, or TCA regimen (including Wellbutrin) for treatment of major depressive disorder or generalized anxiety disorder (without approval and involvement of the patient's treating psychiatrist to taper cases off these medications prior to study treatment)"
6080,NCT01910818,"8:22:chronic_disease,26:32:chronic_disease,,125:140:chronic_disease",Active Herpes Simplex or Zoster at the time of treatment or having experienced more than three episodes of Herpes Simplex / Zoster eruption within a year of study enrollment
6081,NCT01910818,"6:32:chronic_disease,24:32:chronic_disease,37:51:chronic_disease,",with radiation-induced fibrosis and depigmentation. The fibrosis must have occurred at least 1 year prior to the date of enrollment
6082,NCT01908777,"19:22:treatment,47:94:chronic_disease,96:115:chronic_disease,120:131:chronic_disease,,","Other significant ECG abnormalities including 2nd degree atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min)"
6083,NCT01906385,"37:109:treatment,122:145:treatment,151:162:treatment,202:224:treatment","Progression following both standard combined modality treatment with radiation and temozolomide chemotherapy, as well as anti-angiogenic therapy (ie, bevacizumab; patients not eligible for or refusing antiangiogenic therapy will also be allowed)"
6084,NCT01905709,"8:30:chronic_disease,36:51:chronic_disease,71:87:treatment,102:106:treatment","Severe C. difficile infection with toxic megacolon, not responding to standard therapy or the use of IVIg"
6085,NCT01904136,"1:31:cancer,110:119:treatment,,136:162:treatment","Chronic myeloid leukemia (CML): a. failed to achieve cytogenetic remission or have cytogenetic relapse after treatment with at least 2 tyrosine kinase inhibitors, or b. accelerated phase or blast phase at any time"
6086,NCT01903330,"1:17:chronic_disease,28:37:treatment,45:70:chronic_disease,79:107:chronic_disease,116:121:chronic_disease,134:168:treatment","Active infection requiring treatment, known immunosuppressive disease, active systemic autoimmune diseases such as lupus, receipt of systemic immunosuppressive therapy"
6087,NCT01903330,"86:112:cancer,114:137:cancer,142:153:cancer",Patients must have histologically confirmed diagnosis of a recurrent/progressive WHO grade IV malignant gliomas (glioblastoma multiforme and gliosarcoma)
6088,NCT01903330,"19:31:treatment,35:44:treatment,,101:109:chronic_disease","Resolution of all chemotherapy or radiation-related toxicities ? CTCAE Grade 1 severity, except for alopecia and hematologic toxicity"
6089,NCT01902810,"1:11:cancer,33:42:treatment,57:73:treatment,",Malignancy currently undergoing treatment or history of cancer treatment within 5 years
6090,NCT01900301,"57:72:treatment,74:84:treatment,86:106:treatment,108:118:treatment,120:129:treatment,131:139:treatment,141:155:treatment,157:168:treatment,170:179:treatment,181:192:treatment,194:203:treatment,205:214:treatment,216:225:treatment,227:242:treatment,244:251:treatment,253:265:treatment,267:283:treatment,285:292:treatment,294:306:treatment,308:317:treatment,319:333:treatment,335:343:treatment,345:355:treatment,357:372:treatment,374:386:treatment,388:402:treatment,404:419:treatment,421:430:treatment,432:452:treatment,454:464:treatment,466:491:treatment,493:505:treatment,507:519:treatment,525:534:treatment","Other drugs that will be reasons for exclusion include: antimuscarinics, nifedipine, parasympathomimetics, amantadine, amoxapine, antacids, antidiarrheals, anxiolytics, hypnotics, atomexetine, bupropion, cisapride, clozapine, cyclobenzaprine, digoxin, disopyramide, dronabinol (THC), ethanol, maprotilline, memantine, metoclopramide, nabilone, olanzapine, opiate agonists, orphenadrine, phenothiazines, potassium salts, quinidine, sedating H1-blockers, topiramate, tricyclic antidepressants, erthyromycin, ketoconazole, and tegaserod"
6091,NCT01898793,"16:31:treatment,46:76:treatment,,152:165:treatment",Able to be off corticosteroids and any other immune suppressive medications beginning on Day -3 and continuing until 30 days after the infusion of the CIML NK cells
6092,NCT01898793,",25:45:treatment,79:82:cancer,99:102:cancer",More than one course of salvage chemotherapy for primary induction failure or AML relapsing after CR1 (phase II only)
6093,NCT01898793,"4:34:cancer,30:33:cancer,,,64:83:chronic_disease,116:144:treatment,,298:309:treatment,328:338:treatment,498:518:treatment,523:549:treatment","OR Myelodysplastic syndrome (MDS) with excess blasts (>5%) and progressive disease at any time after initiation of DNA hypomethylator treatment during the past 2 years, OR failure to achieve complete or partial response or hematological improvement (see section 12.4) after at least six cycles of azacytidine or four cycles of decitabine administered during the past 2 years, OR intolerance to azacytidine or decitabine. MDS patients with isolated 5q- abnormalities that meet these criteria after lenalidomide therapy and DNA hypomethylator therapy are also eligible"
6094,NCT01897259,"39:48:treatment,87:102:treatment,113:129:treatment,","pain over the lateral epicondyle (via palpation over the lateral epicondyle, resisted wrist extension, resisted finger extension of the middle finger) for less than six-months duration prior to enrollment"
6095,NCT01896999,",,,74:87:chronic_disease,102:108:chronic_disease,130:153:chronic_disease,158:178:treatment,197:205:chronic_disease","Patients must not have New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia"
6096,NCT01896999,"58:82:treatment,119:134:treatment,229:248:treatment",for the purposes of this study monoclonal antibodies and antibody drug conjugates are not considered to be activating immunotherapies and there are no additional time restrictions on prior exposure to these agents (except prior brentuximab vedotin)
6097,NCT01896921,"1:17:treatment,27:39:treatment,41:53:treatment,55:69:treatment,71:81:treatment,87:100:treatment","CYP3A inhibitors (such as ketoconazole, itraconazole, clarithromycin, nefazodone, and telithromycin)"
6098,NCT01895881,",34:64:chronic_disease,78:98:treatment,100:130:treatment,134:165:treatment","At least one documented saccular intracranial cerebral aneurysm detected via catheter angiography, magnetic resonance angiography or computed tomography angiography"
6099,NCT01895777,"1:31:treatment,56:63:treatment,113:131:chronic_disease",unwarranted radiation exposure as a result of a repeat CT scan at day 84 for a patient with an isolated case of pulmonary embolism evaluated at baseline solely by a CT scan
6100,NCT01894061,"34:44:cancer,71:76:cancer,80:115:cancer,119:161:cancer,,,196:202:cancer,232:250:treatment","Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix and breast, adequately treated stage I or II cancer from which the patient is in complete remission"
6101,NCT01893554,"14:24:treatment,14:34:treatment,,84:104:treatment",Has received salicylate (aspirin) or salicylate-containing products within 28 days prior to inoculation
6102,NCT01893554,"1:5:chronic_disease,9:22:chronic_disease,56:79:chronic_disease","Lung or heart disease, including any wheezing event or reactive airway disease"
6103,NCT01893554,"20:43:treatment,47:67:treatment,,100:127:treatment",Receipt of another investigational vaccine or investigational drug 28 days prior to receiving this investigational RSV vaccine
6104,NCT01891812,",,132:158:treatment,165:174:treatment,176:184:treatment,189:195:treatment","Present to the pediatric emergency department with VOC and whose pain scores remain greater than or equal to 7/10 on the NRS after initial standard treatment (i.e. IV fluids, morphine and NSAIDs)"
6105,NCT01890395,"29:48:treatment,66:82:treatment,98:102:treatment,104:114:treatment,116:122:treatment,132:158:treatment,160:187:treatment,196:212:treatment,214:230:treatment,244:263:treatment,323:352:chronic_disease","Patients @ USAMC undergoing surgical operations expected to have microcirculatory changes, i.e., CABG, open heart, aortic or other revascularizing operations, general surgical operations such as colon resections, bowel resections or any other surgical procedures in which the subject could be expected to or might develop multiple system organ failure"
6106,NCT01884740,"10:19:treatment,25:32:treatment,37:46:treatment",Previous treatment with Avastin and Cetuximab
6107,NCT01883258,"25:48:chronic_disease,50:71:chronic_disease,73:88:chronic_disease,101:131:treatment,135:146:treatment,148:172:chronic_disease,177:187:chronic_disease","History of any relevant cardiovascular diseases (myocardial infarction, angina pectoris, history of coronary artery bypass surgery or angioplasty, congestive heart failure, or arrhythmia)"
6108,NCT01880567,"17:20:chronic_disease,28:31:chronic_disease,64:75:chronic_disease",Newly diagnosed MCL: Known HIV infection; patients with active hepatitis B infection
6109,NCT01880567,"17:20:chronic_disease,28:37:treatment,43:52:treatment",Newly diagnosed MCL: Prior treatment with ibrutinib
6110,NCT01880567,"21:24:cancer,26:48:chronic_disease,155:173:chronic_disease,175:213:chronic_disease,229:255:chronic_disease","Relapsed/refractory MCL: Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction"
6111,NCT01880567,"21:24:cancer,35:72:treatment,74:82:treatment,84:95:treatment,97:134:treatment","Relapsed/refractory MCL: Requires treatment with strong cytochrome P450, family 3, subfamily A, polypeptide 4/5 (CYP3A4/5) inhibitors"
6112,NCT01880567,"14:26:chronic_disease,41:58:chronic_disease,79:102:chronic_disease,104:120:chronic_disease,122:139:chronic_disease,144:163:chronic_disease","uncontrolled hypertension, uncontrolled diabetes mellitus, active/symptomatic coronary artery disease, active infection, active hemorrhage, or psychiatric illness"
6113,NCT01878617,"13:25:treatment,18:25:treatment,27:39:treatment,49:60:cancer,89:111:treatment,116:123:treatment","No previous radiotherapy, chemotherapy or other brain tumor directed therapy other than corticosteroid therapy and surgery"
6114,NCT01877382,"59:70:cancer,74:82:cancer,126:144:treatment",Has a histologically or cytologically documented advanced solid tumor or lymphoma that has relapsed from or is refractory to standard treatment
6115,NCT01876511,"30:48:chronic_disease,49:75:chronic_disease,88:106:chronic_disease,111:126:chronic_disease,129:149:chronic_disease,172:181:chronic_disease,183:194:chronic_disease,197:231:chronic_disease,243:253:chronic_disease,255:303:chronic_disease","Patients with history of any autoimmune disease:inflammatory bowel disease, (including ulcerative colitis and Crohn's Disease), rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus (SLE) autoimmune vasculitis, central nervous system (CNS) or motor neuropathy considered to be of autoimmune origin"
6116,NCT01876511,"31:50:treatment,52:72:treatment,74:84:treatment,105:127:treatment,129:153:treatment,161:186:treatment,205:229:treatment,","received any of the following concomitant therapy: Interleukin-2 (IL-2), interferon, or other non-study immunotherapy regimens, immunosuppressive agents, other investigational therapies or chronic use of systemic corticosteroids within one week prior to first dose of study drug"
6117,NCT01872975,"44:50:cancer,67:89:cancer,105:109:cancer,123:140:treatment","Any prior history, not including the index cancer, of ipsilateral invasive breast cancer or ipsilateral DCIS treated with radiation therapy"
6118,NCT01872975,"1:3:cancer,7:17:cancer,44:51:treatment",N2 or N3 disease detected clinically or by imaging
6119,NCT01872975,"54:74:cancer,75:106:treatment,223:236:cancer",Patients must have had HER2 testing performed on the primary breast tumor before neoadjuvant chemotherapy according to the current ASCO/CAP guideline recommendations for human epidermal growth factor receptor 2 testing in Breast Cancer (http://www.asco.org)
6120,NCT01871766,"12:21:cancer,23:31:cancer,33:45:cancer,47:55:cancer,57:73:cancer,78:92:cancer,98:116:cancer","High-risk: Embryonal, botryoid, spindle cell, alveolar, undifferentiated, or anaplastic RMS with metastatic disease at diagnosis (stage 4)"
6121,NCT01871727,"8:18:cancer,31:35:cancer,58:102:cancer,108:125:cancer,108:139:cancer,","Active malignancy (except for CTCL, definitively treated basal or squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix) within the past 24 months"
6122,NCT01871727,"7:51:chronic_disease,66:77:chronic_disease,81:102:chronic_disease",Known human immunodeficiency virus (HIV) infection; known active hepatitis B or hepatitis C infection
6123,NCT01871454,"71:81:cancer,87:99:treatment,101:122:treatment","A reasonable attempt should be made to make a pathologic diagnosis of malignancy (ie. bronchoscopy, CT guided lung biopsy)"
6124,NCT01869114,"33:44:treatment,48:58:treatment,96:99:chronic_disease",Patient may have previously had azacitidine or decitabine will be eligible to enroll on Arm A (MDS)
6125,NCT01869114,"1:11:treatment,18:25:treatment,39:55:treatment,105:114:treatment",Tacrolimus (e.g. Prograf) - May cause liver transplant rejection or serious side effects in patients on sirolimus
6126,NCT01865162,"44:72:treatment,74:83:treatment,88:113:treatment","Documented recurrence or progression after surgical resection/debulking, radiation and temozolamide chemotherapy"
6127,NCT01864265,"34:44:treatment,48:62:treatment,66:76:treatment,105:114:treatment,118:120:chronic_disease",Patients treated before with any biological or small molecule or medication under investigation for the treatment of RA
6128,NCT01861106,"25:35:treatment,79:84:cancer,106:121:treatment",The risk/benefit of the transplant and the possibility of transmitting viable tumor cells at the time of transplantation will be discussed with the patient
6129,NCT01859819,"16:32:cancer,,49:57:cancer,58:66:cancer",ewly diagnosed mature B-lineage (CD20 positive) Leukemia/Lymphoma
6130,NCT01858168,"15:36:treatment,38:50:treatment,,133:142:treatment","Receiving any systemic chemotherapy, radiotherapy (except for palliative reasons), within 2 weeks from the last dose prior to study treatment"
6131,NCT01851369,"34:46:treatment,48:65:treatment,70:86:treatment,,,,201:213:treatment,217:228:treatment,,317:327:treatment,,402:430:treatment,522:552:treatment","Patients must have completed any chemotherapy, radiation therapy, or biologic therapy greater than or equal to 4 weeks (or 5 half-lives, whichever is shorter) prior to entering the study (6 weeks for nitrosoureas or mitomycin C). Patients must be greater than or equal to 2 weeks since any prior administration of a study drug in a Phase 0 or equivalent study and greater than or equal to 1 week from palliative radiation therapy. Patients must have recovered to eligibility levels from prior toxicity or adverse events. Treatment with bisphosphonates is permitted"
6132,NCT01851369,"36:61:cancer,,89:96:treatment,98:103:cancer,143:172:cancer,","Phase II: histologically confirmed colorectal adenocarcinoma post at least two lines of therapy, NSCLC post at least two lines of therapy, or granulosa cell ovarian cancer post at least one line of therapy. Patients must have measurable disease"
6133,NCT01850758,"92:114:treatment,121:127:treatment,149:165:treatment,,","Pain, swelling, or functional disability in the affected knee with activity, having failed conservative treatment (e.g. NSAIDs, physician initiated physical therapy) for at least 3 months or unable to return to normal day to day activities by 6 weeks"
6134,NCT01850355,"23:48:chronic_disease,97:114:chronic_disease,116:135:chronic_disease,140:147:chronic_disease","Fulfills diagnosis of autism spectrum disorders by meeting DSM-IV-TR PDD diagnostic criteria of autistic disorder, Asperger's disorder, or PDD-NOS"
6135,NCT01849146,"1:35:chronic_disease,57:91:treatment,136:164:treatment",Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with AZD1775 (MK-1775)
6136,NCT01849146,"34:46:cancer,90:107:treatment,112:124:treatment",have prior histologically proven glioblastoma that is progressive or recurrent following radiation therapy +/- chemotherapy
6137,NCT01849146,"13:18:cancer,87:96:treatment,113:125:cancer",must have a tumor tissue form indicating availability of archived tissue from initial resection at diagnosis of glioblastoma completed and signed by a pathologist
6138,NCT01842399,"28:41:treatment,43:50:treatment,54:60:treatment,110:123:treatment","Taking supplements such as Ginkgo biloba, Ginseng or Ginger due to their increased risk of bleeding with the muscle biopsy"
6139,NCT01841333,"28:32:treatment,61:85:cancer,101:115:treatment","High risk of relapse after HSCT, defined as the presence of minimal residual disease as measured by flow cytometry in the absence of evidence of morphologic disease on a bone marrow biopsy prior to HSCT"
6140,NCT01835626,"1:4:chronic_disease,38:60:treatment,125:135:treatment","HIV-positive patients on combination antiretroviral therapy, because of the potential for pharmacokinetic interactions with vismodegib"
6141,NCT01835626,"1:24:treatment,7:16:treatment,123:142:treatment","Prior radiation therapy is acceptable but there cannot be major overlap of the previously irradiated tissues with the new radiation treatment volumes anticipated to be delivered for the purposes of this protocol, in such a way that curative intent with radiation cannot be met"
6142,NCT01829958,"18:27:treatment,52:58:treatment,60:67:treatment,71:77:treatment,128:146:treatment","Intended initial treatment to include ?2 cycles of R-CHOP, R-EPOCH or R-CEPP using standard doses and schedule.(68, 69) R-CHOP chemoimmunotherapy may be given every 14 days or every 21 days"
6143,NCT01829360,"50:53:chronic_disease,61:67:chronic_disease,69:93:chronic_disease,95:111:chronic_disease","other disorder that would exclude a diagnosis of SLI (e.g., autism, developmental disability, seizure disorder)"
6144,NCT01827384,"15:30:cancer,34:47:chronic_disease,51:87:treatment,89:98:treatment","Patients with bone metastases or hypercalcemia on intravenous bisphosphonate treatment, denosumab, or similar agents"
6145,NCT01827384,"41:53:cancer,,114:130:treatment,153:162:treatment",Patients with histologically documented solid tumors whose disease has progressed following at least one line of standard therapy and/or no standard of treatment exists that has been shown to prolong survival
6146,NCT01827384,"79:98:chronic_disease,182:206:chronic_disease,208:232:chronic_disease,234:252:chronic_disease,254:275:chronic_disease,,298:324:chronic_disease,329:335:chronic_disease,371:387:chronic_disease,389:402:chronic_disease,411:420:chronic_disease,422:449:chronic_disease,466:483:chronic_disease","Patients with uncontrolled intercurrent illness including, but not limited to psychiatric illness/social situations that would limit compliance with study requirements, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, myocardial infarction in the past 6 months, invasive fungal infections, or active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease, and active and chronic hepatitis (i.e., quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA)"
6147,NCT01824836,"42:55:treatment,60:81:treatment,86:99:cancer",Patients must have completed recommended local therapy and adjuvant chemotherapy for breast cancer
6148,NCT01822522,"1:17:chronic_disease,28:46:treatment,37:46:treatment,",Active infection requiring systemic treatment within 28 days before the first dose of study treatment
6149,NCT01822522,"16:28:treatment,151:169:treatment,205:216:treatment,,,","The effects of cabozantinib on the developing human fetus are unknown; for this reason and because tyrosine kinase inhibitors agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation"
6150,NCT01822522,"10:23:treatment,29:71:treatment,75:113:treatment,142:158:cancer",baseline brain imaging with contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) scans for participants with known brain metastases is required to confirm eligibility
6151,NCT01822522,"15:45:treatment,49:68:treatment,70:79:treatment,81:90:treatment,92:111:treatment,113:123:treatment,125:135:treatment,179:189:treatment,239:273:treatment,325:342:treatment","use of any of anti-retrovirals (delavirdine) or protease inhibitors (ritonavir, indinavir, lopinavir/ritonavir, saquinavir, nelfinavir) is permitted; specifically, ritonavir and cobicistat is permitted for participants considered for the CYP3A4-inhibitor based ART regimen arm (Stratum A) of the trial; because the lists of CYP3A4 inhibitors are constantly changing, it is important to regularly consult a frequently-updated list; medical reference texts such as the physicians' desk reference may also provide this information; as part of the enrollment/informed consent procedures"
6152,NCT01817751,"24:39:chronic_disease,57:76:chronic_disease,86:105:chronic_disease,116:140:chronic_disease,,","Clinically significant cardiac disease, including major cardiac dysfunction, such as uncontrolled angina, clinical congestive heart failure with New York Heart Association (NYHA) class III or higher"
6153,NCT01817751,"61:79:treatment,102:115:treatment,119:128:treatment",efforts may be made by the treating physician to change the antiepileptic drug from another agent to valproic acid or non-EIAED prior to excluding the patient from study
6154,NCT01815359,"21:32:allergy_name,34:44:allergy_name,49:58:allergy_name","Patients with known floxuridine, leucovorin ,or mitomycin allergy"
6155,NCT01811368,"88:115:cancer,191:202:cancer,204:224:cancer,226:252:cancer","Histologically or cytologically confirmed relapsed cluster of differentiation (CD)20+ non-Hodgkin's lymphoma (NHL) (included in this category are follicular grade I, II, III, marginal zone, mantle cell, diffuse large B cell, small lymphocytic lymphoma)"
6156,NCT01807897,"18:42:treatment,18:49:treatment,112:138:treatment,143:170:treatment",Current use of a positive airway pressure device (including continuous or bi-level positive airway pressure or adaptive servo-ventilation) or supplemental oxygen therapy
6157,NCT01807091,"48:59:chronic_disease,63:78:chronic_disease,82:106:chronic_disease",no ongoing cardiac issues such as uncontrolled arrhythmias or unstable angina or congestive heart failure
6158,NCT01804634,"15:37:treatment,43:55:treatment,59:80:treatment",Refractory to induction chemotherapy with COG ANBL0532 or standard chemotherapy
6159,NCT01804465,"7:24:treatment,142:151:treatment,153:160:treatment","If no prior orchiectomy has been performed, patients must remain on luteinizing hormone-releasing hormone (LHRH) agonist or antagonist (e.g. degarelix) therapy"
6160,NCT01802346,"26:39:cancer,50:70:treatment,72:83:treatment,89:105:treatment,178:201:cancer",Histologically confirmed breast cancer for which chemotherapy with AC (doxorubicin plus cyclophosphamide) is being utilized in the neoadjuvant or adjuvant setting OR metastatic prostate adenocarcinoma for which Docetaxel will be administered
6161,NCT01801072,"63:69:treatment,71:79:treatment,81:89:treatment,91:99:treatment,101:108:treatment","Currently prescribed medication with anti-epileptic activity (keppra, dilantin, tegretol, lamictal, topamax, etc.)"
6162,NCT01799538,"47:68:cancer,70:87:cancer,89:109:chronic_disease","evidence of lung and other organ involvement (renal angiomyolipomas, chylous effusions, lymphangioleiomyomas)"
6163,NCT01795573,"1:4:chronic_disease,17:22:treatment,26:82:treatment,75:81:treatment","HIV negative by ELISA or reverse transcription polymerase chain reaction (RT-PCR) [if ELISA is positive and RT-PCR is negative, the ELISA is considered false positive]"
6164,NCT01795573,"1:4:cancer,91:104:treatment,112:123:treatment",MDS: Low/intermediate-1 IPSS risk category patients are eligible only if they have failed prior therapy or are transfusion-dependent
6165,NCT01795313,"24:33:treatment,,80:90:treatment,97:106:treatment,165:173:treatment,175:183:treatment,185:194:treatment,197:209:treatment,216:226:treatment","must be off concurrent treatment or medications for at least 1 week including: Interferon (e.g. Intron-A®), allergy desensitization injetions, growth factors (e.g. Pricrut®, Aranesp®, Neulasta®), interleukins (e.g. Proleukin®), and any investigational therapeutic medication"
6166,NCT01794793,"109:120:treatment,124:143:treatment,149:166:chronic_disease,170:180:chronic_disease,294:303:treatment","Patient is currently participating in a Novartis-sponsored study receiving pasireotide (LAR and/or s.c.) on monotherapy or combination therapy (for Cushing's Disease or Acromegaly), and has fulfilled all required assessments in the parent study and patients that are benefiting from the study treatment have no other alternatives"
6167,NCT01794559,"17:28:treatment,,63:76:treatment,94:97:treatment,",ble to stop all medications (wash out) for 5 half-lves of all medication(s) which affect the EEG. Outpatient subjects are eligible if they can be washed out of their medications in 14 days or less
6168,NCT01793519,"14:22:treatment,24:33:treatment,38:49:treatment,","Treated with anakinra, abatacept, or tocilizumab in the last 6 months"
6169,NCT01791543,"8:32:treatment,70:80:chronic_disease,93:97:chronic_disease",Failed prior VT or PVC ablation due to spontaneous recurrence of the arrhythmia or frequent PVCs
6170,NCT01787682,"22:40:chronic_disease,51:58:chronic_disease,62:76:chronic_disease",History of untreated metabolic diseases including hepatic or renal disorder
6171,NCT01787487,"22:32:cancer,134:144:cancer,146:181:cancer,186:227:cancer","Patients with active malignancy of other type than required for this study, are not eligible with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast"
6172,NCT01787409,"15:30:cancer,83:112:cancer,117:133:cancer,137:158:cancer","patients with B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma or post-transplant DLBCL are also eligible"
6173,NCT01781611,"21:28:allergy_name,32:44:allergy_name,84:95:chronic_disease,,,,,","Contraindication to aspirin or dipyridamole, including history of recent or severe GI bleeding, hemoglobin <9 mg/dL, platelet count of <30,000 /mm3 or unstable platelet coun"
6174,NCT01774019,"23:40:cancer,49:90:cancer,101:122:cancer","Diagnosis of probable pancreatic cancer, distal common bile duct (CBD) cholangiocarcinoma and other periampullary cancers (histology not required)"
6175,NCT01773694,"25:43:treatment,47:53:cancer,58:75:cancer",patients undergoing any surgical treatment of benign and malignant lesions by any physician in the Dermatology department
6176,NCT01766297,"23:32:treatment,,52:59:treatment,,90:102:treatment",Must be able to start treatment within 12 weeks of surgery or 8 weeks of finalization of chemotherapy
6177,NCT01760863,"17:50:chronic_disease,92:115:treatment,97:115:treatment","Patients with a fungal prosthetic joint infection, unable to tolerate or refuse to undergo oral antibiotic therapy, unable to follow-up at the specified intervals, allergic to the therapy of preference, or have an organism that is not amenable to oral antibiotic therapy"
6178,NCT01760655,"1:10:cancer,14:36:cancer,,55:64:treatment",Hodgkin's or Non-Hodgkin's lymphoma in 2nd or greater remission or with persistent disease
6179,NCT01760655,"1:14:cancer,16:29:treatment,33:55:cancer",Secondary AML (prior therapy or hematologic malignancy)
6180,NCT01758042,"21:28:treatment,83:90:allergy_name,94:113:allergy_name","Contraindication to therapy with any one of the proposed agents (e.g., history of allergy to rabbit serum in ATG)"
6181,NCT01757418,"11:17:chronic_disease,38:58:treatment,62:88:treatment",Increased stroke risk as assessed by transcranial Doppler or magnetic resonance imaging (all subjects undergo testing)
6182,NCT01754857,"28:39:chronic_disease,96:105:allergy_name,115:142:allergy_name",Severe or life-threatening anaphylaxis or hypersensitivity reaction when previously exposed to rituximab or other monoclonal antibody therapy
6183,NCT01750567,",63:74:treatment,76:88:treatment,90:97:treatment,99:106:treatment,108:120:treatment,125:146:treatment","Patients who relapse after receiving a one or more courses of fludarabine, bendamustine, cytoxan, rituxan, chlorambucil, or campath based therapy"
6184,NCT01742338,"36:43:chronic_disease,45:61:chronic_disease,65:70:chronic_disease","Alternative diagnosis for cause of dyspnea, increased sputum or cough"
6185,NCT01742299,"74:82:treatment,131:141:treatment,173:192:treatment",Patient has participated in a Novartis sponsored combination trial where imatinib was dispensed in combination with another study medication and patient is still receiving combination therapy
6186,NCT01737502,"1:14:treatment,22:32:treatment,35:46:treatment,63:79:chronic_disease,,114:127:treatment,,177:199:treatment,218:240:treatment","Major surgery (i.e., laparotomy), open biopsy, or significant traumatic injury =< 4 weeks prior to registration; minor surgery =< 2 weeks prior to registration; insertion of a vascular access device is not considered major or minor surgery in this regard"
6187,NCT01734512,"44:68:chronic_disease,116:126:treatment,134:152:chronic_disease,167:173:chronic_disease,175:183:chronic_disease,185:193:chronic_disease,195:217:chronic_disease,221:242:treatment","Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection"
6188,NCT01730937,",14:32:cancer,36:61:cancer,,188:229:treatment,233:265:treatment,284:293:chronic_disease,297:321:chronic_disease","At least one solid liver lesion or vascular tumor thrombosis (involving portal vein, inferior vena cava [IVC] and/or hepatic vein) > 1 cm with arterial enhancement and delayed washout on multi-phasic computerized tomography (CT) or magnetic resonance imaging (MRI) in the setting of cirrhosis or chronic hepatitis B or C without cirrhosis"
6189,NCT01730937,"13:28:treatment,57:62:cancer,222:224:treatment,228:231:treatment,","Measureable hepatic disease and/or presence of vascular tumor thrombosis (involving portal vein, IVC and/or hepatic vein) which may not be measureable as per Response Evaluation Criteria in Solid Tumors (RECIST) on liver CT or MRI, within 28 days of registration"
6190,NCT01730937,"1:19:treatment,24:27:cancer,43:49:cancer",prior chemotherapy for HCC or a different cancer
6191,NCT01730118,"24:43:chronic_disease,,95:101:chronic_disease,103:127:chronic_disease,129:150:chronic_disease,152:163:chronic_disease,197:206:treatment,229:241:treatment","Clinically significant cardiac dysfunction defined as a history of >= NYHA Class II symptoms, angina, congestive heart failure, myocardial infarction, arrhythmias or cardiac dysfunction requiring treatment or discontinuation of chemotherapy"
6192,NCT01730118,"10:18:treatment,23:40:chronic_disease,78:95:treatment,105:114:chronic_disease",Negative serology for hepatitis B and C unless the result is consistent with prior vaccination or prior infection with full recovery
6193,NCT01730118,"15:22:cancer,24:32:cancer,34:39:cancer,41:48:cancer,49:74:cancer,76:95:cancer,97:107:cancer,109:116:cancer,118:139:cancer,144:170:cancer,180:192:cancer,,,","Patients with ovarian, cervical, colon, gastric/gastroesophageal junction, non-small cell lung, renal cell, bladder, malignant soft tissue and bone tumor prostate cancer or other solid tumors that is known to be HER2 1+, 2+ or 3+ by IHC OR have a Vysis FISH result greater than or equal to 1.8"
6194,NCT01730118,"1:6:cancer,7:16:cancer,18:21:cancer,23:26:cancer,28:31:cancer,76:81:cancer","Tumor stage T3a, T3b, T4a, T4b and any node positive disease regardless of tumor stage"
6195,NCT01720836,"1:3:cancer,5:9:cancer,12:14:cancer,17:21:cancer,","IB (T2NO), II & IIIA (N2 negative)"
6196,NCT01720147,"20:32:treatment,36:51:treatment,88:97:treatment",Patients receiving cyclosporine or digoxin therapy or are unable to discontinue either treatment due to medical reasons
6197,NCT01715220,",,,,,135:144:treatment,150:174:treatment,178:185:treatment",Patients with right upper quadrant abdominal pain of less than 24 hours' duration between ages 18 and 60 years of age will be offered treatment with sublingual nitroglycerin or placebo
6198,NCT01712308,"13:37:chronic_disease,39:54:chronic_disease,68:86:chronic_disease","Symptomatic congestive heart failure, unstable angina, or unstable cardiac arrhythmia"
6199,NCT01703949,"19:34:cancer,35:46:treatment,47:54:treatment,,",Resolution of all non-hematologic brentuximab vedotin-related adverse events (AEs) to < grade 2
6200,NCT01703117,"12:25:chronic_disease,36:55:chronic_disease,57:76:chronic_disease,78:86:chronic_disease,99:105:chronic_disease,130:145:chronic_disease,207:223:chronic_disease,267:285:chronic_disease,287:305:chronic_disease,307:336:chronic_disease,338:372:cancer,374:394:chronic_disease,396:413:chronic_disease,431:452:chronic_disease","History of brain disease including Parkinson's Disease, severe brain trauma, seizures, history of stroke, clinically significant lacunar infarct in a region important for cognition or multiple lacunes or a cortical infarct or focal lesions of clinical significance, multiple sclerosis, mental retardation, normal pressure hydrocephalus, central nervous system (CNS) tumor, Huntington's disease, subdural hematoma or other serious neurological disorder"
6201,NCT01701986,"1:19:chronic_disease,44:85:chronic_disease,92:99:chronic_disease,101:124:chronic_disease,,,","Active hepatitis B, either active carrier (hepatitis B virus surface antigen [HBsAg] +) or viremic (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] >= 10,000 copies/mL, or >= 2,000 IU/mL)"
6202,NCT01697865,"1:21:chronic_disease,51:58:treatment,60:78:chronic_disease","Chronic rotator cuff tear with severe retraction, atrophy, fatty infiltration"
6203,NCT01697371,"18:31:cancer,48:58:cancer,107:126:cancer",New radiographic liver lesions consistent with metastases in patients with known pathologically confirmed non-lymphoma cancer
6204,NCT01697293,"10:22:treatment,24:35:treatment,51:70:treatment,78:88:treatment,92:102:treatment,106:125:treatment,136:146:cancer","No prior chemotherapy, irradiation, or definitive therapeutic surgery (e.g., mastectomy or lumpectomy or axillary dissection) for this malignancy"
6205,NCT01697293,"1:26:cancer,28:66:cancer,71:100:cancer,108:122:cancer,131:158:treatment,172:189:cancer","lobular carcinoma in situ, contralateral ductal carcinoma in situ, or contralateral invasive ductal and/or lobular cancer (and no prior adjuvant chemotherapy for previous breast malignancy)"
6206,NCT01697293,"13:37:chronic_disease,48:63:chronic_disease,65:83:chronic_disease,88:107:chronic_disease","symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
6207,NCT01696734,"1:9:chronic_disease,11:19:chronic_disease,24:47:chronic_disease","valvular, ischemic, or pulmonary heart disease"
6208,NCT01688388,"1:33:chronic_disease,39:64:chronic_disease,66:91:chronic_disease,93:107:chronic_disease","Mixed connective tissue diseases e.g. rheumatoid poly arthritis, thromboangitis obliterans, systemic lupus"
6209,NCT01684904,"1:16:treatment,21:38:cancer,42:66:treatment",Prior radiation for esophageal cancer or prior chest radiotherapy
6210,NCT01684397,"1:21:cancer,25:48:cancer,89:98:treatment","basal cell carcinoma or squamous cell carcinoma, of skin which were completely cured by resection"
6211,NCT01681589,"12:23:treatment,25:41:chronic_disease,46:53:chronic_disease,82:85:chronic_disease","History of craniectomy, active infection, or seizure activity beyond 1 week post-TBI"
6212,NCT01681264,"24:46:chronic_disease,53:63:chronic_disease,,,98:121:chronic_disease,123:130:chronic_disease,134:150:chronic_disease,152:165:chronic_disease,167:186:chronic_disease,202:209:chronic_disease","Has known pre-existing cardiovascular disease (i.e. arrhythmia - prolonged QT interval > 440ms), cerebrovascular disease, hepatic or renal impairment, CNS condition, metabolic condition, or history of syncope"
6213,NCT01681264,"30:37:treatment,39:52:treatment,54:63:treatment,68:88:treatment","Tests positive for non-study opioids, illicit drugs, marijuana, or non-prescribed drugs"
6214,NCT01676753,"24:39:chronic_disease,41:53:chronic_disease,94:102:allergy_name,106:126:allergy_name,136:174:allergy_name,184:211:allergy_name","Patient has history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or prior allogeneic bone marrow transplantation or prior solid organ transplantation"
6215,NCT01676259,"1:7:chronic_disease,9:31:chronic_disease,33:38:chronic_disease,43:60:chronic_disease,72:88:treatment","Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy"
6216,NCT01676259,"8:27:chronic_disease,37:54:chronic_disease,60:69:chronic_disease,,,157:171:treatment","Severe chronic obstructive or other pulmonary disease with hypoxemia (requires supplementary oxygen, symptoms due to hypoxemia or oxygen saturation <90% by pulse oximetry after a 2 minute walk) or in the opinion of the investigator any physiological state likely to cause systemic or regional hypoxemia"
6217,NCT01670877,"24:39:chronic_disease,41:61:chronic_disease,79:90:chronic_disease","History of significant cardiac disease, cardiac risk factors, or uncontrolled arrhythmias"
6218,NCT01670877,"14:34:chronic_disease,77:93:chronic_disease,95:119:chronic_disease,121:139:chronic_disease,144:181:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
6219,NCT01668082,"1:31:treatment,48:59:cancer,54:59:cancer,63:84:treatment,104:110:treatment,",Pre-operative brain MR imaging suggestive of a brain tumor or pre-operative imaging showing a tumor or biopsy of a tumor mass prior to planned resection of the mass
6220,NCT01660607,"21:30:chronic_disease,32:37:chronic_disease,41:57:chronic_disease,87:108:treatment","Active uncontrolled bacterial, viral or fungal infection, defined as currently taking antimicrobial therapy and progression of clinical symptoms"
6221,NCT01659541,"1:10:chronic_disease,12:32:chronic_disease,37:51:chronic_disease","Scoliosis, chest wall deformity, or marked obesity"
6222,NCT01653080,"1:24:chronic_disease,36:57:chronic_disease,68:103:treatment",Acute renal dysfunction due to the hepato-renal syndrome or in the perioperative liver transplantation period
6223,NCT01648751,"87:92:chronic_disease,94:114:chronic_disease,116:127:chronic_disease,129:146:chronic_disease,148:163:chronic_disease,169:191:chronic_disease","Connective tissue diseases known to affect collagen or elastin remodeling (including: Lupus, Rheumatoid Arthritis, Scleroderma, Sjogrens syndrome, Marfan syndrome, and Ehlers-Danlos syndrome)"
6224,NCT01648023,"12:26:allergy_name,55:68:treatment,75:83:treatment",Allergy to contrast media that cannot be managed with standard care (e.g. steroids)
6225,NCT01648023,"54:64:allergy_name,66:77:allergy_name,82:91:allergy_name","Patients with prior contraindications for the use of irinotecan, gemcitabine, or cisplatin"
6226,NCT01639508,"13:38:treatment,,99:114:treatment,,186:190:treatment,194:207:treatment","Any type of systemic anticancer agent (including investigational) within 3 weeks of first dose of study treatment, or within 5 half-lives of the agent whichever is shorter. Subjects on LHRH or GnRH agonists may be maintained on these agents"
6227,NCT01639508,"36:48:cancer,52:71:cancer,,112:124:treatment",The subject has any evidence of an endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib
6228,NCT01639508,"1:7:chronic_disease,19:22:chronic_disease,33:41:chronic_disease,49:70:chronic_disease","stroke (including TIA, or other ischemic event) myocardial infarction"
6229,NCT01631617,"46:56:treatment,57:82:treatment,84:105:treatment,110:137:treatment","Subjects receiving or planning to receive an IND agent, ultraviolet light therapy, monoclonal antibodies, or systemic immunosuppressants"
6230,NCT01631617,"8:15:treatment,19:34:treatment,,67:76:treatment",Use of topical or oral CAM agents within 4 weeks of initiation of treatment
6231,NCT01627301,"1:10:treatment,16:27:treatment,76:85:treatment,87:100:treatment,102:116:treatment","treatment with medications known to affect the sympathetic nervous system (clonidine, beta blockers, ACE inhibitors)"
6232,NCT01626079,"1:45:chronic_disease,72:86:treatment,109:121:treatment",Chronic Obstructive Pulmonary Disease (COPD) requiring continuous home oxygen therapy or chronic outpatient oral steroid use
6233,NCT01626079,"1:28:chronic_disease,30:56:chronic_disease,58:83:chronic_disease,98:122:chronic_disease,131:144:chronic_disease,156:178:chronic_disease,189:197:chronic_disease,201:213:chronic_disease","Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non ischemic etiology"
6234,NCT01626079,"36:58:treatment,36:45:treatment,132:134:treatment","Leaflet anatomy which may preclude MitraClip implantation, proper MitraClip positioning on the leaflets or sufficient reduction in MR by the MitraClip"
6235,NCT01626079,"1:28:treatment,33:52:treatment,89:109:treatment",Transseptal catheterization and femoral vein access is determined to be feasible by the MitraClip implanting investigator
6236,NCT01625923,"31:44:chronic_disease,55:87:chronic_disease,111:129:chronic_disease,133:156:chronic_disease","Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)"
6237,NCT01625923,"62:72:treatment,83:91:treatment,93:102:treatment,104:111:treatment,113:126:treatment,128:139:treatment,156:166:treatment,183:199:treatment,201:209:treatment,214:230:treatment,277:284:treatment,288:297:treatment","Subjects who are taking drugs that potentially interact with olanzapine including diazepam, lorazepam, alcohol, carbamazepine, fluvoxamine, olanzapine and fluoxetine in combination, CNS acting drugs, levodopa and dopamine agonist, and olanzapine when used in combination with lithium or valproate"
6238,NCT01625234,"17:30:treatment,58:68:treatment,94:102:treatment",Patients may be ALK TKI-naive or may have received prior crizotinib and/or second generation ALK TKIs
6239,NCT01624090,"1:8:treatment,12:42:treatment,71:81:chronic_disease","Aspirin or salicylate-containing products, which may increase risk of hemorrhage"
6240,NCT01624090,"38:55:treatment,48:55:treatment,96:108:treatment,","Patients may have received localized radiation therapy to non-target lesions provided that the radiotherapy is completed 14 days prior to commencing therapy, and the patient has recovered from any toxicity"
6241,NCT01624090,"63:75:cancer,80:101:cancer,103:119:cancer,121:137:cancer,139:170:cancer,174:193:cancer","Patients with measurable inoperable, histologically confirmed primary lung and esophageal carcinomas, thymic neoplasms, germ cell tumors, malignant pleural mesotheliomas or chest wall sarcomas"
6242,NCT01623167,"27:36:chronic_disease,85:97:treatment,102:113:treatment,,",Subjects with known liver cirrhosis in severity that would preclude tolerability of cyclosporine and eltrombopag as evidenced by albumin < 35g/L
6243,NCT01622868,"1:29:treatment,7:24:treatment,57:66:treatment,",Prior radiation therapy (RT) (any site) with concurrent lapatinib defined as 1 or more days on which the patient received both radiation therapy and lapatinib on the same day
6244,NCT01620216,"5:36:cancer,38:53:treatment,58:73:treatment,86:94:treatment,99:107:treatment,111:120:treatment,124:133:treatment","for Philadelphia positive (Ph+) ALL, initial therapy and salvage therapy may include steroids and imatinib or dasatinib or nilotinib"
6245,NCT01619761,"1:35:cancer,78:87:treatment,113:122:treatment,145:152:treatment","Acute lymphoblastic leukemia (ALL): induction failure, primary refractory to treatment (do not achieve complete remission after first course of therapy) or are beyond first remission including second or greater remission or active disease"
6246,NCT01619761,"41:65:cancer,67:99:cancer,85:93:cancer,209:245:treatment,283:307:chronic_disease,352:370:treatment,391:415:cancer","Patients must have one of the following hematologic malignancies: acute myelogenous leukemia (AML), induction failure, high-risk for relapse first remission (with intermediate-risk or high-risk cytogenetics, fms-related tyrosine kinase 3 [FLT3] mutation positive and/or evidence of minimal residual disease by flow cytometry), secondary leukemia from prior chemotherapy and/or arising from myelodysplastic syndrome, any disease beyond first remission"
6247,NCT01618357,"1:16:treatment,18:46:treatment,52:63:treatment","Bisphosphonates, hormone modification therapy, and trastuzumab are permitted without restriction"
6248,NCT01618357,"16:26:cancer,68:78:chronic_disease,82:107:cancer,101:107:cancer,109:132:cancer,","No other prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the patient has been disease-free for 5 years"
6249,NCT01618357,"1:37:chronic_disease,39:63:chronic_disease,68:86:chronic_disease","Symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia"
6250,NCT01617161,"22:26:chronic_disease,,,74:77:chronic_disease,98:111:treatment",Individuals who have AIDS (CD4 < 200 or an AIDS-defining illness) or are HIV positive and not on HAART therapy
6251,NCT01614990,"10:19:treatment,21:35:treatment,37:53:treatment,55:72:treatment,64:72:treatment,74:87:treatment,89:101:treatment","having a pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, or other implants"
6252,NCT01614197,"1:19:treatment,82:89:treatment,97:115:treatment,117:134:treatment,138:151:treatment","Anti-cancer Agents: Patients who are currently receiving or may receive while on therapy, other anti-cancer agents, radiation therapy or immunotherapy are not eligible"
6253,NCT01614197,"1:29:treatment,,73:98:treatment,105:113:treatment,,129:155:treatment",Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor
6254,NCT01614197,"1:19:treatment,53:65:chronic_disease,,111:121:treatment,125:143:treatment",Stem Cell Infusion: No evidence of active graft vs. host disease and at least 84 days must have elapsed after transplant or stem cell infusion
6255,NCT01608438,"1:9:chronic_disease,11:20:chronic_disease,22:29:chronic_disease,31:41:chronic_disease,46:75:chronic_disease,101:108:chronic_disease,122:147:treatment","Vascular, traumatic, tumoral, infectious, or metabolic lesion of the brain, even without history of seizure, and without anticonvulsant medication"
6256,NCT01604512,"53:61:cancer,96:102:cancer,118:128:cancer,143:153:cancer,173:196:treatment","Pathological or clinical/radiological diagnosis of aneoplasm , either primary (e.g., malignant glioma) or secondary (metastasis from systemic malignancy) with a history of brain radiation therapy"
6257,NCT01599559,"1:19:chronic_disease,46:54:cancer,114:129:chronic_disease",Cardiac impairment due to local extension of lymphoma will not be an exclusion criterion in the absence of other cardiac disease
6258,NCT01597518,"28:43:chronic_disease,105:124:chronic_disease,126:145:chronic_disease,156:176:chronic_disease,182:196:chronic_disease,204:213:chronic_disease,217:230:chronic_disease","Pre-existent neurologic or mental disorder which would preclude accurate evaluation and follow-up (i.e. Alzheimer's disease, Parkinson's disease, unstable psychiatric disorder with hallucinations and/or delusions or schizophrenia)"
6259,NCT01595529,"16:34:chronic_disease,52:55:chronic_disease,57:67:cancer,69:91:treatment,119:134:treatment,144:168:treatment","Presence of an immunocompromising condition (e.g., HIV, malignancy, solid-organ transplant recipients, use of chronic corticosteroids or other immunosuppressive agents)"
6260,NCT01591356,"45:106:allergy_name,108:117:allergy_name,122:146:allergy_name","History of allergic reactions attributed to compounds of similar chemical or biologic composition to DOPC, Magnevist, or fluorodeoxyglucose (FDG)"
6261,NCT01591356,"38:60:chronic_disease,90:102:chronic_disease,126:147:chronic_disease,151:166:chronic_disease,,,252:284:chronic_disease,294:312:chronic_disease,347:382:chronic_disease,409:446:chronic_disease,465:477:chronic_disease","Patients with clinically significant cardiovascular disease; this includes: uncontrolled hypertension (greater than 140/90); myocardial infarction or unstable angina within 6 months prior to registration; New York Heart Association (NYHA) grade II or greater congestive heart failure; serious cardiac arrhythmia requiring medication; grade II or greater peripheral vascular disease; patients with clinically significant peripheral artery disease, e.g., those with claudication, within 6 months of first date of treatment on this study"
6262,NCT01591356,"19:22:treatment,60:62:treatment,,,,,354:365:treatment","when imaging (DCE-MRI, DW-MRI and PET-computed tomography [CT] imaging) is being performed for secondary objectives (dose level III [or when the dose reaches at least 1,500 ug/m^2] and during the expansion phase) at least one lesion (>= 2 cm) not adjacent to the diaphragm will be required when measured by conventional techniques, including palpation, plain x-ray, CT, and MRI"
6263,NCT01589263,"1:23:chronic_disease,25:35:chronic_disease,37:75:chronic_disease,80:98:chronic_disease","Eaton-Lambert syndrome, hemophilia, hereditary clotting factors deficiency, or bleeding diathesis"
6264,NCT01589263,"32:57:cancer,61:68:cancer,70:86:treatment,90:97:treatment,99:117:chronic_disease,122:146:treatment","History or current evidence of carcinoma of the prostate or bladder, pelvic radiation or surgery, urethral stricture, or bladder neck obstruction"
6265,NCT01584076,"16:26:treatment,35:44:treatment,48:52:chronic_disease,56:79:chronic_disease",Current use of medication for the treatment of ADHD or psychological disorders
6266,NCT01582191,",57:79:treatment,,185:201:treatment,277:294:treatment,296:330:treatment,415:424:treatment","Patients must be at least 3 weeks beyond their previous cytotoxic chemotherapy; patient must be at least 5 half-lives or 3 weeks, whichever is shorter, from their previous targeted or biologic therapy; in addition, patients must be at least 3 weeks beyond the last session of radiation therapy; local palliative radiation therapy that is not delivered to all target lesions is allowed immediately before or during treatment"
6267,NCT01581580,"36:59:treatment,,,103:105:chronic_disease,113:119:treatment","History of appropriate response to dopaminergic medication, with at least a 30% improvement in motor UPDRS with L-DOPA by history or in-clinic testing, for the PD patients"
6268,NCT01576575,"8:52:treatment,54:61:treatment,65:70:treatment,149:168:treatment","Use of prescription or non-prescription medications, herbals or foods known to be metabolized by or affect CYP3A activity (this includes the use of oral contraceptives)"
6269,NCT01572480,"16:26:chronic_disease,60:86:chronic_disease,91:106:treatment","Has refractory GI disease with refractory nausea/vomiting, inflammatory bowel disease, or bowel resection that would prevent absorption"
6270,NCT01570998,"21:47:treatment,38:47:treatment,49:57:treatment,61:73:treatment,122:127:cancer",Patients undergoing primary systemic treatment (hormones or chemotherapy) as initial treatment with neoadjuvant reducing tumor size
6271,NCT01568177,"21:30:treatment,41:47:chronic_disease,49:60:chronic_disease,91:109:chronic_disease,123:127:chronic_disease,,","Contraindication to Adenosine including asthma, heart block (second and third degree) and sinus node disease, significant COPD/asthma, or systemic hypotension (<90mmHg)"
6272,NCT01562626,",104:109:cancer,150:167:treatment,202:204:treatment,208:218:treatment,226:244:treatment","Patients enrolled at Dose Level 6 or higher in the phase I portion of the trial must have at least one tumor mass suitable and easily accessible for excisional biopsy, or alternatively, accessible for CT or ultrasound guided core needle biopsy"
6273,NCT01562626,"14:22:chronic_disease,31:39:chronic_disease,43:49:chronic_disease,79:82:chronic_disease,94:104:treatment,106:111:treatment,113:118:treatment,129:157:treatment,165:181:chronic_disease","any existing thrombus (either arterial or venous) as well as known history of DVT, permanent pacemakers, AICDs, LVADs, or other intravascular cardiac device, known AV malformations"
6274,NCT01555554,"30:52:chronic_disease,61:70:treatment,90:120:chronic_disease,138:149:chronic_disease,,,,,227:250:chronic_disease,259:285:chronic_disease,291:308:chronic_disease","Medical exclusions criteria: high grade heart block without pacemaker (all patients with 2nd and 3rd degree heart block), marked resting bradycardia (heart rate ? 55 beats per minute), blood pressure < 100 mmHg, uncompensated congested heart failure, severe hyperactive airway disease, and Raynaud's disease"
6275,NCT01554371,"1:25:chronic_disease,50:68:chronic_disease,103:124:chronic_disease,,168:179:treatment,245:260:chronic_disease","Congestive heart failure, Clinically significant cardiac arrhythmia, history or current evidence of a myocardial infarction during the last 6 months, and/or a current ECG tracing that is abnormal in the opinion of the treating Investigator, or unstable angina"
6276,NCT01553942,"27:35:allergy_name,37:46:allergy_name,51:61:allergy_name","Known hypersensitivity to afatinib, cisplatin, or pemetrexed"
6277,NCT01553071,"62:72:cancer,131:139:treatment,143:162:treatment",Patients must have histologically or cytologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
6278,NCT01553071,"1:18:treatment,20:32:treatment,,,94:105:treatment,109:120:treatment,140:151:treatment,154:162:treatment","Radiation therapy, chemotherapy, and other investigational agents within 3weeks (6 weeks for nitrosourea or mitomycin C) prior to starting fenretinide + safingol"
6279,NCT01553071,"35:42:treatment,44:53:treatment,84:100:cancer,124:146:treatment,,178:194:treatment","patients with previously treated (surgery, radiation or both), clinically inactive brain metastases, who have not received corticosteroid therapy within three weeks of starting protocol therapy"
6280,NCT01543490,"15:31:chronic_disease,33:42:chronic_disease,44:49:chronic_disease,53:59:chronic_disease,71:90:chronic_disease,102:113:chronic_disease","Have an acute ocular infection (bacterial, viral or fungal) or active ocular inflammation other than blepharitis in the study eye"
6281,NCT01539109,"1:16:treatment,18:24:treatment,29:45:treatment","Implanted pumps, shunts, or neurostimulators"
6282,NCT01538966,"31:41:chronic_disease,59:66:treatment,70:85:treatment",Newly diagnosed patients with acromegaly who have not had surgery or medical therapy
6283,NCT01532687,"1:13:treatment,15:28:treatment,30:46:treatment,48:71:treatment,75:91:treatment","Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy"
6284,NCT01532687,"1:27:chronic_disease,34:52:chronic_disease,54:69:chronic_disease,81:108:chronic_disease,132:143:chronic_disease","Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other gastrointestinal conditions with increased risk of perforation"
6285,NCT01532687,"17:34:chronic_disease,36:44:chronic_disease,49:54:chronic_disease,75:93:treatment","presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major"
6286,NCT01522768,"51:57:treatment,123:131:treatment,139:155:cancer,180:189:treatment,209:218:treatment,225:227:treatment",All patients with disease technically amenable to biopsy will be asked to undergo a biopsy. Patient must agree to allow 2 biopsies of any malignant lesion that can be accessed by endoscopy or with the aid or radiology (i.e. CT guided)
6287,NCT01522768,"1:24:treatment,69:78:treatment,190:197:chronic_disease","Concurrent radiotherapy is not permitted for disease progression on treatment on protocol (except in the context specified in section 9.0), but might be allowed for pre-existing non-target lesions"
6288,NCT01522768,"21:32:treatment,78:88:cancer,126:141:treatment,167:183:treatment",Previously received trastuzumab as part of a regimen in the perioperative or metastatic setting with evidence of progression 9Zr-trastuzumab use as imaging agent for 89Zr-trastuzumab PET permitted
6289,NCT01516788,"34:63:chronic_disease,68:83:chronic_disease,96:111:chronic_disease,123:150:chronic_disease","Participants with a diagnosis of Erythropoietic Protoporphyria and Solar Urticaria, or another photodermatoses other than Polymorphous light eruption"
6290,NCT01508390,"1:8:cancer,38:40:treatment,48:51:treatment,57:66:treatment","M-stage determined by physical exam, CT and/or MRI, and bone scan"
6291,NCT01505569,",,51:69:treatment,122:132:cancer,164:173:treatment","Children less than 8 months of age at the time of definitive surgery (for histopathologic diagnosis), any histology, any metastatic state, with total or sub-total resection"
6292,NCT01505569,"1:14:cancer,44:64:cancer,141:152:cancer,182:215:treatment",Neuroblastoma (ICD-O morphology 9500/3) or ganglioneuroblastoma (nodular or intermixed) verified by histology or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamine metabolites
6293,NCT01505569,"74:77:cancer,79:89:cancer,91:101:cancer,103:118:cancer,122:138:cancer,,,,,215:225:cancer","This would require a clinical situation consistent with the diagnosis of GCT (testicular, peritoneal, retroperitoneal or mediastinal mass, elevated tumor marker levels {HCG ? 500; AFP ? 500} and typical pattern of metastases)"
6294,NCT01505062,"39:60:treatment,75:98:treatment,,130:137:treatment",Current or anticipated treatment with anticoagulant therapy or the use of anticoagulation therapy within the four weeks prior to surgery
6295,NCT01500551,"37:71:chronic_disease,73:84:chronic_disease,88:105:chronic_disease","A subject known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus"
6296,NCT01495637,"1:28:chronic_disease,30:55:cancer,,124:130:allergy_name","Autoimmune thrombocytopenia, myelodysplastic syndromes with > 20% marrow blast cells, or known allergy/hypersensitivity to GM-CSF"
6297,NCT01494662,",33:50:treatment,56:78:treatment,80:89:treatment,97:105:treatment,109:125:treatment,130:147:treatment","At least 2 weeks washout period post chemotherapy, any prior protocol therapy, lapatinib, other targeted or biologic therapy, or radiation therapy is required prior to study entry"
6298,NCT01494662,"127:136:allergy_name,141:146:allergy_name,183:227:allergy_name,239:248:allergy_name,250:263:allergy_name,265:278:allergy_name,280:292:allergy_name,294:307:allergy_name,309:322:allergy_name,327:336:allergy_name","History of severe allergic reactions or intolerability attributed to compounds of similar chemical or biologic composition to neratinib and T-DM1 for Cohorts 4A-4C Concurrent use of enzyme-inducing antiepileptic drugs (EIAEDs), including phenytoin, carbamazepine, oxcarbazepine, fosphenytoin, phenobarbital, pentobarbital, or primidone"
6299,NCT01494662,"27:39:treatment,43:55:treatment,67:89:treatment,,",Participants who have had chemotherapy or radiotherapy (including investigational agents) within 2 weeks prior to entering the study or those who have not recovered adequately from adverse events due to agents administered more than 4 weeks earlier
6300,NCT01494662,"41:44:treatment,62:71:treatment,73:81:treatment","Patients with known contraindication to MRI, such as cardiac pacemaker, shrapnel, or ocular foreign body"
6301,NCT01481974,"58:70:treatment,122:149:treatment,173:194:treatment","Be receiving any investigational drug (a drug other than Treprostinil administered under an IND) or participating in any other investigational study, with the exception of alemtuzumab (Campath)"
6302,NCT01474889,"16:45:treatment,68:94:treatment,107:133:treatment,137:184:treatment,,,273:308:treatment,,","Involvement in intensive diabetes management defined as the use of basal-bolus insulin analog delivery by multi-dose injection (MDI) or continuous subcutaneous insulin infusion (CSII) together with self-monitoring of blood glucose values four or more times daily, without continuous glucose monitoring (CGM), under the direction of an endocrinologist, diabetologist, or diabetes nurse practitioner with at least 3 clinical evaluations during the previous 12 months"
6303,NCT01464034,"2:16:chronic_disease,18:30:chronic_disease,32:46:chronic_disease","(polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)"
6304,NCT01464034,"24:46:treatment,90:108:chronic_disease,144:152:treatment,,,,193:221:treatment,238:266:chronic_disease,267:290:chronic_disease","Pts must agree to take enteric-coated aspirin 81 mg orally daily, or if history of prior thrombotic disease, must be fully anticoagulated with warfarin (INR 2-3) or be treated with full-dose, low molecular weight heparin, as if to treat deep venous thrombosis (DVT)/pulmonary embolism (PE)at the investigator's discretion"
6305,NCT01459107,"58:79:chronic_disease,84:95:chronic_disease,131:161:chronic_disease,167:180:chronic_disease",Conditions that may impact functional outcomes including Lipopolysaccharidosis and amyloidosis (may impact nerve regeneration) or rare disorders of bone healing like osteopetrosis
6306,NCT01459107,"119:137:treatment,244:253:treatment,356:387:treatment","No co-existing medical condition which, in the opinion of the study team, could affect the immunomodulatory protocol, surgical procedure, or functional results (see Donor and Recipient Exclusion Criteria below. If the condition is amenable to treatment, the study team must agree that said condition should not significantly enhance the surgical risks of upper extremity transplantation.)"
6307,NCT01445821,"4:15:treatment,87:128:treatment,141:152:chronic_disease,161:199:treatment","On cardiac MRI, a diastolic septal bounce or diastolic septal flattering (D-sign), or diffuse myocardial gadolinium enhancement, or diffuse hypokinesis (patchy late gadolinium myocardial enhancement are not exclusion criteria)"
6308,NCT01444209,"28:33:cancer,54:57:treatment,61:63:treatment",Patients must have visible tumor on imaging studies (MRI or CT)
6309,NCT01436968,"1:16:treatment,21:36:cancer,45:49:treatment,53:56:treatment","Prior treatment for prostate cancer, except TURP or ADT"
6310,NCT01434472,"71:86:cancer,88:125:cancer,127:148:cancer,,213:244:treatment","Patients must have a histologically confirmed diagnosis of aggressive B-cell lymphoma (diffuse large B-cell lymphoma [DLBCL], Burkitt lymphoma [BL], etc.) expressing the CD20 antigen and have failed at least one prior standard systemic therapy"
6311,NCT01434316,"37:56:treatment,58:67:treatment,69:77:treatment,79:88:treatment,93:101:treatment,,161:172:treatment,197:212:treatment,266:283:treatment,285:300:treatment,330:339:treatment,344:359:cancer,,433:471:treatment,473:507:treatment","Patients must not receive any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement) while on this study except for medications that are prescribed for supportive care but may potentially have an anti-cancer effect (i.e. megestrol acetate, bisphosphonates); in addition, men receiving treatment for prostate cancer will be maintained at castrate levels of testosterone by continuation of luteinizing-releasing hormone agonists; palliative radiation therapy (XRT) can be administered on study after documented discussion with the principal investigator; for patients in expansion cohorts, this must not involve target lesions"
6312,NCT01434316,"33:61:cancer,57:60:cancer,63:68:cancer,70:100:cancer,96:99:cancer",Subjects with treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic syndrome (MDS) or with features suggestive of AML/MDS
6313,NCT01434316,"28:67:cancer,,163:172:treatment,181:198:treatment","patients with a history of central nervous system (CNS) metastases that have been treated must be stable with no symptoms for > 3 months after completion of that treatment and off steroid treatment, with image documentation required prior to study enrollment"
6314,NCT01433315,"61:75:treatment,77:87:treatment,89:101:treatment,103:116:treatment,118:128:treatment","On no prescription medications other than second generation antihistamines (Cetirizine, Fexofenadine, Desloratadine, Loratadine, etc), oral contraceptive pills, or intrauterine devices"
6315,NCT01430390,"41:53:cancer,60:80:cancer,98:113:treatment,137:171:treatment",History of relapsed or refractory CD19+ malignancies (e.g. Non Hodgkin Lymphoma) who have failed prior treatment and require autologous hematopoietic stem cell transplant
6316,NCT01430390,"8:21:treatment,23:46:treatment,,74:82:treatment",Recent prior therapy: Systematic chemotherapy less than 2 weeks prior to infusion
6317,NCT01430390,"15:19:treatment,100:113:treatment,165:177:treatment,","The patient's HSCT donor, or if HSCT donor is not available a third party donor, must consent to a leukapheresis or whole blood donation(s) obtained at one or more phlebotomies which, in aggregate, will total approximately 250 ml for adults and no more than 5ml/kg per draw from pediatric donors"
6318,NCT01422746,"4:15:treatment,152:176:treatment,178:188:treatment,190:199:treatment,201:216:treatment,222:235:treatment","No medications known to affect the reproductive system or glucose metabolism can be taken in the 3 months prior to the study. Such medications include oral contraceptive pills, progestins, metformin, glucocorticoids, and psychotropics"
6319,NCT01421810,"1:8:chronic_disease,37:53:chronic_disease,60:81:chronic_disease",Obesity associated with a diagnosed genetic syndrome (e.g. Prader-Willi syndrome)
6320,NCT01420887,"16:39:chronic_disease,43:51:chronic_disease,86:100:chronic_disease","Progressive or recalcitrant neuropathy or neuritis, except for isolated intermittent ulnar neuritis"
6321,NCT01419561,"1:6:chronic_disease,8:15:chronic_disease,17:39:chronic_disease,44:62:chronic_disease","Cough, dyspnea, airway hyperreactivity, or nasal inflammation"
6322,NCT01415882,"11:26:treatment,28:51:treatment,53:64:treatment,68:80:treatment,","High dose corticosteroids, immune modulatory drugs (thalidomide or lenalidomide) =< 7 days prior to registration"
6323,NCT01415882,"1:14:treatment,24:44:treatment,56:66:treatment,70:81:treatment",Prior therapy with any proteasome inhibitor other than bortezomib or carfilzomib
6324,NCT01415752,"25:36:treatment,41:78:chronic_disease,86:93:treatment,,,","Must be willing to take prophylaxis for Pneumocystis jiroveci pneumonia (PCP) during therapy and until at least 2 months following the completion of therapy or until the CD4 cells recover to over 250 cells/mm³, whichever occurs later"
6325,NCT01415752,"49:69:chronic_disease,99:106:treatment,,,129:144:treatment",Patients on Arms G and H without a history of a thromboembolic event are required to take a daily aspirin (81 mg or 325 mg) for DVT prophylaxis
6326,NCT01409161,",,,101:109:cancer,139:148:chronic_disease,162:169:chronic_disease",Patients with creatinine > 2.5 times upper limit of normal unless felt to be related the underlying leukemia by the treating physician or hemolysis or Gilbert's disease
6327,NCT01407809,"6:26:chronic_disease,,,,,,,258:267:treatment,275:285:treatment","Mild visual function loss, defined as grades 0,1 or 2 on the Humphrey Visual Field Analyzer SITA Standard 24-2 Test grading scale (Table 4) at presentation and a worsening to moderate or greater visual function loss, defined as grades 3-5, after 1 month of treatment and/or medication intolerance"
6328,NCT01389024,"7:27:chronic_disease,60:68:treatment,69:79:treatment",Known airway abnormalities that would increase the risk of sedation/anesthesia
6329,NCT01389024,"1:35:treatment,39:50:treatment,,82:91:treatment",Treatment with anti-sickling drugs or hydroxyurea within 3 months or anticipated treatment during the course of the study
6330,NCT01384513,"1:31:cancer,54:76:chronic_disease,80:129:chronic_disease","MDS (myelodysplastic syndrome), specific subtypes of RA (refractory anemia) or RARS (refractory anemia with ringed sideroblasts) subtypes"
6331,NCT01379573,"39:56:chronic_disease,65:68:chronic_disease,72:74:chronic_disease,158:161:chronic_disease","Mother may be asymptomatic, or have a rheumatic disease such as SLE or SS. Maternal health status has not been considered an influence on the development of CHB"
6332,NCT01371630,"18:36:cancer,40:48:cancer,50:86:cancer","Ph-positive ALL, Burkitt's leukemia or lymphoma, T-cell ALL or lymphoblastic lymphoma"
6333,NCT01367444,"1:16:treatment,51:68:treatment,70:82:treatment","Laboratory test abnormalities or abnormalities in electrocardiogram, chest X-rays that in the opinion of the Principal Investigator would make the patient unsuitable for participation in the study"
6334,NCT01366612,"19:30:chronic_disease,35:60:chronic_disease,75:84:treatment",Recovery from all hematologic and non-hematology toxicities from previous therapies
6335,NCT01365169,"35:42:cancer,44:68:cancer,70:84:cancer,86:100:cancer,111:131:chronic_disease,133:153:cancer","Diagnosis of any of the following cancers: stage 1-4b oropharyngeal, hypopharyngeal, nasopharyngeal, salivary gland or oral cavity; stage 3-4b laryngeal"
6336,NCT01365169,"21:28:chronic_disease,32:49:chronic_disease,65:80:chronic_disease,82:135:chronic_disease,138:141:chronic_disease",Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease (New York Heart Association functional class III or IV) (PCS study)
6337,NCT01360606,"14:35:chronic_disease,77:93:chronic_disease,,,206:230:chronic_disease,,,285:314:chronic_disease,316:335:chronic_disease,346:369:treatment,381:394:treatment,398:405:treatment,408:433:chronic_disease","Uncontrolled inter-current illness including, but not limited to ongoing or active infection (> grade 2 National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version 4.0), congestive heart failure (> New York Heart Association (NYHA) class 2), active coronary artery disease (CAD), cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin), uncontrolled hypertension and any condition which could jeopardize the safety of the patient and his/her compliance in the study"
6338,NCT01351103,"1:40:chronic_disease,44:68:chronic_disease,116:127:treatment,169:175:chronic_disease,177:185:chronic_disease,187:195:chronic_disease,197:219:chronic_disease,221:242:treatment","Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of oral LGK974 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection)"
6339,NCT01349101,"19:21:chronic_disease,,33:44:chronic_disease,66:76:treatment,89:98:treatment",For patients with RA or RARS or isolated 5q- they can proceed to transplant without any treatment
6340,NCT01345344,"20:36:treatment,83:94:treatment,110:124:treatment",on stable doses of medication prior to entering the study and agree not to change medications or dosages (or CAM treatments) during the trial
6341,NCT01341080,"34:54:chronic_disease,56:86:treatment,95:110:chronic_disease,112:130:chronic_disease,135:154:chronic_disease","Subjects with a history of major psychiatric disorder, deep brain stimulation surgery, recent cerebral trauma, cardiac arrhythmia, or renal insufficiency"
6342,NCT01333046,"5:13:cancer,26:36:cancer,44:74:cancer,100:107:treatment",the lymphoma is a second malignancy e.g. a Richters transformation of CLL after failing front line therapy
6343,NCT01313533,"12:42:treatment,43:78:treatment,83:124:treatment,129:165:treatment","First time coronary artery bypass surgery,redo coronary artery bypass surgery and combined valve repair/replacement surgery and coronary artery bypass graft surgery are eligible to participate in study"
6344,NCT01312857,"1:17:chronic_disease,19:26:chronic_disease,28:50:chronic_disease","Active infection, ascites, hepatic encephalopathy"
6345,NCT01312857,"35:46:chronic_disease,48:49:chronic_disease,51:52:chronic_disease,58:74:chronic_disease","Patients with current evidence of hepatitis A, B, C (ie, active hepatitis)"
6346,NCT01306045,"20:38:chronic_disease,65:71:treatment,76:95:treatment",Patients must have biopsiable disease and be willing to undergo biopsy for molecular profiling
6347,NCT01306045,"36:47:treatment,57:86:treatment,203:232:treatment,,381:424:treatment,479:506:cancer,522:559:treatment,673:682:treatment","The eligibility of patients taking medications that are potent inducers or inhibitors of that enzyme will be determined following a review of their case by the Principal Investigator. (A list of potent CYP3A4 inducers or inhibitors can be found in Appendix F). Every effort should be made to switch patients taking such agents or substances to other medications before they begin treatment with one of the experimental drug included in this protocol, particularly patients with gliomas or brain metastases who are taking enzyme-inducing anticonvulsant agents. A comprehensive list of medications and substances known or with the potential to alter the pharmacokinetics of sunitinib through CYP3A4"
6348,NCT01306019,"1:26:chronic_disease,41:47:chronic_disease,51:70:chronic_disease,74:106:chronic_disease,110:133:chronic_disease",Mucocutaneous candidiasis (chronic oral thrush or candida esophagitis or candida intertriginous infection or candida nail infections; must be culture positive to satisfy this criterion)
6349,NCT01280994,"1:20:chronic_disease,26:35:chronic_disease,39:53:chronic_disease,,72:75:treatment",Respiratory illness of a bacterial or viral etiology within 30 days of MRI
6350,NCT01280669,"1:21:treatment,25:47:treatment,51:59:treatment,",Posterior subtenon's or intravitreal injection of steroids 90 days prior to Baseline
6351,NCT01270724,"37:46:cancer,51:56:cancer,68:90:cancer,92:106:cancer,109:128:cancer,130:145:cancer,150:171:cancer","Patients with histologically proven germinoma and MMGCT, including endodermal sinus tumor (yolk sac tumor), embryonal carcinoma, choriocarcinoma and mixed germ cell tumor"
6352,NCT01261728,"1:15:chronic_disease,32:37:cancer,41:47:treatment",Hydronephrosis associated with tumor on biopsy will be considered invasive by definition
6353,NCT01261728,"10:18:treatment,,83:90:treatment,95:121:treatment",low dose warfarin up to 2 mg po daily or use of subcutaneous low molecular weight heparin for thromboembolic prophylaxis
6354,NCT01245712,"34:39:cancer,48:79:cancer,92:120:cancer","On histological examination, the tumor must be ductal carcinoma in situ (DCIS) or invasive adenocarcinoma of the breast"
6355,NCT01245712,"1:31:cancer,107:116:treatment,120:137:treatment,146:154:treatment","Suspicious microcalcifications, or densities (in the ipsilateral or contralateral breast as documented on mammogram or breast ultrasound) unless biopsied and found to be benign"
6356,NCT01241708,"1:13:treatment,17:29:treatment,,58:67:treatment",Chemotherapy or radiotherapy within 8 days of initiating treatment in this study
6357,NCT01220583,"15:43:treatment,51:56:treatment,60:73:treatment,82:94:treatment","No concurrent hematopoietic growth factors (e.g., G-CSF or pegfilgrastim) during radiotherapy"
6358,NCT01220583,"4:31:treatment,35:52:treatment,57:82:cancer,84:102:treatment,119:125:cancer",No prior systemic chemotherapy or radiation therapy for salivary gland malignancy (prior chemotherapy for a different cancer is allowable)
6359,NCT01200940,",73:82:treatment,108:130:treatment,158:172:treatment","Recent (past 2 months) use of drugs that alter glucose metabolism (e.g. metformin), alter gastric pH (e.g. proton pump inhibitors) or gastric emptying (e.g. metoclopramide)"
6360,NCT01185132,"13:16:treatment,85:95:treatment,134:144:treatment",Findings on MRI scanning revealing relevant suspicion of disease outside of planned lumpectomy volume should be further evaluated by ultrasound
6361,NCT01184547,"14:20:chronic_disease,24:41:chronic_disease,48:57:chronic_disease,59:63:chronic_disease","Uncontrolled asthma or pulmonary disease (e.g. emphysema, COPD)"
6362,NCT01174121,"15:27:cancer,56:63:treatment,65:82:treatment,88:100:treatment,111:125:cancer,119:125:cancer,138:147:treatment","Patients with glioblastoma must have received standard surgery, radiation therapy, and chemotherapy for their primary tumors and require resection of their tumors for palliative or other clinical indication"
6363,NCT01174108,"1:26:chronic_disease,30:43:chronic_disease,76:91:treatment",Major anticipated illness or organ failure incompatible with survival from PBSC transplant
6364,NCT01174108,"29:43:chronic_disease,45:62:chronic_disease,64:72:chronic_disease,73:88:chronic_disease",Screening test positive for Chagas disease (Trypanosoma cruzi /T. cruzi/trypanosomiasis) confirmed by the Center for Disease Control (CDC)
6365,NCT01130077,"30:48:cancer,50:77:cancer,81:92:cancer","Eligible histologies include glioblastoma (GBM), anaplastic astrocytoma (AA) or gliosarcoma"
6366,NCT01130077,"17:35:cancer,40:58:cancer,72:84:treatment,92:109:treatment",Newly diagnosed high-grade gliomas* or brain stem gliomas who received chemotherapy during radiation therapy. Patients may not have received chemotherapy after radiation therapy was completed
6367,NCT01130077,"74:87:treatment,,128:159:treatment,163:198:treatment,,241:278:treatment",Patients on Strata C and D must have recovered from the toxic effects of prior therapy: at least 3 weeks form the last dose of standard cytotoxic chemotherapy or myelosuppressive biological therapy and at least 1 week from the last dose of non-myelosuppressive biologic therapy
6368,NCT01128816,"16:19:treatment,23:27:treatment,31:60:treatment,65:74:treatment,78:89:chronic_disease,110:133:treatment,,178:187:treatment",Current use of ASV or CPAP or mandibular advancement device for treatment of sleep apnea or treated with any investigational therapy during the last 4 weeks (including approved therapies being used in unapproved indications)
6369,NCT01101451,"15:28:cancer,60:69:treatment,73:85:treatment",Patients with cervix cancer who have received any previous radiation or chemotherapy
6370,NCT01099644,"5:11:cancer,5:10:cancer,23:28:cancer,139:155:treatment,","For tumors other than DSRCT, patients must have a history of tumor progression or recurrence or failure to achieve complete response with standard therapy or <20% chance of long term disease-free survival"
6371,NCT01096368,"4:19:treatment,31:52:treatment,57:72:treatment,,132:141:treatment",No prior treatment other than surgical intervention and corticosteroids; patients are allowed to have had more than one attempt at resection prior to enrollment
6372,NCT01087294,"1:25:treatment,32:40:treatment,,,53:62:chronic_disease","Donor T cell engraftment after alloHSCT (>50% donor chimerism of the T cell compartment and a peripheral blood T cell number from the NIH, CC clinical lab of at least 50 CD3+ cells/uL)"
6373,NCT01087294,"1:16:treatment,69:72:cancer,74:89:cancer,111:120:cancer,125:154:cancer","Prior (DCI) DLI is not an eligibility requirement for patients with ALL, Burkitt lyphoma, ALL like high-grade lymphomas, or diffuse large B-cell lymphoma"
6374,NCT01061515,"1:26:chronic_disease,83:100:chronic_disease,102:120:chronic_disease","Gastrointestinal ailments that may alter the absorption of oral medications (i.e. bowel obstruction, short-gut syndrome)"
6375,NCT01061515,"20:42:treatment,43:90:treatment,95:98:chronic_disease",Patients receiving antiretroviral therapy Highly Active Anti Retroviral Treatment (HAART) for HIV infection are excluded from the study because of possible pharmacokinetic interactions
6376,NCT01059786,",46:64:cancer,100:104:treatment,112:117:treatment","Patients with flow cytometry consistent with HCL variant (HCLv) are eligible, including those with CD25 and/or CD103 negative disease"
6377,NCT01059786,"1:10:treatment,,,159:175:treatment,213:228:treatment","Treatment indicated based on demonstration of at least one of the following no more than 4 weeks from the time of enrollment, and no less than 6 months after prior cladribine and no less than 4 weeks after other prior treatment"
6378,NCT01054196,"1:21:chronic_disease,64:80:chronic_disease,94:118:chronic_disease,120:144:chronic_disease,146:164:chronic_disease,169:206:chronic_disease","Uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
6379,NCT01045148,"1:16:treatment,21:46:cancer,48:70:treatment,72:93:treatment","Radical surgery for carcinoma of the prostate, prior pelvic radiation, pelvic surgical clips or other metallic foreign bodies"
6380,NCT01042522,"34:55:cancer,79:103:cancer,152:162:cancer,","Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years"
6381,NCT01037790,"1:29:cancer,47:51:cancer,55:68:cancer",Metastatic colorectal cancer that harbors the Kras or BRAF mutation (15-30 enrollment slots)
6382,NCT01028846,"28:50:chronic_disease,62:72:treatment,74:130:treatment,132:146:treatment,151:159:treatment","Medications for medical or psychiatric conditions including: dofetilide, fosphenytoin/phenytoin trichlormethiazide (any thiazide), chlorpromazine and warfarin"
6383,NCT01011777,"38:59:treatment,61:79:treatment,81:100:treatment,102:127:treatment,129:184:treatment,186:200:treatment","Negative Study Donor Virology Panel (Hep B surface antigen, HIV 1 / 2 antibody, Hep B core antibody, Rapid Plasma Reagin (RPR), Human T-cell Lymphotrophic Virus (HTLV) I / II antibody, Hep C antibody)"
6384,NCT00977977,"1:34:chronic_disease,45:66:treatment,78:93:chronic_disease,95:98:chronic_disease,100:116:chronic_disease,118:132:chronic_disease,134:156:chronic_disease,158:168:chronic_disease","Active acute or chronic infection requiring antimicrobial therapy or serious viral infection (HIV, hepatitis B or C, herpes simplex, varicella zoster virus, parvovirus)"
6385,NCT00977977,",,69:99:treatment,101:114:treatment,118:121:treatment,",Nephrotic range proteinuria (>3.5 g/24 hours) that persists despite angiotensin antagonist therapy (ACE inhibitor or ARB) for at least 2 months unless intolerant
6386,NCT00975520,"51:68:treatment,77:94:treatment,116:133:chronic_disease",Intercurrent illness that will interfere with the radiation therapy such as immunosuppression due to medication or medical condition
6387,NCT00975520,"1:56:treatment,68:97:treatment,101:114:cancer,118:138:cancer,179:185:cancer","Previous radical radiation therapy to the head and neck, excluding superficial radiation therapy to cutaneous SCC or basal cell carcinoma, which is not within or overlapping the tumour bed"
6388,NCT00969111,"8:20:treatment,24:36:treatment,91:100:treatment",Taking Saw Palmetto or methotrexate and unable or unwilling to discontinue its use during radiation
6389,NCT00967577,"1:30:treatment,32:43:treatment,,74:83:treatment",Prior investigational therapy (medications or devices) within 6 weeks of treatment
6390,NCT00967577,"56:77:cancer,79:89:cancer,91:104:cancer,106:112:cancer,114:133:cancer,135:145:cancer,147:155:cancer,157:162:cancer,164:173:cancer,178:185:cancer","This will include, but is not limited to patients with cancers of the kidney, urothelium, head and neck, breast, non-small cell lung, colorectal, pancreas, ovary, esophagus and gliomas"
6391,NCT00959140,"1:4:cancer,5:8:cancer,15:28:cancer",AML/ALL: with Bi-phenotypic features
6392,NCT00930228,"1:8:chronic_disease,37:55:chronic_disease,57:64:chronic_disease,76:87:treatment,95:110:treatment","Obesity associated with a diagnosed (genetic) syndrome, obesity related to medications (e.g., glucocorticoids), etc"
6393,NCT00929006,"23:29:cancer,31:38:cancer,43:61:cancer","A personal history of breast, ovarian, or endometrial cancer"
6394,NCT00929006,"53:82:chronic_disease,102:121:chronic_disease,144:167:chronic_disease","History and/or physical exam findings suggestive of hypogonadotropic hypogonadism (e.g., symptoms of estrogen deficiency) including functional hypothalamic amenorrhea (which may be suggested by a constellation of symptoms including restrictive eating patterns, excessive exercise, psychological stress, etc.)"
6395,NCT00929006,"35:56:chronic_disease,83:107:chronic_disease,109:115:chronic_disease,139:163:treatment","Significant history of cardiac or pulmonary dysfunction (e.g., known or suspected congestive heart failure, asthma requiring intermittent systemic corticosteroids, etc.)"
6396,NCT00924027,"16:21:cancer,58:71:treatment,146:163:treatment",Any patient or tumor/anatomical factors that may prevent brachytherapy apparatus from being properly and safely inserted and positioned and from radiation therapy being administered per ABS guidelines
6397,NCT00924027,"36:43:treatment,58:67:treatment,94:112:cancer",Patients who are unable to undergo surgery and must have treatment for an inoperable primary endometrial cancer
6398,NCT00919503,"33:50:treatment,54:71:treatment,76:89:treatment",DONOR: Deemed unable to undergo marrow harvesting or PBSC mobilization and leukapheresis
6399,NCT00911560,"1:13:cancer,,,85:98:treatment,105:122:treatment","High-risk NB (as defined above) and in 1) first CR at 6 ? months from initiation of immunotherapy using anti-GD2 antibody, or 2) second or subsequent remission"
6400,NCT00909909,"1:13:treatment,,102:114:treatment,139:171:treatment,175:197:treatment","Chemotherapy is not administered for ? 21 days before, during, and for ? 21 days after completion of radiotherapy (for patients receiving external beam radiotherapy boost or chest wall irradiation)"
6401,NCT00909909,"4:29:chronic_disease,44:72:chronic_disease,74:85:chronic_disease,90:105:chronic_disease","No collagen vascular disease, specifically systemic lupus erythematosus, scleroderma, or dermatomyositis"
6402,NCT00906984,"106:116:cancer,164:170:cancer,183:188:cancer","The histopathology confirmation criterion may be waived in patients with a radiographically identifiable liver mass, known laboratory or clinical risk factors for cancer or elevated tumor markers such as Alpha-fetoprotein assay (AFP) (clinical diagnosis)"
6403,NCT00896493,"29:32:treatment,85:96:treatment,100:104:treatment","Have a related or unrelated HLA-identical donor or one antigen/allele mismatched in HLA-A, B, C or DRB1"
6404,NCT00887146,"21:42:treatment,73:82:treatment,99:107:chronic_disease",Receiving any other investigational agent that would be considered as a treatment for the primary neoplasm
6405,NCT00887146,"20:44:treatment,,68:84:cancer,126:141:treatment,145:163:treatment","if they have had a prior surgical procedure > 3 months earlier for low grade glioma, as long as the patient has not received prior radiation or prior chemotherapy"
6406,NCT00887146,"25:43:treatment,47:64:treatment,73:79:cancer",who have never received prior chemotherapy or radiation therapy for the glioma
6407,NCT00871260,"1:19:treatment,33:36:treatment,38:47:treatment,49:62:treatment","Contra-indications to MRI (i.e. ICD, pacemaker, aneurysm clip, etc)"
6408,NCT00862433,"12:22:treatment,34:41:treatment,54:78:treatment,80:103:treatment,108:119:treatment","No regular medication other than aspirin (other than oral hypoglycemic agents, hormonal contraceptives and medications taken only on an as-needed basis)"
6409,NCT00862433,"77:102:chronic_disease,,,133:155:chronic_disease,157:181:chronic_disease,183:210:chronic_disease,215:236:chronic_disease","with no known target organ damage (End organ damage includes the following: proliferative retinopathy, serum creatinine < 1.8 m/dl, ischemic heart disease, congestive heart failure, peripheral vascular disease and peripheral neuropathy)"
6410,NCT00819208,"1:32:treatment,23:32:treatment,37:49:cancer,57:86:treatment",Adjuvant chemotherapy treatment for colon cancer with a 5-fluorouracil- based regimen received with an intent to provide a complete course of treatment
6411,NCT00819208,"10:22:treatment,41:50:treatment,55:68:cancer",No prior radiotherapy as a component of treatment for primary tumor
6412,NCT00801489,"20:43:treatment,26:43:treatment,222:244:treatment","Up to one cycle of prior induction therapy will be permitted to include patients in whom presence of good-risk cytogenetics was initially missed; if the patient is in remission from induction therapy, he/she will receive post-remission therapy; if the patient is not in remission then he/she will receive induction therapy"
6413,NCT00788164,"4:32:treatment,40:55:treatment,65:105:treatment,113:125:treatment,","No immunosuppressive medication (i.e., steroid therapy or other immunosuppressive/immunomodulating drugs [e.g., cyclosporine]) within the past 2 months"
6414,NCT00739362,"1:28:chronic_disease,40:77:chronic_disease,154:186:chronic_disease","Chronic pulmonary disorders, including chronic obstructive pulmonary disease that would limit ability to follow the protocol (investigator judgment) and obstructive sleep apnea syndrome"
6415,NCT00739362,"1:14:chronic_disease,16:25:chronic_disease,34:50:chronic_disease,,,","Liver disease (cirrhosis, active hepatitis B or C, and AST or ALT greater than or equal to 1.5 times normal)"
6416,NCT00737893,"30:43:chronic_disease,47:67:treatment,71:82:treatment",The patient has a history of spinal trauma or surgery to the brain or spinal cord
6417,NCT00720785,",34:50:treatment,62:84:treatment,110:120:cancer",At least 4 weeks since any prior systemic therapy (excluding corticosteroid therapy) to treat the underlying malignancy (standard or investigational)
6418,NCT00720785,"1:8:cancer,78:87:treatment,93:103:treatment",Myeloma patients are required to have disease which has progressed following treatment with bortezomib
6419,NCT00720785,"25:35:cancer,63:80:treatment,84:105:treatment",disease confirmed to be metastatic and unresectable for which standard curative or beneficial treatments are no longer effective
6420,NCT00719888,"1:29:cancer,31:57:cancer,59:62:cancer,63:66:cancer,69:98:cancer,100:126:cancer,130:149:cancer,,200:215:treatment","Chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, lymphoplasmacytic lymphoma or follicular lymphoma that have progressed after at least two different prior therapies"
6421,NCT00719888,"14:37:chronic_disease,39:48:chronic_disease,66:85:chronic_disease,98:106:chronic_disease,108:127:chronic_disease,129:147:chronic_disease,191:213:chronic_disease,230:259:chronic_disease,293:309:treatment,311:318:chronic_disease,351:360:chronic_disease,364:378:chronic_disease,380:399:chronic_disease,401:424:chronic_disease,,,479:494:chronic_disease","atients with fulminant liver failure, cirrhosis with evidence of portal hypertension or bridging fibrosis, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, or correctable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3 mg/dL, and symptomatic biliary disease will be excluded"
6422,NCT00716066,"1:33:chronic_disease,35:51:chronic_disease,53:68:chronic_disease,70:78:chronic_disease,80:96:chronic_disease,98:112:chronic_disease","Autoimmune peripheral neuropathy (anti-Hu [Anna-1], anti-GM1 [GD1b], anti-MAG, anti-ganglioside, anti-sulfatide)"
6423,NCT00715611,"18:34:chronic_disease,48:68:treatment,70:79:treatment,84:105:treatment","Patients with an active infection that require systemic antibiotics, antiviral, or antifungal treatments"
6424,NCT00711373,"1:25:chronic_disease,39:46:chronic_disease,47:54:chronic_disease,55:63:chronic_disease",Congenital Abnormalities: co-existent absence/atrophy/agenesis of any tissue may affect post transplant results
6425,NCT00703105,"33:44:treatment,,88:93:cancer,193:215:treatment",Patients must not have received irradiation for the four weeks prior to removal of the tumor and no previously irradiated tumor deposits may be used for tumor lysate in the development of the dendritic cell vaccine
6426,NCT00695214,"34:42:treatment,56:72:treatment,76:92:treatment",Other contraindication to use of propofol (decision of anesthesiologist or otolaryngologist.)
6427,NCT00670358,"28:64:treatment,81:88:treatment,121:132:treatment,140:148:treatment,152:180:treatment","Able to receive concurrent prophylactic anticoagulation therapy (e.g., low-dose aspirin [81 mg] daily or an alternative prophylaxis [e.g., warfarin or low molecular weight heparin])"
6428,NCT00670358,"15:27:treatment,29:41:treatment,46:59:treatment,79:89:cancer","No concurrent radiotherapy, chemotherapy, or immunotherapy for another active malignancy"
6429,NCT00632853,"79:109:cancer,121:138:cancer,140:181:cancer,187:226:cancer","Limited-stage disease patients with disease restricted to one hemithorax with regional lymph node metastases, including ipsilateral hilar, ipsilateral and contralateral mediastinal, and ipsilateral supraclavicular lymph nodes"
6430,NCT00630565,"15:40:chronic_disease,75:82:cancer,84:92:cancer,127:142:treatment","Patients with cytogenetic abnormalities suggesting an improved prognosis [t(8:21), t(15;17) and inv(16)] will be eligible for transplantation in first remission"
6431,NCT00630253,"15:17:chronic_disease,46:66:chronic_disease,74:104:cancer,143:168:chronic_disease","Patients with FA must have moderately severe aplastic anemia (AA), early myelodysplastic syndrome (MDS) with no excess blasts with or without chromosomal abnormalities"
6432,NCT00594217,",12:16:chronic_disease,62:78:chronic_disease,84:98:chronic_disease,131:147:chronic_disease","women with PCOS (defined as clinical/biochemical evidence of hyperandrogenism plus oligomenorrhea, but with no evidence for other endocrinopathies)"
6433,NCT00584649,"26:34:treatment,73:90:chronic_disease,154:176:treatment,204:210:treatment,212:226:treatment,231:242:treatment","who are scheduled for an ablation procedure for suspected inappropriate sinus tachycardia, with symptomatic palpitations during periods where documented electrogram recordings suggest sinus tachycardia (holter, event recorder, or 12 lead ECG)"
6434,NCT00573027,"16:39:chronic_disease,,,86:105:chronic_disease,,142:153:treatment",No obstructive coronary artery disease performed within the previous 24 months (<50% luminal obstruction in one or more coronary arteries on angiography)
6435,NCT00542373,"15:34:cancer,99:110:chronic_disease,114:127:chronic_disease","Subjects with premalignant lesion, or potentially premalignant lesion, of the oral cavity mucosa (leukoplakia or erythroplakia)"
6436,NCT00492778,"28:49:treatment,42:49:treatment,57:78:treatment,",Patients may have received prior hormone therapy and/or systemic chemotherapy; such therapy must have been completed at least 6 months prior to study entry and the patient has clear evidence of disease subsequent to such therapy
6437,NCT00492778,"38:56:treatment,47:56:treatment,74:79:cancer,149:151:treatment,155:166:treatment","Patients who have undergone complete surgical resection of the recurrent tumor and have no evidence of residual disease evaluable clinically and by CT or MRI imaging, following resection"
6438,NCT00483249,"18:25:allergy_name,27:42:allergy_name,47:56:allergy_name","Known allergy to Nitinol, stainless steel, or polyester"
6439,NCT00432094,"26:31:cancer,74:93:chronic_disease,112:122:treatment",Patients with increasing tumor markers only (i.e. no imaging evidence of progressive disease) are eligible for transplant
6440,NCT00383656,",32:61:chronic_disease,85:97:cancer,101:116:cancer,130:137:treatment,167:179:treatment,196:220:treatment,224:242:treatment,247:255:cancer,259:281:cancer",Women and minors with acquired hypogonadotropic hypogonadism will have a history of hypothalamic or pituitary tumor treated with surgery alone or in combination with radiotherapy or a history of hypothalamic irradiation as adjunctive therapy for leukemia or craniofacial neoplasms
6441,NCT00368355,"25:28:cancer,,,75:78:cancer,107:133:chronic_disease,137:162:chronic_disease",Patients with high risk ALL in CR1 or ALL or high grade (stage III or IV) NHL after first relapse or with primary refractory disease or minimal residual diseases
6442,NCT00358657,"63:76:chronic_disease,78:87:chronic_disease,118:137:chronic_disease,158:177:chronic_disease,179:197:chronic_disease,241:263:chronic_disease,435:454:chronic_disease","patients will be excluded if they are found to have fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, bridging fibrosis, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction"
6443,NCT00338377,"3:22:treatment,24:39:treatment,41:52:treatment,54:79:treatment,120:136:chronic_disease,,157:172:treatment,190:216:treatment","A stress cardiac test (stress thallium, stress MUGA, dobutamine echocardiogram or other stress test that will rule out cardiac ischemia) within 6 months of lymphodepletion. (Turnstile II - Chemotherapy/Cell Infusion-Inclusion Criteria)"
6444,NCT00338377,"18:33:treatment,61:73:treatment,74:87:treatment",Is not receiving B-RAF treatment (Cohort C) (Turnstile II - Chemotherapy/Cell Infusion Exclusion Criteria)
6445,NCT00338377,"20:39:cancer,41:55:cancer,59:79:cancer,83:105:chronic_disease","Patients must have metastatic melanoma, uveal melanoma or stage III in-transit or regional nodal disease. (Turnstile I)"
6446,NCT00338377,"15:24:treatment,97:111:treatment,,165:180:treatment,192:213:treatment,217:242:treatment,,292:307:treatment,,376:379:cancer","Patients with VP shunts must have VP shunts with on/off valves and must be expected to tolerate VP shunt valve off for more than 6 hours Patients who have received CNS irradiation, including whole brain radiation or stereotactic radiosurgery, are eligible, if they are at least 1 weeks post CNS-irradiation (Cohort D)Patients who are currently being treated with IT IL-2 for LMD are eligible. No wash out period is required. (Cohort D)"
6447,NCT00338377,",,74:92:chronic_disease,,,162:174:treatment,175:188:treatment","Total bilirubin less than or equal to 2.0 mg/dl, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl. (Turnstile II - Chemotherapy/Cell Infusion - Inclusion Criteria)"
6448,NCT00285935,"11:30:treatment,88:95:treatment,99:110:treatment,138:157:treatment,161:169:treatment",Taking no medication or drugs likely to interfere with the study objectives (including statins or medications that affect hormones [e.g. birth control pills or steroids])
6449,NCT00169806,"70:91:treatment,96:111:chronic_disease,121:137:chronic_disease","Patients of Methodist Urology in Indianapolis, IN who are undergoing endoscopic procedures for nephrolithiasis or other urologic disease"
6450,NCT00147056,"8:15:treatment,,,91:106:treatment,,127:136:treatment",Use of Avastin in the preceding two weeks or planned use in the forthcoming two weeks and VEGF inhibitors within + 30 days of treatment
6451,NCT00107289,"1:5:treatment,21:24:treatment,50:59:treatment",MIBG-avid malignant CCT and evaluable disease on MIBG scan at time of enrollment on protocol
6452,NCT00092222,"21:31:cancer,50:59:treatment,108:118:treatment,168:171:chronic_disease",Presence of another malignancy requiring current treatment that would preclude the use of all of the study treatments or the ability to monitor the natural history of MCD untreated
6453,NCT00075387,"14:31:chronic_disease,61:74:treatment,76:87:treatment,92:110:treatment","diagnosis of high-grade glioma will be made on the basis of needle biopsy, open biopsy, or surgical resection"
6454,NCT00001337,"25:53:cancer,,85:109:cancer,113:127:cancer",No history of unrelated (non-lymphomatous) neoplasms within past 5 years other than non-melanoma skin cancer or in-situ cancer
